Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O


Delineation	O
of	O
the	O
CD28	B-protein
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
.	O


The	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
mediates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
enhancer	I-DNA
activation	O
in	O
monocytes	B-cell_type
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


Only	O
stably	O
transfected	B-cell_line
target	I-cell_line
cells	I-cell_line
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B-protein
proteins	I-protein
in	O
Ad-infected	B-cell_line
targets	I-cell_line
.	O


This	O
delay	O
is	O
associated	O
with	O
down-regulation	O
of	O
many	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
,	O
including	O
alpha-	B-DNA
and	I-DNA
beta-globin	I-DNA
,	O
band	O
3	O
,	O
band	O
4.1	O
,	O
and	O
the	O
erythroid	B-protein
cell-specific	I-protein
histone	I-protein
H5	B-protein
.	O


To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA-1	B-protein
,	O
an	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	B-cell_type
.	O


Mapping	O
experiments	O
indicate	O
that	O
GATA-1	B-protein
and	O
the	O
ER	B-protein
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N-terminal	B-protein
activation	I-protein
domain	I-protein
of	O
GATA-1	B-protein
.	O


We	O
have	O
shown	O
that	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
and	O
IL-2	B-protein
control	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
transcription	O
in	O
CD4-CD8-	B-cell_line
murine	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
precursors	I-cell_line
.	O


Finally	O
,	O
the	O
status	O
of	O
our	O
current	O
knowledge	O
concerning	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
the	O
commitment	O
to	O
erythroid	B-cell_type
,	I-cell_type
myeloid	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
cell	I-cell_type
types	I-cell_type
is	O
summarized	O
.	O


A	O
key	O
cytokine	B-protein
induced	O
during	O
the	O
immune	O
response	O
is	O
IL-2	B-protein
.	O


In	O
turn	O
,	O
secreted	O
IL-2	B-protein
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	B-protein
.	O


Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
produce	O
IFN-gamma	B-protein
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O


Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	B-protein
alone	O
in	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
leads	O
to	O
activation	O
of	O
the	O
nuclear	B-protein
factors	I-protein
,	O
including	O
NFAT	B-protein
,	O
involved	O
in	O
interleukin-2	B-protein
expression	O
.	O


PEBP2	B-protein
alpha	I-protein
A1	I-protein
,	O
alpha	B-protein
B1	I-protein
,	O
and	O
alpha	B-protein
B2	I-protein
proteins	I-protein
bound	O
the	O
PEBP2	B-DNA
site	I-DNA
within	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O


Priming	O
by	O
IFN-gamma	B-protein
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
.	O


A	O
Myc-associated	B-DNA
zinc	I-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
is	O
one	O
of	O
four	O
important	O
functional	B-DNA
regions	I-DNA
in	O
the	O
CD4	B-DNA
promoter	I-DNA
.	O


We	O
also	O
demonstrate	O
that	O
the	O
Myc-associated	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
MAZ	B-protein
)	O
appears	O
to	O
be	O
the	O
predominant	B-protein
factor	I-protein
binding	O
to	O
one	O
of	O
these	O
sites	O
.	O


This	O
last	O
site	O
closely	O
resembles	O
the	O
ME1a1	B-DNA
G3AG4AG3	I-DNA
motif	I-DNA
previously	O
shown	O
to	O
be	O
a	O
critical	O
element	O
in	O
the	O
P2	B-DNA
promoter	I-DNA
of	O
the	O
c-myc	B-DNA
gene	I-DNA
.	O


TAL1	B-protein
expression	O
by	O
erythroid	B-cell_type
cells	I-cell_type
in	O
vivo	O
and	O
in	O
chemical-induced	B-cell_line
erythroleukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O


Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	B-protein
hormone	I-protein
erythropoietin	I-protein
(	O
Epo	B-protein
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
and	O
its	O
protein	B-protein
products	I-protein
were	O
affected	O
by	O
Epo	B-protein
in	O
splenic	B-cell_type
erythroblasts	I-cell_type
from	O
mice	O
infected	O
with	O
an	O
anemia-inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O


The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
observed	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Control	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
proteolysis	O
by	O
site-specific	O
,	O
signal-induced	O
phosphorylation	O
.	O


This	O
liberates	O
NF-kappa	B-protein
B	I-protein
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	B-DNA
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O


Rather	O
,	O
hEpoR	B-protein
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	B-protein
and	O
GATA-1	B-protein
with	O
other	O
cell-specific	B-protein
factors	I-protein
,	O
including	O
possibly	O
other	O
Sp1-like	B-protein
binding	I-protein
proteins	I-protein
,	O
to	O
provide	O
high	O
level	O
,	O
tissue-specific	O
expression	O
.	O


We	O
have	O
identified	O
a	O
cDNA	B-DNA
clone	I-DNA
,	O
DR-nm23	B-protein
,	O
differentially	O
expressed	O
in	O
a	O
blast-crisis	B-DNA
cDNA	I-DNA
library	I-DNA
,	I-DNA
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	B-DNA
metastatic	I-DNA
suppressor	I-DNA
genes	I-DNA
,	O
nm23-H1	B-DNA
and	O
nm23-H2	B-DNA
.	O


DR-nm23	B-RNA
mRNA	I-RNA
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
.	O


These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR-nm23	B-protein
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O


Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
without	O
a	O
TATA	B-DNA
box	I-DNA
.	O


Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L-N-monomethyl-arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM-1	B-protein
,	O
but	O
did	O
not	O
augment	O
cytokine-induced	O
VCAM-1	B-protein
expression	O
.	O


Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	B-DNA
binding	I-DNA
site	I-DNA
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O


We	O
have	O
shown	O
that	O
the	O
interaction	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-5	I-protein
with	O
the	O
receptor	O
activates	O
Lyn	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1	O
min	O
and	O
Jak2	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1-3	O
min	O
.	O


The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	B-protein
cytomegalovirus	I-protein
IE2	I-protein
protein	I-protein
.	O


We	O
found	O
that	O
the	O
retinoblastoma	B-protein
susceptibility	I-protein
gene	I-protein
product	I-protein
(	O
Rb	B-protein
)	O
dramatically	O
suppressed	O
this	O
IE2	B-protein
transactivation	O
of	O
various	B-DNA
promoters	I-DNA
.	O


Expression	O
of	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	I-protein
,	O
which	O
is	O
homologous	O
to	O
the	O
nm23	B-protein
gene	I-protein
product	I-protein
in	O
a	O
variety	O
of	O
species	O
,	O
has	O
been	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
metastatic	O
potential	O
.	O


However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O


However	O
,	O
the	O
difference	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
KA	O
and	O
SCC	O
was	O
not	O
statistically	O
significant	O
.	O


The	O
mechanism	O
of	O
overexpression	O
in	O
various	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
its	O
biological	O
significance	O
in	O
cutaneous	O
carcinogenesis	O
remain	O
to	O
be	O
determined	O
.	O


CIITA	B-DNA
is	O
a	O
class	B-DNA
II	I-DNA
gene	I-DNA
transactivator	I-DNA
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
.	O


Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB-defective	B-cell_line
cells	I-cell_line
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	B-DNA
inducibility	O
.	O


DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O


A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	B-protein
tyrosine	I-protein
kinase	I-protein
.	O


The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O


The	O
components	O
tyrosine	O
phosphorylated	O
subsequent	O
to	O
cell	O
adhesion	O
include	O
paxillin	B-protein
,	O
pp125FAK	B-protein
,	O
and	O
the	O
SH2	B-protein
domain	I-protein
containing	I-protein
tyrosine	I-protein
kinase	I-protein
Syk	I-protein
.	O


In	O
contrast	O
,	O
integrin	B-protein
ligation	O
with	O
antibodies	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	B-protein
but	O
not	O
of	O
FAK	B-protein
or	O
paxillin	B-protein
.	O


This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	B-cell_type
cells	I-cell_type
by	O
disrupting	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
GATA1	B-protein
erythroid	I-protein
transcription	I-protein
factor	I-protein
.	O


The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B-protein
kinase	I-protein
(	O
pp90rsk	B-protein
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B-protein
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	B-cell_line
treated	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O


In	O
different	O
genes	B-DNA
,	O
the	O
core	B-DNA
sequences	I-DNA
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O


The	O
expression	O
of	O
the	O
TINUR	B-DNA
gene	I-DNA
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross-linking	O
of	O
the	O
T	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
complex	I-protein
.	O


However	O
,	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
by	O
both	O
TNF-alpha	B-protein
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


We	O
further	O
demonstrate	O
that	O
TNF-alpha-	O
and	O
calyculin	O
A-induced	O
I	O
kappa	O
B	O
alpha	O
degradation	O
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O


We	O
further	O
show	O
that	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
is	O
required	O
for	O
the	O
activation	O
of	O
alpha-globin	B-DNA
gene	I-DNA
expression	O
during	O
erythroid	O
differentiation	O
.	O


Gel-shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
CHO-DR	B-protein
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
required	O
costimulation	O
.	O


Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
costimulation	O
on	O
the	O
activity	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O


These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	B-protein
acts	O
to	O
reverse	O
LPS-mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on-going	O
LPS	O
signal	O
.	O


Antigen	O
complexed	O
with	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
or	I-protein
II	I-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
interacts	O
with	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
on	O
the	O
surface	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
initiates	O
an	O
activation	O
cascade	O
.	O


Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
promoter	I-DNA
.	O


Functional	O
characterization	O
of	O
novel	O
IL-2	B-protein
transcriptional	O
inhibitors	O
.	O


Formation	O
of	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	I-protein
on	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
essential	O
for	O
IL-2	B-protein
transcription	O
.	O


These	O
compounds	O
also	O
inhibited	O
beta-galactosidase	B-RNA
mRNA	I-RNA
levels	O
.	O


Similar	O
inhibition	O
of	O
NFAT	B-protein
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	B-cell_line
line	I-cell_line
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	B-DNA
regulatory	I-DNA
elements	I-DNA
linked	O
to	O
the	O
reporter	B-DNA
gene	I-DNA
for	I-DNA
sCD8	I-DNA
.	O


We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
(	O
Ramos	B-cell_line
and	O
Daudi	B-cell_line
)	O
as	O
well	O
as	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Jurkat	B-cell_line
)	O
.	O


By	O
contrast	O
,	O
cAMP	O
in	O
the	O
presence	O
of	O
calcium	O
shows	O
no	O
synergy	O
in	O
c-fos	B-DNA
induction	O
.	O


IL-10	B-protein
treatment	O
of	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
results	O
in	O
the	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
,	O
but	O
not	O
Jak2	B-protein
or	O
Jak3	B-protein
.	O


The	O
inert	O
quality	O
of	O
MRL-Ipr/Ipr	B-cell_line
(	I-cell_line
Ipr	I-cell_line
)	I-cell_line
peripheral	I-cell_line
CD4-CD8-	I-cell_line
(	I-cell_line
CD4-8-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL-2	B-protein
in	O
response	O
to	O
TCR	B-protein
or	O
mitogenic	O
stimulation	O
.	O


The	O
generation	O
of	O
second	O
messengers	O
in	O
T	B-cell_type
cells	I-cell_type
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O


This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor-ligand	O
interactions	O
.	O


The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N-terminal	B-protein
acidic	I-protein
domain	I-protein
(	O
amino	B-protein
acids	I-protein
26-137	I-protein
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	B-protein
viral	I-protein
transcription-activating	I-protein
domain	I-protein
.	O


Functional	O
roles	O
of	O
in	B-DNA
vivo	I-DNA
footprinted	I-DNA
DNA	I-DNA
motifs	I-DNA
within	O
an	O
alpha-globin	B-DNA
enhancer	I-DNA
.	O


Previous	O
protein-DNA	O
binding	O
studies	O
have	O
shown	O
that	O
HS-40	B-DNA
consists	O
of	O
multiple	O
nuclear	B-DNA
factor	I-DNA
binding	I-DNA
motifs	I-DNA
that	O
are	O
occupied	O
in	O
vivo	O
in	O
an	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
manner	O
.	O


The	O
remarkable	O
correlation	O
between	O
genomic	O
footprinting	O
data	O
and	O
the	O
mutagenesis	O
results	O
also	O
suggests	O
that	O
the	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
regulation	O
of	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
promoters	I-DNA
is	O
indeed	O
modulated	O
by	O
stable	O
binding	O
of	O
specific	B-protein
nuclear	I-protein
factors	I-protein
in	O
vivo	O
.	O


Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	B-DNA
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP-bound	B-protein
p21ras	I-protein
.	O


Interleukin-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
controlled	O
by	O
nuclear	B-protein
factor-chi	I-protein
B	I-protein
.	O


However	O
,	O
B	B-cell_type
cells	I-cell_type
can	O
also	O
synthesize	O
IL-2	B-protein
.	O


In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
B	I-cell_line
cell	I-cell_line
clones	I-cell_line
which	O
are	O
capable	O
of	O
secreting	O
IL-2	B-protein
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2+	O
ionophore	O
ionomycin	O
.	O


In	O
EBV-transformed	B-cell_line
B	I-cell_line
clones	I-cell_line
,	O
the	O
chi	B-DNA
B	I-DNA
site	I-DNA
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF-AT	B-DNA
binding	I-DNA
sites	I-DNA
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Does	O
thyroidectomy	O
,	O
radioactive	O
iodine	O
therapy	O
,	O
or	O
antithyroid	O
drug	O
treatment	O
alter	O
reactivity	O
of	O
patients	O
'	O
T	B-cell_type
cells	I-cell_type
to	O
epitopes	O
of	O
thyrotropin	B-protein
receptor	I-protein
in	O
autoimmune	O
thyroid	O
diseases	O
?	O


Expression	O
studies	O
on	O
TCF-1	B-protein
protein	I-protein
have	O
been	O
hampered	O
by	O
the	O
difficulty	O
to	O
raise	O
antibodies	B-protein
due	O
to	O
extreme	O
evolutionary	O
conservation	O
.	O


Wild-type	O
littermates	O
remain	O
unresponsive	O
to	O
TCF-1	B-protein
while	O
they	O
mount	O
a	O
high-titer	O
antibody	O
response	O
to	O
the	O
fusion	B-protein
protein	I-protein
,	O
Maltose	B-protein
Binding	I-protein
Protein	I-protein
(	O
MBP	B-protein
)	O
.	O


Subsequently	O
,	O
TCF-1-specific	B-cell_line
hybridomas	I-cell_line
could	O
be	O
prepared	O
from	O
the	O
spleens	O
of	O
immunized	O
knock-out	O
mice	O
.	O


The	O
prostate-specific	B-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O


Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	B-cell_type
cell	I-cell_type
characteristics	O
.	O


These	O
functions	O
of	O
PAF	B-protein
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	B-protein
surface	I-protein
PAF	I-protein
receptors	I-protein
,	O
as	O
two	O
PAF	B-protein
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	B-protein
.	O


Mapping	O
of	O
the	O
interaction	B-protein
site	I-protein
of	O
the	O
defective	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex	I-cell_line
mutant	I-cell_line
cell	I-cell_line
line	I-cell_line
clone-13	I-cell_line
to	O
the	O
divergent	B-DNA
X2-box	I-DNA
.	O


Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	B-DNA
X-box	I-DNA
(	O
but	O
not	O
the	O
DQB-W	B-DNA
region	I-DNA
or	O
the	O
DQB	B-DNA
Y-box	I-DNA
)	O
upstream	B-DNA
of	I-DNA
-141	I-DNA
in	O
a	O
DRA	B-DNA
reporter	I-DNA
plasmid	I-DNA
rescued	O
expression	O
to	O
nearly	O
wild-type	O
levels	O
.	O


ZEBRA	B-protein
is	O
a	O
bZIP	B-protein
transcriptional	I-protein
activator	I-protein
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	B-DNA
response	I-DNA
elements	I-DNA
within	O
EBV	B-DNA
promoters	I-DNA
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	B-DNA
lytic	I-DNA
origin	I-DNA
.	O


The	O
ZEBRA	B-protein
activation	I-protein
region	I-protein
was	O
replaced	O
with	O
the	O
potent	O
acid	B-protein
activation	I-protein
region	I-protein
from	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
VP16	I-protein
protein	I-protein
or	O
with	O
the	O
activation	B-protein
region	I-protein
of	O
the	O
EBV	B-protein
R	I-protein
protein	I-protein
.	O


Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
,	O
we	O
determined	O
whether	O
antibodies	B-protein
to	I-protein
Stat	I-protein
proteins	I-protein
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B-protein
to	I-protein
IL-4	I-protein
Stat	I-protein
,	O
also	O
known	O
as	O
Stat6	B-protein
,	O
but	O
not	O
antibodies	B-protein
to	O
other	O
Stat	B-protein
proteins	I-protein
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	B-protein
NAF	I-protein
complex	I-protein
.	O


HL60	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes-macrophages	B-cell_type
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5-	O
to	O
2-fold	O
increase	O
of	O
AhR	B-RNA
mRNA	I-RNA
.	O


The	O
HEL	B-cell_line
cells	I-cell_line
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	B-RNA
mRNA	I-RNA
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte-macrophage	B-cell_type
cells	I-cell_type
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O


These	O
results	O
indicated	O
that	O
expression	O
of	O
AhR	B-RNA
mRNA	I-RNA
was	O
significantly	O
induced	O
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	B-cell_type
cells	I-cell_type
were	O
responsive	O
to	O
xenobiotics	O
.	O


p21ras	B-protein
plays	O
an	O
essential	O
role	O
in	O
T	O
cell	O
activation	O
.	O


Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	B-protein
active	I-protein
PKCs	I-protein
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	B-protein
.	O


The	O
data	O
indicate	O
that	O
PKC-epsilon	B-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
PKC-alpha	B-protein
but	O
not	O
-zeta	B-protein
,	O
can	O
regulate	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
nuclear	O
factor	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT-1	B-protein
)	O
.	O


The	O
molecular	O
mechanism	O
for	O
this	O
steroid	O
resistance	O
is	O
unclear	O
.	O


Scatchard	O
analysis	O
of	O
glucocorticoid	B-protein
receptor	I-protein
-	O
GRE	B-DNA
binding	O
showed	O
no	O
change	O
in	O
binding	O
affinity	O
but	O
did	O
show	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
DNA	O
binding	O
in	O
the	O
steroid-resistant	O
patients	O
.	O


IL-3	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
induced	O
,	O
similar	O
to	O
IL-5	B-protein
,	O
two	O
DNA-binding	B-protein
complexes	I-protein
in	O
human	B-cell_type
eosinophils	I-cell_type
,	O
including	O
Stat1	B-protein
alpha	I-protein
.	O


To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	B-protein
mutants	I-protein
,	O
including	O
two	O
stop	B-protein
codon	I-protein
mutants	I-protein
and	O
one	O
deletion	B-protein
mutant	I-protein
using	O
replication-competent	B-DNA
HIV-1	I-DNA
constructs	I-DNA
carrying	O
wild-type	B-DNA
or	I-DNA
mutant	I-DNA
LTRs	I-DNA
with	O
modifications	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
and/or	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
.	O


It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B-protein
mutants	I-protein
containing	O
wild-type	B-DNA
LTRs	I-DNA
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR-modified	B-protein
Tat	I-protein
mutants	I-protein
.	O


However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR-modified	B-protein
tat	I-protein
mutants	I-protein
was	O
restricted	O
to	O
some	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O


Direct	O
sequencing	O
of	O
the	O
viral	B-DNA
genomes	I-DNA
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B-protein
-virus	O
.	O


The	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
HLA-DRA	B-DNA
is	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
in	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O


Heterogeneous	O
expression	O
of	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
proteins	I-protein
in	O
endemic	O
Burkitt	O
's	O
lymphoma	O
.	O


In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
six	O
EBV-encoded	B-protein
nuclear	I-protein
antigens	I-protein
(	O
EBNA1	B-protein
,	I-protein
2	I-protein
,	I-protein
3A	I-protein
,	I-protein
3B	I-protein
,	I-protein
3C	I-protein
,	I-protein
-LP	I-protein
)	O
,	O
three	O
latent	B-protein
membrane	I-protein
proteins	I-protein
(	O
LMP1	B-protein
,	O
2A	B-protein
,	O
2B	B-protein
)	O
,	O
and	O
two	O
nuclear	B-RNA
RNAs	I-RNA
(	O
EBERs	B-RNA
)	O
are	O
expressed	O
.	O


In	O
EBV-positive	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
,	O
the	O
EBERs	B-RNA
,	O
EBNA1	B-protein
,	O
and	O
the	O
LMPs	B-protein
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	B-RNA
and	O
EBNA1	B-protein
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O


A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O


The	O
activation	O
of	O
Jak	B-protein
2	I-protein
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	B-protein
kinase	I-protein
.	O


Jak	B-protein
2	I-protein
coprecipitated	O
with	O
the	O
beta-subunit	O
of	O
the	O
IL-5	B-protein
receptor	I-protein
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	B-protein
with	O
the	O
receptor	O
.	O


The	O
presence	O
of	O
STAT-1	B-protein
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O


Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
gene	I-DNA
.	O


A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	B-DNA
site	I-DNA
of	I-DNA
transcription	I-DNA
in	O
the	O
first	O
exon	B-DNA
of	O
the	O
DR	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position-dependent	O
manner	O
.	O


Activity	O
was	O
mediated	O
through	O
the	O
core	B-DNA
elements	I-DNA
.	O


These	O
data	O
indicate	O
that	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibit	O
cytokine	B-protein
production	O
by	O
different	O
mechanisms	O
.	O


LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
by	O
targeting	O
the	O
inhibitory	B-protein
molecule	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


The	O
mechanisms	O
by	O
which	O
LMP-1	B-protein
upregulates	O
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP-1	B-protein
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	B-protein
factors	I-protein
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	B-DNA
genes	I-DNA
.	O


The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O


Our	O
data	O
indicate	O
that	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B-lymphoid	B-cell_type
cells	I-cell_type
stably	O
or	O
transiently	O
expressing	O
LMP-1	B-protein
.	O


I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
selectively	O
modified	O
in	O
LMP-1-expressing	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O


A	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
increased	O
protein	O
turnover-degradation	O
correlate	O
with	O
increased	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
.	O


These	O
results	O
indicate	O
that	O
LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
B-cell	B-cell_line
lines	I-cell_line
by	O
targeting	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE-SV40	B-DNA
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	B-DNA
response	I-DNA
element	I-DNA
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O


Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	B-DNA
beta	I-DNA
and	O
MYH11	B-DNA
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	B-RNA
transcripts	I-RNA
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O


Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	B-DNA
beta	I-DNA
-	O
MYH11	B-RNA
transcripts	I-RNA
in	O
the	O
absence	O
of	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT-PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	B-RNA
transcript	I-RNA
.	O


This	O
study	O
demonstrates	O
that	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
protein	I-protein
amplifies	O
the	O
activity	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV-1	O
replication	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


A	O
similar	O
potentiation	O
of	O
TNF	B-protein
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	B-cell_line
cells	I-cell_line
treated	O
with	O
soluble	O
Tat	B-protein
protein	I-protein
.	O


Increasing	O
success	O
in	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
has	O
led	O
to	O
increasing	O
awareness	O
of	O
avascular	O
necrosis	O
of	O
bone	O
as	O
a	O
potentially	O
disabling	O
sequela	O
of	O
glucocorticoid	O
therapy	O
,	O
especially	O
in	O
adolescent	O
and	O
young	O
adult	O
patients	O
.	O


Lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
:	O
predictor	O
of	O
sertraline	O
response	O
in	O
adolescent	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O


Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O


The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O


In	O
an	O
open-label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM-III-R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	B-protein
GCII	I-protein
sites	I-protein
per	O
cell	O
(	O
sites/cell	O
)	O
values	O
of	O
793	O
+/-	O
106	O
versus	O
2	O
,	O
563	O
+/-	O
499	O
(	O
+/-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3.5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.001	O
)	O
.	O


GCII	B-protein
was	O
bimodally	O
distributed	O
,	O
with	O
SRI	O
responders	O
differing	O
from	O
nonresponders	O
(	O
t	O
=	O
3.9	O
;	O
df	O
=	O
14	O
;	O
p	O
<	O
.001	O
)	O
.	O


The	O
role	O
of	O
NFATp	B-protein
in	O
cyclosporin	B-DNA
A-sensitive	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor-alpha	I-DNA
gene	I-DNA
transcription	O
.	O


The	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
(	I-DNA
TNF	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
in	O
that	O
it	O
is	O
rapidly	O
induced	O
without	O
a	O
requirement	O
for	O
protein	O
synthesis	O
.	O


Thus	O
,	O
although	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp-binding	B-DNA
sites	I-DNA
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin-sensitive	B-DNA
promoter	I-DNA
element	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B-protein
.	O


The	O
results	O
varied	O
with	O
the	O
agent	O
,	O
cell	O
type	O
,	O
and	O
stage	O
of	O
differentiation	O
.	O


These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O


Coordinate	O
with	O
temporal	O
changes	O
in	O
Ig	B-protein
synthesis	O
,	O
the	O
DNA-binding	O
activity	O
and	O
the	O
synthesis	O
of	O
the	O
B	B-protein
cell-enriched	I-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
are	O
regulated	O
.	O


Thus	O
,	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
IL-6	B-protein
in	O
vitro	O
recapitulates	O
the	O
hallmarks	O
of	O
terminal	O
B	O
differentiation	O
in	O
vivo	O
;	O
Oct-2	B-protein
may	O
have	O
a	O
role	O
in	O
this	O
process	O
.	O


Both	O
positive	B-DNA
and	I-DNA
negative	I-DNA
regulatory	I-DNA
elements	I-DNA
were	O
identified	O
in	O
the	O
proximal	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
IL-3	B-DNA
gene	I-DNA
.	O


The	O
promoter	B-DNA
region	I-DNA
between	O
-173	B-DNA
and	I-DNA
-60	I-DNA
contained	O
the	O
strongest	O
activating	B-DNA
elements	I-DNA
.	O


The	O
PEBP2	B-DNA
alpha	I-DNA
A	I-DNA
and	I-DNA
PEBP2	I-DNA
alpha	I-DNA
B	I-DNA
genes	I-DNA
encode	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
a	O
murine	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
,	O
which	O
is	O
implicated	O
as	O
a	O
T-cell-specific	B-protein
transcriptional	I-protein
regulator	I-protein
.	O


The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	B-protein
is	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
.	O


Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	B-protein
factor	I-protein
binding	O
to	O
DNA	O
.	O


This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O


During	O
the	O
induction	O
of	O
anergy	O
,	O
T	B-cell_type
cells	I-cell_type
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O


In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	B-protein
factors	I-protein
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O


The	O
inducible	B-protein
factors	I-protein
NK-kappa	B-protein
B	I-protein
,	O
beta	B-protein
E2	I-protein
,	O
CD28RC	B-protein
,	O
and	O
AP-1	B-protein
are	O
not	O
expressed	O
in	O
resting	B-cell_type
cells	I-cell_type
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O


In	O
contrast	O
,	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF-AT	B-protein
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	B-protein
factors	I-protein
that	O
regulates	O
IL-2	B-DNA
gene	I-DNA
transcription	O
.	O


The	O
receptor	O
was	O
tested	O
immunocytochemically	O
,	O
in	O
steroid	O
binding	O
assays	O
,	O
and	O
by	O
a	O
mutation	O
screening	O
(	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
of	O
the	O
receptor-cDNA	B-protein
.	O


Expression	O
of	O
the	O
kappa	O
immunoglobulin	O
light	O
chain	O
gene	O
requires	O
developmental-	O
and	O
tissue-specific	O
regulation	O
by	O
trans-acting	B-protein
factors	I-protein
which	O
interact	O
with	O
two	O
distinct	O
enhancer	B-DNA
elements	I-DNA
.	O


Mutation	O
of	O
the	O
AP1	B-DNA
motif	I-DNA
in	O
the	O
context	O
of	O
the	O
intron	B-DNA
enhancer	I-DNA
was	O
shown	O
to	O
decrease	O
enhancer-mediated	O
activation	O
of	O
the	O
promoter	O
in	O
both	O
pre-B	B-cell_type
cells	I-cell_type
induced	O
with	O
LPS	O
and	O
constitutive	O
expression	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Distinct	O
DNase-I	B-DNA
hypersensitive	I-DNA
sites	I-DNA
are	O
associated	O
with	O
TAL-1	B-protein
transcription	O
in	O
erythroid	B-cell_line
and	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O


When	O
the	O
supplemented	O
cytokine	B-protein
was	O
switched	O
from	O
GM-CSF	B-protein
to	O
EPO	B-protein
,	O
hemoglobin	B-protein
synthesis	O
in	O
M-TAT/GM-CSF	B-cell_line
cells	I-cell_line
increased	O
rapidly	O
(	O
within	O
5	O
h	O
)	O
,	O
and	O
the	O
level	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
increased	O
.	O


These	O
results	O
support	O
the	O
hypothesis	O
that	O
EPO	B-protein
actively	O
influences	O
the	O
programming	O
of	O
gene	O
expression	O
required	O
for	O
erythroid	B-cell_type
progenitor	I-cell_type
cell	I-cell_type
differentiation	O
.	O


Regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
p105	B-protein
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
persistently	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
.	O


Another	O
protein	O
with	O
I	O
kappa	O
B	O
function	O
,	O
p105	B-protein
,	O
is	O
also	O
modified	O
in	O
HIV-infected	O
cells	O
:	O
p105	B-protein
and	O
p50	B-protein
steady-state	O
protein	O
levels	O
are	O
increased	O
as	O
a	O
result	O
of	O
increased	O
synthesis	O
and	O
proteolytic	O
processing	O
of	O
p105	B-protein
.	O


Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity	O
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O


HIV	O
type	O
1	O
protease	B-protein
activation	O
of	O
NF-kappa	B-protein
B	I-protein
within	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


Deletion	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
significantly	O
inhibited	O
Tat	B-protein
-mediated	O
transactivation	O
in	O
T-cell	B-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	B-cell_line
line	I-cell_line
,	O
U937	B-cell_line
.	O


Insertion	O
of	O
this	O
chimeric	B-DNA
promoter	I-DNA
(	O
ISG15	B-DNA
LTR	I-DNA
)	O
upstream	O
of	O
the	O
human	B-DNA
IFNA2	I-DNA
gene	I-DNA
directed	O
high	O
levels	O
of	O
IFN	B-protein
synthesis	O
in	O
Tat-expressing	B-cell_line
cells	I-cell_line
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
-mediated	O
activation	O
.	O


Virus	O
isolated	O
from	O
IFNA-producing	B-cell_line
cells	I-cell_line
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	B-cell_line
cells	I-cell_line
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	B-cell_line
cells	I-cell_line
transduced	O
with	O
the	O
IFNA	B-DNA
gene	I-DNA
.	O


OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV-1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	B-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
in	O
T-lymphoid	B-cell_line
and	I-cell_line
monocytoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O


As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well-known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O


The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B-binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O


RESULTS	O
:	O
The	O
results	O
showed	O
high	O
GATA-1	B-protein
binding	O
activity	O
and	O
very	O
low	O
SP1	B-protein
activity	O
in	O
the	O
fetal	B-cell_line
liver	I-cell_line
cultures	I-cell_line
.	O


This	O
pattern	O
was	O
in	O
contrast	O
to	O
cultures	O
derived	O
from	O
normal	O
adult	O
peripheral	O
blood	O
,	O
in	O
which	O
both	O
GATA-1	B-protein
and	O
SP1	B-protein
activities	O
were	O
high	O
.	O


The	O
demonstration	O
that	O
NF-kappa	B-protein
B	I-protein
can	O
regulate	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	O
in	O
steady-state	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcriptional	O
stimulation	O
of	O
the	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
.	O


We	O
propose	O
that	O
adherent	B-cell_type
monocytes	I-cell_type
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
,	O
thereby	O
increasing	O
mRNA	O
levels	O
without	O
stimulating	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
.	O


It	O
contains	O
a	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
motif	I-protein
contiguous	O
with	O
a	O
Per-Arnt-Sim	B-protein
(	I-protein
PAS	I-protein
)	I-protein
homology	I-protein
region	I-protein
.	O


In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90-kDa	B-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
hsp90	B-protein
)	O
,	O
a	O
molecular	B-protein
chaperone	I-protein
.	O


At	O
least	O
two	O
distinct	O
domains	O
of	O
the	O
receptor	O
mediated	O
interaction	O
with	O
hsp90	B-protein
:	O
the	O
ligand-binding	B-protein
domain	I-protein
located	O
within	O
the	O
PAS	B-protein
region	I-protein
and	O
,	O
surprisingly	O
,	O
the	O
bHLH	B-protein
domain	I-protein
.	O


Several	O
distinct	O
roles	O
for	O
hsp90	B-protein
in	O
modulating	O
dioxin	B-protein
receptor	I-protein
function	O
are	O
therefore	O
likely	O
:	O
correct	O
folding	O
of	O
the	O
ligand-binding	O
domain	O
,	O
interference	O
with	O
Arnt	B-protein
heterodimerization	O
,	O
and	O
folding	O
of	O
a	O
DNA-binding	O
conformation	O
of	O
the	O
bHLH	B-protein
domain	I-protein
.	O


Induction	O
of	O
transcription	B-protein
factors	I-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
aspirin-like	O
drugs	O
.	O


To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD-treated	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	B-protein
kinase	I-protein
(	O
PKC	B-protein
)	O
but	O
have	O
no	O
effect	O
(	O
in	O
comparison	O
to	O
anti-CD3	B-protein
antibodies	I-protein
)	O
on	O
protein	O
tyrosine	O
phosphorylation	O
nor	O
on	O
PCL	O
gamma	O
1	O
tyrosine	O
phosphorylation	O
.	O


Although	O
we	O
detected	O
no	O
IL-2	B-RNA
mRNA	I-RNA
in	O
ALD-treated	B-cell_line
cells	I-cell_line
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	B-DNA
sequences	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
region	I-DNA
:	O
NFAT	B-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
AP-1	B-protein
.	O


The	O
signal	O
is	O
transmitted	O
to	O
the	O
nucleus	O
and	O
induces	O
DNA-binding	O
activity	O
by	O
several	O
transcription	B-protein
factors	I-protein
.	O


Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	B-DNA
.	O


Glucocorticoid-induced	O
apoptosis	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O


The	O
role	O
of	O
chromatin	B-DNA
degradation	O
and	O
endonucleases	B-protein
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	B-DNA
in	O
glucocorticoid-induced	O
cell	O
lysis	O
.	O


In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid-induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O


Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF-kappa	B-protein
B/I	I-protein
kappa	I-protein
B	I-protein
components	I-protein
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF-kappa	B-protein
B	I-protein
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF-kappa	B-protein
B/I	I-protein
kappa	I-protein
B	I-protein
protein	I-protein
families	I-protein
.	O


Surprisingly	O
,	O
even	O
p65	B-protein
,	O
but	O
not	O
c-rel	B-protein
,	O
was	O
phosphorylated	O
after	O
induction	O
in	O
vivo	O
,	O
suggesting	O
that	O
TNF-alpha	B-protein
selectively	O
activates	O
only	O
specific	O
NF-kappa	B-protein
B	I-protein
heteromers	O
and	O
that	O
modifications	O
regulate	O
not	O
only	O
I	B-protein
kappa	I-protein
B	I-protein
molecules	I-protein
but	O
also	O
NF-kappa	B-protein
B	I-protein
molecules	O
.	O


Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
vivo	O
.	O


Similar	O
results	O
were	O
obtained	O
when	O
HL60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
all-trans	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
.	O


Isolation	O
of	O
differentially	O
expressed	O
sequence	O
tags	O
from	O
steroid-responsive	B-cell_type
cells	I-cell_type
using	O
mRNA	B-RNA
differential	O
display	O
.	O


GIG10	B-DNA
is	O
a	O
novel	O
sequence	O
and	O
GIG18	B-DNA
is	O
the	O
mouse	O
homologue	O
of	O
a	O
human	B-DNA
expressed	I-DNA
sequence	I-DNA
tag	I-DNA
isolated	O
from	O
activated	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


Triggering	O
through	O
CD2	B-protein
is	O
mitogenic	O
for	O
mature	O
,	O
but	O
not	O
immature	O
,	O
T	B-cell_type
cells	I-cell_type
.	O


Serum	O
cortisol	O
,	O
osteocalcin	O
and	O
urinary	O
cortisol	O
levels	O
were	O
also	O
determined	O
.	O


These	O
effects	O
are	O
receptor-dependent	O
,	O
reversible	O
,	O
and	O
according	O
to	O
serum	O
and	O
urinary	O
cortisol	O
levels	O
and	O
ITT	O
,	O
leave	O
the	O
hypothalamic-pituitary-adrenal	O
function	O
intact	O
.	O


To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
regulation	O
further	O
,	O
a	O
cDNA	B-DNA
library	I-DNA
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	B-DNA
element	I-DNA
and	O
the	O
nearby	O
J	B-DNA
element	I-DNA
of	O
the	O
human	B-DNA
DPA	I-DNA
gene	I-DNA
.	O


An	O
acidic	B-protein
activation	I-protein
domain	I-protein
is	O
located	O
between	O
the	O
N-terminal	B-protein
conserved	I-protein
region	I-protein
of	O
clone	B-protein
18	I-protein
and	O
its	O
zinc	B-protein
fingers	I-protein
.	O


Antisense	O
cDNA	O
to	O
clone	B-protein
18	I-protein
inhibited	O
the	O
expression	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
DPA	B-DNA
promoter	I-DNA
,	O
indicating	O
its	O
functional	O
importance	O
in	O
the	O
expression	O
of	O
this	O
class	B-DNA
II	I-DNA
gene	I-DNA
.	O


These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


The	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
is	O
a	O
composite	O
cis-element	B-DNA
which	O
binds	O
Oct-1	B-protein
and	O
Oct-2	B-protein
as	O
well	O
as	O
a	O
TPA/Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-inducible	I-protein
nuclear	I-protein
factor	I-protein
,	O
previously	O
termed	O
octamer-associated	B-protein
protein	I-protein
(	O
OAP40	B-protein
)	O
.	O


The	O
presence	O
of	O
an	O
intact	B-protein
COOH-terminal	I-protein
domain	I-protein
of	O
Oct-2	B-protein
contributes	O
to	O
both	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
transactivation	O
and	O
the	O
RA-mediated	O
repression	O
.	O


We	O
also	O
show	O
that	O
both	O
Fos	B-protein
and	O
Jun	B-protein
components	O
of	O
the	O
AP-1	B-protein
factors	O
participate	O
in	O
the	O
OAP40	B-protein
complex	I-protein
.	O


OAP	B-protein
confers	O
to	O
Oct-2	B-protein
responsivity	O
to	O
both	O
TPA/Ca2+	O
and	O
RA	O
,	O
since	O
specific	O
mutations	O
of	O
the	O
AP-1/OAP-binding	B-DNA
site	I-DNA
significantly	O
reduce	O
the	O
transactivation	O
by	O
Oct-2	B-protein
in	O
response	O
to	O
TPA	O
and	O
Ca2+	O
and	O
abolish	O
the	O
inhibition	O
by	O
RA	O
.	O


Missense	O
mutation	O
in	O
exon	B-DNA
7	I-DNA
of	O
the	O
common	B-DNA
gamma	I-DNA
chain	I-DNA
gene	I-DNA
causes	O
a	O
moderate	O
form	O
of	O
X-linked	O
combined	O
immunodeficiency	O
.	O


Posttranscriptional	O
regulation	O
of	O
macrophage	O
tissue	B-protein
factor	I-protein
expression	O
by	O
antioxidants	O
.	O


However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	B-protein
alpha	I-protein
protein	I-protein
as	O
well	O
as	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
dose-dependent	O
manner	O
.	O


Physiological	O
concentration	O
of	O
estradiol	O
inhibits	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
chemotaxis	O
via	O
a	O
receptor	O
mediated	O
system	O
.	O


The	O
receptor	O
for	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
or	O
colony-stimulating	B-protein
factor	I-protein
1	I-protein
[	O
CSF-1	B-protein
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	B-cell_type
cells	I-cell_type
and	O
placental	B-cell_type
trophoblasts	I-cell_type
.	O


Two	O
gel	B-protein
shift	I-protein
complexes	I-protein
(	O
Mono	B-protein
A	I-protein
and	O
Mono	B-protein
B	I-protein
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O


Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	B-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	O
thymocytes	B-cell_type
.	O


Treatment	O
of	O
a	O
human	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HL-60	B-cell_line
,	O
with	O
10	O
micrograms/mL	O
etoposide	O
or	O
2	O
microM	O
1-beta-D-arabinofuranosylcytosine	O
induced	O
NF-kappa	B-protein
B	I-protein
activation	O
within	O
1	O
hr	O
and	O
subsequently	O
caused	O
apoptosis	O
within	O
3-4	O
hr	O
.	O


However	O
,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	B-protein
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates	O
.	O


These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O


Two	O
groups	O
of	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
were	O
obtained	O
by	O
limiting	O
dilution	O
cloning	O
which	O
differed	O
strikingly	O
in	O
their	O
ability	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O


The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo-monocytic	B-cell_line
cells	I-cell_line
.	O


Because	O
inhibition	O
of	O
DNA-binding	O
activity	O
is	O
associated	O
with	O
increasing	O
intracellular	O
glutathione	O
disulfide	O
levels	O
and	O
GSSG	B-protein
can	O
be	O
shown	O
to	O
inhibit	O
the	O
DNA-binding	O
activity	O
directly	O
in	O
cell-free	O
systems	O
,	O
our	O
studies	O
suggest	O
that	O
GSSG	B-protein
is	O
a	O
physiologically	O
relevant	O
inhibitor	O
in	O
intact	B-cell_type
cells	I-cell_type
also	O
.	O


In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NS-Meg	B-cell_line
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O


The	O
NS-Meg	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
alpha-naphthyl	B-protein
acetate	I-protein
esterase	I-protein
and	O
periodic	O
acid-Schiff	O
(	O
PAS	O
)	O
staining	O
and	O
for	O
surface	O
CD4	B-protein
,	O
CD7	B-protein
,	O
CD13	B-protein
,	O
CD34	B-protein
,	O
CD41a	B-protein
,	O
and	O
glycophorin	B-protein
A	I-protein
antigens	I-protein
.	O


Ultrastructurally	O
,	O
the	O
cells	O
had	O
alpha-granules	O
,	O
demarcation	O
membranes	O
,	O
and	O
platelet	B-protein
peroxidase	I-protein
activity	O
.	O


Ten-day	O
exposure	O
to	O
Epo	B-protein
induced	O
mature	B-cell_type
erythroblasts	I-cell_type
and	O
red	B-cell_type
cells	I-cell_type
.	O


In	O
addition	O
to	O
activation	O
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium-independent	O
,	O
CD28	B-protein
-specific	O
pathway	O
.	O


In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross-linking	O
of	O
CD28	B-protein
(	O
but	O
not	O
CD2	B-protein
,	O
CD5	B-protein
,	O
LFA-1	B-protein
,	O
or	O
CD7	B-protein
)	O
leads	O
to	O
an	O
elevation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
,	O
with	O
only	O
minimal	O
activation	O
of	O
c-fos	B-DNA
expression	O
.	O


LTR	B-DNA
-directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	B-DNA
reporter	I-DNA
constructs	I-DNA
that	O
were	O
transiently	O
transfected	O
into	O
cultured	B-cell_line
cells	I-cell_line
.	O


In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
detected	O
without	O
intentional	O
stimulation	O
.	O


Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF-kappa	B-protein
B	I-protein
-binding	O
activity	O
in	O
blood	B-cell_type
monocytes	I-cell_type
,	O
pleural	B-cell_type
macrophages	I-cell_type
and	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O


Constitutive	O
NF-kappa	B-protein
B	I-protein
was	O
not	O
maintained	O
by	O
autocrine	O
action	O
of	O
cytokines	B-protein
TNF	B-protein
,	O
interleukin	B-protein
6	I-protein
,	O
interleukin	B-protein
10	O
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
or	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
since	O
neutralizing	O
antibodies	O
did	O
not	O
reduce	O
constitutive	O
DNA-binding	O
activity	O
.	O


The	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
the	O
cell	O
type-specific	O
regulation	O
of	O
TNF	B-protein
alpha	I-protein
is	O
not	O
known	O
.	O


Finally	O
,	O
a	O
dominant-negative	O
version	O
of	O
C/EBP	B-protein
beta	I-protein
blocked	O
TNF	B-DNA
alpha	I-DNA
promoter	I-DNA
activation	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O


Increased	O
[	O
Ca2+	O
]	O
i	O
activates	O
Ca2+/calmodulin-dependent	B-protein
kinases	I-protein
including	O
the	O
multifunctional	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
II	I-protein
(	O
CaM-K	B-protein
II	I-protein
)	O
,	O
as	O
well	O
as	O
calcineurin	B-protein
,	O
a	O
type	B-protein
2B	I-protein
protein	I-protein
phosphatase	I-protein
.	O


Recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
as	O
a	O
key	O
enzyme	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-4	O
promoter	O
activation	O
.	O


However	O
,	O
the	O
role	O
of	O
CaM-K	B-protein
II	I-protein
remains	O
unknown	O
.	O


Cotransfection	O
of	O
gamma	B-protein
B*CaM-K	I-protein
with	O
the	O
IL-2	B-DNA
promoter	I-DNA
construct	I-DNA
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O


The	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-I	B-protein
or	O
LFA-I	B-protein
in	O
4	B-cell_line
ATL	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
next	O
examined	O
.	O


Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
and	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
in	O
bovine	B-cell_type
leucocytes	I-cell_type
.	O


B-cell	B-cell_type
proliferation	O
and	O
induction	O
of	O
early	O
G1-regulating	B-protein
proteins	I-protein
by	O
Epstein-Barr	O
virus	O
mutants	O
conditional	O
for	O
EBNA2	B-protein
.	O


We	O
generated	O
conditional	O
EBV	O
mutants	O
by	O
expressing	O
EBNA2	B-protein
as	O
chimeric	B-protein
fusion	I-protein
protein	I-protein
with	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
on	O
the	O
genetic	O
background	O
of	O
the	O
virus	O
.	O


In	O
the	O
absence	O
of	O
estrogen	O
about	O
half	O
of	O
the	O
cells	O
enter	O
a	O
quiescent	O
non-proliferative	O
state	O
whereas	O
the	O
others	O
die	O
by	O
apoptosis	O
.	O


Growth	O
arrest	O
occurred	O
at	O
G1	O
and	O
G2	O
stages	O
of	O
the	O
cell	O
cycle	O
,	O
indicating	O
that	O
functional	O
EBNA2	B-protein
is	O
required	O
at	O
different	O
restriction	O
points	O
of	O
the	O
cell	O
cycle	O
.	O


These	O
data	O
suggest	O
that	O
EBV	O
is	O
using	O
a	O
common	O
pathway	O
for	O
B-cell	O
activation	O
bypassing	O
the	O
requirement	O
for	O
antigen	O
,	O
T-cell	O
signals	O
and	O
growth	B-protein
factors	I-protein
.	O


These	O
results	O
suggest	O
that	O
IL-1	B-protein
induces	O
both	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O


Antigen	O
receptor	O
signals	O
prolong	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1	B-protein
-induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
transcription	O
.	O


PCR	O
studies	O
revealed	O
that	O
CAV	O
isolates	O
from	O
across	O
the	O
world	O
all	O
contained	O
this	O
promoter	B-DNA
sequence	I-DNA
.	O


Electrophoretic	O
mobility-shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
individual	B-DNA
DR	I-DNA
units	I-DNA
,	O
as	O
well	O
as	O
the	O
12-bp	B-DNA
insert	I-DNA
,	O
can	O
bind	O
to	O
nuclear	B-protein
factors	I-protein
of	O
chicken	B-cell_type
T-cells	I-cell_type
.	O


A	O
synthetic	O
oligodeoxyribonucleotide	O
containing	O
an	O
SP1-box	B-DNA
(	O
5'-GGGCGG	O
)	O
could	O
compete	O
with	O
factors	O
binding	O
to	O
the	O
12-bp	B-DNA
insert	I-DNA
.	O


T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O


Further	O
,	O
coexpression	O
of	O
a	O
reciprocally	B-protein
mutant	I-protein
Myc	I-protein
protein	I-protein
capable	O
of	O
forming	O
functional	O
heterodimers	B-protein
with	O
the	O
mutant	O
Max	B-protein
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation-induced	O
apoptosis	O
.	O


A	O
protein	O
that	O
is	O
phosphorylated	O
on	O
a	O
tyrosine	O
residue	O
in	O
resting	B-cell_line
PBL-T	I-cell_line
suppresses	O
binding	O
of	O
a	O
component	O
of	O
Band	B-protein
A	I-protein
to	O
the	O
SRE	B-DNA
motif	I-DNA
.	O


Coexpression	O
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-137	B-DNA
to	I-DNA
-64	I-DNA
element	I-DNA
in	O
COS-7	B-cell_line
cells	I-cell_line
.	O


These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein-protein	O
and	O
protein-DNA	O
interactions	O
that	O
regulate	O
cell-type-specific	O
and	O
inducible	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O


Isolation	O
of	O
cDNA	B-DNA
clones	I-DNA
for	O
42	O
different	O
Kruppel-related	B-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
expressed	O
in	O
the	O
human	B-cell_line
monoblast	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
.	O


By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	B-DNA
clones	I-DNA
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	B-DNA
1-42	I-DNA
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O


68	O
%	O
of	O
the	O
contractions	O
were	O
also	O
one	O
or	O
two	O
repeats	O
but	O
six	O
(	O
16	O
%	O
)	O
were	O
very	O
large	O
(	O
12-25	O
repeats	O
)	O
.	O


Aspirin-like	O
drugs	O
can	O
protect	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
benzoquinone	O
cytotoxicity	O
:	O
evidence	O
for	O
a	O
NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
quinone	I-protein
reductase	I-protein
-dependent	O
mechanism	O
.	O


Molt-4	B-cell_line
cells	I-cell_line
(	O
M4	B-cell_line
)	O
,	O
a	O
human	B-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
two	O
ALD	O
,	O
flurbiprofen	O
and	O
sodium	O
diclofenac	O
,	O
and	O
then	O
exposed	O
to	O
BQ	O
.	O


A	O
cDNA	B-DNA
library	I-DNA
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	B-cell_type
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O


Thereby	O
an	O
alternative	O
type	O
of	O
La	B-RNA
mRNA	I-RNA
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	B-RNA
mRNA	I-RNA
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	B-DNA
1	I-DNA
.	O


In	O
the	O
intron	O
,	O
further	O
transcription	B-protein
factor	I-protein
binding	O
sites	O
,	O
including	O
a	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	I-protein
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O


In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
and	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	I-protein
are	O
activated	O
after	O
cross-linking	O
CD40	B-protein
on	O
resting	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
on	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
protease	O
inhibitors	O
N	O
alpha-tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
proteins	I-protein
by	O
preventing	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-protein
protein	I-protein
,	O
TF	B-RNA
mRNA	I-RNA
and	O
TF	B-protein
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O


Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
prevented	O
LPS	O
induction	O
of	O
TF	B-protein
gene	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	B-DNA
locus	I-DNA
on	O
their	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosomes	I-DNA
is	O
either	O
not	O
present	O
or	O
not	O
expressed	O
.	O


Stimulation	O
of	O
T-cells	B-cell_type
by	O
agonistic	O
anti-CD28	B-protein
antibodies	I-protein
in	O
conjunction	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR	B-protein
-derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O


Nef	B-protein
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O


Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	B-protein
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O


Activated	O
Jurkat	B-cell_line
cells	I-cell_line
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	B-DNA
genes	I-DNA
expressing	O
truncated	O
Nefs	B-protein
survived	O
,	O
which	O
rendered	O
Nef	B-protein
nonfunctional	O
.	O


Concomitant	O
with	O
this	O
loss	O
of	O
a	O
,	O
a	O
new	B-protein
Ets-1-containing	I-protein
complex	I-protein
``	O
c	B-protein
``	O
appeared	O
.	O


The	O
TNF	B-protein
alpha	I-protein
-activated	O
NF-kappa	B-protein
B	I-protein
was	O
transcriptionally	O
functional	O
.	O


Full-length	O
ERP	B-protein
expresses	O
only	O
negligible	O
DNA-binding	O
activity	O
by	O
itself	O
.	O


However	O
,	O
within	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
,	O
ERP	B-protein
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B-lymphocyte	B-cell_type
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B-cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	B-DNA
pi	I-DNA
site	I-DNA
.	O


Gene	O
for	O
a	O
tissue-specific	B-protein
transcriptional	I-protein
activator	I-protein
(	O
EBF	B-protein
or	O
Olf-1	B-protein
)	O
,	O
expressed	O
in	O
early	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
adipocytes	B-cell_type
,	O
and	O
olfactory	B-cell_type
neurons	I-cell_type
,	O
is	O
located	O
on	O
human	B-DNA
chromosome	I-DNA
5	I-DNA
,	O
band	B-DNA
q34	I-DNA
,	O
and	O
proximal	B-DNA
mouse	I-DNA
chromosome	I-DNA
11	I-DNA
.	O


Murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
adipocytes	B-cell_type
,	O
and	O
olfactory	B-cell_type
neurons	I-cell_type
contain	O
a	O
DNA-binding	B-protein
protein	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
genes	B-DNA
encoding	O
tissue-specific	O
components	O
of	O
signal	O
transduction	O
.	O


Purification	O
and	O
cloning	O
of	O
this	O
protein	O
,	O
termed	O
early	O
B-cell	B-protein
factor	I-protein
(	O
EBF	B-protein
)	O
,	O
from	O
murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
independent	O
cloning	O
of	O
a	O
protein	O
,	O
termed	O
Olf-1	B-protein
,	O
from	O
olfactory	B-cell_type
neuronal	I-cell_type
cells	I-cell_type
revealed	O
virtual	O
complete	O
amino	O
acid	O
sequence	O
identity	O
between	O
these	O
proteins	O
.	O


In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
significantly	O
augmented	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
containing	O
the	O
GM-kappa	B-DNA
B/GC-box	I-DNA
and	O
the	O
CLE0	B-DNA
(	O
AP-1/NF-AT	B-protein
)	O
.	O


Both	O
constitutively	O
active	O
forms	O
of	O
CN	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O


One	O
of	O
the	O
nuclear	B-protein
factors	I-protein
(	O
NFs	B-protein
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	B-protein
for	O
activated	B-cell_type
t	I-cell_type
cell	I-cell_type
.	O


We	O
attempted	O
to	O
determine	O
whether	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	B-DNA
sequence	I-DNA
,	O
is	O
related	O
to	O
NF-kappa	B-protein
B	I-protein
and	O
nuclear	B-protein
factor	I-protein
for	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	O
NF-AT	B-protein
)	O
.	O


J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
were	O
isolated	O
as	O
a	O
chronically	B-cell_line
infected	I-cell_line
survivor	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
following	O
infection	O
of	O
Jurkat	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
dl-NF	O
,	O
a	O
mutated	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
containing	O
a	O
deletion	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
NF-kappa	B-protein
B	I-protein
sites	O
.	O


T	B-cell_type
lymphocyte	I-cell_type
activation	O
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
production	O
require	O
at	O
least	O
two	O
signals	O
,	O
generated	O
by	O
phorbol	O
ester	O
(	O
TPA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
costimulation	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
the	O
CD28	B-protein
auxiliary	I-protein
receptor	I-protein
.	O


Hence	O
,	O
integration	O
of	O
signals	O
that	O
lead	O
to	O
T	O
cell	O
activation	O
occurs	O
at	O
the	O
level	O
of	O
JNK	B-protein
activation	O
.	O


Rat	B-cell_type
splenocytes	I-cell_type
were	O
found	O
to	O
have	O
greater	O
sensitivity	O
to	O
MPL	O
(	O
EC50	O
=	O
7.9	O
nM	O
)	O
than	O
do	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
EC50	O
=	O
28	O
nM	O
)	O
.	O


Only	O
partial	O
receptor	O
occupancy	O
accompanied	O
complete	O
lymphocyte	O
suppression	O
.	O


Function	O
of	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
invariant	I-DNA
chain	I-DNA
promoter	I-DNA
is	O
dependent	O
on	O
cell-specific	O
binding	O
of	O
different	O
NF-kappa	B-protein
B/Rel	I-protein
subunits	I-protein
.	O


Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA-binding	B-protein
complexes	I-protein
that	O
contain	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
and	O
cRel	B-protein
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	B-protein
correlates	O
with	O
negative	O
regulation	O
.	O


Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4+	B-protein
cell	O
counts	O
(	O
P	O
>	O
0.05	O
)	O
or	O
anti-EBV	O
antibody	O
titres	O
(	O
P	O
>	O
0.05	O
)	O
.	O


Anti-	O
ZEBRA	B-protein
activity	O
was	O
not	O
significantly	O
increased	O
in	O
patients	O
affected	O
with	O
ARNHL	O
,	O
the	O
cells	O
of	O
which	O
expressed	O
replicative	O
gene	O
products	O
(	O
P	O
>	O
0.05	O
)	O
.	O


CONCLUSION	O
:	O
The	O
degree	O
of	O
immunodeficiency	O
does	O
not	O
clearly	O
enhance	O
replicative	O
gene	O
expression	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
ARNHL	O
.	O


EBV	O
serology	O
,	O
including	O
anti-	O
ZEBRA	B-protein
activity	O
,	O
is	O
not	O
a	O
reliable	O
tool	O
for	O
predicting	O
the	O
occurrence	O
of	O
such	O
proliferations	O
.	O


In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF-kappa	B-protein
B	I-protein
(	I-protein
p50/p50	I-protein
)	I-protein
homodimer	I-protein
was	O
observed	O
in	O
a	O
complex	O
formed	O
with	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
in	O
unstimulated	O
SP-B21	O
cells	O
.	O


Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine/threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR-1	B-DNA
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
serine/threonine	I-protein
kinases	I-protein
,	O
pp70S6K	B-protein
and	O
pp90rsk	B-protein
.	O


Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6K	B-protein
activation	O
,	O
had	O
no	O
effect	O
on	O
induction	O
of	O
EGR-1	B-DNA
expression	O
.	O


In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	B-protein
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	B-protein
protein	I-protein
demonstrated	O
stimulation	O
of	O
this	O
kinase	B-protein
in	O
TPA-treated	B-cell_line
U-937	I-cell_line
,	I-cell_line
and	I-cell_line
not	I-cell_line
TUR	I-cell_line
,	I-cell_line
cells	I-cell_line
.	O


Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	B-protein
.	O


Gel-shift	O
analysis	O
in	O
HUVECs	B-cell_line
demonstrated	O
that	O
PDTC	O
prevented	O
NF-kappa	B-protein
B	I-protein
mobilization	O
by	O
TNF	B-protein
,	O
suggesting	O
that	O
only	O
VCAM-1	B-protein
induction	O
was	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
.	O


Inhibition	O
by	O
anti-VCAM-1	B-protein
monoclonal	I-protein
antibody	I-protein
1G11	B-protein
indicated	O
that	O
U937	B-cell_line
adhesion	O
was	O
VCAM-1	B-protein
dependent	O
and	O
suppression	O
by	O
antioxidants	O
was	O
due	O
to	O
reduced	O
VCAM-1	B-protein
induction	O
.	O


This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
therefore	O
NF-kappa	B-protein
B	I-protein
was	O
retained	O
in	O
the	O
cytosol	O
.	O


Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcription	O
from	O
the	O
Ig	B-DNA
kappa	I-DNA
enhancer	I-DNA
and	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
in	O
transfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Effects	O
of	O
the	O
antisense	O
myb	O
expression	O
on	O
hemin-	O
and	O
erythropoietin-	O
induced	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O


The	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
in	O
K562	B-cell_line
cells	I-cell_line
was	O
reduced	O
during	O
the	O
differentiation	O
induced	O
by	O
Epo	B-protein
.	O


Prenatal	O
immune	O
challenge	O
alters	O
the	O
hypothalamic-pituitary-adrenocortical	O
axis	O
in	O
adult	O
rats	O
.	O


The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	B-DNA
gene	I-DNA
in	O
cell	B-cell_line
lines	I-cell_line
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease-free	O
survival	O
.	O


The	O
gC2-	B-cell_line
and	I-cell_line
gD2-specific	I-cell_line
CD4+	I-cell_line
clones	I-cell_line
had	O
cytotoxic	O
activity	O
.	O


The	O
approximate	O
locations	O
of	O
the	O
HSV-2	O
genes	O
encoding	O
HSV-2	O
type-specific	O
CD4+	B-protein
antigens	I-protein
have	O
been	O
determined	O
by	O
using	O
HSV-1	O
x	O
HSV-2	O
intertypic	O
recombinant	O
virus	O
and	O
include	O
the	O
approximate	O
map	O
regions	O
0.30	O
to	O
0.46	O
,	O
0.59	O
to	O
0.67	O
,	O
0.67	O
to	O
0.73	O
,	O
and	O
0.82	O
to	O
1.0	O
units	O
.	O


The	O
antigenic	O
specificity	O
of	O
an	O
HLA	B-cell_line
DQ2-restricted	I-cell_line
,	I-cell_line
HSV-2	I-cell_line
type-specific	I-cell_line
T-cell	I-cell_line
clone	I-cell_line
was	O
mapped	O
to	O
amino	B-protein
acids	I-protein
425	I-protein
to	I-protein
444	I-protein
of	O
VP16	B-protein
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	B-protein
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B-protein
VP16	I-protein
fusion	I-protein
proteins	I-protein
,	O
and	O
synthetic	O
peptides	O
.	O


These	O
findings	O
suggest	O
that	O
the	O
basophils	B-cell_type
which	O
appeared	O
during	O
the	O
ATRA	O
treatment	O
are	O
reactive	O
in	O
nature	O
rather	O
than	O
a	O
leukaemic	B-cell_line
clone	I-cell_line
.	O


The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O


We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	B-protein
(	O
LAM	B-protein
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	B-cell_type
phagocytes	I-cell_type
to	O
release	O
IL-6	B-protein
in	O
a	O
dose-response	O
manner	O
.	O


We	O
conclude	O
that	O
the	O
NF-IL6	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
sites	I-DNA
mediate	O
IL-6	B-protein
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	B-protein
,	O
acting	O
as	O
bacterial	B-DNA
or	I-DNA
mycobacterial	I-DNA
response	I-DNA
elements	I-DNA
.	O


We	O
have	O
recently	O
cloned	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
and	O
demonstrated	O
its	O
tissue-specific	B-DNA
promoter	I-DNA
activity	O
.	O


Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	B-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	B-DNA
-128	I-DNA
to	I-DNA
-70	I-DNA
is	O
the	O
critical	O
region	O
for	O
the	O
induction	O
of	O
CD14	B-protein
expression	O
.	O


DNA-binding	O
and	O
transcriptional	O
regulatory	O
properties	O
of	O
hepatic	B-protein
leukemia	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
and	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
acute	B-protein
lymphoblastic	I-protein
leukemia	I-protein
chimera	I-protein
E2A-HLF	I-protein
.	O


An	O
in	O
vitro	O
binding	O
site	O
selection	O
procedure	O
was	O
used	O
to	O
determine	O
DNA	O
sequences	O
preferentially	O
bound	O
by	O
wild-type	B-protein
HLF	I-protein
and	O
chimeric	B-protein
E2A-HLF	I-protein
proteins	O
isolated	O
from	O
various	O
t	B-cell_line
(	I-cell_line
17	I-cell_line
;	I-cell_line
19	I-cell_line
)	I-cell_line
-bearing	I-cell_line
leukemias	I-cell_line
.	O


All	O
were	O
found	O
to	O
selectively	O
bind	O
the	O
consensus	B-DNA
sequence	I-DNA
5'-GTTACGTAAT-3	O
'	O
with	O
high	O
affinity	O
.	O


Lipopolysaccharide	O
induction	O
of	O
tissue	B-DNA
factor	I-DNA
gene	I-DNA
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
.	O


Tenascin	B-protein
(	O
TN	B-protein
)	O
is	O
an	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O


We	O
show	O
here	O
that	O
soluble	O
TN	B-protein
inhibits	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
alpha	B-protein
CD3	I-protein
Ab	I-protein
co-immobilized	O
with	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
fibronectin	B-protein
(	O
FN	B-protein
)	O
.	O


Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
leading	O
to	O
expression	O
of	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
mRNA	I-RNA
.	O


We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free-radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	B-cell_line
cells	I-cell_line
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	B-cell_line
cells	I-cell_line
.	O


This	O
allows	O
us	O
to	O
characterize	O
these	O
two	O
granule	O
populations	O
with	O
regard	O
to	O
their	O
content	O
of	O
membrane	B-protein
proteins	I-protein
,	O
which	O
become	O
incorporated	O
into	O
the	O
plasma	O
membrane	O
during	O
exocytosis	O
.	O


We	O
found	O
that	O
gelatinase	O
granules	O
,	O
defined	O
as	O
peroxidase-negative	O
granules	O
containing	O
gelatinase	B-protein
but	O
lacking	O
lactoferrin	B-protein
,	O
contain	O
50	O
%	O
of	O
total	O
cell	O
gelatinase	B-protein
,	O
with	O
the	O
remaining	O
residing	O
in	O
specific	O
granules	O
.	O


Although	O
no	O
qualitative	O
difference	O
was	O
observed	O
between	O
specific	O
granules	O
and	O
gelatinase	B-protein
granules	O
with	O
respect	O
to	O
cytochrome	B-protein
b558	I-protein
and	O
Mac-1	B-protein
,	O
stimulation	O
of	O
the	O
neutrophil	B-cell_type
with	O
FMLP	B-protein
resulted	O
in	O
a	O
selective	O
mobilization	O
of	O
the	O
least	O
dense	O
peroxidase-negative	O
granules	O
,	O
ie	O
,	O
gelatinase	B-protein
granules	O
,	O
which	O
,	O
in	O
concert	O
with	O
secretory	O
vesicles	O
,	O
furnish	O
the	O
plasma	O
membrane	O
with	O
Mac-1	B-protein
and	O
cytochrome	B-protein
b558	I-protein
.	O


The	O
regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
expression	O
and	O
nuclear	B-protein
factor	I-protein
(	O
NF	O
)	O
activation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
has	O
been	O
studied	O
.	O


Binding	O
of	O
superantigens	O
to	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O


We	O
demonstrate	O
that	O
the	O
staphylococcal	B-protein
superantigens	I-protein
toxic	B-protein
shock	I-protein
syndrome	I-protein
toxin-1	I-protein
(	O
TSST-1	B-protein
)	O
and	O
staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
(	O
SEA	B-protein
)	O
activate	O
HIV-1-LTR	B-DNA
-driven	O
transcription	O
of	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
.	O


Induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
superantigens	B-protein
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
.	O


By	O
contrast	O
,	O
many	O
studies	O
have	O
reported	O
that	O
mitogen	B-protein
activation	O
of	O
T	B-cell_type
cells	I-cell_type
increases	O
cAMP	O
levels	O
,	O
implying	O
a	O
positive	O
physiological	O
role	O
for	O
cAMP	O
in	O
the	O
activation	O
process	O
.	O


Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
alpha-tcp	O
effect	O
since	O
no	O
suppression	O
of	O
phosphorylation	O
of	O
PKC	B-protein
substrates	O
was	O
observed	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
failed	O
to	O
show	O
an	O
alpha-tcp-induced	O
decrease	O
in	O
activation	O
of	O
this	O
transcription	B-protein
factor	I-protein
after	O
cytokine	B-protein
stimulation	O
.	O


Tat	B-protein
transactivation	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B-DNA
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	B-cell_type
.	O


The	O
novel	O
astrocyte-derived	O
kappa	O
B-binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV-1	O
Tat	B-protein
affinity	O
column	O
,	O
while	O
prototypical	O
NF-kappa	B-protein
B	I-protein
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
is	O
not	O
.	O


Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O


Expression	O
of	O
the	O
beta	B-DNA
2-integrin	I-DNA
genes	I-DNA
,	O
CD11a	B-DNA
and	O
CD11b	B-DNA
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O


Their	O
effects	O
on	O
the	O
src-family	B-DNA
tyrosine	I-DNA
kinase	I-DNA
genes	I-DNA
were	O
different	O
:	O
hck	B-DNA
expression	O
was	O
similarly	O
induced	O
by	O
these	O
agents	O
but	O
lyn	O
expression	O
was	O
stronger	O
and	O
more	O
rapid	O
after	O
RA	O
treatment	O
.	O


As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v-abl	B-protein
protein	I-protein
also	O
suppresses	O
the	O
activity	O
of	O
NF-kappa	B-protein
B/rel	I-protein
and	O
expression	O
controlled	O
by	O
the	O
kappa	B-DNA
intron	I-DNA
enhancer	I-DNA
.	O


The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium-dependent	O
signal	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
that	O
normally	O
leads	O
to	O
T-cell	O
activation	O
.	O


Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	B-cell_type
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL-3	B-DNA
,	I-DNA
GM-CSF	I-DNA
,	I-DNA
FMS	I-DNA
and	I-DNA
EGR-1	I-DNA
genes	I-DNA
which	O
are	O
all	O
located	O
on	O
the	O
long	B-DNA
arm	I-DNA
of	I-DNA
chromosome	I-DNA
5	I-DNA
.	O


A	O
novel	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
,	O
HB9	B-DNA
,	O
was	O
isolated	O
from	O
a	O
cDNA	B-DNA
library	I-DNA
prepared	O
from	O
in	O
vitro	B-cell_type
stimulated	I-cell_type
human	I-cell_type
tonsil	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
from	O
a	O
human	B-DNA
genomic	I-DNA
library	I-DNA
.	O


The	O
predicted	O
HB9	B-protein
protein	I-protein
has	O
a	O
molecular	O
mass	O
of	O
41	O
kilodaltons	O
and	O
is	O
enriched	O
for	O
alanine	O
,	O
glycine	O
,	O
and	O
leucine	O
.	O


HB9	B-RNA
RNA	I-RNA
transcripts	I-RNA
were	O
most	O
prevalent	O
in	O
several	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
.	O


Restriction	O
mapping	O
shows	O
that	O
the	O
transcription	B-DNA
unit	I-DNA
spans	O
approximately	O
35	O
kilobases	O
.	O


A	O
transcription	O
start	O
site	O
is	O
located	O
approximately	O
4	O
kilobases	O
5	O
'	O
to	O
the	O
translation	B-DNA
initiation	I-DNA
codon	I-DNA
,	O
and	O
an	O
RNA	O
splice	O
of	O
3863	O
bases	O
occurs	O
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
to	O
generate	O
mature	B-RNA
HeLa	I-RNA
cell	I-RNA
mRNA	I-RNA
.	O


CD38	B-protein
is	O
a	O
leukocyte	B-protein
differentiation	I-protein
antigen	I-protein
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T-	B-cell_type
and	I-cell_type
B-	I-cell_type
lymphocytes	I-cell_type
.	O


In	O
myeloid	B-cell_type
cells	I-cell_type
,	O
CD38	B-protein
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O


Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
--	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha-tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5-lipoxygenase	O
inhibitor	O
zileuton	O
--	O
did	O
not	O
affect	O
the	O
production	O
of	O
these	O
cytokines	B-protein
.	O


THP	O
and	O
DHA	O
markedly	O
decreased	O
the	O
levels	O
of	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O


Coordinate	O
inhibition	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
inflammatory	O
cytokines	B-protein
could	O
provide	O
a	O
strategy	O
for	O
therapy	O
of	O
diseases	O
with	O
inflammatory	O
pathogenesis	O
and	O
for	O
septic	O
shock	O
.	O


It	O
plays	O
an	O
important	O
role	O
in	O
modulating	O
the	O
balance	O
of	O
T	B-cell_type
helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
cell	I-cell_type
subsets	I-cell_type
,	O
favoring	O
expansion	O
of	O
the	O
Th2	B-cell_type
lineage	I-cell_type
relative	O
to	O
Th1	B-cell_type
.	O


This	O
protein	O
has	O
now	O
been	O
purified	O
and	O
its	O
encoding	O
gene	O
cloned	O
.	O


Study	O
of	O
the	O
inhibitory	O
activities	O
of	O
phosphotyrosine-containing	O
peptides	O
derived	O
from	O
the	O
intracellular	B-protein
domain	I-protein
of	I-protein
the	I-protein
IL-4	I-protein
receptor	I-protein
provided	O
evidence	O
for	O
direct	O
coupling	O
of	O
receptor	B-protein
and	O
transcription	B-protein
factor	I-protein
during	O
the	O
IL-4	B-protein
Stat	I-protein
activation	O
cycle	O
.	O


Such	O
observations	O
indicate	O
that	O
IL-4	B-protein
Stat	I-protein
has	O
the	O
same	O
functional	B-protein
domain	I-protein
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O


For	O
safety	O
reasons	O
,	O
the	O
Ad	O
vectors	O
are	O
rendered	O
replication	O
deficient	O
by	O
deletion	O
of	O
the	O
E1a	B-DNA
region	I-DNA
.	O


Because	O
there	O
is	O
the	O
theoretical	O
possibility	O
of	O
an	O
E1a-	O
replication-deficient	O
vector	O
replicating	O
as	O
a	O
result	O
of	O
recombination	O
or	O
complementation	O
with	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
present	O
in	O
the	O
target	O
cell	O
,	O
this	O
study	O
is	O
directed	O
toward	O
evaluating	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
for	O
the	O
presence	O
of	O
E1a	O
sequences	O
.	O


These	O
results	O
demonstrate	O
that	O
there	O
are	O
detectable	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
of	O
a	O
small	O
percentage	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
.	O


Because	O
of	O
the	O
theoretical	O
potential	O
of	O
such	O
sequences	O
supporting	O
replication	O
of	O
E1a-	O
Ad	O
vectors	O
,	O
human	O
gene	O
therapy	O
protocols	O
for	O
CF	O
utilizing	O
such	O
vectors	O
should	O
consider	O
evaluating	O
study	O
individuals	O
for	O
the	O
presence	O
of	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
.	O


Leiomyosarcoma	O
of	O
the	O
vulva	O
:	O
report	O
of	O
a	O
case	O
.	O


Pathological	O
evaluation	O
revealed	O
a	O
high-grade	O
vulvar	O
leiomyosarcoma	O
.	O


In	O
an	O
effort	O
to	O
better	O
understand	O
the	O
biology	O
of	O
this	O
tumor	O
additional	O
immunohistochemical	O
studies	O
for	O
the	O
protein	B-protein
product	I-protein
of	O
p53	B-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
and	O
estrogen	B-protein
receptor	I-protein
expression	O
by	O
tumor	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
the	O
type	O
of	O
immune	B-cell_type
cells	I-cell_type
infiltrating	O
the	O
tumor	O
were	O
performed	O
.	O


The	O
DNA	B-protein
binding	I-protein
protein	I-protein
NF-kB	I-protein
is	O
a	O
central	O
mediator	O
in	O
cytokine	B-protein
activation	O
of	O
HIV	O
transcription	O
.	O


L227	B-protein
induced	O
an	O
increase	O
in	O
intracellular	O
free	O
Ca2+	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
from	O
the	O
intracellular	O
pool	O
and	O
little	O
or	O
no	O
protein	O
tyrosine	O
phosphorylation	O
,	O
phosphatidyl	O
inositol	O
turnover	O
,	O
or	O
expression	O
of	O
Egr-1	B-RNA
mRNA	I-RNA
,	O
whereas	O
2.06	B-protein
plus	O
GAM	B-protein
induced	O
an	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
from	O
both	O
the	O
intracellular	O
and	O
,	O
in	O
particular	O
,	O
the	O
extracellular	O
pools	O
.	O


These	O
parameters	O
were	O
examined	O
in	O
normal	O
and	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
and	O
compared	O
with	O
1	B-cell_line
alpha	I-cell_line
,	I-cell_line
25-	I-cell_line
(	I-cell_line
OH	I-cell_line
)	I-cell_line
2D3-responsive	I-cell_line
cells	I-cell_line
of	O
the	O
T	B-cell_type
and	I-cell_type
monocytic	I-cell_type
lineages	I-cell_type
.	O


1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O


Furthermore	O
,	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induced	O
24-hydroxylase	B-protein
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	B-cell_line
cells	I-cell_line
and	O
lectin-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
yet	O
failed	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	I-RNA
or	O
its	O
metabolic	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
.	O


Positive	O
and	O
negative	O
regulation	O
of	O
IL-2	B-protein
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O


Interleukin	O
2	O
(	O
IL-2	B-protein
)	O
is	O
an	O
important	O
lymphokine	B-protein
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O


Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
different	O
T	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
the	O
distal	B-DNA
purine	I-DNA
box	I-DNA
(	O
-291	B-DNA
to	I-DNA
-277	I-DNA
)	O
and	O
the	O
proximal	B-DNA
purine	I-DNA
box	I-DNA
sites	I-DNA
(	O
-145	B-DNA
to	I-DNA
-128	I-DNA
)	O
.	O


In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	B-protein
B-like	I-protein
site	I-protein
binding	I-protein
complexes	I-protein
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	B-protein
against	O
the	O
human	B-protein
Rel	I-protein
family	I-protein
proteins	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
,	O
p50	B-protein
,	O
and	O
p49	B-protein
)	O
.	O


The	O
presence	O
of	O
androgen	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
provides	O
for	O
the	O
first	O
time	O
the	O
experimental	O
basis	O
for	O
an	O
hypothesis	O
of	O
direct	O
,	O
receptor-mediated	O
effects	O
of	O
androgens	O
on	O
mature	B-cell_type
immunocompetent	I-cell_type
cells	I-cell_type
.	O


MHC	B-protein
class	I-protein
II	I-protein
signaling	O
in	O
B-cell	B-cell_type
activation	O
[	O
see	O
comments	O
]	O


MHC	B-protein
class	I-protein
II	I-protein
molecules	O
also	O
serve	O
as	O
receptors	O
for	O
B-cell	B-cell_type
stimulation	O
by	O
microbial	B-protein
superantigens	I-protein
.	O


Lymphocytes	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
have	O
diminished	O
receptor	O
density	O
;	O
thus	O
,	O
patients	O
with	O
RA	O
should	O
show	O
partial	O
resistance	O
to	O
glucocorticoids	O
.	O


We	O
determined	O
the	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	B-cell_type
proliferation	O
and	O
cytokine	B-protein
release	O
.	O


Arrested	O
development	O
:	O
understanding	O
v-abl	B-DNA
.	O


A	O
similarity	O
has	O
recently	O
been	O
found	O
between	O
the	O
regulation	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
brain	O
and	O
in	O
lymphoid	O
tissue	O
.	O


We	O
observed	O
that	O
RA	O
did	O
not	O
induced	O
neutrophil	O
differentiation	O
in	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
whereas	O
50	O
nM	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induced	O
maximal	O
monocyte	O
differentiation	O
.	O


[	O
An	O
overexpression	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
blocks	O
myeloid	B-cell_type
cell	I-cell_type
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O


To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	B-protein
alpha	I-protein
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	B-protein
RAR	I-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha	I-protein
)	O
into	O
murine	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	B-DNA
resistant	I-DNA
marker	I-DNA
(	O
Neo	B-DNA
(	I-DNA
r	I-DNA
)	I-DNA
)	O
cultured	O
on	O
the	O
stroma	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
PA6-neo	B-cell_line
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	B-cell_type
cells	I-cell_type
.	O


Most	O
cells	O
infected	O
with	O
hRAR	B-protein
alpha	I-protein
exhibited	O
promyelocytic	B-cell_type
morphology	I-cell_type
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O


Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	B-cell_type
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	B-RNA
for	O
macrophage	B-protein
chemotactic	I-protein
protein-1	I-protein
,	O
another	O
member	O
of	O
the	O
chemokine	B-protein
superfamily	I-protein
of	O
proinflammatory	B-protein
cytokines	I-protein
.	O


IL-8	B-DNA
gene	I-DNA
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	B-cell_type
ECs	I-cell_type
for	O
the	O
NF-kB	O
site	O
.	O


Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O


Thrombin	B-protein
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O


The	O
magnitude	O
of	O
the	O
thrombin	B-protein
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
.	O


We	O
found	O
that	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
a	O
combination	O
of	O
phytohemagglutinin	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B-protein
response	O
.	O


The	O
induction	O
of	O
the	O
AP-1	B-protein
transcription	B-protein
factor	I-protein
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
lymphocyte	O
activation	O
.	O


Wortmannin	O
,	O
an	O
inhibitor	O
of	O
receptor-coupled	O
PLD	B-protein
activation	O
,	O
blocked	O
the	O
anti-CD3	B-protein
-induced	O
increases	O
in	O
both	O
PLD	B-protein
activity	O
and	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O


Furthermore	O
,	O
ethanol	O
,	O
an	O
inhibitor	O
of	O
the	O
PLD	B-protein
pathway	O
,	O
blocked	O
the	O
anti-CD3-stimulated	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O


Furthermore	O
,	O
the	O
PA	O
-and	O
the	O
anti-CD3	B-protein
-induced	O
increases	O
in	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
were	O
blocked	O
by	O
the	O
presence	O
of	O
PKC	B-protein
inhibitors	O
or	O
by	O
PKC	B-protein
down-regulation	O
.	O


These	O
data	O
also	O
provide	O
evidence	O
for	O
a	O
role	O
of	O
PLD	B-protein
-derived	O
lipids	O
in	O
the	O
induction	O
of	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
resulting	O
from	O
stimulation	O
of	O
the	O
TCR/CD3	B-protein
complex	I-protein
,	O
suggesting	O
that	O
increased	O
PLD	B-protein
activity	O
can	O
play	O
an	O
important	O
role	O
in	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
.	O


To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
activity	O
in	O
the	O
nucleus	O
after	O
anti-CD3	B-protein
stimulation	O
.	O


Thus	O
,	O
NF-AT	B-protein
induction	O
and	O
IL-2	B-protein
secretion	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	O
with	O
gross	O
levels	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
induced	O
late	O
following	O
the	O
response	O
.	O


Although	O
two	O
cases	O
expressed	O
CD4	B-protein
,	O
no	O
case	O
expressed	O
CD2	B-protein
,	O
CD3	B-protein
,	O
or	O
CD8	B-protein
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
beta	I-protein
,	I-protein
gamma	I-protein
,	I-protein
delta	I-protein
)	O
.	O


IL-4	B-protein
down-regulates	O
IL-2	B-protein
-	O
,	O
IL-3	B-protein
-	O
,	O
and	O
GM-CSF	B-protein
-induced	O
cytokine	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O


Temporal	O
analysis	O
of	O
the	O
IL-4	B-protein
down-regulatory	O
effect	O
on	O
the	O
IL-2-	O
,	O
IL-3-	O
,	O
or	O
GM-CSF-induced	O
proinflammatory	O
cytokine	O
gene	O
expression	O
in	O
monocytes	B-cell_type
provided	O
evidence	O
that	O
IL-4	B-protein
acts	O
predominantly	O
on	O
the	O
post-transcriptional	O
level	O
.	O


In	O
the	O
primary	B-cell_type
cells	I-cell_type
MDHM-induced	O
elevation	O
of	O
cytokine	B-RNA
mRNA	I-RNA
levels	O
was	O
preceded	O
by	O
a	O
downregulation	O
of	O
c-fos	B-DNA
expression	O
while	O
positive	O
c-jun	B-DNA
expression	O
was	O
not	O
modulated	O
.	O


This	O
aldosterone-selectivity	O
is	O
typical	O
and	O
discriminatory	O
for	O
the	O
new	O
aldosterone	B-protein
membrane	I-protein
receptor	I-protein
.	O


Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
proteins	I-protein
within	O
this	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O


A	O
GC	B-DNA
box	I-DNA
containing	O
a	O
binding	B-DNA
site	I-DNA
for	O
Sp1	B-protein
was	O
identified	O
(	O
nt	B-DNA
4623	I-DNA
to	I-DNA
4631	I-DNA
)	O
.	O


Expression	O
of	O
v-src	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


trans-activation	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
by	O
a	O
cDNA	O
and	O
its	O
genomic	O
clones	O
of	O
human	O
herpesvirus-6	O
.	O


Sequence	O
analyses	O
of	O
pCD41	B-DNA
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
,	O
A	B-DNA
and	O
B	B-DNA
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	B-DNA
found	O
in	O
the	O
genomic	O
clone	O
pGD41	B-DNA
.	O


Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/	O
CD14	B-protein
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
demonstrating	O
that	O
NF-kappa	B-protein
B	I-protein
translocation	O
is	O
an	O
early	O
event	O
.	O


Although	O
TK	O
activity	O
was	O
consistently	O
observed	O
by	O
immunoblotting	O
extracts	O
from	O
activated	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
LPS-induced	O
phosphotyrosine	O
residues	O
were	O
not	O
observed	O
from	O
similarly	O
treated	O
CHO/CD14	B-cell_line
cells	I-cell_line
.	O


Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/CD14	B-cell_line
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS-induced	O
TK	O
activity	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
.	O


These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14	B-protein
-mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O


Cytosols	O
were	O
prepared	O
from	O
lymphocytes	O
of	O
24	O
healthy	O
pregnant	O
women	O
(	O
11	O
first	O
,	O
10	O
second	O
and	O
three	O
third	O
trimester	O
)	O
,	O
seven	O
healthy	O
non-pregnant	O
women	O
,	O
nine	O
women	O
with	O
recurrent	O
spontaneous	O
abortion	O
,	O
and	O
six	O
healthy	O
men	O
.	O


Lymphocytes	B-cell_type
of	O
non-pregnant	O
women	O
,	O
women	O
with	O
threatened	O
pre-term	O
delivery	O
,	O
and	O
men	O
showed	O
equivalent	O
levels	O
:	O
3	O
+/-	O
1	O
,	O
3	O
+/-	O
2	O
and	O
5	O
+/-	O
4	O
fmol/mg	O
respectively	O
.	O


In	O
nuclear	O
run-on	O
analysis	O
,	O
such	O
tolerant	B-cell_type
cells	I-cell_type
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O


Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post-receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O


More	O
frequent	O
use	O
of	O
the	O
classical	O
Oct2a	B-protein
and	O
Oct2b	B-protein
isoforms	O
was	O
observed	O
in	O
the	O
lipopolysaccharide-stimulated	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
a	O
preference	O
for	O
the	O
Oct2ab	B-protein
and	O
Oct2ba	B-protein
isoforms	O
was	O
observed	O
in	O
lipopolysaccharide	B-cell_line
plus	I-cell_line
phorbol-di-butyrate-treated	I-cell_line
cells	I-cell_line
.	O


We	O
show	O
here	O
that	O
proerythroblasts	B-cell_type
and	O
mature	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	O
activation	O
of	O
GATA-1	B-protein
and	O
that	O
this	O
activity	O
decreases	O
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	B-cell_type
cells	I-cell_type
.	O


Analysis	O
of	O
truncated	O
LTRs	B-DNA
confirmed	O
that	O
inhibition	O
of	O
LTR	B-DNA
activation	O
was	O
not	O
mediated	O
through	O
NF-kappa	B-protein
B	I-protein
-binding	O
activity	O
but	O
through	O
the	O
region	O
containing	O
the	O
negative	B-DNA
responding	I-DNA
elements	I-DNA
(	O
NREs	B-DNA
)	O
.	O


Tat-binding	B-protein
protein	I-protein
7	I-protein
is	O
a	O
subunit	O
of	O
the	O
26S	B-protein
protease	I-protein
.	O


In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
are	O
overexpressed	O
in	O
HTLV-I	O
infected	O
and	O
Tax-expressing	B-cell_type
cells	I-cell_type
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O


The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
in	O
B104	B-cell_line
cells	I-cell_line
is	O
discussed	O
.	O


We	O
have	O
investigated	O
the	O
effects	O
of	O
acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
on	O
the	O
LPS-induced	O
synthesis	O
of	O
the	O
pro-coagulant	O
protein	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
the	O
pro-inflammatory	O
protein	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	B-protein
)	O
,	O
as	O
well	O
as	O
the	O
prostaglandin	B-protein
PGE2	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


Both	O
drugs	O
dose-dependently	O
inhibited	O
LPS-induced	B-protein
TF	I-protein
and	O
TNF-alpha	B-protein
synthesis	O
at	O
the	O
mRNA	B-RNA
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	B-protein
production	O
.	O


Neutral	B-protein
sphingomyelinase	I-protein
(	O
SMase	B-protein
)	O
can	O
be	O
activated	O
by	O
extracellular	O
signals	O
to	O
produce	O
ceramide	O
,	O
which	O
may	O
affect	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
activities	O
.	O


PMA	O
,	O
but	O
not	O
Ara-C	O
or	O
ceramides	O
,	O
activated	O
ERK	B-protein
MAPKS	I-protein
,	O
in	O
Jurkat	B-cell_line
and	O
EL4	B-cell_line
.	O


Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B-lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O


We	O
have	O
cloned	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	I-protein
LMP1	I-protein
)	I-protein
homologs	I-protein
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O


Nevertheless	O
,	O
the	O
simian	B-protein
EBV	I-protein
LMP1s	I-protein
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B-protein
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
activity	O
in	O
human	B-cell_type
cells	I-cell_type
,	O
to	O
bind	O
the	O
tumor	B-protein
necrosis	I-protein
factor-associated	I-protein
factor	I-protein
3	I-protein
(	O
TRAF3	B-protein
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor-responsive	I-DNA
genes	I-DNA
,	O
such	O
as	O
ICAM1	B-DNA
,	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


Chromosome	B-DNA
1	I-DNA
aneusomy	O
with	O
1p36	B-DNA
under-representation	O
is	O
related	O
to	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
high	O
c-erb	B-protein
B-2	I-protein
and	O
loss	O
of	O
bcl-2	B-DNA
expression	O
in	O
ductal	O
breast	O
carcinoma	O
.	O


No	O
correlation	O
between	O
chromosome	B-DNA
1	I-DNA
alterations	O
and	O
nuclear	O
grade	O
,	O
age	O
,	O
size	O
,	O
lymph-node	O
involvement	O
,	O
hormonal	O
receptor	O
presence	O
,	O
proliferation	O
activity	O
or	O
p53	B-protein
protein	O
expression	O
was	O
detected	O
.	O


A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	B-protein
cytokine	I-protein
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O


Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
could	O
be	O
enhanced	O
by	O
co-stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O


However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O


Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	B-DNA
encoding	O
the	O
TATA-box	B-protein
binding	I-protein
protein	I-protein
(	O
TBP	B-protein
)	O
,	O
TFIIB	B-protein
,	O
TFIIE	B-protein
alpha	I-protein
,	O
TFIIE	B-protein
beta	I-protein
,	O
RAP30	B-protein
,	O
RAP74	B-protein
and	O
the	O
62	B-protein
kDa	I-protein
subunit	I-protein
,	O
of	O
TFIIH	B-protein
are	O
located	O
at	O
the	O
human	B-DNA
chromosomal	I-DNA
bands	I-DNA
6q26-27	I-DNA
,	I-DNA
1p21-22	I-DNA
,	I-DNA
3q21-24	I-DNA
,	I-DNA
8p12	I-DNA
,	I-DNA
13q14	I-DNA
,	I-DNA
19p13.3	I-DNA
and	I-DNA
11p14-15.1	I-DNA
,	O
respectively	O
.	O


Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL-6	B-protein
gene	I-protein
product	I-protein
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL-6	B-protein
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O


Furthermore	O
,	O
the	O
BCL-6	B-protein
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	B-cell_type
clone	I-cell_type
with	O
sensitive	O
PCR-based	O
techniques	O
.	O


Studies	O
of	O
pluripotent	B-cell_line
islet	I-cell_line
cultures	I-cell_line
.	O


Generation	O
of	O
CD1+RelB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
and	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
from	O
human	B-cell_type
monocytes	I-cell_type
.	O


However	O
,	O
the	O
monocyte-derived	B-cell_line
DC	I-cell_line
were	O
not	O
terminally	B-cell_line
differentiated	I-cell_line
cells	I-cell_line
;	O
they	O
could	O
still	O
convert	O
to	O
macrophages	B-cell_type
in	O
response	O
to	O
M-CSF	B-protein
.	O


Rather	O
,	O
IFN-gamma	B-protein
antagonized	O
the	O
effect	O
of	O
IL-4	B-protein
and	O
suppressed	O
the	O
DC	B-cell_type
and	O
MGC	B-cell_type
formation	O
induced	O
by	O
GM-CSF	B-protein
+	O
IL-4	B-protein
and	O
M-CSF	B-protein
+	O
IL-4	B-protein
,	O
respectively	O
.	O


While	O
Jurkat	B-cell_line
cells	I-cell_line
co-expressed	O
two	O
discrete	O
cell-surface	B-protein
isoforms	I-protein
of	O
CD43	B-protein
,	O
recognized	O
by	O
mAb	B-protein
J393	I-protein
and	O
mAb	B-protein
G10-2	I-protein
,	O
respectively	O
,	O
only	O
J393/CD43	B-protein
signaled	O
apoptosis	O
.	O


Sterol	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	B-DNA
coding	O
for	O
especially	O
low	B-protein
density	I-protein
lipoprotein	I-protein
(	I-protein
LDL	I-protein
)	I-protein
-receptor	I-protein
,	O
3-hydroxy-3-methylglutaryl	B-protein
coenzyme	I-protein
A	I-protein
(	I-protein
HMG-CoA	I-protein
)	I-protein
reductase	I-protein
and	O
HMG-CoA	B-protein
synthase	I-protein
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O


Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
alpha-interferon	B-protein
through	O
its	O
receptor	O
initiates	O
phosphatidic	O
acid	O
dependent	O
signalling	O
which	O
in	O
turn	O
regulates	O
the	O
affinity	O
of	O
47	B-protein
kDa	I-protein
sterol	I-protein
regulatory	I-protein
element	I-protein
binding	I-protein
factor	I-protein
as	O
well	O
as	O
LDL-receptor	B-DNA
gene	I-DNA
transcription	O
in	O
lymphocytes	B-cell_type
from	O
CML	O
patients	O
.	O


In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B-protein
weight	I-protein
species	I-protein
of	I-protein
24	I-protein
and	I-protein
22	I-protein
kDa	I-protein
.	O


In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	B-protein
protein	I-protein
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell-specific	O
manner	O
.	O


Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T-cell	B-cell_type
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
.	O


Contrary	O
to	O
the	O
idea	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
in	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF-kappaB	B-protein
by	O
PHA	B-protein
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O


The	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
was	O
also	O
dependent	O
on	O
a	O
Ca2+	O
influx	O
,	O
because	O
the	O
Ca2+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2+	O
influx	O
,	O
inhibited	O
NF-kappaB	B-protein
activation	O
.	O


Two	O
multicopy	B-DNA
basal	I-DNA
enhancer	I-DNA
motifs	I-DNA
within	O
the	O
SCMV	O
MIE	B-DNA
enhancer	I-DNA
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	B-DNA
response	I-DNA
factor	I-DNA
(	I-DNA
SRF	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
referred	O
to	O
as	O
the	O
SNE	B-DNA
(	O
SRF/NFkappaB-like	B-DNA
element	I-DNA
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	B-cell_type
and	I-cell_type
T-cell	I-cell_type
types	I-cell_type
.	O


The	O
TAL-1	B-DNA
gene	I-DNA
specifies	O
for	O
a	O
basic	O
domain-helix-loop-helix	B-protein
protein	I-protein
,	O
which	O
is	O
involved	O
in	O
the	O
control	O
of	O
normal	O
hematopoiesis	O
.	O


In	O
human	O
pathology	O
,	O
the	O
TAL-1	B-protein
gene	I-protein
product	I-protein
is	O
expressed	O
in	O
a	O
high	O
percentage	O
of	O
T-cell	B-cell_type
acute	O
lymphoblastic	O
leukemias	O
in	O
the	O
pediatric	O
age	O
range	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
established	O
whether	O
the	O
expression	O
has	O
a	O
causal	O
role	O
in	O
oncogenesis	O
.	O


To	O
further	O
unravel	O
the	O
tal-1	B-DNA
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal-1	B-DNA
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53-/-	O
mice	O
;	O
the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one-half	O
when	O
compared	O
with	O
that	O
of	O
tal-1	B-DNA
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T-cell	B-cell_type
lymphomas	O
.	O


TSC2	B-RNA
messenger	I-RNA
RNA	I-RNA
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	B-cell_type
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O


Fas	B-protein
-mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


To	O
examine	O
the	O
behavior	O
of	O
Bcl-2	B-protein
in	O
normal	B-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
were	O
transiently	O
transfected	O
with	O
Bcl-2	B-protein
and	O
related	O
gene	B-protein
products	I-protein
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O


Expression	O
of	O
Bcl-xL	B-protein
and	O
adenovirus	B-protein
E1B	I-protein
19K	I-protein
did	O
not	O
interfere	O
with	O
anti-	O
Fas	B-protein
killing	O
.	O


In	O
contrast	O
,	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac-DEVD-CHO	O
and	O
CrmA	O
blocked	O
Fas	B-protein
-mediated	O
apoptosis	O
.	O


In	O
addition	O
,	O
EL-4	B-cell_type
cells	I-cell_type
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O


Taken	O
together	O
,	O
cipro	O
inhibited	O
IFN-gamma	B-protein
synthesis	O
,	O
but	O
enhanced	O
IL-2	B-protein
production	O
in	O
murine	B-cell_type
lymphocytes	I-cell_type
by	O
means	O
of	O
influencing	O
NFAT-1	B-protein
and	O
causing	O
an	O
increased	O
IL-2	B-protein
transcription	O
.	O


Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T-cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	B-cell_line
human	I-cell_line
CD4	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	B-protein
factors	I-protein
(	O
MyoD	B-protein
,	O
myogenin	B-protein
,	O
myf5	B-protein
,	O
and	O
myf6	B-protein
)	O
that	O
are	O
``	B-protein
basic	I-protein
helix-loop-helix	I-protein
''	I-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
promoters	B-DNA
of	O
muscle-specific	B-DNA
genes	I-DNA
and	O
promote	O
their	O
expression	O
.	O


We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	B-protein
binding	I-protein
basic	I-protein
domain	I-protein
of	O
MyoD	B-protein
confers	O
c-myc	B-DNA
-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O


In	O
this	O
study	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O


Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	B-protein
transcription	I-protein
factors	I-protein
.	O


We	O
then	O
generated	O
new	O
donor	O
anti-pml/RAR-alpha	B-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
.	O


These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1/25	O
.	O


Since	O
APL	B-cell_line
cells	I-cell_line
do	O
not	O
express	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1/9	O
)	O
would	O
generate	O
a	O
CD8	B-protein
/HLA	B-protein
class	I-protein
I	I-protein
-restricted	O
response	O
.	O


The	O
CpG	O
dinucleotide	O
in	O
this	O
element	B-DNA
is	O
selectively	O
methylated	O
in	O
Th2	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
other	O
cells	O
that	O
do	O
not	O
express	O
IFN-gamma	B-protein
,	O
and	O
methylation	O
markedly	O
reduces	O
transcription	B-protein
factor	I-protein
binding	O
.	O


CD40	B-protein
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti-IgM	B-protein
stimulation	O
of	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-protein
.	O


In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	B-protein
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel/nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
factors	I-protein
in	O
primary	B-cell_type
murine	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


We	O
show	O
that	O
triggering	O
of	O
CD40	B-protein
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	B-protein
ligands	I-protein
expressed	O
on	O
L	B-cell_type
cells	I-cell_type
led	O
to	O
strong	O
activation	O
of	O
an	O
NF-kappaB-controlled	B-DNA
beta-globin	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
from	O
transgenic	O
mice	O
.	O


Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	B-protein
proteins	I-protein
after	O
CD40	B-protein
induction	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
showed	O
a	O
strong	O
and	O
long-lasting	O
accumulation	O
of	O
RelB	B-protein
and	O
,	O
less	O
pronounced	O
,	O
of	O
c-Rel	B-protein
.	O


Identification	O
and	O
characterization	O
of	O
a	O
leukocyte-specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O


In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	B-cell_type
cells	I-cell_type
where	O
they	O
bind	O
their	O
cytoplasmic	B-protein
receptor	I-protein
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	B-DNA
response	I-DNA
elements	I-DNA
(	O
GRE	B-DNA
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	B-DNA
genes	I-DNA
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O


CD40	B-protein
-mediated	O
fra-1	B-DNA
induction	O
did	O
require	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O


These	O
results	O
demonstrate	O
that	O
CD40	B-protein
,	O
like	O
sIg	B-protein
,	O
may	O
employ	O
PKC	B-protein
in	O
producing	O
select	O
outcomes	O
,	O
that	O
individual	O
B	B-protein
cell	I-protein
receptors	I-protein
may	O
signal	O
downstream	O
events	O
via	O
both	O
PKC-dependent	O
and	O
PKC-independent	O
pathways	O
,	O
and	O
that	O
multiple	O
signal	O
transduction	O
pathways	O
may	O
be	O
used	O
to	O
activate	O
the	O
expression	O
of	O
closely	O
related	O
genes	B-DNA
.	O


Activation	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
requires	O
cooperative	O
binding	O
of	O
Elf-1	B-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Steroid-resistant	O
asthma	O
.	O


The	O
prevalence	O
of	O
DNA	O
aneuploidy	O
was	O
30	O
%	O
,	O
overexpression	O
of	O
ER	B-protein
10	O
%	O
,	O
and	O
overexpression	O
of	O
EGFR	B-protein
35	O
%	O
,	O
in	O
the	O
206	O
high	O
risk	O
women	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
(	O
projected	O
probability	O
)	O
of	O
developing	O
breast	O
cancer	O
was	O
4.5	O
%	O
.	O


Nonsteroidal	O
anti-inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently	O
.	O


The	O
chemokine	B-protein
RANTES	B-protein
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
inflammatory	O
diseases	O
including	O
asthma	O
and	O
rhinitis	O
which	O
are	O
frequently	O
treated	O
with	O
glucocorticoids	O
.	O


Association	O
of	O
TRAF1	B-protein
,	O
TRAF2	B-protein
,	O
and	O
TRAF3	B-protein
with	O
an	O
Epstein-Barr	B-DNA
virus	I-DNA
LMP1	I-DNA
domain	I-DNA
important	O
for	O
B-lymphocyte	B-cell_type
transformation	O
:	O
role	O
in	O
NF-kappaB	B-protein
activation	O
.	O


NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
(	O
1-231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1	B-protein
/TRAF2	B-protein
heteroaggregates	O
since	O
TRAF1	B-protein
is	O
unique	O
among	O
the	O
TRAFs	B-protein
in	O
coactivating	O
NF-kappaB	B-protein
with	O
LMP1	B-protein
(	O
1-231	O
)	O
,	O
a	O
TRAF2	B-protein
dominant-negative	O
mutant	O
can	O
block	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
as	O
well	O
as	O
TRAF1	B-protein
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	B-protein
is	O
associated	O
with	O
TRAF1	B-protein
in	O
EBV-transformed	O
B	O
cells	O
.	O


Surprisingly	O
,	O
TRAF1	B-protein
,	I-protein
-2	I-protein
,	I-protein
or	I-protein
-3	I-protein
does	O
not	O
interact	O
with	O
the	O
terminal	B-protein
LMP1	I-protein
CT	I-protein
aa	O
333	O
to	O
386	O
which	O
can	O
independently	O
mediate	O
NF-kappaB	B-protein
activation	O
.	O


Lack	O
of	O
IL-12	B-protein
signaling	O
in	O
human	B-cell_line
allergen-specific	I-cell_line
Th2	I-cell_line
cells	I-cell_line
.	O


In	O
the	O
present	O
study	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
IL-12	B-protein
can	O
reverse	O
established	O
Th2	O
responses	O
into	O
Th1/Th0	O
responses	O
by	O
inducing	O
IFN-gamma	B-protein
production	O
in	O
memory	B-cell_line
Th2	I-cell_line
cells	I-cell_line
.	O


To	O
this	O
aim	O
,	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
(	O
TCC	B-cell_line
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	B-protein
profiles	O
were	O
analyzed	O
.	O


Our	O
results	O
indicate	O
that	O
human	O
allergen-specific	O
Th	O
cells	O
with	O
strongly	O
polarized	O
Th2	O
cytokine	B-protein
profiles	O
do	O
not	O
respond	O
to	O
IL-12	B-protein
and	O
,	O
therefore	O
,	O
can	O
not	O
be	O
induced	O
to	O
produce	O
IFN-gamma	B-protein
.	O


The	O
protein	O
from	O
E.	O
coli	O
specifically	O
converted	O
dUTP	O
to	O
dUMP	O
and	O
did	O
not	O
react	O
with	O
other	O
dNTPs	O
or	O
NTPs	O
.	O


In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	B-protein
and	I-protein
catalytic	I-protein
domains	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	B-protein
:	O
TCR-induced	O
IL-2	B-protein
production	O
.	O


Moreover	O
,	O
the	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
was	O
able	O
to	O
induce	O
IL-2	B-protein
cytokine	B-protein
production	O
to	O
an	O
extent	O
similar	O
to	O
that	O
of	O
wild-type	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
.	O


In	O
fact	O
,	O
while	O
the	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
is	O
sufficient	O
to	O
mediate	O
CD4	B-protein
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	B-protein
production	O
,	O
mimicking	O
TCR	B-protein
ligation	O
.	O


[	O
The	O
changes	O
in	O
glucocorticoid	O
receptors	O
in	O
peripheral	B-cell_type
leukocytes	I-cell_type
in	O
asthmatic	O
subjects	O
]	O


The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
in	O
peripheral	B-cell_type
leukocytes	I-cell_type
was	O
determined	O
by	O
radioligand-binding	O
assay	O
in	O
extrinsic	O
and	O
intrinsic	O
asthmatics	O
.	O


Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
.	O


No	O
difference	O
in	O
plasma	O
cortisol	O
level	O
was	O
found	O
between	O
asthmatics	O
and	O
healthy	O
subjects	O
.	O


Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane-related	O
rapid	O
responses	O
.	O


Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro-translated	B-protein
PU.1	I-protein
and	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
just	O
upstream	O
from	O
the	O
major	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O


Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU.1	B-protein
binding	O
decrease	O
M-CSF	B-protein
receptor	I-protein
promoter	O
activity	O
significantly	O
in	O
macrophage	B-cell_line
cell	I-cell_line
lines	I-cell_line
only	O
.	O


BACKGROUND	O
.	O


CONCLUSION	O
.	O


[	O
The	O
value	O
of	O
the	O
clinical	O
test	O
of	O
glucocorticoid	B-protein
receptors	I-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
]	O


Signaling	O
via	O
IL-2	B-protein
and	O
IL-4	B-protein
in	O
JAK3-deficient	B-cell_line
severe	I-cell_line
combined	I-cell_line
immunodeficiency	I-cell_line
lymphocytes	I-cell_line
:	O
JAK3	B-protein
-dependent	O
and	O
independent	O
pathways	O
.	O


Both	O
IL-2	B-protein
and	O
IL-4	B-protein
bind	O
to	O
receptors	O
containing	O
the	O
common	B-protein
gamma	I-protein
chain	I-protein
and	O
JAK3	B-protein
.	O


Here	O
,	O
we	O
have	O
studied	O
IL-2	B-protein
and	O
IL-4	B-protein
signaling	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
lacking	O
JAK3	B-protein
.	O


IL-2R	B-protein
alpha	I-protein
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B-protein
regulatory	I-protein
regions	I-protein
,	O
PRRI	B-DNA
and	O
PRRII	B-DNA
.	O


Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O


Cells	O
with	O
nuclear	O
p50	B-protein
were	O
negative	O
for	O
the	O
CD38	B-protein
,	O
CD20	B-protein
and	O
CD2	B-protein
markers	I-protein
.	O


Tyrosines	O
113	O
,	O
128	O
,	O
and	O
145	O
of	O
SLP-76	B-protein
are	O
required	O
for	O
optimal	O
augmentation	O
of	O
NFAT	B-DNA
promoter	I-DNA
activity	O
.	O


Two	O
tyrosines	O
(	O
Y113	O
and	O
Y128	O
)	O
fall	O
within	O
an	O
identical	O
five	O
amino-acid	O
motif	O
and	O
are	O
shown	O
to	O
be	O
phosphorylated	O
upon	O
TCR	B-protein
ligation	O
.	O


Human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
2	I-DNA
gene	I-DNA
.	O


Interferon	B-protein
regulatory	I-protein
factor	I-protein
2	I-protein
(	O
IRF-2	B-protein
)	O
is	O
a	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
that	O
terminates	O
interferon	B-protein
beta	I-protein
expression	O
initiated	O
by	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
.	O


The	O
IRF-2	B-protein
promoter	B-DNA
region	I-DNA
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	B-DNA
boxes	I-DNA
,	O
a	O
putative	O
NF-kappa	B-DNA
B-binding	I-DNA
site	I-DNA
,	O
and	O
a	O
CAAT	B-DNA
box	I-DNA
,	O
but	O
no	O
TATA	B-DNA
box	I-DNA
.	O


When	O
the	O
promoter	B-DNA
region	I-DNA
was	O
linked	O
with	O
a	O
heterologous	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
we	O
found	O
that	O
the	O
promoter	B-DNA
region	I-DNA
is	O
inducible	O
by	O
both	O
interferons	B-protein
(	O
interferon-alpha	B-protein
and	I-protein
-gamma	I-protein
)	O
and	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
.	O


Interferon	B-protein
alpha	I-protein
selectively	O
affects	O
expression	O
of	O
the	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
in	O
late	B-cell_type
stage	I-cell_type
cells	I-cell_type
in	O
the	O
monocytic	B-cell_type
but	O
not	O
the	O
granulocytic	B-cell_type
lineage	I-cell_type
.	O


The	O
effects	O
of	O
phorbol	O
ester	O
on	O
MNDA	B-RNA
mRNA	I-RNA
appeared	O
to	O
be	O
associated	O
with	O
induced	O
differentiation	O
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	O
alter	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
and	O
cell	O
cycle	O
variation	O
in	O
MNDA	B-RNA
mRNA	I-RNA
levels	O
were	O
not	O
observed	O
.	O


We	O
previously	O
identified	O
and	O
analyzed	O
a	O
45-nucleotide	B-DNA
sequence	I-DNA
(	O
downstream	B-DNA
regulatory	I-DNA
element	I-DNA
1	I-DNA
[	O
DRE	B-DNA
1	I-DNA
]	O
)	O
,	O
+195	B-DNA
to	I-DNA
+240	I-DNA
,	O
at	O
the	O
boundary	O
of	O
the	O
R/U5	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
which	O
is	O
required	O
for	O
HTLV-I	O
basal	O
transcription	O
.	O


An	O
affinity	O
column	O
fraction	O
,	O
containing	O
p37	B-protein
,	O
stimulated	O
HTLV-I	O
transcription	O
approximately	O
12-fold	O
in	O
vitro	O
.	O


The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice/d	O
,	O
30	O
min/exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O


In	O
these	O
cells	O
,	O
nuclear	B-protein
factors	I-protein
involved	O
in	O
activation	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
,	O
which	O
contains	O
the	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O


Sequence	O
analysis	O
and	O
expression	O
in	O
cultured	B-cell_type
lymphocytes	I-cell_type
of	O
the	O
human	O
FOSB	B-DNA
gene	I-DNA
(	O
G0S3	B-DNA
)	O
.	O


The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O


In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O


In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	O
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	B-DNA
.	O


All	O
human	O
adenoviruses	O
transform	O
rodent	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
but	O
only	O
cells	O
transformed	O
by	O
serotypes	O
belonging	O
to	O
subgroups	O
A	O
(	O
Ad12	O
)	O
and	O
B	O
(	O
Ad3	O
)	O
are	O
tumorigenic	O
for	O
immunocompetent	O
animals	O
.	O


Susceptibility	O
of	O
these	O
transformed	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
was	O
determined	O
by	O
cytolytic	O
assays	O
.	O


The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	B-DNA
E1A	I-DNA
domains	I-DNA
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
.	O


For	O
this	O
expression	O
pattern	O
the	O
first	O
280	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
seems	O
to	O
be	O
sufficient	O
.	O


Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
expression	O
of	O
inflammatory	B-protein
cytokines	I-protein
in	O
monocytes/macrophages	B-cell_type
via	O
CD14	B-protein
,	O
one	O
of	O
the	O
LPS	B-protein
receptors	I-protein
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
these	O
cells	O
.	O


Gel	O
shift	O
mobility	O
assay	O
showed	O
stimulation	O
of	O
the	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
contents	O
in	O
P-LPS-treated	O
cells	O
.	O


Antiphosphotyrosine	O
immunoblots	O
of	O
whole	O
cell	O
lysates	O
prepared	O
from	O
neutrophils	B-cell_type
show	O
that	O
the	O
G-CSF	B-protein
rapidly	O
induces	O
prominent	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
of	O
a	O
relative	O
molecular	O
mass	O
of	O
80	O
kDa	O
.	O


IEF-1	B-protein
,	O
a	O
pancreatic	O
beta-cell	O
type-specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	B-protein
molecules	I-protein
.	O


Furthermore	O
,	O
p50	B-protein
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	B-cell_type
.	O


The	O
elevation	O
in	O
intracellular	O
calcium	O
that	O
is	O
induced	O
by	O
interactions	O
at	O
the	O
antigen	B-protein
receptor	I-protein
leads	O
to	O
the	O
activation	O
of	O
the	O
calcium-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
.	O


Induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
by	O
low-density	B-protein
lipoprotein	I-protein
.	O


Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	B-protein
is	O
increased	O
recruitment	O
of	O
monocytes	B-cell_type
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation	O
.	O


The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	B-protein
lipoprotein	I-protein
,	O
LDL	B-protein
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O
Human	O
LDL	B-protein
induces	O
the	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	B-DNA
promoter	I-DNA
.	O


After	O
a	O
2-day	O
incubation	O
in	O
LDL	B-protein
,	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
key	O
oxidative-stress	O
sensor	O
for	O
VCAM	B-protein
regulation	O
,	O
remains	O
at	O
basal	O
level	O
.	O


Therefore	O
we	O
first	O
examined	O
the	O
participation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
germline	B-cell_line
C	I-cell_line
epsilon	I-cell_line
transcription	O
in	O
a	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
DND39	B-cell_line
.	O


Second	O
,	O
we	O
studied	O
the	O
effect	O
of	O
NAC	O
on	O
IgE	B-protein
synthesis	O
in	O
human	O
normal	O
B	O
cells	O
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
mAb	I-protein
.	O


Prostaglandin	O
E2	O
induction	O
of	O
binding	O
activity	O
to	O
CRE	B-DNA
and	O
AP-2	B-DNA
elements	I-DNA
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Since	O
the	O
okadaic	O
acid	O
,	O
a	O
potent	O
protein	O
phosphatase	O
inhibitor	O
,	O
prolongs	O
the	O
induction	O
of	O
the	O
binding	O
activity	O
,	O
phosphorylation	O
events	O
are	O
likely	O
to	O
occur	O
.	O


ISH	O
for	O
EBV-encoded	B-RNA
small	I-RNA
non-polyadenylated	I-RNA
RNAs	I-RNA
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	B-cell_type
cells	I-cell_type
.	O


The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	B-protein
kinases	I-protein
.	O


The	O
involvement	O
of	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
in	O
the	O
regulation	O
of	O
calcium-dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF-AT	B-protein
.	O


The	O
induction	O
of	O
promoters	B-DNA
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK-506	O
)	O
.	O


These	O
data	O
show	O
that	O
this	O
technique	O
is	O
useful	O
for	O
the	O
identification	O
of	O
minimal	O
residual	O
disease	O
in	O
patients	O
with	O
APL	O
and	O
that	O
cytotoxic	O
chemotherapy	O
following	O
ATRA	O
therapy	O
is	O
required	O
for	O
the	O
elimination	O
of	O
APL	B-cell_type
cells	I-cell_type
.	O


In	O
the	O
present	O
in-vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady-state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
)	O
.	O


Dexamethasone	O
was	O
found	O
to	O
induce	O
a	O
significant	O
decrease	O
in	O
membrane	O
structural	O
order	O
at	O
concentrations	O
of	O
about	O
10	O
(	O
-6	O
)	O
M	O
in	O
a	O
concentration-dependent	O
manner	O
.	O


Moreover	O
,	O
TCR	B-protein
-induced	O
phosphorylation	O
of	O
pp36-38	B-protein
,	O
thought	O
to	O
play	O
a	O
role	O
upstream	O
of	O
these	O
pathways	O
,	O
was	O
found	O
to	O
be	O
reduced	O
.	O


In	O
contrast	O
,	O
overexpression	O
of	O
wild-type	B-protein
ZAP-70	I-protein
induced	O
constitutive	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O


This	O
result	O
demonstrates	O
that	O
Tyr-492	O
and	O
Tyr-493	O
are	O
not	O
responsible	O
for	O
the	O
Src	O
homology	O
domain	O
2-mediated	O
association	O
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
with	O
ZAP-70	B-protein
.	O


Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
.	O


The	O
promoter	B-DNA
region	I-DNA
lacked	O
a	O
TATA	B-DNA
box	I-DNA
but	O
contained	O
potential	O
binding	O
sites	O
for	O
the	O
transcriptional	B-protein
factors	I-protein
including	O
two	O
Sp1	B-protein
,	O
CRE	B-protein
,	O
Myb	B-protein
and	O
NFkB	B-protein
located	O
at	O
positions	B-DNA
-153	I-DNA
,	I-DNA
-178	I-DNA
,	I-DNA
-286	I-DNA
,	I-DNA
-875	I-DNA
,	I-DNA
and	I-DNA
-1011	I-DNA
,	O
respectively	O
.	O


Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF-kB2/p52	O
.	O


It	O
remains	O
to	O
be	O
shown	O
which	O
molecular	O
events	O
lead	O
to	O
the	O
specific	O
'pre-activation	O
'	O
,	O
i.e	O
.	O


These	O
ROI-induced	O
effects	O
can	O
,	O
to	O
a	O
large	O
extent	O
,	O
be	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O


When	O
CD45RA+	B-cell_type
(	I-cell_type
naive	I-cell_type
)	I-cell_type
and	O
CD45RO+	B-cell_type
(	I-cell_type
memory	I-cell_type
)	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF-kappaB	B-protein
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	B-cell_type
cells	I-cell_type
than	O
in	O
memory	B-cell_type
cells	I-cell_type
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses	O
.	O


However	O
,	O
anti-	O
CD45	B-protein
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O


Second	O
,	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
lack	O
CD45	B-protein
and	O
can	O
not	O
signal	O
via	O
the	O
TCR	B-protein
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O


This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
in	O
the	O
nucleus	O
of	O
CD45	B-protein
-T	O
cells	O
.	O


Calcineurin	B-protein
potentiates	O
activation	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
:	O
involvement	O
of	O
the	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
0	I-DNA
.	O


Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
extrathymic	B-cell_type
T-cell	I-cell_type
development	O
.	O


Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T-cell	O
differentiation	O
in	O
the	O
liver	O
.	O


The	O
Bcd	B-DNA
proto-oncogene	B-DNA
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	B-DNA
'	I-DNA
UTR	I-DNA
.	O


Within	O
the	O
PBL	B-cell_type
,	O
Bcd	B-DNA
gene	O
expression	O
was	O
restricted	O
to	O
CD19+	B-cell_type
B-cells	I-cell_type
and	O
absent	O
from	O
CD14+	B-cell_type
monocytes	I-cell_type
and	O
T-cells	B-cell_type
.	O


Bcd	B-DNA
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	B-cell_type
samples	O
tested	O
but	O
not	O
in	O
several	O
malignant	B-cell_line
human	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
not	O
in	O
50	O
%	O
of	O
B-cells	B-cell_type
from	O
B-CLL	O
patients	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
with	O
a	O
43-mer	B-DNA
oligonucleotide	I-DNA
derived	O
from	O
the	O
functionally	O
identified	O
cis-acting	B-DNA
element	I-DNA
revealed	O
specific	O
complexes	O
.	O


Expression	O
of	O
Egr-1	B-protein
correlates	O
with	O
the	O
transformed	O
phenotype	O
and	O
the	O
type	O
of	O
viral	O
latency	O
in	O
EBV	B-cell_line
genome	I-cell_line
positive	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Recent	O
work	O
has	O
shown	O
that	O
IL-10	B-protein
induces	O
activation	O
of	O
the	O
JAK	B-protein
-STAT	B-protein
signaling	O
pathway	O
.	O


This	O
study	O
thus	O
supports	O
the	O
concept	O
that	O
utilization	O
of	O
distinct	O
STAT	B-protein
proteins	I-protein
by	O
different	O
cytokine	B-protein
receptors	I-protein
is	O
dependent	O
on	O
the	O
expression	O
of	O
particular	O
ligand-activatable	O
,	O
tyrosine-containing	B-protein
STAT	I-protein
docking	I-protein
sites	I-protein
in	O
receptor	B-protein
intracellular	I-protein
domains	I-protein
.	O


Impaired	O
silencing	O
of	O
gamma-globin	B-protein
expression	O
identifies	O
EKLF	B-protein
as	O
the	O
first	O
transcription	B-protein
factor	I-protein
participating	O
quantitatively	O
in	O
the	O
gamma-globin	B-protein
to	O
beta-globin	B-protein
switch	O
.	O


Zinc	O
is	O
an	O
important	O
trace	O
element	O
for	O
immune	O
function	O
.	O


These	O
results	O
indicate	O
that	O
E3	B-protein
is	O
a	O
hematopoietic-specific	B-DNA
gene	I-DNA
that	O
is	O
an	O
immediate	O
target	O
for	O
the	O
activated	O
RAR	B-protein
alpha	I-protein
during	O
myelopoiesis	O
.	O


Because	O
the	O
-180	B-DNA
site	I-DNA
is	O
not	O
required	O
for	O
trans-activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	B-DNA
IL-2	I-DNA
enhancer	I-DNA
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O


Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca.	B-DNA
bp	I-DNA
-850	I-DNA
upstream	O
of	O
Cp	B-DNA
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O


Protein-tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B-protein
1beta	I-protein
and	O
NFkappaB	B-protein
activation	O
,	O
but	O
not	O
NFkappaB	B-protein
nuclear	O
translocation	O
.	O


In	O
human	B-cell_type
monocytes	I-cell_type
,	O
interleukin	B-protein
1beta	I-protein
protein	O
production	O
and	O
steady	O
state	O
mRNA	O
levels	O
are	O
increased	O
in	O
response	O
to	O
lipopolysaccharide	O
,	O
predominantly	O
as	O
a	O
result	O
of	O
increased	O
transcription	O
of	O
the	O
interleukin	B-protein
1beta	I-protein
gene	O
.	O


However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	B-protein
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O


ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	B-cell_line
cells	I-cell_line
into	O
mature	B-cell_type
granulocytes	I-cell_type
.	O


Because	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
regulatory	I-protein
factors	I-protein
(	O
IRF-1	B-protein
and	O
IRF-2	B-protein
)	O
and	O
other	O
IFN-inducible	B-protein
gene	I-protein
products	I-protein
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O


Loss	O
of	O
heterozygosity	O
in	O
PB	B-cell_type
granulocytes	I-cell_type
would	O
be	O
masked	O
by	O
the	O
presence	O
of	O
significant	O
numbers	O
of	O
normal	B-cell_type
granulocytes	I-cell_type
not	O
derived	O
from	O
the	O
malignant	B-cell_line
clone	I-cell_line
.	O


Therefore	O
,	O
the	O
human	B-protein
androgen	I-protein
receptor	I-protein
assay	O
(	O
HUMARA	O
)	O
was	O
used	O
to	O
determine	O
granulocyte	O
clonality	O
.	O


Soluble	B-protein
factors	I-protein
secreted	O
by	O
activated	B-cell_type
T-lymphocytes	I-cell_type
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	B-protein
cytokine	I-protein
TGF-beta	B-protein
2	I-protein
in	O
glial	B-cell_type
cells	I-cell_type
.	O


In	O
conclusion	O
,	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motifs	O
and	O
interacting	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Here	O
we	O
report	O
that	O
human	B-cell_type
leukaemia	I-cell_type
cells	I-cell_type
carrying	O
the	O
translocation	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
rapidly	O
died	O
by	O
apoptosis	O
when	O
programmed	O
to	O
express	O
a	O
dominant-negative	O
suppressor	O
of	O
the	O
fusion	O
protein	O
E2A-HLF	B-protein
,	O
indicating	O
that	O
the	O
chimaeric	B-protein
oncoprotein	I-protein
probably	O
affects	O
cell	O
survival	O
rather	O
than	O
cell	O
growth	O
.	O


The	O
close	O
homology	O
of	O
the	O
basic	B-protein
region/leucine	I-protein
zipper	I-protein
(	O
bZIP	B-protein
)	O
DNA-binding	O
and	O
dimerization	B-protein
domain	I-protein
of	O
HLF	B-protein
to	O
that	O
of	O
the	O
CES-2	B-protein
cell-death	I-protein
specification	I-protein
protein	I-protein
of	O
Caenorhabditis	O
elegans	O
suggests	O
a	O
model	O
of	O
leukaemogenesis	O
in	O
which	O
E2A-HLF	B-protein
blocks	O
an	O
early	O
step	O
within	O
an	O
evolutionarily	O
conserved	O
cell-death	O
pathway	O
.	O


These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti-tumor	O
CTL	O
responses	O
.	O


As	O
a	O
consequence	O
,	O
the	O
immune	O
response	O
developed	O
in	O
senescent	O
organisms	O
is	O
usually	O
inappropriate	O
,	O
often	O
inefficient	O
,	O
sometimes	O
aberrant	O
,	O
and	O
potentially	O
detrimental	O
.	O


The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
show	O
how	O
the	O
accumulation	O
of	O
various	O
biochemical	O
lesions	O
with	O
advancing	O
age	O
leads	O
to	O
the	O
failure	O
of	O
a	O
critical	O
cell	O
function	O
,	O
namely	O
the	O
activation-induced	O
lymphocyte	O
proliferation	O
.	O


Levels	O
of	O
bcl-2	B-RNA
mRNA	I-RNA
and	O
protein	O
increase	O
with	O
cross-linking	O
of	O
surface	B-protein
immunoglobulin	I-protein
.	O


We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross-linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O


bcl-2	B-protein
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	B-DNA
site	I-DNA
.	O


These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O


Moreover	O
,	O
defective	O
DNA	O
binding	O
was	O
corrected	O
by	O
treatment	O
with	O
acid	O
phosphatase	O
.	O


The	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
/FK506-sensitive	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O


The	O
amino	B-protein
acid	I-protein
sequence	I-protein
of	O
NFATc.beta	B-protein
differs	O
from	O
that	O
of	O
NFATc	B-protein
.	O


Transient	O
expression	O
of	O
NFATc.beta	B-protein
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	B-DNA
NFAT-driven	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
stimulated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
in	O
a	O
CsA-sensitive	O
manner	O
.	O


However	O
,	O
NFATc.beta	B-protein
neither	O
bound	O
to	O
the	O
kappa3	B-DNA
element	I-DNA
(	O
an	O
NFAT-binding	B-DNA
site	I-DNA
)	O
in	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
nor	O
activated	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
in	O
cotransfection	O
assays	O
.	O


Regulation	O
of	O
interferon-gamma	B-protein
gene	O
expression	O
.	O


IFN-gamma	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
expressed	O
predominantly	O
by	O
T	B-cell_type
cells	I-cell_type
and	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
.	O


The	O
IFN-gamma	B-RNA
mRNA	I-RNA
is	O
induced/inhibited	O
in	O
these	O
cell	O
types	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
,	O
thus	O
implicating	O
a	O
number	O
of	O
diverse	O
,	O
yet	O
convergent	O
signal	O
transduction	O
pathways	O
in	O
its	O
transcriptional	O
control	O
.	O


In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV-positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
will	O
benefit	O
.	O


Reverse	O
transcription-PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV-positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	B-RNA
nuclear	I-RNA
antigen	I-RNA
(	I-RNA
EBNA	I-RNA
)	I-RNA
1	I-RNA
mRNA	I-RNA
,	O
but	O
not	O
EBNA2	B-RNA
mRNA	I-RNA
.	O


Both	O
are	O
located	O
in	O
the	O
particulate	O
fraction	O
following	O
platelet	B-cell_type
activation	O
and	O
are	O
also	O
able	O
to	O
bind	O
to	O
a	O
GST-construct	B-protein
containing	O
the	O
SH2	B-protein
and	I-protein
SH3	I-protein
domains	I-protein
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
.	O


These	O
results	O
suggest	O
that	O
IFN-alpha5	B-protein
and	O
IFN-beta	B-protein
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O


We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL-2	B-protein
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL-2	B-protein
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O


Multiple	O
factors	O
including	O
Stat5	B-protein
,	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
and	O
GATA	B-protein
family	I-protein
proteins	I-protein
bind	O
to	O
the	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O


The	O
proximal	B-protein
sequence	I-protein
element	I-protein
(	I-protein
PSE	I-protein
)	I-protein
-binding	I-protein
transcription	I-protein
factor	I-protein
(	O
PTF	B-protein
)	O
,	O
which	O
binds	O
the	O
PSE	B-DNA
of	O
both	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
-and	I-DNA
RNA	I-DNA
polymerase	I-DNA
III-transcribed	I-DNA
mammalian	I-DNA
small	I-DNA
nuclear	I-DNA
RNA	I-DNA
(	I-DNA
snRNA	I-DNA
)	I-DNA
genes	I-DNA
,	O
is	O
essential	O
for	O
their	O
transcription	O
.	O


We	O
previously	O
reported	O
the	O
purification	O
of	O
human	B-protein
PTF	I-protein
,	O
a	O
complex	O
of	O
four	B-protein
subunits	I-protein
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	B-protein
gamma	I-protein
and	I-protein
delta	I-protein
subunits	I-protein
.	O


Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	B-DNA
encoding	O
PTF	B-protein
beta	I-protein
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti-PTF	B-protein
beta	I-protein
antibodies	I-protein
.	O


Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	B-protein
gamma/PTF	I-protein
delta	I-protein
and	O
TBP	B-protein
and	O
the	O
involvement	O
of	O
TFIIIB90	B-protein
in	O
the	O
transcription	O
of	O
class	B-DNA
III	I-DNA
snRNA	I-DNA
genes	I-DNA
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP-containing	B-protein
complex	I-protein
related	O
to	O
TFIIIB	B-protein
is	O
required	O
for	O
the	O
transcription	O
of	O
class	B-DNA
III	I-DNA
snRNA	I-DNA
genes	I-DNA
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four-subunit	B-protein
PTF	I-protein
.	O


Attenuated	O
function	O
of	O
a	O
variant	O
form	O
of	O
the	O
helix-loop-helix	B-protein
protein	I-protein
,	O
Id-3	B-protein
,	O
generated	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O


We	O
report	O
here	O
on	O
the	O
identification	O
of	O
a	O
17	B-protein
kDa	I-protein
variant	I-protein
of	O
the	O
14	B-protein
kDa	I-protein
Id-3	I-protein
protein	O
termed	O
Id-3L	B-protein
(	O
long	O
version	O
)	O
which	O
possesses	O
a	O
unique	O
60	B-protein
amino	I-protein
acid	I-protein
carboxy-terminus	I-protein
generated	O
by	O
read	O
through	O
of	O
a	O
'	O
coding	B-DNA
intron	I-DNA
'	O
and	O
alternative	O
splicing	O
.	O


We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O


Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(	O
from	O
463	O
+/-	O
133	O
to	O
128	O
+/-	O
52	O
centipoise	O
)	O
.	O


The	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
.	O


In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
,	O
tissue	B-protein
factor	I-protein
,	O
endothelial	B-protein
leukocyte	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
genes	I-DNA
.	O


Elevated	O
cAMP	O
did	O
not	O
prevent	O
nuclear	O
translocation	O
of	O
p50/p65	B-protein
and	O
c-Rel/p65	B-protein
heterodimers	I-protein
,	O
decrease	O
nuclear	O
translocation	O
of	O
p65	B-protein
,	O
or	O
significantly	O
modify	O
TNFalpha	B-protein
-induced	O
phosphorylation	O
of	O
p65	B-protein
.	O


Despite	O
the	O
widespread	O
use	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
inflammation	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
hormones	O
exert	O
this	O
beneficial	O
effect	O
in	O
patients	O
with	O
asthma	O
remains	O
to	O
be	O
elucidated	O
.	O


No	O
glucocorticoid	B-DNA
recognition	I-DNA
sequences	I-DNA
are	O
present	O
in	O
this	O
promoter	B-DNA
region	I-DNA
and	O
dexamethasone	O
is	O
still	O
able	O
to	O
repress	O
transcription	O
when	O
the	O
multimerized	B-DNA
NF-kappa	I-DNA
B	I-DNA
sequence	I-DNA
is	O
transactivated	O
by	O
TNF-alpha	B-protein
upon	O
transfection	O
in	O
293	B-cell_line
cells	I-cell_line
.	O


Abnormalities	O
of	O
p16	B-DNA
,	I-DNA
p15	I-DNA
and	I-DNA
CDK4	I-DNA
genes	I-DNA
in	O
recurrent	O
malignant	O
astrocytomas	O
.	O


Abnormalities	O
in	O
the	O
p16	B-DNA
,	I-DNA
p15	I-DNA
and	I-DNA
CDK4	I-DNA
genes	I-DNA
that	O
regulate	O
transition	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
have	O
been	O
implicated	O
in	O
the	O
malignant	O
progression	O
of	O
astrocytomas	O
.	O


BCL-6	B-protein
,	O
a	O
POZ/zinc-finger	B-protein
protein	I-protein
,	O
is	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
repressor	I-protein
.	O


These	O
results	O
indicate	O
that	O
the	O
BCL-6	B-protein
protein	I-protein
can	O
function	O
as	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
repressor	I-protein
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	B-protein
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O


The	O
data	O
obtained	O
demonstrate	O
that	O
phorbol	O
dibutyrate/calcium	O
ionophore	O
A23187	O
(	O
PDBu/iono	O
)	O
combination	O
induced	O
a	O
clearly	O
higher	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
neonatal	B-cell_type
than	I-cell_type
adult	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
antibodies	B-protein
directed	O
against	O
the	O
major	O
components	O
of	O
NF-kappa	B-protein
B	I-protein
the	O
p50	B-protein
and	I-protein
RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
proteins	I-protein
,	O
indicated	O
that	O
the	O
composition	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
similar	O
in	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
cells	I-cell_type
.	O


The	O
effect	O
of	O
the	O
steroid	O
is	O
mediated	O
by	O
its	O
binding	O
to	O
corticosteroid	B-protein
receptors	I-protein
.	O


In	O
the	O
present	O
study	O
,	O
corticosteroid	B-protein
Type	I-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
measured	O
in	O
10	O
elderly	O
subjects	O
and	O
in	O
9	O
young	O
adults	O
,	O
before	O
and	O
after	O
overnight	O
DST	O
(	O
1	O
mg	O
)	O
.	O


The	O
number	O
of	O
Type	B-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
before	O
the	O
test	O
was	O
lower	O
in	O
elderly	O
subjects	O
than	O
in	O
adults	O
.	O


We	O
suggest	O
that	O
in	O
young	O
subjects	O
Type	B-protein
II	I-protein
receptors	I-protein
are	O
initially	O
up-regulated	O
by	O
dexamethasone	O
,	O
and	O
then	O
down-regulated	O
,	O
while	O
in	O
aged	O
subjects	O
an	O
up-regulation	O
can	O
not	O
be	O
achieved	O
,	O
as	O
suggested	O
by	O
the	O
higher	O
values	O
of	O
plasma	O
cortisol	O
usually	O
found	O
in	O
aging	O
subjects	O
.	O


Three	O
subtypes	O
of	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
,	O
termed	O
RAR	B-protein
alpha	I-protein
,	O
RAR	B-protein
beta	I-protein
,	O
and	O
RAR	B-protein
gamma	I-protein
,	O
have	O
been	O
described	O
.	O


In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	O
in	O
the	O
ligand-inducible	O
transactivation	O
function	O
of	O
RAR	B-protein
alpha	I-protein
.	O


Calcineurin	B-protein
mutants	I-protein
render	O
T	B-cell_type
lymphocytes	I-cell_type
resistant	O
to	O
cyclosporin	O
A	O
.	O


CsA	O
and	O
FK506	O
associate	O
with	O
intracellular	B-protein
binding	I-protein
proteins	I-protein
(	O
i.e.	O
,	O
CsA	O
with	O
cyclophilin	B-protein
A	I-protein
and	O
FK506	O
with	O
FKBP12	B-protein
)	O
to	O
form	O
protein/drug	O
complexes	O
that	O
suppress	O
the	O
immune	O
system	O
by	O
preventing	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
antigen	O
presentation	O
.	O


Epstein-Barr	O
viral	O
latency	O
is	O
disrupted	O
by	O
the	O
immediate-early	B-protein
BRLF1	I-protein
protein	I-protein
through	O
a	O
cell-specific	O
mechanism	O
.	O


Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O


The	O
extent	O
to	O
which	O
peptides	O
containing	O
chemically	O
and	O
post-translationally	O
modified	O
amino	B-protein
acid	I-protein
side	I-protein
chains	I-protein
are	O
recognized	O
by	O
primed	B-cell_line
CTL	I-cell_line
has	O
not	O
been	O
clearly	O
defined	O
.	O


In	O
addition	O
,	O
unwanted	O
and	O
potentially	O
hazardous	O
specificities	O
may	O
be	O
elicited	O
when	O
using	O
synthetic	O
peptides	O
in	O
subunit	O
vaccines	O
in	O
which	O
succinimide	O
residues	O
may	O
form	O
spontaneously	O
during	O
storage	O
or	O
chemical	O
synthesis	O
.	O


In	O
addition	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
decrease	O
in	O
basal	O
transcription	O
activity	O
in	O
vitro	O
.	O


In	O
situ	O
hybridization	O
and	O
Northern	O
blot	O
analysis	O
suggest	O
that	O
Spi-B	B-protein
gene	O
expression	O
increases	O
during	O
B	O
cell	O
maturation	O
and	O
decreases	O
during	O
T	O
cell	O
maturation	O
.	O


A	O
critical	O
role	O
of	O
Sp1-	B-protein
and	I-protein
Ets-related	I-protein
transcription	I-protein
factors	I-protein
in	O
maintaining	O
CTL-specific	O
expression	O
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	I-DNA
.	O


To	O
confirm	O
the	O
importance	O
of	O
the	O
three	O
cis-acting	B-DNA
elements	I-DNA
in	O
the	O
perforin	B-DNA
gene	I-DNA
expression	O
,	O
point	O
mutation	O
was	O
introduced	O
again	O
to	O
each	O
proximal	B-DNA
GC	I-DNA
box	I-DNA
,	O
EBS	B-DNA
,	O
and	O
GT	B-DNA
box	I-DNA
of	O
PFP5a	B-DNA
.	O


The	O
point	O
mutations	O
resulted	O
in	O
a	O
2.5-	O
to	O
3-fold	O
reduction	O
of	O
CAT	B-protein
activity	O
.	O


The	O
primary	B-RNA
RNA	I-RNA
transcript	I-RNA
of	O
the	O
gene	O
is	O
subject	O
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O


Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	B-protein
footprinting	O
of	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	B-protein
demonstrated	O
that	O
the	O
-76	B-DNA
site	I-DNA
binds	O
to	O
NFATp	B-protein
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	B-DNA
3	I-DNA
site	I-DNA
.	O


Anergic	B-cell_line
CD4+	I-cell_line
Th	I-cell_line
cells	I-cell_line
do	O
not	O
produce	O
IL-2	B-protein
when	O
challenged	O
with	O
Ag-pulsed	B-cell_line
accessory	I-cell_line
cells	I-cell_line
because	O
of	O
a	O
transcriptional	O
defect	O
.	O


In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
are	O
defective	O
in	O
their	O
ability	O
to	O
up-regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL-2	B-DNA
DNA	I-DNA
enhancer	I-DNA
elements	I-DNA
:	O
NF-AT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	B-protein
NFATp	I-protein
,	I-protein
Fos	I-protein
,	I-protein
and	I-protein
Jun	I-protein
protein	I-protein
complex	I-protein
)	O
and	O
Activator	B-protein
Protein-1	I-protein
(	O
AP-1	B-protein
)	O
(	O
that	O
binds	O
Fos	B-protein
and	I-protein
Jun	I-protein
heterodimers	I-protein
)	O
.	O


B-cell-specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
is	O
mediated	O
by	O
the	O
interaction	O
of	O
a	O
POU	B-DNA
domain	I-DNA
containing	O
transcription	B-protein
factor	I-protein
Oct-1	B-protein
or	O
Oct-2	B-protein
,	O
with	O
the	O
B-cell-specific	B-protein
coactivator	I-protein
OCA-B	B-protein
(	O
Bob-1	B-protein
,	O
OBF-1	B-protein
)	O
and	O
a	O
prototype	B-DNA
octamer	I-DNA
element	I-DNA
.	O


Enzymatic	O
assay	O
of	O
alpha-galactosidase	B-protein
in	O
blood	B-cell_type
leucocytes	I-cell_type
,	O
skin	B-cell_type
fibroblasts	I-cell_type
,	O
Epstein-Barr	B-cell_line
virus	I-cell_line
transformed	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation	O
.	O


The	O
son	O
of	O
the	O
unaffected	O
twin	O
sister	O
was	O
shown	O
to	O
be	O
hemizygous	O
.	O


Analysis	O
of	O
the	O
inactive	B-DNA
X	I-DNA
specific	O
methylation	O
at	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
showed	O
unbalanced	O
inactivation	O
in	O
the	O
twins	O
'	O
fibroblasts	O
and	O
in	O
opposite	O
directions	O
.	O


The	O
core	O
GGAAs	O
of	O
the	O
muA	B-DNA
and	I-DNA
muB	I-DNA
sites	I-DNA
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	B-protein
proteins	I-protein
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O


Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU.1	B-protein
binding	O
but	O
not	O
TFE3	B-protein
or	O
Ets-1	B-protein
bends	O
mu	B-DNA
enhancer	I-DNA
DNA	I-DNA
toward	O
the	O
major	O
groove	O
.	O


Although	O
corticosteroids	O
are	O
the	O
most	O
potent	O
therapeutic	O
agents	O
used	O
for	O
this	O
disease	O
,	O
their	O
anti-inflammatory	O
effect	O
differs	O
from	O
patient	O
to	O
patient	O
.	O


Induction	O
of	O
activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
and	O
nuclear	B-protein
factor-kappaB	I-protein
by	O
CD28	B-protein
stimulation	O
involves	O
both	O
phosphatidylinositol	B-protein
3-kinase	I-protein
and	O
acidic	B-protein
sphingomyelinase	I-protein
signals	O
.	O


To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
blasts	I-cell_type
can	O
be	O
stimulated	O
via	O
the	O
CD28	B-protein
surface	I-protein
molecule	I-protein
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
CD28	B-protein
activation	O
in	O
isolation	O
.	O


In	O
contrast	O
,	O
engagement	O
of	O
the	O
TCR	B-protein
by	O
class	B-protein
II	I-protein
MHC/superantigen	I-protein
,	O
either	O
with	O
or	O
without	O
CD28	B-protein
ligation	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
NF-AT	B-protein
,	O
AP-1	B-protein
,	O
and	O
NF-kappaB	B-protein
as	O
well	O
as	O
IL-2	B-protein
production	O
.	O


Induction	O
by	O
glucocorticoids	O
and	O
enhancement	O
by	O
IFN-beta	B-protein
,	O
IFN-gamma	B-protein
,	O
IL-4	B-protein
,	O
and	O
lipopolysaccharide	O
.	O


The	O
cytokines	B-protein
IFN-beta	B-protein
,	O
IFN-gamma	B-protein
,	O
IL-4	B-protein
,	O
and	O
LPS	O
,	O
although	O
unable	O
to	O
induce	O
sialoadhesin	B-protein
expression	O
by	O
themselves	O
,	O
were	O
able	O
to	O
enhance	O
GC-mediated	O
induction	O
of	O
sialoadhesin	B-protein
.	O


Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	B-cell_type
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	B-protein
.	O


We	O
present	O
a	O
model	O
for	O
HIV	O
replication	O
in	O
which	O
the	O
viral	B-protein
protease	I-protein
depletes	O
the	O
infected	O
cells	O
of	O
bcl-2	B-protein
,	O
leading	O
to	O
oxidative	O
stress-dependent	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
a	O
cellular	B-protein
factor	I-protein
required	O
for	O
HIV	O
transcription	O
,	O
and	O
ultimately	O
to	O
cell	O
death	O
.	O


Nevertheless	O
,	O
forskolin	O
also	O
inhibits	O
PKC	B-protein
downstream	O
events	O
,	O
such	O
as	O
c-jun	B-DNA
expression	O
,	O
which	O
is	O
critical	O
for	O
the	O
activation	O
process	O
of	O
T	B-cell_type
cells	I-cell_type
.	O


Transcriptional	O
and	O
posttranscriptional	O
regulation	O
of	O
erythroid	B-DNA
gene	I-DNA
expression	O
in	O
anthracycline-induced	O
differentiation	O
of	O
human	B-cell_type
erythroleukemic	I-cell_type
cells	I-cell_type
.	O


Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	B-DNA
encoding	O
gamma-globin	B-protein
and	I-protein
porphobilinogen	I-protein
deaminase	I-protein
(	O
PBGD	B-protein
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O


In	O
addition	O
,	O
inhibition	O
of	O
mRNA	B-RNA
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	O
stability	O
of	O
PBGD	B-RNA
and	I-RNA
GATA-1	I-RNA
mRNAs	I-RNA
,	O
whereas	O
ACLA	O
did	O
not	O
affect	O
the	O
half-lives	O
of	O
these	O
mRNAs	B-RNA
.	O


Indeed	O
,	O
erythroid	B-DNA
gene	I-DNA
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O


Interleukin-7	B-protein
signaling	O
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
BAF3	I-cell_line
cells	I-cell_line
involves	O
activation	O
of	O
STAT1	B-protein
and	O
STAT5	B-protein
mediated	O
via	O
the	O
interleukin-7	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
.	O


Supershifts	O
with	O
anti-STAT	O
antibodies	O
identified	O
these	O
as	O
STAT1	B-protein
and	O
STAT5	B-protein
complexes	I-protein
.	O


The	O
percentage	O
of	O
cells	O
expressing	O
CD40	B-protein
in	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
co-cultures	I-cell_line
increased	O
from	O
4.2	O
%	O
to	O
13.8	O
%	O
after	O
oligo	O
stimulation	O
in	O
patients	O
,	O
while	O
it	O
increased	O
form	O
4.7	O
%	O
to	O
48.6	O
%	O
in	O
healthy	O
controls	O
.	O


The	O
proportion	O
of	O
CD40	B-cell_line
cells	I-cell_line
(	O
26	O
%	O
)	O
in	O
a	O
resting	B-cell_line
B-cell	I-cell_line
preparation	I-cell_line
from	O
hepatitis	O
B	O
patients	O
decreased	O
to	O
zero	O
after	O
a	O
5-day	O
culture	O
with	O
sequence	O
I	O
,	O
but	O
IgG	O
levels	O
in	O
the	O
culture	O
supernatant	O
increased	O
.	O


Activation	B-protein
protein	I-protein
1	I-protein
-dependent	O
transcriptional	O
activation	O
of	O
interleukin	B-DNA
2	I-DNA
gene	I-DNA
by	O
Ca2+/calmodulin	B-protein
kinase	I-protein
type	I-protein
IV/Gr	I-protein
.	O


The	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
CaMK	I-protein
)	I-protein
type	I-protein
IV/Gr	I-protein
is	O
selectively	O
expressed	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
is	O
activated	O
after	O
signaling	O
via	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
,	O
indicating	O
that	O
it	O
mediates	O
some	O
of	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
transcriptional	O
events	O
that	O
follow	O
TCR	B-protein
engagement	O
.	O


Here	O
we	O
show	O
that	O
CaMKIV/Gr	B-protein
induces	O
the	O
transcription	B-protein
factor	I-protein
activation	I-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	B-protein
cell	I-protein
mitogens	I-protein
and	O
with	O
the	O
p21ras	B-protein
oncoprotein	I-protein
.	O


AP-1	B-protein
is	O
an	O
integral	O
component	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
transcriptional	I-protein
complex	I-protein
,	O
which	O
is	O
required	O
for	O
interleukin	B-DNA
2	I-DNA
gene	I-DNA
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


We	O
demonstrate	O
that	O
CaMKIV/Gr	B-protein
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	B-protein
to	O
direct	O
transcription	O
from	O
NFAT	B-DNA
sites	I-DNA
in	O
non-	O
T	B-cell_type
cells	I-cell_type
.	O


Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
IL-12	B-protein
-mediated	O
activation	O
of	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
does	O
not	O
involve	O
expression	O
of	O
members	O
of	O
the	O
immediate-early	B-DNA
activation	I-DNA
genes	I-DNA
family	I-DNA
(	O
egr-1	B-DNA
,	O
c-fos	B-DNA
,	O
and	O
junB	B-DNA
)	O
,	O
AP-1	B-protein
transcriptional	O
activity	O
,	O
or	O
bcl-2	B-DNA
expression	O
.	O


This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2-	B-cell_line
and	I-cell_line
IL-12-stimulated	I-cell_line
cells	I-cell_line
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O


Treatment	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
the	O
cytokine	B-protein
IL-4	B-protein
(	O
IL-4	B-protein
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	O
a	O
weak	O
up-regulation	O
of	O
VDR	B-protein
expression	O
but	O
fails	O
to	O
generate	O
vitamin	B-protein
D-responsive	I-protein
element	I-protein
(	I-protein
VDRE	I-protein
)	I-protein
-reactive	I-protein
nuclear	I-protein
protein	I-protein
complexes	I-protein
or	O
to	O
initiate	O
the	O
genomic	O
transcription	O
of	O
25-hydroxyvitamin	B-protein
D3	I-protein
24-hydroxylase	I-protein
.	O


Stimulation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
by	O
either	O
ligation	O
of	O
CD40	B-protein
Ag	I-protein
or	O
cross-linking	O
the	O
Ig	B-protein
receptor	I-protein
is	O
also	O
insufficient	O
to	O
render	O
B	B-cell_type
lymphocytes	I-cell_type
responsive	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O


However	O
,	O
this	O
apparent	O
lack	O
of	O
response	O
to	O
the	O
secosterol	O
can	O
be	O
overcome	O
by	O
stimulation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
a	O
combination	O
of	O
these	O
cellular	O
activation	O
signals	O
,	O
which	O
are	O
sufficient	O
to	O
lead	O
to	O
G1	O
cell	O
cycle	O
progression	O
.	O


Third	O
,	O
a	O
coimmunoprecipitation	O
assay	O
showed	O
that	O
in	O
HTLV-1-infected	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
,	O
Tax	B-protein
and	O
TFIIA	B-protein
were	O
associated	O
.	O


Finally	O
,	O
TFIIA	B-protein
facilitates	O
Tax	B-protein
transactivation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


The	O
regulation	O
of	O
transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
was	O
analyzed	O
in	O
PHA-activated	B-cell_line
mononuclear	I-cell_line
cells	I-cell_line
and	O
in	O
purified	B-cell_line
T	I-cell_line
cells	I-cell_line
activated	O
by	O
cross-linking	O
cell	B-protein
surface	I-protein
CD3	I-protein
.	O


Among	O
the	O
20	O
selected	O
oligonucleotides	O
,	O
two	O
potent	O
15-mer	O
AS	O
oligonucleotides	O
(	O
C-JUN	O
AS	O
oligonucleotides	O
)	O
exhibited	O
significant	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
between	O
2	O
and	O
10	O
microM	O
.	O


These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c-jun	B-DNA
in	O
both	O
cell	O
proliferation	O
and	O
PMA-induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA-induced	O
respiratory	O
burst	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O


In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibited	O
LPS-induced	O
AP-1	B-protein
binding	O
activity	O
.	O


Significantly	O
,	O
the	O
CBF	B-DNA
sites	I-DNA
are	O
in	O
each	O
case	O
contained	O
within	O
the	O
minimum	O
essential	B-DNA
core	I-DNA
regions	I-DNA
required	O
for	O
inducible	O
activation	O
of	O
transcription	O
.	O


Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	B-DNA
linked	I-DNA
binding	I-DNA
sites	I-DNA
for	O
CBF	B-protein
,	O
AP-1	B-protein
,	O
and	O
NFATp	B-protein
.	O


This	O
study	O
adds	O
GM-CSF	B-protein
to	O
a	O
growing	O
list	O
of	O
cytokines	B-protein
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	B-protein
and	O
which	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
.	O


The	O
preferential	O
induction	O
of	O
c-jun	B-DNA
by	O
H2O2	O
did	O
not	O
represent	O
redox	O
stabilization	O
of	O
mRNA	B-RNA
transcripts	I-RNA
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA/PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c-jun	B-DNA
promoter	O
via	O
the	O
proximal	B-DNA
jun1	I-DNA
tumor	I-DNA
promoter-responsive	I-DNA
element	I-DNA
(	I-DNA
TRE	I-DNA
)	I-DNA
-like	I-DNA
promoter	I-DNA
element	I-DNA
.	O


Functional	O
activation	O
of	O
gene	O
expression	O
by	O
Pb	O
was	O
confirmed	O
using	O
primary	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
transfected	O
with	O
an	O
NF-kappa	B-DNA
B	I-DNA
dependent	I-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
.	O


These	O
data	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
an	O
important	O
molecular	O
mediator	O
of	O
Pb-induced	O
immunotoxicity	O
.	O


The	O
use	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
-specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	O
altering	O
the	O
activity	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
HIV-1	B-DNA
LTR	I-DNA
)	O
,	O
a	O
promoter	B-DNA
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-	B-protein
kappa	I-protein
B	I-protein
)	O
.	O


While	O
PKC	B-protein
depletion	O
did	O
not	O
alter	O
the	O
NF-kappa	B-protein
B	I-protein
level	O
,	O
treatment	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
H-89	O
or	O
herbimycin	O
A	O
provoked	O
a	O
decrease	O
in	O
the	O
NF-kappa	B-protein
B	I-protein
level	O
.	O


Norepinephrine	O
and	O
epinephrine	O
also	O
suppressed	O
IL-12	B-protein
production	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
at	O
physiological	O
concentrations	O
;	O
both	O
catecholamines	O
,	O
however	O
,	O
dose-dependently	O
increased	O
the	O
production	O
of	O
IL-10	B-protein
.	O


These	O
findings	O
suggest	O
that	O
the	O
central	O
nervous	O
system	O
may	O
regulate	O
IL-12	O
and	O
IL-10	O
secretion	O
and	O
,	O
hence	O
,	O
TH1/TH2	O
balance	O
via	O
the	O
peripheral	O
end-effectors	O
of	O
the	O
stress	O
system	O
.	O


Like	O
LPS	O
,	O
purified	B-protein
native	I-protein
B.	I-protein
burgdorferi	I-protein
OspA	I-protein
and	O
synthetic	O
analogs	O
of	O
OspA	B-protein
,	O
OspB	B-protein
,	O
and	O
two	O
T.	B-protein
pallidum	I-protein
lipoproteins	I-protein
(	O
Tpp47	B-protein
and	O
Tpp17	B-protein
)	O
all	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
in	O
THP-1	B-cell_type
human	I-cell_type
monocytoid	I-cell_type
cells	I-cell_type
.	O


By	O
using	O
70Z/3-derived	B-cell_line
pre-B-cell	I-cell_line
lines	I-cell_line
either	O
lacking	O
or	O
expressing	O
human	B-protein
CD14	I-protein
(	O
the	O
LPS	B-protein
receptor	I-protein
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	B-protein
CD14	I-protein
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B-protein
or	O
spirochetal	B-protein
lipopeptides	I-protein
(	O
assessed	O
by	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
expression	O
of	O
surface	B-protein
immunoglobulin	I-protein
M	I-protein
)	O
.	O


Transcriptional	O
control	O
of	O
steroid-regulated	O
apoptosis	O
in	O
murine	B-cell_type
thymoma	I-cell_type
cells	I-cell_type
.	O


GR	B-protein
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate-limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	B-protein
-mediated	O
induction	O
of	O
an	O
integrated	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
(	I-DNA
MMTV	I-DNA
)	I-DNA
LTR	I-DNA
reporter	I-DNA
gene	I-DNA
was	O
observed	O
.	O


Analysis	O
of	O
GR	B-protein
chimeric	I-protein
receptors	I-protein
containing	O
the	O
potent	O
VP16	B-DNA
and	I-DNA
E1A	I-DNA
viral	I-DNA
transactivation	I-DNA
domains	I-DNA
in	O
place	O
of	O
the	O
GR	B-protein
N	I-protein
terminus	I-protein
revealed	O
that	O
even	O
low	O
level	O
expression	O
of	O
these	O
receptors	O
resulted	O
in	O
both	O
enhanced	O
steroid	O
sensitivity	O
and	O
MMTV	O
induction	O
,	O
thus	O
supporting	O
a	O
role	O
for	O
transactivation	O
in	O
apoptosis	O
.	O


We	O
found	O
that	O
GIG18	B-DNA
was	O
rapidly	O
induced	O
to	O
comparable	O
levels	O
by	O
both	O
AR	B-protein
and	O
GR	B-protein
,	O
demonstrating	O
that	O
AR	B-protein
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	B-cell_line
cells	I-cell_line
and	O
,	O
moreover	O
,	O
that	O
GIG18	B-DNA
induction	O
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid-treated	O
cells	O
.	O


The	O
transcriptional	O
activity	O
of	O
the	O
NFAT	B-DNA
binding	I-DNA
site	I-DNA
is	O
mediated	O
by	O
a	O
complex	O
comprising	O
a	O
member	O
of	O
the	O
NFAT	B-protein
group	O
and	O
AP-1	B-protein
family	I-protein
proteins	I-protein
.	O


Retinoid	O
differentiation	O
therapy	O
in	O
promyelocytic	O
leukemia	O
.	O


Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
specific	O
type	O
of	O
acute	O
myeloid	O
leukemia	O
characterized	O
by	O
the	O
morphology	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
,	O
a	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
,	O
and	O
risks	O
of	O
definite	O
coagulopathy	O
.	O


The	O
discovery	O
of	O
these	O
signaling	O
pathways	O
has	O
led	O
to	O
important	O
new	O
insights	O
into	O
their	O
role	O
in	O
lymphocyte	O
maturation	O
,	O
as	O
it	O
has	O
emerged	O
that	O
mutations	O
in	O
the	O
genes	O
encoding	O
both	O
gamma	B-protein
c	I-protein
and	O
JAK3	B-protein
result	O
in	O
similar	O
forms	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
.	O


In	O
addition	O
,	O
IL-6	B-protein
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O


Stimulation	O
by	O
RA	O
resulted	O
in	O
increased	O
RAR	B-protein
beta	I-protein
/RXR	B-protein
DNA	O
binding	O
,	O
activated	O
RARE	B-DNA
-dependent	O
transcription	O
,	O
and	O
increased	O
expression	O
of	O
RAR-beta	B-protein
.	O


In	O
contrast	O
,	O
neither	O
the	O
RA-stimulated	O
,	O
RARE	B-DNA
-mediated	O
transcription	O
nor	O
the	O
induced	O
RAR-beta	B-protein
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid-induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	B-DNA
-mediated	O
signal	O
.	O


The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
posttranscriptional	I-protein
trans-activator	I-protein
Rex	B-protein
contains	O
a	O
nuclear	B-protein
export	I-protein
signal	I-protein
.	O


Translocation	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
of	O
B-cell	O
type	O
with	O
BCL6	B-DNA
rearrangement	O
.	O


Histological	O
diagnosis	O
was	O
``	O
malignant	O
lymphoma	O
,	O
diffuse	O
,	O
large	O
cell	O
''	O
type	O
according	O
to	O
an	O
International	O
Working	O
Formulation	O
.	O


This	O
yields	O
a	O
fusion	O
transcript	O
,	O
PML/RARalpha	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
with	O
reported	O
dominant	O
negative	O
functions	O
in	O
the	O
absence	O
of	O
hormone	O
.	O


A	O
full-length	O
PML/RARalpha	B-DNA
cDNA	I-DNA
driven	O
by	O
the	O
CD11b	B-DNA
promoter	I-DNA
was	O
expressed	O
in	O
transgenic	O
mice	O
.	O


Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O


In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	B-DNA
latent	I-DNA
genes	I-DNA
and	O
p53	B-protein
,	O
p53	B-protein
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10-fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
;	O
the	O
induced	O
p53	B-protein
was	O
transcriptionally	O
active	O
.	O


Together	O
the	O
Act-1	B-DNA
and	O
CBF	B-DNA
sites	I-DNA
form	O
a	O
functional	B-DNA
unit	I-DNA
(	O
AC	B-DNA
unit	I-DNA
)	O
with	O
dual	O
activity	O
.	O


This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
fibroblasts	B-cell_type
.	O


Modulation	O
of	O
the	O
expression	O
of	O
the	O
IFN-gamma	B-protein
receptor	I-protein
beta-chain	I-protein
controls	O
responsiveness	O
to	O
IFN-gamma	B-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


In	O
this	O
work	O
,	O
we	O
show	O
that	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
are	O
stimulated	O
through	O
the	O
TCR	B-protein
and	O
expanded	O
with	O
IL-2	B-protein
are	O
unresponsive	O
to	O
IFN-gamma	B-protein
,	O
as	O
determined	O
by	O
a	O
lack	O
of	O
activation	O
of	O
jak	B-protein
kinases	I-protein
and	O
the	O
transcription	B-protein
factor	I-protein
,	O
STAT1	B-protein
(	I-protein
alpha	I-protein
)	I-protein
,	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
.	O


This	O
nonresponsiveness	O
occurs	O
because	O
of	O
a	O
lack	O
of	O
expression	O
of	O
the	O
beta-	B-protein
chain	I-protein
(	O
accessory	O
factor	O
)	O
of	O
the	O
IFN-gamma	B-protein
receptor	I-protein
,	O
while	O
at	O
the	O
same	O
time	O
maintaining	O
IFN-gamma	B-protein
receptor	I-protein
alpha-chain	I-protein
expression	O
.	O


In	O
addition	O
,	O
the	O
results	O
of	O
competition	O
experiments	O
analyzing	O
the	O
normal	O
components	O
of	O
NF-AT	B-protein
showed	O
that	O
the	O
age-related	O
reductions	O
in	O
stimulus-dependent	O
NF-AT	B-protein
complexes	I-protein
corresponded	O
to	O
the	O
slow	O
migrating	O
complexes	O
that	O
were	O
composed	O
of	O
c-Fos/c-Jun	B-protein
AP-1	B-protein
.	O


Furthermore	O
,	O
JAK2	B-protein
associated	O
with	O
the	O
IL-4R	B-protein
p140	I-protein
before	O
and	O
after	O
stimulation	O
with	O
IL-13	B-protein
.	O


Differential	O
regulation	O
of	O
IL-6	B-DNA
gene	I-DNA
transcription	O
and	O
expression	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
in	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


IL-4	B-protein
and	O
IL-10	B-protein
inhibit	O
the	O
cytokine	B-protein
production	O
and	O
mRNA	O
expression	O
by	O
monocytes/macrophages	B-cell_type
.	O


Activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
a	O
cyclosporin	O
A-resistant	O
pathway	O
.	O


In	O
transient	O
transfection	O
assays	O
,	O
both	O
multicopy	O
NFAT	B-protein
-and	O
IL-2	B-DNA
promoter-beta-galactosidase	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
could	O
be	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
/alpha-	O
CD28	B-protein
stimulation	O
,	O
and	O
this	O
activation	O
was	O
resistant	O
to	O
CsA	O
.	O


Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA-resistant	B-protein
NFAT	I-protein
complex	I-protein
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	B-protein
.	O


Collectively	O
,	O
these	O
data	O
suggest	O
that	O
NFAT	B-protein
can	O
be	O
activated	O
and	O
IL-2	B-protein
can	O
be	O
produced	O
in	O
a	O
calcineurin	B-protein
independent	O
manner	O
.	O


IL-10	B-protein
effected	O
dose-dependent	O
inhibition	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
release	O
in	O
PBMC	B-cell_type
stimulated	O
by	O
LPS	O
and	O
C.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0.1	O
U/ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U/ml	O
.	O


IL-10	B-protein
profoundly	O
inhibited	O
release	O
of	O
IL-1beta	B-protein
from	O
PBMC	B-cell_type
stimulated	O
by	O
all	O
three	O
stimuli	O
.	O


Much	O
attention	O
has	O
recently	O
focused	O
on	O
the	O
observation	O
that	O
UV	O
light	O
can	O
activate	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O


In	O
this	O
report	O
,	O
we	O
present	O
data	O
demonstrating	O
that	O
HIV	O
LTR	B-DNA
activation	O
is	O
not	O
a	O
general	O
consequence	O
of	O
cellular	B-DNA
DNA	I-DNA
damage	O
,	O
but	O
rather	O
a	O
process	O
unique	O
to	O
specific	O
genotoxic	O
stimuli	O
,	O
and	O
that	O
it	O
does	O
not	O
necessarily	O
depend	O
on	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


COS-1	B-cell_line
cells	I-cell_line
,	O
co-expressing	O
the	O
human	O
IL-10R	B-protein
and	O
individual	O
STAT	B-protein
proteins	I-protein
,	O
confirmed	O
a	O
preference	O
of	O
the	O
IL-10R	B-protein
for	O
STAT3	B-protein
and	O
STAT1	B-protein
.	O


(	O
2E	O
)	O
-3-	O
[	O
5-	O
(	O
2	O
,	O
3-Dimethoxy-6-methyl-1	O
,	O
4-benzoquinoyl	O
)	O
]	O
-2-nonyl-2-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O


Nuclear	O
run-on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF-alpha	B-DNA
gene	I-DNA
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O


To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted-type	B-DNA
placental	I-DNA
alkaline	I-DNA
phosphatase	I-DNA
(	I-DNA
PLAP	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1.4-kb	B-DNA
human	I-DNA
TNF-alpha	I-DNA
promoter	I-DNA
.	O


E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O


In	O
vitro	O
mutagenesis	O
and	O
transient	O
transfection	O
experiments	O
indicate	O
that	O
the	O
C-terminal	B-protein
serine/threonine/proline-rich	I-protein
region	I-protein
of	O
BSAP	B-protein
contains	O
a	O
potent	O
transactivation	B-protein
domain	I-protein
of	O
55	O
amino	O
acids	O
which	O
is	O
active	O
from	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
positions	I-DNA
.	O


Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	B-DNA
CD36	I-DNA
gene	I-DNA
promoter	I-DNA
:	O
identification	O
of	O
a	O
proximal	O
PEBP2/CBF	B-DNA
site	I-DNA
.	O


Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte/macrophages	B-cell_type
.	O


Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	B-DNA
-158	I-DNA
to	I-DNA
-90	I-DNA
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


The	O
association	O
of	O
specific	O
HLA-DQ	B-DNA
alleles	I-DNA
with	O
autoimmunity	O
is	O
correlated	O
with	O
discrete	O
polymorphisms	O
in	O
the	O
HLA-DQ	B-DNA
sequence	I-DNA
that	O
are	O
localized	O
within	O
sites	O
suitable	O
for	O
peptide	O
recognition	O
.	O


A	O
complementary	O
single-residue	O
substitution	O
in	O
the	O
peptide	O
abolished	O
its	O
binding	O
to	O
DQ3.2	O
and	O
converted	O
it	O
to	O
a	O
peptide	O
that	O
can	O
bind	O
to	O
DQ3.1	O
and	O
DQ3.3	B-protein
Asp-57-positive	I-protein
MHC	I-protein
molecules	I-protein
.	O


The	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
and	O
co-stimulatory	B-protein
molecules	I-protein
,	O
and	O
results	O
in	O
the	O
triggering	O
of	O
several	O
signaling	O
pathways	O
which	O
lead	O
rapidly	O
to	O
the	O
nuclear	O
translocation	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
and	O
NF-AT	B-protein
.	O


While	O
Jurkat	B-cell_line
cells	I-cell_line
both	O
secrete	O
and	O
respond	O
to	O
IFN-gamma	B-protein
in	O
an	O
autocrine	O
loop	O
,	O
it	O
seems	O
likely	O
that	O
the	O
responding	O
cells	O
may	O
differ	O
from	O
those	O
synthesizing	O
this	O
cytokine	B-protein
in	O
the	O
mononuclear	B-cell_line
cell	I-cell_line
cultures	I-cell_line
in	O
the	O
light	O
of	O
the	O
recent	O
report	O
that	O
Th1	B-cell_line
cells	I-cell_line
lack	O
the	O
IFN-gamma	B-protein
receptor	O
chain	O
necessary	O
for	O
activation	O
of	O
STAT1	B-protein
(	O
Pernis	O
,	O
A.	O
,	O
Gupta	O
,	O
S.	O
,	O
Gollob	O
,	O
K.J.	O
,	O
Garfein	O
,	O
E.	O
,	O
Coffman	O
,	O
R.L.	O
,	O
Schindler	O
,	O
C.	O
,	O
and	O
Rothman	O
,	O
P.	O
,	O
Science	O
1995.	O
269	O
:	O
245	O
)	O
.	O


Active	O
Raf-1	B-protein
phosphorylates	O
and	O
activates	O
the	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase/extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
kinase	I-protein
1	I-protein
(	O
MEK1	B-protein
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
and	O
activates	O
the	O
MAP	B-protein
kinases/extracellular	I-protein
signal	I-protein
regulated	I-protein
kinases	I-protein
,	O
ERK1	B-protein
and	O
ERK2	B-protein
.	O


We	O
demonstrated	O
that	O
IL-9	B-DNA
gene	I-DNA
expression	O
is	O
controlled	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
.	O


Transient	O
expression	O
of	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
IL-9	B-DNA
gene	I-DNA
has	O
revealed	O
several	O
positive	O
and	O
negative	B-DNA
regulatory	I-DNA
elements	I-DNA
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	I-DNA
in	O
C5MJ2	B-cell_line
cells	I-cell_line
.	O


Mutations	O
at	O
different	O
sites	O
within	O
this	O
proximal	B-DNA
promoter	I-DNA
region	I-DNA
abolished	O
the	O
promoter	O
activity	O
as	O
well	O
as	O
the	O
DNA	O
binding	O
.	O


Although	O
GM-CSF	B-protein
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
hemopoiesis	O
,	O
overexpression	O
of	O
GM-CSF	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O


We	O
investigated	O
oligonucleotide-directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	B-DNA
sequence	I-DNA
as	O
a	O
potential	O
tool	O
to	O
inhibit	O
GM-CSF	B-protein
gene	O
transcription	O
.	O


Reversible	O
differentiation	O
of	O
human	B-cell_line
monoblastic	I-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
.	O


ML-9-induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML-9	O
plus	O
an	O
anti-cancer	O
drug	O
such	O
as	O
1-beta-D-arabino-furanosylcytosine	O
or	O
daunomycin	O
.	O


Modulation	O
of	O
endogenous	O
IL-1	B-protein
beta	I-protein
and	O
IL-1	B-protein
receptor	I-protein
antagonist	O
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	B-cell_line
infected	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O


In	O
this	O
regard	O
,	O
anti-inflammatory	B-protein
cytokines	I-protein
inhibited	O
LPS	O
plus	O
GM-CSF	B-protein
-stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL-1	B-protein
beta	I-protein
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up-regulation	O
of	O
endogenous	O
IL-1ra	O
production	O
.	O


Like	O
other	O
cytokines	O
,	O
IL-12	B-protein
mediates	O
its	O
biologic	O
activity	O
through	O
high-affinity	O
receptors	O
expressed	O
on	O
responsive	B-cell_type
cells	I-cell_type
.	O


To	O
date	O
,	O
a	O
large	O
number	O
of	O
receptors	O
for	O
IL-12	B-protein
have	O
been	O
found	O
only	O
on	O
PBMC	B-cell_type
following	O
activation	O
with	O
PHA	B-protein
or	O
IL-2	B-protein
.	O


A	O
number	O
of	O
recent	O
studies	O
have	O
described	O
interactions	O
between	O
transcription	B-protein
factors	I-protein
in	O
lymphocytes	O
that	O
provide	O
new	O
insights	O
into	O
mechanisms	O
regulating	O
gene	O
expression	O
.	O


The	O
role	O
of	O
hLH-2	B-DNA
in	O
the	O
development	O
or	O
progression	O
of	O
leukaemia	O
is	O
not	O
known	O
.	O


Lymphoid	O
cell	O
resistance	O
to	O
glucocorticoids	O
in	O
HIV	O
infection	O
.	O


However	O
,	O
chronically	B-cell_type
HIV-infected	I-cell_type
cells	I-cell_type
appear	O
to	O
be	O
resistant	O
to	O
glucocorticoid-evoked	O
cell	O
death	O
.	O


Glucocorticoid	B-protein
receptor	I-protein
-ligand	O
binding	O
studies	O
on	O
patients	O
'	O
cells	O
have	O
shown	O
reduced	O
affinity	O
between	O
the	O
receptor	B-protein
binding	I-protein
sites	I-protein
and	O
test	O
steroids	O
.	O


In	O
vitro	O
,	O
chronically	B-cell_line
HIV-infected	I-cell_line
cells	I-cell_line
of	O
the	O
lymphoid	B-cell_line
CEM	I-cell_line
line	I-cell_line
displayed	O
resistance	O
to	O
glucocorticoid-induced	O
apoptosis	O
.	O


As	O
neutrophils	B-cell_type
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
this	O
fraction	O
,	O
the	O
cells	O
expressing	O
p45	B-protein
is	O
most	O
likely	O
to	O
be	O
neutrophils	B-cell_type
.	O


HL-60	B-cell_line
cells	I-cell_line
were	O
found	O
to	O
express	O
mafK	B-RNA
mRNA	I-RNA
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF-E2	B-protein
complex	I-protein
in	O
the	O
cells	O
.	O


We	O
found	O
nuclear	O
p62c-fos	B-protein
,	O
p39c-jun	B-protein
,	O
and	O
AP-1	B-protein
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	B-cell_line
cells	I-cell_line
and	O
in	O
PHA-stimulated	B-cell_line
PBL	I-cell_line
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	O
transiently	O
in	O
the	O
G0	O
to	O
G1	O
transition	O
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O


Following	O
PHA	B-protein
stimulation	O
of	O
PBL	B-cell_type
,	O
the	O
increase	O
in	O
AP-1	B-protein
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c-jun	B-protein
expression	O
.	O


This	O
B	B-protein
cell	I-protein
restricted	I-protein
coactivator	I-protein
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU.1	B-protein
mediated	O
by	O
the	O
octamer	B-DNA
site	I-DNA
.	O


During	O
T-cell	O
activation	O
,	O
c-myb	B-DNA
expression	O
is	O
induced	O
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O


An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein-DNA	B-protein
complex	I-protein
,	O
referred	O
to	O
as	O
CMAT	B-protein
for	O
c-myb	B-protein
in	I-protein
activated	I-protein
T	I-protein
cells	I-protein
;	O
this	O
complex	O
was	O
not	O
present	O
in	O
unactivated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


U1	B-cell_line
cells	I-cell_line
stimulated	O
with	O
10	O
(	O
-7	O
)	O
M	O
PMA	O
released	O
approximately	O
1	O
ng/ml	O
endogenous	B-protein
TBP-1	I-protein
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	O
PMA	O
stimulation	O
.	O


r-hTBP-1	B-protein
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O


We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli-induced	O
HIV-1	O
expression	O
and	O
NK-	B-protein
kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
in	O
chronically	O
infected	B-cell_type
U1	I-cell_type
cells	I-cell_type
.	O


Transcriptional	O
activation	O
of	O
RNA	B-DNA
polymerase	I-DNA
III-dependent	I-DNA
genes	I-DNA
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
tax	I-protein
protein	I-protein
.	O


The	O
viral	B-protein
protein	I-protein
Tax	I-protein
was	O
likely	O
responsible	O
for	O
this	O
higher	O
level	O
of	O
class	B-DNA
II	I-DNA
gene	I-DNA
transcription	O
,	O
as	O
purified	B-protein
Tax	I-protein
was	O
found	O
to	O
stimulate	O
both	O
genes	O
when	O
added	O
to	O
the	O
uninfected	O
cell	O
extract	O
or	O
in	O
reconstituted	O
systems	O
.	O


The	O
recently	O
cloned	O
TCL1	B-DNA
gene	I-DNA
,	O
also	O
involved	O
in	O
translocations	O
and	O
inversions	O
associated	O
with	O
T-cell	O
proliferations	O
,	O
codes	O
for	O
a	O
14-kD	B-protein
protein	I-protein
that	O
displays	O
significant	O
homology	O
with	O
p13MTCP1	B-protein
.	O


We	O
have	O
generated	O
rabbit	O
antisera	O
against	O
this	O
putative	O
p13MTCP1	B-protein
protein	I-protein
and	O
screened	O
for	O
expression	O
of	O
p13MTCP1	B-protein
normal	O
lymphoid	O
tissues	O
and	O
33	O
cases	O
of	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
lymphoid	I-cell_type
T-cell	I-cell_type
proliferations	I-cell_type
using	O
a	O
sensitive	O
Western	O
blot	O
assay	O
.	O


Newly	O
translated	O
STAT1	B-protein
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	B-protein
and	O
STAT3	B-protein
,	O
but	O
we	O
show	O
that	O
STAT2	B-protein
and	O
STAT3	B-protein
exist	O
in	O
separate	O
heterocomplexes	B-protein
with	O
STAT1	B-protein
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	B-protein
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	B-protein
proteins	I-protein
.	O


Not	O
only	O
was	O
this	O
effect	O
observed	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
DNA	O
binding	O
capacity	O
was	O
affected	O
as	O
well	O
,	O
A	O
strong	O
reduction	O
was	O
observed	O
in	O
the	O
LPS-induced	O
DNA-binding	O
activity	O
of	O
AP-1	B-protein
in	O
the	O
presence	O
of	O
IFN-gamma	B-protein
.	O


MIP-1	B-protein
alpha	I-protein
is	O
a	O
secreted	O
chemokine	B-protein
which	O
can	O
inhibit	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
modulate	O
inflammatory	O
responses	O
.	O


Although	O
Stat	O
binding	O
to	O
the	O
intracellular	B-protein
domain	I-protein
of	O
the	O
cytokine	B-protein
receptor	I-protein
strongly	O
depends	O
on	O
the	O
phosphotyrosine	O
residue	O
,	O
the	O
recruitment	O
of	O
a	O
specific	O
Stat	B-protein
protein	I-protein
is	O
dictated	O
by	O
amino	O
acid	O
residues	O
C-terminal	O
to	O
the	O
phosphotyrosine	O
.	O


Specific	O
docking	B-protein
sites	I-protein
within	O
individual	O
cytokine	B-protein
receptors	I-protein
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	B-protein
proteins	I-protein
.	O


The	O
direct	O
coupling	O
between	O
cytokine	B-protein
receptor	I-protein
and	O
transcription	B-protein
factor	I-protein
helps	O
to	O
explain	O
how	O
different	O
cytokines	B-protein
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O


The	O
immediate-early	B-DNA
gene	I-DNA
egr-1	B-DNA
encodes	O
a	O
transcription	B-protein
factor	I-protein
(	O
EGR1	B-protein
)	O
that	O
links	O
B-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
signals	O
to	O
downstream	O
activation	O
events	O
through	O
the	O
regulation	O
of	O
previously	O
unidentified	O
target	B-DNA
genes	I-DNA
.	O


Cotransfection	O
of	O
a	O
CD44	B-DNA
promoter-chloramphenicol	I-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
with	O
an	O
egr-1	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
a	O
6.5-	O
to	O
8.5-fold	O
induction	O
of	O
transcriptional	O
activity	O
relative	O
to	O
an	O
empty	B-DNA
expression	I-DNA
vector	I-DNA
.	O


In	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
its	O
subclone	O
Wurzburg	B-cell_line
cells	I-cell_line
oxidant	O
challenge	O
elevated	O
[	O
Ca2+	O
]	O
i	O
by	O
mobilizing	O
Ca2+	O
from	O
intracellular	O
stores	O
.	O


Transactivation	O
of	O
the	O
interleukin-1alpha	B-DNA
promoter	I-DNA
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
Tax	I-protein
proteins	I-protein
.	O


IL-1alpha	B-DNA
promoter	I-DNA
constructs	I-DNA
drive	O
transcription	O
of	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
HTLV-I-positive	B-cell_line
MT-2	I-cell_line
cells	I-cell_line
,	O
which	O
constitutively	O
produce	O
IL-1alpha	B-protein
.	O


In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	B-protein
protein	I-protein
of	O
both	O
HTLV-I	O
and	O
HTLV-II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL-1alpha	B-DNA
promoter	I-DNA
in	O
an	O
uninfected	B-cell_line
Jurkat	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


The	O
myeloid-cell-specific	B-DNA
c-fes	I-DNA
promoter	I-DNA
is	O
regulated	O
by	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and	O
a	O
novel	O
transcription	B-protein
factor	I-protein
.	O


DNase	O
I	O
footprinting	O
assays	O
revealed	O
four	O
distinct	O
sites	O
that	O
bind	O
myeloid	B-protein
nuclear	I-protein
proteins	I-protein
(	O
-408	B-DNA
to	I-DNA
-386	I-DNA
,	O
-293	B-DNA
to	I-DNA
-254	I-DNA
,	O
-76	B-DNA
to	I-DNA
-65	I-DNA
,	O
and	O
-34	B-DNA
to	I-DNA
+3	I-DNA
)	O
.	O


Furthermore	O
,	O
transient-cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	B-protein
(	O
and	O
not	O
Elf-1	B-protein
)	O
can	O
transactivate	O
the	O
c-fes	B-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


IL-10	B-protein
inhibits	O
nuclear	B-protein
factor-kappa	I-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
CD3-stimulated	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O


Indeed	O
,	O
monocytes	B-cell_type
pretreated	O
with	O
IL-10	B-protein
are	O
able	O
so	O
inhibit	O
NF-kappa	B-protein
B	I-protein
nuclear	O
activity	O
in	O
purified	O
T	B-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
OKT3	B-protein
.	O


In	O
a	O
panel	O
of	O
32	O
B-cell	B-cell_line
lines	I-cell_line
,	O
A-myb	B-DNA
was	O
very	O
strongly	O
expressed	O
in	O
most	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
but	O
weak	O
or	O
negative	O
in	O
2	O
pre-B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
4	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
6	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
6	O
myeloma	B-cell_line
lines	I-cell_line
.	O


Protein	O
expression	O
paralleled	O
that	O
of	O
the	O
RNA	O
.	O


Unexpectedly	O
,	O
expression	O
of	O
the	O
same	O
EBNA2	B-protein
-oestrogen	O
receptor	O
fusion	O
protein	O
in	O
established	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
resulted	O
in	O
growth	O
retardation	O
or	O
growth	O
arrest	O
upon	O
the	O
addition	O
of	O
oestrogen	O
.	O


The	O
functional	O
Ets	B-DNA
binding	I-DNA
site	I-DNA
was	O
found	O
to	O
bind	O
Ets	B-protein
family	I-protein
proteins	I-protein
,	O
principally	O
GA-binding	B-protein
protein	I-protein
and	O
Elf-1	B-protein
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	B-protein
and	O
-beta	B-protein
synergistically	O
.	O


One	O
of	O
the	O
manifestations	O
of	O
human	O
HIV-1	O
and	O
nonhuman	O
primate	O
SIV	O
infection	O
that	O
lead	O
to	O
disease	O
is	O
reasoned	O
to	O
be	O
secondary	O
to	O
generalized	O
T-cell	O
dysfunction	O
.	O


To	O
address	O
this	O
issue	O
,	O
we	O
sought	O
to	O
utilize	O
the	O
nonhuman	O
primate	O
model	O
to	O
study	O
intracellular	O
signaling	O
events	O
in	O
cells	O
from	O
disease-susceptible	O
rhesus	O
macaques	O
and	O
disease-resistant	O
sooty	O
mangabeys	O
.	O


Of	O
five	O
positive	O
clones	O
isolated	O
from	O
0.75	O
x	O
10	O
(	O
6	O
)	O
yeast	O
colonies	O
,	O
four	O
were	O
members	O
of	O
the	O
CREB/activating	B-protein
transcription	I-protein
factor	I-protein
(	I-protein
ATF	I-protein
)	I-protein
family	I-protein
:	O
CREB	B-protein
,	O
two	B-protein
isoforms	I-protein
of	I-protein
the	I-protein
cyclic	I-protein
AMP-responsive	I-protein
element	I-protein
modulator	I-protein
(	O
CREM	B-protein
)	O
,	O
and	O
ATF-1	B-protein
.	O


This	O
shows	O
that	O
in	O
a	O
eukaryotic	O
nucleus	O
,	O
Tax	B-protein
specifically	O
interacts	O
with	O
the	O
basic	B-protein
domain-leucine	I-protein
zipper	I-protein
region	I-protein
of	O
ATF-1	B-protein
,	O
CREB	B-protein
,	O
and	O
CREM	B-protein
.	O


Interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
and	O
IL-4	B-protein
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23-31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O


As	O
assessed	O
with	O
mutagenized	B-DNA
promoters	I-DNA
,	O
the	O
most	O
important	O
IL-2	B-DNA
cis-regulatory	I-DNA
elements	I-DNA
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
and	O
the	O
NF-	B-DNA
kappaB	I-DNA
site	I-DNA
.	O


Previous	O
studies	O
have	O
shown	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
similar	O
to	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
can	O
act	O
as	O
a	O
bifunctional	O
regulator	O
of	O
the	O
growth	O
of	O
bone	B-cell_type
marrow	I-cell_type
progenitors	I-cell_type
,	O
in	O
that	O
it	O
can	O
stimulate	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
-	O
or	O
interleukin-3	O
(	O
IL-3	O
)	O
-induced	O
GM	O
colony	O
formation	O
,	O
but	O
potently	O
inhibit	O
G-CSF	B-protein
-induced	O
growth	O
.	O


Transactivation	O
studies	O
showed	O
that	O
both	O
the	O
RAR	B-protein
(	O
Ro	O
13-7410	O
)	O
and	O
RXR	B-protein
(	O
Ro	O
25-6603	O
and	O
Ro	O
25-7386	O
)	O
ligands	O
were	O
highly	O
selective	O
at	O
100	O
nmol/L	O
.	O


By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
these	O
differentiation	B-protein
markers	I-protein
in	O
the	O
HL-60	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
in	O
freshly	B-cell_type
isolated	I-cell_type
granulocytes	I-cell_type
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O


These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML-RAR	B-protein
is	O
present	O
.	O


However	O
,	O
in	O
the	O
presence	O
of	O
PML-RAR	B-protein
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	B-DNA
acid-responsive	I-DNA
element-containing	I-DNA
promoters	I-DNA
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	B-protein
alpha	I-protein
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O


We	O
hypothesized	O
that	O
an	O
intracellular	B-protein
vitamin	I-protein
D	I-protein
binding	I-protein
protein	I-protein
(	O
IDBP	B-protein
)	O
,	O
present	O
in	O
both	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
of	O
NWP	B-cell_line
cells	I-cell_line
,	O
or	O
another	O
protein	O
(	O
s	O
)	O
may	O
cause	O
or	O
contribute	O
to	O
the	O
steroid	O
hormone-resistant	O
state	O
in	O
NWP	B-cell_line
by	O
disruption	O
of	O
the	O
receptor	O
dimerization	O
process	O
and/or	O
by	O
interference	O
of	O
receptor	B-protein
complex	I-protein
binding	O
to	O
the	O
consensus	B-DNA
response	I-DNA
elements	I-DNA
present	O
in	O
the	O
enhancer	B-DNA
regions	I-DNA
of	O
steroid-responsive	B-DNA
genes	I-DNA
.	O


The	O
extracts	O
were	O
compared	O
for	O
their	O
ability	O
to	O
retard	O
the	O
migration	O
of	O
radiolabeled	O
double	O
stranded	O
oligomers	O
representative	O
of	O
the	O
VDREs	B-DNA
of	O
the	O
human	B-DNA
osteocalcin	I-DNA
and	I-DNA
the	I-DNA
mouse	I-DNA
osteopontin	I-DNA
gene	I-DNA
promoters	I-DNA
.	O


The	O
present	O
study	O
shows	O
that	O
BCL-6	B-protein
expression	O
is	O
regulated	O
in	O
lymphocytes	B-cell_type
during	O
mitogenic	O
stimulation	O
.	O


Of	O
these	O
,	O
11	O
were	O
found	O
to	O
possess	O
DNA-binding	O
properties	O
.	O


In	O
resting	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
is	O
sequestered	O
in	O
the	O
cytoplasm	O
via	O
interactions	O
with	O
members	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
family	I-protein
of	O
inhibitors	O
,	O
including	O
IkappaBalpha	B-protein
and	O
IkappaBbeta	B-protein
.	O


In	O
contrast	O
to	O
its	O
transient	O
pattern	O
of	O
nuclear	O
induction	O
during	O
an	O
immune	O
response	O
,	O
NF-kappaB	B-protein
is	O
constitutively	O
activated	O
in	O
cells	O
expressing	O
the	O
Tax	B-protein
transforming	I-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-1	O
)	O
.	O


However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	B-protein
protein	I-protein
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF-kappaB	B-protein
response	O
.	O


These	O
findings	O
with	O
IkappaBbeta	B-protein
provide	O
a	O
potential	O
mechanism	O
for	O
the	O
constitutive	O
activation	O
of	O
NF-kappaB	B-protein
in	O
Tax-expressing	B-cell_line
cells	I-cell_line
.	O


Although	O
a	O
role	O
of	O
p16	B-protein
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	B-DNA
suppressor	I-DNA
gene	I-DNA
really	O
affects	O
E2F	B-protein
-mediated	O
regulations	O
.	O


Transient	O
expression	O
of	O
p16	B-protein
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT-4	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	B-protein
protein	I-protein
.	O


However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	B-protein
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF-2	B-protein
or	O
ICSBP	B-protein
in	O
some	O
IFN-responsive	B-DNA
reporter	I-DNA
constructs	I-DNA
.	O


H1-agonists	O
(	O
histamine	O
and	O
2-methylhistamine	O
)	O
caused	O
a	O
transient	O
rise	O
of	O
[	O
Ca2+	O
]	O
,	O
and	O
H1-antagonists	O
(	O
pyrilamine	O
and	O
doxepin	O
)	O
inhibited	O
the	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
more	O
potently	O
than	O
the	O
H2-antagonist	O
(	O
cimetidine	O
)	O
on	O
the	O
H3-antagonist	O
(	O
impromidine	O
)	O
.	O


Binding	O
parameters	O
of	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
were	O
Kd	O
=	O
5.53	O
nM	O
and	O
Bmax	O
=	O
2	O
,	O
647	O
sites/cell	O
.	O


Pretreatment	O
with	O
B.pertussis	O
,	O
V.cholera.	O
or	O
C.botulinum	O
toxin	O
did	O
not	O
influence	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
.	O


A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	B-protein
has	O
recently	O
been	O
elaborated	O
.	O


In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	B-protein
factors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
acute	O
leukemia	O
.	O


We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta-casein	B-DNA
and	I-DNA
IRF-1	I-DNA
gene	I-DNA
promoters	I-DNA
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	B-protein
proteins	I-protein
in	O
nuclear	O
extracts	O
from	O
acute	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
in	O
bandshift	O
assays	O
.	O


It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O


An	O
element	B-DNA
upstream	O
from	O
the	O
human	B-DNA
delta-globin-encoding	I-DNA
gene	I-DNA
specifically	O
enhances	O
beta-globin	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
murine	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O


We	O
have	O
previously	O
shown	O
that	O
a	O
DNA-binding	B-protein
factor	I-protein
specific	O
to	O
adult	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
(	O
polypryrimidine-binding	B-protein
factor	I-protein
,	O
PYBF	B-protein
)	O
binds	O
to	O
a	O
pyrimidine-rich	B-DNA
region	I-DNA
1	B-DNA
kb	I-DNA
upstream	I-DNA
from	O
the	O
human	B-DNA
delta-globin-encoding	I-DNA
gene	I-DNA
(	O
HBD	B-DNA
)	O
.	O


Here	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
an	O
alternatively	O
spliced	O
variant	O
of	O
Spi-B	B-protein
,	O
named	O
deltaSpi-B	B-protein
,	O
which	O
has	O
lost	O
the	O
Ets	B-protein
domain	I-protein
.	O


The	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
and	O
B	B-protein
cell	I-protein
octamer-binding	I-protein
protein	I-protein
1/octamer-binding	I-protein
factor	I-protein
1/Oct	I-protein
coactivator	I-protein
from	O
B	B-cell_type
cells	I-cell_type
(	O
Bob1/OBF-1/OCA-B	B-protein
)	O
represent	O
two	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivators	I-protein
.	O


Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF-kappaB	B-DNA
and/or	O
Sp1	B-DNA
binding	I-DNA
elements	I-DNA
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O


One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	B-cell_line
cells	I-cell_line
(	O
2x	O
NFKappaB	B-protein
>	O
or	O
=	O
SlVmac239	B-protein
approximately	O
deltaNFkappaB	B-protein
approximately	O
deltaSpl234	B-protein
approximately	O
substNFkappaB	B-protein
approximately	O
substSpl2	B-protein
approximately	O
substSp23	B-protein
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	B-cell_line
cells	I-cell_line
(	O
SIVmac239	O
>	O
substSp34	B-protein
>	O
deltaNFkappaBdeltaSpl234	B-protein
approximately	O
deltaNFkappaBdeltaSp1	B-protein
>	O
substSpl234	B-protein
)	O
.	O


This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	B-protein
.	O


The	O
Epstein-Barr	B-protein
virus-encoded	I-protein
nuclear	I-protein
antigen	I-protein
EBNA-5	I-protein
accumulates	O
in	O
PML-containing	O
bodies	O
.	O


In	O
the	O
nuclei	O
of	O
EBV-transformed	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
EBNA-5	B-protein
is	O
preferentially	O
targetted	O
to	O
distinct	O
nuclear	O
foci	O
.	O


A	O
model	O
of	O
latent	O
adenovirus	O
5	O
infection	O
in	O
the	O
guinea	O
pig	O
(	O
Cavia	O
porcellus	O
)	O
.	O


These	O
stable	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
provide	O
a	O
convenient	O
and	O
sensitive	O
tool	O
to	O
study	O
NFAT	B-protein
regulation	O
.	O


The	O
possibility	O
that	O
Oct-2a	B-protein
can	O
act	O
as	O
an	O
activator	O
and/or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct-2a	B-protein
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O


The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor-induced	O
NF-kappaB	B-protein
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
.	O


Exogenous	O
IL-2	B-protein
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti-CD3-	B-cell_line
and	I-cell_line
anti-CD28-treated	I-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
restores	O
production	O
of	O
IL-5	O
,	O
TNF-alpha	B-protein
,	O
and	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-3	B-protein
and	O
GM-CSF	B-protein
expression	O
to	O
approximately	O
normal	O
levels	O
.	O


The	O
IL-2	B-protein
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O


Here	O
we	O
demonstrate	O
that	O
CD28RE	B-DNA
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	B-protein
factor	I-protein
of	I-protein
mitogenic-activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-MATp35	B-protein
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF-	B-protein
kappaB/Rel	I-protein
family	I-protein
members	I-protein
.	O


Studies	O
included	O
structural	O
comparison	O
of	O
the	O
promoters	O
for	O
human	O
and	O
mouse	O
inducible	B-DNA
NO	I-DNA
synthase	I-DNA
(	I-DNA
iNOS	I-DNA
)	I-DNA
genes	I-DNA
,	O
transfection	O
and	O
assay	O
of	O
human	O
and	O
mouse	O
iNOS	B-DNA
promoter	I-DNA
regions	I-DNA
in	O
response	O
to	O
LPS	O
+/-	O
IFN-gamma	B-protein
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
of	O
kappa	B-DNA
B	I-DNA
response	I-DNA
elements	I-DNA
.	O


Viral	B-DNA
DNA	I-DNA
fragments	I-DNA
that	O
potentially	O
contain	O
oriP	B-DNA
were	O
cloned	O
into	O
a	O
plasmid	B-DNA
that	O
contains	O
the	O
hygromycin	B-DNA
resistance	I-DNA
gene	I-DNA
.	O


In	O
vivo	O
,	O
anergy	O
has	O
mainly	O
been	O
studied	O
at	O
the	O
cellular	O
level	O
.	O


In	O
contrast	O
,	O
repeated	O
injections	O
of	O
SEA	B-protein
cause	O
CD4+	B-cell_type
T-cell	I-cell_type
deletion	O
and	O
anergy	O
in	O
the	O
remaining	O
CD4+	O
T	B-cell_type
cells	I-cell_type
,	O
characterized	O
by	O
reduced	O
expression	O
of	O
IL-2	B-protein
at	O
mRNA	O
and	O
protein	O
levels	O
.	O


In	O
contrast	O
,	O
anergic	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
contained	O
severely	O
reduced	O
levels	O
of	O
AP-1	B-protein
and	O
Fos/Jun-containing	B-protein
NF-AT	I-protein
complexes	I-protein
but	O
expressed	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Oct	B-protein
binding	I-protein
proteins	I-protein
after	O
SEA	B-protein
stimulation	O
.	O


Resolution	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
demonstrated	O
predominant	O
expression	O
of	O
p50-p65	B-protein
heterodimers	I-protein
in	O
activated	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
anergic	O
cells	O
mainly	O
expressed	O
the	O
transcriptionally	O
inactive	O
p50	B-protein
homodimer	I-protein
.	O


Fas	B-protein
ligation	O
induces	O
apoptosis	O
and	O
Jun	B-protein
kinase	I-protein
activation	O
independently	O
of	O
CD45	B-protein
and	O
Lck	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


More	O
is	O
known	O
regarding	O
signal	O
transduction	O
events	O
that	O
occur	O
after	O
ligation	O
of	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
.	O


It	O
has	O
been	O
shown	O
that	O
TCR	B-protein
stimulation	O
requires	O
both	O
the	O
membrane	B-protein
tyrosine	I-protein
phosphatase	I-protein
,	O
CD45	B-protein
,	O
and	O
the	O
Src-family	B-protein
kinase	I-protein
,	O
Lck	B-protein
,	O
to	O
result	O
in	O
cellular	O
activation	O
.	O


Our	O
data	O
suggest	O
that	O
although	O
CD45	B-protein
and	O
Lck	B-protein
are	O
not	O
required	O
for	O
Fas	B-protein
signaling	O
,	O
JNK	B-protein
activation	O
may	O
play	O
an	O
important	O
role	O
transducing	O
distal	O
signals	O
that	O
lead	O
to	O
apoptosis	O
after	O
Fas	B-protein
ligation	O
.	O


Globin	O
gene	O
switching	O
.	O


In	O
vivo	O
protein-DNA	O
interactions	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	B-DNA
gene	I-DNA
program	O
.	O


In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	B-DNA
(	I-DNA
CACCC	I-DNA
)	I-DNA
motifs	I-DNA
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O


Antisense	O
inhibition	O
of	O
vitamin	B-protein
D	I-protein
receptor	I-protein
expression	O
induces	O
apoptosis	O
in	O
monoblastoid	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O


A	O
considerable	O
proportion	O
of	O
cells	O
were	O
outside	O
the	O
cycle	O
and	O
DNA	O
fragmentation	O
confirmed	O
apoptosis	O
.	O


We	O
now	O
report	O
that	O
galectin-3	B-protein
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	B-cell_line
T	I-cell_line
lymphotropic	I-cell_line
virus	I-cell_line
(	I-cell_line
HTLV	I-cell_line
)	I-cell_line
-I-infected	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
including	O
F6T	B-cell_line
,	O
HUT	B-cell_line
102	I-cell_line
,	O
K3T	B-cell_line
,	O
MT-2	B-cell_line
,	O
and	O
SLB-I	B-cell_line
,	O
but	O
is	O
not	O
expressed	O
in	O
non-HTLV-I-infected	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
such	O
as	O
Jurkat	B-cell_line
,	O
CEM	B-cell_line
,	O
and	O
MOLT-4	B-cell_line
.	O


In	O
co-transfection	O
experiments	O
,	O
the	O
galectin-3	B-DNA
promoter	I-DNA
was	O
significantly	O
up-regulated	O
by	O
expression	B-DNA
vectors	I-DNA
encoding	O
the	O
40-kd	B-protein
Tax	I-protein
protein	I-protein
,	O
a	O
potent	O
transactivator	O
in	O
HTLV-I	O
.	O


Nuclear	O
extracts	O
from	O
LPS	O
-and	O
zymosan-treated	B-cell_type
cells	I-cell_type
showed	O
strong	O
AP-1	B-protein
activity	O
by	O
gel-shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP-1	B-protein
complexes	I-protein
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
families	I-DNA
.	O


Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	B-protein
induction	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	B-DNA
promoter	I-DNA
sequences	I-DNA
.	O


As	O
AP-1	B-protein
activity	O
is	O
regulated	O
in	O
part	O
by	O
activation	O
of	O
the	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
which	O
phosphorylates	O
and	O
subsequently	O
increases	O
the	O
transcriptional	O
activity	O
of	O
c-Jun	O
,	O
we	O
examined	O
whether	O
LPS	O
treatment	O
of	O
macrophages	B-cell_type
resulted	O
in	O
activation	O
of	O
this	O
kinase	B-protein
.	O


Further	O
addition	O
of	O
E220K	B-protein
significantly	O
enhanced	O
ubiquitinylation	O
of	O
c-Jun	B-protein
in	O
the	O
heterodimer	O
suggesting	O
a	O
regulatory	O
role	O
of	O
E220K	B-protein
.	O


From	O
a	O
murine	B-DNA
B-cell	I-DNA
cDNA-library	I-DNA
we	O
have	O
cloned	O
a	O
cDNA	B-DNA
encoding	O
the	O
murine	B-protein
B-cell	I-protein
specific	I-protein
coactivator	I-protein
mBob1	B-protein
.	O


mBob1	B-protein
interacts	O
with	O
the	O
octamer	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O


These	O
results	O
provide	O
new	O
insights	O
into	O
how	O
gp120	B-protein
can	O
influence	O
the	O
involvement	O
of	O
glial	B-cell_type
cells	I-cell_type
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
complex	O
.	O


IL-10	B-protein
is	O
elevated	O
in	O
HIV-1-infected	O
individuals	O
and	O
has	O
been	O
implicated	O
in	O
disease	O
progression	O
.	O


In	O
combination	O
with	O
TNF-alpha	B-protein
,	O
IL-10	B-protein
stimulated	O
activating	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
binding	O
activities	O
and	O
cooperated	O
to	O
increase	O
HIV-1	O
steady-state	O
mRNA	O
levels	O
and	O
enhance	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-directed	O
transcription	O
through	O
activation	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
,	O
suggesting	O
the	O
IL-10	B-protein
effect	O
occurs	O
at	O
least	O
in	O
part	O
at	O
the	O
transcriptional	O
level	O
.	O


One	O
family	O
of	O
host	B-protein
transcription	I-protein
factors	I-protein
whose	O
activity	O
is	O
altered	O
by	O
Tax	B-protein
includes	O
NF-kappa	B-protein
B/Rel	I-protein
.	O


Inhibition	O
of	O
protein	B-protein
phosphatase	I-protein
2A	I-protein
induces	O
serine/threonine	O
phosphorylation	O
,	O
subcellular	O
redistribution	O
,	O
and	O
functional	O
inhibition	O
of	O
STAT3	B-protein
.	O


Signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
in	O
response	O
to	O
cytokine	B-protein
and	O
growth	B-protein
factor	I-protein
stimulation	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
.	O


Similar	O
results	O
were	O
obtained	O
with	O
other	O
PP2A	O
inhibitors	O
(	O
okadaic	O
acid	O
,	O
endothall	O
thioanhydride	O
)	O
but	O
not	O
with	O
inhibitors	O
of	O
PP1	B-protein
(	O
tautomycin	O
)	O
or	O
PP2B	B-protein
(	O
cyclosporine	O
A	O
)	O
.	O


Polyamines	O
in	O
human	O
breast	O
cancer	O
and	O
its	O
relations	O
to	O
classical	O
prognostic	O
features	O
:	O
clinical	O
implications	O
.	O


Nevertheless	O
how	O
the	O
protective	O
response	O
is	O
exerted	O
by	O
flavonoids	O
is	O
not	O
well	O
characterized	O
.	O


Of	O
six	O
flavonoids	O
tested	O
,	O
myricetin	O
was	O
found	O
to	O
strongly	O
inhibit	O
IKK	B-protein
kinase	O
activity	O
,	O
and	O
prevent	O
the	O
degradation	O
of	O
IkappaBalpha	B-protein
and	O
IkappaBbeta	B-protein
in	O
activated	O
endothelial	O
cells	O
.	O


Phosphorylated	O
Bcl-2	B-protein
can	O
not	O
bind	O
calcineurin	B-protein
,	O
and	O
NFAT	B-protein
activation	O
,	O
FasL	B-protein
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl-2	B-protein
phosphorylation	O
.	O


MHC	B-protein
class	I-protein
II	I-protein
density	O
on	O
the	O
APC	B-cell_type
was	O
modified	O
using	O
DQ2	B-cell_line
homo	I-cell_line
-and	I-cell_line
heterozygous	I-cell_line
B-LCLs	I-cell_line
as	O
APCs	B-cell_type
,	O
however	O
this	O
variation	O
of	O
MHC	O
concentration	O
had	O
no	O
effect	O
on	O
T	B-cell_type
cell	I-cell_type
proliferation	O
.	O


It	O
is	O
interesting	O
that	O
IL-11	B-protein
did	O
not	O
affect	O
BAL	O
fluid	O
content	O
of	O
the	O
CXC	B-protein
chemokines	I-protein
,	O
macrophage	B-protein
inflammatory	I-protein
protein-2	I-protein
(	O
MIP-2	B-protein
)	O
and	O
cytokine-inducible	B-protein
neutrophil	I-protein
chemoattractant	I-protein
(	O
CINC	B-protein
)	O
;	O
the	O
presence	O
of	O
IL-11	B-protein
did	O
not	O
affect	O
these	O
chemokines	B-protein
.	O


Hence	O
,	O
we	O
have	O
investigated	O
whether	O
Stat	B-protein
proteins	I-protein
are	O
present	O
in	O
platelets	B-cell_type
and	O
,	O
if	O
so	O
,	O
whether	O
they	O
become	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
thrombopoietin	B-protein
.	O


Thrombopoietin	B-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
these	O
cells	O
.	O


This	O
review	O
suggests	O
roles	O
for	O
these	O
alterations	O
in	O
the	O
development	O
of	O
lymphoid	O
neoplasms	O
.	O


An	O
understanding	O
of	O
the	O
mechanistic	O
consequences	O
following	O
such	O
genetic	O
alterations	O
is	O
essential	O
to	O
an	O
understanding	O
of	O
the	O
development	O
of	O
these	O
lymphoid	O
neoplasms	O
.	O


Taken	O
together	O
,	O
this	O
review	O
supports	O
the	O
notion	O
that	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
is	O
multifactorial	O
,	O
involving	O
genetic	O
alterations	O
as	O
well	O
as	O
dysregulated	O
cytokine	B-protein
expression	O
.	O


In	O
addition	O
to	O
its	O
role	O
as	O
a	O
precursor	O
for	O
other	O
steroid	O
hormones	O
,	O
DHEA	O
has	O
been	O
proposed	O
to	O
play	O
an	O
important	O
role	O
in	O
immunity	O
.	O


Cytotoxicity	B-protein
markers	I-protein
assessed	O
include	O
tumor	O
cell	O
killing	O
,	O
IL-1	B-protein
secretion	O
,	O
reactive	O
oxygen	O
intermediate	O
release	O
,	O
nitric	B-protein
oxide	I-protein
synthetase	I-protein
activity	O
as	O
measured	O
by	O
the	O
release	O
of	O
reactive	O
nitrogen	O
intermediates	O
,	O
complement	B-protein
receptor-1	I-protein
cell	I-protein
surface	I-protein
protein	I-protein
,	O
and	O
TNF-alpha	B-protein
protein	I-protein
presence	O
.	O


Finally	O
,	O
Scatchard	O
plot	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
a	O
DHEA	O
receptor	O
in	O
monocytes	B-cell_type
,	O
suggesting	O
that	O
DHEA	O
effects	O
on	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
are	O
mediated	O
through	O
a	O
receptor-dependent	O
process	O
.	O


IL-4	B-protein
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	B-protein
transcription	I-protein
factor	I-protein
,	O
STAT6	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-6	I-protein
)	O
.	O


This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B-protein
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	B-protein
for	O
at	O
least	O
1	O
hr	O
before	O
IL-4	B-protein
stimulation	O
.	O


We	O
further	O
explored	O
the	O
effect	O
of	O
dopamine	O
in	O
the	O
presence	O
of	O
phorbol	O
esters	O
or	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
known	O
to	O
activate	O
NF-kappaB	B-protein
.	O


Selective	O
DNA-binding	O
activity	O
of	O
interleukin-10-stimulated	B-protein
STAT	I-protein
molecules	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


Peptides	O
derived	O
from	O
the	O
HSV-2	B-protein
VP16	I-protein
protein	I-protein
were	O
utilized	O
for	O
studies	O
of	O
peptide	O
binding	O
to	O
DQ0302	O
molecules	O
and	O
T	O
cell	O
activation	O
at	O
both	O
neutral	O
and	O
acidic	O
pH	O
.	O


The	O
homologous	O
peptide	O
430-444	O
,	O
442A	O
has	O
an	O
Asp	O
to	O
Ala	O
substitution	O
at	O
position	O
442	O
and	O
binds	O
to	O
DQ0302	O
with	O
a	O
Kd	O
similar	O
to	O
433-442	O
.	O


While	O
the	O
MHC-peptide	B-protein
complexes	I-protein
formed	O
with	O
the	O
native	O
peptide	O
are	O
stable	O
,	O
complexes	O
formed	O
with	O
the	O
Ala-substituted	O
peptide	O
had	O
a	O
functional	O
t1/2	O
of	O
less	O
than	O
4	O
hr	O
at	O
neutral	O
pH	O
.	O


In	O
RAW264.7	B-cell_line
cells	I-cell_line
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	B-cell_line
marrow-derived	I-cell_line
macrophages	I-cell_line
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon-gamma	B-protein
inducible	O
.	O


This	O
may	O
imply	O
a	O
role	O
for	O
ets	B-protein
transcription	I-protein
factors	I-protein
in	O
the	O
production	O
of	O
TNF-alpha	B-protein
.	O


Due	O
to	O
its	O
location	O
within	O
this	O
cluster	O
and	O
its	O
biologic	O
role	O
in	O
Ig	O
class	O
switching	O
and	O
Th2	B-cell_line
cell	I-cell_line
differentiation	O
,	O
the	O
IL-4	B-DNA
gene	I-DNA
has	O
emerged	O
as	O
one	O
major	O
candidate	O
for	O
the	O
atopy	B-DNA
gene	I-DNA
.	O


In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL-4-positive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


In	O
EMSAs	O
,	O
this	O
substitution	O
results	O
in	O
a	O
markedly	O
enhanced	O
affinity	O
for	O
sequence-specific	O
complexes	O
exhibiting	O
an	O
AP-1	B-protein
specificity	O
.	O


In	O
contrast	O
,	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
older	O
individuals	O
show	O
a	O
significant	O
reduction	O
in	O
the	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
response	O
to	O
the	O
same	O
stimuli	O
.	O


We	O
have	O
now	O
further	O
studied	O
the	O
regulation	O
of	O
IL-1ra	B-protein
by	O
the	O
major	O
physiological	O
human	O
glucocorticoid	O
,	O
cortisol	O
.	O


Cell-mediated	O
immunity	O
plays	O
an	O
essential	O
role	O
in	O
the	O
control	O
of	O
infection	O
with	O
the	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
.	O


However	O
,	O
only	O
a	O
few	O
CD8	B-protein
(	I-protein
+	I-protein
)	I-protein
-T-cell	I-protein
epitopes	I-protein
are	O
known	O
,	O
with	O
the	O
majority	O
being	O
contained	O
in	O
the	O
pp65	B-protein
phosphoprotein	I-protein
,	O
which	O
is	O
believed	O
to	O
dominate	O
the	O
CD8	O
(	O
+	O
)	O
-T-cell	O
response	O
to	O
HCMV	O
.	O


Here	O
,	O
we	O
have	O
readdressed	O
the	O
issue	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
specific	O
for	O
the	O
72-kDa	B-protein
major	I-protein
immediate-early	I-protein
protein	I-protein
(	O
IE-1	B-protein
)	O
,	O
which	O
is	O
nonstructural	O
but	O
is	O
found	O
very	O
early	O
and	O
throughout	O
the	O
replicative	O
cycle	O
.	O


The	O
frequencies	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
directed	O
against	O
IE-1	B-protein
were	O
similar	O
to	O
those	O
directed	O
against	O
pp65	B-protein
in	O
donors	O
tested	O
with	O
known	O
pp65	B-protein
-derived	O
peptides	O
.	O


E1A	B-DNA
oncogene	I-DNA
induction	O
of	O
cellular	O
susceptibility	O
to	O
killing	O
by	O
cytolytic	B-cell_type
lymphocytes	I-cell_type
through	O
target	O
cell	O
sensitization	O
to	O
apoptotic	O
injury	O
.	O


Loss	O
of	O
both	O
cytolytic	O
susceptibility	O
and	O
sensitization	O
to	O
chemically	O
induced	O
apoptosis	O
was	O
coselected	O
during	O
in	O
vivo	O
selection	O
of	O
E1A-positive	B-cell_type
sarcoma	I-cell_type
cells	I-cell_type
for	O
increased	O
tumorigenicity	O
.	O


Copyright	O
1999	O
Academic	O
Press	O
.	O


In	O
transient-transfection	O
assays	O
,	O
a	O
Qp-CAT	B-DNA
reporter	I-DNA
was	O
activated	O
by	O
cotransfected	O
JAK-1	B-protein
and	O
by	O
treatment	O
of	O
cells	O
with	O
the	O
cytokine	B-protein
IL-6	B-protein
.	O


The	O
ability	O
of	O
Qp	B-DNA
to	O
bind	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
was	O
directly	O
demonstrated	O
by	O
electrophoretic	O
mobility-shift	O
assay	O
,	O
and	O
mutation	O
of	O
potential	O
STAT-binding	B-DNA
sites	I-DNA
reduced	O
Qp	B-DNA
responsiveness	O
to	O
Janus	B-protein
kinase	I-protein
(	I-protein
JAK	I-protein
)	I-protein
-1	I-protein
.	O


We	O
have	O
previously	O
shown	O
that	O
gene	O
expression	O
directed	O
by	O
the	O
HIV-1	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
elements	I-DNA
is	O
inhibited	O
by	O
CD8	B-protein
+	O
cell-derived	O
supernatants	O
(	O
Copeland	O
et	O
al.	O
,	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
,	O
1995	O
;	O
11	O
:	O
1321-1326	O
)	O
.	O


Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
by	O
anetholdithiolthione	O
.	O


Induction	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
by	O
the	O
cytokine	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
can	O
occur	O
independently	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
activation	O
of	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
)	O
by	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
endothelial	B-cell_type
cells	I-cell_type
.	O


We	O
demonstrate	O
that	O
the	O
PTK	B-protein
inhibitors	O
herbimycin	O
A	O
or	O
genistein	O
suppress	O
induction	O
of	O
endothelial	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
,	O
as	O
well	O
as	O
subsequent	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
TNF	B-protein
.	O


Protein	B-protein
kinase	I-protein
C-zeta	I-protein
mediates	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
immunodeficiency	I-cell_type
virus-infected	I-cell_type
monocytes	I-cell_type
.	O


Although	O
little	O
information	O
as	O
to	O
what	O
signal	O
transduction	O
pathways	O
mediate	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
monocytes-macrophages	B-cell_type
is	O
available	O
,	O
our	O
previous	O
work	O
indicated	O
that	O
classical	O
protein	B-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
isoenzymes	I-protein
were	O
not	O
involved	O
in	O
the	O
HIV-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


Immunoblotting	O
experiments	O
with	O
U937	B-cell_line
cells	I-cell_line
demonstrate	O
that	O
PKC-zeta	B-protein
is	O
present	O
in	O
these	O
cells	O
,	O
and	O
its	O
expression	O
can	O
be	O
downmodulated	O
by	O
antisense	O
oligonucleotides	O
(	O
AO	O
)	O
.	O


In	O
addition	O
,	O
cotransfection	O
of	O
a	O
negative	O
dominant	O
molecule	O
of	O
PKC-zeta	B-protein
(	O
PKC-zeta	B-protein
mut	I-protein
)	O
with	O
NF-kappa	B-protein
B	I-protein
-dependent	O
reporter	O
genes	O
selectively	O
inhibits	O
the	O
HIV	O
-but	O
not	O
phorbol	O
myristate	O
acetate-	O
or	O
lipopolysaccharide-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


Induction	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
expression	O
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
through	O
NF-kappaB	B-protein
in	O
apoptosis-resistant	B-cell_line
T-cell	I-cell_line
transfectants	I-cell_line
with	O
Tax	B-protein
.	O


We	O
have	O
found	O
that	O
the	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS3	B-DNA
depends	O
on	O
the	O
presence	O
of	O
5'HS2	B-DNA
in	O
cis	O
,	O
but	O
the	O
recruitment	O
to	O
5'HS2	B-DNA
does	O
not	O
depend	O
on	O
5'HS3	B-DNA
.	O


The	O
resulting	O
diminished	O
phosphorylation	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
at	O
their	O
NH	B-protein
(	I-protein
2	I-protein
)	I-protein
-termini	I-protein
decreases	O
the	O
ability	O
of	O
these	O
nuclear	O
proteins	O
to	O
autostimulate	O
the	O
expression	O
of	O
the	O
c-Jun	B-DNA
and	I-DNA
JunD	I-DNA
genes	I-DNA
,	O
thus	O
leading	O
to	O
lower	O
production	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
.	O


In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	B-protein
ligation	O
by	O
mAb	B-protein
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	B-protein
-sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-protein
in	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


cDNA	B-DNA
microarrays	I-DNA
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	B-cell_type
mammary	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O


PPARgamma	B-protein
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	B-DNA
fatty	I-DNA
acid	I-DNA
binding	I-DNA
protein	I-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


PPARgamma	B-protein
induces	O
the	O
expression	O
of	O
many	O
genes	B-DNA
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	B-protein
fatty	I-protein
acid	I-protein
binding	I-protein
protein	I-protein
(	O
aP2	B-protein
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	B-cell_type
differentiation	O
.	O


This	O
dephosphorylation	O
was	O
inhibited	O
by	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
cyclosporin	O
A	O
or	O
FK506	O
prior	O
to	O
stimulation	O
.	O


CD40	B-protein
signaling	O
activates	O
downstream	B-protein
effectors	I-protein
,	O
including	O
the	O
tyrosine	B-protein
protein	I-protein
kinase	I-protein
,	O
Lyn	B-protein
,	O
the	O
phosphatidylinositol-3-kinase	B-protein
(	O
PI-3	B-protein
kinase	I-protein
)	O
,	O
and	O
the	O
transcription	O
factor	O
,	O
NF-kappa	B-protein
B	I-protein
.	O


The	O
activation	O
is	O
rapid	O
and	O
transient	O
and	O
is	O
mediated	O
through	O
a	O
cyclosporin	O
A-insensitive	O
pathway	O
.	O


Consistent	O
with	O
these	O
data	O
,	O
CD40	B-protein
signals	O
up-regulate	O
c-jun	B-RNA
but	I-RNA
not	I-RNA
c-fos	I-RNA
mRNA	I-RNA
and	O
alter	O
the	O
transcription	B-protein
factor	I-protein
ATF2	B-protein
but	O
not	O
the	O
Raf-1	B-protein
protein	I-protein
.	O


The	O
tyrosine	B-protein
phosphatase	I-protein
specific	O
inhibitor	O
pervanadate	O
is	O
a	O
potent	O
activator	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
through	O
induction	O
of	O
tyrosine	B-protein
phosphorylation	I-protein
and	O
downstream	O
events	O
of	O
the	O
activation	O
cascade	O
.	O


A	O
variety	O
of	O
factors	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
terminal	O
neutrophil	B-cell_type
maturation	O
,	O
including	O
the	O
vitamin	O
A	O
derivative	O
,	O
retinoic	O
acid	O
.	O


Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
a	O
chronic	O
autoimmune	O
inflammatory	O
disease	O
in	O
which	O
unknown	O
arthrogenic	B-protein
autoantigen	I-protein
is	O
presented	O
to	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


The	O
strong	O
association	O
of	O
the	O
disease	O
with	O
an	O
epitope	B-protein
within	O
the	O
HLA-DR	B-protein
chain	I-protein
shared	O
between	O
various	O
alleles	O
of	O
HLA-DR4	B-protein
and	O
DR1	B-protein
emphasizes	O
the	O
importance	O
of	O
antigen	O
presentation	O
.	O


It	O
is	O
important	O
to	O
note	O
that	O
the	O
effector	O
response	O
is	O
not	O
self-limiting	O
in	O
RA	O
autoimmune	O
inflammation	O
.	O


Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
and	O
interleukin-7	B-protein
(	O
IL-7	B-protein
)	O
,	O
secreted	O
during	O
this	O
interaction	O
,	O
are	O
critical	O
cytokines	O
for	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
transactivation	O
through	O
NF-kappaB	B-protein
-dependent	O
activation	O
.	O


The	O
requirement	O
for	O
TNF	B-protein
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	B-protein
production	O
during	O
their	O
interaction	O
with	O
TEC	B-cell_type
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF-kappaB	B-protein
activity	O
in	O
these	O
freshly	B-cell_type
isolated	I-cell_type
thymocytes	I-cell_type
.	O


The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	B-protein
receptor	I-protein
,	O
namely	O
,	O
the	O
double-positive	B-cell_type
(	I-cell_type
DP	I-cell_type
)	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+/-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus	O
,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	B-protein
and	O
IL-7	B-protein
.	O


However	O
,	O
under	O
conditions	O
of	O
inflammatory	O
response	O
after	O
infection	O
,	O
TNF	B-protein
might	O
also	O
be	O
present	O
in	O
the	O
intermediate	B-cell_type
thymocyte	I-cell_type
compartment	I-cell_type
,	O
leading	O
to	O
efficient	O
HIV	O
replication	O
in	O
these	O
cells	O
.	O


Inhibition	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
by	O
overexpression	O
of	O
a	O
dominant-active	O
inhibitor	O
of	O
NF-kappaB	B-protein
abolished	O
CD40	B-protein
-induced	O
up-regulation	O
of	O
both	O
the	O
Bfl-1	B-protein
and	O
Bcl-x	B-protein
genes	O
and	O
also	O
eliminated	O
the	O
ability	O
of	O
CD40	B-protein
to	O
rescue	O
Fas	B-protein
-induced	O
cell	O
death	O
.	O


However	O
,	O
stimulation	O
with	O
MBP	B-protein
did	O
not	O
produce	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
or	O
activator	B-protein
protein-1	I-protein
.	O


MBP	B-protein
also	O
induced	O
transient	O
increases	O
in	O
mRNA	B-RNA
for	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	I-protein
MIP	I-protein
)	I-protein
-1alpha	I-protein
and	O
MIP-1beta	B-protein
,	O
but	O
did	O
not	O
stimulate	O
the	O
release	O
of	O
either	O
chemokine	B-protein
.	O


We	O
show	O
here	O
,	O
that	O
expression	O
of	O
TCL1	B-protein
occurs	O
in	O
leukaemic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
A-T	O
patients	O
with	O
chromosome	B-DNA
14	I-DNA
rearrangements	O
.	O


Expression	O
of	O
TCL1	B-protein
also	O
occurs	O
in	O
the	O
preleukaemic	B-cell_type
clone	I-cell_type
cells	I-cell_type
of	O
A-T	O
patients	O
containing	O
the	O
primary	O
translocation	O
alone	O
.	O


A	O
high-affinity	O
calcineurin	B-protein
-binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	B-protein
docking	I-protein
motif	I-protein
of	O
NFAT	B-protein
.	O


Other	O
peroxisome	B-protein
proliferator	I-protein
activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	O
ligands	O
,	O
15d-PGJ	O
(	O
2	O
)	O
and	O
troglitazone	O
(	O
PPARgamma	B-protein
)	O
,	O
Wy14	O
,	O
643	O
(	O
PPARalpha	B-protein
)	O
,	O
and	O
PD195599	O
(	O
PPARbeta	B-protein
)	O
inhibited	O
the	O
induction	O
of	O
MCP-1	B-protein
by	O
RA	O
.	O


RA	O
's	O
effect	O
on	O
MCP-1	B-protein
expression	O
in	O
human	O
elutriated	O
monocytes	O
were	O
similar	O
to	O
that	O
observed	O
in	O
the	O
THP-1	B-cell_line
cells	I-cell_line
.	O


IVS1-10T	O
--	O
>	O
C	O
is	O
a	O
unique	O
BRCA1	B-DNA
change	O
that	O
occurs	O
in	O
the	O
last	O
nucleotide	O
of	O
a	O
consensus	B-DNA
sequence	I-DNA
for	O
a	O
branch	B-DNA
site	I-DNA
critical	O
for	O
RNA	O
splicing	O
.	O


Thus	O
,	O
IVS1-10T	O
--	O
>	O
C	O
is	O
not	O
harmful	O
to	O
BRCA1	B-DNA
function	O
,	O
and	O
is	O
classified	O
a	O
benign	O
polymorphism	O
.	O


For	O
example	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
can	O
be	O
found	O
in	O
colonies	O
of	O
GM-CSF-responsive	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
and	O
under	O
experimental	O
conditions	O
are	O
routinely	O
expanded	O
as	O
a	O
population	O
in	O
vitro	O
from	O
GM-CSF-responsive	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O


The	O
differentiated	O
DC	B-cell_type
are	O
potent	O
presenters	O
of	O
antigen	O
in	O
mixed	O
lymphocyte	O
reactions	O
and	O
of	O
soluble	O
antigen	O
to	O
specific	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


A	O
distinctive	O
pattern	O
of	O
differentially	O
expressed	O
cDNAs	B-DNA
is	O
evident	O
where	O
macrophage-specific	B-DNA
cDNAs	I-DNA
are	O
homologous	O
to	O
genes	O
encoding	O
cytoskeletal	B-protein
and	I-protein
cell-surface	I-protein
proteins	I-protein
,	O
whereas	O
the	O
DC	B-cell_type
-specific	O
cDNAs	B-DNA
are	O
homologous	O
to	O
signaling	B-DNA
,	I-DNA
chemokine	I-DNA
,	I-DNA
and	I-DNA
IFN-gamma-inducible	I-DNA
genes	I-DNA
.	O


Western	O
blot	O
analysis	O
showed	O
that	O
the	O
level	O
of	O
L.	O
pneumophila	O
RpoS	B-protein
increased	O
in	O
stationary	O
phase	O
.	O


Monoallelic	O
expression	O
of	O
Pax5	B-protein
:	O
a	O
paradigm	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	B-DNA
Pax	I-DNA
genes	I-DNA
?	O


Hence	O
,	O
the	O
diploid	O
state	O
of	O
the	O
genome	O
offers	O
the	O
advantage	O
that	O
a	O
loss-of-function	O
mutation	O
in	O
one	O
allele	B-DNA
can	O
be	O
compensated	O
for	O
by	O
the	O
remaining	O
wild-type	B-DNA
allele	I-DNA
of	O
the	O
same	O
gene	O
.	O


The	O
allele	B-DNA
-specific	O
regulation	O
of	O
Pax5	B-protein
raises	O
the	O
intriguing	O
possibility	O
that	O
monoallelic	O
expression	O
may	O
also	O
be	O
the	O
mechanism	O
causing	O
the	O
haploinsufficiency	O
of	O
other	O
Pax	B-DNA
genes	I-DNA
.	O


However	O
,	O
signal	O
transduction	O
of	O
IL-10	B-protein
in	O
B	B-cell_type
cells	I-cell_type
is	O
poorly	O
understood	O
.	O


An	O
extensive	O
immunocytochemical	O
evaluation	O
of	O
fixed	O
tissues	O
confirmed	O
MNDA	B-protein
expression	O
in	O
normal	B-cell_type
maturing	I-cell_type
granulocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
in	O
acute	O
nonlymphocytic	O
leukemias	O
and	O
chronic	O
myelogenous	O
leukemia	O
.	O


Both	O
PPAR-alpha	B-RNA
and	I-RNA
PPAR-gamma	I-RNA
mRNAs	I-RNA
were	O
detected	O
in	O
HAECs	B-cell_type
by	O
using	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
a	O
ribonuclease	B-protein
protection	O
assay	O
;	O
however	O
,	O
we	O
have	O
yet	O
to	O
determine	O
which	O
,	O
if	O
any	O
,	O
of	O
the	O
PPARs	B-protein
are	O
mediating	O
this	O
process	O
.	O


The	O
physiological	O
substrates	O
for	O
SHP1	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
however	O
,	O
have	O
remained	O
unclear	O
or	O
controversial	O
.	O


Expression	O
of	O
wild-type	B-protein
SHP1	I-protein
had	O
a	O
very	O
small	O
effect	O
on	O
the	O
TCR-induced	O
tyrosine	O
phosphorylation	O
of	O
ZAP-70	B-protein
and	O
Syk	B-protein
,	O
even	O
when	O
SHP1	B-protein
was	O
overexpressed	O
20	O
-	O
100-fold	O
over	O
endogenous	B-protein
SHP1	I-protein
.	O


Inactive	B-protein
SHP1-D421A	I-protein
and	O
wild-type	B-protein
SHP2	I-protein
were	O
without	O
effects	O
.	O


In	O
contrast	O
,	O
a	O
constitutively	O
active	O
SHP2-DeltaSH2	B-protein
had	O
no	O
statistically	O
significant	O
effect	O
(	O
although	O
it	O
caused	O
a	O
slight	O
augmentation	O
in	O
some	O
individual	O
experiments	O
)	O
.	O


Taken	O
together	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
ZAP-70	B-protein
and	O
Syk	B-protein
can	O
be	O
direct	O
substrates	O
for	O
SHP1	B-protein
in	O
intact	O
cells	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C/EBPbeta	B-protein
protein	O
could	O
bind	O
to	O
the	O
potential	O
C/EBP-binding	B-DNA
site	I-DNA
(	O
bp	B-DNA
-90	I-DNA
to	I-DNA
-82	I-DNA
)	O
in	O
the	O
MBP	B-protein
promoter	O
.	O


STAT3	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	B-protein
or	O
growth	B-protein
factors	I-protein
.	O


The	O
drug	O
was	O
less	O
effective	O
on	O
cytokines	B-protein
:	O
it	O
virtually	O
abolished	O
the	O
response	O
to	O
GM-CSF	B-protein
that	O
occurred	O
5	O
min	O
after	O
stimulation	O
but	O
only	O
partly	O
decreased	O
those	O
at	O
15-30	O
min	O
and	O
did	O
not	O
appreciably	O
alter	O
responses	O
to	O
G-CSF	B-protein
regardless	O
of	O
incubation	O
time	O
.	O


Renal	O
cell	O
carcinoma-derived	O
gangliosides	O
suppress	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	O
expression	O
of	O
the	O
CXC	B-protein
chemokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	O
)	O
.	O


Surprisingly	O
,	O
however	O
,	O
DMSO	O
has	O
no	O
effect	O
on	O
inducible	O
Rel	B-protein
A	I-protein
binding	O
.	O


These	O
data	O
indicate	O
that	O
TNFalpha	B-protein
induces	O
a	O
delayed	O
ROS-dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF-kappaB	B-protein
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O


Estrogen	B-protein
receptors	I-protein
influence	O
non-genomic	O
events	O
,	O
which	O
are	O
rapid	O
in	O
onset	O
and	O
genomic	O
events	O
,	O
which	O
are	O
longer	O
acting	O
responses	O
.	O


Although	O
estrogens	O
initiate	O
vascular	O
responses	O
,	O
genomic	O
sex	O
may	O
influence	O
and/or	O
limit	O
expression	O
of	O
estrogen	O
receptors	O
and	O
therefore	O
actions	O
of	O
sex	O
steroid	O
hormones	O
throughout	O
the	O
vasculature	O
.	O


mRNA	B-RNA
levels	O
for	O
IL-13R	B-protein
alpha1	I-protein
,	O
but	O
not	O
IL-4R	B-protein
alpha	I-protein
,	O
were	O
markedly	O
decreased	O
in	O
in	B-cell_line
vitro	I-cell_line
monocyte-derived	I-cell_line
macrophages	I-cell_line
(	O
MDMac	B-cell_line
)	O
,	O
and	O
with	O
increasing	O
time	O
of	O
monocytes	B-cell_type
in	O
culture	O
correlated	O
with	O
the	O
loss	O
of	O
IL-13	B-protein
regulation	O
of	O
lipopolysaccharide-induced	O
TNF-alpha	B-protein
production	O
.	O


Analysis	O
of	O
cell	B-cell_line
lines	I-cell_line
Daudi	B-cell_line
and	O
THP-1	B-cell_line
that	O
differentially	O
express	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
and	O
IL-13R	B-protein
alpha1	I-protein
showed	O
that	O
IL-13	B-protein
can	O
activate	O
STAT6	B-protein
in	O
IL-13R	B-cell_line
alpha1-positive	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
gamma	B-cell_line
(	I-cell_line
c	I-cell_line
)	I-cell_line
-positive	I-cell_line
,	I-cell_line
IL-13R	I-cell_line
alpha1-negative	I-cell_line
Daudi	I-cell_line
cells	I-cell_line
.	O


However	O
,	O
with	O
reduced	O
IL-13R	B-protein
alpha1	I-protein
expression	O
and	O
low	O
nuclear	O
STAT6	B-protein
activity	O
,	O
some	O
IL-13	B-protein
-induced	O
responses	O
were	O
unaltered	O
in	O
magnitude	O
in	O
MDMac	B-cell_line
.	O


The	O
promoter	B-DNA
and	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
controlling	O
human	O
B29	B-DNA
gene	I-DNA
expression	O
.	O


All	O
these	O
motifs	O
are	O
strikingly	O
conserved	O
in	O
sequence	O
and	O
placement	O
relative	O
to	O
the	O
previously	O
characterized	O
murine	B-DNA
B29	I-DNA
promoter	I-DNA
.	O


A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	B-DNA
conserved	I-DNA
sequence	I-DNA
(	O
BCS	B-DNA
)	O
,	O
found	O
upstream	O
of	O
both	O
human	B-DNA
and	I-DNA
murine	I-DNA
B29	I-DNA
promoters	I-DNA
,	O
appears	O
to	O
stimulate	O
B29	B-protein
transcription	O
through	O
a	O
novel	O
mechanism	O
.	O


Instead	O
,	O
the	O
BCS	B-DNA
stimulated	O
transcription	O
by	O
counteracting	O
5	B-DNA
'	I-DNA
negative	I-DNA
regulatory	I-DNA
DNA	I-DNA
sequences	I-DNA
that	O
block	O
the	O
activity	O
of	O
the	O
B29	B-protein
minimal	B-DNA
promoter	I-DNA
in	O
its	O
absence	O
.	O


Expression	O
of	O
luciferase	B-protein
in	O
these	O
cells	O
was	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
plus	O
a	O
calcium	O
ionophore	O
.	O


The	O
NFAT-controlled	B-DNA
luciferase	I-DNA
gene	I-DNA
system	I-DNA
distinguishes	O
CIF	B-protein
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B-protein
beta	I-protein
1	I-protein
and	O
TGF	B-protein
beta	I-protein
2	I-protein
and	O
the	O
glucocorticoids	O
.	O


Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	B-protein
and	O
cyclosporine	O
.	O


Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF-kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5-3335	O
(	O
HIV-1	O
Tat	B-protein
inhibitor	O
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O


Using	O
a	O
combination	O
of	O
bacterial	O
motility	O
assays	O
in	O
platelet	O
extracts	O
with	O
Escherichia	O
coli	O
expressing	O
the	O
Shigella	B-protein
IcsA	I-protein
protein	I-protein
and	O
in	O
vitro	O
analysis	O
of	O
reconstituted	O
systems	O
from	O
purified	B-protein
proteins	I-protein
,	O
we	O
show	O
here	O
that	O
the	O
bacterial	B-protein
protein	I-protein
IcsA	I-protein
binds	O
N-WASP	B-protein
and	O
activates	O
it	O
in	O
a	O
Cdc42	B-protein
-like	O
fashion	O
.	O


c-Maf	B-protein
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	B-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
.	O


Because	O
the	O
elevated	O
Myb	B-protein
:	I-protein
Maf	I-protein
status	O
seen	O
in	O
differentiating	B-cell_type
cells	I-cell_type
can	O
be	O
recapitulated	O
by	O
overexpression	O
of	O
c-Maf	B-protein
in	O
myeloid	O
cell	O
lines	O
,	O
we	O
inducibly	O
expressed	O
the	O
c-Maf	B-DNA
cDNA	I-DNA
in	O
2	O
bipotent	O
human	B-cell_type
myeloid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O


Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c-Maf	B-protein
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c-Myb	B-protein
regulated	O
targets	O
,	O
such	O
as	O
Bcl-2	B-protein
and	O
CD13/APN	B-protein
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation-promoting	B-DNA
genes	I-DNA
.	O


Furthermore	O
,	O
in	O
vitro	O
binding	O
analysis	O
revealed	O
that	O
the	O
AML1	B-DNA
runt	I-DNA
DNA-binding	I-DNA
domain	I-DNA
physically	O
interacts	O
with	O
the	O
paired	B-DNA
DNA-binding	I-DNA
domain	I-DNA
of	O
BSAP	B-protein
,	O
a	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
.	O


BSAP	B-protein
has	O
been	O
shown	O
previously	O
to	O
be	O
important	O
for	O
B	O
cell-specific	O
regulation	O
of	O
the	O
blk	B-DNA
gene	O
.	O


Physical	O
interaction	O
of	O
AML1	B-protein
with	O
BSAP	B-protein
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	B-protein
and	O
BSAP	B-protein
synergistically	O
activate	O
blk	B-DNA
promoter	O
transcription	O
by	O
more	O
than	O
50-fold	O
.	O


These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	B-protein
and	O
BSAP	B-protein
and	O
suggest	O
that	O
AML1	B-protein
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	B-DNA
cell-specific	I-DNA
gene	I-DNA
,	O
blk	B-DNA
.	O


Expression	O
of	O
the	O
class	B-protein
A	I-protein
macrophage	I-protein
scavenger	I-protein
receptor	I-protein
(	I-protein
MSR	I-protein
)	I-protein
contributes	O
to	O
the	O
uptake	O
of	O
modified	B-protein
low	I-protein
density	I-protein
lipoproteins	I-protein
(	I-protein
LDL	I-protein
)	I-protein
by	O
macrophages	B-cell_type
and	O
transformation	O
of	O
these	O
cells	O
into	O
lipid-laden	B-cell_type
foam	I-cell_type
cells	I-cell_type
,	O
which	O
characterize	O
atherosclerosis	O
.	O


When	O
treated	O
with	O
IL-6	B-protein
,	O
macrophages	B-cell_type
derived	O
from	O
peripheral	B-cell_type
monocytes	I-cell_type
and	O
phorbol	B-cell_line
12-myristate	I-cell_line
13-acetate	I-cell_line
(	I-cell_line
PMA	I-cell_line
)	I-cell_line
-differentiated	I-cell_line
THP-1	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
showed	O
significantly	O
reduced	O
uptake	O
and/or	O
binding	O
of	O
the	O
MSR	B-protein
ligand	O
,	O
acetylated	B-protein
LDL	I-protein
.	O


However	O
,	O
the	O
molecular	O
mechanism	O
of	O
Rb	B-protein
rescue	O
of	O
the	O
class	B-DNA
II	I-DNA
genes	I-DNA
is	O
unknown	O
.	O


BLPs	B-protein
were	O
found	O
to	O
induce	O
apoptosis	O
in	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
through	O
human	B-protein
Toll-like	I-protein
receptor-2	I-protein
(	I-protein
hTLR2	I-protein
)	I-protein
.	O


Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O


This	O
staining	O
pattern	O
clearly	O
differed	O
from	O
that	O
of	O
classical	O
HD	O
,	O
whose	O
cellular	O
background	O
was	O
made	O
up	O
of	O
CD3+/CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
showing	O
the	O
BCL-6	B-protein
-/	O
CD40L	B-protein
+	O
phenotype	O
.	O


Selenium-mediated	O
inhibition	O
of	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
and	O
HIV-1	B-DNA
LTR	I-DNA
promoter	I-DNA
activity	O
.	O


IkappaB	B-protein
levels	O
in	O
MNC	B-cell_type
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O


In	O
our	O
study	O
,	O
we	O
determined	O
the	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


Stimulation	O
with	O
different	O
GC	O
at	O
therapeutic	O
concentrations	O
resulted	O
in	O
monocyte	O
apoptosis	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O


Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
on	O
monocytic	B-protein
IkappaB	I-protein
kinase	I-protein
signalsome	O
activation	O
and	O
IkappaB	B-protein
proteolysis	O
.	O


Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK-alpha/beta	B-protein
heterodimer	I-protein
with	O
NIK	B-protein
,	O
IkappaB-alpha	B-protein
and	O
-epsilon	B-protein
in	O
unstimulated	B-cell_type
cells	I-cell_type
.	O


On	O
the	O
contrary	O
,	O
32Dcl3	B-cell_line
cells	I-cell_line
stably	O
expressing	O
AML1/ETO	B-DNA
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G-CSF	B-protein
.	O


Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	B-protein
lipoproteins	I-protein
through	O
toll-like	B-protein
receptors	I-protein
.	O


The	O
generation	O
of	O
cell-mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O


Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL-12	B-protein
production	O
by	O
macrophages	B-cell_type
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O


Here	O
it	O
is	O
shown	O
that	O
microbial	B-protein
lipoproteins	I-protein
are	O
potent	O
stimulators	O
of	O
IL-12	B-protein
production	O
by	O
human	O
macrophages	B-cell_type
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll-like	B-protein
receptors	I-protein
(	O
TLRs	B-protein
)	O
.	O


Freshly	O
isolated	O
T	B-cell_type
cells	I-cell_type
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	B-protein
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
Abs	I-protein
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane-mediated	O
signaling	O
events	O
.	O


When	O
compared	O
with	O
normal	B-cell_type
cells	I-cell_type
,	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O


Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	B-protein
protein	I-protein
levels	O
.	O


We	O
show	O
that	O
TLR2	B-protein
associates	O
with	O
the	O
high-affinity	B-protein
LPS	I-protein
binding	I-protein
protein	I-protein
membrane	O
CD14	B-protein
to	O
serve	O
as	O
an	O
LPS	B-protein
receptor	I-protein
complex	I-protein
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	B-protein
.	O


Tyrphostin	O
AG-490	O
inhibits	O
cytokine-mediated	O
JAK3	B-protein
/STAT5a/b	B-protein
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen-activated	O
human	O
T	B-cell_type
cells	I-cell_type
.	O


AG-490	O
also	O
inhibited	O
IL-2	B-protein
-mediated	O
proliferative	O
growth	O
in	O
human	O
T	B-cell_type
cells	I-cell_type
with	O
an	O
IC50	O
)	O
=	O
25	O
microM	O
that	O
was	O
partially	O
recoverable	O
.	O


The	O
presence	O
of	O
C/EBP	B-protein
beta	I-protein
was	O
confirmed	O
by	O
immunohistochemistry	O
and	O
Western	O
blot	O
analysis	O
with	O
isolated	O
synovial	B-cell_type
fibroblasts	I-cell_type
.	O


In	O
conclusion	O
,	O
the	O
enhanced	O
nuclear	O
staining	O
for	O
C/EBP	B-protein
beta	I-protein
in	O
the	O
synovial	O
lining	O
,	O
compared	O
to	O
the	O
sublining	O
,	O
suggesting	O
activation	O
in	O
the	O
lining	O
,	O
and	O
the	O
positive	O
correlation	O
of	O
lining	O
layer	O
depth	O
with	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
lining	O
positive	O
for	O
nuclear	O
C/EBP	B-protein
beta	I-protein
,	O
suggest	O
a	O
potential	O
role	O
for	O
C/EBP	B-protein
beta	I-protein
in	O
chronic	O
inflammation	O
.	O


IRF-1	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
regulated	O
by	O
IFNs	B-protein
that	O
is	O
also	O
essential	O
for	O
Th1	B-cell_type
responses	O
.	O


First	O
,	O
STAT4	B-protein
was	O
required	O
for	O
the	O
IL-12	B-protein
-dependent	O
transactivation	O
of	O
an	O
IRF-1	B-DNA
reporter	I-DNA
construct	I-DNA
,	O
and	O
second	O
,	O
STAT4	B-protein
binding	O
to	O
the	O
IRF-1	B-DNA
promoter	I-DNA
was	O
shown	O
using	O
EMSA	O
.	O


Therefore	O
,	O
IRF-1	B-protein
may	O
be	O
an	O
important	O
contributor	O
to	O
IL-12	B-protein
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL-12	B-protein
responses	O
seen	O
in	O
IRF	B-protein
-1-/-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O


One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	B-DNA
1	I-DNA
hypersensitive	I-DNA
sites	I-DNA
in	O
the	O
regions	O
of	O
active	B-DNA
globin	I-DNA
gene	I-DNA
promoters	I-DNA
.	O


We	O
recently	O
reported	O
that	O
prolonged	O
exposure	O
of	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HAEC	B-cell_line
)	O
to	O
low	O
shear	O
stress	O
flow	O
patterns	O
is	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
the	O
activated	O
form	O
of	O
the	O
transcriptional	O
regulator	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O


NFAT	O
transcription	O
factors	O
bind	O
to	O
a	O
sequence	O
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
known	O
as	O
the	O
antigen	B-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
2	I-DNA
(	O
ARRE-2	B-DNA
)	O
.	O


Using	O
in	O
vitro	O
translated	O
polypeptides	O
,	O
we	O
have	O
demonstrated	O
that	O
NF90	B-protein
specifically	O
binds	O
to	O
double-stranded	B-RNA
RNA	I-RNA
.	O


The	O
correlation	O
between	O
C5a-induced	O
kappaB	B-protein
binding	O
activity	O
and	O
IL-8	B-protein
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264.7	B-cell_line
macrophage	I-cell_line
cells	I-cell_line
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	B-DNA
sequence	I-DNA
from	O
IkappaBalpha	B-protein
and	O
IL-8	B-DNA
promoter	I-DNA
regions	I-DNA
.	O


Alternative	O
splicing	O
of	O
the	O
GC	B-RNA
receptor	I-RNA
(	I-RNA
GCR	I-RNA
)	I-RNA
pre-mRNA	I-RNA
generates	O
a	O
second	O
GCR	B-protein
,	O
termed	O
GCRbeta	B-protein
,	O
which	O
does	O
not	O
bind	O
GC	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B-protein
.	O


We	O
also	O
examined	O
the	O
expression	O
of	O
GCRbeta	B-protein
in	O
specimens	O
from	O
the	O
airways	O
of	O
patients	O
with	O
chronic	O
bronchitis	O
.	O


Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O


When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O
The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL-10	B-protein
--	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
--	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL-10	B-protein
is	O
judged	O
.	O


The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O


HIV-1	O
expressing	O
IkappaB-alphaS32/36A	B-protein
down-regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	B-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


Thus	O
,	O
IkappaB-alphaS32/36A	B-protein
offers	O
proof-of-principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O


TCR	B-protein
affinities	O
were	O
then	O
indirectly	O
estimated	O
by	O
blocking	O
CD8	B-protein
interaction	O
with	O
an	O
anti-CD8	B-protein
mAb	I-protein
.	O


During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell-receptor	O
engagement	O
,	O
we	O
identified	O
ALG-4F	B-protein
,	O
a	O
truncated	B-protein
transcript	I-protein
that	O
prevents	O
T	O
cell-receptor-induced	O
FasL	B-protein
upregulation	O
and	O
cell	O
death	O
.	O


Overexpression	O
of	O
full-length	B-protein
ALG-4	I-protein
induced	O
transcription	O
of	O
FasL	B-protein
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O


Further	O
,	O
LMP1	B-protein
does	O
not	O
require	O
TRADD	B-protein
residues	O
294	O
to	O
312	O
for	O
NF-kappaB	B-protein
activation	O
,	O
while	O
TNFR1	B-protein
requires	O
TRADD	B-protein
residues	O
296	O
to	O
302	O
.	O


Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O


Preactivation	O
of	O
T	B-cell_type
cells	I-cell_type
resulting	O
in	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50-induced	O
apoptosis	O
.	O


The	O
Ras	B-protein
-Aiolos	B-protein
interaction	O
was	O
confirmed	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
co-immunoprecipitation	O
.	O


Co-transfection	O
experiments	O
confirm	O
that	O
Aiolos	B-protein
induces	O
Bcl-2	B-protein
expression	O
and	O
prevents	O
apoptosis	O
in	O
IL-2-deprived	B-cell_line
cells	I-cell_line
.	O


Binding	O
of	O
YY1	B-protein
and	O
Oct1	B-protein
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL-5	B-protein
in	O
human	O
T	B-cell_type
cells	I-cell_type
.	O


In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL-5	B-protein
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O


RESULTS	O
:	O
We	O
identified	O
5	O
protein	B-DNA
binding	I-DNA
regions	I-DNA
(	O
BRs	B-DNA
)	O
located	O
within	O
the	O
proximal	B-DNA
hIL-5	I-DNA
promoter	I-DNA
.	O


We	O
show	O
that	O
the	O
BR3	B-DNA
sequence	O
contains	O
a	O
novel	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
at	O
positions	O
-90	O
to	O
-79	O
of	O
the	O
hIL-5	B-DNA
promoter	I-DNA
,	O
which	O
binds	O
Oct1	B-protein
,	O
octamer-like	B-protein
,	O
and	O
YY1	B-protein
nuclear	I-protein
factors	I-protein
.	O


Human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
Tax	I-protein
transforms	O
normal	O
T-cells	B-cell_type
in	O
the	O
presence	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
in	O
vitro	O
.	O


STAT	B-protein
is	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
play	O
a	O
pivotal	O
role	O
in	O
cytokine-induced	O
functions	O
of	O
a	O
various	O
type	O
of	O
cells	O
.	O


The	O
expression	O
of	O
STAT1	B-protein
and	O
STAT5	B-protein
in	O
a	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
was	O
induced	O
by	O
Tax	B-protein
.	O


The	O
role	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O


We	O
found	O
that	O
the	O
spontaneous	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
other	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
NF-kappaB	B-protein
-dependent	O
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti-inflammatory	B-protein
mediators	I-protein
,	O
like	O
IL-10	B-protein
and	I-protein
-11	I-protein
,	O
and	O
the	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
.	O


Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	B-protein
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	B-protein
metalloproteinases	I-protein
1	I-protein
and	I-protein
3	I-protein
while	O
not	O
affecting	O
their	O
tissue	O
inhibitor	O
.	O


Blocking	O
NF-kappaB	B-protein
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O


Our	O
data	O
demonstrate	O
that	O
those	O
cell	B-cell_line
lines	I-cell_line
lacking	O
capability	O
to	O
form	O
metastatic	O
tumors	O
in	O
vivo	O
are	O
susceptible	O
to	O
TNF	B-protein
induced	O
apoptosis	O
in	O
vitro	O
.	O


To	O
ascertain	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
expression	O
of	O
markers	O
for	O
B-cell	O
activation	O
,	O
differentiation	O
,	O
and	O
proliferation	O
in	O
ILFs	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
using	O
surgically	O
resected	O
specimens	O
,	O
and	O
compared	O
them	O
with	O
specimens	O
of	O
perihepatic	O
lymph	O
nodes	O
by	O
an	O
immunohistochemical	O
technique	O
.	O


K562	B-cell_line
cells	I-cell_line
express	O
endogenous	O
WT1	B-DNA
,	O
which	O
is	O
downregulated	O
as	O
a	O
response	O
to	O
induced	O
differentiation	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O


We	O
have	O
previously	O
shown	O
that	O
the	O
membrane-proximal	B-protein
portion	I-protein
in	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
human	B-protein
IL-4R	I-protein
alpha	I-protein
(	O
hIL-4R	B-protein
alpha	I-protein
)	O
is	O
critical	O
for	O
proliferation	O
,	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
and	O
activation	O
of	O
STAT6	B-protein
,	O
based	O
on	O
analyses	O
of	O
truncated	B-protein
hIL-4R	I-protein
alphas	I-protein
.	O


In	O
this	O
study	O
,	O
we	O
found	O
that	O
p47phox	O
,	O
an	O
activator	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	I-protein
,	O
binds	O
to	O
this	O
portion	O
by	O
the	O
two-hybrid	O
system	O
.	O


METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	B-RNA
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT-PCR	O
.	O


These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20-epi	O
analogue	O
in	O
inducing	O
VDR	B-protein
/DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O


Following	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
stimulation	O
,	O
SLP-76	B-protein
and	O
Vav	B-protein
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	B-protein
and	O
phosphorylated	O
tyrosines	O
of	O
SLP-76	B-protein
.	O


Furthermore	O
,	O
SLP-76	B-protein
and	O
Vav	B-protein
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
promoter	I-DNA
activity	O
in	O
T	B-cell_line
cells	I-cell_line
.	O


Rel/NF-kappaB	B-protein
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
by	O
inducing	O
the	O
expression	O
of	O
Jagged1	B-protein
,	O
a	O
ligand	O
for	O
Notch	B-protein
receptors	I-protein
.	O


Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factors	I-protein
ATF-1	B-protein
and	O
CREB	B-protein
;	O
(	O
ii	O
)	O
ATF-1	B-protein
and	O
CREB	B-protein
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	B-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	B-protein
and	O
ATF-1	B-protein
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c-Jun	B-protein
,	O
protein	O
synthesis	O
of	O
JunB	B-protein
and	O
c-Fos	B-protein
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP-1	B-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c-Fos	B-protein
;	O
and	O
(	O
iv	O
)	O
PGN-induced	O
activation	O
of	O
CREB/ATF	B-protein
and	O
AP-1	B-protein
was	O
mediated	O
through	O
CD14	B-protein
.	O


BACKGROUND	O
:	O
Growing	O
evidence	O
indicates	O
that	O
the	O
immune	O
system	O
and	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
are	O
linked	O
by	O
several	O
mechanisms	O
,	O
for	O
example	O
intracellular	O
glucocorticoid	B-protein
receptors	I-protein
(	O
hGR	B-protein
)	O
.	O


PATIENTS	O
AND	O
METHODS	O
:	O
IBD	O
patients	O
were	O
either	O
treated	O
with	O
5-60	O
mg	O
of	O
prednisolone	O
for	O
more	O
than	O
1	O
week	O
or	O
were	O
without	O
glucocorticoid	O
treatment	O
for	O
more	O
than	O
4	O
weeks	O
.	O


ICSAT	B-protein
(	O
Interferon	B-protein
Consensus	I-protein
Sequence	I-protein
binding	I-protein
protein	I-protein
for	I-protein
Activated	I-protein
T	I-protein
cells	I-protein
)	O
is	O
a	O
lymphocyte-specific	O
member	O
of	O
the	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
family	I-protein
of	O
transcription	O
factors	O
,	O
originally	O
identified	O
through	O
Southwestern	O
screening	O
of	O
the	O
ATL	B-DNA
(	I-DNA
Adult	I-DNA
T-cell	I-DNA
leukemia	I-DNA
)	I-DNA
-16T	I-DNA
expression	I-DNA
library	I-DNA
.	O


No	O
difference	O
in	O
cytokine	B-protein
secretion	O
profiles	O
of	O
freshly	B-cell_type
isolated	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
detected	O
between	O
patients	O
and	O
controls	O
.	O


By	O
contrast	O
,	O
priming	O
under	O
those	O
conditions	O
resulted	O
in	O
Th2	O
differentiation	O
in	O
only	O
9	O
of	O
24	O
RA	O
patients	O
.	O


Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite-induced	O
constitutive	O
NF-kappaB	B-protein
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	B-cell_type
cells	I-cell_type
.	O


To	O
find	O
out	O
if	O
the	O
induction	O
by	O
UV	O
light	O
is	O
caused	O
by	O
the	O
formation	O
of	O
an	O
Ah	O
receptor	O
ligand	O
,	O
Hepa-1	B-cell_line
wild-type	I-cell_line
and	I-cell_line
Ah	I-cell_line
receptor	I-cell_line
deficient	I-cell_line
c12	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
applied	O
.	O


Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	B-protein
and	O
its	O
repression	B-protein
domains	I-protein
can	O
interact	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	B-protein
family	I-protein
of	O
co-repressors	O
which	O
bind	O
to	O
histone	B-protein
deacetylases	I-protein
.	O


Protein	B-protein
kinase	I-protein
B	I-protein
(	O
c-Akt	B-protein
)	O
,	O
phosphatidylinositol	B-protein
3-kinase	I-protein
,	O
and	O
STAT5	B-protein
are	O
activated	O
by	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
in	O
HCD57	B-cell_line
erythroid	I-cell_line
cells	I-cell_line
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO-independent	B-cell_line
,	I-cell_line
apoptosis-resistant	I-cell_line
subclone	I-cell_line
(	O
HCD57-SREI	B-cell_line
cells	I-cell_line
)	O
.	O


We	O
found	O
that	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
and	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
activated	B-protein
protein	I-protein
kinase	I-protein
B	I-protein
(	O
PKB/Akt	B-protein
)	O
in	O
EPO-dependent	B-cell_line
HCD57	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
.	O


These	O
observations	O
suggest	O
possible	O
mechanisms	O
by	O
which	O
Id3	B-protein
overexpression	O
can	O
differentially	O
affect	O
development	O
of	O
pre-T	B-cell_type
cells	I-cell_type
into	O
TCRalpha	B-cell_line
beta	I-cell_line
and	I-cell_line
gamma	I-cell_line
delta	I-cell_line
cells	I-cell_line
.	O


We	O
also	O
observed	O
that	O
cell	B-cell_type
surface	I-cell_type
CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
cells	I-cell_type
with	O
rearranged	B-DNA
TCR	I-DNA
genes	I-DNA
developed	O
from	O
Id3-transduced	B-cell_line
but	O
not	O
from	O
control-transduced	B-cell_line
pre-T	I-cell_line
cells	I-cell_line
in	O
an	O
FTOC	B-cell_line
.	O


When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	B-protein
cross-linking	O
by	O
iHIV-1	O
,	O
PBMCs	B-cell_type
from	O
HIV-1-infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O


In	O
contrast	O
,	O
virus	O
reactivation	O
was	O
not	O
observed	O
following	O
CD4	B-protein
oligomerization	O
by	O
antibodies	B-protein
that	O
bind	O
other	O
epitopes	O
in	O
D1	B-protein
,	O
including	O
the	O
D1/CDR3-loop	B-protein
.	O


Signaling	O
through	O
the	O
lymphotoxin-beta	B-protein
receptor	I-protein
stimulates	O
HIV-1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane-bound	B-protein
TNF-alpha	I-protein
.	O


OBJECTIVE	O
:	O
To	O
create	O
monoclonal	B-protein
anti-endothelial	I-protein
cell	I-protein
antibodies	I-protein
(	O
mAECA	B-protein
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVEC	B-cell_line
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O


Cutting	O
edge	O
:	O
expression	O
of	O
the	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
eosinophils	B-cell_type
:	O
regulation	O
by	O
IL-4	B-protein
and	O
IL-5	B-protein
.	O


Only	O
NF-AT1	B-protein
and	O
NF-AT4	B-protein
,	O
but	O
not	O
NF-AT2	B-protein
and	O
NF-AT3	B-protein
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL-4-	B-cell_line
or	I-cell_line
IL-5-stimulated	I-cell_line
eosinophils	I-cell_line
.	O


These	O
findings	O
delineate	O
a	O
novel	O
pathway	O
in	O
the	O
cytokine	O
network	O
in	O
which	O
Th2	B-cell_line
lymphocytes	I-cell_line
``	O
control	O
''	O
eosinophils	B-cell_type
via	O
the	O
release	O
of	O
IL-4	B-protein
and	O
IL-5	B-protein
,	O
and	O
activation	O
of	O
NF-AT	B-protein
in	O
eosinophils	B-cell_type
.	O


Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	B-protein
molecules	I-protein
in	O
ECs	B-cell_type
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O


We	O
show	O
here	O
that	O
the	O
transcriptional	B-protein
co-activators	I-protein
CBP/p300	B-protein
bind	O
to	O
and	O
control	O
the	O
activity	O
of	O
the	O
inducible	B-protein
N-terminal	I-protein
transactivation	I-protein
domain	I-protein
of	O
NF-ATc	B-protein
,	O
TAD-A	B-protein
.	O


Similar	O
to	O
the	O
N	B-protein
terminal	I-protein
transactivation	I-protein
domain	I-protein
of	O
c-Jun	B-protein
,	O
TAD-A	B-protein
is	O
inducibly	O
phosphorylated	O
,	O
but	O
this	O
phosphorylation	O
is	O
dispensable	O
for	O
the	O
interaction	O
with	O
CBP/p300	B-protein
.	O


Considerably	O
higher	O
proportions	O
of	O
low	O
responders	O
were	O
found	O
among	O
the	O
patient	O
population	O
.	O


Thus	O
,	O
our	O
data	O
provide	O
novel	O
evidence	O
that	O
selective	O
modulation	O
of	O
NF-kappaB	B-protein
by	O
adenoviral	O
transfer	O
of	O
IkappaB-alpha	B-protein
impairs	O
the	O
expression	O
of	O
multiple	O
endothelial	B-protein
gene	I-protein
products	I-protein
required	O
for	O
subsequent	O
monocyte	O
arrest	O
and	O
emigration	O
in	O
shear	O
flow	O
and	O
thus	O
for	O
monocyte	O
infiltration	O
in	O
atherosclerotic	O
plaques	O
.	O


A	O
silent	O
mutation	O
in	O
codon	B-DNA
10	I-DNA
of	O
exon	B-DNA
1	I-DNA
,	O
detected	O
in	O
ER-negative	B-cell_line
and	I-cell_line
ER-positive	I-cell_line
human	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
in	O
breast	O
tumors	O
and	O
blood	B-DNA
DNA	I-DNA
from	O
breast	O
cancer	O
patients	O
,	O
has	O
been	O
recognized	O
as	O
a	O
polymorphic	B-DNA
site	I-DNA
.	O


We	O
have	O
detected	O
ER	B-DNA
codon	I-DNA
10	I-DNA
polymorphism	O
in	O
these	O
samples	O
and	O
have	O
compared	O
them	O
to	O
those	O
observed	O
in	O
breast	O
cancer	O
samples	O
.	O


These	O
two	O
proteins	O
physically	O
interact	O
with	O
each	O
other	O
and	O
mutually	O
inhibit	O
their	O
respective	O
biological	O
functions	O
.	O


In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA/NFkappaB1	B-protein
-binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	B-protein
-binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O


While	O
controls	O
showed	O
a	O
moderate	O
correlation	O
between	O
binding	O
affinity	O
of	O
the	O
GR	B-protein
in	O
lymphocytes	O
and	O
regulatory	O
function	O
at	O
the	O
hypothalamic	O
level	O
,	O
the	O
patients	O
did	O
not	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
signaling	O
pathway	O
contributes	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
mononuclear	O
differentiation	O
in	O
the	O
human	B-cell_line
myeloblastic	I-cell_line
leukemia	I-cell_line
ML-1	I-cell_line
cells	I-cell_line
.	O


In	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
into	O
the	O
MNL	B-cell_type
was	O
inversely	O
correlated	O
with	O
urinary	O
free	O
cortisol	O
levels	O
.	O


This	O
core	O
contains	O
a	O
GATA	B-DNA
site	I-DNA
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E-box	B-DNA
motif	I-DNA
.	O


Recent	O
studies	O
have	O
shown	O
that	O
the	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	B-protein
shock	I-protein
transcription	I-protein
factor	I-protein
(	O
HSF1	B-protein
)	O
from	O
a	O
latent	B-protein
cytoplasmic	I-protein
form	I-protein
to	O
a	O
nuclear	B-protein
,	I-protein
DNA	I-protein
binding	I-protein
state	I-protein
.	O


In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	B-RNA
mRNA	I-RNA
species	I-RNA
.	O


These	O
mutations	O
were	O
introduced	O
in	O
the	O
tax	B-DNA
gene	I-DNA
of	O
the	O
ACH	B-DNA
functional	I-DNA
molecular	I-DNA
clone	I-DNA
of	O
HTLV-1	O
,	O
and	O
virus	O
produced	O
from	O
the	O
mutant	B-DNA
ACH	I-DNA
clones	I-DNA
was	O
examined	O
for	O
the	O
ability	O
to	O
replicate	O
and	O
immortalize	O
primary	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O


Analogous	O
to	O
costimulation	O
via	O
CD28	B-protein
,	O
this	O
activity	O
is	O
mediated	O
through	O
activation	O
of	O
Rel/kappaB	B-protein
,	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
known	O
to	O
regulate	O
IL-2	B-protein
and	O
other	O
activation-inducible	B-protein
proteins	I-protein
.	O


This	O
NF-kappaB	B-protein
binding	I-protein
complex	I-protein
is	O
composed	O
of	O
transcriptionally	B-protein
active	I-protein
p65	I-protein
(	I-protein
RelA	I-protein
)	I-protein
/p50	I-protein
heterodimers	I-protein
and	O
results	O
primarily	O
from	O
the	O
targeted	O
degradation	O
of	O
IkappaB-alpha	B-protein
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel/kappaB	B-protein
in	O
the	O
cytoplasm	O
.	O


Escape	O
of	O
human	O
cytomegalovirus	O
from	O
HLA-DR	B-protein
-restricted	O
CD4	O
(	O
+	O
)	O
T-cell	O
response	O
is	O
mediated	O
by	O
repression	O
of	O
gamma	B-protein
interferon	I-protein
-induced	O
class	B-protein
II	I-protein
transactivator	I-protein
expression	O
.	O


Altogether	O
,	O
the	O
data	O
indicate	O
that	O
the	O
defect	O
induced	O
by	O
HCMV	O
resides	O
in	O
the	O
activation	O
of	O
the	O
IFN-gamma-responsive	B-DNA
promoter	I-DNA
of	O
CIITA	B-DNA
.	O


In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
effects	O
of	O
DZA	O
on	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
regulation	O
.	O


C3	O
transferase	O
and	O
cytochalasin	O
D	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
monocyte-binding	B-protein
receptors	I-protein
on	O
endothelial	B-cell_type
cells	I-cell_type
,	O
but	O
did	O
inhibit	O
clustering	O
of	O
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
on	O
the	O
cell	O
surface	O
induced	O
by	O
monocyte	O
adhesion	O
or	O
cross-linking	B-protein
antibodies	I-protein
.	O


Finally	O
,	O
receptor	O
clusters	O
colocalized	O
with	O
ezrin/moesin/radixin	B-protein
proteins	I-protein
.	O


Advances	O
in	O
gene	O
technology	O
have	O
allowed	O
the	O
manipulation	O
of	O
molecular	O
interactions	O
that	O
shape	O
the	O
T	O
cell	O
repertoire	O
.	O


Previous	O
studies	O
have	O
characterized	O
the	O
CD28	B-protein
augmentation	O
of	O
TCR	B-protein
-mediated	O
signaling	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
through	O
transcriptional	O
activation	O
of	O
an	O
IL-2	B-protein
promoter	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O


DTT	O
antagonized	O
and	O
BSO	O
enhanced	O
As2O3-induced	O
ATP	O
depletion	O
,	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
and	O
apoptosis	O
.	O


To	O
interpret	O
the	O
mechanisms	O
by	O
which	O
EBV	O
activates	O
the	O
cell	O
,	O
we	O
have	O
assayed	O
many	O
proteins	O
involved	O
in	O
control	O
of	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
regulation	O
of	O
apoptosis	O
.	O


Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA-4	B-protein
-mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
using	O
Ab	O
cross-linking	O
.	O


In	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O


We	O
conclude	O
that	O
NF-kappaB	B-protein
is	O
a	O
context-dependent	O
apoptosis	O
regulator	O
.	O


SOCS-3	B-protein
protein	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
IL-2	B-protein
stimulation	O
,	O
while	O
CIS	B-protein
was	O
seen	O
only	O
at	O
low	O
levels	O
after	O
2	O
h	O
.	O


We	O
recently	O
reported	O
that	O
human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
do	O
not	O
express	O
AP-1	B-protein
DNA	O
binding	O
activity	O
(	O
Monick	O
,	O
M.	O
M.	O
,	O
Carter	O
,	O
A.	O
B.	O
,	O
Gudmundsson	O
,	O
G.	O
,	O
Geist	O
,	O
L.	O
J.	O
,	O
and	O
Hunninghake	O
,	O
G.	O
W.	O
(	O
1998	O
)	O
Am.	O
J.	O
Physiol.	O
275	O
,	O
L389-L397	O
)	O
.	O


Development	O
and	O
maturation	O
of	O
secondary	O
lymphoid	O
tissues	O
.	O


Studies	O
over	O
the	O
past	O
few	O
years	O
have	O
identified	O
lymphotoxin	O
as	O
a	O
critical	O
signaling	O
molecule	O
not	O
only	O
for	O
the	O
organogenesis	O
of	O
secondary	O
lymphoid	O
tissues	O
but	O
for	O
the	O
maintenance	O
of	O
aspects	O
of	O
their	O
microarchitecture	O
as	O
well	O
.	O


Modulation	O
of	O
CD28	B-protein
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O


In	O
a	O
model	O
where	O
foreign	B-cell_type
cells	I-cell_type
(	O
rat	B-cell_type
fibroblasts	I-cell_type
)	O
were	O
cocultured	O
with	O
human	B-cell_type
IL-2	I-cell_type
activated	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
we	O
observed	O
that	O
NK	B-cell_type
cells	I-cell_type
were	O
capable	O
of	O
efficiently	O
killing	O
their	O
targets	O
only	O
if	O
the	O
cells	O
overexpressed	O
the	O
oncogene	O
c-Myc	B-protein
or	O
E1A	B-protein
.	O


Differences	O
in	O
phosphorylation	O
of	O
the	O
IL-2R	B-protein
associated	I-protein
JAK/STAT	I-protein
proteins	I-protein
between	O
HTLV-I	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
IL-2-independent	I-cell_line
and	I-cell_line
IL-2-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
uncultured	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
adult	O
T-cell	O
lymphoma/leukemia	O
.	O


To	O
determine	O
activation	O
status	O
of	O
the	O
IL-2R	B-protein
-associated	O
(	O
Jak/STAT	B-protein
)	O
pathway	O
in	O
the	O
HTLV-I	B-cell_line
infected	I-cell_line
cells	I-cell_line
,	O
we	O
examined	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
,	O
STAT3	B-protein
,	O
and	O
STAT5	B-protein
in	O
several	O
HTLV-I	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
in	O
uncultured	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
isolated	O
from	O
patients	O
with	O
adult	O
T-cell	O
lymphoma/leukemia	O
(	O
ATLL	O
)	O
.	O


However	O
,	O
stimulation	O
with	O
IL-2	B-protein
resulted	O
in	O
Jak3	B-protein
and	O
STAT5	B-protein
phosphorylation	O
in	O
both	O
leukemic	B-cell_type
ATLL	I-cell_type
cells	I-cell_type
and	O
IL-2-dependent	B-cell_line
lines	I-cell_line
.	O


Of	O
86	O
patients	O
with	O
a	O
chronic	O
MPD	O
,	O
71	O
(	O
82	O
%	O
)	O
exhibited	O
an	O
allele	B-DNA
ratio	O
greater	O
than	O
3	O
:	O
1	O
,	O
whereas	O
only	O
10	O
(	O
12	O
%	O
)	O
of	O
86	O
age-matched	O
control	O
subjects	O
showed	O
a	O
skewed	O
XCI	O
pattern	O
.	O


GATA-1	B-protein
and	O
erythropoietin	B-protein
cooperate	O
to	O
promote	O
erythroid	O
cell	O
survival	O
by	O
regulating	O
bcl-xL	B-protein
expression	O
.	O


The	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
is	O
essential	O
for	O
normal	O
erythropoiesis	O
.	O


The	O
mechanisms	O
by	O
which	O
GATA-1	B-protein
controls	O
cell	O
survival	O
are	O
unknown	O
.	O


Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
,	O
IL-2	B-protein
and	O
PI	B-protein
3-kinase	I-protein
activation	O
of	O
E2Fs	B-protein
have	O
not	O
been	O
characterized	O
.	O


Our	O
present	O
results	O
show	O
that	O
IL-2	B-protein
-and	O
PI	B-protein
3-kinase	I-protein
-induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	B-protein
transcriptional	O
activity	O
include	O
both	O
rapamycin-resistant	O
and	O
rapamycin-sensitive	O
components	O
.	O


In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O


To	O
understand	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
complexes	O
in	O
T	O
cell	O
development	O
and	O
activation	O
,	O
we	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
RelA	B-protein
and	O
c-Rel	B-protein
complexes	I-protein
were	O
selectively	O
inhibited	O
in	O
the	O
T-lineage	B-cell_type
cells	I-cell_type
by	O
specific	O
expression	O
of	O
a	O
trans-dominant	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


In	O
addition	O
to	O
TNF	B-protein
,	O
LPS-induced	O
IL-6	O
and	O
spontaneous	O
IL-1ra	O
production	O
were	O
also	O
enhanced	O
.	O


Furthermore	O
,	O
NFkappaB	O
translocation	O
following	O
LPS	O
activation	O
was	O
higher	O
after	O
IL-10	B-protein
pre-treatment	O
on	O
Teflon	O
than	O
on	O
plastic	O
.	O


Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	B-protein
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
,	O
independently	O
of	O
the	O
pre-culture	O
conditions	O
of	O
the	O
PBMC	B-cell_type
.	O


Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10	B-protein
-induced	O
up-regulation	O
of	O
cytokine	B-protein
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	B-cell_type
cells	I-cell_type
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	B-cell_type
on	O
Teflon	O
.	O


Cell	O
growth-regulated	O
expression	O
of	O
mammalian	B-DNA
MCM5	I-DNA
and	I-DNA
MCM6	I-DNA
genes	I-DNA
mediated	O
by	O
the	O
transcription	B-protein
factor	I-protein
E2F	B-protein
.	O


Expression	O
of	O
all	O
mammalian	B-DNA
genes	I-DNA
of	O
the	O
MCM	B-DNA
family	I-DNA
is	O
induced	O
by	O
growth	O
stimulation	O
,	O
unlike	O
yeast	O
,	O
and	O
the	O
mRNA	O
levels	O
peak	O
at	O
G1/S	O
boundary	O
.	O


However	O
,	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
has	O
not	O
been	O
described	O
.	O


We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	B-protein
enzyme	I-protein
acid	B-protein
sphingomyelinase	I-protein
(	O
ASM	O
;	O
E.C.3.1.4.12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP-1	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	B-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
.	O


This	O
cell-type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O


Nonspecific	O
protein	B-protein
kinase	I-protein
inhibition	O
inhibited	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
release	O
,	O
while	O
specific	O
PKC	B-protein
inhibition	O
with	O
Bis	O
had	O
no	O
effect	O
on	O
LPS-induced	O
NF-kappaB	B-protein
DNA	O
binding	O
or	O
TNF-alpha	B-protein
release	O
.	O


Increased	O
activity	O
of	O
various	O
proteases	B-protein
is	O
observed	O
in	O
both	O
human	O
and	O
experimental	O
pancreatitis	O
;	O
however	O
,	O
the	O
information	O
on	O
the	O
effects	O
of	O
specific	O
protease	O
inhibitors	O
on	O
the	O
disease	O
is	O
limited	O
.	O


Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O


Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF-alpha	B-protein
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF-alpha	B-protein
gene	O
expression	O
must	O
be	O
tightly	O
regulated	O
.	O


Finally	O
,	O
chromosomal	O
localization	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
revealed	O
that	O
LITAF	B-protein
mapped	O
to	O
chromosome	B-DNA
16p12-16p13.3	I-DNA
.	O


There	O
were	O
12	O
independent	O
mutation	O
events	O
at	O
a	O
single	B-DNA
mutation	I-DNA
site	I-DNA
,	O
defining	O
a	O
small	B-DNA
deletion	I-DNA
hotspot	I-DNA
.	O


Neighbouring	O
sequence	O
analysis	O
favours	O
a	O
small	O
deletion	O
model	O
of	O
slipped	O
mispairing	O
events	O
during	O
replication	O
.	O


In	O
vitro	O
transcription	O
and	O
translation	O
analysis	O
showed	O
that	O
the	O
longer	O
5	B-DNA
'	I-DNA
UTR	I-DNA
resulted	O
in	O
about	O
a	O
35	O
%	O
decrease	O
in	O
translation	O
efficiency	O
.	O


Its	O
differential	O
expression	O
in	O
different	O
tissues	O
and	O
cells	O
is	O
regulated	O
not	O
only	O
at	O
the	O
transcriptional	O
level	O
but	O
also	O
at	O
the	O
translational	O
level	O
.	O


In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF-kappaB	B-protein
protects	O
against	O
Fas	B-protein
-mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O


We	O
demonstrate	O
that	O
,	O
in	O
addition	O
to	O
STAT1alpha	B-protein
,	O
STAT3	B-protein
is	O
also	O
activated	O
by	O
IFN-gamma	B-protein
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O


Induction	O
of	O
apoptosis	O
of	O
mononucleated	B-cell_type
cells	I-cell_type
is	O
a	O
physiological	O
process	O
for	O
regulating	O
the	O
intensity	O
of	O
the	O
immune	O
response	O
.	O


The	O
data	O
presented	O
here	O
suggest	O
that	O
the	O
female	B-protein
steroid	I-protein
receptors	I-protein
play	O
a	O
role	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
by	O
preventing	O
apoptosis	O
of	O
monoblastoid	B-cell_type
cells	I-cell_type
;	O
this	O
effect	O
might	O
have	O
important	O
consequences	O
in	O
the	O
clinical	O
use	O
of	O
steroid	O
receptor	O
drugs	O
.	O


--	O
Vegeto	O
,	O
E.	O
,	O
Pollio	O
,	O
G.	O
,	O
Pellicciari	O
,	O
C.	O
,	O
Maggi	O
,	O
A	O
.	O


Inhibition	O
of	O
T	O
cell	O
signaling	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase-targeted	I-protein
hematopoietic	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
HePTP	B-protein
)	O
.	O


Our	O
findings	O
demonstrate	O
that	O
p38	B-protein
MAPK	I-protein
1	O
)	O
plays	O
an	O
important	O
role	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
primary	B-cell_type
mouse	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
2	O
)	O
may	O
be	O
involved	O
in	O
the	O
induction	O
of	O
c-Jun	B-protein
activation	O
and	O
augmentation	O
of	O
AP-1	B-protein
transcriptional	O
activity	O
,	O
and	O
3	O
)	O
regulates	O
whether	O
T	B-cell_type
cells	I-cell_type
enter	O
a	O
state	O
of	O
functional	O
unresponsiveness	O
.	O


These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	B-cell_type
macrophages	I-cell_type
,	O
suppressed	O
activation	O
of	O
lung	B-protein
NF-kappaB	I-protein
in	O
the	O
inflammatory	O
model	O
.	O


Cytokines	B-protein
that	O
bind	O
to	O
the	O
common	O
gamma	B-protein
chain	I-protein
of	O
the	O
IL-2	B-protein
receptor	O
promote	O
the	O
survival	O
of	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
,	O
but	O
also	O
induce	O
proliferation	O
.	O


Copyright	O
1999	O
Academic	O
Press	O
.	O


Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	B-cell_type
.	O


Retinoids	O
are	O
bifunctional	O
regulators	O
of	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O


RA	O
(	O
100	O
nM	O
)	O
induced	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
dead	B-cell_type
cells	I-cell_type
from	O
24	O
%	O
to	O
44	O
%	O
at	O
day	O
6	O
(	O
p	O
<	O
0.05	O
,	O
n	O
=	O
6	O
)	O
as	O
compared	O
to	O
control	B-cell_type
cells	I-cell_type
cultured	O
in	O
medium	O
alone	O
.	O


Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
was	O
demonstrated	O
as	O
the	O
mode	O
of	O
cell	O
death	O
by	O
using	O
the	O
TUNEL	O
assay	O
,	O
which	O
detects	O
single	O
strand	O
nicks	O
in	O
DNA	O
,	O
or	O
by	O
the	O
Nicoletti	O
technique	O
demonstrating	O
a	O
subdiploid	O
population	O
by	O
DNA	O
staining	O
.	O


Suppressive	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
human	B-cell_type
endothelial	I-cell_type
cell	I-cell_type
activation	O
and	O
induction	O
of	O
heat	B-protein
shock	I-protein
proteins	I-protein
.	O


The	O
interactions	O
of	O
Hsp60-specific	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
arterial	O
endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
require	O
expression	O
of	O
both	O
Hsp60	B-protein
and	O
certain	O
adhesion	B-protein
molecules	I-protein
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	B-cell_type
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O


MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O


Before	O
and	O
after	O
treatment	O
,	O
the	O
patients	O
underwent	O
fiberoptic	O
bronchoscopy	O
with	O
endobronchial	O
biopsy	O
and	O
sampling	O
of	O
venous	O
blood	O
for	O
measurements	O
of	O
GR	B-RNA
mRNA	I-RNA
levels	O
.	O


Jeg-3	O
human	O
choriocarcinoma-induced	O
immunosuppression	O
:	O
downregulation	O
of	O
interleukin-2	B-protein
,	O
interleukin-2	B-protein
receptor	I-protein
alpha-chain	I-protein
,	O
and	O
its	O
Jak/Stat	B-protein
signaling	O
pathway	O
.	O


Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
is	O
suppressed	O
approximately	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	B-cell_type
cells	I-cell_type
.	O


The	O
Th2-type	B-protein
cytokines	I-protein
,	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
,	O
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
including	O
FcepsilonRIIb	B-protein
(	O
CD23	B-protein
)	O
,	O
15-lipoxygenase	B-protein
,	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
(	O
IL-1ra	B-protein
)	O
,	O
and	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IL-1	I-protein
receptors	I-protein
(	O
IL-1R	B-protein
)	O
.	O


Type	B-protein
I	I-protein
interferons	I-protein
(	O
IFN-alpha	B-protein
and	O
IFN-beta	B-protein
)	O
and	O
type	B-protein
II	I-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
inhibit	O
induction	O
of	O
these	O
genes	O
by	O
IL-4	B-protein
and	O
IL-13	B-protein
.	O


Inhibition	O
of	O
STAT6	B-protein
activity	O
is	O
not	O
evident	O
unless	O
cells	O
are	O
preincubated	O
with	O
IFN	B-protein
for	O
at	O
least	O
1	O
h	O
before	O
IL-4	B-protein
stimulation	O
.	O


HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
inactivation	O
of	O
Rb	B-protein
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	B-protein
Abs	I-protein
to	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bFGF	B-protein
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	B-protein
receptors	I-protein
in	O
the	O
signaling	O
process	O
.	O


A	O
cdk2	O
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant-negative	B-DNA
cdk2	I-DNA
construct	I-DNA
prevented	O
HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
inactivation	O
of	O
Rb	B-protein
;	O
in	O
contrast	O
,	O
dominant-negative	B-DNA
cdk4	I-DNA
and	I-DNA
cdk6	I-DNA
constructs	I-DNA
had	O
no	O
effect	O
.	O


Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	B-protein
D-associated	I-protein
kinase	I-protein
activity	O
upon	O
HLA	B-protein
class	I-protein
I	I-protein
ligation	O
,	O
suggesting	O
that	O
cyclin	B-protein
E-dependent	I-protein
kinase	I-protein
activity	O
mediates	O
Rb	B-protein
inactivation	O
,	O
leading	O
to	O
E2F	B-protein
activation	O
and	O
cell	O
proliferation	O
.	O


Most	O
erythroleukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
established	O
in	O
vitro	O
coexpress	O
erythrocytic	B-protein
and	I-protein
megakaryocytic	I-protein
markers	I-protein
that	O
often	O
are	O
associated	O
with	O
expression	O
of	O
Spi-1	B-protein
and/or	O
Fli-1	B-protein
transcription	I-protein
factors	I-protein
known	O
as	O
transactivators	B-protein
of	I-protein
megakaryocyte-specific	I-protein
promoters	I-protein
.	O


Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	B-DNA
gene	I-DNA
expression	O
and	O
concomitant	O
decrease	O
in	O
expression	O
of	O
Spi-1	B-protein
,	O
Fli-1	B-protein
,	O
and	O
megakaryocytic	B-DNA
genes	I-DNA
in	O
an	O
erythropoietin	B-protein
-dependent	O
manner	O
.	O


Interestingly	O
,	O
enhanced	O
expression	O
of	O
Spi-1	B-DNA
and	I-DNA
Fli-1	I-DNA
genes	I-DNA
already	O
was	O
detected	O
in	O
the	O
Ter	B-cell_line
119	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
of	O
transgenic	O
mice	O
spleen	O
in	O
vivo	O
.	O


However	O
,	O
like	O
normal	B-cell_line
Ter	I-cell_line
119	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
,	O
these	O
Ter	B-cell_line
119	I-cell_line
positive	I-cell_line
cells	I-cell_line
from	O
transgenic	O
mice	O
still	O
expressed	O
high	O
levels	O
of	O
beta-globin	B-protein
and	O
very	O
low	O
or	O
undetectable	O
glycoprotein	B-protein
IIb	I-protein
and	O
platelet	B-protein
factor	I-protein
4	I-protein
megakaryocytic	I-protein
transcripts	I-protein
.	O


Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O


Whereas	O
the	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
Tax-expressing	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
consisted	O
mostly	O
of	O
p50/c-Rel	B-protein
,	O
fresh	O
ATL	O
samples	O
contained	O
p50/p50	B-protein
and	I-protein
p50/p65	I-protein
heterodimers	I-protein
.	O


Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF-kappaB	B-protein
occurs	O
through	O
a	O
Tax	B-protein
-independent	O
mechanism	O
in	O
leukemic	B-cell_type
cells	I-cell_type
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF-kappaB	B-protein
subunit	O
activation	O
.	O


Therefore	O
,	O
this	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
role	O
of	O
Lck	B-protein
in	O
IFN-alpha	B-protein
signaling	O
by	O
using	O
the	O
Jurkat	O
,	O
JCam	O
(	O
an	O
Lck-defective	B-cell_line
cell	I-cell_line
line	I-cell_line
derived	O
from	O
Jurkat	B-cell_line
)	O
,	O
and	O
JCam/Lck	B-cell_line
(	O
JCam	B-cell_line
cells	I-cell_line
with	O
Lck	B-protein
restored	O
)	O
.	O


The	O
results	O
show	O
that	O
IFN-alpha	B-protein
can	O
induce	O
MAPK	B-protein
activity	O
,	O
but	O
only	O
in	O
cells	O
containing	O
Lck	B-protein
.	O


These	O
data	O
indicate	O
that	O
Lck	B-protein
and	O
active	O
MAPK	B-protein
do	O
not	O
affect	O
IFN-alpha	B-protein
-induced	O
growth	O
arrest	O
or	O
induction	O
of	O
STAT1s1	O
and	O
-3	O
DNA	O
binding	O
ability	O
.	O


Copyright	O
1999	O
Academic	O
Press	O
.	O


Of	O
p38	B-protein
MAPk	I-protein
isoforms	I-protein
studied	O
,	O
only	O
p38alpha	B-protein
and	O
p38delta	B-protein
were	O
detected	O
in	O
neutrophils	B-cell_type
.	O


LPS	O
stimulation	O
selectively	O
activated	O
p38alpha	B-protein
.	O


The	O
evolutionarily	B-DNA
conserved	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
human	B-protein
Ig	I-protein
heavy	I-protein
chain	I-protein
S	I-protein
gamma	I-protein
3	I-protein
region	I-protein
is	O
an	O
inducible	B-DNA
promoter	I-DNA
:	O
synergistic	O
activation	O
by	O
CD40	B-protein
ligand	I-protein
and	O
IL-4	B-protein
via	O
cooperative	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
STAT-6	I-DNA
binding	I-DNA
sites	I-DNA
.	O


In	O
these	O
transfected	O
CL-01	B-cell_line
cells	I-cell_line
,	O
CD40	O
:	O
CD40L	B-protein
engagement	O
and	O
exposure	O
to	O
IL-4	B-protein
synergistically	O
induced	O
gamma	O
3	O
ECS-dependent	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
activation	O
.	O


The	O
transactivator	B-protein
CIITA	B-protein
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O


Expression	O
of	O
GrpL	B-protein
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	B-protein
by	O
having	O
a	O
proline-rich	B-protein
region	I-protein
.	O


GrpL	B-protein
can	O
be	O
coimmunoprecipitated	O
with	O
SLP-76	B-protein
but	O
not	O
with	O
Sos1	B-protein
or	O
Sos2	B-protein
from	O
Jurkat	B-cell_line
cell	I-cell_line
lysates	O
.	O


In	O
contrast	O
,	O
another	O
inducible	O
gene	O
expression	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
a	O
CC	B-protein
chemokine	I-protein
)	O
and	O
the	O
activation	O
of	O
the	O
transcriptional	B-protein
factor	I-protein
(	O
FcRFgamma	B-protein
)	O
bound	O
to	O
the	O
gamma	B-DNA
response	I-DNA
region	I-DNA
were	O
similarly	O
or	O
less	O
abundantly	O
induced	O
by	O
IFNgamma	B-protein
treatment	O
in	O
PMA	O
-or	O
RA-differentiated	O
U937	B-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
increased	O
IP-10	B-RNA
mRNA	I-RNA
induction	O
was	O
not	O
due	O
to	O
the	O
augmented	O
ability	O
of	O
the	O
cells	O
to	O
respond	O
to	O
the	O
presence	O
of	O
IFNgamma	B-protein
.	O


The	O
STP	B-protein
oncoproteins	I-protein
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
(	I-protein
TRAF	I-protein
)	I-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
or	I-protein
3	I-protein
.	O


The	O
HVS	O
STP-C488	B-protein
P10	O
--	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T-lymphocyte	O
transformation	O
to	O
interleukin-2-independent	O
growth	O
but	O
showed	O
wild-type	O
phenotype	O
for	O
marmoset	O
T-lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


Cleavage	O
of	O
transcription	B-protein
factor	I-protein
SP1	B-protein
by	O
caspases	B-protein
during	O
anti-IgM-induced	O
B-cell	B-cell_type
apoptosis	O
.	O


Cleavage	O
could	O
be	O
completely	O
inhibited	O
by	O
zDEVD-fmk	O
,	O
an	O
inhibitor	O
specific	O
for	O
caspase	B-protein
3-like	I-protein
proteases	I-protein
.	O


CD40	B-protein
expression	O
was	O
confirmed	O
in	O
7	O
human	B-cell_line
MM	I-cell_line
cell	I-cell_line
lines	I-cell_line
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
advanced	O
stages	O
were	O
CD40	B-protein
negative	O
.	O


CD40	B-protein
expression	O
could	O
be	O
enhanced	O
in	O
CD40	B-protein
-positive	O
MM	O
by	O
stimulation	O
with	O
IFN-gamma	B-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
but	O
not	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1beta	I-protein
or	O
CD40	B-protein
triggering	O
.	O


Furthermore	O
,	O
CD40	B-protein
ligation	O
of	O
a	O
HLA-A2+	B-cell_line
,	I-cell_line
MelanA/MART1+	I-cell_line
MM	I-cell_line
cell	I-cell_line
line	I-cell_line
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA-A2-restricted	B-cell_line
,	I-cell_line
MelanA/MART-1-specific	I-cell_line
CTL	I-cell_line
clone	I-cell_line
.	O


Finally	O
,	O
CD40	B-protein
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O


Furthermore	O
,	O
we	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
the	O
fusion	O
protein	O
AML1/MDS1/EVI1	B-protein
completely	O
abrogates	O
the	O
growth-inhibitory	O
effect	O
of	O
TGF-beta1	B-protein
and	O
allows	O
32Dcl3	B-cell_line
cells	I-cell_line
to	O
proliferate	O
,	O
expression	O
of	O
the	O
normal	O
protein	O
MDS1/EVI1	B-DNA
has	O
the	O
opposite	O
effect	O
,	O
and	O
it	O
strengthens	O
the	O
response	O
of	O
cells	O
to	O
the	O
growth-inhibitory	O
effect	O
of	O
TGF-beta1	B-protein
.	O


METHODS	O
:	O
Platelets	B-cell_type
were	O
collected	O
from	O
112	O
drug-free	O
patients	O
with	O
bipolar	O
disorder	O
(	O
52	O
euthymic	O
,	O
29	O
depressed	O
,	O
and	O
31	O
manic	O
)	O
and	O
62	O
healthy	O
subjects	O
.	O


Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	B-protein
profiles	O
have	O
been	O
described	O
.	O


Th1	O
cells	O
produce	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
,	O
whereas	O
Th2	B-cell_line
cells	I-cell_line
produce	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-6	B-protein
,	O
IL-10	B-protein
,	O
and	O
IL-13	B-protein
.	O


Beta-catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	B-DNA
segment	I-DNA
polarity	I-DNA
gene	I-DNA
Armadillo	B-DNA
and	O
plays	O
roles	O
in	O
both	O
cell-cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O


Recently	O
,	O
members	O
of	O
the	O
Lef/Tcf	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta-catenin	B-protein
,	O
explaining	O
how	O
beta-catenin	B-protein
alters	O
gene	O
expression	O
.	O


EBNA2	B-protein
-dependent	O
transcriptional	O
induction	O
of	O
the	O
IFN-beta	B-DNA
promoter	I-DNA
occurred	O
in	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
other	O
EBV	B-DNA
genes	I-DNA
were	O
not	O
required	O
for	O
the	O
induction	O
of	O
IFN-beta	B-protein
synthesis	O
.	O


Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG-Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	B-cell_type
isolated	I-cell_type
blood	I-cell_type
leukocytes	I-cell_type
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
PGG-Glucan	O
induced	O
the	O
activation	O
of	O
an	O
NF-kappaB-like	B-protein
nuclear	I-protein
transcription	I-protein
factor	I-protein
in	O
purified	B-cell_type
human	I-cell_type
neutrophils	I-cell_type
.	O


Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	B-cell_type
leukocytes	I-cell_type
.	O


These	O
effects	O
were	O
specific	O
in	O
that	O
the	O
potentiated	O
phagocytosis	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
was	O
completely	O
blocked	O
by	O
the	O
glucocorticoid	B-protein
receptor	I-protein
antagonist	O
RU38486	O
,	O
and	O
glucocorticoids	O
did	O
not	O
promote	O
5-day	O
M	O
phi	O
ingestion	O
of	O
opsonized	B-cell_type
erythrocytes	I-cell_type
.	O


1	O
,	O
25-Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	B-cell_line
acid-resistant	I-cell_line
acute	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
UF-1	B-cell_line
)	O
associated	O
with	O
expression	O
of	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
.	O


Retinoic	O
acid	O
(	O
RA	O
)	O
resistance	O
is	O
a	O
serious	O
problem	O
for	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
who	O
are	O
receiving	O
all-trans	O
RA	O
.	O


RXRs	B-protein
heterodimerize	O
with	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
[	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
]	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O


This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all-trans	O
RA	O
.	O


Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O


Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O


Molecular	O
mechanisms	O
of	O
neutrophil-endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O


These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia/reoxygenation	O
.	O


This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG/GSH	O
cause	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
,	O
which	O
leads	O
to	O
a	O
2-phase	O
neutrophil	B-cell_type
-endothelial	O
adhesion	O
response	O
.	O


Fewer	O
apoptotic	B-cell_type
cell	I-cell_type
bodies	I-cell_type
were	O
present	O
in	O
ectopic	O
pregnancy	O
.	O


The	O
use	O
of	O
tissue	O
obtained	O
from	O
ectopic	O
pregnancy	O
may	O
become	O
an	O
excellent	O
model	O
to	O
identify	O
the	O
mechanism	O
of	O
trophoblast	O
invasion	O
in	O
eutopic	O
pregnancies	O
.	O


The	O
renin	B-protein
-angiotensin	O
system	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O


Moreover	O
,	O
ANG	B-protein
II	I-protein
stimulated	O
NF-kappaB	B-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
but	O
not	O
in	O
lymphocytes	B-cell_type
from	O
the	O
same	O
preparation	O
.	O


These	O
effects	O
were	O
blocked	O
by	O
mAbs	B-protein
against	O
endothelial	B-protein
and/or	I-protein
leukocyte	I-protein
adhesion	I-protein
molecules	I-protein
(	O
beta1	B-protein
and	I-protein
beta2	I-protein
integrins	I-protein
)	O
.	O


She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O


A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13.3	O
mg/24h	O
;	O
N	O
:	O
1.4+/-0.8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3.16	O
mg/24h	O
;	O
N	O
:	O
2.7+/-2.0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE/THF	O
(	O
0.24	O
;	O
N	O
:	O
1.87+/-0.36	O
)	O
and	O
alpha	O
THF/THF	O
(	O
0.35	O
;	O
N	O
:	O
0.92+/-0.42	O
)	O
ratios	O
.	O


Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O


Differential	O
regulation	O
of	O
4E-BP1	B-protein
and	O
4E-BP2	B-protein
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	B-cell_type
myeloid	I-cell_type
cell	I-cell_type
differentiation	O
.	O


Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O


Dephosphorylation	O
of	O
4E-BP1	B-protein
was	O
also	O
observed	O
when	O
U-937	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
into	O
monocytes/macrophages	B-cell_type
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O


Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic/macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O


We	O
have	O
studied	O
mutations	O
in	O
the	O
5	B-DNA
'	I-DNA
noncoding	I-DNA
region	I-DNA
of	O
the	O
Bcl6	B-DNA
gene	I-DNA
in	O
different	O
subtypes	O
of	O
lymphomas	O
.	O


The	O
frequency	O
,	O
distribution	O
,	O
and	O
nature	O
of	O
these	O
mutations	O
were	O
similar	O
to	O
those	O
resulting	O
from	O
the	O
Ig	O
hypermutation	O
process	O
.	O


In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl-6+	B-cell_type
cells	I-cell_type
in	O
the	O
interfollicular	O
zones	O
.	O


(	O
2	O
)	O
Intrafollicular	B-cell_type
CD3+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
many	O
of	O
which	O
were	O
also	O
positive	O
for	O
Bcl-6	B-protein
,	O
were	O
markedly	O
depleted	O
in	O
AITL/GC	O
,	O
with	O
increased	O
interfollicular	O
Bcl-6+/CD3+	B-cell_type
cells	I-cell_type
,	O
suggesting	O
an	O
outward	O
migration	O
of	O
intrafollicular	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
this	O
condition	O
.	O


These	O
experiments	O
showed	O
that	O
,	O
in	O
fact	O
,	O
NF-kappaB	B-protein
was	O
translocated	O
to	O
the	O
nucleus	O
following	O
viral	O
binding	O
or	O
purified	O
viral	O
ligand	O
binding	O
.	O


Regulation	O
of	O
the	O
megakaryocytic	B-DNA
glycoprotein	I-DNA
IX	I-DNA
promoter	I-DNA
by	O
the	O
oncogenic	B-protein
Ets	I-protein
transcription	I-protein
factor	I-protein
Fli-1	B-protein
.	O


However	O
,	O
the	O
Ets	B-protein
protein	I-protein
(	O
s	O
)	O
that	O
regulated	O
GPIX	B-DNA
promoter	I-DNA
expression	O
was	O
unknown	O
.	O


According	O
to	O
current	O
models	O
the	O
inhibitory	O
capacity	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
would	O
be	O
mediated	O
through	O
the	O
retention	O
of	O
Rel/NF-kappaB	B-protein
proteins	I-protein
in	O
the	O
cytosol	B-cell_type
.	O


Unexpectedly	O
,	O
the	O
presence	O
of	O
nuclear	B-protein
I	I-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
did	O
not	O
inhibit	O
NF-kappaB	B-protein
binding	O
to	O
DNA	O
and	O
this	O
phenomenon	O
was	O
not	O
due	O
to	O
the	O
presence	O
of	O
IkappaBbeta	B-protein
at	O
the	O
nuclear	O
level	O
.	O


Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA-activated	B-cell_type
human	I-cell_type
PBL	I-cell_type
,	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
is	O
present	O
in	O
the	O
nucleus	O
in	O
an	O
apparently	O
inactive	O
form	O
unable	O
to	O
disrupt	O
NF-kappaB	B-protein
binding	O
from	O
DNA	O
.	O


Impaired	O
fetal	B-cell_type
thymocyte	I-cell_type
development	O
after	O
efficient	O
adenovirus-mediated	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus-mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O


Fetal	B-cell_type
thymocytes	I-cell_type
infected	O
with	O
adenovirus	O
containing	O
mut-I	B-protein
kappa	I-protein
B	I-protein
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	B-protein
-CD25+	O
,	O
CD4	B-protein
-	O
CD8	B-protein
-	O
double-negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double-positive	O
and	O
single-positive	O
populations	O
was	O
strongly	O
decreased	O
.	O


Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	B-cell_type
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O


No	O
correlations	O
were	O
observed	O
for	O
these	O
variables	O
with	O
blood	O
pressure	O
or	O
serum	B-protein
lipoproteins	I-protein
.	O


Cobalt	O
chloride-induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
transendothelial	O
migration	O
of	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
is	O
blocked	O
by	O
PAF-receptor	O
antagonist	O
.	O


We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O


Inhibitors	O
of	O
MAP	B-protein
kinase	I-protein
(	O
PD98059	O
)	O
or	O
platelet-activating	O
factor	O
(	O
PAF	O
)	O
-	O
receptor	O
antagonist	O
(	O
CV3988	O
)	O
inhibited	O
the	O
CoCl2-induced	O
NF-kappaB	B-protein
activation	O
and	O
VCAM-1	B-protein
expression	O
.	O


Our	O
data	O
suggests	O
that	O
CoCl2-induced	O
cellular	O
signals	O
directing	O
increased	O
expression	O
of	O
VCAM-1	B-protein
in	O
HUVEC	B-cell_type
involve	O
downstream	O
activation	O
of	O
MAP	B-protein
kinase	I-protein
and	O
NF-kappaB	B-protein
,	O
while	O
the	O
phosphorylation	O
of	O
PECAM-1	B-protein
occurs	O
as	O
a	O
result	O
of	O
activation	O
of	O
PKC	B-protein
.	O


We	O
conclude	O
that	O
PAF-receptor	O
antagonist	O
inhibits	O
the	O
CoCl2	O
-or	O
hypoxia-induced	O
increase	O
in	O
the	O
adhesion	O
of	O
SS	B-cell_type
RBC	I-cell_type
,	O
PECAM-1	B-protein
phosphorylation	O
,	O
and	O
the	O
concomitant	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
.	O


LPS-induced	O
NF-kappaB	B-protein
activation	O
was	O
not	O
inhibited	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
TRAF2	B-protein
that	O
is	O
involved	O
in	O
TNF	B-protein
signaling	O
.	O


The	O
E2A-HLF	B-DNA
fusion	I-DNA
gene	I-DNA
,	O
generated	O
by	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
p13	I-DNA
)	I-DNA
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
encodes	O
a	O
chimeric	B-protein
transcription	I-protein
factor	I-protein
in	O
which	O
the	O
trans-activating	B-protein
domains	I-protein
of	O
E2A	B-protein
are	O
fused	O
to	O
the	O
DNA-	B-protein
binding	I-protein
and	I-protein
dimerization	I-protein
domains	I-protein
of	O
hepatic	B-protein
leukemic	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
.	O


These	O
findings	O
indicated	O
that	O
the	O
expression	O
of	O
E2A-HLF	B-protein
induced	O
T-cell	O
apoptosis	O
and	O
B-cell	O
maturation	O
arrest	O
in	O
vivo	O
and	O
that	O
the	O
susceptibility	O
of	O
the	O
transgenic	O
mice	O
to	O
infection	O
was	O
due	O
to	O
immunodeficiency	O
.	O


Moreover	O
,	O
several	O
transgenic	O
mice	O
developed	O
acute	O
leukemia	O
,	O
classified	O
as	O
T-ALL	O
based	O
on	O
the	O
surface	O
marker	O
analysis	O
and	O
DNA	O
rearrangements	O
,	O
suggesting	O
that	O
an	O
additional	O
event	O
is	O
required	O
for	O
malignant	O
transformation	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
expressing	O
E2A-HLF	B-protein
.	O


Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	B-cell_type
promyelocytes	I-cell_type
while	O
potentiating	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
-induced	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte/monocyte	O
lineage	O
.	O


In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	B-protein
-and	O
RAR	B-protein
-specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant-negative	O
activity	O
of	O
the	O
truncated	B-protein
RARalpha	I-protein
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O


In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
we	O
observed	O
that	O
this	O
RXR	B-protein
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	B-protein
-mediated	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte	B-cell_type
lineage	I-cell_type
or	O
in	O
transactivating	O
RAR-RXR	B-DNA
response	I-DNA
elements	I-DNA
.	O


The	O
magnitude	O
of	O
these	O
functional	O
responses	O
is	O
greatly	O
augmented	O
when	O
T	B-cell_type
cells	I-cell_type
are	O
activated	O
by	O
the	O
combination	O
of	O
IL-12	B-protein
and	O
IL-2	B-protein
.	O


Using	O
antibodies	O
against	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
NF-kappaB	B-protein
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	B-protein
and	O
p65	B-protein
proteins	I-protein
was	O
further	O
demonstrated	O
.	O


The	O
work	O
reported	O
here	O
was	O
instigated	O
to	O
identify	O
additional	O
VDR	B-protein
3'-UTR	B-DNA
polymorphisms	O
that	O
may	O
have	O
functional	O
significance	O
and	O
to	O
then	O
test	O
whether	O
these	O
genetic	O
variants	O
alter	O
message	O
stability	O
.	O


IL-2	B-protein
-mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF-kappa	B-protein
B	I-protein
or	O
activating	O
protein-1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O


The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL-2	B-protein
does	O
not	O
induce	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
degradation	O
or	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
respond	O
to	O
IL-2	B-protein
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O


Quantitative	O
thin-layer	O
chromatography	O
(	O
TLC	O
)	O
analyses	O
showed	O
that	O
HL60	B-cell_line
and	O
normal	B-cell_type
cells	I-cell_type
are	O
able	O
to	O
generate	O
estrone	O
(	O
E1	O
)	O
from	O
estradiol	O
(	O
E2	O
)	O
.	O


Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Northern	O
analyses	O
confirmed	O
that	O
normal	O
and	O
leukemic	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
expressed	O
mRNA	B-RNA
for	O
the	O
type	O
I	O
and	O
IV	O
isoforms	O
of	O
17	B-protein
beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
.	O


When	O
HL60	B-cell_line
cells	I-cell_line
or	O
normal	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
were	O
exposed	O
to	O
exogenous	O
E1	O
they	O
became	O
more	O
sensitive	O
to	O
the	O
differentiation-inducing	O
effects	O
of	O
D3	O
.	O


We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	O
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	O
transiently	O
overexpressed	O
in	O
293	B-cell_line
cells	I-cell_line
.	O


Cbl-b	B-protein
,	O
a	O
homologue	O
of	O
Cbl	B-protein
,	O
is	O
widely	O
expressed	O
in	O
many	O
tissues	O
and	O
cells	O
including	O
hematopoietic	B-cell_type
cells	I-cell_type
[	O
6	O
]	O
[	O
7	O
]	O
.	O


Incidentally	O
,	O
Grf40	B-protein
binds	O
to	O
linker	B-protein
for	I-protein
activation	I-protein
of	I-protein
T	I-protein
cells	I-protein
(	O
LAT	B-protein
)	O
possibly	O
via	O
its	O
SH2	B-protein
domain	I-protein
.	O


Overexpression	O
of	O
wild-type	B-protein
Grf40	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
induced	O
a	O
significant	O
increase	O
of	O
SLP-76-dependent	B-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
promoter	I-DNA
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	O
NF-AT	B-protein
)	O
activation	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
stimulation	O
,	O
whereas	O
the	O
COOH-terminal	B-protein
SH3-deleted	I-protein
Grf40	I-protein
mutant	I-protein
lacked	O
any	O
recognizable	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O


In	O
the	O
present	O
report	O
,	O
we	O
identified	O
and	O
monitored	O
the	O
pocket	B-protein
protein-E2F	I-protein
complexes	I-protein
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	I-cell_type
after	O
activation	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
.	O


Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP-1	B-protein
expression	O
in	O
the	O
NKL	B-cell_line
human	I-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


To	O
test	O
this	O
apparent	O
discrepancy	O
,	O
we	O
realized	O
that	O
HTB	O
and	O
triflusal	O
(	O
but	O
neither	O
aspirin	O
nor	O
salicylate	O
)	O
produced	O
a	O
concentration-dependent	O
inhibition	O
of	O
COX-2	B-protein
protein	O
expression	O
in	O
peripheral	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


Involvement	O
of	O
adenylate	B-protein
cyclase	I-protein
and	O
p70	B-protein
(	I-protein
S6	I-protein
)	I-protein
-kinase	I-protein
activation	O
in	O
IL-10	B-protein
up-regulation	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
gp41	B-protein
envelope	I-protein
protein	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O


In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	B-protein
-induced	O
IL-10	B-protein
up-regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF-kappaB	B-protein
pathways	O
.	O


Here	O
we	O
describe	O
methods	O
to	O
investigate	O
whether	O
and	O
how	O
signaling	O
agonists	O
induce	O
myeloid	O
differentiation	O
and	O
how	O
oncoproteins	B-protein
might	O
cause	O
AML	O
by	O
modulating	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
pivotal	O
for	O
normal	O
myeloid	O
development	O
.	O


Interestingly	O
,	O
the	O
self	O
and	O
bacterial	O
peptides	O
equally	O
were	O
substantially	O
less	O
effective	O
than	O
the	O
cognate	O
viral	O
peptide	O
in	O
sensitizing	O
target	O
cell	O
lysis	O
,	O
and	O
also	O
resulted	O
only	O
in	O
a	O
weak	O
reactivation	O
of	O
memory	B-cell_type
CTLs	I-cell_type
in	O
limiting	O
dilution	O
assays	O
,	O
whereas	O
the	O
cognate	O
peptide	O
was	O
highly	O
immunogenic	O
.	O


RANTES	B-protein
is	O
expressed	O
late	O
(	O
3-5	O
days	O
)	O
after	O
activation	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


Using	O
expression	O
cloning	O
,	O
we	O
identified	O
the	O
first	O
``	O
late	O
''	O
T	B-protein
lymphocyte	I-protein
associated	I-protein
transcription	I-protein
factor	I-protein
and	O
named	O
it	O
``	O
RANTES	B-protein
Factor	I-protein
of	I-protein
Late	I-protein
Activated	I-protein
T	I-protein
Lymphocytes-1	I-protein
``	O
(	O
RFLAT-1	B-protein
)	O
.	O


Here	O
,	O
we	O
report	O
that	O
expression	O
of	O
FasL	B-protein
protein	I-protein
and	O
mRNA	B-RNA
in	O
activated	B-cell_type
NK	I-cell_type
cells	I-cell_type
is	O
also	O
regulated	O
by	O
redox	O
.	O


Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine/	O
threonine	B-protein
phosphatase	I-protein
that	O
regulates	O
NFAT	B-protein
activation	O
.	O


Purified	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stimulated	O
with	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
either	O
human	B-protein
CD80	I-protein
(	O
CHO-CD80	B-protein
)	O
or	O
human	B-protein
CD86	I-protein
(	O
CHO-CD86	B-protein
)	O
or	O
with	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
.	O


In	O
addition	O
,	O
the	O
association	O
of	O
phosphoinositide	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
and	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	O
Cgamma	O
were	O
seen	O
after	O
anti-CD28	O
mAb	O
and	O
CHO-CD80	O
stimulation	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
after	O
CHO-CD86	B-protein
stimulation	O
.	O


Binding	O
of	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
elicits	O
structural	O
changes	O
in	O
a	O
silencer	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
.	O


We	O
previously	O
showed	O
that	O
repression	O
of	O
the	O
beta-globin	O
gene	O
appears	O
to	O
be	O
mediated	O
through	O
two	O
DNA	B-DNA
sequences	I-DNA
,	O
silencers	B-DNA
I	I-DNA
and	I-DNA
II	I-DNA
,	O
and	O
identified	O
a	O
protein	O
termed	O
BP1	B-protein
which	O
binds	O
to	O
both	O
silencer	O
sequences	O
.	O


In	O
this	O
study	O
,	O
we	O
cloned	O
two	O
cDNAs	B-DNA
encoding	O
proteins	O
which	O
bind	O
to	O
an	O
oligonucleotide	O
in	O
silencer	B-DNA
I	I-DNA
containing	O
a	O
BP1	B-protein
binding	O
site	O
.	O


Expression	O
studies	O
revealed	O
that	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
is	O
ubiquitously	O
expressed	O
in	O
human	O
tissues	O
that	O
do	O
not	O
express	O
beta-globin	B-protein
,	O
being	O
present	O
in	O
48	O
of	O
50	O
tissues	O
and	O
six	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
examined	O
.	O


Class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
class	I-DNA
II	I-DNA
)	I-DNA
genes	I-DNA
are	O
regulated	O
in	O
a	O
B-cell-specific	O
and	O
gamma	O
interferon-inducible	O
fashion	O
.	O


We	O
measured	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
in	O
15	O
term	O
and	O
in	O
20	O
preterm	O
babies	O
.	O


In	O
this	O
study	O
on	O
the	O
number	O
and	O
function	O
of	O
GR	B-protein
in	O
lymphocytes	B-cell_type
,	O
we	O
were	O
unable	O
to	O
find	O
a	O
relation	O
between	O
the	O
functionality	O
of	O
the	O
GR	B-protein
and	O
the	O
development	O
of	O
NRDS	O
.	O


Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
regulates	O
IgA	B-protein
production	O
.	O


CD44	O
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O


Using	O
synovial	O
cells	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
we	O
demonstrated	O
that	O
CD44	O
cross-linking	O
and	O
binding	O
to	O
hyaluronan	O
augmented	O
VCAM-1	B-protein
expression	O
and	O
subsequently	O
VCAM-1	B-protein
-mediated	O
cell	O
adhesion	O
.	O


These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	B-cell_type
synovial	I-cell_type
cells	I-cell_type
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	B-protein
could	O
up-regulate	O
VCAM-1	B-protein
expression	O
and	O
VCAM-1	B-protein
-mediated	O
adhesion	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
synovial	B-cell_type
cells	I-cell_type
in	O
RA	O
synovitis	O
.	O


Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	B-cell_type
neutrophils	I-cell_type
and	O
eosinophils	B-cell_type
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration-dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	O
by	O
its	O
inactive	O
analog	O
methylthiogliotoxin	O
.	O


Gliotoxin	O
also	O
augmented	O
dramatically	O
the	O
early	O
(	O
2-6	O
h	O
)	O
pro-apoptotic	O
effects	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
neutrophils	B-cell_type
and	O
unmasked	O
the	O
ability	O
of	O
TNF-alpha	B-protein
to	O
induce	O
eosinophil	B-cell_type
apoptosis	O
.	O


FasL-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
in	O
MRL-lpr/lpr	B-cell_line
and	I-cell_line
C3H-gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	B-DNA
family	I-DNA
binding	I-DNA
element	I-DNA
.	O


We	O
show	O
that	O
the	O
lack	O
of	O
NF-YA	B-protein
protein	I-protein
is	O
due	O
to	O
posttranscriptional	O
regulation	O
and	O
not	O
to	O
a	O
specific	O
proteolytic	O
activity	O
.	O


After	O
T-cell	B-protein
receptor	I-protein
stimulation	O
,	O
ZAP-70	B-protein
associates	O
with	O
the	O
receptor	O
and	O
is	O
phosphorylated	O
on	O
many	O
tyrosines	O
,	O
including	O
Y292	O
,	O
Y315	O
,	O
and	O
Y319	O
within	O
interdomain	O
B	O
.	O


This	O
is	O
manifested	O
by	O
the	O
ability	O
of	O
Delta	B-protein
to	O
restore	O
induction	O
of	O
calcium	O
fluxes	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
and	O
by	O
the	O
ability	O
of	O
dominant	O
negative	O
Ras	B-protein
and	O
FK506	B-protein
to	O
block	O
the	O
induction	O
of	O
NF-AT	B-protein
activity	O
mediated	O
by	O
Delta	B-protein
.	O


Differential	O
induction	O
of	O
DNA-binding	B-protein
activities	I-protein
following	O
CD19	B-protein
cross-linking	O
in	O
human	B-cell_type
B	I-cell_type
lineage	I-cell_type
cells	I-cell_type
.	O


The	O
cells	O
used	O
were	O
the	O
BLIN-1	B-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
expressing	O
low	O
levels	O
of	O
cell	B-protein
surface	I-protein
mu	I-protein
heavy	I-protein
chain	I-protein
associated	O
with	O
surrogate	B-protein
light	I-protein
chain	I-protein
and	O
the	O
1E8	O
immature	O
B	O
cell	O
line	O
expressing	O
cell	B-protein
surface	I-protein
mu/kappa	I-protein
.	O


Oxidants	O
,	O
transcription	B-protein
factors	I-protein
,	O
and	O
intestinal	O
inflammation	O
.	O


Oxidants	O
are	O
also	O
known	O
to	O
activate	O
another	O
transcription	B-protein
factor	I-protein
,	O
activator	B-protein
protein-1	I-protein
.	O


Identification	O
of	O
target	B-DNA
genes	I-DNA
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct2	I-protein
.	O


The	O
Oct2	B-protein
transcription	B-protein
factor	I-protein
is	O
expressed	O
predominantly	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
plays	O
an	O
essential	O
role	O
during	O
the	O
terminal	O
phase	O
of	O
B	O
cell	O
differentiation	O
.	O


RFX-B	B-DNA
is	O
the	O
gene	O
responsible	O
for	O
the	O
most	O
common	O
cause	O
of	O
the	O
bare	O
lymphocyte	O
syndrome	O
,	O
an	O
MHC	B-protein
class	I-protein
II	I-protein
immunodeficiency	O
[	O
published	O
erratum	O
appears	O
in	O
Immunity	O
1999	O
Mar	O
;	O
10	O
(	O
3	O
)	O
:	O
399	O
]	O


We	O
have	O
purified	O
the	O
RFX	B-protein
complex	I-protein
and	O
sequenced	O
its	O
three	O
subunits	O
.	O


Although	O
NF-kappaB/Rel	B-protein
factors	I-protein
are	O
known	O
to	O
induce	O
the	O
expression	O
of	O
T-cell	B-protein
growth	I-protein
factor	I-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
it	O
is	O
unclear	O
how	O
they	O
participate	O
in	O
the	O
IL-2	B-protein
-independent	O
growth	O
of	O
HTLV-I-transformed	B-cell_line
cells	I-cell_line
.	O


To	O
investigate	O
the	O
events	O
involved	O
in	O
activation-induced	O
Fas	B-protein
upregulation	O
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	O
promoter	O
activity	O
,	O
and	O
protein	O
expression	O
in	O
the	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P/I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T-cell	B-protein
receptor	I-protein
activation	O
.	O


Using	O
sequential	B-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
human	B-DNA
fas	I-DNA
promoter	I-DNA
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47-bp	B-DNA
sequence	I-DNA
(	O
positions	B-DNA
-306	I-DNA
to	I-DNA
-260	I-DNA
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation-driven	O
fas	O
upregulation	O
.	O


Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	B-DNA
composite	I-DNA
binding	I-DNA
site	I-DNA
for	O
both	O
the	O
Sp1	B-protein
and	O
NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
at	O
positions	B-DNA
-295	I-DNA
to	I-DNA
-286	I-DNA
.	O


Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	O
of	O
Sp1	B-protein
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	O
binding	O
of	O
p50-p65	B-protein
NF-kappaB	I-protein
heterodimers	I-protein
after	O
P/I	O
activation	O
.	O


Instead	O
,	O
signal	O
transduction	O
to	O
the	O
human	O
IL-2	B-DNA
gene	I-DNA
became	O
disrupted	O
.	O


Following	O
integration	O
into	O
the	O
host	O
cell	O
genome	O
,	O
HTLV-I	O
replication	O
is	O
regulated	O
by	O
both	O
host	O
and	O
viral	O
mechanisms	O
that	O
control	O
transcription	O
.	O


Further	O
studies	O
indicated	O
that	O
inhibition	O
of	O
GTP-cyclohydrolase	B-protein
I	I-protein
(	O
an	O
enzyme	O
involved	O
in	O
de	O
novo	O
synthesis	O
of	O
an	O
important	O
cofactor	O
for	O
NOS	B-protein
activity	O
,	O
tetrahydrobiopterin	O
)	O
prevented	O
the	O
generation	O
of	O
NO	O
in	O
A/R-tolerant	B-cell_line
cells	I-cell_line
.	O


Mildly	O
oxidized	O
low-density	B-protein
lipoproteins	I-protein
decrease	O
early	O
production	O
of	O
interleukin	B-protein
2	I-protein
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
binding	O
to	O
DNA	O
in	O
activated	B-cell_type
T-lymphocytes	I-cell_type
.	O


Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
immunosuppressive	O
effect	O
of	O
oxLDLs	B-protein
might	O
operate	O
via	O
a	O
dysregulation	O
of	O
the	O
T-lymphocyte	B-cell_type
activation	O
mechanisms	O
.	O


Early	B-protein
B-cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
suggested	O
as	O
essential	O
for	O
early	O
B-lymphocyte	B-cell_type
development	O
by	O
findings	O
in	O
mice	O
where	O
the	O
coding	O
gene	O
has	O
been	O
inactivated	O
by	O
homologous	O
disruption	O
.	O


This	O
makes	O
the	O
identification	O
of	O
genetic	O
targets	O
for	O
this	O
transcription	B-protein
factor	I-protein
pertinent	O
for	O
the	O
understanding	O
of	O
early	O
B-cell	O
development	O
.	O


The	O
lack	O
of	O
B29	B-RNA
transcripts	I-RNA
,	O
coding	O
for	O
the	O
beta	B-protein
subunit	I-protein
of	O
the	O
B-cell	O
receptor	O
complex	O
,	O
in	O
pro-B	B-cell_type
cells	I-cell_type
from	O
EBF	B-protein
-deficient	O
mice	O
suggested	O
that	O
B29	O
might	O
be	O
a	O
genetic	O
target	O
for	O
EBF	B-protein
.	O


These	O
data	O
suggest	O
that	O
the	O
B29	B-DNA
gene	I-DNA
is	O
a	O
genetic	O
target	O
for	O
EBF	B-protein
in	O
early	O
B-cell	O
development	O
.	O


Although	O
DOR1	B-protein
signaling	O
increased	O
[	O
Ca2+	O
]	O
i	O
,	O
deltorphin	O
enhanced	O
transcriptional	O
activity	O
of	O
the	O
NF-AT/AP-1-binding	B-DNA
site	I-DNA
via	O
a	O
mechanism	O
independent	O
of	O
calcineurin	B-protein
and	O
distinct	O
from	O
the	O
effects	O
of	O
elevated	O
[	O
Ca2+	O
]	O
i	O
.	O


Moreover	O
,	O
transfection	O
of	O
Daudi	B-cell_line
cells	I-cell_line
with	O
the	O
polymerized	O
NF-kappaB	B-DNA
binding	I-DNA
sequence	I-DNA
ligated	O
to	O
a	O
thymidine	B-DNA
kinase/chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
plasmid	I-DNA
greatly	O
induced	O
CAT	B-protein
activity	O
,	O
but	O
transfection	O
with	O
the	O
polymerized	B-DNA
mutated	I-DNA
NF-kappaB	I-DNA
binding	I-DNA
sequence	I-DNA
did	O
not	O
.	O


T-cell	O
expression	O
of	O
the	O
human	B-DNA
GATA-3	I-DNA
gene	I-DNA
is	O
regulated	O
by	O
a	O
non-lineage-specific	B-DNA
silencer	I-DNA
.	O


The	O
first	B-DNA
intron	I-DNA
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position-dependent	O
manner	O
and	O
with	O
no	O
cell-type	O
specificity	O
.	O


Two	O
CAGGTG	O
E-boxes	O
,	O
located	O
at	O
the	O
5'-	B-DNA
and	I-DNA
3'-ends	I-DNA
of	O
the	O
silencer	O
,	O
were	O
necessary	O
for	O
this	O
silencer	O
activity	O
.	O


To	O
clarify	O
the	O
etiological	O
relationship	O
between	O
the	O
two	O
variants	O
,	O
we	O
analyzed	O
responsiveness	O
to	O
IL-4	B-protein
of	O
transfectants	O
with	O
four	O
kinds	O
of	O
IL-4Ralpha	B-protein
carrying	O
either	O
Val	O
or	O
Ile	O
at	O
50	B-protein
and	O
either	O
Gln	O
or	O
Arg	O
at	O
551	B-protein
.	O


We	O
developed	O
mice	O
transgenic	O
for	O
human	O
CSF-1R	B-protein
because	O
mouse	O
CSF-1	B-protein
can	O
not	O
activate	O
human	O
CSF-1R	B-protein
.	O


Then	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
transgenic	O
mice	O
were	O
plated	O
onto	O
MS-5	O
stromal	O
cells	O
expressing	O
the	O
membrane	B-protein
form	I-protein
of	O
human	B-protein
CSF-1	I-protein
(	O
2M-1	B-cell_line
cells	I-cell_line
)	O
in	O
order	O
to	O
combine	O
the	O
hematopoietic	O
supporting	O
properties	O
of	O
stromal	B-cell_type
cells	I-cell_type
and	O
the	O
proliferative	O
effects	O
of	O
CSF-1	B-protein
.	O


Under	O
these	O
conditions	O
,	O
about	O
0.5	O
%	O
of	O
47.10	B-cell_line
cells	I-cell_line
formed	O
large	O
14-day	O
colonies	O
(	O
>	O
1	O
mm	O
)	O
composed	O
of	O
mature	B-cell_type
monocytes	I-cell_type
and	O
granulocytes	B-cell_type
,	O
reflecting	O
the	O
presence	O
of	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
(	O
HPP-47.10	B-cell_line
cells	I-cell_line
)	O
.	O


Previous	O
studies	O
found	O
that	O
P1	B-DNA
,	O
an	O
element	O
of	O
the	O
interleukin	B-DNA
4	I-DNA
(	I-DNA
IL-4	I-DNA
)	I-DNA
promoter	I-DNA
that	O
binds	O
AP-1	O
,	O
is	O
important	O
for	O
Th2-restricted	O
IL-4	B-protein
expression	O
.	O


JunB	B-protein
has	O
previously	O
been	O
considered	O
to	O
be	O
a	O
negative	O
regulator	O
of	O
transcription	O
.	O


We	O
conclude	O
that	O
the	O
transrepressive	O
effect	O
of	O
glucocorticoids	O
on	O
IL-2	B-DNA
gene	I-DNA
transcription	O
is	O
exclusively	O
mediated	O
by	O
GRalpha	B-protein
.	O


When	O
immunoglobulin	B-cell_type
(	I-cell_type
Ig	I-cell_type
)	I-cell_type
expressing	I-cell_type
B	I-cell_type
cells	I-cell_type
are	O
fused	O
with	O
non-B	B-cell_type
cells	I-cell_type
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O


The	O
immunophilin	B-protein
FKBP51	I-protein
was	O
13-fold	O
higher	O
in	O
SML	B-cell_type
than	O
in	O
HL	O
cytosol	O
;	O
FKBP52	B-protein
in	O
SML	B-cell_type
was	O
42	O
%	O
of	O
that	O
in	O
HL	O
cytosol	O
.	O


The	O
cotransfection	O
of	O
this	O
LTR	B-DNA
with	O
a	O
mutated	O
IkappaBalpha	B-protein
molecule	I-protein
formally	O
demonstrates	O
that	O
LTR	B-DNA
transactivation	O
is	O
regulated	O
by	O
members	O
of	O
the	O
Rel/NF-kappaB	B-protein
family	I-protein
in	O
thymocytes	B-cell_type
.	O


However	O
IL-7	B-protein
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	O
mainly	O
by	O
TEC	B-cell_type
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF-kappaB	B-protein
activation	O
elicited	O
by	O
TNF	B-protein
or	O
IL-1	B-protein
.	O


In	O
vitro	O
apoptosis	O
induction	O
in	O
CLL	B-cell_line
cells	I-cell_line
was	O
delayed	O
in	O
response	O
to	O
GCs	O
,	O
but	O
not	O
to	O
other	O
apoptosis	O
inducers	O
.	O


Western	O
blot	O
with	O
an	O
N-terminal	O
antibody	O
showed	O
normal	O
levels	O
of	O
immunoreactive	B-protein
GR	I-protein
,	O
but	O
quantitative	O
analysis	O
with	O
isoform-specific	O
C-terminal	B-protein
antibodies	I-protein
revealed	O
a	O
markedly	O
reduced	O
GRalpha	B-protein
expression	O
,	O
and	O
high	O
GRbeta	B-protein
expression	O
.	O


Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	B-DNA
box	I-DNA
were	O
found	O
to	O
contribute	O
to	O
elk-1	B-DNA
promoter	O
activity	O
.	O


Because	O
Egr-1	B-RNA
mRNA	I-RNA
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	O
significantly	O
before	O
induction	O
of	O
elk-1	B-DNA
expression	O
,	O
we	O
propose	O
that	O
Egr-1	B-protein
is	O
important	O
for	O
the	O
regulation	O
of	O
elk-1	B-DNA
transcription	O
in	O
differentiating	O
monocytes	B-cell_type
.	O


Three	O
of	O
the	O
27	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
showed	O
slight	O
expression	O
of	O
c-fos	O
in	O
their	O
tumor	O
cells	O
before	O
and/or	O
at	O
4	O
or	O
10	O
Gy	O
of	O
radiotherapy	O
.	O


Paternal	O
expression	O
of	O
WT1	B-protein
in	O
human	B-cell_type
fibroblasts	I-cell_type
and	O
lymphocytes	B-cell_type
.	O


Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	B-protein
in	O
fibroblasts	B-cell_type
and	O
lymphocytes	B-cell_type
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele-specific	O
regulatory	O
system	O
of	O
WT1	B-protein
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue-	O
and	O
individual-specific	O
modifier	O
.	O


CONCLUSION	O
.	O


We	O
previously	O
reported	O
that	O
gold	O
compounds	O
,	O
especially	O
aurothioglucose	O
(	O
AuTG	O
)	O
containing	O
monovalent	O
gold	O
ion	O
,	O
inhibited	O
the	O
DNA-binding	O
of	O
NF-kappaB	B-protein
in	O
vitro	O
.	O


In	O
this	O
report	O
we	O
have	O
examined	O
the	O
efficacy	O
of	O
the	O
gold	O
compound	O
AuTG	O
as	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
latently	O
infected	O
OM10.1	B-cell_line
and	I-cell_line
Ach2	I-cell_line
cells	I-cell_line
.	O


Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
-induced	O
HIV-1	O
replication	O
in	O
OM10.1	B-cell_line
or	O
Ach2	B-cell_line
cells	I-cell_line
was	O
significantly	O
inhibited	O
by	O
non-cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10.1	O
cells	O
and	O
>	O
25	O
F.M	O
in	O
Ach2	B-cell_line
cells	I-cell_line
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter-anion	B-protein
thioglucose	I-protein
(	O
TG	B-protein
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	O
effect	O
.	O


Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF-kappaB	B-protein
-DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O


These	O
observations	O
indicate	O
that	O
the	O
monovalent	O
gold	O
compound	O
AuTG	O
is	O
a	O
potentially	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
HIV	O
.	O


The	O
idiopathic	O
hypereosinophilic	O
syndrome	O
(	O
IHES	O
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
unexplained	O
,	O
persistent	O
eosinophilia	O
associated	O
with	O
multiple	O
organ	O
dysfunction	O
due	O
to	O
eosinophilic	O
tissue	O
infiltration	O
.	O


Peripheral	B-cell_type
blood	I-cell_type
eosinophils	I-cell_type
were	O
isolated	O
by	O
their	O
autofluoresence	O
using	O
flow	O
cytometric	O
sorting	O
.	O


Eosinophils	B-cell_type
purified	O
from	O
a	O
female	O
patient	O
presenting	O
with	O
IHES	O
were	O
found	O
to	O
show	O
a	O
clonal	O
pattern	O
of	O
X-inactivation	O
.	O


In	O
concert	O
with	O
the	O
coactivator	B-protein
CREB	I-protein
binding	I-protein
protein/p300	I-protein
,	O
which	O
interacts	O
with	O
GABPalpha	B-protein
,	O
the	O
binding	O
of	O
GABPalpha	B-protein
and	O
-beta	B-protein
to	O
the	O
dyad	B-DNA
symmetry	I-DNA
element	I-DNA
controls	O
the	O
induction	O
of	O
IL-16	B-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O


The	O
expression	O
of	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O


Regulation	O
of	O
fas-ligand	O
expression	O
during	O
activation-induced	O
cell	O
death	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
via	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O


A	O
number	O
of	O
potential	B-DNA
regulatory	I-DNA
sequences	I-DNA
similar	O
to	O
those	O
found	O
in	O
mammals	O
have	O
been	O
identified	O
in	O
the	O
promoter	B-DNA
.	O


Sequence	O
comparisons	O
also	O
predict	O
other	O
potential	O
transcription	O
factor	O
binding	O
sites	O
as	O
yet	O
undescribed	O
in	O
mammalian	B-DNA
IL2	I-DNA
promoters	I-DNA
.	O


A	O
Taq	B-DNA
I	I-DNA
polymorphism	I-DNA
was	O
identified	O
which	O
enabled	O
chicken	O
IL2	B-protein
to	O
be	O
mapped	O
to	O
chromosome	B-DNA
4	I-DNA
,	O
linked	O
to	O
ANX5	B-DNA
,	O
with	O
synteny	O
with	O
mouse	B-DNA
chromosome	I-DNA
3	I-DNA
and	O
human	B-DNA
chromosome	I-DNA
4	I-DNA
.	O


An	O
inhibition	O
of	O
MCP-1	B-protein
production	O
was	O
observed	O
that	O
was	O
specifically	O
caused	O
by	O
mixture	O
of	O
IFN-gamma	B-protein
with	O
heparin-like	O
,	O
and	O
therefore	O
cytokine-binding	O
,	O
GAGs	O
.	O


These	O
activities	O
may	O
contribute	O
to	O
the	O
immunomodulatory	O
properties	O
of	O
heparin	O
.	O


Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	B-protein
can	O
potentiate	O
STAT	B-protein
-dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence-specific	B-protein
transcription	I-protein
factors	I-protein
.	O


Activation	O
of	O
the	O
LTR	B-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
was	O
strongly	O
enhanced	O
by	O
vanadate	O
and	O
inhibited	O
by	O
catalase	B-protein
,	O
implicating	O
H2O2	O
.	O


Activated	O
primed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
contain	O
more	O
NFAT1	B-protein
and	O
support	O
greater	O
NFAT	B-protein
-directed	O
transcription	O
than	O
unprimed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
activator	B-protein
protein	I-protein
1	I-protein
binding	O
and	O
activator	B-protein
protein	I-protein
1	I-protein
-mediated	O
transcription	O
by	O
both	O
cell	O
types	O
is	O
similar	O
.	O


Here	O
,	O
we	O
demonstrate	O
the	O
testosterone	O
responsiveness	O
of	O
murine	B-cell_type
splenic	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
as	O
well	O
as	O
the	O
presence	O
of	O
unconventional	B-protein
cell	I-protein
surface	I-protein
receptors	I-protein
for	O
testosterone	O
and	O
classical	B-protein
intracellular	I-protein
AR	I-protein
.	O


Binding	O
of	O
the	O
plasma	O
membrane	O
impermeable	O
testosterone-BSA	B-protein
conjugate	I-protein
induces	O
a	O
rapid	O
rise	O
(	O
<	O
5	O
s	O
)	O
in	O
[	O
Ca2+	O
]	O
i	O
of	O
Fura-2-loaded	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	B-protein
receptors	I-protein
.	O


Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin-4	B-DNA
gene	I-DNA
.	O


Serine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
was	O
seen	O
occasionally	O
in	O
other	O
leukemias	O
,	O
but	O
it	O
was	O
a	O
universal	O
finding	O
only	O
in	O
CLL	O
.	O


The	O
serine	O
phosphorylation	O
of	O
these	O
STATs	B-protein
was	O
a	O
continuous	O
process	O
,	O
as	O
incubation	O
of	O
CLL	B-cell_line
cells	I-cell_line
with	O
the	O
kinase	B-protein
inhibitor	I-protein
H7	I-protein
led	O
to	O
the	O
dephosphorylation	O
of	O
these	O
serine	O
residues	O
.	O


The	O
X-inactivation	O
patterns	O
of	O
circulating	O
PMNCs	B-cell_type
and	O
T	B-cell_type
lymphocytes	I-cell_type
as	O
well	O
as	O
individual	O
granulocyte	B-cell_line
colonies	I-cell_line
grown	O
in	O
vitro	O
from	O
bone	O
marrow	O
cells	O
were	O
analyzed	O
.	O


Immunohistochemical	O
evidence	O
of	O
low	O
proliferative	O
activity	O
and	O
virtual	O
absence	O
of	O
mutation	O
of	O
the	O
p53	B-DNA
tumor-suppressor	I-DNA
gene	I-DNA
.	O


All	O
of	O
the	O
tumors	O
exhibited	O
typical	O
morphology	O
,	O
were	O
limited	O
to	O
the	O
ovary	O
(	O
stage	O
I	O
)	O
,	O
and	O
7	O
cases	O
followed	O
a	O
benign	O
clinical	O
course	O
.	O


Members	O
of	O
this	O
family	O
have	O
been	O
isolated	O
from	O
invertebrates	O
as	O
well	O
as	O
vertebrates	O
.	O


The	O
data	O
presented	O
below	O
indicate	O
that	O
Notch-1	B-protein
expression	O
provides	O
significant	O
protection	O
to	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
TCR	B-protein
-mediated	O
apoptosis	O
.	O


The	O
induction	O
of	O
CD4+	B-protein
T	O
cell	O
proliferative	O
responses	O
to	O
eight	O
synthetic	O
peptides	O
representing	O
amino	O
acid	O
sequences	O
of	O
the	O
VZV	B-protein
IE62	I-protein
protein	I-protein
was	O
assessed	O
using	O
T	B-cell_type
cells	I-cell_type
and	O
DC	B-cell_type
from	O
VZV-susceptible	O
donors	O
.	O


Monocytes	B-cell_type
were	O
effective	O
APC	B-cell_type
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O


These	O
include	O
Fc	B-protein
epsilonRII	I-protein
(	O
CD23	B-protein
)	O
,	O
15-lipoxygenase	B-protein
,	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
(	O
IL-1ra	B-protein
)	O
,	O
and	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IL-1	I-protein
receptors	I-protein
(	O
IL-1R	B-protein
)	O
.	O


These	O
findings	O
demonstrate	O
that	O
certain	O
cytokines	O
,	O
including	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
,	O
antagonize	O
the	O
ability	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
to	O
induce	O
increased	O
expression	O
of	O
the	O
IL-1RI	O
and	O
IL-1RII	B-DNA
genes	I-DNA
in	O
monocytes	B-cell_type
.	O


To	O
explore	O
long-term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	B-protein
transcription	I-protein
factor	I-protein
proteins	I-protein
after	O
their	O
activation	O
.	O


We	O
identified	O
a	O
cell-type-specific	O
differential	O
response	O
:	O
CREB	B-DNA
,	I-DNA
CTF	I-DNA
,	I-DNA
OTF-1	I-DNA
,	I-DNA
OFT-2	I-DNA
,	I-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
genes	I-DNA
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	B-cell_type
no	O
significant	O
changes	O
were	O
detected	O
.	O


In	O
infected	O
monocytes	B-cell_type
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	B-protein
,	O
CTF	B-protein
,	O
and	O
OTF-2	B-protein
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O


In	O
conclusion	O
,	O
the	O
long-term	O
regulation	O
of	O
transcription	B-protein
factor	I-protein
gene	O
expression	O
in	O
non-proliferating	B-cell_type
cells	I-cell_type
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	B-cell_type
cells	I-cell_type
an	O
immediate	O
availability	O
of	O
transcription	B-protein
factor	I-protein
proteins	I-protein
is	O
required	O
.	O


NF-kappaB	B-protein
binding	O
activity	O
correlated	O
with	O
the	O
degree	O
of	O
albuminuria	O
(	O
r	O
=	O
0.316	O
)	O
and	O
with	O
thrombomodulin	B-protein
plasma	O
concentrations	O
(	O
r	O
=	O
0.33	O
)	O
,	O
indicative	O
for	O
albuminuria	O
associated	O
endothelial	O
dysfunction	O
.	O


Transcripts	O
for	O
osteoprotegerin	B-protein
ligand	I-protein
(	O
OPGL	B-protein
)	O
,	O
an	O
osteoclast	B-protein
differentiation	I-protein
factor	I-protein
(	O
also	O
known	O
as	O
RANKL	B-protein
and	O
TRANCE	B-protein
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	B-cell_type
cells	I-cell_type
.	O


At	O
10	O
to	O
100	O
micromol/L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	O
the	O
expression	O
of	O
all	O
adhesion	B-protein
molecules	I-protein
tested	O
.	O


Adhesion	O
of	O
monocytoid	B-cell_line
U937	I-cell_line
cells	I-cell_line
to	O
LPS-treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O


Oleate	O
also	O
produced	O
a	O
quantitatively	O
similar	O
reduction	O
of	O
VCAM-1	B-RNA
mRNA	I-RNA
levels	O
on	O
Northern	O
blot	O
analysis	O
and	O
inhibited	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
on	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O


Moreover	O
,	O
IL-6	B-protein
induced	O
macrophage-differentiation	O
and	O
apoptosis	O
of	O
1A9-M	B-cell_line
cells	I-cell_line
.	O


Whereas	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
(	O
Stat3	B-protein
)	O
was	O
phosphorylated	O
and	O
activated	O
,	O
there	O
was	O
no	O
effect	O
on	O
either	O
Stat1	B-protein
or	O
Stat5	B-protein
.	O


Interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
is	O
a	O
chemokine	B-protein
that	O
belongs	O
to	O
the	O
alpha-chemokine	B-protein
or	O
CXC	B-protein
subfamily	I-protein
and	O
is	O
produced	O
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	B-cell_type
and	O
polymorphonuclear	B-cell_type
cells	I-cell_type
(	O
PMN	B-cell_type
)	O
.	O


Since	O
C3a	B-protein
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	B-cell_type
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
PGE2	O
in	O
C3a	B-protein
-mediated	O
enhancement	O
of	O
LPS-	O
and	O
IL-1beta-induced	O
IL-6	O
production	O
.	O


Indomethacin	O
blocked	O
PGE2	O
release	O
,	O
but	O
had	O
no	O
influence	O
on	O
the	O
observed	O
effects	O
of	O
C3a	B-protein
,	O
suggesting	O
that	O
the	O
effects	O
of	O
C3a	B-protein
on	O
IL-6	B-protein
production	O
are	O
independent	O
of	O
PGE2	O
formation	O
by	O
monocytes	B-cell_type
.	O


These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	B-protein
and	O
its	O
circulating	O
des-Arg	B-protein
form	I-protein
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O


Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV-1	O
expression	O
.	O


Since	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
known	O
to	O
be	O
favored	O
under	O
oxidative	O
stress	O
conditions	O
,	O
ex	O
vivo	O
experiments	O
using	O
uninfected	O
PBMCs	B-cell_type
,	O
primary	B-cell_type
monocytes	I-cell_type
or	O
a	O
latently	O
infected	O
promonocytic	B-cell_line
U1	I-cell_line
cell	I-cell_line
line	I-cell_line
show	O
that	O
HIV-1	O
replication	O
and	O
reactivation	O
,	O
monitored	O
by	O
p24	B-protein
antigen	I-protein
measurement	O
,	O
are	O
inhibited	O
by	O
PAO	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O


Recently	O
,	O
fibromyalgia	O
(	O
FMS	O
)	O
was	O
shown	O
to	O
be	O
a	O
disorder	O
associated	O
with	O
an	O
altered	O
functioning	O
of	O
the	O
stress	O
response	O
system	O
.	O


We	O
suggested	O
that	O
negative	O
feedback	O
of	O
cortisol	O
could	O
be	O
deranged	O
.	O


Urinary	O
free	O
cortisol	O
excretion	O
in	O
FMS	O
and	O
LBP	O
patients	O
was	O
lower	O
compared	O
to	O
controls	O
.	O


Only	O
FMS	O
patients	O
displayed	O
lower	O
CBG	O
and	O
basal	O
serum	O
cortisol	O
concentrations	O
when	O
compared	O
to	O
controls	O
.	O


There	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
GR	B-protein
per	O
cell	O
among	O
the	O
three	O
groups	O
(	O
FMS	O
:	O
6498	O
+/-	O
252	O
,	O
LBP	O
:	O
6625	O
+/-	O
284	O
,	O
controls	O
:	O
6576	O
+/-	O
304	O
)	O
,	O
but	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
the	O
FMS	O
(	O
14.5	O
+/-	O
0.9	O
nmol/l	O
)	O
and	O
LBP	O
(	O
14.7	O
+/-	O
1.3	O
nmol/l	O
)	O
subjects	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
controls	O
(	O
10.9	O
+/-	O
0.8	O
nmol/l	O
)	O
(	O
p	O
<	O
.05	O
)	O
.	O


The	O
actual	O
binding	O
of	O
these	O
peptides	O
was	O
analysed	O
in	O
a	O
stabilization	O
assay	O
.	O


The	O
stability	O
of	O
already	O
formed	O
complexed	O
was	O
somewhat	O
different	O
in	O
the	O
HLA-A3	B-protein
and	O
HLA-Cw*0702	B-protein
system	O
:	O
both	O
were	O
more	O
stable	O
at	O
26	O
degrees	O
C	O
than	O
at	O
37	O
degrees	O
C	O
but	O
while	O
the	O
beta	B-protein
2-m	I-protein
and	O
FCS	O
did	O
not	O
influence	O
the	O
stability	O
of	O
the	O
HLA-A3/peptide	B-protein
complex	I-protein
,	O
they	O
seemed	O
to	O
cause	O
opposite	O
effects	O
in	O
the	O
HLA-Cw*0702	B-protein
system	O
(	O
beta	B-protein
2-m	I-protein
stabilized	O
and	O
FCS	O
destabilized	O
the	O
complex	O
)	O
.	O


Further	O
optimization	O
of	O
culture	O
conditions	O
,	O
type	O
of	O
Antigen	B-cell_type
Presenting	I-cell_type
Cells	I-cell_type
(	O
APC	B-cell_type
)	O
,	O
peptides	O
,	O
use	O
of	O
stabilizers	O
like	O
beta	B-protein
2-m	I-protein
are	O
still	O
needed	O
.	O


Phosphatidylinositol	B-protein
3-kinase	I-protein
couples	O
the	O
interleukin-2	B-protein
receptor	I-protein
to	O
the	O
cell	B-protein
cycle	I-protein
regulator	I-protein
E2F	B-protein
.	O


We	O
eliminate	O
both	O
Stat5	B-protein
and	O
Raf	B-protein
/MEK	B-protein
pathways	O
from	O
E2F	B-protein
regulation	O
.	O


The	O
Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
into	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


In	O
transfection	O
assays	O
,	O
TRADD	B-protein
and	O
TES2	B-protein
synergistically	O
mediated	O
high-level	O
NF-kappaB	B-protein
activation	O
.	O


Inhibition	O
of	O
T	B-cell_type
cell	I-cell_type
and	O
promotion	O
of	O
natural	O
killer	O
cell	O
development	O
by	O
the	O
dominant	B-protein
negative	I-protein
helix	I-protein
loop	I-protein
helix	I-protein
factor	I-protein
Id3	B-protein
.	O


The	O
mechanisms	O
controlling	O
this	O
developmental	O
choice	O
are	O
unknown	O
.	O


The	O
natural	O
dominant	B-protein
negative	I-protein
HLH	I-protein
factor	I-protein
Id3	B-protein
,	O
which	O
blocks	O
transcriptional	O
activity	O
of	O
a	O
number	O
of	O
known	O
bHLH	B-protein
factors	I-protein
,	O
was	O
expressed	O
in	O
CD34+	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
by	O
retrovirus-mediated	O
gene	O
transfer	O
.	O


NB4	B-cell_line
cells	I-cell_line
pulse-exposed	O
(	O
30	O
minutes	O
)	O
to	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
washed	O
,	O
and	O
cultured	O
(	O
3	O
days	O
)	O
with	O
either	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
had	O
a	O
prominent	O
increase	O
in	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
and	O
an	O
increase	O
in	O
granulocytic	O
differentiation	O
,	O
but	O
exposure	O
to	O
either	O
DMSO	O
or	O
HMBA	O
alone	O
had	O
no	O
effect	O
on	O
base	O
levels	O
of	O
C/EBP	O
epsilon	O
and	O
did	O
not	O
induce	O
differentiation	O
.	O


ATRA	O
also	O
induced	O
expression	O
of	O
C/EBP	B-protein
epsilon	I-protein
protein	I-protein
in	O
NB4	B-cell_line
cells	I-cell_line
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O


Dual	O
effects	O
of	O
LPS	B-protein
antibodies	I-protein
on	O
cellular	O
uptake	O
of	O
LPS	O
and	O
LPS-induced	O
proinflammatory	O
functions	O
.	O


Ab-associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC-LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	B-cell_line
CD14-transfected	I-cell_line
Chinese	I-cell_line
hamster	I-cell_line
ovary	I-cell_line
fibroblasts	I-cell_line
(	O
CHO-CD14	B-cell_line
cells	I-cell_line
)	O
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O


LPS-specific	B-protein
Abs	I-protein
thus	O
mediate	O
anti-inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	B-protein
and	O
augmenting	O
uptake	O
through	O
CR1	B-protein
or	O
other	O
cell	B-protein
receptors	I-protein
.	O


Activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
family	I-protein
proteins	I-protein
interacted	O
with	O
CLE0	B-DNA
,	O
P	O
,	O
P2	B-DNA
and	O
P4	B-DNA
.	O


The	O
described	O
conditions	O
which	O
inhibited	O
or	O
prevented	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
kinase	I-protein
similarly	O
impaired	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
EL4	B-cell_line
cells	I-cell_line
.	O


Involvement	O
of	O
different	O
transduction	O
pathways	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
several	O
inducers	B-DNA
.	O


Double-stimulation	O
was	O
used	O
to	O
demonstrate	O
that	O
,	O
in	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
CEM	B-cell_line
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
rapidly	O
induced	O
NF-kappa	B-protein
B	I-protein
through	O
a	O
signaling	O
pathway	O
which	O
did	O
not	O
involve	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
was	O
different	O
from	O
the	O
activation	O
triggered	O
by	O
either	O
H2O2	O
or	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O


In	O
UCSD-AML1	B-cell_line
,	O
we	O
have	O
also	O
identified	O
fusion	B-RNA
transcripts	I-RNA
between	O
the	O
ecotropic	B-DNA
viral	I-DNA
insertion	I-DNA
site	I-DNA
I	I-DNA
(	I-DNA
EVI1	I-DNA
)	I-DNA
gene	I-DNA
in	O
3q26	B-DNA
and	O
GR6	B-DNA
and	O
between	O
EVI1	B-DNA
and	O
Ribophorin	B-DNA
I	I-DNA
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	B-DNA
in	O
3q21	B-DNA
.	O


The	O
v-myb	B-DNA
oncogene	I-DNA
,	O
carried	O
by	O
avian	O
defective	O
retroviruses	O
,	O
causes	O
leukaemias	O
in	O
the	O
chicken	O
and	O
transforms	O
haematopoietic	B-cell_type
cells	I-cell_type
in	O
vitro	O
.	O


The	O
third	O
member	O
of	O
the	O
family	B-protein
,	O
A-myb	B-protein
,	O
shows	O
the	O
most	O
restricted	O
pattern	O
of	O
expression	O
,	O
suggesting	O
a	O
very	O
specific	O
role	O
for	O
this	O
transcription	B-protein
factor	I-protein
.	O


It	O
was	O
recently	O
shown	O
by	O
us	O
that	O
the	O
protein	O
is	O
located	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
their	O
neoplastic	B-cell_type
counterparts	I-cell_type
.	O


In	O
the	O
present	O
study	O
,	O
the	O
expression	O
of	O
bcl-6	B-protein
protein	I-protein
on	O
normal	O
epidermis	O
,	O
benign	O
,	O
and	O
malignant	O
tumors	O
originating	O
from	O
epidermal	B-cell_type
cells	I-cell_type
,	O
and	O
squamous	B-cell_line
cell	I-cell_line
carcinoma	I-cell_line
(	I-cell_line
SCC	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
are	O
investigated	O
.	O


Papillomas	O
and	O
keratoacanthomas	O
copied	O
their	O
normal	O
counterparts	O
in	O
the	O
mode	O
of	O
expression	O
.	O


In	O
previous	O
experiments	O
,	O
the	O
-70	B-DNA
to	I-DNA
-65	I-DNA
and	I-DNA
-121	I-DNA
to	I-DNA
-103	I-DNA
regions	I-DNA
of	O
the	O
CD11c	B-DNA
promoter	I-DNA
and	O
the	O
-66	B-DNA
to	I-DNA
-59	I-DNA
region	I-DNA
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
were	O
shown	O
to	O
be	O
essential	O
for	O
Sp1-	B-protein
mediated	O
activation	O
of	O
these	O
genes	O
.	O


Cotransfection	O
of	O
Sp3	B-protein
along	O
with	O
CD11c	B-DNA
promoter-luciferase	I-DNA
constructs	I-DNA
into	O
Sp-deficient	B-cell_line
Drosophila	I-cell_line
Schneider	I-cell_line
2	I-cell_line
cells	I-cell_line
showed	O
that	O
Sp3	B-protein
could	O
activate	O
the	O
CD11c	B-DNA
promoter	I-DNA
.	O


Deletion	O
of	O
both	O
the	O
-70	B-DNA
to	I-DNA
-65	I-DNA
and	I-DNA
-121	I-DNA
to	I-DNA
-103	I-DNA
regions	I-DNA
of	O
the	O
CD11c	B-DNA
promoter	I-DNA
resulted	O
in	O
the	O
loss	O
of	O
activation	O
by	O
Sp3	B-protein
.	O


We	O
recently	O
identified	O
the	O
winged-helix	B-protein
transcription	I-protein
factor	I-protein
Trident	B-protein
and	O
described	O
its	O
expression	O
pattern	O
in	O
synchronized	B-cell_type
fibroblasts	I-cell_type
.	O


These	O
results	O
suggest	O
that	O
additional	O
factor	O
(	O
s	O
)	O
are	O
necessary	O
for	O
full	O
ER	B-protein
function	O
.	O


The	O
functions	O
of	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
in	O
activating	O
differentiation-linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
Id	B-protein
family	I-protein
of	I-protein
HLH	I-protein
proteins	I-protein
.	O


In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	B-RNA
transcript	I-RNA
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	B-protein
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


TNFalpha	B-protein
cooperates	O
with	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
pathway	O
to	O
synergistically	O
increase	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
via	O
downstream	O
TRE-like	B-DNA
cAMP	I-DNA
response	I-DNA
elements	I-DNA
.	O


These	O
downstream	B-DNA
sequence	I-DNA
elements	I-DNA
,	O
termed	O
DSE	B-DNA
,	O
can	O
bind	O
both	O
AP-1	B-protein
and	O
CREB/ATF	B-protein
transcription	B-protein
factors	I-protein
.	O


Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	B-DNA
are	O
also	O
cAMP-responsive	B-DNA
elements	I-DNA
(	O
CRE	B-DNA
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	B-protein
toxin	I-protein
(	O
Ctx	B-protein
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP-dependent	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
signal	O
transduction	O
pathway	O
.	O


These	O
data	O
are	O
consistent	O
with	O
EBNA3C	B-protein
contributing	O
to	O
the	O
regulation	O
of	O
EBNA	B-protein
expression	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
through	O
CBF1/RBP-Jkappa	B-protein
and	O
another	O
factor	O
,	O
but	O
this	O
need	O
not	O
directly	O
involve	O
EBNA2	B-protein
.	O


Finally	O
,	O
although	O
it	O
has	O
been	O
reported	O
that	O
EBNA3C	B-protein
can	O
upregulate	O
CD21	B-protein
in	O
some	O
B	B-cell_type
cells	I-cell_type
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
effect	O
of	O
EBNA3C	B-protein
on	O
reporter	B-DNA
plasmids	I-DNA
which	O
contain	O
the	O
CD21	B-DNA
promoter	I-DNA
.	O


Relationship	O
between	O
glucocorticoid	B-protein
receptor	I-protein
and	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
ulcerative	O
colitis	O
.	O


IgE	B-DNA
germline	I-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
carrying	O
point	O
mutations	O
in	O
the	O
NF	B-protein
kappa	I-protein
B2	I-protein
site	O
were	O
largely	O
unresponsive	O
to	O
IL-4	B-protein
stimulation	O
in	O
transient	O
transfection	O
experiments	O
,	O
while	O
plasmids	O
with	O
similar	O
mutations	O
in	O
the	O
NF	B-protein
kappa	I-protein
B1	I-protein
site	O
responded	O
to	O
cytokine	B-protein
stimulation	O
better	O
than	O
the	O
wild-type	B-DNA
promoter	I-DNA
.	O


Considering	O
that	O
nuclear	B-protein
regulatory	I-protein
factor-kappa	I-protein
beta	I-protein
(	B-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
is	O
a	O
common	O
regulatory	B-protein
element	I-protein
of	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
herein	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
acute	O
ethanol	O
affects	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


Adherence-isolated	B-cell_line
monocytes	I-cell_line
showed	O
constitutive	O
DNA	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


Tolerant	O
cells	O
still	O
express	O
the	O
CD14	B-protein
receptor	I-protein
and	O
they	O
can	O
still	O
be	O
activated	O
to	O
mobilize	O
NF-kappa	B-protein
B	I-protein
into	O
nucleus	O
.	O


Cyclosporin	O
A	O
(	O
CsA	O
)	O
may	O
achieve	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
calcium-	B-protein
and	I-protein
calmodulin-dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
which	O
is	O
required	O
for	O
activation	O
of	O
target	B-DNA
genes	I-DNA
by	O
members	O
of	O
the	O
NFAT	B-protein
(	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O


Among	O
these	O
target	B-DNA
genes	I-DNA
is	O
the	O
gene	O
encoding	O
interleukin-2	B-protein
(	O
IL2	B-protein
)	O
,	O
a	O
cytokine	B-protein
facilitating	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O


In	O
cells	O
that	O
have	O
been	O
preincubated	O
to	O
lower	O
mRNA	O
levels	O
,	O
there	O
is	O
a	O
transient	O
increase	O
in	O
G0S2	B-RNA
mRNA	I-RNA
,	O
peaking	O
between	O
1-2	O
h	O
,	O
in	O
response	O
to	O
Concanavalin-A	O
(	O
ConA	O
)	O
,	O
or	O
to	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
TPA	O
)	O
,	O
and	O
the	O
calcium	O
ionophore	O
,	O
ionomycin	O
.	O


To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
gene	I-DNA
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF-kappaB	B-DNA
like	I-DNA
site	I-DNA
in	O
the	O
5637	B-cell_line
non-lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM-CSF	B-protein
.	O


Repression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
through	O
the	O
novel	O
cooperation	O
of	O
human	B-protein
factors	I-protein
YY1	B-protein
and	O
LSF	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Virol	O
1998	O
Feb	O
;	O
72	O
(	O
2	O
)	O
:	O
1709	O
]	O


Few	O
host	O
factors	O
that	O
directly	O
limit	O
HIV-1	O
transcription	O
and	O
could	O
support	O
this	O
state	O
of	O
nonproductive	O
HIV-1	O
infection	O
have	O
been	O
described	O
.	O


This	O
cooperative	O
function	O
may	O
account	O
for	O
the	O
divergent	O
effects	O
of	O
LSF	B-protein
previously	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


Here	O
we	O
report	O
a	O
real-time	O
study	O
of	O
factor/DNA	O
interactions	O
using	O
a	O
surface	O
plasmon	O
resonance	O
approach	O
and	O
further	O
characterization	O
of	O
recovered	B-protein
proteins	I-protein
involved	O
in	O
this	O
interaction	O
.	O


Finally	O
,	O
recovered	O
protein	O
was	O
identified	O
as	O
genuine	O
huGATA-3	B-protein
by	O
SDS-PAGE	O
,	O
Western	O
blotting	O
,	O
and	O
bandshift	O
assays	O
.	O


Recruitment	O
and	O
extravasation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
the	O
blood-brain	O
barrier	O
are	O
favored	O
by	O
adhesion	B-protein
molecule	I-protein
-mediated	O
interactions	O
of	O
circulating	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
endothelial	B-cell_type
cells	I-cell_type
.	O


However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	B-protein
modulates	O
T-cell	O
receptor	O
(	O
TCR	B-protein
)	O
-triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O


Tissue	O
transglutaminase-dependent	O
posttranslational	O
modification	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
in	O
promonocytic	B-cell_line
cells	I-cell_line
undergoing	O
apoptosis	O
.	O


The	O
shift	O
in	O
pRB	B-protein
molecular	O
weight	O
was	O
reproduced	O
by	O
adding	O
exogenous	O
purified	O
tTG	O
to	O
extracts	O
obtained	O
from	O
viable	O
U937	B-cell_line
cells	I-cell_line
and	O
was	O
prevented	O
by	O
dansylcadaverine	O
,	O
a	O
potent	O
enzyme	O
inhibitor	O
.	O


The	O
phosphorylation	O
of	O
STAT	B-protein
proteins	I-protein
on	O
serine	O
residues	O
is	O
also	O
required	O
for	O
competent	O
STAT	B-protein
transcription	O
.	O


Our	O
results	O
show	O
that	O
phosphorylation	O
of	O
STAT3alpha	B-protein
on	O
serine	O
727	O
is	O
not	O
constitutive	O
in	O
quiescent	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
can	O
be	O
induced	O
by	O
the	O
cytokine	B-protein
IL-2	I-protein
.	O


These	O
results	O
thus	O
show	O
that	O
STAT3	B-protein
proteins	I-protein
are	O
targets	O
for	O
multiple	O
kinase	O
pathways	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
can	O
integrate	O
signals	O
from	O
both	O
cytokine	B-protein
receptors	I-protein
and	O
antigen	B-protein
receptors	I-protein
.	O


NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
members	I-protein
regulating	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
in	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O


The	O
second	O
complex	O
contained	O
RelA	B-protein
,	O
and	O
exhibited	O
higher	O
affinity	O
towards	O
the	O
ICAM-1	B-DNA
kappa	I-DNA
B	I-DNA
than	O
to	O
the	O
HIV	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O


The	O
distinct	O
N-terminal	B-protein
half	I-protein
of	O
MZF-2	B-protein
carries	O
two	O
characteristic	O
domains	O
,	O
a	O
leucine-rich	B-protein
domain	I-protein
called	O
LeR	B-protein
and	O
an	O
acidic	B-protein
domain	I-protein
,	O
which	O
suggests	O
a	O
unique	O
function	O
of	O
MZF-2	B-protein
in	O
neutrophil	O
development	O
.	O


We	O
calculated	O
binding	O
affinity	O
(	O
Kd	O
;	O
nmol/L	O
)	O
and	O
capacity	O
(	O
Bmax	O
;	O
sites/cell	O
)	O
for	O
dexamethasone	O
and	O
cortisol	O
from	O
homologous	O
and	O
heterologous	O
competition	O
curves	O
for	O
specific	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
sites	O
on	O
HML	B-cell_type
isolated	O
from	O
the	O
blood	O
of	O
normotensive	O
volunteers	O
and	O
subjects	O
with	O
essential	O
hypertension	O
.	O


Kd	O
values	O
(	O
mean+/-SE	O
)	O
for	O
cortisol	O
in	O
HML	B-cell_type
of	O
hypertensive	O
patients	O
were	O
higher	O
than	O
in	O
control	O
subjects	O
(	O
24.6+/-2.4	O
versus	O
17.5+/-1.7	O
nmol/L	O
,	O
P	O
<	O
.04	O
)	O
.	O


Binding	O
capacity	O
(	O
4978+/-391	O
versus	O
4131+/-321	O
sites/cell	O
)	O
,	O
Kd	O
values	O
for	O
dexamethasone	O
(	O
6.7+/-0.5	O
versus	O
5.7+/-0.3	O
nmol/L	O
)	O
,	O
and	O
IC50	O
values	O
for	O
dexamethasone	O
(	O
3.4+/-0.3	O
versus	O
3.1+/-0.2	O
nmol/L	O
)	O
and	O
cortisol	O
(	O
12.2+/-1.6	O
versus	O
9.5+/-0.3	O
nmol/L	O
)	O
were	O
not	O
significantly	O
different	O
.	O


Both	O
Kd	O
(	O
30.3+/-2.5	O
versus	O
19.2+/-2.4	O
nmol/L	O
)	O
and	O
IC50	O
values	O
(	O
15.5+/-1.8	O
versus	O
8.9+/-1.2	O
nmol/L	O
)	O
for	O
cortisol	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
lower	O
renin	B-protein
values	O
(	O
P	O
<	O
.03	O
)	O
.	O


Other	O
variables	O
,	O
including	O
plasma	O
hormone	O
and	O
electrolyte	O
values	O
and	O
binding	O
characteristics	O
for	O
dexamethasone	O
,	O
were	O
not	O
different	O
.	O


These	O
data	O
suggest	O
that	O
cortisol	O
binding	O
to	O
glucocorticoid	B-protein
receptor	I-protein
is	O
slightly	O
impaired	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O


The	O
-45	B-DNA
site	I-DNA
is	O
an	O
E	B-DNA
box	I-DNA
that	O
binds	O
basic	B-protein
helix-loop-helix-zipper	I-protein
proteins	I-protein
whereas	O
the	O
-160	B-DNA
site	I-DNA
is	O
a	O
composite	B-DNA
PU.1	I-DNA
and	I-DNA
Pip	I-DNA
binding	I-DNA
site	I-DNA
.	O


Ten	O
HIV-infected	O
patients	O
with	O
normal	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS-C	O
)	O
,	O
10	O
HIV-infected	O
patients	O
with	O
low	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS-GR	O
)	O
,	O
and	O
20	O
healthy	O
subjects	O
were	O
studied	O
.	O


Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	B-cell_type
during	O
the	O
respiratory	O
burst	O
.	O


Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30-50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	B-protein
activator	O
.	O


The	O
NH2Cl-treated	B-cell_line
neutrophils	I-cell_line
showed	O
a	O
decrease	O
in	O
both	O
PKC	B-protein
activity	O
and	O
PMA-induced	O
phosphorylation	O
of	O
a	O
47-kDa	B-protein
protein	I-protein
,	O
which	O
corresponds	O
to	O
the	O
cytosolic	B-protein
factor	I-protein
of	O
NADPH	B-protein
oxidase	I-protein
,	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
.	O


This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	B-protein
activity	O
and	O
nuclear	O
transcription	O
factor-	O
kappaB	B-protein
activation	O
,	O
also	O
without	O
loss	O
of	O
cell	O
viability	O
.	O


Evidence	O
that	O
calcineurin	O
is	O
rate-limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O


In	O
clinical	O
use	O
,	O
CsA	O
treatment	O
inhibits	O
50-75	O
%	O
of	O
CN	B-protein
activity	O
in	O
circulating	B-cell_type
leukocytes	I-cell_type
.	O


Here	O
we	O
show	O
that	O
in	O
E29.1	B-cell_line
T	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
are	O
equally	O
associated	O
with	O
p65	B-protein
and	O
that	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
degraded	O
in	O
response	O
to	O
TNF	B-protein
alpha	I-protein
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O


Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	B-protein
form	I-protein
.	O


The	O
molecule	O
bound	O
CD40	B-protein
with	O
a	O
high	O
affinity	O
(	O
2.2	O
nM	O
)	O
and	O
was	O
a	O
monomer	O
in	O
solution	O
.	O


Basal	O
activity	O
of	O
a	O
3070	B-DNA
bp	I-DNA
CRH	I-DNA
promoter	I-DNA
fragment	I-DNA
was	O
only	O
seen	O
in	O
neuronal	O
and	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


A	O
similar	O
spectrum	O
of	O
transcript	O
deletions	O
has	O
previously	O
been	O
described	O
in	O
the	O
putative	B-DNA
tumour	I-DNA
suppressor	I-DNA
gene	I-DNA
FHIT	B-DNA
.	O


In	O
addition	O
,	O
transcripts	O
from	O
TSG101	B-DNA
,	O
FHIT	B-DNA
and	O
seven	O
other	O
genes	O
were	O
analysed	O
in	O
RNA	O
isolated	O
from	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O


Our	O
findings	O
demonstrate	O
that	O
truncated	B-RNA
TSG101	I-RNA
and	I-RNA
FHIT	I-RNA
transcripts	I-RNA
are	O
commonly	O
detected	O
in	O
both	O
normal	O
and	O
malignant	O
tissues	O
and	O
that	O
a	O
significant	O
fraction	O
of	O
these	O
are	O
likely	O
to	O
be	O
the	O
result	O
of	O
aberrant	O
splicing	O
.	O


In	O
this	O
study	O
,	O
we	O
observed	O
that	O
curcumin	O
(	O
50	O
microM	O
)	O
inhibited	O
proliferation	O
of	O
rat	B-cell_type
thymocytes	I-cell_type
stimulated	O
with	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
as	O
well	O
as	O
that	O
of	O
human	B-cell_type
Jurkat	I-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O


The	O
pigment	O
also	O
inhibited	O
apoptosis	O
in	O
dexamethasone-treated	B-cell_line
rat	I-cell_line
thymocytes	I-cell_line
and	O
in	O
UV-irradiated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
as	O
judged	O
by	O
DNA	O
ladder	O
formation	O
,	O
cellular	O
morphological	O
changes	O
,	O
and	O
flow	O
cytometry	O
analysis	O
.	O


T-cell	B-protein
receptor	I-protein
(	B-protein
TCR	I-protein
)	I-protein
/CD3	I-protein
engagement	O
results	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFAT	B-protein
)	O
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
,	O
whereas	O
the	O
CD28	B-protein
responsive	I-protein
complex	I-protein
(	O
CD28RC	B-protein
)	O
is	O
activated	O
in	O
response	O
to	O
the	O
CD28	B-protein
signal	O
.	O


Finally	O
,	O
a	O
110-kDa	B-protein
protein	I-protein
has	O
been	O
identified	O
in	O
the	O
nuclei	O
of	O
all	O
the	O
B	B-cell_line
,	I-cell_line
but	I-cell_line
not	I-cell_line
T	I-cell_line
,	I-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
specifically	O
binds	O
to	O
this	O
A-MYB	B-protein
N-terminal	I-protein
domain	I-protein
.	O


Most	O
interestingly	O
,	O
expression	O
of	O
CD95	B-protein
(	O
Fas/Apo-1	B-protein
)	O
and	O
of	O
CD23	B-protein
was	O
down-regulated	O
in	O
all	O
K46	B-cell_line
transfectants	I-cell_line
.	O


As	O
a	O
consequence	O
,	O
they	O
became	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
anti-CD95	B-protein
Ab	I-protein
treatment	O
.	O


Similarly	O
,	O
the	O
Egr-1-expressing	B-cell_line
Ramos	I-cell_line
cells	I-cell_line
showed	O
reduced	O
levels	O
of	O
CD95	B-protein
expression	O
.	O


TCR	B-protein
-contact	O
site	O
heterogeneity	O
was	O
excluded	O
as	O
the	O
selective	O
force	O
in	O
diversity	O
generation	O
since	O
the	O
epitope-encoded	O
sequences	O
were	O
found	O
to	O
be	O
identical	O
within	O
endogenous	O
virus	O
isolates	O
.	O


Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R	O
elicits	O
a	O
two-phase	O
neutrophil-endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
.	O


CD40	B-protein
ligation	O
leads	O
to	O
B	O
cell	O
activation	O
events	O
such	O
as	O
proliferation	O
,	O
Ig	O
secretion	O
,	O
isotype	O
switching	O
,	O
and	O
up-regulation	O
of	O
cell	B-protein
surface	I-protein
molecules	I-protein
,	O
as	O
well	O
as	O
the	O
generation	O
of	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


However	O
,	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
insufficient	O
for	O
CD40	B-protein
-mediated	O
up-regulation	O
of	O
B7-1	B-protein
,	O
Fas	B-protein
,	O
and	O
CD23	B-protein
.	O


CD30	B-protein
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	B-cell_type
.	O


Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant-negative	B-protein
form	I-protein
of	O
TRAF2	B-protein
was	O
found	O
to	O
potentiate	O
TNFR1	B-protein
-mediated	O
death	O
.	O


By	O
contrast	O
,	O
the	O
monocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	I-protein
was	O
largely	O
absent	O
at	O
this	O
stage	O
and	O
in	O
the	O
CD34+Thy-1-CD45RA-	B-cell_line
subsets	I-cell_line
.	O


Addition	O
of	O
GM-CSF	B-protein
to	O
this	O
basic	O
cocktail	O
consistently	O
increased	O
the	O
clonogenic	O
capacity	O
of	O
single	B-cell_line
CD34+Thy-1+	I-cell_line
cells	I-cell_line
,	O
and	O
this	O
effect	O
was	O
further	O
enhanced	O
(	O
up	O
to	O
72.3	O
+/-	O
4.3	O
%	O
on	O
day	O
7	O
)	O
by	O
the	O
inclusion	O
of	O
TNF-alpha	B-protein
.	O


Recent	O
studies	O
from	O
our	O
laboratory	O
have	O
indicated	O
that	O
protein	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
PTPase	B-protein
)	O
inhibitors	O
can	O
down-modulate	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
-mediated	O
activation	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
ML-1a	B-cell_line
,	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Singh	O
and	O
Aggarwal	O
,	O
J.	O
Biol.	O
Chem.	O
1995	O
:	O
270	O
:	O
10631	O
)	O
.	O


Like	O
ML-1a	B-cell_line
,	O
human	B-cell_line
dermal	I-cell_line
microvessel	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
MVEC	B-cell_line
)	O
treated	O
with	O
TNF	B-protein
rapidly	O
activated	O
(	O
within	O
30	O
min	O
)	O
NF-kappa	B-protein
B	I-protein
;	O
this	O
effect	O
was	O
completely	O
abolished	O
by	O
co-treatment	O
with	O
phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
PTPase	B-protein
.	O


Consistent	O
with	O
these	O
results	O
,	O
the	O
attachment	O
of	O
monocytes	O
to	O
MVEC	B-cell_line
was	O
also	O
blocked	O
by	O
the	O
PTPase	B-protein
inhibitors	O
.	O


Spi-1/PU.1	B-protein
is	O
a	O
myeloid-	B-protein
and	I-protein
B-cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
which	O
is	O
also	O
involved	O
in	O
Friend	O
virus-induced	O
murine	O
erythroleukemia	O
.	O


Analysis	O
of	O
erythroblasts	O
co-expressing	O
Spi-1	B-protein
and	O
the	O
wild-type	B-protein
mouse	I-protein
EpoR	I-protein
showed	O
that	O
differentiation	O
arrest	O
and	O
inhibition	O
of	O
apoptosis	O
depended	O
on	O
specific	O
cooperation	O
between	O
Spi-1	B-protein
and	O
EpoR	B-protein
(	I-protein
R129C	I-protein
)	I-protein
.	O


Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IL-5	B-protein
synthesis	O
in	O
atopic	O
diseases	O
:	O
a	O
study	O
with	O
allergen-specific	B-cell_line
human	I-cell_line
helper	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Elucidation	O
of	O
IL-5	B-protein
-specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O


The	O
finding	O
that	O
Oct-2	B-protein
is	O
under	O
NF-kappaB	B-protein
control	O
highlights	O
an	O
important	O
cross-talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	B-protein
factor	I-protein
families	I-protein
that	O
regulate	O
B	B-cell_type
lymphocyte	I-cell_type
function	O
.	O


The	O
active	O
ingredients	O
mediating	O
the	O
pharmacological	O
effect	O
are	O
mainly	O
sesquiterpene	O
lactones	O
,	O
such	O
as	O
helenalin	O
,	O
11alpha	O
,	O
13-dihydrohelenalin	O
,	O
chamissonolid	O
and	O
their	O
ester	O
derivatives	O
.	O


These	O
data	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
anti-inflammatory	O
effect	O
of	O
sesquiterpene	O
lactones	O
,	O
which	O
differs	O
from	O
that	O
of	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
indomethacin	O
and	O
acetyl	O
salicylic	O
acid	O
.	O


Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	B-protein
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	B-protein
and	O
NGFI-A/Egr-1	B-protein
using	O
a	O
TRE1	B-DNA
probe	I-DNA
.	O


Analysis	O
of	O
Tax	B-protein
mutants	I-protein
showed	O
that	O
two	O
mutants	O
,	O
IEXC29S	B-protein
and	O
IEXL320G	B-protein
,	O
were	O
unable	O
to	O
significantly	O
transactivate	O
the	O
c-sis/PDGF-B	B-DNA
promoter	I-DNA
.	O


The	O
phenotype	O
of	O
RelB	B-protein
knockout	O
mice	O
implicates	O
this	O
member	O
of	O
the	O
NF	B-protein
kappa	I-protein
B/Rel	I-protein
family	I-protein
in	O
DC	B-cell_type
differentiation	O
.	O


A	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	O
for	O
CAML	B-protein
.	O


Although	O
IL-4	B-protein
activated	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
6	I-protein
in	O
addition	O
to	O
NF-kappaB	B-protein
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF-kappaB	B-protein
or	O
STAT6	B-protein
only	O
partly	O
blocked	O
IL-4	B-protein
-induced	O
germline	B-DNA
Cepsilon	O
transcription	O
.	O


These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF-kappaB	B-protein
and	O
STAT6	B-protein
may	O
be	O
required	O
for	O
induction	O
of	O
germline	B-DNA
Cepsilon	O
transcription	O
by	O
IL-4	B-protein
,	O
and	O
that	O
CD40	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	B-DNA
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	B-protein
.	O


There	O
are	O
many	O
hypotheses	O
concerning	O
the	O
pathogenesis	O
of	O
endometriosis	O
,	O
though	O
no	O
single	O
theory	O
can	O
explain	O
all	O
cases	O
.	O


Recent	O
evidence	O
has	O
implicated	O
components	O
of	O
the	O
immune	O
system	O
in	O
the	O
pathogenesis	O
of	O
endometriosis	O
.	O


One	O
ATF/CRE	B-DNA
motif	I-DNA
is	O
located	O
in	O
the	O
distal	B-DNA
promoter	I-DNA
at	O
the	O
nuclear	B-DNA
matrix-associated	I-DNA
Site	I-DNA
IV	I-DNA
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	B-DNA
promoter	I-DNA
at	O
Site	B-DNA
I	I-DNA
.	O


Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF/CREB	B-protein
factors	I-protein
functionally	O
modulate	O
histone	B-DNA
H4	I-DNA
gene	I-DNA
transcription	O
at	O
distal	B-DNA
and	I-DNA
proximal	I-DNA
promoter	I-DNA
elements	I-DNA
.	O


Furthermore	O
,	O
we	O
propose	O
that	O
these	O
putative	O
CD	O
peptides	O
bind	O
to	O
oligosaccharide	O
residues	O
on	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
distal	O
to	O
the	O
peptide-binding	B-protein
groove	I-protein
invoking	O
recognition	O
and	O
binding	O
by	O
specialized	O
subsets	O
of	O
gamma	B-cell_type
delta	I-cell_type
T	I-cell_type
cell	I-cell_type
receptor-bearing	I-cell_type
lymphocytes	I-cell_type
.	O


Finally	O
,	O
we	O
speculate	O
that	O
molecular	O
mimicry	O
between	O
one	O
or	O
more	O
gliadin	O
peptides	O
and	O
some	O
,	O
as	O
yet	O
unidentified	O
,	O
bacterial	B-protein
or	I-protein
viral	I-protein
superantigen	I-protein
plays	O
a	O
role	O
in	O
disease	O
pathogenesis	O
.	O


Here	O
we	O
show	O
that	O
LMP-1	B-protein
induces	O
the	O
activity	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
,	O
a	O
dimer	O
of	O
Jun/Jun	B-protein
or	I-protein
Jun/Fos	I-protein
proteins	I-protein
.	O


JNK	B-protein
-mediated	O
transcriptional	O
activation	O
of	O
AP-1	B-protein
is	O
the	O
direct	O
output	O
of	O
LMP	B-protein
-1-triggered	O
signaling	O
,	O
as	O
shown	O
by	O
an	O
inducible	O
LMP-1	B-protein
mutant	I-protein
.	O


4.	O
When	O
apoptotic	B-cell_type
lymphocytes	I-cell_type
from	O
exposed	O
individuals	O
were	O
compared	O
to	O
apoptotic	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
control	O
group	O
,	O
statistically-significant	O
differences	O
between	O
each	O
mean	O
group	O
were	O
detected	O
(	O
26.4	O
+/-	O
1.8	O
and	O
12.1	O
+/-	O
1.3	O
,	O
respectively	O
)	O
,	O
indicating	O
an	O
increased	O
rate	O
of	O
apoptosis	O
in	O
80.5	O
%	O
of	O
exposed	O
individuals	O
(	O
P	O
<	O
0.0001	O
,	O
Mann-Whitney	O
U-Test	O
)	O
.	O


Subcellular	O
localization	O
analysis	O
in	O
various	O
cells	O
,	O
using	O
a	O
specific	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
against	O
SR-BP	B-protein
,	O
demonstrated	O
that	O
this	O
protein	O
was	O
associated	O
with	O
the	O
nuclear	O
envelope	O
.	O


Such	O
genes	O
disclose	O
a	O
common	O
element	O
within	O
their	O
promoters	B-DNA
,	O
defined	O
Interferon	B-DNA
Stimulated	I-DNA
Response	I-DNA
Element	I-DNA
(	O
ISRE	B-DNA
)	O
,	O
which	O
binds	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
(	O
ISGF3	B-protein
)	O
after	O
the	O
binding	O
of	O
interferon	B-protein
(	O
IFN	B-protein
)	O
to	O
the	O
specific	O
receptor	O
.	O


Here	O
we	O
report	O
the	O
induction	O
of	O
the	O
synthesis	O
and	O
of	O
the	O
hydrolytic	O
activity	O
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
(	O
PLC	B-protein
gamma	I-protein
1	I-protein
)	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
IFN-beta	B-protein
.	O


In	O
addition	O
,	O
the	O
ability	O
of	O
this	O
enzyme	B-protein
to	O
hydrolyse	O
PIP2	O
,	O
also	O
in	O
the	O
presence	O
of	O
genistein	O
,	O
implies	O
the	O
possibility	O
that	O
this	O
enzyme	O
can	O
exert	O
its	O
hydrolytic	O
activity	O
independently	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activation	O
.	O


Hypoxia	O
enhances	O
induction	O
of	O
endothelial	B-protein
ICAM-1	I-protein
:	O
role	O
for	O
metabolic	O
acidosis	O
and	O
proteasomes	B-protein
.	O


Immunoprecipitation	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
revealed	O
that	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B-protein
and	O
activation	O
of	O
STAT5	B-protein
were	O
induced	O
upon	O
stimulation	O
with	O
hIL-5	B-protein
in	O
all	O
three	O
cell	O
types	O
,	O
while	O
STAT1	B-protein
activation	O
was	O
only	O
observed	O
in	O
eosinophils	B-cell_type
.	O


Our	O
results	O
demonstrate	O
that	O
short-term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	B-protein
activated	I-protein
p50/p65	I-protein
containing	O
NF-kappa	B-protein
B	I-protein
dimers	I-protein
and	O
induced	O
the	O
expression	O
of	O
the	O
target	B-DNA
gene	I-DNA
IL-8	I-DNA
.	O


This	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	B-protein
inhibitor	O
PSI	O
.	O


After	O
stimulation	O
,	O
neutrophils	O
separated	O
from	O
a	O
healthy	O
human	O
volunteer	O
were	O
added	O
with	O
or	O
without	O
anti-CD18	B-protein
antibody	I-protein
.	O


Pretreatment	O
with	O
dexamethasone	O
tapered	O
NFkappaB	B-protein
translocation	O
into	O
the	O
nucleus	O
.	O


The	O
transcriptional	B-DNA
start	I-DNA
sites	I-DNA
were	O
identified	O
by	O
an	O
RNase	B-protein
protection	O
assay	O
.	O


The	O
ability	O
of	O
BHRF1	B-protein
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O


In	O
addition	O
,	O
BHRF1	B-protein
protected	O
these	O
cells	O
from	O
monocyte-mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O


Among	O
the	O
regulatory	B-DNA
promoter	I-DNA
elements	I-DNA
potentially	O
regulating	O
eotaxin	B-DNA
gene	I-DNA
expression	O
and/or	O
mediating	O
the	O
effects	O
of	O
anti-inflammatory	O
drugs	O
we	O
identified	O
consensus	B-DNA
sequences	I-DNA
known	O
to	O
interact	O
with	O
nuclear	B-protein
factors	I-protein
like	O
NF-IL6	B-protein
,	O
AP-1	B-protein
,	O
a	O
NF-kappa-B	B-DNA
like	I-DNA
consensus	I-DNA
sequence	I-DNA
and	O
gamma-interferon-	B-DNA
as	I-DNA
well	I-DNA
as	I-DNA
glucocorticoid	I-DNA
response	I-DNA
elements	I-DNA
.	O


Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV-1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV-1	O
transcription	O
and	O
replication	O
.	O


Dexamethasone	O
,	O
up	O
to	O
a	O
concentration	O
of	O
1	O
mumol/L	O
,	O
neither	O
affected	O
significantly	O
the	O
release	O
of	O
granule	B-protein
enzymes	I-protein
nor	O
interfered	O
with	O
PAF	B-protein
binding	O
to	O
its	O
membrane	B-protein
receptors	I-protein
.	O


Although	O
IL-2Rbeta	B-protein
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O


In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
induction	O
of	O
PIF	B-protein
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O


Interestingly	O
,	O
PIF	B-protein
was	O
constitutively	O
activated	O
in	O
human	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
1-transformed	I-cell_line
MT-2	I-cell_line
cells	I-cell_line
.	O


In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL-2Rbeta	B-protein
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr-1	B-protein
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O


The	O
MHC	B-protein
class	I-protein
II	I-protein
homologous	I-protein
proteins	I-protein
HLA-DMA	B-protein
and	O
HLA-DMB	B-protein
function	O
in	O
the	O
loading	O
of	O
peptides	O
onto	O
class	B-protein
II	I-protein
molecules	I-protein
.	O


In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	O
being	O
internalized	O
.	O


The	O
human	B-protein
myeloid	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
is	O
expressed	O
specifically	O
in	O
maturing	B-cell_type
cells	I-cell_type
of	O
the	O
myelomonocytic	O
lineage	O
and	O
in	O
monocytes	B-cell_type
and	O
granulocytes	B-cell_type
.	O


However	O
,	O
analysis	O
of	O
deletion	B-DNA
mutants	I-DNA
localized	O
nearly	O
all	O
of	O
the	O
promoter	O
activity	O
to	O
a	O
short	O
region	O
(	O
-73	B-DNA
to	I-DNA
-16	I-DNA
)	O
that	O
did	O
not	O
include	O
the	O
cluster	O
of	O
c-Myb	B-DNA
sites	I-DNA
.	O


A	O
4-bp	O
mutation	O
of	O
the	O
core	B-DNA
Sp1	I-DNA
consensus	I-DNA
element	I-DNA
(	O
GC	B-DNA
box	I-DNA
)	O
(	O
-20	O
)	O
reduced	O
overall	O
promoter	O
activity	O
of	O
the	O
1-kb	B-DNA
fragment	I-DNA
.	O


Critical	O
cytoplasmic	B-protein
domains	I-protein
of	O
human	B-protein
interleukin-9	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
in	O
interleukin	B-protein
-9-mediated	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O


Deletion	O
of	O
this	O
region	O
or	O
internal	O
deletion	O
of	O
the	O
BOX1	B-protein
motif	I-protein
abrogated	O
IL-9	B-protein
-induced	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O


These	O
results	O
suggest	O
that	O
cooperation	O
or	O
cross-talk	O
of	O
signaling	O
molecules	O
associated	O
with	O
different	O
domains	O
of	O
IL-9Ralpha	B-protein
other	O
than	O
STAT3	B-protein
is	O
essential	O
for	O
IL-9	B-protein
-mediated	O
cell	O
growth	O
.	O


The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	B-cell_line
cells	I-cell_line
was	O
significantly	O
inhibited	O
by	O
overexpression	O
of	O
the	O
Bcl-2	B-protein
protein	I-protein
.	O


Mutations	O
in	O
these	O
liver-enriched	B-protein
transcription	I-protein
factors	I-protein
result	O
in	O
two	O
forms	O
of	O
early-onset	O
type	O
2	O
diabetes	O
(	O
maturity-onset	O
diabetes	O
of	O
the	O
young	O
[	O
MODY	O
]	O
)	O
,	O
MODY3	O
and	O
MODY1	O
,	O
which	O
are	O
characterized	O
by	O
impaired	O
glucose-stimulated	O
insulin	O
secretion	O
,	O
early	O
disease	O
onset	O
,	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O


Together	O
,	O
these	O
results	O
suggest	O
that	O
class	O
I	O
triggering	O
can	O
induce	O
the	O
activity	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
thereby	O
modulating	O
the	O
expression	O
of	O
genes	O
regulated	O
by	O
these	O
transcription	B-protein
factors	I-protein
.	O


We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	B-protein
and	O
CIITA	B-protein
are	O
responsible	O
for	O
activation	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O


However	O
,	O
the	O
cellular	O
or	O
molecular	B-protein
factors	I-protein
responsible	O
for	O
a	O
delay	O
in	O
B-CLL	O
cell	O
death	O
are	O
unknown	O
.	O


Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B-CLL	B-cell_line
cells	I-cell_line
,	O
the	O
addition	O
of	O
IL-10	B-protein
inhibited	O
B-CLL	B-cell_line
proliferation	O
,	O
enhanced	O
B-CLL	B-cell_line
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O


For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	B-protein
protein	I-protein
including	O
the	O
sequence	O
Thr729-Lys984	B-protein
of	O
hMR	B-protein
.	O


By	O
using	O
several	O
HBD	B-protein
subfragments	I-protein
,	O
the	O
mAb	B-protein
18C7	I-protein
epitope	I-protein
was	O
located	O
in	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
HBD	B-protein
from	O
Thr729	B-protein
to	I-protein
Leu765	I-protein
.	O


Previous	O
work	O
has	O
demonstrated	O
that	O
SLP-76	B-protein
,	O
a	O
Grb2-associated	B-protein
tyrosine-phosphorylated	I-protein
protein	I-protein
,	O
augments	O
Interleukin-2	B-DNA
promoter	I-DNA
activity	O
when	O
overexpressed	O
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


This	O
review	O
focuses	O
on	O
the	O
molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O


Emphasis	O
is	O
given	O
to	O
recent	O
information	O
about	O
the	O
molecular	O
mechanisms	O
of	O
prolactin	O
receptor	O
signal	O
transduction	O
,	O
and	O
the	O
signaling	B-protein
molecules	I-protein
and	O
prolactin-inducible	B-DNA
target	I-DNA
genes	I-DNA
that	O
participate	O
in	O
these	O
responses	O
.	O


Activation	O
of	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
by	O
phagocytic	O
stimuli	O
in	O
human	O
neutrophils	O
.	O


We	O
conclude	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	B-DNA
B-responsive	I-DNA
genes	I-DNA
is	O
enhanced	O
in	O
phagocytosing	B-cell_type
neutrophils	I-cell_type
.	O


Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
was	O
examined	O
.	O


Thus	O
,	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
through	O
a	O
TNF-alpha-	O
and	O
NF-kappaB-dependent	O
mechanism	O
.	O


The	O
double	B-DNA
NF-kappaB	I-DNA
site	I-DNA
identified	O
in	O
the	O
LTR	B-DNA
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
necessary	O
for	O
efficient	O
viral	O
transcription	O
.	O


At	O
least	O
four	O
different	O
specific	O
NF-kappaB	B-protein
complexes	I-protein
are	O
present	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O


The	O
correlation	O
is	O
specific	O
as	O
the	O
level	O
of	O
at	O
least	O
three	O
other	O
transcription	B-protein
factors	I-protein
did	O
not	O
change	O
.	O


c-Myb	B-DNA
and	O
Ets	B-protein
proteins	I-protein
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B-protein
.	O


We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive/negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-protein
integrin	I-protein
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	B-cell_type
leukocytes	I-cell_type
.	O


Stat	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
and	O
Jak	B-protein
(	O
Janus	B-protein
kinases	I-protein
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O


They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	B-protein
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O


Upon	O
ligand	O
binding	O
and	O
cytokine	B-protein
receptor	I-protein
dimerization	O
,	O
Stat	B-protein
proteins	I-protein
are	O
phosphorylated	O
on	O
tyrosine	O
residues	O
by	O
Jak	B-protein
kinases	I-protein
.	O


IL-4	B-protein
-dependent	O
activation	O
of	O
Stat6	B-protein
was	O
also	O
observed	O
in	O
HC11	B-cell_line
mammary	I-cell_line
epithelial	I-cell_line
cells	I-cell_line
.	O


The	O
glucocorticoid	B-protein
receptor	I-protein
was	O
able	O
to	O
further	O
enhance	O
IL-4	B-protein
-induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	B-protein
.	O


Deletion	O
analysis	O
of	O
the	O
carboxyl-terminal	B-protein
region	I-protein
of	O
Stat6	B-protein
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-protein
.	O


The	O
potencies	O
of	O
the	O
transactivation	B-protein
domains	I-protein
of	O
Stat5	B-protein
,	O
Stat6	B-protein
,	O
and	O
viral	B-protein
protein	I-protein
VP16	I-protein
were	O
compared	O
.	O


ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
synergistically	O
transactivate	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O


This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose-dependent	O
reduction	O
in	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
with	O
the	O
CD8	B-cell_type
lineage	I-cell_type
being	O
more	O
severely	O
affected	O
.	O


The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	B-protein
expressed	O
on	O
lung	B-cell_type
fibroblasts	I-cell_type
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	B-cell_type
cells	I-cell_type
.	O


Communication	O
between	O
resident	O
tissue	O
fibroblasts	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
necessary	O
for	O
normal	O
wound	O
healing	O
,	O
and	O
can	O
be	O
pathologic	O
,	O
resulting	O
in	O
tissue	O
fibrosis	O
.	O


Signaling	O
through	O
CD40	B-protein
with	O
soluble	O
CD40	B-protein
ligand	O
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor-kappaB	O
and	O
by	O
induction	O
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	B-protein
IL-6	B-protein
and	O
IL-8	B-protein
.	O


Fine	O
mapping	O
by	O
in	O
vivo	O
footprinting	O
demonstrated	O
five	O
transcription	O
factor	O
binding	O
sites	O
that	O
are	O
occupied	O
in	O
both	O
resting	O
and	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
;	O
these	O
are	O
tandem	B-DNA
CRE	I-DNA
motifs	I-DNA
,	O
a	O
Sp1	B-DNA
site	I-DNA
,	O
an	O
overlapping	O
Egr-1/Sp1	B-DNA
site	I-DNA
,	O
and	O
a	O
novel	O
palindromic	B-DNA
octamer	I-DNA
sequence	I-DNA
(	O
POS	B-DNA
)	O
.	O


Distinct	O
mechanisms	O
for	O
N-acetylcysteine	O
inhibition	O
of	O
cytokine-induced	B-protein
E-selectin	I-protein
and	O
VCAM-1	B-protein
expression	O
.	O


Although	O
NAC	O
reduced	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
in	O
EC	B-cell_type
as	O
measured	O
by	O
gel-shift	O
assays	O
using	O
an	O
oligonucleotide	B-DNA
probe	I-DNA
corresponding	O
to	O
the	O
consensus	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
of	O
the	O
VCAM-1	B-DNA
gene	I-DNA
(	O
VCAM-NF-kappa	B-protein
B	I-protein
)	O
,	O
the	O
antioxidant	O
had	O
no	O
appreciable	O
effect	O
when	O
an	O
oligomer	O
corresponding	O
to	O
the	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
of	O
the	O
E-selectin	B-DNA
gene	I-DNA
(	O
E-selectin	B-protein
-NF-kappa	B-protein
B	I-protein
)	O
was	O
used	O
.	O


We	O
here	O
report	O
that	O
(	O
i	O
)	O
like	O
PML-RAR	B-protein
alpha	I-protein
expression	O
,	O
PLZF-RAR	B-protein
alpha	I-protein
expression	O
blocks	O
terminal	O
differentiation	O
of	O
hematopoietic	O
precursor	O
cell	O
lines	O
(	O
U937	B-cell_line
and	O
HL-60	B-cell_line
)	O
in	O
response	O
to	O
different	O
stimuli	O
(	O
vitamin	O
D3	O
,	O
transforming	O
growth	O
factor	O
beta1	O
,	O
and	O
dimethyl	O
sulfoxide	O
)	O
;	O
(	O
ii	O
)	O
PML-RAR	B-protein
alpha	I-protein
,	O
but	O
not	O
PLZF-RAR	B-protein
alpha	I-protein
,	O
increases	O
RA	O
sensitivity	O
of	O
hematopoietic	B-cell_type
precursor	I-cell_type
cells	I-cell_type
and	O
restores	O
RA	O
sensitivity	O
of	O
RA-resistant	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
;	O
(	O
iii	O
)	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
have	O
similar	O
RA	O
binding	O
affinities	O
;	O
and	O
(	O
iv	O
)	O
PML-RAR	B-protein
alpha	I-protein
enhances	O
the	O
RA	O
response	O
of	O
RA	B-DNA
target	I-DNA
genes	I-DNA
(	O
those	O
for	O
RAR	B-protein
beta	I-protein
,	O
RAR	B-protein
gamma	I-protein
,	O
and	O
transglutaminase	B-protein
type	I-protein
II	I-protein
[	O
TGase	B-protein
]	O
)	O
in	O
vivo	O
,	O
while	O
PLZF-RAR	B-protein
alpha	I-protein
expression	O
has	O
either	O
no	O
effect	O
(	O
RAR	B-protein
beta	I-protein
)	O
or	O
an	O
inhibitory	O
activity	O
(	O
RAR	B-protein
gamma	I-protein
and	O
type	B-protein
II	I-protein
TGase	I-protein
)	O
.	O


Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF-kappaB	B-protein
to	O
DNA	O
in	O
TNF-alpha-stimulated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O


Construction	O
and	O
biological	O
characterization	O
of	O
an	O
interleukin-12	B-protein
fusion	I-protein
protein	I-protein
(	O
Flexi-12	B-protein
)	O
:	O
delivery	O
to	O
acute	B-cell_type
myeloid	I-cell_type
leukemic	I-cell_type
blasts	I-cell_type
using	O
adeno-associated	O
virus	O
.	O


Production	O
of	O
functional	B-protein
IL-12	I-protein
requires	O
the	O
coordinated	O
expression	O
of	O
both	O
genes	O
.	O


These	O
studies	O
also	O
confirm	O
that	O
AAV	O
is	O
an	O
efficient	O
delivery	O
vehicle	O
for	O
cytokines	B-protein
to	O
leukemic	O
cells	O
.	O


The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	B-protein
engagement	O
that	O
are	O
important	O
for	O
regulating	O
CD95	B-protein
ligand	I-protein
gene	O
expression	O
.	O


This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O


In	O
one	O
case	O
,	O
the	O
PTT	O
shift	O
was	O
explained	O
by	O
in-frame	O
splicing	O
out	O
of	O
exon	B-RNA
10	I-RNA
,	O
in	O
the	O
presence	O
of	O
a	O
normal	B-DNA
exon	I-DNA
10	I-DNA
genomic	I-DNA
sequence	I-DNA
.	O


Confirmed	O
mutations	O
were	O
identified	O
in	O
28	O
%	O
of	O
the	O
families	O
studied	O
and	O
on	O
the	O
assumption	O
that	O
half	O
of	O
the	O
sporadic	O
cases	O
should	O
have	O
TSC2	B-DNA
mutations	I-DNA
,	O
a	O
crude	O
estimate	O
of	O
the	O
detection	O
rate	O
would	O
be	O
60	O
%	O
.	O


In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
vitamin	O
E	O
derivative	O
TCP	O
succinate	O
prevents	O
monocytic	O
cell	O
adhesion	O
to	O
cytokine-stimulated	O
endothelial	B-cell_type
cells	I-cell_type
by	O
inhibiting	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
further	O
emphasizing	O
the	O
antiatherosclerotic	O
potential	O
of	O
lipid	O
soluble	O
antioxidants	O
.	O


Using	O
a	O
fragment	O
of	O
K	B-protein
protein	I-protein
as	O
bait	O
in	O
the	O
yeast	O
two-hybrid	O
screen	O
,	O
we	O
isolated	O
a	O
cDNA	B-DNA
that	O
encodes	O
a	O
protein	O
whose	O
primary	O
structure	O
has	O
extensive	O
similarity	O
to	O
the	O
Drosophila	B-protein
melanogaster	I-protein
extra	I-protein
sex	I-protein
combs	I-protein
(	I-protein
esc	I-protein
)	I-protein
gene	I-protein
product	I-protein
,	O
Esc	B-protein
,	O
a	O
putative	O
silencer	O
of	O
homeotic	B-DNA
genes	I-DNA
.	O


Eed	B-protein
also	O
represses	O
transcription	O
when	O
recruited	O
to	O
a	O
target	O
promoter	O
by	O
Gal4-K	B-protein
protein	I-protein
.	O


Interferons	B-protein
up-regulate	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
IRF	B-protein
family	O
transcription	O
factor	O
gene	O
expression	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O


IRF-2	B-DNA
gene	I-DNA
was	O
apparently	O
only	O
weakly	O
responsive	O
to	O
IFNs	B-protein
in	O
these	O
cells	O
.	O


These	O
studies	O
demonstrate	O
that	O
E2a-Pbx1	B-protein
initiates	O
programmed	O
cell	O
death	O
of	O
hematopoietic	B-cell_type
precursers	I-cell_type
by	O
a	O
mechanism	O
that	O
requires	O
its	O
chimeric	O
transcriptional	O
properties	O
,	O
but	O
,	O
unlike	O
other	O
nuclear	B-protein
oncoproteins	I-protein
,	O
is	O
independent	O
of	O
p53	B-protein
.	O


These	O
transcripts	O
can	O
encode	O
three	O
proteins	O
of	O
calculated	O
molecular	O
mass	O
32.2	B-RNA
kDa	I-RNA
,	O
27.8	B-RNA
kDa	I-RNA
,	O
and	O
14.3	B-RNA
kDa	I-RNA
.	O


We	O
previously	O
showed	O
that	O
PO-B	B-protein
DNA-binding	O
is	O
progressively	O
induced	O
during	O
differentiation	O
of	O
promyelomonocytic	B-cell_line
leukemic	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
to	O
the	O
macrophage-like	B-cell_type
lineage	I-cell_type
(	O
with	O
phorbol	O
esters	O
)	O
.	O


In	O
gel	O
mobility	O
shift	O
assays	O
,	O
hT86	O
attenuated	O
the	O
intensity	O
of	O
the	O
retarded	O
band	O
composed	O
of	O
the	O
octamer	B-DNA
probe	I-DNA
and	O
Oct-2	B-protein
,	O
suggesting	O
a	O
dominant	O
negative	O
effect	O
on	O
the	O
DNA-binding	O
activity	O
of	O
Oct-2	B-protein
.	O


The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein-protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O


Leukocyte	B-protein
integrins	I-protein
are	O
fundamentally	O
important	O
in	O
modulating	O
adhesion	O
to	O
extracellular	O
matrix	O
components	O
and	O
to	O
other	O
cells	O
.	O


Moreover	O
,	O
integrin	B-protein
-ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O


By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	O
in	O
mRNA	B-RNA
was	O
associated	O
with	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
STAT1-containing	B-protein
DNA-binding	I-protein
complex	I-protein
that	O
binds	O
to	O
Fc	B-DNA
gammaRI	I-DNA
promoter	I-DNA
elements	I-DNA
.	O


The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	B-protein
regulator	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O


Activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
SP-A	B-protein
doses	O
as	O
low	O
as	O
1	O
microgram/ml	O
occurred	O
within	O
30	O
min	O
of	O
SP-A	B-protein
treatment	O
,	O
peaked	O
at	O
60	O
min	O
,	O
and	O
then	O
declined	O
.	O


GABP	B-protein
factors	I-protein
bind	O
to	O
a	O
distal	B-DNA
interleukin	I-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
enhancer	I-DNA
and	O
contribute	O
to	O
c-Raf	B-protein
-mediated	O
increase	O
in	O
IL-2	B-protein
induction	O
.	O


Overexpression	O
of	O
BXB	B-protein
,	O
a	O
constitutive	O
active	O
version	O
of	O
c-Raf	B-protein
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	B-protein
-	O
Raf	B-protein
-	O
Erk	B-protein
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	B-protein
-mediated	O
promoter-enhancer	O
induction	O
.	O


Regulation	O
by	O
Egr-1	B-protein
,	O
c-Jun	B-protein
,	O
and	O
NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
.	O


Rescue	O
by	O
cytokines	B-protein
of	O
apoptotic	O
cell	O
death	O
induced	O
by	O
IL-2	B-protein
deprivation	O
of	O
human	B-cell_line
antigen-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O


However	O
,	O
IL-10	B-protein
did	O
not	O
affect	O
IFN-gamma	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT-1alpha	B-protein
or	O
alter	O
STAT-1alpha	B-protein
binding	O
to	O
the	O
IFN-gamma	B-DNA
response	I-DNA
element	I-DNA
(	O
IRE	B-DNA
)	O
in	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
.	O


These	O
data	O
indicate	O
that	O
IL-10	B-protein
inhibits	O
IFN-gamma	B-protein
-induced	O
transcription	O
of	O
the	O
ICAM-1	B-DNA
gene	I-DNA
by	O
a	O
regulatory	O
mechanism	O
that	O
may	O
involve	O
NF-kappaB	B-protein
.	O


Furthermore	O
,	O
these	O
plasmids	B-DNA
were	O
not	O
active	O
in	O
RJ2.2.5	B-cell_line
,	O
an	O
in	O
vitro	O
mutagenized	O
derivative	O
of	O
Raji	B-cell_line
in	O
which	O
both	O
copies	O
of	O
CIITA	B-protein
are	O
defective	O
.	O


Following	O
TcR	B-protein
stimulation	O
,	O
activation	O
of	O
Erk2	B-protein
was	O
only	O
inhibited	O
by	O
a	O
previously	O
described	O
truncated	B-protein
form	I-protein
of	I-protein
p85	I-protein
that	O
can	O
not	O
bind	O
the	O
catalytic	B-protein
subunit	I-protein
,	O
but	O
not	O
by	O
other	O
constructs	O
of	O
p85	B-protein
.	O


In	O
contrast	O
,	O
several	O
mutant	O
p85	B-protein
alleles	O
had	O
dramatic	O
effects	O
on	O
NFAT	B-protein
activation	O
.	O


Analysis	O
of	O
phosphotyrosine-containing	B-protein
proteins	I-protein
bound	O
to	O
truncated	O
p85	B-protein
constructs	I-protein
revealed	O
cooperative	O
binding	O
of	O
the	O
two	B-protein
SH2	I-protein
domains	I-protein
but	O
no	O
apparent	O
differences	O
between	O
the	O
N-	B-protein
and	I-protein
C-	I-protein
terminal	I-protein
SH2	I-protein
domains	I-protein
.	O


Wortmannin	O
did	O
not	O
interfere	O
with	O
NFAT	B-protein
activation	O
,	O
although	O
it	O
inhibited	O
PI3-K	B-protein
and	O
Erk2	B-protein
activation	O
in	O
the	O
same	O
experiment	O
.	O


We	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
the	O
PML/RARalpha	B-protein
fusion	I-protein
protein	I-protein
is	O
specifically	O
expressed	O
in	O
the	O
myeloid-promyelocytic	B-cell_type
lineage	I-cell_type
.	O


During	O
their	O
first	O
year	O
of	O
life	O
,	O
all	O
the	O
PML/	O
RARalpha	B-protein
transgenic	O
mice	O
have	O
an	O
abnormal	O
hematopoiesis	O
that	O
can	O
best	O
be	O
described	O
as	O
a	O
myeloproliferative	O
disorder	O
.	O


Constitutive	O
and	O
inducible	O
protein/DNA	O
interactions	O
of	O
the	O
IFN-gamma	B-DNA
promoter	I-DNA
in	O
vivo	O
were	O
detected	O
in	O
all	O
T	B-cell_type
cells	I-cell_type
tested	O
.	O


Interestingly	O
,	O
an	O
inducible	O
footprint	O
between	O
-183	B-DNA
and	I-DNA
-196	I-DNA
was	O
consistently	O
observed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
CD45RA	B-cell_type
and	I-cell_type
CD45R0	I-cell_type
T	I-cell_type
helper	I-cell_type
subsets	I-cell_type
upon	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate+	O
phytohemagglutinin	B-protein
(	O
PMA+	O
PHA	B-protein
)	O
that	O
was	O
highly	O
sensitive	O
to	O
treatment	O
with	O
corticosteroids	O
.	O


We	O
propose	O
a	O
model	O
where	O
basal	O
transcription	O
is	O
maintained	O
by	O
binding	O
of	O
various	O
transcription	B-protein
factors	I-protein
to	O
the	O
IFN-gamma	B-DNA
promoter	I-DNA
,	O
whereas	O
PMA+	O
PHA	B-protein
-inducible	O
IFN-gamma	B-protein
transcription	O
in	O
CD45R0	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
binding	O
of	O
AP-1	B-protein
to	O
the	O
C-site	B-DNA
.	O


ZEBRA	B-protein
is	O
also	O
indispensable	O
for	O
viral	O
replication	O
and	O
binds	O
directly	O
to	O
the	O
EBV	O
lytic	O
origin	O
of	O
replication	O
.	O


The	O
tissue-specific	B-DNA
core	I-DNA
promoter	I-DNA
structure	I-DNA
is	O
apparently	O
conserved	O
in	O
other	O
T-cell-specifically	B-DNA
expressed	I-DNA
genes	I-DNA
such	O
as	O
the	O
CD4	B-DNA
gene	I-DNA
.	O


The	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
mimics	O
PAM	B-cell_type
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
and	O
sensitivity	O
to	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O


We	O
utilized	O
THP-1	B-cell_line
cells	I-cell_line
to	O
examine	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
macrophage	O
activation	O
.	O


The	O
antagonistic	O
effects	O
of	O
gamma-IFN	B-protein
are	O
not	O
merely	O
restricted	O
to	O
enzymatic	O
activities	O
.	O


CIITA	B-protein
is	O
a	O
positive	O
regulator	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	O
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex-negative	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Cyclin	B-protein
A	I-protein
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	B-protein
CD2	I-protein
+	O
CD28	B-protein
whereas	O
stimulation	O
by	O
anti	B-protein
CD2	I-protein
or	O
anti	B-protein
CD28	I-protein
alone	O
was	O
not	O
effective	O
.	O


They	O
bind	O
in	O
vitro	O
respectively	O
ATF-1	B-protein
and	O
NF-Y	B-protein
proteins	I-protein
.	O


Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	B-protein
CD2	I-protein
+	O
anti	B-protein
CD28	I-protein
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O


T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
alpha	I-protein
and	O
delta	O
gene	O
segments	O
are	O
organized	O
within	O
a	O
single	O
genetic	O
locus	O
but	O
are	O
differentially	O
regulated	O
during	O
T	O
cell	O
development	O
.	O


Cells	O
in	O
the	O
B	O
series	O
with	O
4C	O
DNA	O
content	O
(	O
100B	O
and	O
200B	O
)	O
also	O
differed	O
from	O
the	O
A	B-cell_line
series	I-cell_line
4C	I-cell_line
cells	I-cell_line
by	O
the	O
absence	O
of	O
DNA	O
binding	O
by	O
the	O
full-length	O
Sp1	B-protein
transcription	B-protein
factor	I-protein
.	O


These	O
results	O
show	O
that	O
the	O
initial	O
steps	O
in	O
the	O
1	O
,	O
25D3	O
signaling	O
pathway	O
are	O
intact	O
in	O
B	O
series	O
resistant	O
cells	O
and	O
lead	O
to	O
the	O
appearance	O
of	O
early	O
markers	O
of	O
monocytic	O
differentiation	O
.	O


Tat	O
also	O
superactivates	O
the	O
HIV-1	B-DNA
promoter	I-DNA
through	O
a	O
TAR	B-DNA
-independent	O
mechanism	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha-induced	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	B-protein
)	O
-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
inhibitors	O
of	O
Tat	B-protein
and	O
NF-kappa	B-protein
B	I-protein
cooperatively	O
down-regulate	O
this	O
Tat	B-protein
-mediated	O
LTR	B-DNA
superactivation	O
.	O


There	O
are	O
other	O
elements	O
regulating	O
IL-4	B-DNA
gene	I-DNA
expression	O
,	O
however	O
,	O
and	O
the	O
relative	O
importance	O
of	O
these	O
recently	O
identified	O
proteins	O
has	O
yet	O
to	O
be	O
determined	O
.	O


Previous	O
reports	O
have	O
suggested	O
the	O
CD28	B-protein
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
up-regulating	O
the	O
activity	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
AP-1	B-protein
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
/Rel	I-protein
family	I-protein
members	I-protein
as	O
well	O
as	O
an	O
uncharacterized	B-protein
transcription	I-protein
factor	I-protein
called	O
CD28	B-protein
response	O
complex	O
.	O


Recent	O
studies	O
suggest	O
that	O
the	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	B-DNA
promoter	I-DNA
proximal	I-DNA
AP-1-binding	I-DNA
site	I-DNA
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O


BOB.1/OBF.1	B-protein
is	O
a	O
transcriptional	B-protein
coactivator	I-protein
that	O
is	O
constitutively	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
interacts	O
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	B-protein
factors	I-protein
.	O


Thus	O
,	O
BOB.1/OBF.1	B-protein
is	O
a	O
transcriptional	B-protein
coactivator	I-protein
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type-specific	O
gene	O
expression	O
.	O


It	O
is	O
hypothesized	O
that	O
individuals	O
who	O
differ	O
in	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
may	O
also	O
differ	O
in	O
the	O
expression	O
of	O
certain	O
cAMP-dependent	B-DNA
genes	I-DNA
.	O


In	O
this	O
study	O
,	O
using	O
a	O
chromogenic	O
assay	O
,	O
we	O
have	O
shown	O
thrombin	B-protein
generation	O
by	O
apoptotic	B-cell_type
VSMCs	I-cell_type
expressing	O
c-myc	B-protein
(	O
VSMC-myc	B-cell_line
)	O
with	O
an	O
area	O
under	O
the	O
thrombin	B-protein
-generation	O
curve	O
(	O
AUC	O
)	O
of	O
305	O
+/-	O
17	O
nmol	O
x	O
min/L	O
and	O
a	O
peak	O
thrombin	B-protein
(	O
PT	O
)	O
of	O
154	O
+/-	O
9	O
nmol/L	O
.	O


The	O
thrombin	B-protein
-generating	O
potential	O
of	O
the	O
apoptotic	B-cell_line
VSMC-myc	I-cell_line
cells	I-cell_line
was	O
greater	O
than	O
that	O
of	O
unactivated	B-cell_type
platelets	I-cell_type
(	O
P	O
=	O
.003	O
for	O
AUC	O
;	O
P	O
=	O
.0002	O
for	O
PT	O
)	O
and	O
similar	O
to	O
calcium-ionophore	O
activated	B-cell_type
platelets	I-cell_type
(	O
AUC	O
of	O
332	O
+/-	O
15	O
nmol	O
x	O
min/L	O
,	O
P	O
=	O
.3	O
;	O
PT	O
of	O
172	O
+/-	O
8	O
nmol/L	O
,	O
P	O
=	O
.2	O
)	O
.	O


IL-4	B-protein
induces	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
and	O
IgE	B-protein
isotype	I-protein
switching	O
in	O
B	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
gammac	B-protein
chain	I-protein
deficiency	O
.	O


Elf-1	B-protein
is	O
a	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
belongs	O
to	O
the	O
ETS	B-protein
protein	I-protein
family	I-protein
.	O


It	O
can	O
bind	O
to	O
DNA	O
target	O
sequences	O
within	O
a	O
variety	O
of	O
cytokine	B-DNA
genes	I-DNA
.	O


This	O
Tax1	B-protein
-induced	O
activation	O
of	O
cellular	B-DNA
genes	I-DNA
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T-cell	O
transformation	O
by	O
HTLV-I	O
.	O


To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	B-protein
-inducible	O
transcriptional	O
pathway	O
in	O
T-cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	B-protein
mutants	I-protein
with	O
different	O
trans-activating	O
phenotypes	O
into	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
by	O
retroviral	O
vectors	O
.	O


Importantly	O
,	O
despite	O
high	O
ligand	O
binding	O
affinity	O
,	O
the	O
prototypic	O
dissociated	O
compound	O
,	O
RU24858	O
,	O
acted	O
as	O
a	O
weak	O
agonist	O
and	O
did	O
not	O
efficiently	O
antagonize	O
dexamethasone-induced	O
transcription	O
in	O
transfected	B-cell_type
cells	I-cell_type
.	O


Phorbol	O
ester	O
treatment	O
of	O
a	O
pre-B	B-cell_line
cell	I-cell_line
line	I-cell_line
up-regulated	O
CD19	B-protein
expression	O
,	O
induced	O
Egr-1	B-protein
,	O
and	O
enhanced	O
the	O
footprint	O
over	O
the	O
GC	O
box	O
.	O


Early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
and	O
E47	B-protein
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O


Multiple	O
functionally	O
important	O
EBF	B-DNA
and	I-DNA
E47	I-DNA
binding	I-DNA
sites	I-DNA
were	O
identified	O
in	O
the	O
lambda5	B-DNA
promoter/enhancer	I-DNA
region	I-DNA
,	O
indicating	O
that	O
lambda5	B-DNA
is	O
a	O
direct	O
genetic	O
target	O
for	O
these	O
transcription	B-protein
factors	I-protein
.	O


The	O
common	B-protein
gamma-chain	I-protein
(	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
)	O
is	O
a	O
functional	O
component	O
of	O
the	O
IL-4R	B-protein
,	O
yet	O
cells	O
lacking	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
are	O
able	O
to	O
respond	O
to	O
IL-4	B-protein
.	O


An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
,	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O


To	O
test	O
this	O
latter	O
possibility	O
,	O
a	O
chimeric	B-protein
receptor	I-protein
containing	O
the	O
extracellular	B-protein
domain	I-protein
of	O
c-kit	B-protein
(	O
the	O
stem	B-protein
cell	I-protein
factor	I-protein
(	I-protein
SCF	I-protein
)	I-protein
receptor	I-protein
)	O
and	O
the	O
cytoplasmic	B-protein
and	I-protein
transmembrane	I-protein
domains	I-protein
of	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
was	O
generated	O
.	O


Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
IL-4R	B-protein
alpha	I-protein
cytoplasmic	I-protein
domain	I-protein
is	O
sufficient	O
to	O
activate	O
JAK-1	B-protein
and	O
STAT6	B-protein
and	O
to	O
induce	O
expression	O
of	O
IL-4	B-DNA
target	I-DNA
genes	I-DNA
,	O
thus	O
identifying	O
a	O
mechanism	O
by	O
which	O
IL-4	B-protein
signaling	O
can	O
proceed	O
in	O
the	O
absence	O
of	O
JAK-3	B-protein
and	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
.	O


Dibutyryl	O
cAMP	O
also	O
increased	O
c-fos	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
,	O
and	O
levels	O
remained	O
elevated	O
even	O
after	O
12	O
hr	O
of	O
treatment	O
.	O


Inhibition	O
of	O
binding	O
by	O
anti-P	B-protein
selectin	I-protein
antibodies	I-protein
reduced	O
the	O
effect	O
of	O
activated	B-cell_type
platelets	I-cell_type
on	O
cytokine	B-protein
production	O
.	O


Triggering	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
by	O
the	O
anti-HLA-DR	B-protein
monoclonal	I-protein
antibody	I-protein
(	I-protein
mAb	I-protein
)	I-protein
L243	I-protein
significantly	O
(	O
P	O
<	O
0.05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
by	O
the	O
non-Hodgkin	B-cell_type
's	I-cell_type
lymphoma	I-cell_type
cells	I-cell_type
Ri-I	B-cell_line
,	O
Ci-I	B-cell_line
,	O
and	O
Sc-I	B-cell_line
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
Raji	I-cell_line
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF-alpha	B-protein
release	O
by	O
the	O
pre-B	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
Nalm-6	B-cell_line
and	O
BV173	B-cell_line
.	O


Transcription	B-protein
factor	I-protein
GATA-3	I-protein
is	O
differentially	O
expressed	O
in	O
murine	B-cell_line
Th1	I-cell_line
and	I-cell_line
Th2	I-cell_line
cells	I-cell_line
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	B-DNA
gene	I-DNA
.	O


Using	O
homologous	O
recombination	O
,	O
both	O
EKLF	B-DNA
alleles	I-DNA
in	O
murine	B-cell_line
embryonic	I-cell_line
stem	I-cell_line
(	I-cell_line
ES	I-cell_line
)	I-cell_line
cells	I-cell_line
were	O
inactivated	O
.	O


The	O
ratio	O
of	O
adult	B-RNA
beta-globin/alpha-globin	I-RNA
mRNA	I-RNA
in	O
the	O
mutant	B-cell_line
ES	I-cell_line
cells	I-cell_line
was	O
1/15	O
of	O
that	O
in	O
wild-type	B-cell_type
ES	I-cell_type
cells	I-cell_type
.	O


We	O
show	O
for	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
primary	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	O
nuclear	O
translocation	O
of	O
the	O
Rel	B-protein
proteins	I-protein
c-Rel	B-protein
,	O
RelA/p65	B-protein
and	O
NF-kappa	B-protein
B1/p50	I-protein
,	O
whereas	O
the	O
nuclear	O
appearance	O
of	O
RelB	B-protein
remains	O
unaffected	O
.	O


For	O
purposes	O
of	O
comparison	O
,	O
microglia	B-cell_type
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF-kappa	B-protein
B	I-protein
inducer	O
.	O


Glucocorticoid-mediated	O
repression	O
of	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	O
arteritis-SCID	B-protein
chimeras	I-protein
.	O


Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large-sized	O
arteries	O
.	O


Defective	O
survival	O
and	O
activation	O
of	O
thymocytes	B-cell_type
in	O
transgenic	O
mice	O
expressing	O
a	O
catalytically	B-protein
inactive	I-protein
form	I-protein
of	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
.	O


Because	O
transgene	O
expression	O
was	O
regulated	O
by	O
the	O
proximal	B-DNA
promoter	I-DNA
of	O
the	O
murine	B-DNA
lck	I-DNA
gene	I-DNA
and	O
this	O
promoter	O
is	O
inactivated	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
exit	O
the	O
thymus	O
,	O
the	O
mutant	B-protein
hCaMKIV	I-protein
is	O
not	O
present	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Whereas	O
the	O
pathway	O
responsible	O
for	O
this	O
latter	O
role	O
is	O
yet	O
to	O
be	O
elucidated	O
,	O
it	O
is	O
unlikely	O
to	O
include	O
CREB	B-protein
phosphorylation	O
.	O


This	O
gene	O
,	O
SRG3	B-DNA
,	O
showed	O
a	O
significant	O
sequence	O
homology	O
to	O
SWI3	B-DNA
,	O
a	O
yeast	B-DNA
transcriptional	I-DNA
activator	I-DNA
,	O
and	O
its	O
human	B-DNA
homolog	I-DNA
BAF155	I-DNA
.	O


The	O
expression	O
of	O
anti-sense	B-protein
RNA	I-protein
to	O
SRG3	B-RNA
mRNA	I-RNA
in	O
a	O
thymoma	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
S49.1	B-cell_line
,	O
reduced	O
the	O
expression	O
level	O
of	O
the	O
SRG3	B-protein
protein	I-protein
,	O
and	O
decreased	O
the	O
apoptotic	O
cell	O
death	O
induced	O
by	O
glucocorticoids	O
.	O


Rapid	O
and	O
strong	O
induction	O
of	O
promoter	O
activity	O
was	O
lost	O
in	O
constructs	O
with	O
a	O
mutant	B-DNA
AP-1	I-DNA
element	I-DNA
;	O
however	O
,	O
at	O
16-96	O
h	O
post-PMA	O
,	O
the	O
mutant	B-DNA
collagenase-1	I-DNA
promoter	I-DNA
displayed	O
AP-1	B-protein
independent	O
PMA-mediated	O
transactivation	O
.	O


Our	O
findings	O
suggest	O
that	O
distinct	O
regulatory	B-DNA
elements	I-DNA
,	O
acting	O
somewhat	O
independently	O
of	O
each	O
other	O
,	O
control	O
expression	O
of	O
collagenase-1	B-protein
.	O


It	O
has	O
been	O
recently	O
claimed	O
that	O
polymorphism	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
influences	O
several	O
aspects	O
of	O
calcium	O
and	O
bone	O
metabolism	O
.	O


The	O
concentration	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
was	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-7	O
)	O
g/g	O
of	O
total	O
RNA	O
in	O
cell-sorted	B-cell_type
monocytes	I-cell_type
and	O
in	O
in	B-cell_type
vitro	I-cell_type
activated	I-cell_type
lymphocytes	I-cell_type
,	O
but	O
only	O
10	O
(	O
-12	O
)	O
g/g	O
of	O
total	O
mRNA	O
in	O
resting	O
lymphocytes	B-cell_type
,	O
establishing	O
that	O
the	O
VDR	B-RNA
mRNA	I-RNA
determined	O
by	O
our	O
method	O
in	O
PBMCs	B-cell_type
is	O
due	O
to	O
constitutive	O
expression	O
in	O
monocytes	B-cell_type
.	O


Following	O
an	O
initial	O
genotype	O
screening	O
of	O
85	O
normal	O
volunteers	O
by	O
polymerase	O
chain	O
reaction	O
or	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
analysis	O
,	O
14	O
individuals	O
with	O
the	O
Bb	O
genotype	O
,	O
12	O
with	O
the	O
bb	O
genotype	O
,	O
and	O
12	O
with	O
the	O
BB	O
genotype	O
were	O
selected	O
.	O


This	O
gene	O
,	O
originally	O
named	O
AML1	B-DNA
,	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	B-DNA
gene	I-DNA
runt	I-DNA
that	O
controls	O
early	O
events	O
in	O
fly	O
embryogenesis	O
.	O


Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	B-cell_type
and	I-cell_type
adult	I-cell_type
hematopoietic	I-cell_type
populations	I-cell_type
shows	O
several	O
runt	B-protein
isoforms	I-protein
.	O


Our	O
data	O
indicate	O
that	O
although	O
PBSC	B-cell_type
harvests	O
collected	O
after	O
consolidation	O
chemotherapy	O
are	O
contaminated	O
by	O
leukemic	B-cell_type
cells	I-cell_type
,	O
the	O
degree	O
of	O
leukemic	O
cell	O
contamination	O
decreases	O
with	O
repeated	O
cycles	O
of	O
chemotherapy	O
.	O


Furthermore	O
,	O
the	O
MRD	O
in	O
PBSC	B-cell_type
harvests	O
is	O
less	O
than	O
in	O
the	O
corresponding	O
bone	O
marrow	O
obtained	O
on	O
the	O
day	O
of	O
the	O
PBSC	B-cell_type
collection	O
.	O


However	O
,	O
a	O
substantial	O
decrease	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
was	O
seen	O
following	O
autologous	O
PBSCT	O
.	O


Exogenous	O
recombinant	B-protein
Tat	I-protein
protein	I-protein
was	O
also	O
able	O
to	O
upregulate	O
c-fos	B-DNA
promoter	I-DNA
activity	O
in	O
serum-activated	O
Jurkat	O
and	O
U937	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
endogenous	O
c-fos	B-RNA
mRNA	I-RNA
expression	O
and	O
c-Fos	B-protein
protein	O
synthesis	O
in	O
both	O
serum-activated	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
primary	B-cell_type
PBMC	I-cell_type
.	O


Cytokines	B-protein
control	O
growth	O
,	O
differentiation	O
,	O
death	O
,	O
and	O
function	O
of	O
cells	O
of	O
lymphocytic	B-cell_type
,	I-cell_type
hemopoietic	I-cell_type
systems	I-cell_type
,	O
and	O
together	O
with	O
nerve	B-cell_type
cells	I-cell_type
provide	O
a	O
pertinent	O
model	O
to	O
study	O
intercellular	O
communications	O
and	O
intercellular	O
signal	O
networks	O
.	O


Tissue	B-protein
factor	I-protein
(	O
TF	O
)	O
expression	O
by	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O


The	O
two	O
AP-1	B-DNA
sites	I-DNA
bound	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
in	O
both	O
unstimulated	B-cell_type
and	I-cell_type
LPS-stimulated	I-cell_type
cells	I-cell_type
.	O


Synergistic	O
transactivation	O
of	O
the	O
LPS	B-DNA
response	I-DNA
element	I-DNA
in	O
Drosophila	B-cell_line
Schneider	I-cell_line
cells	I-cell_line
by	O
coexpression	O
of	O
c-Fos	B-protein
,	O
c-Jun	B-protein
,	O
c-Rel	B-protein
,	O
and	O
p65	B-protein
or	O
c-Jun	B-protein
and	O
p65	B-protein
required	O
the	O
transactivation	B-protein
domains	I-protein
of	O
c-Jun	B-protein
and	O
p65	B-protein
.	O


These	O
data	O
indicated	O
that	O
c-Fos	B-protein
/c-Jun	B-protein
,	O
c-Rel	B-protein
/p65	B-protein
,	O
and	O
Sp1	B-protein
regulate	O
TF	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O


The	O
GH-induced	O
inhibitory	O
effect	O
was	O
also	O
observed	O
using	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O


The	O
capacity	O
of	O
GH	O
to	O
inhibit	O
LPS-induced	O
TNF-alpha	B-protein
production	O
by	O
monocytes	B-cell_type
without	O
altering	O
other	O
pathways	O
leading	O
to	O
TNF-alpha	B-protein
production	O
may	O
be	O
of	O
potential	O
relevance	O
in	O
septic	O
shock	O
,	O
since	O
GH	O
is	O
available	O
for	O
clinical	O
use	O
.	O


Nuclear	B-protein
factor-kappaB	I-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
stimulated	O
with	O
lipopolysaccharide	O
is	O
inhibited	O
by	O
fibroblast	O
conditioned	O
medium	O
and	O
exogenous	O
PGE2	O
.	O


On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	O
inhibit	O
NF-kappaB	B-protein
activation	O
by	O
LPS	O
.	O


Immunoblot	O
and	O
flow	O
cytometry	O
analysis	O
revealed	O
a	O
limited	O
proteolysis	O
of	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
the	O
alphaIIb	B-protein
subunit	I-protein
heavy	I-protein
chain	I-protein
(	O
alphaIIbH	B-protein
)	O
,	O
as	O
judged	O
by	O
the	O
disappearance	O
of	O
the	O
epitope	O
for	O
the	O
monoclonal	B-protein
antibody	I-protein
PMI-1	I-protein
.	O


The	O
malignant	B-cell_type
cells	I-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
contain	O
a	O
reciprocal	O
chromosomal	O
translocation	O
that	O
fuses	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	O
)	O
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O


PMLRAR	O
alpha	O
transgenic	O
mice	O
exhibited	O
impaired	O
neutrophil	O
maturation	O
early	O
in	O
life	O
,	O
which	O
progressed	O
at	O
a	O
low	O
frequency	O
over	O
the	O
course	O
of	O
several	O
months	O
to	O
overt	O
APL	O
.	O


The	O
APL	O
recapitulated	O
features	O
of	O
the	O
human	O
disease	O
,	O
including	O
a	O
response	O
to	O
retinoic	O
acid	O
.	O


Hypermethylation	O
within	O
the	O
promoters	B-DNA
of	O
some	O
genes	O
appear	O
to	O
be	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
neoplasia	O
(	O
ER	B-DNA
,	O
P15	B-DNA
)	O
,	O
while	O
other	O
genes	O
seem	O
to	O
become	O
methylated	O
during	O
the	O
progression	O
of	O
leukemias	O
(	O
HIC1	O
,	O
c-abl	O
)	O
.	O


Using	O
the	O
yeast	O
two-hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B-protein
,	O
we	O
isolated	O
the	O
B	B-protein
subunit	I-protein
of	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF-Y	B-protein
from	O
a	O
HeLa	B-DNA
cDNA	I-DNA
library	I-DNA
.	O


Further	O
,	O
Tax1	B-protein
coimmunoprecipitated	O
with	O
NF-Y	B-protein
from	O
nuclear	O
extracts	O
of	O
HTLV-1-transformed	B-cell_type
cells	I-cell_type
,	O
providing	O
evidence	O
for	O
in	O
vivo	O
interaction	O
of	O
Tax1	B-protein
and	O
NF-YB	B-protein
.	O


In	O
addition	O
,	O
mutation	O
of	O
the	O
Y-box	B-DNA
element	I-DNA
alone	O
abrogated	O
Tax1	B-protein
-mediated	O
activation	O
.	O


In	O
murine	B-cell_line
Ba/F3	I-cell_line
cells	I-cell_line
transfected	O
with	O
the	O
human	B-protein
G-CSFR	I-protein
and	O
NFS-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
the	O
murine	B-protein
G-CSFR	I-protein
,	O
G-CSF	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Tyk2	B-protein
.	O


Activation	O
of	O
the	O
Jak	B-protein
-Stat	B-protein
pathway	O
correlates	O
with	O
proliferative	O
signaling	O
by	O
the	O
G-CSFR	B-protein
and	O
requires	O
the	O
membrane-proximal	B-protein
box	I-protein
1	I-protein
PXP	I-protein
motif	I-protein
,	O
which	O
is	O
conserved	O
in	O
members	O
of	O
the	O
cytokine	B-protein
receptor	I-protein
superfamily	I-protein
.	O


The	O
activation	O
of	O
transcriptional	B-protein
factor	I-protein
c-Fos/c-Jun	O
AP-1	B-protein
is	O
essential	O
for	O
normal	O
T	B-cell_type
cell	I-cell_type
responsiveness	O
and	O
is	O
often	O
impaired	O
in	O
T	B-cell_type
cells	I-cell_type
during	O
aging	O
.	O


Furthermore	O
,	O
the	O
nuclear	B-protein
protein	I-protein
complexes	I-protein
binding	O
the	O
SRE	B-DNA
motif	I-DNA
induced	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	B-protein
response	I-protein
factor	I-protein
and	O
Elk-1	B-protein
pointing	O
toward	O
age-related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
distinct	O
from	O
c-jun/AP-1	B-protein
.	O


These	O
results	O
suggest	O
that	O
underlying	O
aberrancies	O
in	O
the	O
induction	O
of	O
c-fos/c-jun	B-DNA
as	O
well	O
as	O
their	O
nuclear	B-protein
regulatory	I-protein
proteins	I-protein
may	O
contribute	O
to	O
the	O
age-related	O
impairments	O
of	O
AP-1	B-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Investigating	O
cytokines	B-protein
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL-6	B-protein
production	O
is	O
augmented	O
by	O
RA	O
.	O


Total	O
mRNA	B-RNA
was	O
extracted	O
from	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
using	O
RT-PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL-2	B-protein
and	O
RA	B-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
-	O
alpha	B-RNA
,	O
beta	B-RNA
,	O
gamma	B-RNA
mRNA	I-RNA
were	O
determined	O
.	O


We	O
and	O
others	O
have	O
shown	O
that	O
SAA	B-protein
gene	O
is	O
induced	O
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O


Cytomegalovirus	B-DNA
immediate	I-DNA
early	I-DNA
genes	I-DNA
upregulate	O
interleukin-6	B-protein
gene	O
expression	O
.	O


METHODS	O
:	O
THP-1	B-cell_line
cells	I-cell_line
,	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
.	O


RESULTS	O
:	O
Interleukin-6	B-protein
protein	I-protein
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS-stimulated	B-cell_line
control	I-cell_line
cells	I-cell_line
.	O


An	O
additional	O
complex	O
composed	O
of	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
heterodimers	I-protein
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	B-cell_type
.	O


Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	B-cell_type
and	O
MDMs	B-cell_type
.	O


However	O
,	O
the	O
intensity	O
of	O
p65	B-protein
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	B-cell_type
from	O
the	O
medulla	O
.	O


With	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
the	O
function	O
of	O
context-dependent	B-protein
activation	I-protein
domains	I-protein
,	O
we	O
cloned	O
ALY	B-protein
,	O
a	O
novel	O
LEF-1-interacting	B-protein
protein	I-protein
.	O


We	O
overexpressed	O
AML1a	B-protein
(	O
without	O
the	O
transcription-activating	B-protein
domain	I-protein
)	O
and	O
AML1b	B-protein
(	O
with	O
the	O
domain	O
)	O
proteins	O
in	O
K562	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
which	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
hemoglobin-producing	B-cell_type
cells	I-cell_type
and	O
megakaryocytes	B-cell_type
.	O


The	O
AML1a-transfected	B-cell_line
K562	I-cell_line
cells	I-cell_line
had	O
a	O
reduced	O
capacity	O
to	O
differentiate	O
in	O
the	O
presence	O
of	O
sodium	O
n-butyrate	O
but	O
not	O
in	O
the	O
presence	O
of	O
other	O
inducers	O
,	O
such	O
as	O
hemin	O
,	O
1-beta-D-arabinofuranosylcytosine	O
,	O
and	O
herbimycin	O
A	O
.	O


We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B-protein
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
from	O
the	O
ER-positive	B-cell_line
MCF-7	I-cell_line
and	O
the	O
ER-negative	B-cell_line
MDA-MB-231	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	B-protein
-negative	O
phenotype	O
of	O
some	O
tumors	O
.	O


IL-4	B-protein
is	O
secreted	O
by	O
activated	O
Th2	B-cell_type
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	B-cell_type
Th	I-cell_type
cells	I-cell_type
toward	O
the	O
Th2	B-cell_type
phenotype	I-cell_type
.	O


In	O
the	O
mouse	B-cell_line
Th2	I-cell_line
D10	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
human	B-cell_line
Th2	I-cell_line
clones	I-cell_line
,	O
POS-1	B-protein
(	O
designated	O
POS-1b	B-protein
)	O
contains	O
NF-IL6beta	B-protein
,	O
Jun	B-protein
,	O
and	O
NF-ATc/p	B-protein
.	O


Germline	B-protein
transcripts	I-protein
initiate	O
from	O
promoters	B-DNA
upstream	O
of	O
the	O
immunoglobulin	B-DNA
switch	I-DNA
region	I-DNA
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O


BSAP	B-protein
is	O
unique	O
among	O
the	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
epsilon	O
germline	B-DNA
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	B-protein
switching	O
.	O


Two	O
sets	O
of	O
independent	O
evidences	O
are	O
presented	O
here	O
that	O
demonstrate	O
a	O
biological	O
relevance	O
for	O
this	O
model	O
.	O


Antibodies	O
recognizing	O
double-stranded	O
DNA	O
were	O
confined	O
to	O
patients	O
with	O
frequent	O
polyomavirus	O
reactivations	O
.	O


Transcription	B-protein
factors	I-protein
required	O
for	O
lymphoid	O
lineage	O
commitment	O
.	O


Using	O
various	O
constructs	O
expressing	O
a	O
lacZ	B-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
intact	O
or	O
three	O
deleted	O
forms	O
of	O
HIV-1	B-DNA
LTR	I-DNA
,	O
we	O
obtained	O
evidence	O
that	O
the	O
kappaB	B-DNA
regulatory	I-DNA
elements	I-DNA
located	O
in	O
the	O
U3	B-DNA
region	I-DNA
are	O
involved	O
in	O
cell-to-cell	O
activation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
.	O


Cell-to-cell	O
contact	O
activation	O
of	O
NF-kappaB	B-protein
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	O
not	O
correlated	O
with	O
a	O
significant	O
decrease	O
of	O
cellular	B-protein
inhibitor	I-protein
kappaB	I-protein
alpha	I-protein
.	O


NAC	O
was	O
also	O
effective	O
in	O
diminishing	O
germline	B-DNA
C	O
epsilon	O
transcription	O
,	O
and	O
its	O
potency	O
was	O
higher	O
in	O
cultures	O
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
mAb	I-protein
than	O
in	O
those	O
stimulated	O
with	O
IL-4	B-protein
alone	O
.	O


We	O
have	O
compared	O
the	O
action	O
on	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
of	O
two	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O


By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse-treatment	O
with	O
6	O
microM	O
ICRF-193	O
.	O


However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O


By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O


When	O
used	O
at	O
differentiation-inducing	O
concentrations	O
,	O
both	O
topoisomerase	B-protein
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP-1	B-protein
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide-treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193-treated	B-cell_type
cells	I-cell_type
.	O


It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O


The	O
onset	O
of	O
both	O
processes	O
was	O
found	O
to	O
be	O
closely	O
paralleled	O
by	O
,	O
and	O
dependent	O
on	O
,	O
IkappaB-alpha	B-protein
degradation	O
.	O


Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3/BCL6	B-protein
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non-B	O
NHL	O
.	O


In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
LAZ3/BCL6	B-protein
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O


The	O
LAZ3/BCL6	B-RNA
transcript	I-RNA
was	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O


Hence	O
,	O
the	O
expression	O
of	O
LAZ3/BCL6	B-protein
does	O
not	O
correlate	O
to	O
malignancy	O
,	O
but	O
reflects	O
the	O
origin	O
of	O
B	B-cell_type
cells	I-cell_type
from	O
the	O
germinal	O
centers	O
.	O


Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro-inflammatory	B-protein
mediators	I-protein
and	O
adhesion	B-protein
molecules	I-protein
.	O


However	O
,	O
the	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	B-cell_type
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O


When	O
B10	O
mice	O
were	O
inoculated	O
multiple	O
times	O
either	O
i.p	O
.	O


Platelet/endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
PECAM-1	B-protein
)	O
is	O
a	O
130-kD	B-protein
member	I-protein
of	O
the	O
Ig	B-DNA
gene	I-DNA
superfamily	I-DNA
that	O
is	O
expressed	O
on	O
platelets	B-cell_type
,	O
endothelial	B-cell_type
cells	I-cell_type
,	O
and	O
certain	O
leukocyte	B-cell_type
subsets	I-cell_type
.	O


Within	O
this	O
region	O
,	O
a	O
19-bp	B-DNA
nuclear	I-DNA
factor	I-DNA
binding	I-DNA
site	I-DNA
(	O
-570	B-DNA
to	I-DNA
-552	I-DNA
)	O
was	O
characterized	O
by	O
DNase	B-protein
I	I-protein
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O


This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	B-DNA
regulatory	I-DNA
region	I-DNA
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	B-DNA
gene	I-DNA
.	O


Mutations	O
which	O
abrogated	O
the	O
gene-suppressive	O
activity	O
of	O
NRE	B-DNA
gamma	I-DNA
prevented	O
RFX1	B-protein
from	O
binding	O
to	O
NRE	B-DNA
gamma	I-DNA
.	O


In	O
CRF	O
patients	O
,	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
6.04	O
+/-	O
2.35	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
3.49	O
+/-	O
1.72	O
nM	O
,	O
respectively	O
,	O
while	O
those	O
in	O
PBMC	B-cell_type
of	O
the	O
GC-resistant	O
group	O
were	O
5.13	O
+/-	O
2.31	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.04	O
+/-	O
1.62	O
nM	O
,	O
respectively	O
.	O


IL-2	B-protein
superinduction	O
by	O
Tat	B-protein
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
was	O
mediated	O
by	O
the	O
CD28-responsive	B-DNA
element	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
was	O
exclusively	O
dependent	O
on	O
the	O
29	B-protein
amino	I-protein
acids	I-protein
encoded	O
by	O
the	O
second	B-DNA
exon	I-DNA
of	I-DNA
Tat	I-DNA
.	O


Most	O
patients	O
will	O
respond	O
but	O
a	O
few	O
patients	O
respond	O
less	O
to	O
these	O
drugs	O
.	O


CONCLUSIONS	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
topical	O
fluticasone	O
propionate	O
in	O
patients	O
with	O
rhinitis	O
and	O
allergy	O
to	O
house	O
dust	O
mite	O
is	O
not	O
correlated	O
with	O
the	O
characteristics	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O


The	O
replacement	O
of	O
p50	B-protein
homodimers	I-protein
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	B-cell_type
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O


Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
lymphocytic	I-cell_type
cells	I-cell_type
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	B-protein
cytokine	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O


Interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
is	O
expressed	O
primarily	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Here	O
we	O
identified	O
an	O
inducible	O
T	B-DNA
cell-specific	I-DNA
enhancer	I-DNA
14	O
kb	O
upstream	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
that	O
responded	O
to	O
activation	O
of	O
T	B-protein
cell	I-protein
receptor	I-protein
signaling	O
pathways	O
.	O


We	O
suggest	O
that	O
the	O
T	O
cell-specific	O
expression	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	B-protein
and	I-protein
NFAT	I-protein
family	I-protein
proteins	I-protein
.	O


Inefficient	O
DNA	O
replication	O
is	O
also	O
found	O
in	O
another	O
monocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line


Activation	O
of	O
Ras	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
by	O
terminal	B-protein
complement	I-protein
complexes	I-protein
is	O
G	B-protein
protein	I-protein
dependent	O
.	O


Both	O
C5b-9	B-protein
and	O
C5b-7	B-protein
,	O
but	O
not	O
C5b6	B-protein
,	O
increased	O
Raf-1	B-protein
kinase	O
activity	O
maximum	O
3.3-fold	O
at	O
2	O
min	O
and	O
2.8-fold	O
at	O
5	O
min	O
,	O
respectively	O
.	O


ERK1	B-protein
activity	O
was	O
2-fold	O
increased	O
by	O
C5b-9	B-protein
at	O
2	O
min	O
and	O
by	O
C5b-7	B-protein
at	O
10	O
min	O
,	O
over	O
the	O
C5b6	B-protein
level	O
.	O


The	O
role	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
on	O
TCC	B-protein
-inducible	O
mitotic	O
signaling	O
was	O
evaluated	O
by	O
assessing	O
DNA	O
synthesis	O
and	O
activator	B-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
DNA-binding	O
activity	O
.	O


The	O
MAPK/ERK-specific	O
inhibitor	O
PD	O
098	O
,	O
059	O
abolished	O
the	O
C5b-9	B-protein
-induced	O
DNA	O
synthesis	O
.	O


Overexpression	O
of	O
beta-adrenergic	O
receptor	O
kinase	O
1	O
carboxyl-terminal	O
peptide	O
in	O
JY25	B-cell_line
cells	I-cell_line
also	O
inhibited	O
Raf-1	B-protein
and	O
ERK1	B-protein
activity	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
G	O
betagamma	O
subunits	O
in	O
the	O
signal	O
transduction	O
generated	O
through	O
activation	O
of	O
MAPK	B-protein
pathway	O
by	O
TCC	B-protein
assembly	O
in	O
the	O
plasma	O
membrane	O
.	O


Spontaneous	O
occurrence	O
of	O
early	O
region	O
1A	O
reiteration	O
mutants	O
of	O
type	O
5	O
adenovirus	O
in	O
persistently	B-cell_type
infected	I-cell_type
human	I-cell_type
T-lymphocytes	I-cell_type
.	O


In	O
this	O
report	O
,	O
we	O
demonstrate	O
a	O
functional	O
correlate	O
of	O
DQA1	O
polymorphism	O
.	O


T	B-cell_type
cells	I-cell_type
infiltrating	O
a	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
lesion	O
from	O
a	O
HLA	O
DQ	O
2	O
,	O
7	O
individual	O
yielded	O
a	O
virus-specific	B-cell_line
CD4+	I-cell_line
clone	I-cell_line
restricted	O
by	O
DQ2	B-protein
.	O


The	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
is	O
constitutive	O
in	O
professional	B-cell_type
antigen	I-cell_type
presenting	I-cell_type
cells	I-cell_type
(	O
APCs	B-cell_type
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	B-cell_type
APCs	I-cell_type
(	O
e.g	O
.	O
fibroblasts	B-cell_type
)	O
.	O


Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	B-protein
in	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
since	O
over-expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	B-RNA
class	I-RNA
II	I-RNA
mRNA	I-RNA
expression	O
.	O


Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
pTh	I-cell_type
)	I-cell_type
cells	I-cell_type
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	B-cell_type
cells	I-cell_type
(	O
eTh1	B-cell_type
and	O
eTh2	B-cell_type
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	B-protein
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O


Regulation	O
of	O
NFAT	B-protein
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	B-cell_type
or	O
eTh2	B-cell_type
.	O


c-Rel	B-protein
is	O
a	O
target	O
of	O
pentoxifylline-mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O


However	O
,	O
induction	O
of	O
NF-AT	B-protein
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c-Rel	B-protein
induction	O
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O


We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	B-protein
region	I-protein
of	O
the	O
HTLV-III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL-2	B-protein
-driven	O
T	O
cell	O
proliferation	O
.	O


BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T-cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O


The	O
Pax-5	B-DNA
gene	I-DNA
is	O
alternatively	O
spliced	O
during	O
B-cell	O
development	O
.	O


The	O
Syk	B-protein
-mediated	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
-induced	O
MAPK	B-protein
activation	O
was	O
detectable	O
within	O
1	O
min	O
of	O
receptor	O
stimulation	O
and	O
peaked	O
at	O
3-5	O
min	O
.	O


For	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
to	O
mount	O
a	O
host	O
defence	O
response	O
to	O
infection	O
,	O
they	O
must	O
recognize	O
products	O
of	O
microbial	O
pathogens	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
the	O
endotoxin	O
secreted	O
by	O
Gram-negative	O
bacteria	O
.	O


The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
or	O
long-term	B-cell_line
cultured	I-cell_line
NK	I-cell_line
clones	I-cell_line
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
measured	O
by	O
gel	O
retardation	O
.	O


On	O
electromobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
a	O
single	O
E2F-DNA	B-protein
binding	I-protein
complex	I-protein
was	O
detected	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
which	O
was	O
shown	O
to	O
contain	O
E2F-4	B-protein
,	O
DP-1	B-protein
and	O
p130	B-protein
,	O
indicating	O
that	O
all	O
quiescent	B-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
have	O
the	O
same	O
complex	O
.	O


Examination	O
of	O
18	O
AML	O
samples	O
by	O
EMSA	O
revealed	O
the	O
presence	O
of	O
E2F	B-protein
binding	O
and	O
no	O
gross	O
abnormalities	O
were	O
detected	O
.	O


Associated	O
with	O
its	O
inhibitor	O
,	O
I	B-protein
kappaB	I-protein
,	O
NF-kappaB	B-protein
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O


Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	B-protein
kappaB	I-protein
is	O
proteolyzed	O
and	O
NF-kappaB	B-protein
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O


The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	B-protein
kappaB	I-protein
inactivation	O
remain	O
poorly	O
understood	O
.	O


Analysis	O
of	O
the	O
redox	O
status	O
of	O
1.3E2	B-cell_line
does	O
not	O
reveal	O
any	O
difference	O
from	O
wild-type	B-cell_line
70Z/3	I-cell_line
.	O


Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	B-protein
kappaB	I-protein
molecules	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
and	O
the	O
recently	O
identified	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
,	O
are	O
not	O
degraded	O
in	O
the	O
1.3E2	B-cell_line
cell	O
line	O
following	O
stimulation	O
.	O


In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	B-protein
kappaB	I-protein
alpha	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
,	O
and	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
degradation	O
.	O


In	O
order	O
to	O
evaluate	O
the	O
conditions	O
for	O
optimal	O
expression	O
and	O
immunogenicity	O
of	O
varicella-zoster	B-protein
virus	I-protein
(	I-protein
VZV	I-protein
)	I-protein
proteins	I-protein
in	O
a	O
herpes	O
simplex	O
virus-1	O
(	O
HSV-1	O
)	O
vector	O
,	O
we	O
selected	O
the	O
VZV	B-protein
glycoprotein	I-protein
E	I-protein
(	O
gE	B-protein
)	O
,	O
encoded	O
by	O
ORF	B-DNA
68	I-DNA
and	O
the	O
VZV	B-protein
product	I-protein
of	O
ORF	B-DNA
62	I-DNA
,	O
an	O
immediate-early	B-protein
major	I-protein
tegument	I-protein
protein	I-protein
(	O
IE62	B-protein
)	O
.	O


In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
active	O
form	O
of	O
NF-AT1	B-protein
is	O
also	O
present	O
in	O
the	O
nuclei	O
of	O
HTLV-I-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
express	O
the	O
Tax	B-protein
protein	I-protein
.	O


NFAT4/x	B-protein
was	O
very	O
weakly	O
expressed	O
in	O
unstimulated	O
cells	O
,	O
and	O
its	O
level	O
did	O
not	O
increase	O
upon	O
treatment	O
with	O
activating	O
agents	O
.	O


These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA-4	B-protein
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	B-DNA
gene	I-DNA
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA-binding	B-protein
proteins	I-protein
are	O
expressed	O
.	O


The	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
regulates	O
cytokine	B-DNA
gene	I-DNA
expression	O
in	O
T	B-cell_type
cells	I-cell_type
through	O
cis-acting	B-DNA
elements	I-DNA
located	O
in	O
the	O
promoters	B-DNA
of	O
several	O
cytokine	B-DNA
genes	I-DNA
.	O


We	O
also	O
show	O
that	O
calcineurin	B-protein
associated	O
with	O
the	O
N-terminal	B-protein
domain	I-protein
of	O
NFATx1	B-protein
at	O
multiple	B-protein
docking	I-protein
sites	I-protein
and	O
caused	O
a	O
reduction	O
of	O
size	O
,	O
indicative	O
of	O
dephosphorylation	O
,	O
in	O
NFATx1	B-protein
.	O


The	O
transcriptional	O
activity	O
of	O
the	O
IgH-luciferase	B-DNA
construct	I-DNA
was	O
induced	O
upon	O
ligation	O
of	O
the	O
full-length	B-protein
chimeric	I-protein
receptor	I-protein
but	O
not	O
by	O
truncated	B-protein
gp130	I-protein
receptors	I-protein
.	O


The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	B-cell_type
filarial	I-cell_type
antigen-specific	I-cell_type
T-cells	I-cell_type
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O


Cotransfection	O
with	O
a	O
transdominant	B-protein
negative	I-protein
mutant	I-protein
of	O
the	O
NF-YA	B-protein
subunit	I-protein
abolishes	O
the	O
transcriptional	O
activation	O
by	O
heme	B-protein
,	O
indicating	O
that	O
NF-Y	B-protein
plays	O
an	O
essential	O
role	O
in	O
this	O
activation	O
.	O


We	O
have	O
also	O
observed	O
a	O
differential	O
expression	O
of	O
the	O
NF-YA	B-protein
subunit	I-protein
in	O
heme-treated	O
and	O
control	O
FLCs	B-cell_line
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O


Concomitant	O
downregulation	O
of	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
activity	O
and	O
c-myc	B-DNA
expression	O
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	O
of	O
translocated	O
c-myc	B-DNA
.	O


Western	O
blot	O
analysis	O
of	O
the	O
NF-kappaB	B-protein
inhibitory	I-protein
subunits	I-protein
(	O
IkappaB	B-protein
)	O
demonstrated	O
that	O
both	O
IkappaB	B-protein
-alpha	O
proteolysis	O
and	O
p105	B-protein
processing	O
were	O
induced	O
by	O
the	O
treatment	O
.	O


NF-kappaB	B-protein
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O


Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p-bromophenacyl-bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF-kappaB	B-protein
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O


The	O
importance	O
of	O
TNF-alpha	B-protein
release	O
in	O
NF-kappaB	B-protein
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF-kappaB	B-protein
was	O
promoted	O
in	O
untreated	B-cell_line
cells	I-cell_line
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF-alpha	B-protein
and	O
HOCl	O
was	O
detected	O
.	O


Binding	O
to	O
RBD	B-protein
increased	O
from	O
undetectable	O
levels	O
in	O
resting	B-cell_type
platelets	I-cell_type
to	O
>	O
50	O
%	O
of	O
total	O
Rap1	B-protein
within	O
30	O
s	O
after	O
stimulation	O
.	O


Physical	O
interactions	O
between	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
play	O
an	O
important	O
role	O
in	O
their	O
cooperative	O
activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O


This	O
interaction	O
is	O
mediated	O
by	O
the	O
Ets	B-DNA
domain	I-DNA
of	O
Ets	B-protein
proteins	I-protein
and	O
the	O
C-terminal	O
region	O
of	O
the	O
Rel	O
homology	O
domains	O
of	O
NF-kappaB/NFAT	B-protein
proteins	I-protein
.	O


A	O
dominant-negative	O
mutant	O
of	O
NF-kappaB	B-protein
p50	I-protein
that	O
binds	O
DNA	O
but	O
fails	O
to	O
interact	O
with	O
Ets	B-protein
proteins	I-protein
inhibits	O
the	O
synergistic	O
activation	O
of	O
the	O
HIV-1	B-DNA
and	I-DNA
HIV-2	I-DNA
enhancers	I-DNA
by	O
NF-kappaB	B-protein
(	O
p50	B-protein
+	O
p65	B-protein
)	O
and	O
Ets-1	B-protein
,	O
suggesting	O
that	O
physical	O
interaction	O
between	O
Ets	B-protein
and	O
NF-kappaB	B-protein
proteins	I-protein
is	O
required	O
for	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	B-DNA
and	I-DNA
HIV-2	I-DNA
enhancers	I-DNA
.	O


From	O
AML1	B-DNA
gene	I-DNA
,	O
two	O
representative	O
forms	O
of	O
proteins	O
,	O
AML1a	B-protein
and	O
AML1b	B-protein
,	O
are	O
produced	O
by	O
an	O
alternative	O
splicing	O
.	O


We	O
considered	O
four	O
bZIP	B-protein
transcription	I-protein
factors	I-protein
as	O
candidates	O
for	O
this	O
putative	O
IL-3-regulated	B-protein
factor	I-protein
,	O
each	O
of	O
which	O
binds	O
avidly	O
to	O
the	O
DNA	B-DNA
consensus	I-DNA
sequence	I-DNA
recognized	O
by	O
E2A-HLF	B-protein
and	O
is	O
related	O
to	O
the	O
Caenorhabditis	B-protein
elegans	I-protein
CES-2	I-protein
(	O
cell	B-protein
death	I-protein
specification	I-protein
protein	I-protein
)	O
neuron-specific	B-protein
mediator	I-protein
of	I-protein
cell	I-protein
death	I-protein
.	O


Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O


In	O
addition	O
,	O
assay	O
of	O
PBMC	B-cell_type
by	O
the	O
adenovirus-specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O


A	O
specific	O
p38	B-protein
MAPk	I-protein
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	B-protein
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	B-protein
or	O
FMLP	B-protein
.	O


Northern	O
blot	O
analyses	O
indicated	O
a	O
highly	O
restricted	O
mRNA	O
expression	O
pattern	O
,	O
with	O
the	O
strongest	O
expression	O
occurring	O
in	O
promyelocyte	B-cell_line
and	I-cell_line
late-myeloblast-like	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
tumour	B-protein
associated	I-protein
cell	I-protein
surface	I-protein
antigen	I-protein
A6H	B-protein
is	O
costimulatory	O
for	O
human	B-cell_type
CD4+	I-cell_type
but	I-cell_type
not	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


As	O
a	O
first	O
step	O
in	O
understanding	O
the	O
mechanism	O
of	O
decreased	O
binding	O
affinity	O
in	O
New	O
World	O
primates	O
,	O
we	O
used	O
reverse	O
transcription-PCR	O
to	O
clone	O
the	O
glucocorticoid	B-protein
receptor	I-protein
from	O
squirrel	O
monkey	O
liver	O
and	O
have	O
compared	O
the	O
sequence	O
to	O
receptor	O
sequences	O
obtained	O
from	O
owl	O
monkey	O
liver	O
,	O
cotton-top	B-cell_line
tamarin	I-cell_line
B95-8	I-cell_line
cells	I-cell_line
,	O
and	O
human	B-cell_type
lymphocytes	I-cell_type
.	O


None	O
of	O
the	O
substitutions	O
in	O
the	O
ligand-binding	B-protein
domain	I-protein
matched	O
mutations	O
known	O
to	O
influence	O
binding	O
affinity	O
in	O
other	O
species	O
.	O


Shared	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
subunit	I-protein
within	O
the	O
human	B-protein
interleukin-7	I-protein
receptor	I-protein
complex	I-protein
.	O


The	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
subunit	I-protein
can	O
be	O
employed	O
in	O
receptor	B-protein
complexes	I-protein
for	O
IL-2	B-protein
,	I-protein
-4	I-protein
,	I-protein
-7	I-protein
,	I-protein
-9	I-protein
,	I-protein
and	I-protein
-15	I-protein
,	O
and	O
the	O
multiple	O
signaling	O
defects	O
that	O
would	O
result	O
from	O
a	O
defective	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
chain	I-protein
in	O
these	O
receptors	O
are	O
proposed	O
to	O
cause	O
the	O
severe	O
phenotype	O
of	O
X-SCID	O
patients	O
.	O


Furthermore	O
,	O
replacement	O
of	O
the	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
cytoplasmic	B-protein
domain	I-protein
by	O
a	O
severely	B-protein
truncated	I-protein
erythropoeitin	I-protein
receptor	I-protein
does	O
not	O
affect	O
measured	O
IL-7R	B-protein
signaling	O
events	O
.	O


Activated	O
NF-kappa	B-protein
B	I-protein
in	O
nuclear	O
extracts	O
was	O
measured	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
32P-labeled	B-DNA
probe	I-DNA
.	O


Northern	O
analyses	O
showed	O
similar	O
levels	O
of	O
two	O
elf-2	B-RNA
transcripts	I-RNA
(	O
3.5	O
kb	O
and	O
3.8	O
kb	O
)	O
in	O
all	O
tissues	O
except	O
thymus	O
.	O


The	O
expression	O
patterns	O
suggest	O
that	O
RBTN-2	B-protein
normally	O
interacts	O
equally	O
with	O
elf-2a	B-protein
and	O
elf-2b	B-protein
.	O


The	O
low	O
frequency	O
with	O
which	O
these	O
Ig-expressing	B-cell_line
hybrids	I-cell_line
are	O
recovered	O
,	O
along	O
with	O
the	O
fact	O
that	O
cell	O
fusions	O
can	O
lead	O
to	O
chromosome	O
loss	O
,	O
led	O
us	O
to	O
propose	O
that	O
this	O
rare	O
phenotype	O
was	O
due	O
to	O
loss	O
of	O
a	O
T-cell-derived	B-protein
chromosome	I-protein
encoding	I-protein
a	I-protein
factor	I-protein
or	O
factors	O
with	O
gene	O
silencing	O
activity	O
.	O


Here	O
we	O
show	O
that	O
deregulated	O
expression	O
of	O
a	O
single	O
viral	B-DNA
gene	I-DNA
,	O
ORF	B-DNA
50	I-DNA
,	O
which	O
encodes	O
a	O
transactivator	O
able	O
to	O
selectively	O
upregulate	O
delayed-early	B-DNA
viral	I-DNA
genes	I-DNA
,	O
suffices	O
to	O
disrupt	O
latency	O
and	O
induce	O
the	O
lytic	O
gene	O
cascade	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O


The	O
identification	O
of	O
this	O
gene	O
opens	O
the	O
way	O
to	O
studies	O
of	O
the	O
physiologic	O
mechanisms	O
controlling	O
reactvation	O
of	O
KSHV	O
from	O
latency	O
.	O


The	O
addition	O
of	O
rCTLA4Ig	O
,	O
which	O
blocks	O
CD28	B-protein
binding	O
to	O
its	O
ligand	O
,	O
to	O
the	O
cultures	O
decreased	O
IL-2	B-DNA
promoter	I-DNA
activation	O
by	O
>	O
80	O
%	O
.	O


B	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
have	O
a	O
pivotal	O
role	O
in	O
the	O
life	O
cycle	O
of	O
the	O
virus	O
.	O


Using	O
a	O
yeast	O
two-hybrid	O
screen	O
to	O
identify	O
Syk	B-protein
kinases-interacting	I-protein
proteins	I-protein
(	O
SKIPs	B-protein
)	O
,	O
we	O
isolated	O
3BP2	B-protein
,	O
an	O
Abl	B-protein
SH3-interacting	I-protein
protein	I-protein
of	O
unknown	O
function	O
.	O


In	O
addition	O
to	O
Zap-70	B-protein
,	O
the	O
3BP2	B-protein
SH2	I-protein
domain	I-protein
associated	O
in	O
vitro	O
with	O
LAT	B-protein
,	O
Grb2	B-protein
,	O
PLCgamma1	B-protein
,	O
and	O
Cbl	B-protein
from	O
activated	O
T	O
cell	O
lysates	O
.	O


Thus	O
,	O
3BP2	B-protein
is	O
an	O
important	O
adaptor	O
that	O
may	O
couple	O
activated	O
Zap-70/Syk	B-protein
to	O
a	O
LAT-containing	B-protein
signaling	I-protein
complex	I-protein
involved	O
in	O
TCR-mediated	O
gene	O
transcription	O
.	O


In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	B-cell_type
cells	I-cell_type
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases-1	B-protein
.	O


Results	O
indicate	O
that	O
TIMP-1-positive	B-cell_line
BL	I-cell_line
lines	I-cell_line
show	O
resistance	O
to	O
cold-shock-induced	O
apoptosis	O
.	O


Carboxylesterases	B-protein
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte/macrophage	O
system	O
.	O


Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	B-protein
and	O
IRBP	B-protein
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation-dependent	O
transcription	O
of	O
this	O
human	B-DNA
carboxylesterase	I-DNA
gene	I-DNA
.	O


During	O
fetal	O
development	O
,	O
it	O
is	O
required	O
at	O
the	O
earliest	O
stage	O
of	O
T	O
cell	O
and	O
B	O
cell	O
specification	O
.	O


In	O
the	O
adult	O
,	O
however	O
,	O
lymphoid	B-cell_type
lineages	I-cell_type
rely	O
on	O
Ikaros	B-DNA
at	O
distinct	O
phases	O
of	O
their	O
development	O
.	O


Its	O
activity	O
is	O
essential	O
for	O
the	O
generation	O
of	O
B	B-cell_type
cell	I-cell_type
but	O
not	O
of	O
T	B-cell_type
cell	I-cell_type
precursors	I-cell_type
,	O
although	O
the	O
differentiation	O
of	O
the	O
latter	O
is	O
not	O
normal	O
.	O


Changes	O
in	O
this	O
regulatory	O
network	O
may	O
reflect	O
differentiation	O
and	O
proliferation	O
adjustments	O
made	O
in	O
hemo-lymphoid	B-cell_type
progenitors	I-cell_type
and	O
precursors	B-cell_type
as	O
they	O
give	O
rise	O
to	O
the	O
cells	O
of	O
our	O
immune	O
system	O
.	O


STAT1	B-protein
pathway	O
is	O
involved	O
in	O
activation	O
of	O
caprine	O
arthritis-encephalitis	B-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
monocytes	B-cell_type
.	O


At	O
the	O
5	B-DNA
'	I-DNA
end	I-DNA
,	O
this	O
70-bp	B-DNA
IFN-gamma	I-DNA
response	I-DNA
element	I-DNA
contains	O
sequence	O
similarity	O
to	O
the	O
gamma	B-DNA
activated	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
.	O


Consistent	O
with	O
the	O
binding	O
data	O
,	O
the	O
same	O
mutations	O
in	O
the	O
GAS	B-DNA
element	I-DNA
eliminate	O
responsiveness	O
to	O
IFN-gamma	B-protein
in	O
the	O
context	O
of	O
both	O
a	O
functional	O
CAEV	B-DNA
LTR	I-DNA
and	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O


The	O
cellular	O
factor	O
that	O
binds	O
to	O
the	O
GAS	B-DNA
element	I-DNA
is	O
present	O
from	O
5	O
min	O
to	O
14	O
h	O
after	O
stimulation	O
with	O
IFN-gamma	B-protein
.	O


Transcription	B-protein
factor	I-protein
binding	O
to	O
the	O
core	B-DNA
promoter	I-DNA
of	O
the	O
human	B-DNA
monoamine	I-DNA
oxidase	I-DNA
B	I-DNA
gene	I-DNA
in	O
the	O
cerebral	O
cortex	O
and	O
in	O
blood	B-cell_type
cells	I-cell_type
.	O


Many	O
studies	O
show	O
that	O
monoamine	B-protein
oxidase	I-protein
B	I-protein
in	O
blood	B-cell_type
cells	I-cell_type
is	O
a	O
biological	O
marker	O
for	O
personality	O
characteristics	O
such	O
as	O
sensation	O
seeking	O
.	O


These	O
data	O
are	O
well	O
in	O
line	O
with	O
the	O
long-standing	O
notion	O
that	O
interindividual	O
differences	O
in	O
platelet	B-protein
monoamine	I-protein
oxidase	I-protein
may	O
represent	O
differences	O
in	O
expression	O
of	O
the	O
enzyme	O
rather	O
than	O
genotypic	O
variation	O
.	O


Enhanced	O
differentiation	O
of	O
HL-60	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
to	O
macrophages	B-cell_type
induced	O
by	O
ciprofibrate	O
.	O


In	O
particular	O
,	O
TRAF6	B-protein
interacted	O
with	O
membrane-proximal	B-protein
determinants	I-protein
distinct	O
from	O
those	O
binding	O
TRAFs	B-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
5	I-protein
.	O


When	O
this	O
membrane-proximal	B-protein
TRAF6	I-protein
interaction	I-protein
domain	I-protein
was	O
deleted	O
,	O
RANK	B-protein
-mediated	O
NF-kappaB	B-protein
signaling	O
was	O
completely	O
inhibited	O
while	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
activation	O
was	O
partially	O
inhibited	O
.	O


In	O
Th2	O
cells	O
,	O
IL-4	B-protein
gene	O
expression	O
is	O
tightly	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
by	O
the	O
coordinated	O
binding	O
of	O
multiple	O
transcription	B-protein
factors	I-protein
to	O
regulatory	O
elements	O
in	O
the	O
proximal	O
promoter	B-DNA
region	I-DNA
.	O


Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
members	I-protein
play	O
a	O
critical	O
role	O
in	O
regulating	O
IL-4	B-protein
transcription	O
and	O
interact	O
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O


The	O
molecular	O
mechanisms	O
by	O
which	O
IL-4	B-protein
induces	O
expression	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
are	O
not	O
known	O
,	O
although	O
the	O
IL-4-activated	B-protein
transcription	I-protein
factor	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
6	I-protein
(	O
Stat6	B-protein
)	O
is	O
required	O
for	O
this	O
effect	O
.	O


BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O


During	O
monocyte-to-macrophage	O
differentiation	O
,	O
the	O
cellular	O
content	O
of	O
vacuolar	B-protein
H+-ATPase	I-protein
(	O
V-ATPase	B-protein
)	O
increases	O
more	O
than	O
4-fold	O
.	O


c-Jun	O
and	O
GST-pi	O
expression	O
in	O
human	B-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O


The	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
not	O
related	O
to	O
clinical	O
or	O
laboratory	O
data	O
.	O


The	O
IL-3	B-protein
,	O
IL-5	B-protein
and	O
GM-CSF	B-protein
receptors	I-protein
share	O
a	O
common	B-protein
signal	I-protein
transducer	I-protein
that	O
possesses	O
no	O
intrinsic	B-protein
kinase	I-protein
domain	I-protein
.	O


Requirement	O
of	O
GATA-1	B-protein
and	O
p45	B-protein
NF-E2	I-protein
expression	O
in	O
butyric	O
acid-induced	O
erythroid	O
differentiation	O
.	O


Epstein-Barr	O
virus	O
,	O
a	O
human	O
gammaherpesvirus	O
,	O
possesses	O
a	O
unique	O
set	O
of	O
latent	B-DNA
genes	I-DNA
whose	O
constitutive	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
leads	O
to	O
cell	O
growth	O
transformation	O
.	O


The	O
upstream	O
regions	O
UAS3	B-DNA
(	O
-1168	B-DNA
to	I-DNA
-440	I-DNA
)	O
and	O
UAS2	B-DNA
(	O
-352	B-DNA
to	I-DNA
-264	I-DNA
)	O
both	O
functioned	O
in	O
a	O
cell	O
lineage-independent	O
manner	O
and	O
were	O
together	O
responsible	O
for	O
the	O
bulk	O
of	O
Wp	O
activity	O
in	O
non-B	B-cell_type
cells	I-cell_type
;	O
mutational	O
analysis	O
indicated	O
the	O
importance	O
of	O
a	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
in	O
UAS2	B-DNA
in	O
that	O
context	O
.	O


By	O
contrast	O
,	O
UAS1	B-DNA
(	O
-140	B-DNA
to	I-DNA
-87	I-DNA
)	O
was	O
B	O
cell	O
specific	O
and	O
was	O
the	O
key	O
determinant	O
of	O
the	O
promoter	O
's	O
increased	O
activity	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


AIDS-related	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
T	O
cell	O
lymphomas	O
are	O
emerging	O
as	O
a	O
new	O
,	O
distinct	O
histopathological	O
entity	O
.	O


Demonstration	O
of	O
EBV	B-RNA
mRNA	I-RNA
transcripts	I-RNA
encoding	O
immediate-early	B-protein
transcriptional	I-protein
transactivators	I-protein
in	O
EBV-infected	B-cell_type
T	I-cell_type
cells	I-cell_type
provides	O
the	O
first	O
evidence	O
for	O
a	O
possible	O
mechanism	O
whereby	O
EBV	O
could	O
contribute	O
to	O
T	O
cell	O
proliferation	O
and	O
EBV-associated	O
T	O
cell	O
malignancies	O
.	O


T-lineage	O
precursor	O
populations	O
from	O
the	O
adult	O
mouse	O
thymus	O
,	O
prior	O
to	O
T-cell	O
receptor	O
gene	O
rearrangement	O
,	O
display	O
a	O
capacity	O
to	O
produce	O
DC	B-cell_type
as	O
well	O
as	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
,	O
and	O
are	O
very	O
efficient	O
precursors	O
of	O
DC	B-cell_type
in	O
culture	O
.	O


These	O
lymphoid/DC	B-cell_type
precursors	I-cell_type
have	O
little	O
capacity	O
to	O
form	O
myeloid	B-cell_type
cells	I-cell_type
,	O
indicating	O
that	O
thymic	B-cell_type
DC	I-cell_type
are	O
a	O
lymphoid-related	O
rather	O
than	O
myeloid-related	B-cell_type
lineage	I-cell_type
.	O


DC	B-cell_type
can	O
develop	O
in	O
mutant	O
mice	O
lacking	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
provided	O
the	O
common	O
precursors	O
are	O
present	O
.	O


The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	B-cell_type
cells	I-cell_type
with	O
mutant	B-protein
TNFRI	I-protein
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	B-cell_type
cells	I-cell_type
to	O
activate	O
EC	B-cell_type


Ras	B-protein
-dependent	O
,	O
Ca2+-stimulated	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
by	O
a	O
constitutively	O
active	O
Cbl	B-protein
mutant	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O


As	O
a	O
first	O
step	O
toward	O
elucidating	O
the	O
function	O
of	O
Cbl	B-protein
in	O
TCR	B-protein
-initiated	O
signaling	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
wild-type	B-protein
Cbl	I-protein
or	O
a	O
transforming	O
Cbl	B-protein
mutant	I-protein
(	O
70Z/3	O
)	O
to	O
induce	O
transcriptional	O
activation	O
of	O
a	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
element	I-DNA
derived	O
from	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL2	I-DNA
)	I-DNA
promoter	I-DNA
in	O
transiently	O
cotransfected	O
Jurkat-TAg	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Additional	O
mapping	O
studies	O
indicated	O
that	O
defined	O
deletions	O
of	O
C-terminal	O
70Z/3	B-protein
sequences	O
affected	O
to	O
a	O
variable	O
degree	O
its	O
ability	O
to	O
stimulate	O
NFAT	B-protein
activity	O
.	O


These	O
results	O
implicate	O
Cbl	B-protein
in	O
Ras	B-protein
-dependent	O
signaling	O
pathways	O
which	O
lead	O
to	O
NFAT	B-protein
activation	O
.	O


Lipopolysaccharide	O
(	O
LPS	O
)	O
-prestimulated	O
and	O
untreated	O
THP-1	B-cell_line
cells	I-cell_line
were	O
cocultured	O
with	O
resting	B-cell_type
human	I-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVEC	B-cell_type
)	O
for	O
3	O
and	O
24	O
h	O
in	O
the	O
presence	O
of	O
colimycin	O
to	O
neutralize	O
LPS	O
traces	O
.	O


Addition	O
of	O
untreated	O
THP-1	B-cell_line
cells	I-cell_line
had	O
little	O
effect	O
on	O
HUVEC	B-cell_type
adhesiveness	O
.	O


Under	O
these	O
conditions	O
HUVEC	B-protein
adhesion	I-protein
molecules	I-protein
,	O
E-selectin	B-protein
,	O
VCAM-1	B-protein
and	O
ICAM-1	B-protein
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM-1	B-protein
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O


CD15	O
cross-linking	O
also	O
concomitantly	O
increased	O
interleukin-1	B-RNA
beta	I-RNA
(	I-RNA
IL-1	I-RNA
beta	I-RNA
)	I-RNA
mRNA	I-RNA
,	O
while	O
no	O
apparent	O
change	O
was	O
observed	O
in	O
the	O
levels	O
of	O
beta-actin	B-RNA
mRNA	I-RNA
,	O
indicating	O
specificity	O
.	O


To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	B-DNA
genes	I-DNA
by	O
CD15	O
engagement	O
,	O
a	O
CAT	O
plasmid	O
reporter	O
construct	O
containing	O
IL-1	B-DNA
beta	I-DNA
promoter/enhancer	I-DNA
sequences	I-DNA
was	O
introduced	O
into	O
MM6	B-cell_line
.	O


We	O
conclude	O
that	O
engagement	O
of	O
CD15	O
on	O
monocytes	O
results	O
in	O
monocyte	O
activation	O
.	O


CD2	B-protein
,	O
but	O
not	O
CD3	B-protein
,	O
cross-linking	O
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O


Both	O
CD2	B-protein
and	O
CD3	B-protein
cross-linking	O
increased	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O


The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS-related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O


Our	O
results	O
demonstrate	O
that	O
the	O
altered	O
CCAAT	B-DNA
box	I-DNA
(	O
CCAAC	O
)	O
and	O
the	O
lack	O
of	O
an	O
EKLF	B-DNA
binding	I-DNA
site	I-DNA
in	O
delta-globin	B-protein
contribute	O
to	O
its	O
low	O
level	O
of	O
expression	O
in	O
the	O
hAEC	B-cell_line
model	I-cell_line
as	O
well	O
.	O


The	O
lung	B-cell_type
macrophage	I-cell_type
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	B-protein
mediators	I-protein
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
the	O
chemokines	B-protein
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	I-protein
and	I-protein
-6	I-protein
,	O
and	O
matrix	B-protein
metalloproteinase-9	I-protein
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O


This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress-induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O


Signaling	O
pathways	O
mediated	O
by	O
the	O
TNF-	B-protein
and	I-protein
cytokine-receptor	I-protein
families	O
target	O
a	O
common	O
cis-element	B-DNA
of	O
the	O
IFN	B-DNA
regulatory	I-DNA
factor	I-DNA
1	I-DNA
promoter	I-DNA
.	O


We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	B-protein
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN	B-protein
-induced	O
IL-1beta	B-protein
response	O
.	O


The	O
integral	O
membrane	O
glycoprotein	B-protein
CD36	I-protein
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte-macrophages	B-cell_type
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36	B-protein
-Ox	O
LDL	O
interaction	O
are	O
unknown	O
.	O


We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF-kappaB	B-DNA
sequence	I-DNA
following	O
activation	O
of	O
CD36-producing	B-cell_line
CHO	I-cell_line
cells	I-cell_line
with	O
the	O
proinflammatory	B-protein
cytokine	I-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O


The	O
structural	O
organization	O
of	O
the	O
393	B-protein
amino	I-protein
acid	I-protein
long	I-protein
human	I-protein
TRAMP	I-protein
is	O
most	O
homologous	O
to	O
TNF	B-protein
receptor	I-protein
1	I-protein
.	O


IL-4	B-protein
and	O
IL-13	B-protein
up-regulated	O
the	O
expression	O
of	O
both	O
genomic	O
and	O
spliced	O
HIV	B-RNA
mRNA	I-RNA
in	O
monocytes	B-cell_type
cultured	O
on	O
Teflon	O
,	O
as	O
determined	O
by	O
Northern	O
analysis	O
and	O
p24	B-protein
Ag	I-protein
assay	O
.	O


Conversely	O
,	O
IL-4	B-protein
and	O
IL-13	B-protein
markedly	O
and	O
significantly	O
inhibited	O
HIV	O
replication	O
at	O
the	O
transcriptional	O
level	O
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
,	O
and	O
this	O
occurred	O
whether	O
these	O
cytokines	B-protein
were	O
added	O
before	O
or	O
after	O
HIV	O
infection	O
.	O


IL-4	B-protein
enhanced	O
CD11b	B-protein
,	O
but	O
inhibited	O
CD26	B-protein
expression	O
and	O
delayed	O
CD13	B-protein
loss	O
.	O


IL-10	B-protein
attenuated	O
LPS-stimulated	O
TNF-alpha	B-protein
production	O
(	O
297+/-54	O
;	O
p	O
<	O
.001	O
versus	O
LPS	O
alone	O
)	O
.	O


Therefore	O
in	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
role	O
of	O
glucocorticoid	B-protein
receptor/s	I-protein
(	O
GR	B-protein
)	O
characteristics	O
in	O
the	O
developing	O
of	O
these	O
abnormalities	O
in	O
patients	O
with	O
PCOS	O
.	O


Heterogeneous	O
expression	O
of	O
the	O
lipocalin	B-protein
NGAL	I-protein
in	O
primary	O
breast	O
cancers	O
.	O


When	O
breast	O
cancers	O
were	O
examined	O
for	O
NGAL	O
mRNA	O
and	O
protein	O
levels	O
,	O
they	O
were	O
found	O
to	O
exhibit	O
heterogeneous	O
expression	O
.	O


Interestingly	O
,	O
unlike	O
NRL	B-protein
in	O
rat	O
mammary	O
carcinomas	O
,	O
no	O
significant	O
association	O
between	O
NGAL	B-protein
expression	O
and	O
HER-2/neu	B-protein
activation	O
was	O
found	O
in	O
human	O
breast	O
tumors	O
.	O


In	O
contrast	O
,	O
a	O
significant	O
correlation	O
between	O
NGAL	B-protein
expression	O
in	O
breast	O
cancer	O
was	O
found	O
with	O
several	O
other	O
markers	O
of	O
poor	O
prognosis	O
,	O
including	O
estrogen	O
and	O
progesterone	B-protein
receptor	I-protein
-negative	O
status	O
and	O
high	O
proliferation	O
(	O
S-phase	O
fraction	O
)	O
.	O


Overexpression	O
of	O
BASH	B-protein
results	O
in	O
suppression	O
of	O
the	O
NF-AT	B-protein
activation	O
induced	O
by	O
BCR	B-protein
-cross-linking	O
.	O


StatG	B-protein
in	O
normal	B-cell_type
immature	I-cell_type
human	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
i.e	O
.	O
adult	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
was	O
composed	O
of	O
Stat3beta	B-protein
.	O


Because	O
this	O
region	O
of	O
Stat3alpha	B-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
,	O
our	O
findings	O
suggest	O
the	O
possibility	O
that	O
Stat3gamma	B-protein
may	O
be	O
transcriptionally	O
inactive	O
and	O
may	O
compete	O
with	O
Stat3alpha	B-protein
for	O
Stat3	B-DNA
binding	I-DNA
sites	I-DNA
in	O
these	O
terminally	B-cell_type
differentiated	I-cell_type
myeloid	I-cell_type
cells	I-cell_type


These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV-1	O
provirus	O
to	O
the	O
genome	O
of	O
T	B-cell_type
cell	I-cell_type
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	O
of	O
ICAM-1	B-protein
molecules	I-protein
.	O


Finally	O
,	O
it	O
was	O
observed	O
that	O
the	O
rate	O
of	O
decay	O
of	O
vimentin	B-RNA
mRNA	I-RNA
upon	O
actinomycin	O
D	O
administration	O
was	O
decreased	O
in	O
heat-	B-cell_line
and	I-cell_line
cadmium-pretreated	I-cell_line
cells	I-cell_line
in	O
comparison	O
to	O
untreated	B-cell_type
cells	I-cell_type
.	O


Since	O
the	O
AES	B-protein
proteins	I-protein
are	O
part	O
of	O
a	O
set	O
of	O
transcriptional	O
repressors	O
encoded	O
by	O
the	O
Enhancer	B-DNA
of	I-DNA
split	I-DNA
[	I-DNA
E	I-DNA
(	I-DNA
spl	I-DNA
)	I-DNA
]	I-DNA
genes	I-DNA
,	O
and	O
since	O
these	O
repressors	O
are	O
activated	O
to	O
suppress	O
cell	O
differentiation	O
in	O
response	O
to	O
Notch	B-protein
receptors	I-protein
signalling	O
,	O
the	O
AES	O
peptides	O
may	O
represent	O
a	O
novel	O
class	O
of	O
self-antigens	B-protein
that	O
deserve	O
further	O
consideration	O
as	O
tumor	B-protein
Ag	I-protein
in	O
epithelial	O
cancers	O
.	O


Our	O
data	O
suggest	O
that	O
stimulation	O
of	O
PML	B-DNA
expression	O
by	O
interferons	B-protein
and	O
IL-1	B-protein
may	O
account	O
for	O
upregulation	O
of	O
PML	B-protein
proteins	I-protein
observed	O
in	O
inflammatory	O
tissues	O
and	O
in	O
proliferative	O
states	O
.	O


Previously	O
we	O
demonstrated	O
that	O
heterologous	B-protein
activation	I-protein
domains	I-protein
can	O
fully	O
substitute	O
for	O
the	O
ZEBRA	B-protein
activation	I-protein
domain	I-protein
.	O


Their	O
mean	O
Kd	O
(	O
affinity	O
)	O
was	O
also	O
significantly	O
lower	O
than	O
that	O
found	O
in	O
the	O
healthy	O
controls	O
(	O
obese	O
Kd	O
:	O
2.92	O
+/-	O
0.84	O
nmol/l	O
,	O
control	O
Kd	O
:	O
4.55	O
+/-	O
0.67	O
nM	O
,	O
p	O
<	O
0.05	O
)	O
.	O


At	O
the	O
same	O
time	O
,	O
3-O-MG	O
transport	O
was	O
determined	O
in	O
the	O
same	O
subjects	O
.	O


These	O
results	O
indicated	O
that	O
,	O
in	O
abdominal	O
obesity	O
,	O
the	O
GR	B-protein
binding	O
capacity	O
in	O
MNL	B-cell_type
is	O
influenced	O
by	O
the	O
changes	O
in	O
glucose	O
transport	O
.	O


DNA	O
taken	O
from	O
families	O
with	O
an	O
asthmatic	O
proband	O
was	O
examined	O
for	O
base	O
exchanges	O
by	O
single-stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
.	O


The	O
Tpl-2	B-protein
kinase	I-protein
activates	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
and	O
induces	O
IL-2	B-protein
expression	O
in	O
T-cell	B-cell_line
lines	I-cell_line
.	O


Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
is	O
inhibited	O
by	O
mutant	B-protein
signaling	I-protein
molecules	I-protein
that	O
inhibit	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
or	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	B-protein
molecules	I-protein
that	O
activate	O
these	O
pathways	O
.	O


We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	B-protein
and	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
.	O


The	O
activation	O
of	O
both	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	I-DNA
were	O
shown	O
to	O
depend	O
on	O
signals	O
transduced	O
by	O
Raf1	B-protein
.	O


Since	O
the	O
activation	O
of	O
NFAT	B-protein
is	O
MAPK	B-protein
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
Tpl-2	B-protein
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B-protein
and	O
MEK2	B-protein
.	O


Experiments	O
in	O
COS-1	B-cell_line
and	O
EL-4	B-cell_line
cells	I-cell_line
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	B-protein
is	O
NF-kappaB	B-protein
.	O


While	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
NFAT	B-protein
delta418	I-protein
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	B-protein
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	B-protein
-mediated	O
NFAT	B-protein
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin-dependent	O
and	O
independent	O
pathways	O
.	O


Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	B-protein
or	O
Bcl-X	B-protein
(	I-protein
L	I-protein
)	I-protein
.	O


Representational	O
difference	O
analysis	O
has	O
been	O
used	O
to	O
isolate	O
cDNA	B-DNA
clones	I-DNA
corresponding	O
to	O
mRNA	B-RNA
species	I-RNA
activated	O
following	O
stable	O
expression	O
of	O
HOX11	B-protein
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
.	O


NF-X2	B-DNA
,	O
which	O
contains	O
members	O
of	O
the	O
AP-1/ATF/CREB	B-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
interacts	O
with	O
the	O
X2	B-DNA
box	I-DNA
(	O
5'-TGCGTCA-3	O
'	O
)	O
from	O
positions	O
-97	O
to	O
-91	O
in	O
the	O
DRA	B-DNA
promoter	I-DNA
.	O


In	O
sharp	O
contrast	O
,	O
in	O
B	B-cell_type
cells	I-cell_type
treated	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
strong	O
interactions	O
between	O
the	O
X2	B-DNA
box	I-DNA
and	O
NF-X2	B-DNA
containing	O
c-Fos	B-protein
were	O
observed	O
.	O


Immunofluorescence	O
studies	O
on	O
thymic	B-cell_type
populations	I-cell_type
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	B-DNA
DNA	I-DNA
elements	I-DNA
revealed	O
that	O
thymocytes	B-cell_type
control	O
the	O
CD4	B-DNA
gene	I-DNA
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Direct	O
suppression	O
of	O
Stat1	B-protein
function	O
during	O
adenoviral	O
infection	O
.	O


Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha-zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O


Dendritic	B-cell_type
cells	I-cell_type
and	O
autologous	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
a	O
series	O
of	O
density-gradient	O
centrifugations	O
or	O
magnetic	O
bead	O
separations	O
(	O
or	O
both	O
)	O
.	O


Three	O
VZV-susceptible	O
donors	O
were	O
tested	O
,	O
and	O
all	O
demonstrated	O
an	O
in	O
vitro	O
response	O
to	O
multiple	O
VZV	O
peptides	O
.	O


Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O


Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	B-protein
natural	I-protein
antibodies	I-protein
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O


At	O
variance	O
,	O
in	O
PAEC	B-cell_line
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF-kappa	B-protein
B	I-protein
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O


C5a	B-protein
and	O
C3a	B-protein
stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
resulted	O
in	O
nuclear	O
expression	O
of	O
a	O
DNA	O
binding	O
activity	O
with	O
specificity	O
to	O
the	O
kappaB	B-DNA
sequence	I-DNA
.	O


Thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
,	O
the	O
primary	O
physiological	O
regulator	O
of	O
platelet	O
production	O
,	O
was	O
initially	O
thought	O
to	O
be	O
a	O
lineage-specific	O
factor	O
acting	O
predominantly	O
on	O
megakaryocytopoiesis	O
.	O


Preclinical	O
and	O
clinical	O
studies	O
demonstrate	O
the	O
potential	O
use	O
of	O
TPO	B-protein
in	O
a	O
variety	O
of	O
contexts	O
,	O
but	O
it	O
is	O
too	O
early	O
to	O
evaluate	O
its	O
benefit	O
in	O
reducing	O
platelet	O
transfusion	O
.	O


Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	B-protein
and	O
the	O
LIM-only	B-DNA
protein	I-DNA
gene	I-DNA
(	O
LMO	B-DNA
)	O
are	O
regularly	O
coactivated	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
.	O


As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so-called	O
glucose	O
toxicity	O
to	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
,	O
we	O
induced	O
glycation	O
in	O
HIT-T15	B-cell_type
cells	I-cell_type
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D-ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O


In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	B-RNA
mRNA	I-RNA
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation-induced	B-cell_type
cells	I-cell_type
.	O


OBJECTIVE	O
:	O
The	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
or	O
inflammatory	O
response	O
at	O
the	O
transcriptional	O
level	O
.	O


CONCLUSION	O
:	O
Overall	O
,	O
the	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
may	O
play	O
a	O
central	O
part	O
in	O
the	O
activation	O
of	O
infiltrating	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O


The	O
rapid	O
expansion	O
of	O
the	O
number	O
of	O
women	O
now	O
suitable	O
for	O
X	O
inactivation	O
analysis	O
has	O
however	O
given	O
rise	O
to	O
new	O
controversies	O
,	O
one	O
of	O
the	O
more	O
troublesome	O
being	O
the	O
possibility	O
of	O
a	O
modification	O
of	O
the	O
pattern	O
of	O
X-	B-DNA
chromosome	I-DNA
inactivation	O
pattern	O
in	O
blood	B-cell_type
cells	I-cell_type
of	O
elderly	O
women	O
.	O


Type	B-protein
I	I-protein
IFNs	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
,	O
in	O
addition	O
to	O
IL-12	B-protein
,	O
have	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
human	O
,	O
but	O
not	O
mouse	O
,	O
Th	B-cell_type
cells	I-cell_type
.	O


However	O
,	O
restimulation	O
of	O
human	B-cell_line
Th2	I-cell_line
lines	I-cell_line
and	O
clones	O
in	O
the	O
presence	O
of	O
IFN-alpha	B-protein
does	O
not	O
induce	O
the	O
production	O
of	O
IFN-gamma	B-protein
.	O


These	O
results	O
suggest	O
that	O
activation	O
of	O
Stat4	B-protein
,	O
which	O
is	O
necessary	O
for	O
the	O
differentiation	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
into	O
polarized	O
Th1	B-cell_type
cells	I-cell_type
,	O
is	O
not	O
sufficient	O
to	O
induce	O
phenotype	O
reversal	O
of	O
human	B-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O


Molecular	O
cloning	O
of	O
FKHRL1P2	B-protein
,	O
a	O
member	O
of	O
the	O
developmentally	O
regulated	O
fork	B-protein
head	I-protein
domain	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O


Inhibition	O
of	O
Th1	O
development	O
mediated	O
by	O
GATA-3	B-protein
through	O
an	O
IL-4-independent	O
mechanism	O
.	O


Recently	O
,	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	B-protein
was	O
shown	O
to	O
be	O
selectively	O
expressed	O
in	O
Th2	O
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
and	O
to	O
augment	O
Th2-specific	B-protein
cytokines	I-protein
.	O


GATA-3	B-protein
inhibits	O
Th1	B-protein
cytokines	I-protein
by	O
a	O
cell-intrinsic	O
mechanism	O
that	O
is	O
not	O
dependent	O
on	O
IL-4	B-protein
and	O
that	O
may	O
involve	O
repression	O
of	O
IL-12	B-protein
signaling	O
.	O


These	O
domains	O
,	O
which	O
have	O
been	O
characterized	O
as	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
HSs	B-DNA
)	O
,	O
comprise	O
the	O
active	O
elements	O
of	O
the	O
LCR	B-DNA
.	O


Cloning	O
of	O
ARE-containing	B-DNA
genes	I-DNA
by	O
AU-motif-directed	O
display	O
.	O


These	O
motifs	O
are	O
regulatory	B-DNA
sequences	I-DNA
within	O
the	O
so-called	O
AU-rich	B-DNA
elements	I-DNA
(	O
AREs	B-DNA
)	O
often	O
found	O
in	O
3	B-DNA
'	I-DNA
untranslated	I-DNA
regions	I-DNA
of	O
genes	O
such	O
as	O
cytokines	B-protein
,	O
proto-oncogenes	B-DNA
,	O
and	O
transcription	B-protein
factors	I-protein
.	O


It	O
has	O
been	O
applied	O
to	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
a	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
to	O
isolate	O
59	B-DNA
cDNA	I-DNA
fragments	I-DNA
associated	O
to	O
activation	O
.	O


The	O
tissular	O
patterns	O
of	O
CIITA	O
and	O
MHC	O
class	O
II	O
gene	O
expression	O
are	O
tightly	O
correlated	O
:	O
CIITA	B-RNA
mRNA	I-RNA
is	O
highly	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
is	O
induced	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFN-gamma	B-protein
)	O
in	O
macrophage	B-cell_line
and	I-cell_line
epithelial	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


eGLs	B-cell_type
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O


In	O
group	B-cell_line
I	I-cell_line
BL	I-cell_line
cells	I-cell_line
,	O
containing	O
low	O
levels	O
of	O
NF-kappaB	B-protein
,	O
only	O
RBP	B-protein
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF-kappaB	B-protein
binding	O
could	O
be	O
demonstrated	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
containing	O
high	O
levels	O
of	O
activated	O
NF-kappaB	B-protein
.	O


Flow	O
cytometric	O
and	O
morphological	O
analyses	O
demonstrated	O
that	O
the	O
addition	O
of	O
CD70	O
transfectants	O
to	O
B	B-cell_line
cell	I-cell_line
cultures	I-cell_line
remarkably	O
promoted	O
differentiation	O
into	O
plasma	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
IL-4	B-protein
and	O
CD40	B-protein
signaling	O
.	O


Much	O
attention	O
has	O
focused	O
on	O
the	O
series	O
of	O
sequence	O
elements	O
upstream	O
of	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	I-DNA
in	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
LTR	B-DNA
including	O
the	O
Sp1	B-protein
and	O
NF-kappaB	B-protein
binding	B-DNA
sites	I-DNA
.	O


Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5'-untranslated	B-DNA
leader	I-DNA
region	I-DNA
(	O
5'-UTR	B-DNA
)	O
also	O
contains	O
important	O
transcriptional	B-DNA
elements	I-DNA
.	O


We	O
propose	O
that	O
the	O
inducible	B-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
5'-UTR	B-DNA
comprise	O
a	O
downstream	B-DNA
enhancer	I-DNA
domain	I-DNA
that	O
can	O
function	O
independent	O
of	O
,	O
or	O
in	O
concert	O
with	O
,	O
the	O
LTR	B-DNA
promoter	I-DNA
to	O
rapidly	O
increase	O
latent	O
proviral	O
transcription	O
in	O
response	O
to	O
cell	O
activation	O
signals	O
.	O


In	O
this	O
review	O
,	O
we	O
describe	O
the	O
host-cell	B-protein
transcription	I-protein
factors	I-protein
that	O
interact	O
with	O
the	O
5'-UTR	B-DNA
and	O
discuss	O
their	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
HIV-1	O
gene	O
expression	O
.	O


LOX-1	B-protein
is	O
an	O
endothelial	B-protein
receptor	I-protein
for	O
oxidized	B-protein
low-density	I-protein
lipoprotein	I-protein
that	O
plays	O
essential	O
roles	O
in	O
atherogenesis	O
.	O


Fluorescence	O
in	O
situ	O
hybridization	O
and	O
analyses	O
of	O
a	O
yeast	O
artificial	O
chromosome	O
contig	O
revealed	O
that	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
is	O
located	O
in	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
on	O
chromosome	B-DNA
12p12-p13	I-DNA
,	O
where	O
the	O
genes	O
of	O
the	O
natural	B-protein
killer	I-protein
cell	I-protein
receptors	I-protein
cluster	O
.	O


A	O
1753-bp	B-DNA
fragment	I-DNA
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
LOX-1	B-DNA
gene	I-DNA
had	O
a	O
functional	O
promoter	O
activity	O
.	O


This	O
region	O
contains	O
binding	B-DNA
sites	I-DNA
for	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
the	O
STAT	B-protein
family	I-protein
and	O
NF-IL6	B-protein
,	O
and	O
the	O
expression	O
of	O
LOX-1	B-protein
was	O
upregulated	O
by	O
several	O
cytokines	B-protein
.	O


Copyright	O
1998	O
Academic	O
Press	O
.	O


The	O
beta-casein	B-DNA
promoter	I-DNA
has	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
activation	O
of	O
STAT	B-protein
(	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	I-protein
5	I-protein
since	O
STAT5	B-protein
was	O
originally	O
found	O
as	O
a	O
mediator	O
of	O
PRL-inducible	O
beta-casein	B-protein
expression	O
.	O


IL-2	B-protein
-induced	O
beta-casein	B-protein
expression	O
was	O
enhanced	O
by	O
dexamethasone	O
,	O
and	O
this	O
synergistic	O
effect	O
of	O
Dexamethasone	O
requires	O
the	O
sequence	O
between	O
-155	B-DNA
and	I-DNA
-193	I-DNA
in	O
the	O
beta-casein	B-DNA
promoter	I-DNA
.	O


Coincidentally	O
,	O
a	O
deletion	O
of	O
this	O
region	O
enhanced	O
the	O
IL-2	B-protein
-induced	O
expression	O
of	O
beta-casein	B-protein
.	O


Expression	O
of	O
an	O
active	O
form	O
of	O
Ras	B-protein
,	O
Ras	B-protein
(	I-protein
G12V	I-protein
)	I-protein
,	O
suppressed	O
the	O
IL-2	B-protein
-induced	O
beta-casein	B-protein
and	O
OSM	B-protein
gene	O
expression	O
,	O
and	O
the	O
negative	O
effect	O
of	O
Ras	B-protein
is	O
mediated	O
by	O
the	O
region	O
between	O
-105	B-DNA
and	I-DNA
-193	I-DNA
in	O
the	O
beta-casein	B-DNA
promoter	I-DNA
.	O


Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	B-protein
signaling	I-protein
proteins	I-protein
,	O
including	O
Vav	B-protein
,	O
Cbl	B-protein
,	O
p85	B-protein
phosphoinositide	I-protein
3-kinase	I-protein
,	O
and	O
the	O
Src	B-protein
family	I-protein
kinases	I-protein
Lck	B-protein
and	O
Fyn	B-protein
.	O


Costimulation	O
through	O
CD28	B-protein
and/or	O
CD2	B-protein
did	O
not	O
modulate	O
the	O
CD3	B-protein
-dependent	O
phosphorylation	O
of	O
HS1	B-protein
.	O


RESULTS	O
:	O
Cord	O
lymphocytes	O
revealed	O
a	O
greater	O
proliferation	O
rate	O
with	O
PHA	B-protein
and	O
alphaCD3	B-protein
than	O
adult	O
lymphocytes	O
(	O
p	O
=	O
0.0081	O
and	O
0.0023	O
,	O
respectively	O
)	O
.	O


CONCLUSION	O
:	O
Although	O
cord	B-cell_type
lymphocyte	I-cell_type
proliferation	O
rates	O
were	O
significantly	O
greater	O
than	O
those	O
of	O
adult	O
lymphocytes	O
following	O
stimulation	O
,	O
lymphocyte	O
activation	O
,	O
as	O
analyzed	O
by	O
c-fos	O
and	O
c-jun	O
mRNA	O
expression	O
,	O
appears	O
similar	O
in	O
both	O
cord	O
and	O
adult	O
samples	O
.	O


Using	O
the	O
specific	O
MAPK	B-protein
/extracellular	O
signal-regulated	O
kinase	O
kinase	O
(	O
MAPK	O
kinase	O
)	O
inhibitor	O
PD98059	O
,	O
we	O
found	O
that	O
MAPK	B-protein
activation	O
is	O
necessary	O
for	O
FcR	B-protein
-dependent	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O


Accordingly	O
,	O
an	O
expanded	O
survey	O
in	O
lymphoid	O
malignancies	O
showed	O
that	O
BCL-6	B-protein
mutations	O
are	O
restricted	O
to	O
B	O
cell	O
tumors	O
displaying	O
GC	O
or	O
post-GC	O
phenotype	O
and	O
carrying	O
mutated	B-DNA
Ig	I-DNA
variable	I-DNA
heavy	I-DNA
chain	I-DNA
sequences	I-DNA
.	O


Since	O
neither	O
DNA	O
binding	O
nor	O
protein	O
dimerization	O
through	O
the	O
bZIP	B-protein
domain	I-protein
of	O
HLF	B-protein
is	O
required	O
for	O
this	O
effect	O
,	O
we	O
propose	O
mechanisms	O
whereby	O
protein-protein	O
interactions	O
with	O
the	O
amino-terminal	O
region	O
of	O
E2A	B-protein
allow	O
the	O
chimera	B-protein
to	O
act	O
as	O
a	O
transcriptional	O
cofactor	O
to	O
alter	O
the	O
expression	O
of	O
genes	O
regulating	O
the	O
apoptotic	O
machinery	O
in	O
pro-B	B-cell_type
cells	I-cell_type
.	O


Hepatocytes	O
achieve	O
an	O
efficient	O
hormonal	O
control	O
of	O
this	O
promoter	O
through	O
a	O
functional	O
interaction	O
between	O
the	O
estrogen	B-DNA
responsive	I-DNA
elements	I-DNA
and	O
a	O
promoter	B-DNA
proximal	I-DNA
region	I-DNA
upstream	O
of	O
the	O
TATA	B-DNA
box	I-DNA
,	O
which	O
is	O
characterized	O
by	O
a	O
high	O
density	O
of	O
binding	O
sites	O
for	O
the	O
transcription	B-protein
factors	I-protein
CTF/NF-1	B-protein
,	O
C/EBP	B-protein
and	O
HNF3	B-protein
.	O


Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	B-protein
and	O
STAT5b	B-protein
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O


A	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
CD95	B-DNA
(	I-DNA
APO-1/Fas	I-DNA
)	I-DNA
ligand	I-DNA
promoter	I-DNA
is	O
essential	O
for	O
responsiveness	O
to	O
TCR	B-protein
-mediated	O
activation	O
.	O


The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O


We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K+	B-protein
channels	I-protein
in	O
T	B-cell_type
cells	I-cell_type
by	O
progesterone	O
contributes	O
to	O
progesterone-induced	O
immunosuppression	O
.	O


Transgenic	O
mice	O
with	O
human	B-DNA
CD3epsilon	I-DNA
gene	I-DNA
have	O
been	O
shown	O
to	O
exhibit	O
early	O
arrest	O
of	O
T	O
cell	O
development	O
in	O
the	O
thymus	O
.	O


In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA-less	B-DNA
blr1	I-DNA
core	I-DNA
promoter	I-DNA
that	O
confer	O
cell	O
type-	O
and	O
differentiation-specific	O
expression	O
in	O
the	O
B	B-cell_type
cells	I-cell_type
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	B-DNA
promoter	I-DNA
region	I-DNA
(	O
-36	O
with	O
respect	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
)	O
,	O
a	O
NF-kappaB	B-DNA
motif	I-DNA
(	O
+44	O
)	O
,	O
and	O
a	O
noncanonical	B-DNA
octamer	I-DNA
motif	I-DNA
(	O
+157	O
)	O
.	O


CD4	B-DNA
promoter	I-DNA
transactivation	O
by	O
human	O
herpesvirus	O
6	O
.	O


Our	O
objective	O
was	O
to	O
identify	O
the	O
mechanisms	O
underlying	O
such	O
phenomena	O
.	O


Neutrophil	O
maturation	O
was	O
impaired	O
in	O
PEBP2betaMYH11	B-protein
transgenic	O
mice	O
.	O


Human	O
T	O
cell	O
leukemia	O
virus-I	O
(	O
HTLV-I	O
)	O
Tax	B-protein
-mediated	O
apoptosis	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
requires	O
an	O
enhanced	O
intracellular	O
prooxidant	O
state	O
.	O


Additional	O
stimulation	O
of	O
the	O
CD3	B-protein
/TCR	B-protein
pathway	O
enhances	O
the	O
oxidative	O
and	O
apoptotic	O
effects	O
.	O


However	O
,	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
anytime	O
during	O
the	O
first	O
18	O
h	O
of	O
steroid	O
treatment	O
was	O
as	O
effective	O
in	O
blocking	O
chromatin	O
fragmentation	O
as	O
inhibition	O
for	O
the	O
entire	O
period	O
,	O
suggesting	O
that	O
synthesis	O
of	O
a	O
component	O
with	O
a	O
rapid	O
turnover	O
rate	O
is	O
required	O
.	O


It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF-alpha	B-protein
transcription	O
via	O
a	O
Tat	B-protein
-induced	O
tar-independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF-kappaB	B-protein
activation	O
of	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O


We	O
determined	O
whether	O
Hsp70	B-protein
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	B-protein
transcription	I-protein
factor	I-protein
,	O
HSF	B-protein
.	O


Th1	O
and	O
Th2	O
effector	O
functions	O
and	O
their	O
development	O
are	O
attributable	O
to	O
their	O
distinct	O
cytokine	B-protein
expression	O
patterns	O
.	O


It	O
is	O
,	O
therefore	O
,	O
suggested	O
that	O
clarification	O
of	O
the	O
mechanisms	O
of	O
differential	O
gene	O
expression	O
in	O
Th1/Th2	B-cell_line
should	O
lead	O
to	O
rational	O
strategies	O
for	O
manipulating	O
pathological	O
immune	O
responses	O
.	O


Activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
mediated	O
by	O
the	O
T	O
cell	O
receptor	O
induces	O
a	O
series	O
of	O
biochemical	O
events	O
.	O


The	O
molecular	O
cloning	O
of	O
the	O
NFAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
facilitated	O
rapid	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signalling	O
mechanisms	O
that	O
control	O
the	O
activity	O
of	O
NFAT	B-protein
.	O


Northern	O
analysis	O
confirmed	O
that	O
expression	O
of	O
both	O
mRNAs	B-RNA
was	O
reduced	O
in	O
cells	O
with	O
decreased	O
numbers	O
of	O
VDR	B-protein
.	O


Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	O
in	O
17beta-HSD	B-protein
IV	I-protein
or	O
DNA-PK	B-RNA
(	I-RNA
CS	I-RNA
)	I-RNA
mRNA	I-RNA
levels	O
following	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	O
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O


Prostaglandin	O
E2	O
Up-regulates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
gene	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
via	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O


Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF-kappaB/Rel	B-protein
and	O
STAT	B-protein
proteins	I-protein
.	O


Low	O
CD3+CD28-induced	O
interleukin-2	B-protein
production	O
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


PDBu	O
+	O
iono	O
induced	O
equally	O
high	O
IL-2	B-protein
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate-bound	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
,	O
the	O
IL-2	B-protein
secretion	O
by	O
neonatal	B-cell_type
cells	I-cell_type
was	O
undetectable	O
and	O
adult	B-cell_type
cells	I-cell_type
produced	O
low	O
amounts	O
of	O
IL-2	B-protein
(	O
mean	O
331	O
+/-	O
86	O
pg/ml	O
)	O
.	O


The	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
to	O
anti-CD3-stimulated	B-cell_line
cells	I-cell_line
markedly	O
increased	O
IL-2	B-protein
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL-2	B-protein
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
respective	O
mean	O
values	O
:	O
385	O
+/-	O
109	O
pg/ml	O
and	O
4494	O
+/-	O
1199	O
pg/ml	O
)	O
.	O


As	O
NF-kappa	B-protein
B	I-protein
is	O
a	O
critical	O
transcription	B-protein
factor	I-protein
in	O
the	O
control	O
of	O
IL-2	B-protein
expression	O
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
T	I-cell_type
cells	I-cell_type
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI-reactive	O
fluorochrome	O
DCFH-DA	O
and	O
flow	O
cytometry	O
.	O


Our	O
results	O
suggest	O
that	O
reduced	O
IL-2	B-protein
production	O
by	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
specific	O
for	O
anti-CD3	B-protein
and	O
anti-CD3	B-protein
+	O
anti-CD28	B-protein
-mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI	O
-NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


CD30	B-protein
is	O
a	O
CD40-inducible	B-protein
molecule	I-protein
that	O
negatively	O
regulates	O
CD40-mediated	B-protein
immunoglobulin	I-protein
class	O
switching	O
in	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O


Switching	O
is	O
hampered	O
by	O
CD30	B-protein
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	B-protein
-mediated	O
NF-kappaB	B-protein
-dependent	O
transcriptional	O
activation	O
of	O
downstream	B-DNA
C	I-DNA
(	I-DNA
H	I-DNA
)	I-DNA
genes	I-DNA
.	O


But	O
many	O
puzzles	O
of	O
the	O
drugs	O
remain	O
.	O


What	O
is	O
the	O
role	O
of	O
CyA	O
in	O
the	O
activation	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
,	O
particularly	O
in	O
relationship	O
to	O
nephrotoxicity	O
and	O
fibrogenesis	O
?	O


Interleukin	B-protein
2	I-protein
and	I-protein
15	I-protein
activate	O
Stat3alpha	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Copyright	O
1998	O
Academic	O
Press	O
.	O


Transcriptional	O
regulation	O
of	O
lysosomal	B-protein
acid	I-protein
lipase	I-protein
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
AP-2	B-protein
.	O


Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O


LMP1	B-protein
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
one	O
through	O
interactions	O
with	O
TRAF	B-protein
proteins	I-protein
and	O
the	O
other	O
with	O
the	O
TRADD	B-protein
protein	I-protein
.	O


Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	B-protein
and	O
recruitment	O
of	O
neutrophils	B-cell_type
(	O
PMN	B-cell_type
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O


Intratracheal	O
instillation	O
of	O
IL-6	B-protein
alone	O
into	O
normal	O
rats	O
resulted	O
in	O
PMN	O
infiltration	O
into	O
lung	O
interstitium	O
and	O
alveoli	O
,	O
marked	O
elevation	O
of	O
bronchoalveolar	O
lavage	O
cellularity	O
,	O
and	O
increased	O
wet-to-dry	O
ratio	O
.	O


The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
alpha	I-protein
(	O
PPARalpha	B-protein
)	O
ligand	O
WY	O
14	O
,	O
643	O
does	O
not	O
interfere	O
with	O
leukotriene	O
B4	O
induced	O
adhesion	O
of	O
neutrophils	B-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
.	O


When	O
endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
WY	O
14	O
,	O
643	O
prior	O
to	O
activation	O
with	O
LTB4	O
(	O
or	O
fMLP	B-protein
,	O
IL-1beta	B-protein
or	O
TNFalpha	B-protein
,	O
as	O
controls	O
)	O
we	O
could	O
not	O
document	O
any	O
effect	O
on	O
the	O
number	O
of	O
adhering	B-cell_type
PMN	I-cell_type
or	O
duration	O
of	O
the	O
response	O
.	O


We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	B-cell_type
RBC	I-cell_type
with	O
cultured	O
endothelial	B-cell_type
cells	I-cell_type
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
(	O
CAMs	B-protein
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	B-cell_type
and	O
the	O
adherence	O
of	O
SS	B-cell_type
reticulocytes	I-cell_type
.	O


We	O
showed	O
that	O
the	O
interaction	O
of	O
SS	B-cell_type
RBC	I-cell_type
at	O
2	O
%	O
concentration	O
in	O
the	O
presence	O
of	O
multimers	O
of	O
von	B-protein
Willebrand	I-protein
factor	I-protein
(	O
vWf	B-protein
)	O
,	O
derived	O
from	O
endothelial	O
cell-derived	O
conditioned	O
medium	O
(	O
E-CM	O
)	O
with	O
cultured	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVEC	B-cell_line
)	O
,	O
resulted	O
in	O
a	O
fivefold	O
increased	O
formation	O
of	O
thiobarbituric	O
acid-reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
,	O
both	O
indicators	O
of	O
cellular	O
oxidant	O
stress	O
.	O


Additionally	O
,	O
preincubation	O
of	O
HUVEC	B-cell_line
with	O
a	O
synthetic	O
peptide	O
Arg-Gly-Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf	B-protein
-mediated	O
adhesion	O
of	O
SS	B-cell_type
RBC	I-cell_type
reduced	O
the	O
surface	O
expression	O
of	O
VCAM-1	B-protein
and	O
NF-kB	B-protein
activation	O
.	O


Furthermore	O
,	O
SS	B-cell_type
RBC	I-cell_type
-induced	O
oxidant	O
stress	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
transendothelial	O
migration	O
of	O
both	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
and	O
approximately	O
a	O
sixfold	O
increase	O
in	O
platelet-endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
PECAM-1	B-protein
)	O
phosphorylation	O
,	O
each	O
of	O
which	O
was	O
blocked	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	O
and	O
antioxidants	O
.	O


Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O


TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
were	O
detected	O
in	O
the	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O


Activation	O
of	O
NFkappaB	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
inducible	O
during	O
cytokine	B-protein
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	B-protein
activity	O
prior	O
to	O
therapy	O
.	O


Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	B-protein
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B-protein
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B-protein
levels	O
were	O
present	O
although	O
kappaB	B-protein
binding	O
was	O
not	O
inducible	O
.	O


Degenerate	O
primers	O
corresponding	O
to	O
the	O
TFIIIA	B-DNA
zinc-finger	I-DNA
consensus	I-DNA
amino	I-DNA
acid	I-DNA
sequences	I-DNA
and	O
to	O
the	O
POU-homeodomain	B-protein
and	O
POU-specific	B-protein
domain	I-protein
were	O
used	O
to	O
amplify	O
genes	O
on	O
the	O
basis	O
that	O
they	O
contained	O
similarities	O
in	O
structural	O
motifs	O
shared	O
within	O
these	O
families	O
of	O
transcription	B-protein
factors	I-protein
.	O


PCR	B-DNA
fragments	I-DNA
were	O
cloned	O
,	O
sequenced	O
,	O
clustered	O
into	O
homologous	O
groups	O
,	O
and	O
the	O
group	O
sequences	O
searched	O
on	O
the	O
GenBank	O
database	O
.	O


The	O
Oct	O
1	O
transcription	B-protein
factor	I-protein
,	O
and	O
a	O
very	O
close	O
homologue	O
,	O
KIAA0144	B-DNA
,	O
was	O
identified	O
using	O
the	O
POU	O
family	O
primers	O
.	O


Position	O
effect	O
of	O
translocations	O
involving	O
the	O
inactive	B-DNA
X	I-DNA
chromosome	I-DNA
:	O
physical	O
linkage	O
to	O
XIC/XIST	B-DNA
does	O
not	O
lead	O
to	O
long-range	O
de	O
novo	O
inactivation	O
in	O
human	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
.	O


We	O
have	O
analyzed	O
de	O
novo	O
radiation-induced	O
translocations	O
between	O
the	O
Xi	B-DNA
and	O
autosomes	B-DNA
to	O
study	O
the	O
maintenance	O
and	O
spreading	O
of	O
X-chromosome	B-DNA
inactivation	O
(	O
X	O
inactivation	O
)	O
in	O
relation	O
to	O
the	O
position	O
of	O
the	O
X-inactivation	O
center	O
(	B-DNA
XIC	I-DNA
)	I-DNA
/XIST	I-DNA
in	O
differentiated	B-cell_type
cells	I-cell_type
.	O


Interleukin-4	B-protein
and	I-protein
-13	I-protein
induce	O
upregulation	O
of	O
the	O
murine	O
macrophage	O
12/15-lipoxygenase	B-protein
activity	I-protein
:	O
evidence	O
for	O
the	O
involvement	O
of	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
.	O


The	O
IL-4-induced	B-protein
complex	I-protein
reacted	O
with	O
anti-STAT	B-protein
(	I-protein
signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
6	I-protein
,	O
resulting	O
in	O
a	O
supershift	O
whereas	O
the	O
formation	O
of	O
the	O
IFN-gamma-induced	B-protein
complex	I-protein
was	O
inhibited	O
by	O
anti-STAT	B-protein
1	I-protein
.	O


The	O
intermediate	O
complex	O
appeared	O
to	O
react	O
with	O
both	O
anti-STAT	B-protein
6	I-protein
and	O
anti-STAT	B-protein
1	I-protein
.	O


Hence	O
in	O
the	O
absence	O
of	O
p56	B-protein
,	O
T	B-protein
cell	I-protein
receptor	I-protein
triggered	O
activation	O
does	O
not	O
occur	O
.	O


These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	O
iNOS	B-protein
expression	O
in	O
macrophages	B-cell_type
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O


Detection	O
of	O
oestrogen	B-protein
receptor	I-protein
variants	I-protein
in	O
endometrium	O
,	O
myometrium	O
,	O
leiomyoma	O
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
comparison	O
to	O
variants	O
present	O
in	O
breast	O
cancer	O
.	O


The	O
presence	O
of	O
aberrant	O
ER	B-protein
forms	O
in	O
Oestrogen-dependent	O
tumours	O
has	O
been	O
discussed	O
in	O
correlation	O
with	O
tumour	O
progression	O
.	O


We	O
have	O
detected	O
variant	O
ER	B-protein
in	O
these	O
samples	O
and	O
have	O
compared	O
the	O
variant	O
profile	O
to	O
that	O
observed	O
in	O
breast	O
cancer	O
.	O


Variants	O
with	O
exon	B-DNA
5	I-DNA
deleted	O
were	O
detected	O
only	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
in	O
breast	O
cancer	O
.	O


The	O
physiological	O
significance	O
and	O
possible	O
clinical	O
relevance	O
of	O
the	O
variant	O
ER	B-protein
forms	O
remain	O
to	O
be	O
elucidated	O
.	O


p21ras	B-protein
is	O
activated	O
by	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
then	O
co-ordinates	O
important	O
signaling	O
pathways	O
for	O
T	B-protein
lymphocyte	I-protein
activation	O
.	O


We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt/PKB	B-protein
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


In	O
contrast	O
,	O
p21ras	B-protein
signals	O
are	O
unable	O
to	O
induce	O
Akt/PKB	B-protein
activity	O
in	O
T	B-cell_type
cell	I-cell_type
nor	O
is	O
Ras	B-protein
function	O
required	O
for	O
Akt/PKB	B-protein
activation	O
in	O
response	O
to	O
the	O
TCR	B-protein
.	O


The	O
effects	O
of	O
MCM	O
on	O
cellular	O
proliferation	O
,	O
AR	B-protein
protein	I-protein
and	O
PSA	B-protein
secretion	O
were	O
abolished	O
by	O
pretreatment	O
of	O
MCM	O
with	O
a	O
neutralizing	O
anti-IL-1beta	B-protein
antibody	I-protein
.	O


Our	O
findings	O
reveal	O
that	O
monocyte-derived	B-protein
IL-1beta	I-protein
inhibits	O
the	O
proliferation	O
of	O
androgen-responsive	B-cell_type
prostate	I-cell_type
tumour	I-cell_type
cells	I-cell_type
and	O
reduces	O
AR	B-protein
and	O
PSA	B-protein
levels	O
.	O


However	O
,	O
it	O
is	O
unclear	O
whether	O
similar	O
molecular	O
mechanisms	O
underlie	O
transcription	O
of	O
the	O
two	O
genes	B-DNA
.	O


The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha	I-DNA
chain/CD25	I-DNA
promoter	I-DNA
is	O
a	O
target	O
for	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O


Our	O
data	O
indicate	O
an	O
important	O
role	O
for	O
NF-AT	B-protein
in	O
the	O
faithful	O
expression	O
of	O
high	B-protein
affinity	I-protein
IL-2	I-protein
receptors	I-protein
and	O
a	O
close	O
link	O
between	O
the	O
TCR	B-protein
-mediated	O
induction	O
of	O
IL-2	B-protein
and	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
promoters	I-DNA
,	O
both	O
of	O
which	O
are	O
regulated	O
by	O
NF-AT	B-protein
factors	I-protein
.	O


A	O
novel	O
mutation	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
FY*B	B-DNA
allele	I-DNA
of	O
the	O
Duffy	B-DNA
chemokine	I-DNA
receptor	I-DNA
gene	I-DNA
is	O
associated	O
with	O
an	O
altered	O
erythrocyte	O
phenotype	O
.	O


The	O
Duffy	O
blood	O
group	O
system	O
is	O
of	O
clinical	O
and	O
biological	O
significance	O
.	O


In	O
particular	O
,	O
these	O
cell	B-cell_line
lines	I-cell_line
may	O
help	O
understand	O
the	O
relative	O
contribution	O
of	O
HHV-8	O
and	O
EBV	O
to	O
PEL	O
growth	O
and	O
development	O
and	O
may	O
facilitate	O
the	O
identification	O
of	O
recurrent	O
cytogenetic	O
abnormalities	O
highlighting	O
putative	O
novel	O
cancer	O
related	O
loci	O
relevant	O
to	O
PEL	B-cell_line
.	O


Two-site	O
interaction	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
with	O
activated	O
calcineurin	B-protein
.	O


Upon	O
cell	O
activation	O
,	O
displacement	O
of	O
the	O
autoinhibitory	B-protein
domain	I-protein
by	O
calmodulin	B-protein
binding	O
allows	O
NFAT	B-protein
to	O
bind	O
additionally	O
to	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
,	O
thus	O
positioning	O
NFAT	B-protein
for	O
immediate	O
dephosphorylation	O
at	O
functional	O
phosphoserine	O
residues	O
.	O


Nuclear	B-protein
factor-kappaB	I-protein
induction	O
in	O
CD45RO+	B-cell_type
and	I-cell_type
CD45RA+	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
during	O
aging	O
.	O


Expression	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
requires	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
stimulation	O
of	O
the	O
TCR	B-protein
and	O
costimulation	O
through	O
accessory	B-protein
receptors	I-protein
.	O


We	O
have	O
found	O
recently	O
that	O
okadaic	B-protein
acid-sensitive	I-protein
Ser/Thr	I-protein
phosphatases	I-protein
are	O
involved	O
in	O
a	O
cyclosporin	O
A-insensitive	O
pathway	O
that	O
selectively	O
transmits	O
costimulatory	O
signals	O
.	O


Insulin	O
dose-dependently	O
increased	O
the	O
PI-3	O
,	O
4	O
,	O
5-P3	O
production	O
but	O
YM268	O
had	O
no	O
significant	O
effect	O
on	O
the	O
insulin-dependent	O
and	O
-independent	O
PI	O
3-kinase	O
activation	O
.	O


BCL-6	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
/syn-1	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
tumor	I-cell_line
cells	I-cell_line
of	O
CHD	O
are	O
mostly	O
found	O
surrounded	O
by	O
T	B-cell_type
cells	I-cell_type
expressing	O
CD40L	B-protein
,	O
consistent	O
with	O
the	O
observation	O
that	O
CD40	B-protein
signaling	O
downregulates	O
BCL-6	B-protein
expression	O
.	O


These	O
observations	O
demonstrate	O
that	O
CD4	B-protein
signaling	O
mediates	O
HIV-induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	B-protein
-Fas	B-protein
ligand	I-protein
interaction	O
,	O
does	O
not	O
require	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	B-protein
dimerization	O
.	O


We	O
have	O
determined	O
how	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
family	I-protein
(	O
pRb	B-protein
,	O
p107	B-protein
,	O
and	O
p130	B-protein
)	O
is	O
governed	O
in	O
individual	O
cell	O
cycle	O
phases	O
of	O
Daudi	B-cell_line
B-cells	I-cell_line
during	O
cell	O
cycle	O
exit	O
triggered	O
by	O
alpha-interferon	B-protein
(	O
alpha-IFN	B-protein
)	O
.	O


The	O
entry	O
of	O
microorganisms	O
into	O
the	O
body	O
induces	O
inflammatory	O
processes	O
.	O


Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti-inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	B-cell_type
cells	I-cell_type
.	O


MHC	B-protein
class	I-protein
II	I-protein
expression	O
was	O
examined	O
in	O
macrophages	B-cell_type
infected	O
with	O
Mycobacterium	O
tuberculosis	O
.	O


Despite	O
this	O
effect	O
,	O
steady	O
state	O
levels	O
of	O
HLA-DRalpha	B-protein
,	O
HLA-DRbeta	B-protein
,	O
and	O
invariant	B-protein
(	I-protein
Ii	I-protein
)	I-protein
chains	I-protein
were	O
equivalent	O
in	O
control	B-cell_type
and	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O


However	O
,	O
results	O
of	O
intracellular	O
staining	O
and	O
dual	O
color	O
confocal	O
microscopy	O
revealed	O
a	O
significant	O
defect	O
in	O
transport	O
of	O
newly	O
synthesized	O
class	B-protein
II	I-protein
molecules	I-protein
through	O
the	O
endocytic	O
compartment	O
.	O


In	O
CAT	B-DNA
reporter	I-DNA
constructions	I-DNA
no	O
appreciable	O
level	O
of	O
CAT	B-protein
activity	O
was	O
supported	O
by	O
the	O
beta	B-DNA
globin	I-DNA
promoter	I-DNA
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	B-DNA
promoter	I-DNA
.	O


BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
class	O
switching	O
to	O
IgE	B-protein
by	O
cytokines	B-protein
is	O
mediated	O
by	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O


This	O
transactivation	O
sequence	O
is	O
altered	O
by	O
tissue-specific	O
alternative	O
splicing	O
in	O
newly	O
isolated	O
NFATx	B-protein
isoforms	I-protein
,	O
resulting	O
in	O
lower	O
transactivation	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


NFATx1	B-protein
is	O
expressed	O
predominantly	O
in	O
the	O
thymus	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocyte	I-cell_type
,	O
while	O
the	O
skeletal	O
muscle	O
expressed	O
primarily	O
NFATx2	B-protein
.	O


In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
transcription	O
from	O
the	O
NFAT	B-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
activated	O
strongly	O
by	O
NFATx1	B-protein
but	O
only	O
weakly	O
by	O
NFATx2	B-protein
.	O


These	O
data	O
demonstrate	O
that	O
the	O
15-amino	B-protein
acid	I-protein
sequence	I-protein
of	O
NFATx1	B-protein
is	O
a	O
major	B-protein
transactivation	I-protein
sequence	I-protein
required	O
for	O
induction	O
of	O
genes	O
by	O
NFATx1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
and	O
possibly	O
regulates	O
NFAT	B-protein
activity	O
through	O
tissue-specific	O
alternative	O
splicing	O
.	O


CIITA	B-protein
B-cell-specific	B-DNA
promoter	I-DNA
suppression	O
in	O
MHC	B-cell_line
class	I-cell_line
II-silenced	I-cell_line
cell	I-cell_line
hybrids	I-cell_line
.	O


We	O
first	O
demonstrate	O
,	O
in	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line
intraspecies	I-cell_line
hybrids	I-cell_line
,	O
the	O
coordinate	O
suppression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
,	O
Ii	B-protein
(	O
invariant	B-protein
chain	I-protein
)	O
and	O
HLA-DM	B-DNA
gene	I-DNA
transcription	O
,	O
and	O
the	O
release	O
of	O
the	O
silencing	O
by	O
the	O
addition	O
of	O
interferon	B-protein
gamma	I-protein
.	O


In	O
this	O
report	O
expression	O
profiles	O
and	O
activation	O
of	O
PKC	B-protein
were	O
analyzed	O
in	O
human	B-cell_line
Raji	I-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
.	O


Finally	O
,	O
functional	O
activation	O
and	O
translocation	O
of	O
PKC	B-protein
were	O
investigated	O
with	O
a	O
selective	O
in	O
vitro	O
kinase	O
assay	O
.	O


Thus	O
,	O
the	O
translocation	O
event	O
per	O
se	O
occurs	O
independently	O
of	O
PKC	B-protein
activation	O
in	O
these	O
cells	O
.	O


Sequence-specific	O
DNA-binding	O
small	O
molecules	O
that	O
can	O
permeate	O
human	B-cell_type
cells	I-cell_type
potentially	O
could	O
regulate	O
transcription	O
of	O
specific	O
genes	O
.	O


The	O
ability	O
of	O
small	O
molecules	O
to	O
target	O
predetermined	O
DNA	B-DNA
sequences	I-DNA
located	O
within	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
suggests	O
a	O
general	O
approach	O
for	O
regulation	O
of	O
gene	O
expression	O
,	O
as	O
well	O
as	O
a	O
mechanism	O
for	O
the	O
inhibition	O
of	O
viral	O
replication	O
.	O


Musculin	O
protein	O
is	O
closely	O
related	O
to	O
human	B-protein
ABF-1	I-protein
,	O
which	O
is	O
expressed	O
in	O
activated	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
to	O
epicardin/capsulin/Pod-1	B-protein
,	O
which	O
is	O
expressed	O
in	O
branchial	B-cell_type
myoblasts	I-cell_type
,	O
visceral	O
and	O
urogenital	O
mesoderm	O
and	O
epicardium	O
.	O


Previously	O
,	O
we	O
demonstrated	O
that	O
granulocyte	B-RNA
colony-stimulating	I-RNA
factor	I-RNA
(	I-RNA
G-CSF	I-RNA
)	I-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
undetectable	O
and	O
granulocyte	O
maturation	O
blocked	O
in	O
CCAAT	B-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
alpha	I-protein
(	O
C/EBPalpha	B-protein
)	O
-deficient	O
mice	O
.	O


Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	B-protein
(	O
membrane	B-protein
CD14	I-protein
)	O
,	O
a	O
cell-surface	O
receptor	O
found	O
principally	O
on	O
monocytes	B-cell_type
and	O
neutrophils	B-cell_type
,	O
host-derived	O
mCD14	B-protein
ligands	O
are	O
poorly	O
defined	O
.	O


To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti-CD40	B-protein
+	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
-mediated	O
B-cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
RA	O
was	O
studied	O
in	O
anti-CD40	B-protein
(	O
1	O
microgram/mL	O
)	O
+	O
IL-4	B-protein
(	O
5	O
ng/mL	O
)	O
-mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
B	B-cell_type
cells	I-cell_type
in	O
healthy	O
donors	O
.	O


Tax	B-protein
expression	O
promotes	O
N-terminal	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaB	B-protein
alpha	I-protein
,	O
a	O
principal	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappaB	B-protein
.	O


Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	B-protein
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O


The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	B-cell_type
cells	I-cell_type
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	B-protein
and	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
.	O


In	O
transfection	O
experiments	O
,	O
overexpression	O
of	O
wild	O
type	O
IKK1	B-protein
,	O
a	O
dominant	B-protein
negative	I-protein
mutant	I-protein
IKK1	I-protein
(	O
K44M	B-protein
)	O
,	O
or	O
wild	B-protein
type	I-protein
IKK2	I-protein
did	O
not	O
affect	O
LPS-induced	O
kappaB	B-protein
-dependent	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	B-protein
inhibited	O
LPS	O
induction	O
of	O
kappaB	B-protein
-dependent	O
transcription	O
in	O
a	O
dose-dependent	O
manner	O
.	O


The	O
mechanism	O
by	O
which	O
early	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
are	O
selectively	O
transformed	O
by	O
v-Abl	B-protein
is	O
currently	O
unknown	O
.	O


Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL-4	B-protein
and	O
IL-7	B-protein
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
JAK	I-protein
)	I-protein
1	I-protein
,	O
JAK3	B-protein
,	O
STAT5	B-protein
,	O
and	O
STAT6	B-protein
,	O
in	O
pre-B	B-cell_type
cells	I-cell_type
transformed	O
by	O
v-Abl	B-protein
.	O


To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v-Abl	B-protein
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL-4	B-protein
and	O
IL-7	B-protein
on	O
pre-B	B-cell_type
cells	I-cell_type
transformed	O
with	O
a	O
temperature-sensitive	B-protein
v-Abl	I-protein
mutant	I-protein
were	O
examined	O
.	O


In	O
contrast	O
,	O
induction	O
of	O
differentiation	O
but	O
not	O
of	O
proliferation	O
was	O
followed	O
by	O
a	O
25-	O
to	O
30-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
tumor	B-protein
suppressor	I-protein
proteins	I-protein
p53	I-protein
(	O
wild	O
type	O
)	O
,	O
pRb	B-protein
,	O
and	O
p130/Rb2	B-protein
and	O
of	O
the	O
p53-dependent	B-protein
cyclin	I-protein
kinase	I-protein
inhibitor	I-protein
p21/Cip1	B-protein
.	O


As	O
a	O
result	O
,	O
G1-S-associated	B-DNA
DNA	I-DNA
and	O
mRNA	O
synthesis	O
is	O
inhibited	O
,	O
growth	O
uncoupled	O
from	O
differentiation	O
,	O
and	O
maturation	O
enabled	O
to	O
proceed	O
.	O


However	O
,	O
the	O
cells	O
obtained	O
from	O
IL-2	B-protein
-treated	O
patients	O
did	O
not	O
have	O
low-level	O
constitutive	O
expression	O
of	O
STAT	B-protein
binding	I-protein
factors	I-protein
as	O
did	O
LAK	B-protein
cells	I-protein
.	O


These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	B-cell_type
cells	I-cell_type
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL-2	B-protein
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	B-cell_type
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL-2	B-protein
.	O


Activated	B-cell_type
platelets	I-cell_type
induce	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	I-cell_type
on	O
endothelial	B-cell_type
cells	I-cell_type
[	O
see	O
comments	O
]	O


The	O
role	O
of	O
platelets	O
for	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	I-cell_type
(	O
ICAM-1	B-protein
)	O
on	O
endothelial	B-cell_type
cells	I-cell_type
has	O
been	O
assessed	O
.	O


In	O
the	O
presence	O
of	O
ADP-activated	B-cell_type
platelets	I-cell_type
,	O
both	O
MCP-1	B-protein
secretion	O
and	O
ICAM-1	B-protein
surface	O
expression	O
were	O
significantly	O
increased	O
compared	O
with	O
nonstimulated	B-cell_type
platelets	I-cell_type
(	O
P	O
<	O
0.02	O
)	O
.	O


Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB	B-protein
-dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	B-cell_type
platelets	I-cell_type
.	O


Additionally	O
,	O
to	O
determine	O
the	O
impact	O
of	O
RXR	B-protein
for	O
erythroid	O
cell	O
development	O
,	O
dominant	O
interfering	O
mutant	B-protein
RXRs	I-protein
,	O
lacking	O
the	O
transcriptional	O
activator	O
functions	O
AF-1	B-protein
and	O
AF-2	B-protein
,	O
or	O
AF-2	B-protein
only	O
,	O
or	O
the	O
entire	B-DNA
DNA-binding	I-DNA
domain	I-DNA
,	O
were	O
introduced	O
into	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
via	O
recombinant	O
retrovirus	O
vectors	O
and	O
analyzed	O
for	O
RXR	B-protein
-specific	O
effects	O
.	O


T	B-cell_type
lymphocytes	I-cell_type
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	B-protein
phosphatase	I-protein
,	O
map	B-protein
kinase	I-protein
phosphatase-1	I-protein
(	O
MKP-1	B-protein
)	O
.	O


Abnormalities	O
of	O
I	O
or	O
more	O
signaling	B-protein
molecules	I-protein
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	B-cell_type
cells	I-cell_type
that	O
exhibited	O
all	O
5	O
defects	O
.	O


For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	B-protein
molecule	I-protein
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T-cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O


In	O
the	O
first	O
series	O
we	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
dissociation	O
constant	O
did	O
not	O
depend	O
on	O
the	O
season	O
,	O
on	O
the	O
age	O
of	O
subjects	O
nor	O
on	O
cortisol	O
concentrations	O
in	O
blood	O
.	O


The	O
Rho	B-protein
family	O
of	O
small	B-protein
GTP-binding	I-protein
proteins	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O


Overexpression	O
of	O
a	O
V14Rho	B-DNA
construct	I-DNA
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	B-DNA
deleted	I-DNA
)	O
abolishes	O
PMA-induced	O
AP-1	B-protein
transcriptional	O
activation	O
.	O


One	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	B-protein
can	O
be	O
increased	O
expression	O
of	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
pathways	O
.	O


Therefore	O
,	O
we	O
also	O
evaluated	O
activation	O
of	O
the	O
MAP	B-protein
kinase	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
2	I-protein
by	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O


These	O
studies	O
show	O
that	O
the	O
differential	O
expression	O
of	O
PKC	B-protein
isoforms	I-protein
in	O
alveolar	B-cell_type
macrophages	I-cell_type
and	O
blood	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
important	O
functional	O
alterations	O
in	O
the	O
cells	O
.	O


We	O
have	O
recently	O
described	O
an	O
inherited	O
over-expression	O
of	O
the	O
macrophage	B-protein
scavenger	I-protein
receptor	I-protein
(	O
SR	B-protein
)	O
in	O
blood	B-cell_type
monocytes	I-cell_type
from	O
members	O
of	O
a	O
kindred	O
,	O
only	O
two	O
of	O
whom	O
displayed	O
extensive	O
xanthomatosis	O
.	O


The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF-kappaB	B-protein
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O


Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF-kappaB	B-protein
activation	O
may	O
be	O
relevant	O
to	O
immune-related	O
diseases	O
and	O
to	O
aging	O
.	O


We	O
found	O
that	O
EPO	B-protein
did	O
not	O
activate	O
Stat1alpha	B-protein
or	O
Stat3	B-protein
in	O
UT-7/GM	B-cell_line
cells	I-cell_line
.	O


Indeed	O
,	O
USA-derived	B-protein
PC2	I-protein
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	B-protein
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O


Data	O
obtained	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
suggested	O
that	O
the	O
activated	B-protein
Stat-3	I-protein
protein	I-protein
associates	O
with	O
the	O
human	B-DNA
serum-inducible	I-DNA
element	I-DNA
(	I-DNA
hSIE	I-DNA
)	I-DNA
DNA-probe	I-DNA
derived	O
from	O
the	O
interferon-gamma	B-DNA
activated	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
in	O
the	O
c-fos	B-DNA
promoter	I-DNA
,	O
a	O
common	O
DNA	O
sequence	O
for	O
Stat	B-protein
protein	I-protein
binding	O
.	O


This	O
dominant-negative	B-protein
acting	I-protein
Stat-3	I-protein
isoform	I-protein
significantly	O
inhibited	O
apoptosis	O
induced	O
by	O
ligation	O
of	O
MHC-I	B-protein
.	O


This	O
inhibition	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
in	O
viability	O
,	O
and	O
DMDTC-treated	B-cell_type
T	I-cell_type
cells	I-cell_type
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O


The	O
15-LO	B-protein
promoter	O
is	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
5'-end	B-DNA
of	O
the	O
gene	O
,	O
and	O
sequence	O
analysis	O
reveals	O
putative	O
Sp1	B-DNA
and	I-DNA
Ap2	I-DNA
binding	I-DNA
site/s	I-DNA
and	O
absence	O
of	O
TATA	B-DNA
or	I-DNA
CAAT	I-DNA
motifs	I-DNA
.	O


Using	O
deletion	B-DNA
constructs	I-DNA
,	O
we	O
have	O
defined	O
an	O
active	B-DNA
promoter	I-DNA
region	I-DNA
of	O
1056	O
bp	O
.	O


The	O
efficacy	O
of	O
the	O
activated	B-cell_type
LN	I-cell_type
cells	I-cell_type
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	B-cell_line
modified	I-cell_line
variant	I-cell_line
(	O
designated	O
D5G6	B-cell_line
)	O
that	O
secretes	O
granulocyte/macrophage-colony-stimulating	B-protein
factor	I-protein
.	O


After	O
5-day	O
anti-CD3	B-protein
/IL-2	B-protein
activation	O
,	O
levels	O
of	O
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O


Transient	O
transfectants	O
of	O
the	O
porcine	B-cell_line
B-cell	I-cell_line
line	I-cell_line
L23	I-cell_line
with	O
the	O
mutated	O
CIITA	B-DNA
constructs	I-DNA
were	O
tested	O
for	O
the	O
suppression	O
of	O
constitutive	O
SLA-DR	O
and	O
SLA-DQ	O
expression	O
.	O


T-cell	O
proliferation	O
studies	O
were	O
performed	O
using	O
highly	O
purified	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Normal	O
artery	O
specimens	O
(	O
n	O
=	O
6	O
)	O
reveal	O
minimal	B-protein
immunoreactive	I-protein
PPARgamma	I-protein
.	O


Crkl	B-protein
,	O
an	O
SH2/SH3	B-protein
adapter	I-protein
protein	I-protein
,	O
becomes	O
coimmunoprecipitated	O
specifically	O
with	O
STAT5	B-protein
from	O
erythropoietin-stimulated	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
;	O
although	O
it	O
was	O
shown	O
to	O
become	O
associated	O
with	O
c-Cbl	B-protein
in	O
the	O
studies	O
using	O
cell	B-cell_line
lines	I-cell_line
.	O


This	O
report	O
sets	O
a	O
basis	O
for	O
further	O
studies	O
on	O
signaling	O
in	O
primary	B-cell_type
cultured	I-cell_type
human	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
,	O
which	O
in	O
turn	O
contribute	O
to	O
our	O
better	O
understanding	O
in	O
the	O
differentiation	O
processes	O
of	O
erythrocytes	B-cell_type
and	O
their	O
precursors	O
.	O


DNA-binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	B-protein
factors	I-protein
:	O
NFkappaB	B-protein
,	O
AP-1	B-protein
and	O
NFAT	B-protein
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	B-cell_type
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O


TGFs	B-protein
play	O
important	O
roles	O
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O


We	O
have	O
previously	O
demonstrated	O
that	O
eosinophils	B-cell_type
infiltrating	O
into	O
different	O
pathologic	O
processes	O
elaborate	O
TGF-alpha	B-protein
and	O
TGF-beta1	B-protein
.	O


Supernatants	O
from	O
these	O
cultures	O
were	O
assayed	O
for	O
secreted	O
TGF-alpha	B-protein
and	O
TGF-beta1	B-protein
using	O
TGF	B-protein
-specific	O
ELISAs	O
.	O


Consistent	O
with	O
the	O
ability	O
of	O
IL-4	B-protein
to	O
regulate	O
eosinophil	O
responses	O
,	O
IL-4	B-protein
signaling	I-protein
molecules	I-protein
are	O
present	O
in	O
human	B-cell_type
eosinophils	I-cell_type
.	O


The	O
translocation	B-DNA
t	I-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q14	I-DNA
)	I-DNA
has	O
been	O
observed	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
as	O
well	O
as	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O


In	O
all	O
3	O
cases	O
,	O
a	O
characteristic	O
immunophenotype	O
was	O
identified	O
(	O
CD4+	B-protein
,	O
CD13	B-protein
-	O
,	O
CD33+	O
,	O
CD65s+	O
)	O
.	O


The	O
role	O
of	O
E-proteins	B-protein
in	O
B-	O
and	O
T-lymphocyte	O
development	O
.	O


In	O
this	O
review	O
we	O
describe	O
the	O
defects	O
in	O
B-	O
and	O
T-	O
lymphocyte	O
development	O
in	O
mice	O
carrying	O
targeted	O
mutations	O
in	O
the	O
E-protein	B-DNA
genes	I-DNA
and	O
discuss	O
our	O
current	O
understanding	O
of	O
the	O
role	O
of	O
these	O
proteins	O
in	O
lymphoid	O
development	O


One	O
site	O
is	O
similar	O
to	O
activated	O
TNFRII	B-protein
in	O
associating	O
with	O
TNFR-associated	B-protein
factors	I-protein
TRAF1	B-protein
and	O
TRAF2	B-protein
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	B-protein
in	O
associating	O
with	O
the	O
TNFRI	B-protein
death	I-protein
domain	I-protein
interacting	I-protein
protein	I-protein
TRADD	B-protein
.	O


In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
or	O
by	O
each	O
of	O
its	O
effector	B-protein
sites	I-protein
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	B-protein
,	O
IKKalpha	B-protein
,	O
and	O
IKKbeta	B-protein
.	O


Exposure	O
of	O
cells	O
to	O
adverse	O
environmental	O
conditions	O
invokes	O
a	O
genetically	O
programmed	O
series	O
of	O
events	O
resulting	O
in	O
the	O
induction	O
of	O
specific	B-DNA
genes	I-DNA
.	O


In	O
the	O
present	O
investigation	O
,	O
the	O
effect	O
of	O
ciprofloxacin	O
at	O
supratherapeutic	O
concentrations	O
on	O
immediate-early	O
(	O
<	O
2	O
h	O
)	O
gene	O
expression	O
in	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
was	O
studied	O
with	O
Northern	O
blots	O
.	O


We	O
have	O
recently	O
developed	O
a	O
novel	O
RAR	B-protein
-selective	O
antagonist	O
(	O
ER27191	O
)	O
which	O
prevents	O
RAR	B-protein
activation	O
by	O
retinoids	O
.	O


Additional	O
experiments	O
showed	O
that	O
levels	O
of	O
BCL-2	B-protein
protein	I-protein
decreased	O
during	O
differentiation	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O


Furthermore	O
,	O
HL-60	B-cell_line
cells	I-cell_line
transduced	O
with	O
a	O
bcl-2	B-DNA
expression	I-DNA
vector	I-DNA
showed	O
the	O
same	O
differentiation	O
response	O
to	O
retinoids	O
as	O
did	O
parental	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
even	O
though	O
apoptosis	O
was	O
inhibited	O
in	O
these	O
bcl-2-transduced	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
differentiation	O
and	O
apoptosis	O
are	O
regulated	O
independently	O
in	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O


More	O
than	O
50	O
%	O
of	O
TPO-treated	B-cell_line
UT-7/GMT	I-cell_line
cells	I-cell_line
positively	O
stained	O
for	O
Hb	B-protein
.	O


Biologic	O
effects	O
of	O
IL-13	B-protein
on	O
primary	B-cell_type
human	I-cell_type
NK	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
well	O
defined	O
.	O


Furthermore	O
,	O
we	O
demonstrate	O
that	O
IL-13	B-protein
,	O
like	O
IL-4	B-protein
,	O
induces	O
distinct	O
STAT6-DNA	B-protein
binding	I-protein
complexes	I-protein
and	O
tyrosine	O
phosphorylation	O
of	O
STAT6	B-protein
and	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
in	O
NK	O
and	O
T	B-cell_type
cells	I-cell_type
.	O


These	O
findings	O
show	O
that	O
IL-13	B-protein
and	O
IL-4	B-protein
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL-13	B-protein
is	O
a	O
potent	O
regulator	O
of	O
STAT6	B-protein
and	O
JAK3	B-protein
in	O
these	O
cell	O
types	O
.	O


Inhibition	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O


NFkappaB	B-protein
activity	O
is	O
independent	O
from	O
FADD	B-protein
,	O
caspases	B-protein
,	O
and	O
apoptosis	O
induction	O
.	O


Pax-5	B-protein
codes	O
for	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
which	O
is	O
expressed	O
throughout	O
B	O
cell	O
development	O
except	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O


Gene	O
targeting	O
experiments	O
in	O
the	O
mouse	O
revealed	O
a	O
differential	O
dependency	O
of	O
fetal	O
and	O
adult	O
B-lymphopoiesis	O
on	O
this	O
transcription	B-protein
factor	I-protein
.	O


The	O
functional	O
effects	O
of	O
these	O
interactions	O
are	O
that	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	B-protein
,	O
enhance	O
EKLF	B-protein
's	O
transcriptional	O
activation	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O


Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O


NF-kappa	B-protein
B	I-protein
activation	O
,	O
minimal	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	B-protein
.	O


Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	O
receptor	O
transcripts	O
similar	O
to	O
those	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O


Some	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
estradiol	O
,	O
PMA	O
,	O
and	O
ionomycin	O
.	O


There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	B-RNA
transcripts	I-RNA
between	O
patients	O
and	O
healthy	O
controls	O
.	O


Precise	O
deletion	O
of	O
the	O
exons	O
suggests	O
that	O
they	O
are	O
alternatively	O
spliced	O
transcripts	O
.	O


A	O
1.2	O
kb	O
FasL	B-DNA
promoter	I-DNA
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	B-protein
Rel	I-protein
or	O
Fos/Jun	B-protein
.	O


Although	O
all	O
MRD-positive	O
patients	O
in	O
LT	O
remission	O
are	O
still	O
until	O
now	O
event-free	O
,	O
3	O
of	O
the	O
7	O
MRD-positive	O
(	O
MRD+	O
)	O
patients	O
in	O
ST	O
remission	O
soon	O
relapsed	O
.	O


The	O
CD8	B-protein
+	O
CD28	B-protein
+	O
population	O
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O


The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	B-cell_type
cell	I-cell_type
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O


Differences	O
in	O
LTR	B-DNA
sequence	I-DNA
also	O
resulted	O
in	O
differences	O
in	O
transcription	O
factor	O
recruitment	O
to	O
cis-acting	B-DNA
sites	I-DNA
within	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
LTR	B-DNA
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O


These	O
findings	O
suggest	O
that	O
LTR	B-DNA
sequence	I-DNA
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	B-DNA
function	O
and	O
transcription	B-protein
factor	I-protein
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O


In	O
lymphocyte	B-cell_type
differentiation	O
,	O
several	O
HMG	B-protein
box	I-protein
proteins	I-protein
play	O
a	O
decisive	O
role	O
.	O


Proliferation	O
index	O
as	O
a	O
prognostic	O
marker	O
in	O
breast	O
cancer	O
.	O


Life-table	O
analysis	O
(	O
Mantel-Cox	O
)	O
was	O
used	O
to	O
assess	O
the	O
probability	O
of	O
disease-free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O


In	O
addition	O
,	O
this	O
proliferative	O
parameter	O
maintained	O
its	O
prognostic	O
significance	O
when	O
the	O
patients	O
were	O
stratified	O
according	O
to	O
lymph	O
node	O
involvement	O
,	O
menopausal	O
status	O
,	O
and	O
nuclear	B-protein
estrogen	I-protein
receptor	I-protein
content	O
.	O


Tumor	O
proliferative	O
activity	O
as	O
evaluated	O
by	O
the	O
monoclonal	B-protein
antibody	I-protein
Ki-67	I-protein
seems	O
to	O
be	O
an	O
effective	O
indicator	O
of	O
prognosis	O
in	O
breast	O
cancer	O
for	O
DFS	O
and	O
OS	O
.	O


Co-immunoprecipitation	O
experiments	O
demonstrated	O
an	O
association	O
between	O
Elf-1	B-protein
and	O
Rb	B-protein
in	O
resting	B-cell_type
normal	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


These	O
results	O
demonstrate	O
that	O
Rb	B-protein
interacts	O
specifically	O
with	O
a	O
lineage-restricted	B-protein
Ets	I-protein
transcription	I-protein
factor	I-protein
.	O


Human	B-cell_line
CD3-CD16+	I-cell_line
natural	I-cell_line
killer	I-cell_line
cells	I-cell_line
express	O
the	O
hGATA-3	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
and	O
an	O
unrearranged	O
2.3-kb	B-protein
TcR	I-protein
delta	I-protein
transcript	I-protein
.	O


Multiple	O
TcR	B-protein
delta	I-protein
transcripts	I-protein
deriving	O
from	O
an	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
were	O
detected	O
in	O
both	O
polyclonal	B-cell_line
and	I-cell_line
clonal	I-cell_line
CD3-CD16+	I-cell_line
natural	I-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


All	O
NK	B-cell_line
clones	I-cell_line
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA-3-specific	B-RNA
mRNA	I-RNA
,	O
suggesting	O
that	O
hGATA-3	B-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
expression	O
in	O
NK	B-cell_type
cells	I-cell_type
.	O


The	O
activated	O
form	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
rapidly	O
taken	O
up	O
into	O
nuclei	O
,	O
initiates	O
transcription	O
from	O
immediate	O
early	O
genes	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O


Most	O
of	O
the	O
target	O
genes	O
for	O
NF-kappa	B-protein
B	I-protein
are	O
of	O
relevance	O
for	O
the	O
immune	O
response	O
and	O
can	O
be	O
grouped	O
into	O
those	O
encoding	O
cytokines	B-protein
,	O
cell	B-protein
surface	I-protein
receptors	I-protein
,	O
acute	B-protein
phase	I-protein
proteins	I-protein
and	O
viral	B-DNA
genomes	I-DNA
,	O
such	O
as	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O


Differential	O
contribution	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
1	I-protein
gene	I-protein
products	I-protein
and	O
cellular	B-protein
factors	I-protein
to	O
the	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
provirus	O
.	O


Transcriptional	O
activation	O
of	O
the	O
macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
by	O
IL-2	B-protein
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
protein	I-protein
by	O
monocytes	B-cell_type
and	O
involves	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O


Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
Mo	B-cell_type
)	O
constitutively	O
display	O
the	O
beta-chain	O
of	O
the	O
receptor	O
for	O
IL-2	B-protein
,	O
whereas	O
expression	O
of	O
the	O
IL-2R	B-protein
alpha-chain	I-protein
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL-2	B-protein
.	O


Transcriptional	O
activation	O
of	O
the	O
M-CSF	B-DNA
gene	I-DNA
by	O
IL-2	B-protein
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M-CSF	B-DNA
gene	I-DNA
.	O


Regulation	O
of	O
the	O
interleukin-1	B-DNA
beta	I-DNA
(	I-DNA
IL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	I-DNA
by	O
mycobacterial	B-protein
components	I-protein
and	O
lipopolysaccharide	O
is	O
mediated	O
by	O
two	O
nuclear	B-DNA
factor-IL6	I-DNA
motifs	I-DNA
.	O


Within	O
this	O
DNA	O
fragment	O
,	O
there	O
were	O
two	O
novel	O
9-bp	O
motifs	O
(	O
-90/-82	O
and	O
-40/-32	O
)	O
with	O
high	O
homology	O
to	O
the	O
nuclear	B-DNA
factor-IL6	I-DNA
(	I-DNA
NF-IL6	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
.	O


We	O
found	O
that	O
Nef	B-protein
inhibited	O
the	O
recruitment	O
of	O
AP-1	B-protein
DNA-binding	O
activity	O
in	O
mitogen-stimulated	O
human	B-cell_type
T-cells	I-cell_type
.	O


Recent	O
studies	O
have	O
provided	O
new	O
insights	O
into	O
how	O
the	O
individual	O
genes	O
of	O
the	O
cluster	O
are	O
regulated	O
through	O
development	O
.	O


Two	O
transcriptional	O
elements	O
in	O
the	O
TSP	B-protein
1	I-protein
promoter	O
,	O
a	O
distal	O
element	O
at	O
-1280	O
and	O
a	O
proximal	O
element	O
at	O
-65	O
,	O
were	O
required	O
for	O
the	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
to	O
serum	O
.	O


Deletions	O
or	O
mutations	O
in	O
this	O
element	O
reduced	O
the	O
serum	O
response	O
of	O
the	O
TSP	B-DNA
1	I-DNA
gene	I-DNA
by	O
80-90	O
%	O
.	O


Cell-type-specific	O
transactivation	O
of	O
the	O
parathyroid	B-DNA
hormone-related	I-DNA
protein	I-DNA
gene	I-DNA
promoter	I-DNA
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
tax	I-protein
and	O
HTLV-II	B-protein
tax	I-protein
proteins	I-protein
.	O


They	O
are	O
part	O
of	O
the	O
high	B-protein
affinity	I-protein
IgE	I-protein
receptor	I-protein
in	O
mast	B-cell_type
cells	I-cell_type
,	O
basophils	B-cell_type
,	O
Langerhans	B-cell_type
cells	I-cell_type
,	O
and	O
possibly	O
other	O
cells	O
;	O
a	O
component	O
of	O
the	O
low	O
affinity	O
receptor	O
for	O
IgG	B-protein
(	O
Fc	B-protein
gamma	I-protein
RIIIA	I-protein
or	O
CD16	B-protein
)	O
in	O
natural	O
killer	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
;	O
and	O
part	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
in	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
.	O


Chlorinated	O
dibenzo-p-dioxins	O
and	O
dibenzofurans	O
and	O
the	O
human	O
immune	O
system	O
.	O


With	O
one	O
exception	O
,	O
these	O
were	O
all	O
increases	O
.	O


None	O
of	O
the	O
alterations	O
observed	O
are	O
of	O
medical	O
relevance	O
.	O


The	O
initial	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
most	O
individuals	O
usually	O
results	O
in	O
the	O
establishment	O
of	O
a	O
latent	O
or	O
chronic	O
infection	O
before	O
eventual	O
progression	O
toward	O
acquired	O
immunodeficiency	O
syndrome	O
.	O


Expression	O
of	O
mRNA	B-RNA
for	O
the	O
GATA-binding	B-protein
proteins	I-protein
in	O
human	B-cell_type
eosinophils	I-cell_type
and	O
basophils	B-cell_type
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O


Oxidoreductive	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O


We	O
have	O
investigated	O
an	O
oxidoreductive	O
regulatory	O
pathway	O
for	O
the	O
DNA	O
binding	O
activity	O
of	O
a	O
pleiotropic	B-protein
cellular	I-protein
transcription	I-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
has	O
been	O
investigated	O
by	O
using	O
NF	B-protein
kappa	I-protein
B	I-protein
prepared	O
from	O
the	O
nucleus	O
and	O
the	O
cytosol	O
of	O
the	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Here	O
we	O
demonstrate	O
that	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
induced	O
K562	B-cell_line
cells	I-cell_line
to	O
differentiate	O
along	O
a	O
third	O
pathway	O
.	O


Stimulation	O
of	O
highly	B-cell_type
purified	I-cell_type
human	I-cell_type
T-cells	I-cell_type
via	O
CD2	B-protein
and	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O


This	O
potent	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-dependent	O
activation	O
does	O
not	O
require	O
monocytes	B-cell_type
or	O
accessory	B-cell_type
cells	I-cell_type
.	O


Increase	O
of	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
to	O
its	O
consensus	B-DNA
sequence	I-DNA
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
.	O


Resting	O
T-cell	O
nuclear	O
extracts	O
contained	O
KBF1/p50	B-protein
homodimer	I-protein
.	O


After	O
stimulation	O
,	O
two	O
new	O
kappa	B-protein
B-specific	I-protein
complexes	I-protein
were	O
identified	O
as	O
NF-kappa	B-protein
B	I-protein
p50-p65	B-protein
heterodimer	I-protein
and	O
putative	O
c-Rel	B-protein
homodimer	I-protein
or	O
c-Rel-p65	B-protein
heterodimer	I-protein
.	O


A	O
new	O
approach	O
to	O
facilitate	O
immobilization	O
and	O
affinity	O
purification	O
of	O
recombinant	B-protein
proteins	I-protein
and	O
selected	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
has	O
been	O
developed	O
.	O


In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	B-protein
blocked	O
both	O
activated	O
ras	B-protein
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	B-protein
upstream	O
of	O
PKC	B-protein
.	O


NF-AT	B-protein
is	O
thought	O
to	O
consist	O
of	O
two	O
components	O
:	O
a	O
ubiquitous	B-protein
,	I-protein
inducible	I-protein
nuclear	I-protein
component	I-protein
that	O
we	O
have	O
identified	O
as	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
,	O
and	O
a	O
preexisting	O
,	O
T	B-protein
cell-specific	I-protein
component	I-protein
(	O
NF-ATp	B-protein
)	O
which	O
is	O
the	O
target	O
for	O
the	O
immunosuppressive	O
agents	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O


The	O
transcription	B-protein
factor	I-protein
E2F	B-protein
activates	O
the	O
expression	O
of	O
multiple	O
genes	B-DNA
involved	O
in	O
cell	O
proliferation	O
,	O
such	O
as	O
c-myc	B-DNA
and	O
the	O
dihydrofolate	B-DNA
reductase	I-DNA
gene	I-DNA
.	O


Regulation	O
of	O
E2F	B-protein
involves	O
its	O
interactions	O
with	O
other	O
cellular	B-protein
proteins	I-protein
,	O
including	O
the	O
retinoblastoma	B-protein
protein	I-protein
(	O
Rb	B-protein
)	O
,	O
the	O
Rb-related	B-protein
protein	I-protein
p107	B-protein
,	O
cyclin	B-protein
A	I-protein
,	O
and	O
cdk2	B-protein
.	O


Three	O
E2F	B-protein
DNA-binding	O
activities	O
were	O
identified	O
in	O
resting	O
(	O
G0	O
)	O
T	B-cell_type
cells	I-cell_type
with	O
mobilities	O
in	O
gel	O
shift	O
assays	O
distinct	O
from	O
those	O
of	O
previously	O
defined	O
E2F	B-protein
complexes	O
.	O


However	O
,	O
X	B-protein
failed	O
to	O
react	O
with	O
a	O
variety	O
of	O
antibodies	O
against	O
Rb	B-protein
or	O
p107	B-protein
,	O
implicating	O
the	O
involvement	O
of	O
an	O
E1A-binding	B-protein
protein	I-protein
other	O
than	O
Rb	B-protein
or	O
p107	B-protein
.	O


These	O
species	O
showed	O
different	O
cell	O
cycle	O
kinetics	O
.	O


Together	O
,	O
these	O
results	O
suggest	O
that	O
E2F	B-protein
consists	O
of	O
multiple	O
,	O
biochemically	O
distinct	O
DNA-binding	B-protein
proteins	I-protein
which	O
function	O
at	O
different	O
points	O
in	O
the	O
cell	O
cycle	O
.	O


The	O
finding	O
that	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c-jun	B-DNA
expression	O
,	O
suggests	O
that	O
c-jun	B-DNA
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O


Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun-B	B-DNA
and	O
fra-1	B-DNA
genes	B-DNA
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL-60/vinc	B-cell_line
and	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
,	O
whereas	O
c-fos	B-DNA
expression	O
is	O
attenuated	O
in	O
the	O
HL-60/vinc	O
line	O
.	O


FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O


p105	B-protein
and	O
p98	B-protein
precursor	B-protein
proteins	I-protein
play	O
an	O
active	O
role	O
in	O
NF-kappa	B-protein
B	I-protein
-mediated	O
signal	O
transduction	O
.	O


Association	O
with	O
the	O
precursors	O
is	O
sufficient	O
for	O
cytoplasmic	O
retention	O
of	O
either	O
p65	B-protein
or	O
c-Rel	B-protein
,	O
both	O
of	O
which	O
are	O
otherwise	O
nuclear	O
.	O


Together	O
,	O
these	O
results	O
show	O
that	O
NF-kappa	B-protein
B	I-protein
controls	O
the	O
expression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O


A	O
cell-type-independent	B-DNA
lipopolysaccharide	I-DNA
(	I-DNA
LPS	I-DNA
)	I-DNA
-responsive	I-DNA
enhancer	I-DNA
element	I-DNA
located	O
between	O
-3757	B-DNA
and	I-DNA
-2729	I-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
cap	B-DNA
site	I-DNA
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	B-cell_line
monocytes	I-cell_line
.	O


Deletion	O
and	O
base	O
substitution	O
mutations	O
along	O
with	O
DNA	O
binding	O
studies	O
demonstrated	O
that	O
the	O
enhancer	O
contained	O
a	O
minimum	O
of	O
three	O
functional	O
protein	B-DNA
binding	I-DNA
sequences	I-DNA
,	O
two	O
of	O
which	O
appeared	O
to	O
be	O
important	O
for	O
gene	O
induction	O
.	O


When	O
ligated	O
to	O
the	O
proIL-1	B-DNA
beta	I-DNA
cap	I-DNA
site	I-DNA
-proximal	B-DNA
region	I-DNA
(	O
located	O
between	O
-131	O
to	O
+12	O
)	O
,	O
both	O
the	O
proIL-1	B-DNA
beta	I-DNA
and	I-DNA
the	I-DNA
simian	I-DNA
virus	I-DNA
40	I-DNA
enhancer	I-DNA
elements	I-DNA
functioned	O
more	O
efficiently	O
in	O
monocytes	B-cell_type
than	O
in	O
HeLa	B-cell_type
cells	I-cell_type
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL-1	B-protein
beta	I-protein
expression	O
.	O


The	O
PILOT	B-protein
protein	O
has	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
42.6	O
kDa	O
and	O
contains	O
three	O
zinc	B-protein
fingers	I-protein
of	O
the	O
C2H2-type	B-protein
at	O
the	O
carboxyl-terminus	B-protein
which	O
are	O
highly	O
homologous	O
to	O
the	O
zinc	B-protein
finger	I-protein
regions	I-protein
of	O
the	O
transcription	B-protein
factors	I-protein
EGR1	B-protein
,	O
EGR2	B-protein
,	O
and	O
pAT	B-protein
133	I-protein
.	O


This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
distinct	O
regions	O
of	O
the	O
promoter	B-DNA
elements	I-DNA
of	O
numerous	O
genes	O
,	O
including	O
cytokines	B-protein
,	O
growth	B-protein
factor	I-protein
receptors	I-protein
,	O
and	O
adhesion	B-protein
molecules	I-protein
.	O


A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	B-protein
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O


This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	B-cell_line
sulfoxide-differentiated	I-cell_line
HL-60	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
stimulated	O
by	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O


Both	O
overexpressed	O
p65	B-protein
and	O
coexpressed	O
p50	B-protein
are	O
cytoplasmic	O
,	O
whereas	O
p65	B-protein
delta	I-protein
is	O
partly	O
nuclear	O
,	O
indicating	O
that	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
induced	O
by	O
p65	B-protein
can	O
maintain	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
cytoplasm	O
.	O


Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c-Rel	B-protein
,	O
p105	B-protein
,	O
and	O
p50	B-protein
in	O
the	O
cytosol	O
.	O


LPS	O
activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
phosphorylation	O
of	O
MAD3	B-protein
(	O
an	O
I	B-protein
kappa	I-protein
B	I-protein
-like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	B-RNA
mRNA	I-RNA
,	O
and	O
an	O
increase	O
in	O
MAD3	B-protein
protein	O
by	O
2	O
h	O
.	O


At	O
nucleotide	O
2	O
,	O
317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O


The	O
transactivator	O
HTLV-I	B-protein
Tax	I-protein
activates	O
the	O
promoter	B-DNA
of	O
the	O
gene	O
coding	O
for	O
the	O
interleukin	B-protein
2	I-protein
alpha-chain	I-protein
receptor	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
via	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
that	O
can	O
bind	O
several	O
protein	O
species	O
of	O
the	O
rel	B-protein
family	I-protein
.	O


Overexpression	O
of	O
the	O
p50	B-protein
,	O
p65	B-protein
and	O
Rel	B-protein
proteins	I-protein
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL-2R	B-protein
alpha	I-protein
kappa	B-DNA
B	I-DNA
site	I-DNA
was	O
observed	O
only	O
with	O
Rel	B-protein
and	O
Rel	B-protein
plus	O
p65	B-protein
.	O


Moreover	O
,	O
whereas	O
both	O
Tax	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
are	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
the	O
IL-2R	B-DNA
alpha	I-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
,	O
PMA	O
is	O
functionally	O
inactive	O
.	O


Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	B-protein
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	O
.	O


The	O
data	O
also	O
indicate	O
that	O
CD2	B-protein
receptor	O
activation	O
and	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
stimulation	O
augment	O
T	O
cell	O
IL3	B-protein
gene	O
expression	O
through	O
the	O
same	O
cis-	O
and	O
trans-activating	O
signals	O
.	O


Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	B-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O


The	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
and	O
the	O
5	B-DNA
'	I-DNA
regulatory	I-DNA
region	I-DNA
of	O
the	O
gene	O
encoding	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
share	O
functional	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
elements	I-DNA
involved	O
in	O
the	O
regulation	O
of	O
these	O
inducible	O
transcription	O
units	O
during	O
T-cell	O
activation	O
.	O


Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c-Rel	B-protein
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
and	O
IL-2R	B-protein
alpha	I-protein
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B-protein
.	O


We	O
therefore	O
propose	O
a	O
model	O
whereby	O
a	O
core	O
NFAT	B-protein
complex	I-protein
consisting	O
of	O
Jun	B-protein
,	O
Fos	B-protein
,	O
and	O
a	O
constitutive	B-protein
nuclear	I-protein
factor	I-protein
is	O
formed	O
in	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
an	O
additional	O
factor	O
and/or	O
post-translational	O
modification	O
of	O
a	O
factor	O
,	O
missing	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
might	O
be	O
required	O
for	O
transactivation	O
by	O
NFAT	B-protein
.	O


Positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid-resistant	B-cell_line
CEM-C1	I-cell_line
cells	I-cell_line
,	O
which	O
contain	O
functional	O
GR	B-protein
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O


Measurement	O
of	O
GR	B-RNA
mRNA	I-RNA
turnover	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
treated	O
with	O
actinomycin-D	O
revealed	O
a	O
half-life	O
of	O
2.5	O
h	O
,	O
which	O
was	O
unaffected	O
by	O
dexamethasone	O
treatment	O
.	O


These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid-mediated	O
autoregulation	O
of	O
GR	O
expression	O
is	O
a	O
tissue-specific	O
primary	O
transcriptional	O
response	O
.	O


The	O
relationship	O
between	O
glucocorticoid	O
effect	O
and	O
regulation	O
of	O
cell	B-protein
surface	I-protein
antigens	I-protein
was	O
investigated	O
in	O
two	O
models	O
of	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CEM	B-cell_line
C7	I-cell_line
denoted	O
(	O
r+	O
,	O
ly+	O
)	O
and	O
CEM	B-cell_line
C1	I-cell_line
(	O
r+	O
,	O
ly-	O
)	O
.	O


The	O
reactivity	O
of	O
murine	B-protein
monoclonal	I-protein
antibodies	I-protein
,	O
anti-CD4-FITC	B-protein
,	O
anti-CD8-FITC	B-protein
,	O
anti-CD2-FITC	B-protein
and	O
anti-calla-FITC	B-protein
,	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
.	O


In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	B-protein
antigen	I-protein
expression	O
in	O
a	O
CD4+	B-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	B-cell_line
receptor	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
.	O


Adenovirus	O
E1A	O
inhibits	O
IFN	B-protein
-induced	O
resistance	O
to	O
cytolysis	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O


To	O
test	O
this	O
hypothesis	O
,	O
4-h	O
NK	O
cytolysis	O
assays	O
were	O
performed	O
on	O
IFN-gamma-treated	B-cell_line
human	I-cell_line
cells	I-cell_line
infected	O
with	O
an	O
Ad5	O
E1A	B-DNA
deletion	O
mutant	O
,	O
dl343	O
,	O
or	O
transfected	O
with	O
the	O
Ad5	B-DNA
E1A	I-DNA
gene	I-DNA
.	O


IFN	B-protein
-MCP	O
was	O
not	O
inhibited	O
by	O
infection	O
with	O
dl343	O
,	O
despite	O
the	O
production	O
of	O
large	O
amounts	O
of	O
both	O
early	O
(	O
E1B	B-protein
,	O
p55	B-protein
)	O
and	O
late	O
(	O
hexon	B-protein
)	O
Ad	B-protein
proteins	I-protein
.	O


Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
is	O
a	O
transcriptional	B-protein
activator	I-protein
involved	O
in	O
the	O
induction	O
of	O
IL-2	B-protein
gene	O
expression	O
.	O


We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	B-cell_type
cells	I-cell_type
,	O
an	O
AP-1	B-protein
protein	I-protein
is	O
a	O
component	O
of	O
the	O
NF-AT	B-protein
protein	I-protein
complex	I-protein
.	O


This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
to	O
compete	O
with	O
the	O
NF-AT	B-protein
site	O
for	O
binding	O
to	O
NF-AT	B-protein
and	O
by	O
the	O
capacity	O
of	O
immobilized	B-protein
anti-Jun	I-protein
and	O
anti-Fos	B-protein
antibodies	O
to	O
deplete	O
NF-AT	B-protein
-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


The	O
IL-2R	B-protein
alpha	I-protein
enhancer	O
binds	O
NF-kappa	B-protein
B	I-protein
poorly	O
and	O
is	O
only	O
weakly	O
activated	O
by	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
alone	O
.	O


Surprisingly	O
,	O
the	O
levels	O
of	O
SRF	B-protein
constitutively	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
are	O
consistently	O
higher	O
than	O
in	O
other	O
cell	O
types	O
.	O


The	O
NK-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
is	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
the	O
inhibitory	O
protein	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
(	O
MAD-3	B-protein
)	O
.	O


Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O


Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	B-DNA
to	I-DNA
-130	I-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O


By	O
ablating	O
the	O
expression	O
of	O
the	O
endogenous	O
GATA-1	B-DNA
gene	I-DNA
,	O
we	O
are	O
in	O
a	O
position	O
to	O
introduce	O
a	O
variety	O
of	O
constructs	O
that	O
harbor	O
subtle	O
modifications	O
in	O
flanking	O
or	O
protein-coding	B-DNA
sequences	I-DNA
.	O


Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	O
be	O
possible	O
to	O
define	O
important	O
regulatory	O
domains	O
that	O
can	O
then	O
be	O
assayed	O
using	O
less	O
stringent	O
systems	O
,	O
such	O
as	O
cell-free	O
extracts	O
for	O
in	O
vitro	O
transcription	O
.	O


Structure-function	O
studies	O
of	O
the	O
GATA-1	B-protein
protein	O
could	O
be	O
greatly	O
simplified	O
and	O
a	O
larger	O
number	O
of	O
mutants	O
studied	O
.	O


However	O
,	O
the	O
ES	O
cell	O
system	O
can	O
be	O
used	O
as	O
an	O
alternative	O
until	O
targeted	B-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
become	O
available	O
.	O


If	O
they	O
can	O
not	O
,	O
chimeric	B-protein
proteins	I-protein
can	O
be	O
tested	O
to	O
identify	O
which	O
amino	O
acids	O
distinguish	O
the	O
different	O
family	O
members	O
.	O


We	O
feel	O
that	O
these	O
experiments	O
are	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
GATA-1	B-protein
during	O
erythroid	O
ontogeny	O
.	O


Comparison	O
of	O
a	O
full-length	B-DNA
cDNA	I-DNA
sequence	I-DNA
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
326	O
amino	O
acids	O
,	O
distributed	O
across	O
two	O
exons	B-DNA
.	O


Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	B-protein
region	I-protein
and	O
an	O
``	O
arginine	B-protein
element	I-protein
``	O
(	O
RRLPIF	B-protein
)	O
at	O
the	O
carboxyl	B-protein
terminus	I-protein
.	O


A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O


Regulation	O
of	O
lymphoid-specific	B-DNA
immunoglobulin	I-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
enhancer	I-DNA
by	O
ETS-domain	O
proteins	O
.	O


The	O
enhancer	B-DNA
for	O
the	O
immunoglobulin	B-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
(	O
IgH	B-protein
)	O
activates	O
a	O
heterologous	B-DNA
gene	I-DNA
at	O
the	O
pre-B	O
cell	O
stage	O
of	O
B	B-cell_type
lymphocyte	I-cell_type
differentiation	O
.	O


1	O
,	O
25-Dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
synergistically	O
induce	O
monocytic	B-cell_type
cell	I-cell_type
differentiation	O
:	O
FOS	B-protein
and	O
RB	B-protein
expression	O
.	O


Mice	O
deficient	O
for	O
the	O
55	B-protein
kd	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L.	O
monocytogenes	O
infection	O
.	O


Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	B-protein
-deficient	O
mouse	O
strain	O
.	O


Cells	O
from	O
TNFRp55-/-mutant	O
mice	O
lack	O
expression	O
of	O
TNFRp55	B-protein
but	O
display	O
normal	O
numbers	O
of	O
high	B-protein
affinity	I-protein
TNFRp75	I-protein
molecules	I-protein
.	O


Enhanced	O
IL-2	B-protein
transcription	O
correlates	O
with	O
increased	O
c-fos	B-protein
synthesis	O
and	O
increased	O
Fos	B-protein
content	O
of	O
AP-1	B-protein
.	O


This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function-associated	O
Ag-3	O
pathway	O
.	O


We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	B-DNA
embryonic	I-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
and	O
the	O
alpha	B-DNA
globin	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
HS-40	B-DNA
)	O
located	O
40	B-DNA
kb	I-DNA
upstream	I-DNA
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
.	O


Although	O
sequences	O
located	O
between	O
-559	O
and	O
-88	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	B-DNA
plasmids	I-DNA
,	O
they	O
were	O
required	O
for	O
the	O
HS-40	B-DNA
enhancer	I-DNA
-mediated	O
activity	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
.	O


Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS-40	B-DNA
enhancer	I-DNA
region	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
,	O
adult	B-cell_line
nucleated	I-cell_line
erythroblasts	I-cell_line
,	O
and	O
different	O
nonerythroid	B-cell_type
cells	I-cell_type
.	O


To	O
further	O
evaluate	O
the	O
role	O
of	O
X	B-protein
box	I-protein
DNA-binding	I-protein
proteins	I-protein
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
,	O
the	O
role	O
of	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
was	O
examined	O
in	O
both	O
class	B-cell_line
II-positive	I-cell_line
and	O
-negative	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
.	O


The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	B-cell_line
cells	I-cell_line
and	O
on	O
HIV	O
infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
or	O
continuous	B-cell_line
T-leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
evaluated	O
.	O


Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein-tyrosine	B-protein
kinase	I-protein
regulatory	O
pathway	O
.	O


We	O
show	O
that	O
in	O
B-lymphocyte	B-cell_type
precursors	I-cell_type
,	O
irradiation	O
with	O
gamma-rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine-specific	B-protein
protein	I-protein
kinases	I-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	I-protein
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O


Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation-induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O


Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O


Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	B-DNA
type	I-DNA
2	I-DNA
genome	I-DNA
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O


OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter-relationship	O
between	O
HIV-1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV-1	O
replication	O
.	O


A	O
series	O
of	O
uninfected	B-cell_line
parental	I-cell_line
HL-60	I-cell_line
subclones	I-cell_line
all	O
reduced	O
TR75	B-protein
surface	O
expression	O
in	O
response	O
to	O
TNF-alpha	B-protein
treatment	O
.	O


Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O


When	O
co-transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B-protein
kinase	I-protein
p59fyn	B-protein
,	O
the	O
reporter	B-DNA
gene	I-DNA
was	O
activated	O
by	O
PMA	B-protein
alone	O
.	O


Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	B-protein
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
UT-7	B-cell_line
.	O


In	O
comparison	O
,	O
UT-7	B-cell_line
Epo	I-cell_line
cells	I-cell_line
expressed	O
alpha-globin	O
and	O
higher	O
levels	O
of	O
gamma-globin	B-protein
(	O
5-fold	O
)	O
and	O
beta-globin	B-protein
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O


Globin	B-protein
chains	I-protein
(	O
alpha	B-protein
,	O
beta	B-protein
and	O
gamma	B-protein
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT-7	B-protein
Epo	I-protein
but	O
not	O
in	O
UT-7	B-cell_line
cells	I-cell_line
.	O


The	O
number	O
of	O
gamma-positive	B-cell_line
cells	I-cell_line
and	O
their	O
fluorescence	O
intensity	O
were	O
higher	O
in	O
UT-7	B-protein
Epo	I-protein
than	O
in	O
UT-7	B-cell_line
cells	I-cell_line
(	O
0	O
to	O
17	O
%	O
barely	O
positive	O
cells	O
and	O
23	O
to	O
40	O
%	O
clearly	O
positive	O
cells	O
,	O
respectively	O
)	O
,	O
indicating	O
that	O
the	O
increase	O
in	O
globin	B-RNA
mRNA	I-RNA
observed	O
in	O
UT-7	B-protein
Epo	I-protein
is	O
due	O
to	O
both	O
an	O
increase	O
of	O
gene	O
expression	O
per	O
cell	O
and	O
an	O
increase	O
in	O
numbers	O
of	O
cells	O
containing	O
gamma-globin	B-protein
.	O


Recent	O
isolation	O
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
shows	O
that	O
92	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
5'-flanking	B-DNA
DNA	I-DNA
are	O
sufficient	O
to	O
direct	O
myeloid-specific	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
.	O


We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid-specific	B-protein
factor	I-protein
(	O
PU.1	B-protein
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	B-protein
)	O
to	O
bind	O
in	O
a	O
tissue-specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid-specific	O
expression	O
of	O
CD11b	B-cell_line
.	O


Stimulation	O
of	O
interleukin-1	B-DNA
gene	I-DNA
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	B-protein
factor	I-protein
activities	O
,	O
including	O
those	O
of	O
AP-1	B-protein
,	O
by	O
these	O
protein	B-protein
phosphatase	I-protein
inhibitors	O
.	O


The	O
functional	O
significance	O
of	O
c-Rel	B-protein
involvement	O
in	O
the	O
CD28-responsive	B-protein
complex	I-protein
is	O
demonstrated	O
by	O
transient	O
transfection	O
analysis	O
,	O
where	O
cotransfection	O
of	O
c-Rel	B-protein
augments	O
the	O
level	O
of	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
the	O
CD28-responsive	B-DNA
element	I-DNA
.	O


Two	O
stable	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
established	O
:	O
R59Z	B-cell_line
activator	I-cell_line
cells	I-cell_line
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	B-protein
1	I-protein
trans-activator	I-protein
(	O
Zta	B-protein
)	O
.	O


R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	B-DNA
origin	I-DNA
of	I-DNA
EBV	I-DNA
replication	I-DNA
(	O
ori	B-DNA
Lyt	I-DNA
)	O
.	O


No	O
lytic	O
effect	O
on	O
the	O
reporter	O
cells	O
could	O
be	O
measured	O
,	O
neither	O
by	O
cocultivation	O
of	O
activator	B-cell_line
cells	I-cell_line
nor	O
by	O
coincubation	O
of	O
BZLF	B-protein
1	I-protein
-containing	O
cell	O
lysates	O
.	O


Neither	O
Bt2cAMP	O
nor	O
PMA	O
individually	O
mediated	O
these	O
sustained	O
effects	O
,	O
which	O
therefore	O
appear	O
as	O
a	O
consequence	O
of	O
the	O
interplay	O
between	O
both	O
metabolic	O
stimuli	O
.	O


Tax	B-protein
was	O
transfected	O
into	O
HTLV-I-negative	B-cell_line
human	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O


PMA	O
induced	O
the	O
expression	O
of	O
both	O
CD14	B-protein
and	O
CD23	B-RNA
mRNA	I-RNA
and	O
protein	O
.	O


Southwestern	O
blotting	O
and	O
UV	O
cross-linking	O
studies	O
confirmed	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O


One	O
cDNA	B-DNA
clone	I-DNA
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	B-protein
,	O
a	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
.	O


HL-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
an	O
Egr-1	B-DNA
transgene	I-DNA
(	O
HL-60Egr-1	B-DNA
)	O
could	O
be	O
induced	O
for	O
macrophage	B-cell_type
,	O
but	O
not	O
granulocyte	B-cell_type
,	O
differentiation	O
.	O


In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O


Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM-LDL	B-protein
.	O


Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte-endothelial	O
interactions	O
.	O


Further	O
,	O
deletion	O
of	O
the	O
hGATA-3	B-DNA
transcriptional	I-DNA
activation	I-DNA
domain	I-DNA
abolished	O
GATA-dependent	O
HIV-1	O
trans-activation	O
,	O
showing	O
that	O
the	O
stimulation	O
of	O
viral	O
transcription	O
observed	O
is	O
a	O
direct	O
effect	O
of	O
cotransfected	B-protein
hGATA-3	I-protein
.	O


Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O


Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	B-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


Conversely	O
,	O
several	O
cytokines	B-protein
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	B-cell_type
lymphocytic	I-cell_type
and	I-cell_type
mononuclear	I-cell_type
phagocytic	I-cell_type
lineage	I-cell_type
.	O


Cell-specific	O
expression	O
of	O
helix-loop-helix	B-protein
transcription	I-protein
factors	I-protein
encoded	O
by	O
the	O
E2A	B-DNA
gene	I-DNA
.	O


Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	B-DNA
cDNA	I-DNA
leads	O
to	O
appearance	O
of	O
protein	O
co-migrating	O
with	O
the	O
73	B-protein
kDa	I-protein
protein	I-protein
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co-migrating	O
with	O
LEF1/BCF1	B-protein
on	O
mobility	O
shift	O
analysis	O
.	O


Hypertension	O
in	O
pregnancy	O
.	O


Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O


The	O
data	O
show	O
that	O
hypertension	O
in	O
preeclamptic	O
women	O
can	O
be	O
treated	O
by	O
Urapidil	O
without	O
side	O
effects	O
or	O
reflex-tachycardia	O
.	O


Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O


Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	B-protein
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	B-protein
limited	I-protein
transcription	I-protein
factor	I-protein
NF-E2	O
.	O


Over	O
its	O
3	B-DNA
'	I-DNA
end	I-DNA
,	O
it	O
binds	O
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O


Furthermore	O
,	O
and	O
despite	O
a	O
lack	O
of	O
sequence	O
homology	O
,	O
the	O
promoters	O
of	O
IL-3	B-protein
and	O
IL-2	B-protein
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	O
is	O
likely	O
to	O
be	O
important	O
for	O
the	O
T-cell-specific	O
expression	O
of	O
these	O
genes	O
.	O


These	O
genes	O
encode	O
proteins	O
that	O
form	O
the	O
dimeric	B-protein
complex	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
which	O
is	O
active	O
as	O
a	O
transcriptional	B-protein
factor	I-protein
.	O


The	O
inhibition	O
of	O
c-fos	B-DNA
and	O
c-jun	O
expression	O
by	O
IL-4	B-protein
in	O
LPS-treated	B-cell_type
cells	I-cell_type
was	O
shown	O
to	O
be	O
due	O
to	O
a	O
lower	O
transcription	O
rate	O
of	O
the	O
c-fos	B-DNA
and	I-DNA
c-jun	I-DNA
genes	I-DNA
.	O


These	O
involve	O
activation	O
of	O
the	O
sodium/proton	B-protein
exchanger	I-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
min	O
.	O


The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O


Production	O
of	O
HIV-1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T-cell	B-protein
mitogens	I-protein
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A.	O
Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600-602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C.	O
Gallo	O
,	O
Science	O
231	O
:	O
850-853	O
,	O
1986	O
)	O
.	O


Further	O
evidence	O
suggests	O
that	O
Nef	B-protein
inhibits	O
NF-kappa	B-protein
B	I-protein
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
complex	I-protein
.	O


In	O
PHA-activated	B-cell_line
PBL	I-cell_line
,	O
no	O
age-related	O
differences	O
were	O
observed	O
in	O
c-fos	O
or	O
jun	O
B	O
mRNA	O
expression	O
.	O


However	O
,	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
decreased	O
significantly	O
(	O
1.73	O
+/-	O
0.08	O
vs.	O
1.16	O
+/-	O
0.09	O
arbitrary	O
units	O
,	O
P	O
<	O
0.01	O
,	O
young	O
vs.	O
old	O
)	O
in	O
PBL	B-cell_type
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	B-protein
.	O


Oct2	B-protein
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	B-DNA
octamer	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
however	O
.	O


We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	B-protein
isoforms	I-protein
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	B-DNA
enhancer	I-DNA
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
and	O
a	O
B-cell	B-cell_line
line	I-cell_line
.	O


The	O
glutamine-rich	B-protein
activation	I-protein
domain	I-protein
present	O
in	O
the	O
amino-terminal	B-protein
portion	I-protein
of	I-protein
Oct2	I-protein
and	O
the	O
POU	B-protein
domain	I-protein
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O


The	O
promoter	B-DNA
of	O
the	O
CD19	B-DNA
gene	I-DNA
is	O
a	O
target	O
for	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
.	O


Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre-	O
and	O
postoperative	O
values	O
.	O


Except	O
for	O
PGF2	O
alpha	O
,	O
HHT	O
and	O
15-HETE	O
no	O
detectable	O
quantities	O
of	O
eicosanoids	O
were	O
found	O
in	O
the	O
non-tumor	O
material	O
,	O
whereas	O
in	O
the	O
malignant	O
tumor	O
material	O
substantial	O
quantities	O
of	O
a	O
number	O
of	O
eicosanoid	O
metabolites	O
were	O
present	O
.	O


Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
status	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
the	O
2	O
groups	O
.	O


Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O


The	O
11	O
beta-methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O


Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
but	O
increase	O
the	O
affinity	O
to	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
.	O


1	O
.	O


2	O
.	O


Initial	O
and	O
post-dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	O
different	O
between	O
major	O
depressive	O
disorder	O
and	O
non-depressed	O
control	O
subjects	O
.	O


High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	B-cell_type
leukocytes	I-cell_type
:	O
is	O
there	O
a	O
membrane	B-protein
receptor	I-protein
for	O
mineralocorticoids	O
?	O


The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	O
,	O
but	O
not	O
for	O
cortisol	O
.	O


This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	B-DNA
DNA	I-DNA
sequence	I-DNA
(	O
CTG-motif	B-DNA
)	O
.	O


The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG-monomer	O
virus	O
outcompeted	O
the	O
CTG-dimer	O
virus	O
in	O
42	O
days	O
.	O


To	O
address	O
the	O
role	O
of	O
Oct-2	B-protein
in	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
nontransformed	B-cell_line
human	I-cell_line
and	I-cell_line
mouse	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL-1	B-protein
and	O
GR	B-protein
in	O
aged	O
long-distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O


Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
in	O
mononuclear	B-cell_type
leucocytes	I-cell_type
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O


Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
examined	O
after	O
exposure	O
of	O
whole	B-cell_type
cells	I-cell_type
to	O
10	O
(	O
-9	O
)	O
M/l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O


Pulse	O
exposure	O
of	O
HL60	B-cell_line
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	O
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	B-protein
radiolabeled	I-protein
VDR	I-protein
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	B-protein
by	O
24	O
h	O
.	O


No	O
effect	O
was	O
seen	O
in	O
ethanol	B-cell_line
treated	I-cell_line
controls	I-cell_line
.	O


Enhanced	O
activity	O
of	O
topoisomerases	B-protein
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B-protein
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA-unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O


Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	B-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O


E2-stimulated	B-cell_line
ER+	I-cell_line
cells	I-cell_line
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	B-cell_type
cells	I-cell_type
than	O
corresponding	O
TAM-treated	B-cell_line
or	O
control	B-cell_type
cells	I-cell_type
,	O
while	O
treatment	O
of	O
ER-	B-cell_line
cells	I-cell_line
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	O
alter	O
from	O
control	O
their	O
susceptibility	O
to	O
this	O
immune-mediated	O
lysis	O
.	O


Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
which	O
is	O
itself	O
a	O
DNA-binding	B-protein
protein	I-protein
and	O
transcriptional	B-protein
transactivator	I-protein
,	O
can	O
interact	O
synergistically	O
with	O
Z	B-protein
in	O
activating	O
the	O
BMRF1	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
T-cell	B-cell_line
line	I-cell_line
)	O
or	O
Raji	B-cell_line
cells	I-cell_line
(	O
an	O
EBV-positive	B-cell_line
B-cell	I-cell_line
)	O
,	O
whereas	O
the	O
c-myb	B-protein
gene	I-protein
product	I-protein
by	O
itself	O
has	O
little	O
effect	O
.	O


The	O
simian	B-DNA
virus	I-DNA
40	I-DNA
early	I-DNA
promoter	I-DNA
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
.	O


That	O
the	O
c-myb	B-protein
oncogene	I-protein
product	I-protein
can	O
interact	O
synergistically	O
with	O
an	O
EBV-encoded	B-protein
member	I-protein
of	O
the	O
leucine	B-protein
zipper	I-protein
protein	I-protein
family	I-protein
suggests	O
c-myb	B-DNA
is	O
likely	O
to	O
engage	O
in	O
similar	O
interactions	O
with	O
cellularly	B-protein
encoded	I-protein
transcription	I-protein
factors	I-protein
.	O


Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O


Reticuloendotheliosis	B-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
elements	I-DNA
are	O
efficient	O
promoters	B-DNA
in	O
cells	O
of	O
various	O
species	O
and	O
tissue	O
origin	O
,	O
including	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


REVs	O
do	O
not	O
encode	O
a	O
transactivator	O
targeted	O
to	O
the	O
viral	B-DNA
LTR	I-DNA
,	O
and	O
cells	O
infected	O
with	O
Marek	O
's	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	O
express	O
factors	O
that	O
preferentially	O
enhance	O
expression	O
from	O
REV	O
or	O
avian	B-DNA
sarcoma/leukemia	I-DNA
virus	I-DNA
LTRs	I-DNA
.	O


REV	B-DNA
LTRs	I-DNA
work	O
efficiently	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
and	O
are	O
viable	O
alternatives	O
to	O
promoters	B-DNA
commonly	O
used	O
for	O
expression	O
of	O
cloned	B-DNA
genes	I-DNA
.	O


Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O


Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
.	O


In	O
all	O
subjects	O
,	O
in	O
addition	O
,	O
lymphocyte	B-cell_type
subsets	I-cell_type
were	O
determined	O
as	O
an	O
index	O
of	O
corticosteroid	O
action	O
.	O


All	O
of	O
the	O
parameters	O
were	O
also	O
tested	O
for	O
correlation	O
,	O
and	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
age	O
and	O
type	B-protein
I	I-protein
and	O
type	B-protein
II	I-protein
receptors	I-protein
when	O
all	O
subjects	O
were	O
plotted	O
and	O
between	O
aged	O
and	O
CD4	B-cell_type
and	O
age	O
and	O
CD4/CD8	B-cell_type
in	O
the	O
aged	O
group	O
.	O


These	O
data	O
show	O
that	O
aged	O
subjects	O
have	O
reductions	O
of	O
corticosteroid	B-protein
receptors	I-protein
that	O
are	O
not	O
associated	O
with	O
increase	O
of	O
related	O
steroids	O
and	O
that	O
this	O
situation	O
probably	O
represents	O
a	O
concomitant	O
of	O
the	O
normal	O
aging	O
process	O
.	O


T	O
cell-specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	B-protein
cytokine	I-protein
IL-4	I-protein
.	O


The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	B-cell_type
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	B-DNA
positive	I-DNA
and	I-DNA
negative	I-DNA
transcriptional	I-DNA
regulatory	I-DNA
elements	I-DNA
.	O


Photoaffinity	O
labeling	O
of	O
plasma	B-protein
membrane	I-protein
receptors	I-protein
for	O
aldosterone	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O


Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O


We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O


BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA-	O
or	O
TNF-induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV-enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
both	O
lymphoblastoid	B-cell_line
T	I-cell_line
(	O
J.Jhan	B-cell_line
)	O
and	O
monocytic	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	B-protein
or	O
p65	B-protein
.	O


Similarly	O
,	O
in	O
transfection	O
experiments	O
in	O
which	O
the	O
selective	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
,	O
the	O
p65	B-DNA
-and	I-DNA
p50-selected	I-DNA
motifs	I-DNA
were	O
activated	O
only	O
in	O
the	O
presence	O
of	O
p65	B-protein
and	O
p50/65	B-protein
(	O
a	O
chimeric	B-protein
protein	I-protein
with	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
and	O
p65	B-protein
activation	I-protein
domain	I-protein
)	O
expression	O
vectors	O
,	O
respectively	O
,	O
and	O
neither	O
demonstrated	O
a	O
significant	O
response	O
to	O
stimuli	O
that	O
induce	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O


Deletions	O
in	O
this	O
promoter	B-DNA
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	O
through	O
the	O
NF-kappa	O
B-	O
but	O
not	O
the	O
AP-1-binding	B-DNA
motif	I-DNA
,	O
by	O
bona	O
fide	O
p50/p65	B-protein
heterodimers	I-protein
.	O


T3SO4	O
had	O
no	O
thyromimetic	O
effect	O
on	O
the	O
activity	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
in	O
human	O
erythrocyte	O
membranes	O
at	O
doses	O
up	O
to	O
10	O
,	O
000	O
times	O
the	O
maximally	O
effective	O
dose	O
of	O
T3	O
(	O
10	O
(	O
-10	O
)	O
mol/L	O
)	O
.	O


Propylthiouracil	O
(	O
50	O
mumol/L	O
)	O
did	O
not	O
affect	O
the	O
action	O
of	O
T3SO4	O
,	O
suggesting	O
that	O
deiodination	O
was	O
not	O
important	O
for	O
this	O
activity	O
of	O
T3SO4	O
.	O


We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	B-protein
activity	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/	O
CD69	B-protein
activation	O
pathway	O
.	O


Phorbol	O
esters	O
are	O
required	O
to	O
induce	O
AIM/CD69	B-protein
cell-surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
conjunction	O
with	O
anti-AIM	B-protein
mAb	I-protein
.	O


The	O
increase	O
in	O
AP-1	B-protein
-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	B-protein
but	O
not	O
that	O
of	O
c-jun	B-protein
.	O


Blockade	O
of	O
the	O
DNA-binding	B-protein
complexes	I-protein
with	O
an	O
anti-Fos	B-protein
mAb	I-protein
demonstrated	O
a	O
direct	O
participation	O
of	O
c-Fos	B-protein
in	O
the	O
AP-1	B-protein
complexes	I-protein
induced	O
by	O
anti-AIM	B-protein
mAb	I-protein
.	O


On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester-induced	O
production	O
of	O
O2-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	O
gangliosides	O
.	O


The	O
cDNA	B-DNA
has	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
900	B-DNA
amino	I-DNA
acids	I-DNA
capable	O
of	O
encoding	O
a	O
97-kDa	B-protein
protein	I-protein
.	O


In	O
vitro-translated	B-protein
proteins	I-protein
,	O
truncated	O
downstream	O
of	O
the	O
Rel	B-DNA
domain	I-DNA
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O


The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	I-protein
.	O


Proliferation	O
in	O
response	O
to	O
TG	B-protein
was	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O


Stable	O
expression	O
of	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O


The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	B-protein
protein	I-protein
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	B-protein
,	O
Pol	B-protein
,	O
and	O
Env	B-protein
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O


In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	B-protein
have	O
been	O
identified	O
that	O
inhibit	O
wild-type	O
Rev	B-protein
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O


While	O
all	O
the	O
M10-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV-1	O
.	O


Mitogen	O
stimulation	O
of	O
T-cells	O
increases	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O


PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP-1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O


The	O
binding	B-protein
protein	I-protein
(	O
s	O
)	O
that	O
recognize	O
the	O
P	B-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
were	O
identified	O
by	O
DNA-mobility-shift	O
assays	O
.	O


In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	B-protein
factors	I-protein
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
after	O
LTB4	O
stimulation	O
.	O


Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	B-DNA
,	O
GC-box	B-DNA
and	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
(	O
CLE0	B-DNA
)	O
.	O


Viral	B-protein
trans-activators	I-protein
such	O
as	O
Tax	B-protein
(	O
human	O
T	O
cell	O
leukemia	O
virus-1	O
,	O
HTLV-1	O
)	O
and	O
E2	B-protein
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	B-DNA
gene	I-DNA
expression	O
by	O
bypassing	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
mediated	O
signaling	O
.	O


The	O
trans-activation	O
domain	O
of	O
E2	B-protein
and	O
Tax	B-protein
is	O
interchangeable	O
although	O
they	O
have	O
no	O
obvious	O
sequence	O
homology	O
between	O
them	O
.	O


Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	B-protein
and	O
a	O
combination	O
of	O
the	O
adenosine	B-protein
receptor	I-protein
agonist	O
NECA	O
(	O
5'-	O
(	O
N-ethyl	O
)	O
-carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c-Fos	B-protein
and	O
Jun	B-protein
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O


During	O
the	O
inflammatory	O
response	O
increased	O
levels	O
of	O
PGE2	O
bind	O
to	O
their	O
receptors	O
on	O
T	B-cell_type
cells	I-cell_type
and	O
thus	O
alter	O
responsiveness	O
.	O


2	O
.	O


Thus	O
,	O
the	O
DRA	B-DNA
promoter	I-DNA
discriminates	O
against	O
OTF-1	B-protein
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	B-cell_line
line	I-cell_line
.	O


Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-protein
receptors	I-protein
which	O
is	O
a	O
whole-cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-dexamethasone	O
as	O
radioligand	O
.	O


Our	O
results	O
indicate	O
that	O
the	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B-protein
responsiveness	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O


The	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
was	O
increased	O
in	O
hypertensives	O
vs	O
normotensives	O
.	O


Leukotriene	O
B4	O
(	O
LTB4	O
)	O
is	O
a	O
notable	O
participant	O
in	O
inflammation	O
and	O
chemotaxis	O
.	O


Here	O
,	O
Stanley	O
Korsmeyer	O
provides	O
a	O
brief	O
overview	O
of	O
bcl-2	B-protein
,	O
concentrating	O
on	O
its	O
roles	O
in	O
B-	O
and	O
T-cell	O
development	O
and	O
in	O
oncogenesis	O
.	O


The	O
insertion	O
was	O
not	O
required	O
for	O
Fc	B-protein
gamma	I-protein
RII	I-protein
to	O
modulate	O
surface	B-protein
immunoglobulin	I-protein
-triggered	O
B-cell	O
activation	O
.	O


Instead	O
,	O
regulation	O
of	O
activation	O
involved	O
a	O
region	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
common	O
to	O
both	O
the	O
lymphocyte	B-protein
and	I-protein
macrophage	I-protein
receptor	I-protein
isoforms	I-protein
.	O


[	O
Age-related	O
changes	O
in	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O


The	O
mechanisms	O
of	O
hormone-receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O
the	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
grows	O
in	O
hypertensive	O
patients	O
.	O


The	O
mechanism	O
of	O
action	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
.	O


PLB-IIIB	B-cell_line
cells	I-cell_line
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	B-cell_type
myeloblasts	I-cell_type
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	B-protein
surface	I-protein
markers	I-protein
,	O
and	O
transcription	O
of	O
the	O
c-fms	B-DNA
proto-oncogene	I-DNA
.	O


All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20-30	O
yr	O
with	O
acne	O
,	O
hirsutism	O
,	O
and	O
irregular	O
menstruations	O
.	O


All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O


There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	O
,	O
cortisol	O
,	O
and	O
GH	O
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin-induced	O
hypoglycemia	O
,	O
while	O
cortisol	O
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O


Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O


However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O


The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	B-DNA
for	O
rearrangement	O
are	O
still	O
not	O
known	O
.	O


Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O


Whereas	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen-driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	O
is	O
exactly	O
the	O
same	O
phenomenon	O
that	O
occurs	O
in	O
the	O
thymic	O
cortex	O
.	O


The	O
active	O
nuclear	O
form	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
is	O
composed	O
of	O
two	O
DNA	B-protein
binding	I-protein
subunits	I-protein
,	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
and	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
,	O
both	O
of	O
which	O
share	O
extensive	O
N-terminal	O
sequence	O
homology	O
with	O
the	O
v-rel	B-protein
oncogene	I-protein
product	I-protein
.	O


To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF-kappa	B-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
,	O
a	O
series	O
of	O
human	B-protein
NF-kappa	I-protein
B	I-protein
p65	I-protein
mutants	I-protein
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
-mediated	O
inhibition	O
,	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
-induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O


This	O
factor	O
has	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	B-protein
proteins	I-protein
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O


The	O
candidate	B-protein
oncoprotein	I-protein
Bcl-3	I-protein
is	O
an	O
antagonist	O
of	O
p50/NF-kappa	B-protein
B	I-protein
-mediated	O
inhibition	O
.	O


In	O
addition	O
,	O
activation	O
of	O
c-raf	B-protein
kinase	I-protein
was	O
normal	O
.	O


Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	B-protein
component	I-protein
of	O
NF-AT	B-protein
is	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
.	O


The	O
affinity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
+/-	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
+/-	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
+/-	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O


[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose-dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
abnormality	O
.	O


The	O
resultant	O
primer	B-DNA
products	I-DNA
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O


It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	B-protein
domain	I-protein
of	O
TF	B-protein
with	O
VIIa	B-protein
to	O
form	O
the	O
binary	O
TF.VIIa	B-protein
complex	I-protein
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	B-protein
domain	I-protein
of	O
VIIa	B-protein
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	B-protein
substrate	I-protein
.	O


This	O
provides	O
substantial	O
evidence	O
for	O
an	O
allosteric	O
effect	O
on	O
the	O
catalytic	O
cleft	O
of	O
VIIa	B-protein
that	O
is	O
imparted	O
by	O
binding	O
to	O
TF	B-protein
,	O
its	O
cognate	O
catalytic	O
cofactor	B-protein
.	O


Treatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	B-protein
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane-associated	B-protein
ELAM-1	I-protein
and	O
ICAM-1	B-protein
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O


Dexamethasone	O
markedly	O
inhibited	O
LPS-stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	B-protein
and	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4-9	O
)	O
;	O
inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4-6	O
)	O
.	O


These	O
results	O
suggest	O
a	O
microenvironment-directed	O
,	O
two-step	O
model	O
for	O
GATA-1	B-protein
expression	O
in	O
differentiating	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
that	O
involves	O
(	O
i	O
)	O
cycle-dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage-dependent	O
maintenance	O
or	O
suppression	O
.	O


Specific	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
act	O
in	O
concert	O
with	O
Tat	B-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O


We	O
have	O
found	O
that	O
the	O
p49	B-protein
(	I-protein
100	I-protein
)	I-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
,	O
together	O
with	O
p65	B-protein
,	O
can	O
act	O
in	O
concert	O
with	O
Tat-I	B-protein
to	O
stimulate	O
the	O
expression	O
of	O
HIV-CAT	B-DNA
plasmid	I-DNA
.	O


It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v-erb	B-protein
A	I-protein
function	O
.	O


Within	O
the	O
human	B-DNA
enhancer	I-DNA
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B-protein
I	I-protein
footprints	O
,	O
NFAT-1	B-DNA
and	O
NFIL-2B	B-DNA
,	O
respectively	O
.	O


Furthermore	O
,	O
in	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
inducible	O
interleukin-2	B-DNA
enhancer	I-DNA
function	O
requires	O
the	O
presence	O
of	O
either	O
EBS1	O
or	O
EBS2	B-DNA
.	O


Transcription	O
of	O
the	O
hypersensitive	B-DNA
site	I-DNA
HS2	I-DNA
enhancer	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O


The	O
palindromic	B-DNA
site	I-DNA
(	O
site	B-DNA
B	I-DNA
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	B-DNA
binding	I-DNA
sites	I-DNA
of	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
.	O


This	O
protein	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
including	O
the	O
COUP	B-protein
protein	I-protein
which	O
has	O
a	O
closely	O
related	O
DNA	O
binding	O
specificity	O
.	O


This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O


In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS-derived	B-cell_line
cells	I-cell_line
Tat	B-protein
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR	B-DNA
-independent	O
pathway	O
.	O


A	O
Tat-responsive	B-DNA
element	I-DNA
is	O
found	O
upstream	O
within	O
the	O
viral	B-DNA
promoter	I-DNA
that	O
in	O
glial-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	B-RNA
.	O


Transcription	B-protein
factor	I-protein
AP-2	I-protein
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O


Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	B-protein
produced	I-protein
AP-2	I-protein
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
,	O
and	O
that	O
it	O
required	O
the	O
core	B-DNA
sequence	I-DNA
AGGC	O
for	O
specific	O
binding	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Recombinant	B-protein
OTF-2	I-protein
protein	I-protein
produced	O
by	O
in	O
vitro	O
transcription/translation	O
could	O
also	O
enhance	O
DRA	B-DNA
gene	I-DNA
transcription	O
in	O
vitro	O
.	O


Although	O
IFN-gamma	B-protein
alone	O
does	O
not	O
induce	O
ISG	O
expression	O
,	O
IFN-gamma	B-protein
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


cells/tube	O
in	O
the	O
assay	O
volume	O
0.25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O


We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
.	O


Activation	O
of	O
expression	O
of	O
genes	B-DNA
encoding	O
transcription	B-protein
factors	I-protein
:	O
c-fos	B-DNA
and	O
c-jun	B-DNA
and	O
formation	O
of	O
AP1	B-protein
transcriptional	I-protein
complex	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
was	O
investigated	O
.	O


It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c-fos	B-DNA
and	O
c-jun	B-DNA
expression	O
as	O
well	O
as	O
AP1	B-protein
formation	O
.	O


When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA-induced	B-RNA
mRNA	I-RNA
)	O
.	O


Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O


Expression	O
of	O
Tax	B-protein
protein	I-protein
in	O
19D	B-cell_line
and	O
9J	B-cell_line
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	B-DNA
NF-kappa	I-DNA
B-dependent	I-DNA
granulocyte-macrophage	I-DNA
colony	I-DNA
stimulating	I-DNA
factor	I-DNA
gene	I-DNA
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF-kappa	B-DNA
B-regulated	I-DNA
promoters	I-DNA
.	O


Activation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
antigen	O
,	O
lectin	B-protein
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	B-protein
,	O
including	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O


The	O
GM2	B-DNA
sequence	I-DNA
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	B-protein
factor	I-protein
NF-GM2	I-protein
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	B-protein
factors	I-protein
A1	B-protein
,	O
A2	B-protein
,	O
and	O
B	B-protein
.	O


Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
appearance	O
in	O
response	O
to	O
LPS	O
.	O


Clone	B-DNA
pAT	I-DNA
133	I-DNA
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	B-DNA
factor-induced	I-DNA
genes	I-DNA
with	O
almost	O
identical	O
zinc-finger	B-protein
domains	I-protein
.	O


Except	O
for	O
the	O
conserved	O
zinc-finger	B-protein
domains	I-protein
,	O
the	O
amino	B-protein
acid	I-protein
sequences	I-protein
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O


However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O


Here	O
,	O
we	O
show	O
that	O
v-erbA	B-protein
and	O
c-erbA	B-protein
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	B-DNA
of	O
the	O
erythrocyte-specific	B-protein
carbonic	I-protein
anhydrase	I-protein
II	I-protein
(	O
CAII	B-DNA
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v-erbA	B-protein
.	O


These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B-protein
with	O
its	O
natural	O
ligand	O
,	O
LFA-3	B-protein
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O


Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O


The	O
dimerization	B-protein
domain	I-protein
of	O
KBF1/p50	B-protein
is	O
contained	O
between	B-protein
amino	I-protein
acids	I-protein
201	I-protein
and	I-protein
367	I-protein
.	O


Tissue-specific	O
expression	O
of	O
the	O
platelet	B-DNA
GPIIb	I-DNA
gene	I-DNA
.	O


For	O
these	O
reasons	O
,	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
GPIIb	B-DNA
gene	I-DNA
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA-binding	B-protein
nuclear	I-protein
factors	I-protein
.	O


A	O
fragment	O
extending	O
from	O
-643	B-DNA
to	I-DNA
+33	I-DNA
is	O
capable	O
of	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
the	O
CAT	B-DNA
gene	I-DNA
in	O
transfection	O
experiments	O
.	O


Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
enhancer	I-DNA
(	O
or	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	B-DNA
.	O


Thus	O
,	O
we	O
postulated	O
that	O
the	O
circadian	O
modification	O
of	O
GR	B-protein
was	O
independent	O
of	O
the	O
diurnal	O
fluctuations	O
in	O
plasma	O
cortisol	O
level	O
or	O
the	O
circadian	O
variations	O
in	O
environmental	O
lighting	O
and	O
that	O
the	O
rhythmicity	O
might	O
be	O
regulated	O
by	O
the	O
'circadian	O
pacemaker	O
'	O
located	O
in	O
the	O
human	O
basal	O
brain	O
.	O


Transcription	B-protein
factor	I-protein
requirements	O
for	O
U2	B-RNA
snRNA	I-RNA
-encoding	O
gene	O
activation	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so-called	O
TCEd	B-DNA
(	O
distal	B-DNA
T	I-DNA
cell	I-DNA
element	I-DNA
)	O
acts	O
as	O
an	O
inducible	O
proto-enhancer	B-DNA
element	I-DNA
in	O
E14	B-cell_line
T	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O


The	O
conversion	O
of	O
the	O
TCEd	B-DNA
to	O
a	O
'perfect	B-DNA
'	I-DNA
NF-kB	I-DNA
binding	I-DNA
site	I-DNA
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF-kB	B-protein
to	O
TCEd	B-DNA
DNA	I-DNA
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'converted	B-DNA
'	I-DNA
TCEd	I-DNA
motifs	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O


A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	B-protein
or	O
to	O
the	O
SV40	O
promoter	O
.	O


The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	B-DNA
GATA-1	I-DNA
binding	I-DNA
site	I-DNA
.	O


Glucocorticoid	B-protein
receptors	I-protein
(	O
GcR	B-protein
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	B-cell_type
mononulear	I-cell_type
leukocytes	I-cell_type
(	O
hMNL	B-cell_type
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
's	O
disease	O
patients	O
with	O
or	O
without	O
ketoconazole	O
therapy	O
.	O


Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O


We	O
showed	O
here	O
by	O
mobility-shift	O
assay	O
that	O
T-cell	B-cell_line
lines	I-cell_line
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	B-protein
activities	O
.	O


The	O
Tax1-inducible	B-protein
transcription	I-protein
factors	I-protein
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O


The	O
concentration	O
of	O
corticosteroid	O
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	O
,	O
methylprednisolone	O
,	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
in	O
monocytes	B-cell_type
from	O
CS	O
individuals	O
.	O


There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O


However	O
,	O
in	O
either	O
EL-4	B-cell_line
(	I-cell_line
T	I-cell_line
)	I-cell_line
cells	I-cell_line
or	O
S194	B-cell_line
cells	I-cell_line
,	O
both	O
lower-affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	B-protein
gene	I-protein
product	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF-kappa	B-protein
B	I-protein
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O


In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	B-DNA
IRF-1	I-DNA
gene	I-DNA
linked	O
to	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O


Glucocorticoid	O
pharmacokinetics	O
,	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	I-cell_type
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
.	O


The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA-induced	O
increases	O
in	O
c-jun	O
and	O
c-fos	O
mRNA	O
levels	O
in	O
U-937	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O


Other	O
studies	O
have	O
demonstrated	O
that	O
TPA-induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	B-DNA
and	O
c-fos	B-DNA
genes	I-DNA
in	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
are	O
regulated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O


This	O
induction	O
of	O
CAT	B-protein
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O


These	O
findings	O
suggest	O
that	O
dexamethasone	O
down-regulates	O
TPA-induced	O
transcription	O
of	O
the	O
c-jun	B-DNA
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
.	O


Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O


A	O
family	O
of	O
transcriptional	B-protein
activators	I-protein
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	B-protein
activators	I-protein
recognize	O
a	O
common	O
consensus	B-DNA
motif	I-DNA
(	O
WGATAR	B-DNA
)	O
through	O
a	O
conserved	O
C4	B-protein
zinc	I-protein
finger	I-protein
DNA-binding	I-protein
domain	I-protein
.	O


T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O


Most	O
B	B-cell_line
lymphocyte	I-cell_line
lines	I-cell_line
expressed	O
negligible	O
levels	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid/myeloid	B-cell_line
somatic	I-cell_line
hybrid	I-cell_line
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
may	O
be	O
a	O
dominant	O
characteristic	O
.	O


Levels	O
of	O
occupied	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
protein	I-protein
increased	O
in	O
these	O
HL-60	B-cell_line
cells	I-cell_line
;	O
but	O
the	O
total	O
number	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O


In	O
contrast	O
,	O
nondividing	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
increased	O
markedly	O
.	O


The	O
three	O
jun	B-DNA
genes	I-DNA
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O


The	O
29-kDa	B-protein
proteins	I-protein
phosphorylated	O
in	O
thrombin-activated	B-cell_line
human	I-cell_line
platelets	I-cell_line
are	O
forms	O
of	O
the	O
estrogen	B-protein
receptor-related	I-protein
27-kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
.	O


A	O
murine	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
to	O
an	O
unidentified	B-protein
estrogen	I-protein
receptor-related	I-protein
29-kDa	I-protein
protein	I-protein
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	B-protein
27-kDa	I-protein
protein	I-protein
.	O


We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
active	O
at	O
the	O
pre-B-cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	B-DNA
negative-acting	I-DNA
elements	I-DNA
.	O


The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	B-protein
activators	I-protein
as	O
well	O
as	O
transcriptional	B-protein
repressors	I-protein
.	O


The	O
derived	O
103-amino-acid	B-protein
basic	I-protein
protein	I-protein
has	O
two	O
potential	O
alpha-helical	B-protein
domains	I-protein
separated	O
by	O
a	O
hydrophobic	B-protein
region	I-protein
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O


Consistent	O
with	O
involvement	O
in	O
the	O
G0/G1	B-DNA
switch	I-DNA
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
casein	B-protein
kinase	I-protein
II	I-protein
.	O


Potential	O
sites	O
for	O
transcription	B-protein
factors	I-protein
AP1	B-protein
,	O
AP2	B-protein
,	O
and	O
AP3	B-protein
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O


The	O
transcription	B-protein
factor	I-protein
HIV-TF1	B-protein
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


These	O
results	O
suggest	O
that	O
HIV-TF1	B-protein
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O


Severe	O
5-fluorouracil	O
toxicity	O
secondary	O
to	O
dihydropyrimidine	B-protein
dehydrogenase	I-protein
deficiency	O
.	O


Monitoring	O
DPD	B-protein
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	O
chemotherapy	O
.	O


A	O
thymus-specific	B-protein
member	I-protein
of	O
the	O
HMG	B-protein
protein	I-protein
family	I-protein
regulates	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
C	I-DNA
alpha	I-DNA
enhancer	I-DNA
.	O


The	O
interaction	O
of	O
the	O
Oct2	B-protein
transcription	I-protein
factor	I-protein
with	O
the	O
cognate	B-DNA
octamer	I-DNA
motif	I-DNA
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O


Ectopic	O
expression	O
of	O
cloned	B-DNA
Oct2	I-DNA
cDNA	I-DNA
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non-lymphoid	B-cell_type
cells	I-cell_type
.	O


Different	O
amounts	O
of	O
the	O
various	O
isoforms	B-protein
are	O
present	O
within	O
the	O
same	O
B-cell	B-cell_type
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B-cell	B-cell_type
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	B-protein
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O


[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O


The	O
rate	O
of	O
endogenous	O
cholesterol	O
synthesis	O
in	O
blood	B-cell_type
lymphocytes	I-cell_type
and	O
skin	B-cell_type
fibroblasts	I-cell_type
from	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
was	O
found	O
to	O
be	O
increased	O
in	O
comparison	O
with	O
healthy	O
donors	O
.	O


Thus	O
,	O
both	O
NF-kappa	B-protein
B-binding	I-protein
complexes	I-protein
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O


An	O
age-related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B-protein
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B-protein
.	O


However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	B-protein
in	O
MNL	B-cell_type
did	O
not	O
demonstrate	O
circadian	O
variation	O
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O


However	O
,	O
the	O
C26	B-DNA
element	I-DNA
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	B-protein
,	O
unlike	O
other	O
NF-kappa	B-DNA
B-binding	I-DNA
elements	I-DNA
.	O


These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
contains	O
multiple	B-DNA
functional	I-DNA
elements	I-DNA
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	B-protein
and	I-protein
NF-kappa	I-protein
B-like	I-protein
factors	I-protein
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
in	O
response	O
to	O
p40tax	B-protein
.	O


Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	B-RNA
mRNA	I-RNA
induction	O
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF-kappa	B-protein
B	I-protein
binding	O
activities	O
displayed	O
by	O
different	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
BZLF1	B-protein
protein	I-protein
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
key	O
immediate-early	B-protein
protein	I-protein
which	O
has	O
been	O
shown	O
to	O
disrupt	O
virus	O
latency	O
in	O
EBV-infected	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


We	O
have	O
generated	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
BZ1	B-protein
,	O
to	O
BZLF1	B-protein
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B-protein
,	I-protein
dimeric	I-protein
form	I-protein
and	O
the	O
inactive	B-protein
,	I-protein
monomeric	I-protein
form	I-protein
of	O
the	O
protein	O
.	O


Biopsies	O
of	O
oral	O
hairy	O
leukoplakia	O
,	O
an	O
AIDS-associated	O
lesion	O
characterized	O
by	O
high-level	O
EBV	O
replication	O
,	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
the	O
BZ1	B-protein
monoclonal	B-protein
antibody	I-protein
.	O


Induction	O
of	O
NF-kappa	B-protein
B	I-protein
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV-gene	O
expression	O
.	O


Cells	O
of	O
the	O
monocyte-macrophage	B-cell_type
lineage	I-cell_type
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O


These	O
results	O
indicate	O
that	O
the	O
demonstration	O
of	O
hormone	B-protein
receptor	I-protein
proteins	I-protein
in	O
cells	O
from	O
malignant	O
effusions	O
is	O
possible	O
and	O
that	O
there	O
is	O
a	O
correlation	O
with	O
the	O
status	O
of	O
the	O
primary	O
site	O
of	O
cancer	O
.	O


Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	B-cell_type
have	O
a	O
constitutively	B-protein
active	I-protein
form	I-protein
of	O
NF-kB	B-protein
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O


The	O
regulatory	O
effect	O
of	O
insulin	B-protein
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
of	O
human	B-cell_type
leukocytes	I-cell_type
was	O
assessed	O
by	O
the	O
unoccupied	B-protein
receptor	I-protein
sites	I-protein
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	O
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	B-protein
added	O
to	O
the	O
medium	O
.	O


Thus	O
the	O
inhibitory	O
effect	O
of	O
insulin	B-protein
on	O
the	O
GR	B-protein
binding	O
power	O
is	O
both	O
dose-	O
and	O
time-dependent	O
,	O
which	O
strongly	O
suggests	O
that	O
GR	B-protein
is	O
tonically	O
controlled	O
by	O
insulin	B-protein
concentration	O
change	O
under	O
physiological	O
conditions	O
.	O


An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	O
levels	O
decreased	O
during	O
the	O
follow-up	O
period	O
.	O


This	O
decrease	O
was	O
seen	O
in	O
patients	O
who	O
responded	O
to	O
the	O
therapy	O
as	O
well	O
as	O
in	O
those	O
who	O
did	O
not	O
.	O


5-Aminolevulinate	B-protein
synthase	I-protein
(	O
ALAS	B-protein
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	B-protein
biosynthetic	O
pathway	O
.	O


The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B-protein
ALAS	I-protein
isozymes	I-protein
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O


The	O
two	O
isozymes	B-protein
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N-terminal	B-protein
signal	I-protein
sequences	I-protein
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C-terminal	B-protein
two-thirds	I-protein
of	O
their	O
proteins	O
.	O


Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B-protein
receptors	I-protein
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O


The	O
binding	O
affinity	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O


Upon	O
cotransfection	O
into	O
non-T	B-cell_type
cells	I-cell_type
,	O
TCF-1	B-protein
could	O
transactivate	O
through	O
its	O
cognate	O
motif	O
.	O


However	O
,	O
longer	O
periods	O
of	O
incubation	O
were	O
associated	O
with	O
a	O
return	O
to	O
the	O
distribution	O
of	O
PKC	B-protein
in	O
control	O
cells	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N-ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O


In	B-protein
vitro	I-protein
translated	I-protein
hGR	I-protein
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
.	O


Oligonucleotides	O
containing	O
the	O
consensus	B-DNA
GRE	I-DNA
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	B-DNA
sequences	I-DNA
from	O
glucocorticoid-repressible	B-DNA
genes	I-DNA
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus-long	I-DNA
terminal	I-DNA
repeat	I-DNA
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O


Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O


1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O


The	O
percentage	O
of	O
lavage	B-cell_type
T-lymphocytes	I-cell_type
expressing	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	O
presenting	O
with	O
isolated	O
hilar	O
adenopathy	O
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and/or	O
cavities	O
.	O


These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	O
the	O
gene	O
encoding	O
EBNA	B-protein
2	I-protein
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	B-DNA
usage	O
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	B-DNA
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-429	B-DNA
to	I-DNA
-245	I-DNA
base	I-DNA
pairs	I-DNA
upstream	O
of	O
Cp	B-DNA
is	O
essential	O
for	O
Cp	B-DNA
activity	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
sequences	I-DNA
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
;	O
and	O
(	O
iv	O
)	O
DNase	B-protein
I	I-protein
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
revealed	O
a	O
B-cell-specific	B-DNA
footprint	I-DNA
in	O
the	O
region	O
of	O
the	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
.	O


These	O
data	O
establish	O
for	O
the	O
first	O
time	O
HBxAg	B-protein
as	O
an	O
antigen	O
in	O
the	O
cellular	O
immune	O
response	O
.	O


[	O
Changes	O
in	O
leucocytic	B-protein
estrogen	I-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O


The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
and	I-DNA
NFAT-1	I-DNA
deletion	I-DNA
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	B-protein
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


As	O
a	O
homodimer	O
JunB	B-protein
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	B-protein
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O


These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	B-protein
protein	I-protein
is	O
regulated	O
by	O
the	O
cAMP-dependent	O
second-messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-protein
and	O
other	O
AP-1-related	B-protein
proteins	I-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP-dependent	O
intracellular	O
signaling	O
pathways	O
.	O


PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16-27	O
years	O
,	O
with	O
a	O
mean	O
+/-	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
+/-	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O


RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	O
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	O
;	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	O
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
+/-	O
1750	O
vs	O
7347	O
+/-	O
1285	O
sites/cell	O
;	O
Kd	O
:	O
7.7	O
+/-	O
2.4	O
vs	O
7.4	O
+/-	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O


Inhibition	O
of	O
protein	B-protein
phosphatases	I-protein
by	O
okadaic	O
acid	O
induces	O
AP1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c-jun	B-RNA
mRNA	I-RNA
by	O
okadaic	O
acid	O
.	O


Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	B-protein
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O


A	O
new	O
homeobox	B-DNA
gene	I-DNA
,	O
HB24	B-DNA
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B-lymphocyte	O
cDNA	O
library	O
.	O


In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	B-protein
factor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O


Moreover	O
,	O
platelet-activating	B-protein
factor	I-protein
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B-DNA
proto-oncogenes	I-DNA
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O


In	O
summary	O
,	O
platelet-activating	B-protein
factor	I-protein
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


Tandem	O
copies	O
of	O
this	O
67-bp	B-DNA
MnlI-AluI	I-DNA
fragment	I-DNA
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
driven	O
by	O
the	O
conalbumin	B-DNA
promoter	I-DNA
,	O
stimulated	O
transcription	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O


In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	B-DNA
motif	I-DNA
stimulated	O
transcription	O
in	O
ARH77	B-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
Jurkat	B-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O


However	O
,	O
blockade	O
of	O
the	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channel	I-protein
is	O
not	O
associated	O
with	O
changes	O
in	O
cell-cycle	O
gene	O
activation	O
,	O
IL-2	B-protein
production	O
,	O
IL-2R	B-protein
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O


These	O
results	O
suggest	O
that	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
LTR	I-DNA
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	B-cell_type
types	I-cell_type
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	B-protein
factors	I-protein
present	O
.	O


This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1/ISGF2	B-protein
.	O


TNF	B-protein
alpha	I-protein
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O


The	O
functional	O
domains	O
of	O
the	O
murine	B-DNA
Thy-1	I-DNA
gene	I-DNA
promoter	I-DNA
.	O


It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	B-DNA
site	I-DNA
.	O


DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	B-protein
factors	I-protein
to	O
these	O
elements	B-DNA
,	O
including	O
Sp1	B-protein
and	O
CP1	B-protein
.	O


Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	B-DNA
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
CP1	B-protein
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	B-DNA
sequences	I-DNA
.	O


The	O
purified	O
homodimer	B-protein
(	O
two	O
p50s	B-protein
)	O
of	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
binds	O
the	O
B2	B-DNA
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B-protein
(	O
two	O
p65s	B-protein
plus	O
two	O
p50s	B-protein
)	O
form	O
of	O
the	O
factor	O
.	O


In	O
nuclear	O
extracts	O
from	O
monocytes	B-cell_type
or	O
macrophages	B-cell_type
,	O
induction	O
of	O
NF-KB	B-protein
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O


Thus	O
,	O
in	O
lymphocytes	B-cell_type
,	O
growth-affecting	B-DNA
genes	I-DNA
other	O
than	O
immune	B-protein
receptors	I-protein
risk	O
rearrangements	O
.	O


TR	B-protein
alpha	I-protein
1	I-protein
and	O
TR	B-protein
beta	I-protein
2	I-protein
each	O
formed	O
a	O
single	O
major	O
TR	B-protein
:	I-protein
TREp	I-protein
complex	I-protein
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-protein
beta	I-protein
1	I-protein
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	B-DNA
as	O
an	O
oligomer	B-protein
.	O


A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	B-protein
:	I-protein
TRE	I-protein
complex	I-protein
was	O
also	O
present	O
in	O
NE	O
from	O
T3-unresponsive	B-cell_line
JEG-3	I-cell_line
cells	I-cell_line
.	O


Cell-specific	O
differences	O
in	O
activation	O
of	O
NF-kappa	B-DNA
B	I-DNA
regulatory	I-DNA
elements	I-DNA
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
and	I-DNA
beta	I-DNA
interferon	I-DNA
promoters	I-DNA
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
.	O


Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B-RNA
RNA	I-RNA
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
compared	O
with	O
U937	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
HIV-infected	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
produced	O
higher	O
levels	O
of	O
TNF-alpha	B-protein
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O


TNF-alpha	B-protein
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
TNF-alpha	B-protein
did	O
not	O
induce	O
the	O
HIV	B-DNA
LTR	I-DNA
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B-protein
B	I-protein
in	O
U937	B-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O


The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
before	O
treatment	O
with	O
LPS	O
.	O


This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	B-RNA
RNA	I-RNA
and	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O


The	O
effect	O
of	O
LPS	O
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O


Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O


A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O


The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O


Erythroid-specific	B-DNA
genes	I-DNA
contain	O
binding	O
sites	O
for	O
NF-E1	B-protein
(	O
also	O
called	O
GF-1	B-protein
and	O
Eryf-1	B-protein
;	O
refs	O
1-3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA-binding	B-protein
protein	I-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
.	O


Transcriptional	O
down-regulation	O
of	O
c-myc	B-DNA
expression	O
by	O
protein	O
synthesis-dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c-myc	B-DNA
transcription	O
.	O


Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O


The	O
calcium	O
ionophore-induced	O
c-myc	B-DNA
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O


Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c-myc	B-DNA
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O


Oestrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
are	O
present	O
in	O
neoplastic	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
have	O
been	O
considered	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
differentiation	O
.	O


It	O
is	O
of	O
interest	O
that	O
one	O
of	O
the	O
positive	O
cases	O
was	O
diagnosed	O
as	O
CLL	O
with	O
Richter	O
's	O
transformation	O
confirming	O
earlier	O
findings	O
.	O


Competition	O
analysis	O
showed	O
that	O
the	O
anti-estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type-II	B-protein
EBS	I-protein
.	O


Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose-dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O


Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti-estrogen	O
concentrations	O
and	O
flavonoids	O
may	O
regulate	O
IM-9	B-cell_line
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type-II	B-protein
EBS	I-protein
.	O


Lymphocytic	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko-Cushing	O
's	O
syndrome	O
.	O


Effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	B-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
RWLeu-4	B-cell_line
.	O


The	O
effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	B-cell_line
chromosome-positive	I-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
RWLeu-4	B-cell_line
,	O
were	O
investigated	O
.	O


c-myc	B-RNA
RNA	I-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	B-cell_line
cells	I-cell_line
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O


A	O
complementary	B-DNA
DNA	I-DNA
encoding	O
a	O
DNA-binding	B-protein
protein	I-protein
(	O
human	B-protein
X	I-protein
box	I-protein
binding	I-protein
protein	I-protein
,	O
hXBP-1	B-protein
)	O
whose	O
target	O
is	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
X	I-DNA
box	I-DNA
and	O
the	O
3	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
has	O
now	O
been	O
cloned	O
.	O


Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O
,	O
perceived	O
social	O
support	O
from	O
the	O
patient	O
's	O
physician	O
,	O
estrogen	B-protein
receptor	I-protein
-negative	O
tumor	O
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(	O
R2	O
=	O
0.33	O
,	O
F	O
(	O
5	O
,	O
55	O
)	O
=	O
5.5	O
,	O
p	O
less	O
than	O
0.0004	O
)	O
.	O


Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	O
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O
play	O
in	O
modulating	O
such	O
activity	O
.	O


An	O
in	O
vitro	O
globin	B-DNA
gene	I-DNA
switching	O
model	O
based	O
on	O
differentiated	B-cell_type
embryonic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O


We	O
show	O
that	O
ES-derived	B-cell_type
embryoid	I-cell_type
bodies	I-cell_type
express	O
the	O
full	O
complement	O
of	O
mouse	B-DNA
embryonic	I-DNA
globin	I-DNA
genes	I-DNA
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	B-DNA
genes	I-DNA
.	O


We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	B-DNA
enhancer	I-DNA
B	B-DNA
domain	I-DNA
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R-activating	O
signal	O
to	O
the	O
rabbit	B-DNA
beta-globin	I-DNA
promoter	I-DNA
.	O


In	O
the	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
chronic	O
renal	O
failure	O
and	O
hepatic	O
cirrhosis	O
,	O
the	O
nuclear	B-protein
T3R	I-protein
MBC	O
of	O
lymphocytes	B-cell_type
was	O
about	O
1.5-1.6	O
times	O
of	O
the	O
normal	O
controls	O
.	O


Three	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
patients	O
with	O
VDDR-II	O
(	O
Rh-	O
VDR	B-protein
,	O
Sh-	O
VDR	B-protein
,	O
and	O
Ab-	O
VDR	B-protein
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
a	O
receptor	B-protein
and	O
treatment	O
of	O
the	O
cultured	B-cell_line
cells	I-cell_line
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	O
,	O
25-dihydroxy-vitamin	O
D3	O
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O


Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cells	I-cell_line
.	O


Treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c-jun	B-DNA
transcription	O
.	O


[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O


Transfections	O
of	O
E3	B-DNA
constructs	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	I-DNA
(	O
L2	B-DNA
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	B-cell_type
cells	I-cell_type
.	O


Characterization	O
of	O
defensin	B-protein
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B-DNA
virulence	I-DNA
regulon	I-DNA
of	O
Salmonella	O
typhimurium	O
.	O


The	O
defensin	B-protein
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP/phoQ	B-DNA
two-component	I-DNA
virulence	I-DNA
regulon	I-DNA
were	O
tested	O
by	O
using	O
purified	B-protein
defensins	I-protein
NP-1	B-protein
and	O
NP-2	B-protein
.	O


The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B-DNA
-phoQ	B-DNA
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B-protein
proteins	I-protein
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	B-cell_type
.	O


We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B-protein
B	I-protein
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	B-DNA
LTR	I-DNA
or	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O


Interleukin	B-protein
2	I-protein
induced	O
proliferation	O
but	O
not	O
NF-kappa	B-protein
B	I-protein
translocation	O
or	O
LTR	B-DNA
transactivation	O
.	O


The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-protein
B	I-protein
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O


Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O


On	O
the	O
contrary	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate-supplemented	O
patients	O
(	O
58.3	O
+/-	O
2.7	O
)	O
and	O
controls	O
.	O


There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B-protein
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O


Two	O
distinct	O
forms	O
of	O
active	B-protein
transcription	I-protein
factor	I-protein
CREB	I-protein
(	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
.	O


As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	B-protein
proteins	I-protein
bind	O
DNA	O
as	O
dimers	O
.	O


BSAP	B-protein
is	O
exclusively	O
restricted	O
to	O
the	O
B-cell	O
lineage	O
of	O
lymphoid	O
differentiation	O
.	O


Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O


Octamer	B-protein
transcription	I-protein
factors	I-protein
and	O
the	O
cell	B-DNA
type-specificity	I-DNA
of	I-DNA
immunoglobulin	I-DNA
gene	I-DNA
expression	O
.	O


The	O
octamer	B-DNA
sequence	I-DNA
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	B-DNA
and	O
the	O
enhancer	B-DNA
of	O
Ig	B-DNA
genes	I-DNA
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O


It	O
appears	O
that	O
the	O
B	O
cell-specific	O
expression	O
of	O
Ig	B-DNA
genes	I-DNA
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type-specific	B-protein
Oct	I-protein
factors	I-protein
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	B-protein
and	O
Oct-2	B-protein
factors	I-protein
.	O


Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	B-RNA
transcript	I-RNA
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O


The	O
transcriptional	B-DNA
enhancer	I-DNA
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
constant	I-DNA
region	I-DNA
is	O
a	O
major	O
determinant	O
of	O
B-cell-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O


It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	B-cell_type
cells	I-cell_type
and	O
non-B	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O
of	O
p24	B-protein
gag	I-protein
protein	I-protein
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	O
constructs	O
.	O


High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	B-DNA
mutant	I-DNA
constructs	I-DNA
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	B-DNA
region	I-DNA
or	O
by	O
disruption	O
of	O
the	O
tat	B-DNA
gene	I-DNA
.	O


Under	O
carbimazole	O
,	O
the	O
plasma	O
T4	O
markedly	O
decreased	O
(	O
27.7	O
+/-	O
3.6	O
nmol/l	O
)	O
but	O
the	O
patient	O
remained	O
euthyroid	O
.	O


Inducible	O
nuclear	B-protein
factor	I-protein
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal-dependent	O
manner	O
.	O


In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O


The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	B-protein
phytohemagglutinin	B-protein
whereas	O
phorbol	O
myristate	O
acetate-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O


The	O
differentiation	O
of	O
T	B-cell_type
cells	I-cell_type
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O


DNA-protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B-protein
molecular	I-protein
weight	I-protein
complex	I-protein
on	O
the	O
enhancer	B-DNA
.	O


The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	B-DNA
sites	I-DNA
and	O
correlates	O
with	O
maximal	O
enhancer	B-DNA
activity	O
.	O


Identification	O
of	O
a	O
novel	B-protein
factor	I-protein
that	O
interacts	O
with	O
an	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B-protein
cell-specific	I-protein
factor	I-protein
OTF2	B-protein
.	O


The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B-DNA
element	I-DNA
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B-protein
factors	I-protein
involves	O
cooperation	O
between	O
octamer	B-DNA
and	I-DNA
heptamer	I-DNA
sites	I-DNA
in	O
this	O
promoter	B-DNA
.	O


In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	B-DNA
element	I-DNA
,	O
the	O
N	B-DNA
element	I-DNA
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3'	O
.	O


As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O
and	O
oligonucleotide	O
competition	O
experiments	O
,	O
purified	O
NF-kappa	B-protein
B	I-protein
binds	O
at	O
positions	B-DNA
-82	I-DNA
to	I-DNA
-91	I-DNA
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	B-DNA
functional	I-DNA
kappa	I-DNA
B	I-DNA
motif	I-DNA
in	O
the	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
(	O
GGGAAATTCC	O
)	O
.	O


Alone	O
,	O
PMA	O
and	O
calcium	O
ionophore	O
A23187	O
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
,	O
leucine	O
and	O
,	O
in	O
particular	O
,	O
thymidine	O
incorporation	O
.	O


Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language	O
.	O


On	O
the	O
other	O
hand	O
,	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O


The	O
increased	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
observed	O
in	O
adherent	B-cell_type
monocytes	I-cell_type
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	B-RNA
of	O
the	O
early	B-DNA
growth	I-DNA
response	I-DNA
genes	I-DNA
c-fos	B-DNA
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O


Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O


We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF-AT	B-protein
transcriptional	O
activity	O
among	O
T	B-cell_type
cells	I-cell_type
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
directs	O
transcription	O
of	O
the	O
lacZ	B-DNA
gene	I-DNA
.	O


Further	O
results	O
,	O
in	O
which	O
beta-gal	B-protein
activity	O
is	O
correlated	O
with	O
NF-AT	B-protein
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	B-protein
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O


Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
entire	O
interleukin-2	B-DNA
enhancer	I-DNA
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B-protein
factors	I-protein
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B-DNA
genes	I-DNA
.	O


Complementary	B-DNA
DNA	I-DNA
encoding	O
the	O
human	B-protein
T-cell	I-protein
FK506-binding	I-protein
protein	I-protein
,	O
a	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
distinct	O
from	O
cyclophilin	B-protein
.	O


In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
cDNA	B-DNA
coding	O
for	O
FK506-binding	O
protein	O
(	O
FKBP	B-protein
)	O
from	O
human	O
peripheral	O
blood	O
T	B-cell_type
cells	I-cell_type
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
,	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	O
,	O
reported	O
for	O
bovine	B-protein
FKBP	I-protein
.	O


Computer-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
indicates	O
that	O
FKBP	B-protein
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	B-protein
.	O


Involvement	O
of	O
a	O
second	O
lymphoid-specific	B-DNA
enhancer	I-DNA
element	I-DNA
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
gene	I-DNA
expression	O
.	O


This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	B-DNA
site	I-DNA
.	O


Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	B-DNA
motif	I-DNA
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O


The	O
transactivator	B-DNA
(	I-DNA
IE-2	I-DNA
)	I-DNA
gene	I-DNA
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O


Both	O
HIV-2	O
and	O
CMV	B-DNA
transactivators	I-DNA
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	B-DNA
transactivator	I-DNA
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O


These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O


The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O


Reactivity	O
of	O
lymphocytes	B-cell_line
to	O
a	O
progesterone	B-protein
receptor-specific	I-protein
monoclonal	I-protein
antibody	I-protein
.	O


Using	O
an	O
avidin	B-protein
-biotin	B-protein
peroxidase	I-protein
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+/-	O
3.7	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
27	O
)	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
,	O
while	O
only	O
0.47	O
+/-	O
0.33	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	B-cell_type
lymphocytes	I-cell_type
reacted	O
with	O
the	O
antibody	O
.	O


To	O
characterize	O
the	O
receptor-bearing	O
subset	O
,	O
CD8+	B-cell_line
and	I-cell_line
CD4+	I-cell_line
cells	I-cell_line
were	O
depleted	O
by	O
complement-dependent	O
lysis	O
.	O


Fibronectin	B-protein
synergized	O
with	O
anti-CD3	B-protein
antibody	I-protein
to	O
promote	O
CD4	B-protein
cell	O
proliferation	O
in	O
a	O
serum-free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-cell_line
cells	I-cell_line
were	O
cultured	O
with	O
anti-CD3	B-protein
alone	O
or	O
fibronectin	B-protein
alone	O
.	O


In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B-protein
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-protein
-VLA-5	O
fibronectin	B-protein
receptor	I-protein
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B-protein
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B-protein
transcriptional	I-protein
factor	I-protein
.	O


No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O
T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ	O
.	O


We	O
propose	O
that	O
malignant	O
cell	O
cytokine	B-protein
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O


The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O


The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O


Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	B-protein
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O


A	O
novel	O
T-cell	B-protein
trans-activator	I-protein
that	O
recognizes	O
a	O
phorbol	B-DNA
ester-inducible	I-DNA
element	I-DNA
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O


These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O


The	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	I-DNA
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	B-DNA
(	O
Tax-response	B-DNA
element	I-DNA
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	B-protein
encoded	I-protein
transactivator	I-protein
protein	I-protein
Tax	B-protein
.	O


We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B-protein
proteins	I-protein
from	O
C81-66-45	O
cells	O
,	O
an	O
HTLV-I	B-cell_line
immortalized	I-cell_line
Tax-expressing	I-cell_line
human	I-cell_line
T-lymphocyte	I-cell_line
line	I-cell_line
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE-DNA	B-DNA
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax-protein	B-protein
.	O


Two	O
complementary	B-DNA
DNAs	I-DNA
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF-1	B-protein
and	O
ITF-2	B-protein
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5/kappa	B-DNA
2	I-DNA
motif	I-DNA
found	O
in	O
both	O
heavy	B-DNA
and	I-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancers	I-DNA
.	O


The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


The	O
internal	O
methionine	O
codons	O
of	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
II	I-DNA
rex	I-DNA
gene	I-DNA
are	O
not	O
required	O
for	O
p24rex	B-protein
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O


These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	B-cell_line
glioblastoma	I-cell_line
and	I-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Rex	B-protein
is	O
a	O
phosphoprotein	B-protein
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O


Cell	O
proliferation	O
of	O
CEM-C7	B-cell_line
cells	O
cultured	O
in	O
both	O
serum-free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O


In	O
this	O
work	O
,	O
the	O
mixed	B-cell_type
leucocytes	I-cell_type
were	O
further	O
separated	O
into	O
mononuclear	B-cell_type
(	I-cell_type
MNL	I-cell_type
)	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
(	I-cell_type
PML	I-cell_type
)	I-cell_type
leucocytes	I-cell_type
,	O
and	O
GCR	B-protein
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	B-cell_type
.	O


GCR	B-protein
on	O
MNL	B-cell_type
,	O
PML	B-cell_type
and	O
mixed	B-cell_type
leucocytes	I-cell_type
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O


All	O
immunoglobulin	B-DNA
genes	I-DNA
contain	O
a	O
conserved	O
octanucleotide	B-DNA
promoter	I-DNA
element	I-DNA
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell-specific	O
transcription	O
.	O


Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	B-protein
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	B-protein
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O


These	O
results	O
suggest	O
that	O
OTF-1	B-protein
,	O
without	O
OTF-2	B-protein
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
and	O
that	O
OTF-2	B-protein
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
.	O


Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O


A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O


Octamer-dependent	O
activation	O
of	O
a	O
reporter	B-DNA
plasmid	I-DNA
or	O
NF-kappa	B-protein
B	I-protein
-dependent	O
activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
enhancer	I-DNA
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	B-cell_line
transfected	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	B-protein
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B-protein
proteins	I-protein
.	O


Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	B-cell_line
cells	I-cell_line
stabilized	O
the	O
c-myc	B-RNA
mRNA	I-RNA
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min	O
.	O


The	O
immune	O
response	O
to	O
the	O
X	B-protein
protein	I-protein
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	B-protein
fusion	I-protein
proteins	I-protein
and	O
synthetic	O
peptides	O
.	O


Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O


The	O
carboxy-terminal	B-protein
half	I-protein
of	O
the	O
HBx	B-protein
protein	I-protein
was	O
preferentially	O
recognized	O
by	O
antibodies	B-protein
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	B-protein
antigenic	I-protein
region	I-protein
with	O
at	O
least	O
two	O
major	O
nonoverlapping	B-protein
epitopes	I-protein
.	O


Heterogeneity	O
of	O
antigen	B-protein
molecules	I-protein
recognized	O
by	O
anti-tax1	B-protein
monoclonal	I-protein
antibody	I-protein
Lt-4	B-protein
in	O
cell	O
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O


Using	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
Lt-4	B-protein
,	O
directed	O
against	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
trans-activator	I-protein
(	I-protein
tax1	I-protein
)	I-protein
antigen	I-protein
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B-protein
and	O
related	O
antigens	B-protein
in	O
a	O
variety	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
bearing	O
HTLV-I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV-I	O
)	O
and	O
HTLV-II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O


In	O
the	O
STLV-I-bearing	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
tax1-related	B-protein
antigen	I-protein
molecules	I-protein
detected	O
by	O
Lt-4	B-protein
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36-41	O
kd	O
.	O


Both	O
C1	B-protein
and	O
C2	B-protein
proteins	I-protein
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	I-DNA
.	O


In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O


Several	O
new	O
4	O
,	O
19-substituted	O
steroids	O
and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	B-protein
1	I-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O


11	O
beta	O
,	O
19-epoxy-4	O
,	O
21-dihydroxypregn-4-ene-3	O
,	O
20-dione	O
(	O
2	O
)	O
was	O
hydrogenated	O
with	O
Pd-C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21-diacetoxy-11	O
beta	O
,	O
19-epoxy-3-hydroxypregnan-20-one	O
(	O
6	O
)	O
and	O
21-acetoxy-11	O
beta	O
,	O
19-epoxy-4-hydroxypregnane-3	O
,	O
20-dione	O
(	O
7	O
)	O
.	O


This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O


NFAT-1	B-protein
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	B-cell_type
T-lymphocytes	I-cell_type
upon	O
release	O
of	O
intracellular	B-cell_type
calcium	I-cell_type
.	O


By	O
targeting	O
NFAT-1	B-protein
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	B-protein
activity	O
.	O


A	O
novel	O
T-cell	B-protein
protein	I-protein
which	O
recognizes	O
a	O
palindromic	B-DNA
sequence	I-DNA
in	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O


This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
is	O
mediated	O
by	O
specific	O
progesterone	B-protein
receptors	I-protein
.	O


In	O
a	O
study	O
of	O
cellular	B-protein
proteins	I-protein
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
murine	O
retroviruses	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
we	O
have	O
discovered	O
that	O
a	O
member	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	I-DNA
encodes	O
a	O
sequence-specific	B-protein
DNA-binding	I-protein
protein	I-protein
.	O


In	O
this	O
study	O
,	O
the	O
fluctuations	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
during	O
the	O
menstrual	O
cycle	O
were	O
analyzed	O
in	O
6	O
normally	O
menstruating	O
women	O
.	O


Ras-related	B-protein
GTP-binding	I-protein
proteins	I-protein
and	O
leukocyte	B-cell_type
signal	O
transduction	O
.	O


B-cell-specific	B-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
Pax-gene	B-DNA
family	I-DNA
of	O
transcription	B-protein
factors	I-protein
;	O
in	O
the	O
lymphoid	O
system	O
,	O
BSAP	B-protein
is	O
produced	O
only	O
in	O
B	B-cell_type
cells	I-cell_type
.	O


When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased	O
.	O


MZF-1	B-DNA
represses	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
via	O
GAL4	B-protein
binding	O
sites	O
in	O
the	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
NIH	B-cell_line
3T3	I-cell_line
and	O
293	B-cell_line
.	O


In	O
contrast	O
,	O
MZF-1	B-DNA
activates	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
the	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
K562	B-cell_line
and	O
Jurkat	B-cell_line
.	O


These	O
results	O
suggest	O
that	O
BCL6	B-protein
plays	O
a	O
role	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
as	O
an	O
immediate	O
early	O
gene	O
.	O


The	O
DNA-binding	O
properties	O
of	O
two	B-protein
heat	I-protein
shock	I-protein
factors	I-protein
,	O
HSF1	B-protein
and	O
HSF3	B-protein
,	O
are	O
induced	O
in	O
the	O
avian	B-cell_line
erythroblast	I-cell_line
cell	I-cell_line
line	I-cell_line
HD6	B-cell_line
.	O


As	O
occurs	O
for	O
HSF1	B-protein
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B-protein
to	O
the	O
nucleus	O
.	O


Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B-protein
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B-protein
dephosphorylation	O
.	O


Activation	O
and	O
expression	O
of	O
the	O
nuclear	B-protein
factors	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
in	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
:	O
regulation	O
upon	O
CD16	B-protein
ligand	O
binding	O
.	O


The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B-protein
synthesis	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O


NK	B-cell_type
cells	I-cell_type
do	O
not	O
express	O
NFATc	B-protein
constitutively	O
,	O
but	O
NFATc	B-RNA
mRNA	I-RNA
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O


The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B-protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O


While	O
the	O
binding	O
of	O
IL-2	B-protein
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	B-protein
,	O
Jak-1	B-protein
and	O
Jak-3	B-protein
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O


Menopause	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
blood	O
monocyte	O
number	O
and	O
a	O
relative	O
decrease	O
in	O
the	O
expression	O
of	O
estrogen	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O


RESULTS	O
:	O
During	O
menopause	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
the	O
percentage	O
of	O
ER	B-cell_type
positive	I-cell_type
monocytes	I-cell_type
,	O
and	O
an	O
increase	O
in	O
blood	B-cell_type
monocyte	I-cell_type
number	O
,	O
which	O
declines	O
following	O
estrogen	O
replacement	O
therapy	O
to	O
values	O
of	O
the	O
young	O
.	O


Staphylococcal	B-protein
enterotoxins	I-protein
(	O
SE	B-protein
)	O
stimulate	O
T	B-cell_type
cells	I-cell_type
expressing	O
the	O
appropriate	O
variable	B-protein
region	I-protein
beta	I-protein
chain	I-protein
of	I-protein
(	I-protein
V	I-protein
beta	I-protein
)	I-protein
T-cell	I-protein
receptors	I-protein
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O


Here	O
,	O
we	O
show	O
that	O
SE	B-protein
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
beta	I-protein
and	I-protein
gamma	I-protein
chains	I-protein
(	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
)	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O


Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B-protein
and	O
SEB	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
was	O
down-regulated	O
,	O
IL-2R	B-protein
gamma	I-protein
was	O
slightly	O
up-regulated	O
,	O
while	O
IL-2R	B-protein
alpha	I-protein
remained	O
largely	O
unaffected	O
.	O


Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
fibroblasts	B-cell_type
.	O


IL-7	B-protein
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose-dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-protein
1	I-protein
and	O
Jak	B-protein
3	I-protein
and	O
concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	B-protein
proteins	I-protein
.	O


The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	B-protein
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O


Although	O
the	O
interrelationship	O
between	O
the	O
two	O
messengers	O
Ca2+	O
and	O
cyclic	O
AMP	O
in	O
platelet	O
function	O
is	O
well	O
documented	O
,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established	O
.	O


We	O
could	O
show	O
a	O
decrease	O
in	O
the	O
expression	O
as	O
well	O
as	O
in	O
the	O
phosphorylation	O
of	O
Rap1	B-protein
protein	I-protein
and	O
demonstrate	O
a	O
lower	O
effect	O
of	O
C.	B-protein
Sub	I-protein
.	I-protein
on	O
Ca2+	O
transport	O
.	O


The	O
tumour	B-protein
suppressor	I-protein
p53	I-protein
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	B-cell_type
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53	B-protein
-independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen-activated	B-cell_line
mature	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O


Ectopic	O
overexpression	O
of	O
IRF-1	B-protein
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	B-DNA
gene	I-DNA
for	O
ICE	B-protein
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation-induced	O
apoptosis	O
.	O


2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	B-cell_type
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B-protein
.	O


Identification	O
of	O
an	O
ionomycin/cyclosporin	B-DNA
A-responsive	I-DNA
element	I-DNA
within	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
enhancer	I-DNA
.	O


Coexpression	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell-T-cell	O
syncytia	O
.	O


These	O
results	O
indicate	O
that	O
Cu2+	O
inhibits	O
the	O
release	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


The	O
B4-2	B-DNA
clone	O
coded	O
for	O
an	O
mRNA	B-RNA
of	O
2061	O
bp	O
in	O
length	O
.	O


A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B-protein
B4-2	I-protein
recognizes	O
a	O
32-34	B-protein
kDa	I-protein
protein	I-protein
in	O
lymphocytes	B-cell_type
.	O


Activation	O
of	O
JAK3	B-protein
,	O
but	O
not	O
JAK1	B-protein
,	O
is	O
critical	O
for	O
IL-2	B-protein
-induced	O
proliferation	O
and	O
STAT5	B-protein
recruitment	O
by	O
a	O
COOH-terminal	B-protein
region	I-protein
of	O
the	O
IL-2	B-protein
receptor	I-protein
beta-chain	I-protein
.	O


Furthermore	O
,	O
when	O
human	B-protein
IL-2R	I-protein
beta	I-protein
was	O
stably	O
expressed	O
in	O
murine	B-cell_line
BA/F3	I-cell_line
cells	I-cell_line
,	O
robust	O
IL-2	B-protein
-induced	O
proliferation	O
and	O
JAK3	B-protein
activation	O
occurred	O
without	O
detectable	O
involvement	O
of	O
either	O
JAK1	B-protein
,	O
JAK2	B-protein
or	O
TYK2	B-protein
.	O


It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B-protein
-proteasome	B-protein
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	B-protein
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O


OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long-term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-protein
receptor	I-protein
status	O
,	O
in	O
hirsute	O
women	O
.	O


A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH-stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha-hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O


An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
compared	O
with	O
control	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
observed	O
.	O


Lastly	O
,	O
the	O
different	O
mobilities	O
of	O
osteoblast	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
compared	O
with	O
T-cell	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
,	O
along	O
with	O
the	O
inability	O
of	O
OSF2	B-protein
to	O
be	O
upregulated	O
by	O
retinoic	O
acid	O
,	O
unlike	O
the	O
other	O
PEBP2	B-protein
alpha	I-protein
factors	I-protein
,	O
suggest	O
that	O
OSF2	B-protein
is	O
a	O
new	O
member	O
of	O
this	O
family	O
of	O
transcription	B-protein
factors	I-protein
.	O


We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	B-protein
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	B-protein
and	O
that	O
the	O
dimer	B-protein
is	O
the	O
relevant	B-protein
DNA-binding	I-protein
species	I-protein
.	O


The	O
evolutionarily	O
conserved	O
N-terminal	B-protein
half	I-protein
of	O
IBR/F	B-protein
harbors	O
the	O
DNA-binding/dimerization	B-protein
domain	I-protein
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	B-protein
kinase	I-protein
II	I-protein
sites	I-protein
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	B-protein
nuclear	I-protein
localization	I-protein
signal	I-protein
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O


Triggering	O
of	O
the	O
human	O
interleukin-6	O
gene	O
by	O
interferon-gamma	O
and	O
tumor	O
necrosis	O
factor-alpha	O
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-protein
regulatory	I-protein
factor-1	I-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
.	O


An	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
cell	I-cell_line
line	I-cell_line
derived	O
from	O
her	O
lymphocytes	B-cell_type
had	O
normal	O
gamma	B-protein
c	I-protein
expression	O
but	O
lacked	O
Jak3	B-protein
protein	I-protein
and	O
had	O
greatly	O
diminished	O
Jak3	B-RNA
messenger	I-RNA
RNA	I-RNA
.	O


The	O
lack	O
of	O
Jak3	B-protein
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL-4	B-protein
to	O
activate	O
Stat6	B-protein
in	O
the	O
EBV-transformed	B-cell_line
cell	I-cell_line
line	I-cell_line
from	O
the	O
patient.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B-protein
c	I-protein
are	O
dependent	O
on	O
Jak3	B-protein
and	O
that	O
Jak3	B-protein
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O


Constitutive	O
overexpression	O
of	O
the	O
L-selectin	B-DNA
gene	I-DNA
in	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
of	O
adult	O
T-cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
.	O


Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L-selectin	B-DNA
gene	I-DNA
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O


The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L-selectin	B-protein
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+/-	O
SD	O
,	O
4	O
,	O
215.4	O
+/-	O
4	O
,	O
111	O
ng/mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+/-	O
SD	O
,	O
1	O
,	O
148.0	O
+/-	O
269.0	O
ng/mL	O
and	O
991.9	O
+/-	O
224	O
ng/mL	O
,	O
respectively	O
)	O
.	O


We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
(	O
Bsm	O
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	B-DNA
gene	I-DNA
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race-	O
and	O
age-matched	O
control	O
subjects	O
.	O


Platelet	B-protein
thromboxane	I-protein
receptors	I-protein
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O


These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	B-protein
thromboxane	I-protein
receptors	I-protein
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
in	O
platelet-progenitor	B-cell_type
cells	I-cell_type
.	O


As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value	O
,	O
we	O
sought	O
to	O
test	O
the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow-up	O
NK	O
activity	O
in	O
this	O
serially	O
assessed	O
group	O
of	O
patients	O
.	O


Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O


Now	O
,	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
sequence-specific	B-protein
HMG-box	I-protein
of	O
the	O
SRY-related	B-protein
protein	I-protein
Sox-4	B-protein
.	O


These	O
results	O
suggested	O
that	O
the	O
bound	B-protein
kinase	I-protein
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C-terminal	B-protein
region	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
subsequent	O
dissociation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
.	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
complex	I-protein
.	O


The	O
TCF-1	B-DNA
gene	I-DNA
encodes	O
a	O
putative	B-protein
transcription	I-protein
factor	I-protein
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T-cell	B-DNA
enhancers	I-DNA
.	O


In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O


Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF-1	B-protein
protein	I-protein
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3+	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
peripheral	O
lymphoid	O
tissues	O
.	O


Elevation	O
of	O
the	O
levels	O
of	O
circulating	B-protein
immune	I-protein
complexes	I-protein
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O


In	O
THP-1	B-cell_line
cells	I-cell_line
,	O
Fc	B-protein
gamma	I-protein
R	I-protein
cross-linking	O
induced	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O
Anti-TNF-alpha	B-protein
antibody	I-protein
but	O
not	O
anti-IL-1	B-protein
beta	I-protein
antibody	I-protein
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
Fc	B-protein
gamma	I-protein
R	I-protein
cross-linking	O
.	O


Anti-	O
CD28	B-protein
MoAb	I-protein
costimulation	O
increased	O
NF	B-protein
kappa	I-protein
B	I-protein
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O


We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C/EBP	B-protein
proteins	I-protein
and	O
C/EBP	B-DNA
sites	I-DNA
in	O
regulating	O
transcription	O
from	O
the	O
HIV-	B-DNA
1	I-DNA
LTR	I-DNA
in	O
monocytes/macrophages	B-cell_type
.	O


Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O


We	O
report	O
here	O
that	O
both	O
NF-M-dependent	B-DNA
promoter	I-DNA
constructs	I-DNA
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta-estradiol	O
to	O
the	O
NF-M-estrogen	B-cell_line
receptor	I-cell_line
expressing	I-cell_line
progenitors	I-cell_line
.	O


PRL	B-protein
and	O
IL-2	B-protein
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak/Stat	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	O
pathway	O
.	O


We	O
investigated	O
the	O
ability	O
of	O
PRL	B-protein
and	O
IL-2	B-protein
to	O
activate	O
Stat	B-protein
proteins	I-protein
in	O
different	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	B-protein
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	B-protein
factors	I-protein
mammary	B-protein
gland	I-protein
factor-Stat5	I-protein
and	O
Stat1	B-protein
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O


Cis-acting	B-DNA
elements	I-DNA
with	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
AP-1	B-protein
and	O
ETS-like	B-DNA
motifs	I-DNA
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O


The	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B-protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B-protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O


Data	O
from	O
cell	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
TR	B-protein
expression	O
may	O
be	O
regulated	O
to	O
modulate	O
target	O
organ	O
responsiveness	O
to	O
thyroid	O
hormone	O
.	O


Human	B-RNA
TR	I-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
lymphocytes	B-cell_type
were	O
1.8	O
+/-	O
0.4	O
,	O
1.9	O
+/-	O
0.5	O
,	O
1.1	O
+/-	O
0.4	O
10	O
(	O
-18	O
)	O
mol/microgram	O
RNA	O
in	O
hypo-	O
,	O
eu	O
-and	O
hyperthyroid	O
patients	O
,	O
respectively	O
,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell	O
.	O


A	O
strong	O
repressor	B-protein
element	I-protein
,	O
termed	O
nuclear	B-protein
inhibitory	I-protein
protein	I-protein
(	O
NIP	B-protein
)	O
,	O
was	O
previously	O
mapped	O
to	O
a	O
segment	O
of	O
the	O
IL-3	B-DNA
promoter	I-DNA
between	O
nucleotides	B-DNA
-271	I-DNA
and	I-DNA
-250	I-DNA
.	O


DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O


Complex	B-protein
1	I-protein
results	O
from	O
binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3	B-DNA
'	I-DNA
portion	I-DNA
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O
.	O


B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B-DNA
motif	I-DNA
requires	O
the	O
Oct1	B-protein
or	O
Oct2	B-protein
protein	I-protein
and	O
additional	O
B	B-protein
cell-restricted	I-protein
cofactors	I-protein
.	O


Stimulation	O
of	O
cells	O
with	O
anti-IgM	B-protein
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	B-protein
kinase	I-protein
that	O
could	O
phosphorylate	O
the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN-62	O
.	O


In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
higher	O
activation	O
levels	O
were	O
observed	O
,	O
suggesting	O
that	O
distinct	O
B-cell-specific	B-protein
cofactors	I-protein
in	O
concert	O
with	O
the	O
effector	B-protein
domains	I-protein
of	O
Oct-2a	B-protein
might	O
be	O
involved	O
in	O
mediating	O
transcription	O
from	O
proximal	O
and	O
remote	O
positions	O
.	O


Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O


In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	B-cell_line
cells	I-cell_line
(	O
Hodgkin	B-cell_line
's	I-cell_line
disease-derived	I-cell_line
,	I-cell_line
T	I-cell_line
cell-like	I-cell_line
,	I-cell_line
CD30+	I-cell_line
cells	I-cell_line
)	O
with	O
the	O
agonistic	B-protein
anti-CD30	I-protein
monoclonal	I-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
M44	B-protein
and	O
M67	B-protein
,	O
two	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O


Moreover	O
,	O
in	O
human	B-cell_line
T	I-cell_line
helper	I-cell_line
(	I-cell_line
Th	I-cell_line
)	I-cell_line
clones	I-cell_line
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30+	O
,	O
respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30	B-protein
-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30+	B-cell_line
cells	I-cell_line
.	O


Pathogenesis	O
of	O
atherosclerosis	O
.	O


RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	B-protein
receptors	I-protein
.	O


Associations	O
between	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
autoantibodies	B-protein
to	O
the	O
ribonucleoproteins	B-protein
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
and	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
have	O
been	O
reported	O
in	O
these	O
patients	O
.	O


The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	B-DNA
and	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
previously	O
associated	O
with	O
the	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
response	O
make	O
this	O
antibody	O
,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	B-DNA
occur	I-DNA
in	O
response	O
to	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
.	O


In	O
contrast	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
or	O
RelA	B-protein
overexpression	O
does	O
not	O
affect	O
the	O
activity	O
of	O
a	O
human	B-DNA
IL4	I-DNA
promoter	I-DNA
containing	O
a	O
mouse	B-DNA
P	I-DNA
sequence	I-DNA
,	O
which	O
is	O
a	O
higher-affinity	B-DNA
site	I-DNA
for	O
NF-ATp	B-protein
and	O
a	O
lower-affinity	B-DNA
site	I-DNA
for	O
RelA	B-protein
.	O


We	O
used	O
mononuclear	B-cell_line
cell	I-cell_line
priming	I-cell_line
cultures	I-cell_line
and	O
inflammatory	B-cell_type
synovial	I-cell_type
fluids	I-cell_type
(	O
SFs	B-cell_type
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	B-protein
production	O
and	O
STAT	B-protein
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O


Monocyte/macrophages	B-cell_type
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O


Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	B-cell_type
monocytes	I-cell_type
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement-opsonized	B-protein
particles	I-protein
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	B-protein
receptor	I-protein
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O


The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B-protein
interferon	I-protein
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
,	O
including	O
the	O
Janus	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak2	B-protein
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
Stat1	I-protein
.	O


Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon-treated	B-cell_line
cells	I-cell_line
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O


The	O
observation	O
that	O
binding	O
sites	O
for	O
the	O
nuclear	B-protein
factor-mu	I-protein
negative	I-protein
regulator	I-protein
(	I-protein
NF-muNR	I-protein
)	I-protein
enhancer	I-protein
repressor	I-protein
overlap	I-protein
nuclear	I-protein
matrix	I-protein
attachment	I-protein
regions	I-protein
(	O
MARs	B-protein
)	O
in	O
this	O
enhancer	B-DNA
has	O
lead	O
to	O
the	O
hypothesis	O
that	O
the	O
cell	O
type	O
specificity	O
of	O
the	O
enhancer	B-DNA
might	O
be	O
controlled	O
by	O
regulating	O
nuclear	O
matrix	O
attachment	O
(	O
Scheuermann	O
,	O
R.	O
H.	O
,	O
and	O
Chen	O
,	O
U.	O
(	O
1989	O
)	O
Genes	O
&	O
Dev.	O
3	O
,	O
1255-1266	O
)	O
.	O


PU.1	B-protein
(	O
Spi-1	B-protein
)	O
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O


C/EBP	B-protein
alpha	I-protein
is	O
the	O
major	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	O
C/EBP	B-protein
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O


Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA
site	I-DNA
or	O
the	O
C/EBP	B-DNA
site	I-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
only	O
.	O


Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	B-protein
protein	I-protein
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	B-protein
transformed	B-cell_line
fibroblast	I-cell_line
B	I-cell_line
line	I-cell_line
and	O
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
thymocytes	B-cell_type
from	O
Thy-tax	O
transgenic	O
mice	O
.	O


These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post-transcription	O
regulation	O
of	O
c-jun	B-DNA
during	O
erythroid	O
differentiation	O
.	O


Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O


Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O


Correspondingly	O
,	O
RNase	B-protein
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O


In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O


The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B-protein
and	O
E7	B-protein
proteins	I-protein
to	O
target	B-cell_type
cells	I-cell_type
for	O
rejection	O
by	O
the	O
host	B-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
response	O
.	O


Cells	O
expressing	O
the	O
E1A	B-protein
oncoprotein	I-protein
were	O
selectively	O
killed	O
by	O
unstimulated	B-cell_line
NK	I-cell_line
cells	I-cell_line
,	O
while	O
the	O
same	O
parental	B-cell_type
cells	I-cell_type
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	B-protein
oncoprotein	I-protein
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O


Oxidative	O
stress	O
enhances	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activity	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B-protein
cytokines	I-protein
.	O


In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
an	O
increase	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
.	O


By	O
combining	O
partially	B-protein
purified	I-protein
proteins	I-protein
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	B-protein
complex	I-protein
upon	O
inclusion	O
of	O
VDR	B-protein
or	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
.	O


Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
heterodimer	I-protein
blocks	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF-AT-1	B-DNA
element	I-DNA
.	O


These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
sites	I-DNA
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	B-DNA
lox	I-DNA
promoter	I-DNA
fragment	I-DNA
.	O


Transcription	B-protein
factors	I-protein
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O


In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O


It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O


Taking	O
the	O
IL-2	B-DNA
gene	I-DNA
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	B-DNA
gene	I-DNA
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
and	O
Oct1	B-protein
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B-protein
mRNA	O
.	O


Twenty	O
two	O
healthy	O
men	O
aged	O
21-66	O
yr	O
(	O
mean	O
+/-	O
SD	O
41.0	O
+/-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22-60	O
yr	O
(	O
38.9	O
+/-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O


Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	B-protein
receptors	I-protein
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O


Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O


In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O


Critical	O
role	O
for	O
IL-6	B-protein
.	O


The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B-protein
with	O
TCR	B-protein
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O


In	O
purified	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
nuclear	B-protein
STAT	I-protein
proteins	I-protein
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	B-protein
Abs	I-protein
.	O


Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B-RNA
mRNA	I-RNA
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	B-cell_line
and	I-cell_line
anti-CD3-treated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O


BLR2-specific	B-RNA
mRNA	I-RNA
could	O
be	O
detected	O
in	O
all	O
Epstein-Barr	B-cell_line
virus	I-cell_line
positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O


Addition	O
of	O
TFE-3	B-protein
,	O
which	O
binds	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
upstream	O
of	O
the	O
LEF-1	B-DNA
and	I-DNA
Ets-1	I-DNA
sites	I-DNA
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O


Immunoprecipitation	O
of	O
the	O
gp	B-protein
160	I-protein
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-protein
antibodies	I-protein
to	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
indicates	O
that	O
AP-1	B-protein
complex	I-protein
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O


Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O


Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
seen	O
in	O
monocytes	B-cell_type
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O


The	O
inability	O
of	O
E1A	B-DNA
gene	I-DNA
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	B-cell_type
cells	I-cell_type
or	O
by	O
viral	B-DNA
gene	I-DNA
effects	O
on	O
class	B-protein
I	I-protein
MHC	I-protein
antigen	I-protein
expression	O
on	O
target	B-cell_type
cells	I-cell_type
.	O


Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B-protein
epitopes	I-protein
.	O


The	O
CD4	B-protein
coreceptor	I-protein
interacts	O
with	O
non-polymorphic	B-protein
regions	I-protein
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
molecules	I-protein
on	O
antigen-presenting	B-cell_type
cells	I-cell_type
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O


Whereas	O
different	O
anti-CD4	B-protein
mAb	I-protein
or	O
HIV-1	B-protein
gp120	I-protein
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adaptor	I-protein
protein	I-protein
,	O
which	O
mediates	O
signals	O
to	O
Ras	B-protein
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	B-protein
.	O


The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B-protein
on	O
the	O
CD4	B-protein
coreceptor	I-protein
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcium	O
pathways	O
.	O


To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA-1	B-protein
,	O
an	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	B-cell_type
.	O


We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA-1	B-protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
a	O
ligand-dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4-hydroxytamoxifen	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	B-DNA
enhancer	I-DNA
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	B-protein
I	I-protein
hypersensitive	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
in	O
which	O
IL-2R	B-protein
alpha	I-protein
expression	O
has	O
been	O
induced	O
.	O


We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	B-cell_type
.	O


This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	B-cell_type
cells	I-cell_type
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O


The	O
appearance	O
of	O
the	O
BamHI	B-protein
ZLF-1	I-protein
gene	I-protein
product	I-protein
,	O
ZEBRA	B-protein
,	O
by	O
RT-PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O


Transcripts	O
encoding	O
gp350/220	B-protein
,	O
the	O
major	B-protein
coat	I-protein
protein	I-protein
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	B-DNA
or	O
EBER-1	B-DNA
loci	I-DNA
in	O
infected	O
thymocytes	B-cell_type
.	O


Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
were	O
observed	O
to	O
contain	O
several	O
IL-2	B-protein
-inducible	O
DNA	O
binding	O
activities	O
.	O


Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
,	O
termed	O
YT	B-cell_line
.	O


We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL-2-inducible	B-protein
component	I-protein
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin-induced	B-protein
transcription	I-protein
factor	I-protein
first	O
identified	O
in	O
sheep	B-cell_type
mammary	I-cell_type
gland	I-cell_type
tissue	I-cell_type
.	O


E2F-1	B-protein
and	O
a	O
cyclin-like	B-protein
DNA	I-protein
repair	I-protein
enzyme	I-protein
,	O
uracil-DNA	B-protein
glycosylase	I-protein
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O


Overexpression	O
of	O
UDG	B-protein
in	O
Saos	B-cell_line
2	I-cell_line
cells	I-cell_line
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O


This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	B-protein
.	O


In	O
contrast	O
,	O
NFAT	B-protein
activation	O
by	O
a	O
G-protein-coupled	B-protein
receptor	I-protein
is	O
not	O
modulated	O
by	O
p95vav	B-protein
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	B-protein
signaling	O
pathways	O
.	O


There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	B-DNA
A	I-DNA
and	O
alpha	B-DNA
B	I-DNA
,	O
encoding	O
the	O
alpha	B-protein
subunit	I-protein
.	O


Coexpression	O
of	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-protein
B1	I-protein
/alpha	B-protein
B2	I-protein
ratio	O
.	O


Priming	O
by	O
IFN-gamma	B-protein
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
.	O


Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN-gamma	B-protein
or	O
GM-CSF	B-protein
,	O
but	O
not	O
M-CSF	B-protein
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


We	O
determined	O
that	O
an	O
initiator-like	B-DNA
sequence	I-DNA
present	O
at	O
the	O
cap	B-DNA
site	I-DNA
and	O
an	O
Ets	B-DNA
consensus	I-DNA
sequence	I-DNA
are	O
required	O
for	O
full	O
promoter	B-DNA
function	O
.	O


The	O
protein	B-protein
products	I-protein
of	O
this	O
gene	O
contain	O
the	O
basic-helix-loop-helix	B-protein
motif	I-protein
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
canonical	B-DNA
DNA	I-DNA
sequence	I-DNA
CANNTG	I-DNA
as	O
protein	B-protein
heterodimers	I-protein
.	O


An	O
Epo	B-protein
-inducible	O
TAL1	B-protein
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	B-RNA
and	O
protein	O
.	O


The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
observed	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Activation	O
of	O
NF-kappa	B-protein
B	I-protein
correlates	O
with	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O


Regulation	O
of	O
transcription	O
of	O
the	O
human	B-DNA
erythropoietin	I-DNA
receptor	I-DNA
gene	I-DNA
by	O
proteins	O
binding	O
to	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
motifs	I-DNA
.	O


We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
to	O
examine	O
the	O
transcription	B-DNA
control	I-DNA
elements	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
EpoR	I-DNA
gene	I-DNA
.	O


The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O


We	O
have	O
identified	O
a	O
cDNA	B-DNA
clone	I-DNA
,	O
DR-nm23	B-protein
,	O
differentially	O
expressed	O
in	O
a	O
blast-crisis	B-DNA
cDNA	I-DNA
library	I-DNA
,	I-DNA
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	B-DNA
metastatic	I-DNA
suppressor	I-DNA
genes	I-DNA
,	O
nm23-H1	B-DNA
and	O
nm23-H2	B-DNA
.	O


DR-nm23	B-RNA
mRNA	I-RNA
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
.	O


Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
without	O
a	O
TATA	B-DNA
box	I-DNA
.	O


A	O
17-bp	B-DNA
sequence	I-DNA
between	O
positions	O
-51	O
and	O
-35	O
conferred	O
IFN-gamma	B-protein
responsiveness	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O


Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	B-protein
alpha	I-protein
protein	I-protein
bound	O
to	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
in	O
response	O
to	O
IFN-gamma	B-protein
treatment	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O


Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(	O
also	O
termed	O
HTLV-I-associated	O
myelopathy	O
)	O
.	O


Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
proinflammatory	B-protein
cytokines	I-protein
.	O


The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


We	O
found	O
that	O
the	O
retinoblastoma	B-protein
susceptibility	I-protein
gene	I-protein
product	I-protein
(	O
Rb	B-protein
)	O
dramatically	O
suppressed	O
this	O
IE2	B-protein
transactivation	O
of	O
various	B-DNA
promoters	I-DNA
.	O


Expression	O
of	O
the	O
nucleoside	B-protein
diphosphate	I-protein
kinase	I-protein
in	O
human	O
skin	O
cancers	O
:	O
an	O
immunohistochemical	O
study	O
.	O


In	O
order	O
to	O
determine	O
whether	O
NDP	B-protein
kinase	I-protein
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O


The	O
expression	O
of	O
NDP	B-protein
kinase	I-protein
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O


RB-defective	B-cell_line
tumor	I-cell_line
lines	I-cell_line
are	O
non-inducible	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-DNA
expression	I-DNA
vectors	I-DNA
re-establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O


Therefore	O
,	O
we	O
examined	O
the	O
RB	B-protein
status	O
of	O
a	O
series	O
of	O
B-cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O


CIITA	B-DNA
is	O
a	O
class	B-DNA
II	I-DNA
gene	I-DNA
transactivator	I-DNA
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
.	O


Interleukin	B-protein
12	I-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O


Interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
cytokine	I-protein
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B-protein
receptor	I-protein
superfamily	I-protein
.	O


We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
with	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
JAK2	B-protein
and	O
Tyk2	B-protein
,	O
implicating	O
these	O
kinases	B-protein
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	B-protein
.	O


OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O


DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O


The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic-pituitary-adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
affinity	O
.	O


A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	B-protein
tyrosine	I-protein
kinase	I-protein
.	O


Activation	O
of	O
cytoplasmic	B-protein
tyrosine	I-protein
kinases	I-protein
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	B-protein
.	O


In	O
addition	O
,	O
integrin	B-protein
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
,	O
to	O
activation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
driven	O
by	O
a	O
promoter	B-DNA
containing	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	B-RNA
for	O
immediate-early	B-DNA
genes	I-DNA
,	O
including	O
the	O
cytokine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
.	O


The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	B-protein
sensitive	O
.	O


These	O
data	O
demonstrate	O
that	O
B95-8	B-cell_type
cells	I-cell_type
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	B-protein
receptor	I-protein
.	O


In	O
DNA	O
mobility	O
shift	O
assays	O
,	O
this	O
sequence	O
can	O
give	O
either	O
six	O
different	O
specific	O
bands	O
which	O
are	O
competed	O
out	O
by	O
different	O
parts	O
of	O
the	O
sequence	O
or	O
one	O
specific	O
band	O
which	O
is	O
competed	O
out	O
by	O
each	O
of	O
the	O
inverted	O
repeats	O
,	O
depending	O
on	O
the	O
reconstitution	O
conditions	O
.	O


We	O
also	O
propose	O
that	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O


However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	B-DNA
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha-globin	B-DNA
promoter	I-DNA
retaining	O
this	O
region	O
.	O


The	O
Ah	B-protein
receptor	I-protein
recognizes	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin-mediated	O
alteration	O
of	O
CD19	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	B-RNA
mRNA	I-RNA
by	O
67	O
%	O
in	O
the	O
IM-9	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O


In	O
addition	O
,	O
the	O
Ah	B-protein
receptor	I-protein
complex	I-protein
recognized	O
a	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
for	O
B	B-protein
cell	I-protein
lineage-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
human	O
CD19	B-DNA
gene	I-DNA
which	O
is	O
similar	O
to	O
the	O
consensus	B-DNA
Ah	I-DNA
receptor	I-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
.	O


Moreover	O
,	O
both	O
the	O
mutant	B-protein
nm23-H2His	I-protein
protein	I-protein
and	O
truncated	B-protein
nm23-H2	I-protein
protein	I-protein
containing	O
N-terminal	B-protein
(	I-protein
1-60	I-protein
)	I-protein
peptide	I-protein
,	O
which	O
do	O
not	O
have	O
NDP	B-protein
kinase	I-protein
activity	O
,	O
also	O
inhibited	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
.	O


Endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
LPS	O
express	O
E-selectin	B-protein
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	B-cell_type
adhesion	O
during	O
inflammation	O
.	O


GM-CSF	B-protein
and	O
IL-2	B-protein
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B-protein
cytokines	I-protein
produced	O
by	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O


The	O
activation	O
of	O
NFAT	B-protein
by	O
TCR	B-protein
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
promoter	I-DNA
.	O


This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM-CSF	B-protein
and	O
IL-2	B-protein
respond	O
to	O
TCR	B-protein
signals	O
via	O
NFAT	B-protein
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT-1	B-DNA
regulatory	I-DNA
element	I-DNA
linked	O
to	O
a	O
lac-Z	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
beta-galactosidase	B-protein
activity	O
.	O


WIN	O
53071	O
inhibited	O
IL-2	B-protein
production	O
induced	O
in	O
the	O
calcium-dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O


Conversely	O
,	O
calcium-independent	B-protein
anti-CD28	I-protein
Ab	I-protein
and	O
PMA-induced	O
IL-2	B-protein
production	O
was	O
resistant	O
.	O


Monocyte-macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	B-protein
vacuolar	I-protein
H	I-protein
(	I-protein
+	I-protein
)	I-protein
-ATPase	I-protein
(	O
V-ATPase	B-protein
)	O
.	O


Synergy	O
between	O
signal	O
transduction	O
pathways	O
is	O
obligatory	O
for	O
expression	O
of	O
c-fos	B-DNA
in	O
B	B-cell_line
and	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
implication	O
for	O
c-fos	B-DNA
control	O
via	O
surface	B-protein
immunoglobulin	I-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O


Expression	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
is	O
controlled	O
by	O
three	O
main	O
regulatory	O
pathways	O
involving	O
kinase	B-protein
C	I-protein
,	O
cAMP	O
,	O
and	O
calcium	O
.	O


The	O
main	O
difference	O
between	O
Ramos	B-cell_line
(	O
B	B-cell_type
cells	I-cell_type
)	O
and	O
Jurkat	B-cell_line
(	O
T	B-cell_type
cells	I-cell_type
)	O
in	O
the	O
regulation	O
of	O
c-fos	B-DNA
is	O
that	O
cAMP	O
plus	O
calcium	O
is	O
strongly	O
synergistic	O
in	O
Jurkat	B-cell_line
and	O
is	O
without	O
effect	O
in	O
Ramos	B-cell_line
.	O


Use	O
of	O
new	O
biologic	O
markers	O
in	O
the	O
ovulation	O
induction	O
.	O


Abnormal	O
regulation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
lpr	O
CD4-CD8-	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	B-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-binding	I-protein
factor	I-protein
.	O


Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	B-protein
-mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O


Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF-AT-binding	B-protein
factor	I-protein
is	O
rapidly	O
down-regulated	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Thus	O
,	O
CD30	B-protein
-CD30L	B-protein
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B-protein
.	O


Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O


The	O
transactivation	O
of	O
multiple	B-DNA
cis	I-DNA
elements	I-DNA
,	O
especially	O
S	B-DNA
and	O
X2	B-DNA
,	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
proximal	I-DNA
promoter	I-DNA
in	O
group	B-cell_line
II	I-cell_line
CID	I-cell_line
cells	I-cell_line
is	O
CIITA	B-protein
dependent	O
.	O


Since	O
CIITA	B-protein
overexpression	O
in	O
normal	B-cell_type
cells	I-cell_type
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B-protein
expression	O
serves	O
as	O
the	O
on-off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O


These	O
results	O
demonstrate	O
that	O
P-selectin	B-protein
,	O
through	O
its	O
ligands	O
on	O
monocytes	B-cell_type
,	O
may	O
locally	O
regulate	O
cytokine	B-protein
secretion	O
in	O
inflamed	O
tissues	O
.	O


In	O
vitro	O
studies	O
using	O
pure	B-protein
recombinant	I-protein
p21ras	I-protein
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O


Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B-DNA
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O


Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B-protein
is	O
essential	O
for	O
NO-induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B-protein
in	O
the	O
same	O
cell	O
.	O


These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
NO	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B-DNA
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factors	I-protein
.	O


Interleukin-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
controlled	O
by	O
nuclear	B-protein
factor-chi	I-protein
B	I-protein
.	O


An	O
IL-2	B-DNA
promoter	I-DNA
bearing	O
a	O
defective	O
NF-chi	B-DNA
B	I-DNA
site	I-DNA
was	O
completely	O
inactive	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Similarly	O
,	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	B-protein
B	I-protein
factors	I-protein
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	B-cell_line
producing	I-cell_line
EBV-B	I-cell_line
cells	I-cell_line
,	O
but	O
inactive	O
in	O
the	O
non-IL-2-producing	B-cell_line
cells	I-cell_line
.	O


Three	O
to	O
6	O
months	O
after	O
RAI	O
,	O
T	O
cell	O
responses	O
to	O
TSHR	B-protein
peptides	O
were	O
less	O
than	O
those	O
6-8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
but	O
still	O
higher	O
than	O
the	O
values	O
on	O
day	O
0	O
.	O


We	O
have	O
used	O
these	O
mice	O
to	O
generate	O
anti-TCF-1	B-protein
antibodies	I-protein
.	O


Wild-type	O
littermates	O
remain	O
unresponsive	O
to	O
TCF-1	B-protein
while	O
they	O
mount	O
a	O
high-titer	O
antibody	O
response	O
to	O
the	O
fusion	B-protein
protein	I-protein
,	O
Maltose	B-protein
Binding	I-protein
Protein	I-protein
(	O
MBP	B-protein
)	O
.	O


The	O
PuF	B-DNA
site	I-DNA
on	O
the	O
silent	B-DNA
normal	I-DNA
c-myc	I-DNA
allele	I-DNA
was	O
unoccupied	O
.	O


These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O


These	O
included	O
vimentin	B-protein
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	B-protein
8	I-protein
and	I-protein
18	I-protein
,	O
associated	O
with	O
differentiated	B-cell_type
cell	I-cell_type
types	I-cell_type
of	O
prostate	O
epithelia	O
,	O
and	O
neuron-specific	B-protein
enolase	I-protein
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	B-cell_type
cells	I-cell_type
.	O


This	O
growth	B-protein
modulator	I-protein
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O


Platelet-activating	B-protein
factor	I-protein
stimulates	O
transcription	O
of	O
the	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
in	O
monocytes	B-cell_type
.	O


Pretreatment	O
of	O
monocytes	B-cell_type
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	B-protein
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O


These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	B-protein
in	O
HB-EGF	B-protein
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O


Mapping	O
of	O
the	O
interaction	B-protein
site	I-protein
of	O
the	O
defective	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex	I-cell_line
mutant	I-cell_line
cell	I-cell_line
line	I-cell_line
clone-13	I-cell_line
to	O
the	O
divergent	B-DNA
X2-box	I-DNA
.	O


We	O
have	O
employed	O
the	O
ZEBRA	B-protein
/EBV	O
biological	O
system	O
to	O
test	O
whether	O
a	O
heterologous	B-protein
activation	I-protein
domain	I-protein
can	O
substitute	O
for	O
another	O
activation	O
domain	O
(	O
the	O
ZEBRA	B-protein
domain	I-protein
)	O
.	O


These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B-protein
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B-protein
domain	I-protein
present	I-protein
within	O
ZEBRA	B-protein
.	O


Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B-protein
kinase	I-protein
3	I-protein
and	O
interleukin-4	B-protein
Stat	I-protein
.	O


Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	B-protein
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	B-cell_line
and	O
HEL	B-cell_line
cells	I-cell_line
.	O


The	O
HEL	B-cell_line
cells	I-cell_line
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	B-RNA
mRNA	I-RNA
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte-macrophage	B-cell_type
cells	I-cell_type
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O


The	O
promoters	B-DNA
were	O
used	O
without	O
enhancers	B-DNA
,	O
or	O
with	O
enhancers	B-DNA
derived	O
from	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
and	O
the	O
alpha-globin	B-DNA
HS-40	I-DNA
enhancer	I-DNA
.	O


Point	O
mutation	O
of	O
a	O
CCACC	B-DNA
site	I-DNA
at	O
-240	O
had	O
no	O
effect	O
.	O


Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B-protein
Ras	I-protein
and	O
PKC	B-protein
mutants	I-protein
suggest	O
that	O
PKC-alpha	B-protein
,	O
p21ras	B-protein
,	O
and	O
PKC-epsilon	B-protein
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O


Moreover	O
,	O
IL-5	B-protein
induced	O
at	O
least	O
two	O
DNA-binding	B-protein
complexes	I-protein
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	B-cell_type
eosinophils	I-cell_type
and	O
the	O
IL-6/interferon-gamma	B-DNA
response	I-DNA
element	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
(	O
ICAM-1	B-DNA
pIRE	I-DNA
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O


Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	B-DNA
and	O
tat	B-protein
mutations	I-protein
in	O
primary	B-cell_type
and	I-cell_type
long-term	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR-modified	B-protein
tat	I-protein
mutants	I-protein
was	O
restricted	O
to	O
some	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O


Functional	O
roles	O
of	O
the	O
transcription	B-protein
factor	I-protein
Oct-2A	I-protein
and	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
I/Y	B-protein
in	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
.	O


In	O
addition	O
,	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O


Coexpression	O
of	O
HMG	B-protein
I/Y	I-protein
and	O
Oct-2	B-protein
in	O
cell	B-cell_line
lines	I-cell_line
lacking	O
Oct-2	B-protein
results	O
in	O
high	O
levels	O
of	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
,	O
and	O
in	O
vitro	O
DNA-binding	O
studies	O
reveal	O
that	O
HMG	O
I/Y	B-protein
stimulates	O
Oct-2A	B-protein
binding	O
to	O
the	O
HLA-DRA	B-DNA
promoter	I-DNA
.	O


By	O
contrast	O
,	O
Oct-2A	B-protein
is	O
not	O
involved	O
in	O
the	O
IFN-gamma	B-protein
induction	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
antisense	B-DNA
HMG	I-DNA
I/Y	I-DNA
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O


In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
six	O
EBV-encoded	B-protein
nuclear	I-protein
antigens	I-protein
(	O
EBNA1	B-protein
,	I-protein
2	I-protein
,	I-protein
3A	I-protein
,	I-protein
3B	I-protein
,	I-protein
3C	I-protein
,	I-protein
-LP	I-protein
)	O
,	O
three	O
latent	B-protein
membrane	I-protein
proteins	I-protein
(	O
LMP1	B-protein
,	O
2A	B-protein
,	O
2B	B-protein
)	O
,	O
and	O
two	O
nuclear	B-RNA
RNAs	I-RNA
(	O
EBERs	B-RNA
)	O
are	O
expressed	O
.	O


Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O


The	O
core	B-DNA
elements	I-DNA
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T-cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


An	O
exogenously	O
expressed	O
Cbf	B-protein
alpha	I-protein
2-encoded	I-protein
subunit	I-protein
(	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	B-DNA
enhancer	I-DNA
in	O
P19	B-protein
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O


Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B-protein
alpha	I-protein
,	O
IL-10	B-protein
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O
Several	O
other	O
transcription	B-protein
factors	I-protein
including	O
NF-	O
IL-6	B-protein
,	O
AP-1	B-protein
,	O
AP-2	B-protein
,	O
GR	B-protein
,	O
CREB	B-protein
,	O
Oct-1	B-protein
,	O
and	O
Sp-1	B-protein
are	O
not	O
affected	O
by	O
IL-10	B-protein
.	O


Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL-10	B-protein
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


LMP-1	B-protein
,	O
an	O
Epstein-Barr	B-protein
virus	I-protein
membrane	I-protein
protein	I-protein
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	B-cell_type
and	O
rodent	B-cell_type
fibroblasts	I-cell_type
.	O


The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O


These	O
data	O
show	O
that	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10	O
%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest	O
.	O


Therefore	O
,	O
Tat	B-protein
-mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O


In	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_line
cells	I-cell_line
HIV-1	B-protein
Tat	I-protein
suppressed	O
the	O
expression	O
of	O
Mn-dependent	B-protein
superoxide	I-protein
dismutase	I-protein
(	O
Mn-SOD	B-protein
)	O
,	O
a	O
mitochondrial	B-protein
enzyme	I-protein
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Binding	O
sites	O
were	O
mapped	O
for	O
each	O
factor	O
.	O


Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O


In	O
an	O
open-label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM-III-R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	B-protein
GCII	I-protein
sites	I-protein
per	O
cell	O
(	O
sites/cell	O
)	O
values	O
of	O
793	O
+/-	O
106	O
versus	O
2	O
,	O
563	O
+/-	O
499	O
(	O
+/-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3.5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.001	O
)	O
.	O


NFATp	B-protein
binds	O
to	O
two	O
sites	O
within	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
,	O
and	O
occupancy	O
of	O
both	O
sites	O
is	O
required	O
for	O
TNF	B-protein
alpha	O
gene	O
induction	O
.	O


The	O
results	O
varied	O
with	O
the	O
agent	O
,	O
cell	O
type	O
,	O
and	O
stage	O
of	O
differentiation	O
.	O


None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA-2	B-protein
with	O
the	O
DNA	O
via	O
protein-protein	O
interactions	O
.	O


Thus	O
,	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
IL-6	B-protein
in	O
vitro	O
recapitulates	O
the	O
hallmarks	O
of	O
terminal	O
B	O
differentiation	O
in	O
vivo	O
;	O
Oct-2	B-protein
may	O
have	O
a	O
role	O
in	O
this	O
process	O
.	O


Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O


The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	B-protein
is	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
.	O


TNF-alpha	O
,	O
IL-1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP-1	B-protein
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	B-protein
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60-min	O
time	O
course	O
.	O


This	O
enhancement	O
by	O
BDP	O
was	O
found	O
either	O
for	O
constitutive	O
expression	O
of	O
gcRs	B-protein
or	O
in	O
experiments	O
when	O
the	O
lymphocytes	B-cell_type
were	O
stimulated	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-6	I-protein
.	O


HS	B-DNA
I	I-DNA
,	I-DNA
IV	I-DNA
,	I-DNA
and	I-DNA
V	I-DNA
were	O
exclusively	O
observed	O
in	O
the	O
erythroid/megakaryocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
express	O
tal-1	B-DNA
from	O
the	O
promoters	B-DNA
1a	I-DNA
and	I-DNA
1b	I-DNA
.	O


cdc2	B-RNA
mRNA	I-RNA
transcripts	I-RNA
were	O
detected	O
in	O
immature	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
and	O
became	O
undetectable	O
along	O
with	O
differentiation	O
.	O


Transient	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assay	O
revealed	O
that	O
the	O
region	O
containing	O
E2F	B-DNA
binding	I-DNA
site	I-DNA
had	O
a	O
strong	O
promoter	O
activity	O
,	O
and	O
introduction	O
of	O
the	O
mutation	O
at	O
the	O
E2F	B-DNA
binding	I-DNA
site	I-DNA
resulted	O
in	O
a	O
significant	O
loss	O
of	O
the	O
activity	O
.	O


Whether	O
virus-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
a	O
mechanism	O
that	O
favors	O
continuous	O
viral	O
replication	O
in	O
macrophages	B-cell_type
remains	O
unknown	O
.	O


First	O
,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	B-cell_type
.	O


In	O
HIV-infected	O
cells	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	O
levels	O
are	O
decreased	O
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O


Glucocorticoid-induced	O
apoptosis	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O


NF-kappa	B-protein
B	I-protein
is	O
a	O
nuclear	B-protein
protein	I-protein
of	O
the	O
rel	B-protein
oncogene	I-protein
family	I-protein
capable	O
of	O
enhancing	O
transcription	O
of	O
several	B-DNA
cellular	I-DNA
genes	I-DNA
,	O
including	O
IL-2	B-protein
and	O
the	O
IL-2	B-protein
receptor	I-protein
,	O
and	O
viral	B-DNA
genes	I-DNA
transcribed	O
from	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O


In	O
this	O
study	O
the	O
effects	O
of	O
HIV	O
protease	O
on	O
NF-kappa	B-protein
B	I-protein
precursor	O
activation	O
were	O
examined	O
in	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
by	O
introducing	O
a	O
protease	B-DNA
expression	I-DNA
vector	I-DNA
into	O
the	O
cells	O
.	O


We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	B-protein
(	O
IFN	B-protein
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti-human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O


The	O
genes	O
KOX	B-DNA
4	I-DNA
and	O
KOX	B-DNA
9	I-DNA
,	O
mapped	O
on	O
chromosome	B-DNA
8q24	I-DNA
,	O
were	O
found	O
to	O
be	O
located	O
within	O
a	O
DNA	B-DNA
fragment	I-DNA
of	O
450	O
kb	O
.	O


Mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
young	O
or	O
elderly	O
persons	O
were	O
sham-exposed	O
or	O
exposed	O
to	O
influenza	O
virus	O
for	O
1	O
,	O
24	O
,	O
and	O
72	O
h	O
.	O


Fewer	O
virus-exposed	O
cells	O
from	O
elderly	O
donors	O
stained	O
for	O
Fos	B-protein
and	O
Jun	B-protein
at	O
each	O
data	O
point	O
compared	O
with	O
cells	O
from	O
young	O
donors	O
.	O


OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV-1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	B-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
in	O
T-lymphoid	B-cell_line
and	I-cell_line
monocytoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
expression	O
levels	O
of	O
human	B-protein
RAR	I-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha	I-protein
,	I-protein
receptor	I-protein
for	O
all-trans	O
RA	O
)	O
and	O
the	O
human	B-protein
retinoid-X	I-protein
receptor	I-protein
alpha	I-protein
(	O
hRXR	B-protein
alpha	I-protein
receptor	I-protein
for	O
9-cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O


RESULTS	O
:	O
Both	O
all-trans	O
and	O
9-cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV-1	B-cell_line
IIIB-infected	I-cell_line
monocytoid	I-cell_line
cells	I-cell_line
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co-stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O


Human	B-protein
RAR	I-protein
alpha	I-protein
was	O
expressed	O
in	O
H9	B-cell_line
,	O
U937	B-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
,	O
but	O
almost	O
undetectable	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O


Human	B-protein
RXR	I-protein
alpha	I-protein
was	O
significantly	O
expressed	O
in	O
U937	B-cell_line
and	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
,	O
weakly	O
expressed	O
in	O
H9	B-cell_line
cells	I-cell_line
and	O
not	O
detectable	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O


Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	B-cell_line
and	O
CEM	B-cell_line
cells	I-cell_line
,	O
and	O
elevated	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
after	O
PMA	O
stimulation	O
.	O


At	O
low	O
GSSG	O
levels	O
,	O
T	B-cell_type
cells	I-cell_type
can	O
not	O
optimally	O
activate	O
the	O
immunologically	O
important	O
transcription	B-protein
factor	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O


The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	B-protein
(	O
TRX	B-protein
)	O
.	O


As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well-known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O


As	O
HIV-infected	O
patients	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O


Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T-cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O


We	O
report	O
that	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif-specific	O
DNA-binding	O
activity	O
.	O


The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	B-cell_type
patient	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
similar	O
to	O
that	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O


The	O
altered	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O


MATERIALS	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
,	O
the	O
activities	O
of	O
GATA-1	B-protein
and	O
SP1	B-protein
during	O
differentiation	O
of	O
cultured	O
erythroid	B-cell_type
progenitors	I-cell_type
derived	O
from	O
cord	O
blood	O
and	O
from	O
fetal	O
livers	O
,	O
as	O
well	O
as	O
from	O
beta	O
zero-thalassemia	O
patients	O
.	O


The	O
demonstration	O
that	O
NF-kappa	B-protein
B	I-protein
can	O
regulate	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	O
in	O
steady-state	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcriptional	O
stimulation	O
of	O
the	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
.	O


The	O
adherence-dependent	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
was	O
also	O
not	O
a	O
consequence	O
of	O
mRNA	B-RNA
stabilization	O
events	O
.	O


In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90-kDa	B-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
hsp90	B-protein
)	O
,	O
a	O
molecular	B-protein
chaperone	I-protein
.	O


Thus	O
,	O
the	O
dioxin	B-protein
receptor	I-protein
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	B-protein
factors	I-protein
by	O
hsp90	B-protein
.	O


To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD-treated	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Although	O
we	O
detected	O
no	O
IL-2	B-RNA
mRNA	I-RNA
in	O
ALD-treated	B-cell_line
cells	I-cell_line
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	B-DNA
sequences	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
region	I-DNA
:	O
NFAT	B-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
AP-1	B-protein
.	O


Protein	B-protein
kinase	I-protein
C	I-protein
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	B-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Oct-1	B-protein
and	O
Oct-2	B-protein
are	O
human	O
transcriptional	B-protein
activators	I-protein
that	O
bind	O
to	O
the	O
same	O
DNA	O
element	O
but	O
activate	O
distinct	O
sets	O
of	O
genes	O
.	O


Transfer	O
of	O
the	O
Oct-2	B-protein
C-terminal	I-protein
domain	I-protein
onto	O
either	O
Oct-1	B-protein
(	O
Oct1.2	B-protein
)	O
or	O
a	O
nonactivating	B-protein
DNA-binding	I-protein
domain	I-protein
from	O
GAL4	B-protein
created	O
activators	O
capable	O
of	O
greater	O
than	O
15	O
and	O
10-fold	O
stimulation	O
of	O
activity	O
,	O
respectively	O
.	O


Glucocorticoid-induced	O
apoptosis	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O


Taken	O
together	O
,	O
we	O
report	O
that	O
IL-2	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-protein
and	O
an	O
as	O
yet	O
undefined	O
84-kDa	B-protein
protein	I-protein
in	O
antigen-specific	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Tax	B-protein
-stimulated	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
both	O
HTLV-I-infected	B-cell_line
and	I-cell_line
Tax-transfected	I-cell_line
human	I-cell_line
T	I-cell_line
cells	I-cell_line
is	O
associated	O
with	O
the	O
phosphorylation	O
and	O
rapid	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
remains	O
physically	O
associated	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	O
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O


Transcriptional	O
control	O
of	O
steroid-regulated	B-DNA
gene	I-DNA
networks	I-DNA
by	O
nuclear	B-protein
receptor	I-protein
proteins	I-protein
results	O
in	O
the	O
coordinate	O
expression	O
of	O
a	O
limited	O
number	O
of	O
target	B-DNA
genes	I-DNA
.	O


We	O
also	O
used	O
DDPCR	O
to	O
isolate	O
DESTs	B-DNA
from	O
androgen-modulated	O
rat	O
ventral	O
prostate	O
tissue	O
,	O
one	O
of	O
which	O
we	O
characterized	O
and	O
found	O
to	O
correspond	O
to	O
the	O
3	B-RNA
'	I-RNA
end	I-RNA
of	O
prostatic	B-RNA
spermine	I-RNA
binding	I-RNA
protein	I-RNA
mRNA	I-RNA
,	O
a	O
known	O
androgen-regulated	B-DNA
gene	I-DNA
.	O


We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	B-cell_type
,	I-cell_type
immature	I-cell_type
cells	I-cell_type
expresses	O
CD21	B-protein
.	O


These	O
components	O
included	O
transcription	O
of	O
BZLF-1	B-DNA
,	O
an	O
early	B-DNA
gene	I-DNA
that	O
characterizes	O
EBV-infected	B-cell_type
B	I-cell_type
cells	I-cell_type
after	O
disruption	O
of	O
latency	O
.	O


Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
antiinflammatory	O
agents	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
rhinitis	O
.	O


Serum	O
osteocalcin	B-protein
decreased	O
significantly	O
during	O
treatment	O
with	O
both	O
BUD	O
and	O
FP	O
.	O


These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR/CD3	B-protein
signals	O
is	O
biphasic	O
:	O
TcR/CD3	B-protein
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF-alpha	B-protein
is	O
present	O
.	O


The	O
cis-acting	B-DNA
region	I-DNA
,	O
GM-kappa	B-DNA
B/GC-box	I-DNA
(	O
positions	B-DNA
-95	I-DNA
and	O
-73	B-DNA
)	O
,	O
within	O
the	O
murine	B-DNA
GM-CSF	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
required	O
for	O
maximal	O
induction	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


A	O
factor	O
that	O
regulates	O
the	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
DPA	B-DNA
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	B-protein
finger	I-protein
proteins	I-protein
that	O
includes	O
a	O
Drosophila	B-protein
developmental	I-protein
control	I-protein
protein	I-protein
.	O


One	O
of	O
the	O
Drosophila	B-DNA
sequences	I-DNA
,	O
ttk	B-DNA
,	O
is	O
a	O
developmental	B-DNA
control	I-DNA
gene	I-DNA
,	O
while	O
a	O
second	O
does	O
not	O
contain	O
a	O
zinc	B-protein
finger	I-protein
region	I-protein
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O


We	O
include	O
a	O
redox-regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
in	O
which	O
oxidants	O
do	O
n't	O
activate	O
NF-kappa	B-protein
B	I-protein
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O


Deleted	O
chromosome	B-DNA
20	I-DNA
from	O
a	O
patient	O
with	O
Alagille	O
syndrome	O
isolated	O
in	O
a	O
cell	O
hybrid	O
through	O
leucine	O
transport	O
selection	O
:	O
study	O
of	O
three	O
candidate	O
genes	O
.	O


Alagille	O
syndrome	O
(	O
AGS	O
)	O
is	O
a	O
well-defined	O
genetic	O
entity	O
assigned	O
to	O
the	O
short	B-DNA
arm	I-DNA
of	O
Chromosome	B-DNA
(	I-DNA
Chr	I-DNA
)	I-DNA
20	I-DNA
by	O
a	O
series	O
of	O
observations	O
of	O
AGS	O
patients	O
associated	O
with	O
microdeletions	O
in	O
this	O
region	O
.	O


This	O
hybrid	O
clone	O
,	O
designated	O
NR2	B-cell_line
,	O
was	O
characterized	O
by	O
several	O
methods	O
,	O
including	O
PCR	O
,	O
with	O
eight	O
pairs	O
of	O
oligonucleotides	O
mapped	O
to	O
Chr	B-DNA
20	I-DNA
:	O
D20S5	B-DNA
,	O
D20S41	B-DNA
,	O
D20S42	B-DNA
,	O
D20S56	B-DNA
,	O
D20S57	B-DNA
,	O
D20S58	B-DNA
,	O
adenosine	B-DNA
deaminase	I-DNA
(	O
ADA	B-protein
)	O
,	O
and	O
Prion	B-DNA
protein	I-DNA
(	O
PRIP	B-protein
)	O
;	O
Restriction	O
Fragment	O
Length	O
Polymorphism	O
(	O
RFLP	B-DNA
)	O
analyses	O
with	O
four	O
genomic	B-DNA
anonymous	I-DNA
probes	I-DNA
(	O
D20S5	B-DNA
,	O
cD3H12	B-DNA
,	O
D20S17	B-DNA
,	O
D20S18	B-DNA
)	O
;	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
total	B-DNA
human	I-DNA
DNA	I-DNA
and	O
D20Z1	B-DNA
,	O
a	O
sequence	O
specific	O
to	O
the	O
human	B-DNA
Chr	I-DNA
20	I-DNA
centromere	I-DNA
,	O
as	O
probes	O
.	O


The	O
NR2	B-cell_line
hybrid	I-cell_line
allowed	O
us	O
to	O
exclude	O
three	O
candidate	B-DNA
genes	I-DNA
for	O
AGS	O
:	O
hepatic	B-DNA
nuclear	I-DNA
factor	I-DNA
3	I-DNA
beta	I-DNA
(	O
HNF3	B-DNA
beta	I-DNA
)	O
,	O
paired	B-DNA
box	I-DNA
1	I-DNA
(	O
PAX1	B-DNA
)	O
,	O
and	O
cystatin	B-DNA
C	I-DNA
(	O
CST3	B-DNA
)	O
as	O
shown	O
by	O
their	O
localization	O
outside	O
of	O
the	O
deletion	O
.	O


The	O
differentiating	O
agent	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
previously	O
reported	O
to	O
interfere	O
with	O
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TPA	O
)	O
/Ca	O
(	O
2+	O
)	O
-induced	O
signals	O
for	O
the	O
regulation	O
of	O
the	O
-96	B-DNA
to	I-DNA
-66-bp	I-DNA
octamer	I-DNA
motif	I-DNA
found	O
in	O
the	O
enhancer	O
for	O
the	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
major	O
T	B-protein
lymphocyte	I-protein
growth	I-protein
factor	I-protein
.	O


Furthermore	O
,	O
transfected	O
c-jun	B-DNA
,	I-DNA
jun-B	I-DNA
,	I-DNA
jun-D	I-DNA
,	I-DNA
c-fos	I-DNA
,	I-DNA
or	I-DNA
Fos-B	I-DNA
expression	I-DNA
vectors	I-DNA
partially	O
substitute	O
for	O
TPA	O
and	O
Ca2+	O
and	O
cooperate	O
with	O
Oct-2	B-protein
for	O
the	O
transactivation	O
of	O
the	O
combined	O
OAP/octamer	B-DNA
cis-element	I-DNA
.	O


Furthermore	O
,	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
alpha	O
is	O
able	O
to	O
inhibit	O
in	O
vitro	O
the	O
formation	O
of	O
the	O
complex	O
between	O
the	O
nuclear	O
AP-1	B-protein
/OAP	B-protein
and	O
its	O
specific	O
binding	O
site	O
,	O
resulting	O
in	O
the	O
interference	O
with	O
Oct-2	B-protein
-dependent	O
cis-regulatory	O
function	O
of	O
this	O
AP-1	B-protein
element	O
.	O


As	O
in	O
XSCID	O
,	O
X-chromosome	O
inactivation	O
in	O
obligate	O
carriers	O
of	O
XCID	O
was	O
nonrandom	O
in	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


In	O
addition	O
,	O
X	B-DNA
chromosome	I-DNA
inactivation	O
in	O
PMNs	O
was	O
variable	O
.	O


Tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
expression	O
by	O
cells	O
of	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	B-protein
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O


Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N-acetyl-cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O


Characterization	O
of	O
the	O
CD48	B-DNA
gene	I-DNA
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein-Barr	B-cell_type
virus-immortalized	I-cell_type
B-cell	I-cell_type
lines	I-cell_type
and	O
contains	O
an	O
essential	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
.	O


Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	B-DNA
element	I-DNA
in	O
the	O
CD48	B-DNA
gene	I-DNA
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV-positive	B-cell_line
B-lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	O
IL-2	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O


However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	B-protein
alpha	I-protein
protein	I-protein
as	O
well	O
as	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
dose-dependent	O
manner	O
.	O


In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	B-protein
alpha	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
through	O
a	O
PKC	B-protein
-independent	O
pathway	O
.	O


Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal-ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o-phenanthroline	O
(	O
OP	O
)	O
(	O
metal-ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O


PKC-zeta	B-cell_line
cells	I-cell_line
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	B-protein
enzyme	I-protein
activities	O
and	O
were	O
distinct	O
from	O
parental	B-cell_line
U937	I-cell_line
cells	I-cell_line
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O


Increased	O
expression	O
of	O
the	O
c-jun	B-DNA
protooncogene	O
and	O
an	O
increase	O
in	O
AP-1	B-protein
binding	O
activity	O
in	O
PKC-zeta	B-cell_line
cells	I-cell_line
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O


A	O
family	O
of	O
serine	B-protein
proteases	I-protein
expressed	O
exclusively	O
in	O
myelo-	O
monocytic	B-cell_type
cells	I-cell_type
specifically	O
processes	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
subunit	I-protein
p65	I-protein
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O


These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	O
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	B-cell_line
U937	I-cell_line
clones	I-cell_line
,	O
but	O
not	O
in	O
the	O
plus	B-cell_line
clones	I-cell_line
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	B-protein
G	I-protein
.	O


Peripheral	B-DNA
leucocyte	I-DNA
genomic	I-DNA
DNAs	I-DNA
were	O
obtained	O
from	O
41	O
patients	O
with	O
primary	O
ovarian	O
carcinoma	O
and	O
83	O
controls	O
from	O
Ireland	O
,	O
as	O
well	O
as	O
from	O
26	O
primary	O
ovarian	O
carcinoma	O
patients	O
and	O
101	O
controls	O
in	O
Germany	O
.	O


Furthermore	O
,	O
expression	O
of	O
OBF-1	B-protein
in	O
HeLa	B-cell_line
cells	I-cell_line
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	B-DNA
promoter	I-DNA
in	O
an	O
octamer	B-DNA
site	I-DNA
-dependent	O
manner	O
.	O


Modulation	O
of	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O


The	O
first	O
early-induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	B-RNA
mRNA	I-RNA
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	B-protein
factors	I-protein
,	O
including	O
IL-6	B-protein
.	O


In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NS-Meg	B-cell_line
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O


Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
granulocyte/macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
and	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
promoted	O
the	O
growth	O
of	O
NS-Meg	B-cell_line
cells	I-cell_line
.	O


These	O
benzidine-positive	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
hemoglobin	B-protein
F	O
staining	O
.	O


In	O
addition	O
to	O
activation	O
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium-independent	O
,	O
CD28	B-protein
-specific	O
pathway	O
.	O


Enhanced	O
responsiveness	O
to	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O


Inclusion	O
of	O
this	O
LTR	B-DNA
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	B-cell_line
simian	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
.	O


The	O
level	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	B-cell_type
macrophages	I-cell_type
.	O


BFU-E-derived	B-cell_line
colonies	I-cell_line
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10-fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O


In	O
BFU-E-derived	B-cell_line
colonies	I-cell_line
cultured	O
with	O
Steel	B-protein
factor	I-protein
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O


The	O
response	O
of	O
LFA-3	B-protein
to	O
TaxI	B-protein
induction	O
was	O
,	O
on	O
the	O
other	O
hand	O
,	O
relatively	O
slow	O
and	O
weak	O
,	O
and	O
might	O
be	O
indirect	O
.	O


Transactivation	O
of	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
by	O
TaxI	B-protein
was	O
further	O
shown	O
by	O
co-transfection	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
construct	I-DNA
with	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
and	O
a	O
plasmid	B-DNA
expressing	O
TaxI	B-protein
.	O


No	O
genomic	O
changes	O
were	O
found	O
,	O
and	O
a	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
with	O
the	O
CD18	B-DNA
promoter	I-DNA
was	O
inactive	O
in	O
the	O
3	O
of	O
them	O
,	O
again	O
suggesting	O
lack	O
of	O
(	O
a	O
)	O
transcriptional	B-protein
factor	I-protein
(	O
s	O
)	O
necessary	O
for	O
CD18	B-protein
expression	O
.	O


Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
and	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
in	O
bovine	B-cell_type
leucocytes	I-cell_type
.	O


Theileria	O
annulata	O
infects	O
bovine	B-cell_type
leucocytes	I-cell_type
and	O
results	O
in	O
their	O
reversible	O
transformation	O
such	O
that	O
they	O
become	O
immortalised	O
and	O
metastatic	O
.	O


T.	B-cell_type
annulata-infected	I-cell_type
leucocytes	I-cell_type
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	B-protein
activities	O
.	O


The	O
predicted	O
protein	O
sequence	O
of	O
B1	B-protein
is	O
81	O
%	O
identical	O
to	O
human	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
(	O
MMP9	B-protein
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
bovine	O
homologue	O
of	O
this	O
enzyme	O
.	O


Growth	O
transformation	O
of	O
primary	B-cell_type
normal	I-cell_type
B-cells	I-cell_type
by	O
mutant	O
virus	O
resulted	O
in	O
estrogen-dependent	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
the	O
chimeric	O
EBNA2	B-protein
protein	I-protein
.	O


EBV	O
induces	O
the	O
same	O
cell	O
cycle	O
regulating	O
proteins	O
as	O
polyclonal	O
stimuli	O
in	O
primary	O
B-cells	B-cell_type
.	O


Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
functional	O
activity	O
is	O
independent	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
MAD3	B-protein
)	O
-	O
NF-kappa	B-protein
B	I-protein
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
nuclear	O
translocation	O
.	O


The	O
single	O
promoter	B-DNA
region	I-DNA
in	O
the	O
cloned	O
genome	O
[	O
Noteborn	O
et	O
al.	O
,	O
J.	O
Virol.	O
65	O
(	O
1991	O
)	O
3131-3139	O
]	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
in	O
chicken	B-cell_type
T-cells	I-cell_type
was	O
analysed	O
via	O
CAT	B-protein
assays	O
.	O


A	O
unique	O
region	O
containing	O
four	O
or	O
five	O
near-perfect	O
direct	O
repeats	O
(	O
DR	O
)	O
of	O
21	O
bp	O
with	O
one	O
12-bp	B-DNA
insert	I-DNA
was	O
proven	O
to	O
be	O
the	O
main	O
transcription-activation	B-DNA
element	I-DNA
,	O
with	O
enhancer-like	O
characteristics	O
.	O


Functional	O
Myc-Max	B-protein
heterodimer	I-protein
is	O
required	O
for	O
activation-induced	O
apoptosis	O
in	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
.	O


Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c-Myc	B-protein
protein	I-protein
in	O
the	O
phenomenon	O
of	O
activation-induced	O
apoptosis	O
.	O


Epstein-Barr	B-protein
virus	I-protein
SM	I-protein
protein	I-protein
.	O


The	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
in	O
the	O
c-fos	B-DNA
regulatory	I-DNA
region	I-DNA
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	B-protein
factors	I-protein
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O


We	O
show	O
that	O
an	O
inducible	O
protein	B-protein
complex	I-protein
(	O
Band	B-protein
A	I-protein
)	O
binds	O
to	O
SRE	B-DNA
DNA	I-DNA
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	B-cell_line
PBL-T	I-cell_line
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min	O
.	O


Regulation	O
of	O
cell-type-specific	O
interleukin-2	B-protein
receptor	I-protein
alpha-chain	I-protein
gene	O
expression	O
:	O
potential	O
role	O
of	O
physical	O
interactions	O
between	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
,	O
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O


The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O


This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O


By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	B-DNA
clones	I-DNA
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	B-DNA
1-42	I-DNA
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O


CAG	O
repeat	O
length	O
variation	O
in	O
sperm	B-cell_type
from	O
a	O
patient	O
with	O
Kennedy	O
's	O
disease	O
.	O


ALDs	O
induced	O
QR	B-protein
activity	O
in	O
the	O
M4	O
cells	O
in	O
the	O
same	O
range	O
of	O
concentrations	O
that	O
protected	O
the	O
cells	O
against	O
BQ	O
toxicity	O
.	O


A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0.91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation-inducing	O
activity	O
towards	O
HL-60	B-cell_line
cells	I-cell_line
and	O
that	O
towards	O
NB4	B-cell_line
cells	I-cell_line
was	O
found	O
.	O


Platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
)	O
positively	O
auto-regulates	O
the	O
expression	O
of	O
human	B-protein
PAF	I-protein
receptor	I-protein
transcript	I-protein
1	I-protein
(	O
leukocyte-type	O
)	O
through	O
NF-kappa	B-protein
B	I-protein
.	O


By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
(	O
leukocyte-type	O
)	O
,	O
but	O
not	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
(	O
tissue-type	O
)	O
,	O
are	O
upregulated	O
by	O
PAF	B-protein
as	O
well	O
as	O
by	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	B-cell_line
stomach	I-cell_line
cancer	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
JR-St	B-cell_line
cells	I-cell_line
)	O
which	O
expresses	O
both	O
functional	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
and	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
endogenously	O
.	O


Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	O
of	O
this	O
receptor	O
.	O


The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase-dependent	O
pathway	O
.	O


The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	B-protein
,	O
p65	B-protein
(	O
RelA	B-protein
)	O
,	O
c-Rel	B-protein
,	O
and	O
most	O
likely	O
other	O
components	O
.	O


Tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
is	O
expressed	O
rapidly	O
by	O
human	B-cell_type
monocytes	I-cell_type
exposed	O
to	O
bacterial	B-protein
endotoxin	I-protein
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O


The	O
protease	O
inhibitors	O
N	O
alpha-tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
proteins	I-protein
by	O
preventing	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


A	O
decreased	O
number	O
of	O
calcitriol	B-protein
(	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
)	I-protein
receptors	I-protein
has	O
been	O
observed	O
in	O
parathyroid	O
glands	O
of	O
uremic	O
animals	O
.	O


The	O
two	O
tiny	O
ring	O
X	B-DNA
chromosomes	I-DNA
studied	O
with	O
an	O
antibody	B-protein
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	B-protein
H4	I-protein
marking	O
transcribed	B-DNA
chromatin	I-DNA
domains	I-DNA
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active	O
.	O


Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	B-protein
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O


The	O
activity	O
of	O
constructs	O
containing	O
5	B-DNA
'	I-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
alpha	B-DNA
4	I-DNA
gene	I-DNA
promoter	I-DNA
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	B-cell_line
lines	I-cell_line
that	O
express	O
alpha	B-protein
4	I-protein
and	O
cell	B-cell_line
lines	I-cell_line
that	O
do	O
not	O
.	O


The	O
sequence	O
between	O
position	O
-42	B-DNA
and	I-DNA
-76	I-DNA
base	I-DNA
pairs	I-DNA
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	B-protein
4	I-protein
,	O
but	O
it	O
showed	O
no	O
activity	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
express	O
alpha	B-protein
4	I-protein
.	O


Full-length	O
ERP	B-protein
expresses	O
only	O
negligible	O
DNA-binding	O
activity	O
by	O
itself	O
.	O


At	O
least	O
three	O
ERP-related	B-protein
transcripts	I-protein
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O


These	O
data	O
suggest	O
that	O
ERP	B-protein
might	O
play	O
a	O
role	O
in	O
B-cell	B-cell_type
development	O
and	O
in	O
IgH	B-DNA
gene	I-DNA
regulation	O
.	O


Murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
adipocytes	B-cell_type
,	O
and	O
olfactory	B-cell_type
neurons	I-cell_type
contain	O
a	O
DNA-binding	B-protein
protein	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
genes	B-DNA
encoding	O
tissue-specific	O
components	O
of	O
signal	O
transduction	O
.	O


Purification	O
and	O
cloning	O
of	O
this	O
protein	O
,	O
termed	O
early	O
B-cell	B-protein
factor	I-protein
(	O
EBF	B-protein
)	O
,	O
from	O
murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
independent	O
cloning	O
of	O
a	O
protein	O
,	O
termed	O
Olf-1	B-protein
,	O
from	O
olfactory	B-cell_type
neuronal	I-cell_type
cells	I-cell_type
revealed	O
virtual	O
complete	O
amino	O
acid	O
sequence	O
identity	O
between	O
these	O
proteins	O
.	O


By	O
Southern	O
hybridization	O
analyses	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
with	O
murine	B-DNA
cDNA	I-DNA
probe	I-DNA
,	O
fluorescence	O
chromosomal	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
of	O
human	B-DNA
genomic	I-DNA
clones	I-DNA
,	O
and	O
analysis	O
of	O
recombinant	B-cell_line
inbred	I-cell_line
mouse	I-cell_line
strains	I-cell_line
,	O
we	O
have	O
found	O
single	O
sites	O
for	O
EBF	B-DNA
homologous	I-DNA
sequences	I-DNA
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
5	O
,	O
band	B-DNA
q34	I-DNA
,	O
and	O
on	O
proximal	B-DNA
mouse	I-DNA
Chr	I-DNA
11	I-DNA
,	O
in	O
an	O
evolutionarily	B-DNA
conserved	I-DNA
region	I-DNA
.	O


Calcineurin	B-protein
activates	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
in	O
synergy	O
with	O
either	O
protein	B-protein
kinase	I-protein
C	I-protein
or	O
NF-kappa	B-protein
B	I-protein
/AP-1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O


Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	B-protein
(	O
CN	B-protein
)	O
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF-kappa	B-protein
B	I-protein
/AP-1	B-protein
.	O


One	O
of	O
the	O
nuclear	B-protein
factors	I-protein
(	O
NFs	B-protein
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	B-protein
for	O
activated	B-cell_type
t	I-cell_type
cell	I-cell_type
.	O


The	O
P	B-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
,	O
defined	O
as	O
a	O
responsive	B-DNA
element	I-DNA
for	O
PMA	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
and	I-DNA
the	I-DNA
NF-activated	I-DNA
T	I-DNA
cell	I-DNA
binding	I-DNA
sites	I-DNA
.	O


Because	O
this	O
segment	O
presumably	O
folds	O
upon	O
specific	O
DNA	O
binding	O
,	O
its	O
flexibility	O
in	O
solution	O
may	O
reduce	O
the	O
intrinsic	O
DNA	O
affinity	O
of	O
POUHD	B-protein
in	O
the	O
absence	O
of	O
POUs	B-protein
.	O


HIV-1	O
expression	O
was	O
activated	O
from	O
J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
by	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
sodium	O
butyrate	O
(	O
NaB	O
)	O
,	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
,	O
but	O
not	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
confirming	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
mediating	O
TNF-alpha	B-protein
induction	O
of	O
HIV	O
transcription	O
.	O


JNK	B-protein
is	O
involved	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


Full	O
activation	O
of	O
the	O
MAP	B-protein
kinases	I-protein
that	O
phosphorylate	O
the	O
Jun	B-protein
activation	I-protein
domain	I-protein
,	O
JNK1	B-protein
and	O
JNK2	B-protein
,	O
required	O
costimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
either	O
TPA	O
and	O
Ca2+	O
ionophore	O
or	O
antibodies	O
to	O
TCR	B-protein
and	O
CD28	B-protein
.	O


By	O
contrast	O
,	O
the	O
MAP	B-protein
kinases	I-protein
ERK1	B-protein
and	O
ERK2	B-protein
were	O
fully	O
activated	O
by	O
TPA	O
or	O
TCR	B-protein
stimulation	O
and	O
were	O
not	O
affected	O
by	O
Ca2+	O
,	O
CD28	O
,	O
or	O
CsA	O
.	O


In	O
vivo	O
studies	O
in	O
rats	O
utilized	O
2	O
mg/kg	O
IV	O
bolus	O
doses	O
of	O
liposomal	O
MPL	O
compared	O
to	O
drug	O
in	O
solution	O
.	O


Ii	B-DNA
kappa	I-DNA
B-2	I-DNA
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B-cell	B-cell_line
lines	I-cell_line
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
myelomonocytic	B-cell_line
,	I-cell_line
and	I-cell_line
glial	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4+	B-protein
cell	O
counts	O
(	O
P	O
>	O
0.05	O
)	O
or	O
anti-EBV	O
antibody	O
titres	O
(	O
P	O
>	O
0.05	O
)	O
.	O


CONCLUSION	O
:	O
The	O
degree	O
of	O
immunodeficiency	O
does	O
not	O
clearly	O
enhance	O
replicative	O
gene	O
expression	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
ARNHL	O
.	O


Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	B-protein
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O


NF-kappa	B-protein
B	I-protein
(	O
P65	B-protein
or	O
P65/P50	B-protein
heterodimer	I-protein
)	O
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	B-DNA
sequence	I-DNA
when	O
expression	B-DNA
plasmids	I-DNA
were	O
cotransfected	O
with	O
P	B-DNA
sequence-driven	I-DNA
reporter	I-DNA
plasmids	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Cell	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	B-protein
by	I-protein
tumor	I-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
due	O
to	O
induction	O
of	O
surface	B-protein
receptors	I-protein
,	O
such	O
as	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O


Since	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
are	O
present	O
in	O
VCAM-1	B-DNA
and	I-DNA
intercellular	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
(	I-DNA
ICAM-1	I-DNA
)	I-DNA
promoters	I-DNA
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
of	O
VCAM-1	B-protein
and	O
ICAM-1	B-protein
induction	O
and	O
subsequent	O
monocyte	B-cell_type
adhesion	O
in	O
TNF-treated	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O


Although	O
ICAM-1	B-protein
induction	O
was	O
unaffected	O
,	O
inhibitors	O
of	O
NADPH	B-protein
oxidase	I-protein
(	O
apocynin	O
)	O
or	O
cytochrome	B-protein
P-450	I-protein
(	O
SKF525a	O
)	O
suppressed	O
VCAM-1	B-protein
induction	O
by	O
TNF	O
,	O
revealing	O
that	O
several	O
radical-generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	O
.	O


Displacement	O
of	O
an	O
E-box-binding	B-protein
repressor	I-protein
by	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
:	O
implications	O
for	O
B-cell	O
specificity	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O


This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
therefore	O
NF-kappa	B-protein
B	I-protein
was	O
retained	O
in	O
the	O
cytosol	O
.	O


In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
c-myb	B-DNA
gene	I-DNA
in	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cell	I-cell_line
induced	O
by	O
hemin	B-protein
(	O
Hm	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
we	O
constructed	O
recombinant	B-DNA
plasmid	I-DNA
that	O
could	O
produce	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
after	O
induction	O
with	O
dexamethasone	O
.	O


Fos	B-protein
kinase	I-protein
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c-Fos	B-protein
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O


Moreover	O
,	O
its	O
rapid	O
activation	O
suggests	O
it	O
may	O
have	O
a	O
wider	O
role	O
within	O
signal	O
transduction	O
cascades	O
in	O
lymphocytes	B-cell_type
.	O


We	O
have	O
investigated	O
the	O
antigenic	O
specificity	O
of	O
47	O
HSV-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
the	O
HSV-2	O
buttock	O
and	O
thigh	O
lesions	O
of	O
five	O
patients	O
.	O


Clones	O
with	O
proliferative	O
responses	O
to	O
recombinant	B-protein
truncated	I-protein
glycoprotein	I-protein
B	I-protein
(	O
gB	B-protein
)	O
or	O
gD	B-protein
of	O
HSV-2	O
or	O
purified	O
natural	O
gC	O
of	O
HSV-2	O
comprised	O
a	O
minority	O
of	O
the	O
total	O
number	O
of	O
HSV-specific	B-cell_line
clones	I-cell_line
isolated	O
from	O
lesions	O
.	O


The	O
gC2-	B-cell_line
and	I-cell_line
gD2-specific	I-cell_line
CD4+	I-cell_line
clones	I-cell_line
had	O
cytotoxic	O
activity	O
.	O


The	O
antigenic	O
specificity	O
of	O
an	O
HLA	B-cell_line
DQ2-restricted	I-cell_line
,	I-cell_line
HSV-2	I-cell_line
type-specific	I-cell_line
T-cell	I-cell_line
clone	I-cell_line
was	O
mapped	O
to	O
amino	B-protein
acids	I-protein
425	I-protein
to	I-protein
444	I-protein
of	O
VP16	B-protein
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	B-protein
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B-protein
VP16	I-protein
fusion	I-protein
proteins	I-protein
,	O
and	O
synthetic	O
peptides	O
.	O


Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type-specific	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
reactive	O
with	O
an	O
HSV-2	O
epitope	O
mapping	O
to	O
approximately	O
0.67	O
to	O
0.73	O
map	O
units	O
.	O


The	O
antigenic	O
specificities	O
of	O
lesion-derived	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
quite	O
diverse	O
and	O
include	O
at	O
least	O
10	O
epitopes	O
.	O


The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O


We	O
conclude	O
that	O
the	O
NF-IL6	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
sites	I-DNA
mediate	O
IL-6	B-protein
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	B-protein
,	O
acting	O
as	O
bacterial	B-DNA
or	I-DNA
mycobacterial	I-DNA
response	I-DNA
elements	I-DNA
.	O


CD14	B-protein
,	O
a	O
monocyte/macrophage	B-protein
receptor	I-protein
for	O
the	O
complex	O
of	O
LPS	O
and	O
LPS	B-protein
binding	I-protein
protein	I-protein
,	O
is	O
a	O
differentiation	O
marker	O
for	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O


We	O
have	O
recently	O
cloned	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
and	O
demonstrated	O
its	O
tissue-specific	B-DNA
promoter	I-DNA
activity	O
.	O


All	O
were	O
found	O
to	O
selectively	O
bind	O
the	O
consensus	B-DNA
sequence	I-DNA
5'-GTTACGTAAT-3	O
'	O
with	O
high	O
affinity	O
.	O


These	O
findings	O
establish	O
a	O
spectrum	O
of	O
binding	O
site-specific	O
transcriptional	O
properties	O
for	O
E2A-HLF	B-protein
which	O
may	O
preferentially	O
activate	O
expression	O
of	O
select	O
subordinate	O
genes	O
as	O
a	O
homodimer	O
and	O
potentially	O
antagonize	O
expression	O
of	O
others	O
through	O
heteromeric	O
interactions	O
.	O


However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O


We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
and	O
KG-1	B-cell_line
.	O


In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	B-DNA
site	I-DNA
bound	O
translated	O
c-Rel	B-protein
and	I-protein
p65	I-protein
homodimers	I-protein
but	O
not	O
p50/p65	B-protein
heterodimers	I-protein
or	O
p50	B-protein
homodimers	I-protein
.	O


TN	B-protein
also	O
inhibits	O
proliferation	O
driven	O
by	O
alpha	B-protein
CD3/IL-2	I-protein
or	O
by	O
phorbol	B-protein
ester/IL-2	I-protein
,	I-protein
and	O
it	O
prevents	O
high	O
level	O
induction	O
of	O
IL-2R	B-protein
.	O


To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	B-protein
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
constitutive	O
expression	O
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O


Further	O
characterization	O
of	O
gelatinase	O
granules	O
has	O
been	O
hampered	O
by	O
poor	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
on	O
both	O
two-layer	O
Percoll	O
gradients	O
and	O
sucrose	O
gradients	O
.	O


Treatment	O
of	O
human	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
and	O
the	O
activation	O
of	O
NF.kappa	B-protein
B	I-protein
.	O


Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	O
by	O
endogenously	O
secreted	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	O
by	O
a	O
neutralizing	B-protein
anti-TNF	I-protein
alpha	I-protein
monoclonal	I-protein
antibody	I-protein
.	O


Induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
superantigens	B-protein
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
.	O


A	O
large	O
body	O
of	O
evidence	O
indicates	O
that	O
experimental	O
agents	O
which	O
raise	O
cellular	O
cAMP	O
levels	O
inhibit	O
T	O
cell	O
growth	O
and	O
division	O
.	O


In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
mitogen	B-protein
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
nuclear	O
factors	O
that	O
form	O
complexes	O
with	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O


Human	O
umbilical	O
vein	O
ECs	B-cell_type
were	O
pretreated	O
with	O
alpha-tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL-1	B-protein
(	O
10	O
ng/ml	O
)	O
,	O
LPS	O
(	O
10	O
ng/ml	O
)	O
,	O
thrombin	B-protein
(	O
30	O
U/ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O


The	O
IC50	O
of	O
alpha-tcp	O
on	O
an	O
IL-1	B-protein
-induced	O
response	O
was	O
45	O
microM	O
.	O


Tat	B-protein
transactivation	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B-DNA
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	B-cell_type
.	O


Hence	O
,	O
PPAR	B-protein
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	B-DNA
structure	O
and	O
THR	B-protein
isotype	I-protein
.	O


To	O
test	O
this	O
hypothesis	O
,	O
light-chain	B-DNA
gene	I-DNA
structure	I-DNA
was	O
examined	O
in	O
pre-B	B-cell_line
cells	I-cell_line
transformed	O
by	O
temperature-sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	O
a	O
human	B-DNA
BCL-2	I-DNA
gene	I-DNA
.	O


To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B-protein
B-binding-proteins	I-protein
using	O
the	O
yeast	O
two-hybrid	O
system	O
.	O


CAML	B-protein
appears	O
to	O
be	O
a	O
new	O
participant	O
in	O
the	O
calcium-signal	O
transduction	O
pathway	O
,	O
implicating	O
cyclophilin	B-protein
B	I-protein
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	O
of	O
cyclosporin	O
.	O


Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O


The	O
M-CSF	B-DNA
gene	I-DNA
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	B-DNA
and	O
the	O
EGR-1	B-DNA
genes	I-DNA
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O


A	O
novel	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
,	O
HB9	B-DNA
,	O
was	O
isolated	O
from	O
a	O
cDNA	B-DNA
library	I-DNA
prepared	O
from	O
in	O
vitro	B-cell_type
stimulated	I-cell_type
human	I-cell_type
tonsil	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
from	O
a	O
human	B-DNA
genomic	I-DNA
library	I-DNA
.	O


Transient	O
expression	O
of	O
HIV-1	B-protein
Tat	I-protein
induced	O
a	O
five-	O
to	O
eightfold	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
phytohemagglutinin	B-protein
and	O
phorbol	O
myristate	O
acetate	O
.	O


Alternative	O
splicing	O
of	O
RNA	B-RNA
transcripts	I-RNA
encoded	O
by	O
the	O
murine	B-DNA
p105	I-DNA
NF-kappa	I-DNA
B	I-DNA
gene	I-DNA
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
different	O
inhibitory	O
activities	O
.	O


Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
properties	O
different	O
from	O
those	O
of	O
p70	B-protein
.	O


There	O
are	O
13	O
protein	O
coding	O
exons	B-DNA
in	O
the	O
LBR	B-DNA
gene	I-DNA
.	O


In	O
contrast	O
,	O
CD38	B-protein
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL-60R	B-cell_line
cells	I-cell_line
,	O
transfected	O
with	O
a	O
functional	O
RAR	B-protein
beta	I-protein
,	O
RAR	B-protein
gamma	I-protein
,	O
or	O
RXR	B-protein
alpha	I-protein
receptor	I-protein
.	O


Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	B-protein
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
on	O
normal	B-cell_type
circulating	I-cell_type
granulocytes	I-cell_type
.	O


Some	O
antioxidants	O
,	O
including	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
tetrahydropapaveroline	O
(	O
THP	O
)	O
,	O
nordihydroguiauretic	O
acid	O
,	O
and	O
10	O
,	O
11-dihydroxyaporphine	O
(	O
DHA	O
)	O
,	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
and	O
IL-6	B-protein
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
stimulated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
IC50s	O
in	O
the	O
low	O
micromolar	O
range	O
)	O
.	O


Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	B-protein
factors	I-protein
and	O
of	O
the	O
transcription	O
of	O
genes	B-DNA
for	O
pro-inflammatory	B-protein
cytokines	I-protein
.	O


Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
is	O
an	O
immunomodulatory	O
cytokine	O
secreted	O
by	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
basophils	B-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
.	O


In	O
CF	O
individuals	O
,	O
7	O
of	O
52	O
(	O
13	O
%	O
)	O
had	O
detectable	O
E1a	B-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
,	O
with	O
E1a	O
copy	O
number	O
in	O
the	O
positive	O
samples	O
of	O
80	O
+/-	O
21/10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O


A	O
52-year-old	O
female	O
presented	O
with	O
a	O
progressively	O
enlarging	O
vulvar	O
mass	O
.	O


Immunohistochemical	O
and	O
ultrastructural	O
studies	O
were	O
performed	O
to	O
support	O
the	O
diagnosis	O
.	O


Macrophages	B-cell_type
and	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
infiltrated	O
the	O
tumor	O
in	O
moderate	O
numbers	O
with	O
occasional	O
lymphoid	O
aggregate	O
formation	O
.	O


LIF	B-protein
induced	O
a	O
dose-dependent	O
increase	O
in	O
p24	B-protein
antigen	I-protein
production	O
in	O
the	O
chronically	B-cell_line
infected	I-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
.	O


LIF	B-protein
increased	O
steady-state	O
levels	O
of	O
HIV	B-RNA
mRNA	I-RNA
at	O
2.0	O
,	O
4.3	O
,	O
and	O
9.2	O
kB	O
.	O


Two	O
anti-MHC	B-protein
class	I-protein
II	I-protein
Ab	I-protein
,	O
L227	B-protein
and	O
2.06	B-protein
,	O
inhibited	O
the	O
growth	O
of	O
B104	B-cell_line
cells	I-cell_line
,	O
although	O
2.06	B-protein
,	O
but	O
not	O
L227	B-protein
,	O
needed	O
to	O
be	O
further	O
cross-linked	O
with	O
a	O
goat	B-protein
anti-mouse	I-protein
IgG	I-protein
Ab	I-protein
(	O
GAM	B-protein
)	O
to	O
show	O
the	O
effect	O
.	O


Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	O
express	O
VDR	B-RNA
mRNA	I-RNA
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin-4	B-protein
induced	O
VDR	B-protein
in	O
the	O
absence	O
of	O
exogenously	O
supplemented	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O


1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O


Positive	O
and	O
negative	O
regulation	O
of	O
IL-2	B-protein
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O


One	O
major	B-DNA
and	I-DNA
one	I-DNA
minor	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
were	O
identified	O
101	B-DNA
and	I-DNA
130	I-DNA
base	I-DNA
pairs	I-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
upstream	I-DNA
,	O
respectively	O
,	O
from	O
the	O
protein	B-DNA
translation	I-DNA
start	I-DNA
ATG	I-DNA
.	O


We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B-protein
cytokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O


By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	B-DNA
promoters	I-DNA
,	O
the	O
AP-1	B-DNA
and	I-DNA
kappa	I-DNA
B-like	I-DNA
sites	I-DNA
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O


Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O


OBJECTIVE	O
.	O


Arrested	O
development	O
:	O
understanding	O
v-abl	B-DNA
.	O


Corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
:	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
?	O


That	O
RA	O
promotes	O
both	O
neutrophil	O
and	O
monocyte	O
differentiation	O
has	O
implications	O
for	O
the	O
use	O
of	O
RA	O
and	O
D3	O
in	O
treatment	O
of	O
leukemias	O
and	O
provides	O
insight	O
into	O
mechanisms	O
whereby	O
RAR	O
,	O
VDR	B-protein
and	O
RXR	B-protein
facilitate	O
monocyte	O
differentiation	O
.	O


RARs	B-protein
are	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA-binding	O
and	O
RA	B-protein
(	I-protein
ligand	I-protein
)	I-protein
-binding	I-protein
domains	I-protein
.	O


Most	O
cells	O
infected	O
with	O
hRAR	B-protein
alpha	I-protein
exhibited	O
promyelocytic	B-cell_type
morphology	I-cell_type
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O


These	O
observations	O
suggest	O
that	O
an	O
overexpression	O
of	O
RAR	B-protein
alpha	I-protein
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	B-cell_type
cell	I-cell_type
differentiation	O
and	O
RAR	B-protein
alpha	I-protein
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O


The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	B-DNA
genes	I-DNA
for	O
differentiation	O
of	O
normal	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O


In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30-40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	B-protein
activity	O
in	O
tissue	O
homogenates	O
.	O


Thrombin	B-protein
and	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	B-protein
cross-linking	O
for	O
CD69	B-protein
expression	O
and	O
interleukin	O
2	O
production	O
.	O


A	O
synthetic	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	B-protein
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O


Thrombin	B-protein
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O


As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	B-protein
activated	O
the	O
nuclear	B-protein
factor	I-protein
NF-kB	I-protein
.	O


Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
HPB.ALL	I-cell_line
and	O
the	O
erythroleukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
were	O
responsive	O
to	O
thrombin	B-protein
,	O
whereas	O
others	O
such	O
as	O
THP1	B-cell_line
,	O
a	O
myelomonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
BL2	B-cell_line
,	I-cell_line
a	O
Burkitt	B-cell_line
lymphoma	I-cell_line
were	O
refractory	O
to	O
thrombin	B-protein
or	O
TRP	O
stimulation	O
.	O


We	O
found	O
that	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
a	O
combination	O
of	O
phytohemagglutinin	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B-protein
response	O
.	O


Senescent	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	B-cell_line
passage	I-cell_line
cells	I-cell_line
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O


This	O
decline	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
of	O
nuclear	O
extracts	O
to	O
the	O
consensus	B-DNA
heat	I-DNA
shock	I-DNA
element	I-DNA
.	O


Furthermore	O
,	O
ethanol	O
,	O
an	O
inhibitor	O
of	O
the	O
PLD	B-protein
pathway	O
,	O
blocked	O
the	O
anti-CD3-stimulated	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O


However	O
,	O
this	O
anti-CD3	B-protein
-mediated	O
response	O
was	O
not	O
inhibited	O
by	O
neomycin	O
,	O
an	O
inhibitor	O
of	O
phosphoinositide	O
hydrolysis	O
.	O


Upregulation	O
of	O
bcl-2	B-DNA
by	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
:	O
a	O
B-cell-specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
to	O
induction	O
of	O
cell	B-protein
surface	I-protein
markers	I-protein
.	O


Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B-protein
signal	O
transduction	O
,	O
other	O
cell-specific	B-protein
factors	I-protein
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	B-protein
protein	I-protein
.	O


To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
activity	O
in	O
the	O
nucleus	O
after	O
anti-CD3	B-protein
stimulation	O
.	O


On	O
the	O
other	O
hand	O
,	O
NF-kappa	B-protein
B	I-protein
induction	O
and	O
IL-2	B-protein
receptor	O
expression	O
occurred	O
even	O
with	O
the	O
smaller	O
second	O
messenger	O
response	O
generated	O
by	O
OKT3	B-protein
.	O


Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD33+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
counterpart	I-cell_type
cell	I-cell_type
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O


IL-4	B-protein
also	O
suppressed	O
the	O
IL-2	B-protein
-induced	O
IL-6	B-protein
mRNA	O
expression	O
.	O


This	O
study	O
shows	O
that	O
human	O
peripheral	O
blood	O
monocytes	B-cell_type
(	O
PBMo	B-cell_type
)	O
also	O
respond	O
to	O
MDHM	O
with	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
and	O
TNF	B-protein
alpha	I-protein
expression	O
,	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O


It	O
,	O
thus	O
,	O
appears	O
as	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
.	O


Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
proteins	I-protein
within	O
this	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O


trans-activation	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
by	O
a	O
cDNA	O
and	O
its	O
genomic	O
clones	O
of	O
human	O
herpesvirus-6	O
.	O


Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
is	O
a	O
lymphotropic	O
herpesvirus	O
,	O
and	O
in	O
vitro	O
,	O
it	O
can	O
productively	O
infect	O
human	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
as	O
HIV-1	O
.	O


We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO/CD14	B-cell_line
cells	I-cell_line
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
to	O
the	O
CD14	B-protein
receptor	O
system	O
.	O


Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/	O
CD14	B-protein
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
demonstrating	O
that	O
NF-kappa	B-protein
B	I-protein
translocation	O
is	O
an	O
early	O
event	O
.	O


Signals	O
transduced	O
through	O
the	O
CD4	B-protein
molecule	I-protein
on	O
T	B-cell_type
lymphocytes	I-cell_type
activate	O
NF-kappa	B-protein
B	I-protein
.	O


Stimulation	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	B-protein
like	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
.	O


This	O
increase	O
in	O
p50	B-protein
homodimers	I-protein
coincides	O
with	O
an	O
increase	O
in	O
p105	B-RNA
mRNA	I-RNA
,	O
suggestive	O
of	O
a	O
transcriptional	O
up-regulation	O
of	O
p50	B-protein
.	O


In	O
addition	O
,	O
a	O
new	O
combination	O
isoform	O
containing	O
Oct2a	B-protein
's	I-protein
amino	I-protein
terminal	I-protein
insert	I-protein
(	O
exon	B-DNA
7a	I-DNA
)	O
and	O
Oct2b	B-protein
's	I-protein
carboxy	I-protein
terminal	I-protein
insert	I-protein
(	O
exon	B-DNA
13	I-DNA
)	O
was	O
found	O
that	O
created	O
a	O
novel	O
large	O
isoform	O
,	O
Oct2ab	B-protein
.	O


The	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
,	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O


Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	B-DNA
element	I-DNA
in	O
the	O
distal	B-DNA
promoter	I-DNA
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA-1	B-protein
transcription	O
.	O


In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
construct	I-DNA
containing	O
two	O
NF-kappa	B-DNA
B	I-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
.	O


In	O
comparison	O
to	O
other	O
activators	O
of	O
NF-kappa	B-protein
B	I-protein
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O


Overproduction	O
of	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
:	O
a	O
mechanism	O
for	O
HTLV-I	B-protein
Tax	I-protein
-mediated	O
trans-activation	O
via	O
the	O
NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
.	O


The	O
Tax	B-protein
protein	I-protein
of	O
HTLV-I	O
,	O
a	O
positive	B-protein
transcriptional	I-protein
activator	I-protein
of	O
HTLV-I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	B-DNA
genes	I-DNA
including	O
GM-CSF	B-protein
,	O
IL-2R	B-protein
alpha	I-protein
and	O
IL-2	B-protein
.	O


One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans-activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
pleiotropic	B-protein
regulators	I-protein
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O


Furthermore	O
,	O
the	O
NFKB2	B-protein
precursor	O
is	O
physically	O
associated	O
with	O
c-Rel	B-protein
and	O
with	O
Tax	B-protein
in	O
HTLV-I	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O


In	O
clonogenetic	B-cell_line
fetal	I-cell_line
calf	I-cell_line
serum-supplemented	I-cell_line
(	I-cell_line
FCS+	I-cell_line
)	I-cell_line
or	I-cell_line
-nonsupplemented	I-cell_line
(	I-cell_line
FCS-	I-cell_line
)	I-cell_line
culture	I-cell_line
treated	O
with	O
saturating	O
levels	O
of	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
Ep	B-protein
)	O
(	O
combined	O
with	O
c-kit	B-protein
ligand	O
in	O
FCS	O
(	O
-	O
)	O
-culture	O
conditions	O
)	O
,	O
RA	O
induces	O
a	O
dramatic	O
dose-dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	B-cell_line
clones	I-cell_line
.	O


The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
in	O
B104	B-cell_line
cells	I-cell_line
is	O
discussed	O
.	O


Co-treatment	O
of	O
RBCs	B-cell_type
with	O
TCDD	O
and	O
NaOV	O
completely	O
blocked	O
the	O
TCDD-induced	O
increase	O
in	O
parasitemia	O
.	O


Analysis	O
at	O
the	O
phenotype	O
and	O
genetic	O
level	O
showed	O
that	O
lack	O
of	O
CD5	B-protein
expression	O
was	O
due	O
neither	O
to	O
segregation	O
of	O
human	B-DNA
autosome	I-DNA
11	I-DNA
,	O
on	O
which	O
the	O
CD5	B-DNA
gene	I-DNA
has	O
been	O
mapped	O
,	O
nor	O
to	O
deletion	O
of	O
the	O
CD5	B-DNA
structural	I-DNA
gene	I-DNA
.	O


Furthermore	O
,	O
loss	O
of	O
CD5	B-protein
surface	O
expression	O
correlated	O
with	O
the	O
absence	O
of	O
specific	O
mRNA	B-RNA
.	O


Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes	O
,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non-syntenic	B-DNA
trans-active	I-DNA
locus	I-DNA
,	O
or	O
loci	O
,	O
positively	O
controlling	O
the	O
expression	O
of	O
the	O
human	B-DNA
CD5	I-DNA
gene	I-DNA
.	O


These	O
factors	O
are	O
detected	O
at	O
the	O
time	O
the	O
CD11b	B-DNA
promoter	I-DNA
is	O
activated	O
.	O


Interferon	O
augments	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
in	O
normal	O
myeloid	B-cell_type
and	O
acute	B-cell_type
promyelocytic	I-cell_type
cells	I-cell_type
and	O
cooperates	O
with	O
all-trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid-resistant	B-cell_line
promyelocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


Effects	O
of	O
Ara-C	O
on	O
neutral	B-protein
sphingomyelinase	I-protein
and	O
mitogen-	B-protein
and	I-protein
stress-	I-protein
activated	I-protein
protein	I-protein
kinases	I-protein
in	O
T-lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


However	O
,	O
latent	O
,	O
transformation-associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O


Chromosome	B-DNA
1	I-DNA
aneusomy	O
with	O
1p36	B-DNA
under-representation	O
is	O
related	O
to	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
high	O
c-erb	B-protein
B-2	I-protein
and	O
loss	O
of	O
bcl-2	B-DNA
expression	O
in	O
ductal	O
breast	O
carcinoma	O
.	O


In	O
ductal	O
carcinomas	O
,	O
chromosome	B-DNA
1	I-DNA
alterations	O
increased	O
with	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
loss	O
of	O
bcl-2	O
and	O
high	O
c-erb	B-protein
B-2	I-protein
expression	O
.	O


A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	B-protein
cytokine	I-protein
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O


The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	B-DNA
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor-kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O


Experiments	O
using	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
tyrosine	O
kinase-dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O


Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
could	O
be	O
enhanced	O
by	O
co-stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O


Previous	O
studies	O
have	O
suggested	O
that	O
gangliosides	O
have	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
and	O
recognition	O
.	O


This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O


Furthermore	O
,	O
the	O
BCL-6	B-protein
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	B-cell_type
clone	I-cell_type
with	O
sensitive	O
PCR-based	O
techniques	O
.	O


Studies	O
of	O
pluripotent	B-cell_line
islet	I-cell_line
cultures	I-cell_line
.	O


Generation	O
of	O
CD1+RelB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
and	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
from	O
human	B-cell_type
monocytes	I-cell_type
.	O


However	O
,	O
the	O
monocyte-derived	B-cell_line
DC	I-cell_line
were	O
not	O
terminally	B-cell_line
differentiated	I-cell_line
cells	I-cell_line
;	O
they	O
could	O
still	O
convert	O
to	O
macrophages	B-cell_type
in	O
response	O
to	O
M-CSF	B-protein
.	O


Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	B-protein
and	O
5-lipoxygenase	B-protein
has	O
been	O
shown	O
to	O
inhibit	O
T-cell	O
activation	O
.	O


Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	O
cyclosporin	O
,	O
suppresses	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	B-protein
molecules	I-protein
.	O


Characterization	O
of	O
a	O
CD43/leukosialin	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-lymphoblastoid	I-cell_type
cells	I-cell_type
.	O


Sterol	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	B-DNA
coding	O
for	O
especially	O
low	B-protein
density	I-protein
lipoprotein	I-protein
(	I-protein
LDL	I-protein
)	I-protein
-receptor	I-protein
,	O
3-hydroxy-3-methylglutaryl	B-protein
coenzyme	I-protein
A	I-protein
(	I-protein
HMG-CoA	I-protein
)	I-protein
reductase	I-protein
and	O
HMG-CoA	B-protein
synthase	I-protein
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O


Overexpression	O
of	O
full-length	O
SCL	B-protein
protein	I-protein
in	O
the	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	O
alter	O
cell	O
phenotype	O
and	O
there	O
was	O
no	O
evidence	O
for	O
autoregulation	O
of	O
SCL	B-protein
transcription	O
.	O


The	O
restricted	O
pattern	O
of	O
SCL	B-protein
protein	I-protein
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	B-RNA
mRNA	I-RNA
documented	O
previously	O
.	O


In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	B-protein
protein	I-protein
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell-specific	O
manner	O
.	O


Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T-cell	B-cell_type
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
.	O


We	O
thus	O
conclude	O
that	O
PTPases	B-protein
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	B-cell_type
activation	O
.	O


Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF-kappaB	B-protein
following	O
TCR	B-protein
stimulation	O
.	O


Contrary	O
to	O
the	O
idea	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
in	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF-kappaB	B-protein
by	O
PHA	B-protein
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O


Two	O
multicopy	B-DNA
basal	I-DNA
enhancer	I-DNA
motifs	I-DNA
within	O
the	O
SCMV	O
MIE	B-DNA
enhancer	I-DNA
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	B-DNA
response	I-DNA
factor	I-DNA
(	I-DNA
SRF	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
referred	O
to	O
as	O
the	O
SNE	B-DNA
(	O
SRF/NFkappaB-like	B-DNA
element	I-DNA
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	B-cell_type
and	I-cell_type
T-cell	I-cell_type
types	I-cell_type
.	O


The	O
survival	O
rate	O
of	O
tal-1	B-DNA
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O


Primary	B-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
showed	O
partial	O
independence	O
from	O
exogenous	O
growth	O
stimuli	O
and	O
increased	O
resistance	O
to	O
low-serum	O
apoptosis	O
.	O


TSC2	B-DNA
is	O
a	O
gene	O
on	O
chromosome	B-DNA
16p13.3	I-DNA
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O


By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	B-DNA
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin-labeled	B-DNA
complementary	I-DNA
DNA	I-DNA
probe	I-DNA
to	O
examine	O
TSC2	B-DNA
gene	O
expression	O
in	O
autopsy-	O
or	O
biopsy-derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O


These	O
results	O
suggest	O
that	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl-2	B-protein
and	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O


In	O
addition	O
,	O
EL-4	B-cell_type
cells	I-cell_type
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O


Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T-cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	B-cell_line
human	I-cell_line
CD4	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B-protein
with	O
p100	B-protein
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B-protein
-induced	O
activation	O
of	O
the	O
HTLV-I	O
and	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeats	I-DNA
,	O
reflecting	O
p100	B-protein
-mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B-protein
protein	I-protein
.	O


In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-protein
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF-kappa	B-protein
B	I-protein
expression	O
does	O
not	O
associate	O
with	O
p100	B-protein
.	O


Function	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
immune	O
system	O
.	O


An	O
exception	O
is	O
the	O
Bcl-3	B-protein
protein	I-protein
which	O
in	O
addition	O
can	O
function	O
as	O
a	O
transcription	B-protein
activating	I-protein
subunit	I-protein
in	O
th	O
nucleus	O
.	O


As	O
a	O
target	O
for	O
DNA	O
methylation	O
and	O
for	O
binding	O
of	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
or	O
impede	O
transcription	O
,	O
this	O
element	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
controlling	O
IFN-gamma	B-protein
expression	O
.	O


CD40	B-protein
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti-IgM	B-protein
stimulation	O
of	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-protein
.	O


High	O
levels	O
of	O
Sp140	B-RNA
mRNA	I-RNA
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O


Regulation	O
of	O
cytokine	B-protein
and	O
cytokine	B-protein
receptor	I-protein
expression	O
by	O
glucocorticoids	O
.	O


In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	B-protein
expression	O
,	O
GCS	O
up-regulate	O
cytokine	B-protein
receptor	I-protein
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	B-protein
effects	O
on	O
target	B-cell_type
cells	I-cell_type
.	O


Murine	B-DNA
fra-1	I-DNA
was	O
highly	O
homologous	O
to	O
rat	B-DNA
and	I-DNA
human	I-DNA
fra-1	I-DNA
.	O


Pharmacological	O
modification	O
of	O
cytokine	B-protein
dysregulation	O
,	O
therefore	O
,	O
has	O
been	O
suggested	O
as	O
a	O
therapeutic	O
modality	O
for	O
HIV-1	O
infection	O
.	O


Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O


In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	B-DNA
element	I-DNA
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


These	O
findings	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
alternative	O
treatment	O
approaches	O
for	O
recalcitrant	O
asthma	O
.	O


Low	O
risk	O
women	O
were	O
those	O
without	O
these	O
or	O
other	O
major	O
identifiable	O
risk	O
factors	O
.	O


The	O
prevalence	O
of	O
aneuploidy	O
and	O
overexpressed	O
EGFR	B-protein
was	O
significantly	O
higher	O
in	O
the	O
high	O
risk	O
women	O
than	O
in	O
the	O
25	O
low	O
risk	O
controls	O
(	O
p	O
<	O
0.002	O
)	O
,	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
was	O
0.7	O
%	O
.	O


This	O
may	O
be	O
due	O
to	O
the	O
low	O
prevalence	O
of	O
overexpressed	O
ER	B-protein
and	O
the	O
small	O
number	O
of	O
controls	O
.	O


A	O
significant	O
difference	O
was	O
noted	O
in	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
abnormal	O
biomarkers	O
between	O
the	O
high	O
risk	O
and	O
low	O
risk	O
women	O
(	O
p	O
<	O
0.001	O
)	O
.	O


Inhibition	O
of	O
nuclear	B-RNA
factor	I-RNA
kappa	I-RNA
B	I-RNA
subunit	I-RNA
p65	I-RNA
mRNA	I-RNA
accumulation	O
in	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
treated	O
with	O
sodium	O
salicylate	O
.	O


We	O
observed	O
that	O
dexamethasone	O
dramatically	O
inhibited	O
RANTES	B-RNA
mRNA	I-RNA
expression	O
dose	O
dependently	O
in	O
anti-CD3	B-cell_line
activated	I-cell_line
Hut-78	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
PBMCs	I-cell_type
.	O


Inhibition	O
of	O
RANTES	B-protein
expression	O
did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
IL-2	B-protein
inhibition	O
and	O
required	O
binding	O
to	O
the	O
intracellular	O
glucocorticoid	B-protein
receptor	I-protein
.	O


Association	O
of	O
TRAF1	B-protein
,	O
TRAF2	B-protein
,	O
and	O
TRAF3	B-protein
with	O
an	O
Epstein-Barr	B-DNA
virus	I-DNA
LMP1	I-DNA
domain	I-DNA
important	O
for	O
B-lymphocyte	B-cell_type
transformation	O
:	O
role	O
in	O
NF-kappaB	B-protein
activation	O
.	O


We	O
demonstrated	O
that	O
the	O
virus	B-protein
dUTPase	I-protein
isolated	O
from	O
EBV-infected	B-cell_type
cells	I-cell_type
is	O
a	O
phosphoprotein	B-protein
.	O


The	O
protein	O
expressed	O
in	O
insect	B-cell_type
cells	I-cell_type
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
specific	B-protein
antibodies	I-protein
in	O
sera	O
from	O
normal	O
,	O
healthy	O
carriers	O
and	O
from	O
patients	O
with	O
various	O
diseases	O
.	O


This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O


However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
is	O
sufficient	O
to	O
mediate	O
CD4	B-protein
accessory	O
function	O
.	O


These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	B-protein
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
.	O


These	O
involve	O
activation	O
of	O
the	O
sodium/proton-exchanger	B-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
minutes	O
.	O


The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two-step	O
model	O
for	O
non-genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O


Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU.1	B-protein
binding	O
decrease	O
M-CSF	B-protein
receptor	I-protein
promoter	O
activity	O
significantly	O
in	O
macrophage	B-cell_line
cell	I-cell_line
lines	I-cell_line
only	O
.	O


Furthermore	O
,	O
PU.1	B-protein
transactivates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
in	O
nonmacrophage	B-cell_type
cells	I-cell_type
.	O


The	O
authors	O
investigated	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
HER-2/neu	B-protein
expression	O
and	O
immunologic	O
parameters	O
representing	O
tumor	O
defense	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O


Within	O
this	O
group	O
of	O
patients	O
,	O
NK	B-cell_type
cell	I-cell_type
activity	O
was	O
significantly	O
lower	O
(	O
45.6	O
+/-	O
16.1	O
%	O
)	O
compared	O
with	O
the	O
group	O
with	O
no	O
HER-2/neu	B-protein
overexpression	O
(	O
57.3	O
+/-	O
11.0	O
%	O
)	O
.	O


CONCLUSION	O
.	O


No	O
difference	O
in	O
plasma	O
cortisol	O
was	O
found	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
subjects	O
(	O
P	O
>	O
0.05	O
)	O
.	O


These	O
data	O
indicate	O
that	O
IL-4	B-protein
signaling	O
occurs	O
in	O
the	O
absence	O
of	O
of	O
JAK3	B-protein
,	O
but	O
is	O
comparatively	O
inefficient	O
.	O


IL-2R	B-protein
alpha	I-protein
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B-protein
regulatory	I-protein
regions	I-protein
,	O
PRRI	B-DNA
and	O
PRRII	B-DNA
.	O


However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL-2R	O
alpha	O
transcription	O
by	O
IL-2	B-protein
.	O


To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL-2R	B-protein
alpha	I-protein
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	B-DNA
element	I-DNA
.	O


An	O
overexpression	O
of	O
p50	B-protein
has	O
been	O
described	O
in	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
FDC	B-cell_type
)	O
.	O


In	O
T	O
cell	O
areas	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA-DR+	B-cell_line
cells	I-cell_line
with	O
an	O
antigen-presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O


Cells	O
with	O
nuclear	O
p50	B-protein
were	O
negative	O
for	O
the	O
CD38	B-protein
,	O
CD20	B-protein
and	O
CD2	B-protein
markers	I-protein
.	O


These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	B-protein
,	O
p52	B-protein
and	O
RelB	B-protein
are	O
restricted	O
to	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	B-cell_type
in	O
GC	O
,	O
and	O
DC	B-cell_type
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	B-cell_type
macrophages	I-cell_type
from	O
GC	B-cell_type
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	B-protein
and	O
RelB	B-protein
,	O
whereas	O
macrophages	B-cell_type
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
do	O
have	O
both	O
nuclear	O
p52	B-protein
and	O
RelB	B-protein
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	B-protein
and	O
RelB	B-protein
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a+	B-cell_line
,	O
CD68+	B-cell_line
or	O
both	O
,	O
cells	O
APC	B-cell_type
,	O
whereas	O
p50	B-protein
is	O
restricted	O
to	O
CD1a-	B-cell_type
and	O
CD68-	B-cell_type
APC	I-cell_type
.	O


Intron-exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5'-flanking	B-DNA
region	I-DNA
.	O


These	O
data	O
suggest	O
that	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	B-protein
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF-2	B-protein
.	O


The	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
is	O
expressed	O
constitutively	O
in	O
cells	O
of	O
the	O
myeloid	B-cell_type
lineage	I-cell_type
,	O
appearing	O
in	O
myeloblast	B-cell_type
cells	I-cell_type
in	O
some	O
cases	O
of	O
acute	O
myeloid	O
leukemia	O
and	O
consistently	O
being	O
detected	O
in	O
promyelocyte	B-cell_type
stage	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
all	O
later	B-cell_type
stage	I-cell_type
cells	I-cell_type
including	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
granulocytes	B-cell_type
.	O


The	O
human	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
,	O
express	O
similar	O
levels	O
of	O
immunochemically	O
detectable	O
MNDA	B-protein
.	O


The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
also	O
unaffected	O
by	O
the	O
latter	O
four	O
agents	O
.	O


The	O
effects	O
of	O
phorbol	O
ester	O
on	O
MNDA	B-RNA
mRNA	I-RNA
appeared	O
to	O
be	O
associated	O
with	O
induced	O
differentiation	O
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	O
alter	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
and	O
cell	O
cycle	O
variation	O
in	O
MNDA	B-RNA
mRNA	I-RNA
levels	O
were	O
not	O
observed	O
.	O


An	O
affinity	O
column	O
fraction	O
,	O
containing	O
p37	B-protein
,	O
stimulated	O
HTLV-I	O
transcription	O
approximately	O
12-fold	O
in	O
vitro	O
.	O


In	O
addition	O
,	O
we	O
supplemented	O
one	O
group	O
of	O
individuals	O
with	O
a	O
daily	O
oral	O
replacement	O
dose	O
of	O
T3	O
to	O
isolate	O
the	O
influence	O
of	O
serum	O
thyroxine	O
(	O
T4	O
)	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
levels	O
on	O
receptor	O
kinetics	O
.	O


Mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
isolated	O
from	O
peripheral	O
blood	O
before	O
the	O
cold	O
exposure	O
and	O
drug	O
regimen	O
began	O
,	O
and	O
then	O
after	O
every	O
20	O
exposures	O
.	O


The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
maximum	O
binding	O
capacity	O
(	O
MBC	O
)	O
of	O
the	O
NT3R	B-protein
values	O
were	O
log	O
transformed	O
to	O
minimize	O
between-subject	O
variability	O
.	O


In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O


The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	B-DNA
E1A	I-DNA
domains	I-DNA
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
.	O


For	O
this	O
expression	O
pattern	O
the	O
first	O
280	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
seems	O
to	O
be	O
sufficient	O
.	O


In	O
the	O
erythroleukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
,	O
due	O
to	O
the	O
absence	O
of	O
Spi-B	B-protein
,	O
only	O
PU.1	B-protein
bound	O
to	O
the	O
Btk	B-DNA
promoter	I-DNA
.	O


Implication	O
of	O
viruses	O
such	O
as	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
in	O
rheumatoid	O
arthritis	O
pathogenesis	O
has	O
been	O
suspected	O
on	O
the	O
basis	O
of	O
several	O
indirect	O
observations	O
,	O
but	O
thus	O
far	O
,	O
a	O
direct	O
link	O
between	O
EBV	O
and	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
provided	O
.	O


G-CSF	B-protein
receptors	I-protein
lack	O
intrinsic	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O


The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
was	O
unique	O
to	O
G-CSF	B-protein
in	O
that	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
which	O
also	O
stimulates	O
neutrophils	B-cell_type
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	O
result	O
in	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O


The	O
consequences	O
of	O
p80c-rel	B-protein
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known	O
;	O
however	O
,	O
tyrosine-phosphorylated	O
p80c-rel	B-protein
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G-CSF	B-protein
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c-rel	B-protein
which	O
binds	O
to	O
DNA	O
.	O


These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	B-cell_type
following	O
G-CSF	B-protein
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	B-protein
kinase	I-protein
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O


In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/	O
E2A	B-protein
proteins	I-protein
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B-protein
proteins	I-protein
in	O
GH/PRL-	B-cell_line
and	I-cell_line
insulin-producing	I-cell_line
,	I-cell_line
B-	I-cell_line
and	I-cell_line
T-lymphocyte	I-cell_line
cells	I-cell_line
.	O


Visualization	O
of	O
the	O
endogenous	B-protein
NF-kappa	I-protein
B	I-protein
p50	I-protein
subunit	I-protein
in	O
the	O
nucleus	O
of	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
in	O
germinal	O
centers	O
.	O


NF-kappa	B-protein
B	I-protein
,	O
a	O
50	B-protein
kDa/65	I-protein
kDa	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	I-protein
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	B-DNA
genes	I-DNA
.	O


The	O
elevation	O
in	O
intracellular	O
calcium	O
that	O
is	O
induced	O
by	O
interactions	O
at	O
the	O
antigen	B-protein
receptor	I-protein
leads	O
to	O
the	O
activation	O
of	O
the	O
calcium-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
.	O


NF-ATn	B-protein
is	O
a	O
ubiquitous	O
protein	O
,	O
can	O
be	O
synthesized	O
in	O
response	O
to	O
PMA	O
,	O
and	O
has	O
many	O
similarities	O
to	O
AP-1	B-protein
.	O


The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	B-protein
lipoprotein	I-protein
,	O
LDL	B-protein
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O
Human	O
LDL	B-protein
induces	O
the	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	B-DNA
promoter	I-DNA
.	O


Thus	O
,	O
a	O
component	O
of	O
LDL	B-protein
-enhanced	O
endothelial	O
recruitment	O
of	O
monocytes	B-cell_type
is	O
attributed	O
to	O
VCAM-1	B-protein
expression	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
AP-1	B-protein
and	O
GATA	B-protein
.	O


n-Acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
blocked	O
NF-kappa	B-protein
B	I-protein
activation	O
caused	O
by	O
IL-4	B-protein
and	O
by	O
anti-CD40	B-protein
mAb	I-protein
.	O


Prostaglandin	O
E2	O
induction	O
of	O
binding	O
activity	O
to	O
CRE	B-DNA
and	O
AP-2	B-DNA
elements	I-DNA
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Both	O
NK-	B-cell_type
and	I-cell_type
T-cell	I-cell_type
subtypes	I-cell_type
are	O
closely	O
associated	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O


In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	B-DNA
gene	I-DNA
expression	O
at	O
the	O
single-cell	O
level	O
consisting	O
of	O
both	O
LMP1+	B-cell_type
and	I-cell_type
LMP1-	I-cell_type
tumour	I-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O


Down-regulation	O
of	O
immunogenic	B-protein
proteins	I-protein
(	O
EBNA2-EBNA6	B-protein
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	B-cell_type
cells	I-cell_type
to	O
evade	O
host	O
cytotoxic	O
T-cell	O
surveillance	O
.	O


This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O


Studies	O
with	O
20-epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon-20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20-methyl	O
derivatives	O
of	O
VD	O
.	O


Both	O
compounds	O
show	O
about	O
2-fold	O
lower	O
affinity	O
to	O
the	O
VD	O
receptor	O
(	O
VDR	O
)	O
than	O
VD	O
.	O


Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10-fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium-mobilizing	O
potency	O
as	O
VD	O
.	O


Calcium-dependent	O
immediate-early	B-DNA
gene	I-DNA
induction	O
in	O
lymphocytes	B-cell_type
is	O
negatively	O
regulated	O
by	O
p21Ha-ras	B-protein
.	O


The	O
expression	O
of	O
activated	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
negatively	O
regulated	O
the	O
induction	O
of	O
IE	B-DNA
genes	I-DNA
by	O
calcium	O
ionophore	O
.	O


This	O
inhibition	O
of	O
calcium-activated	O
IE	B-DNA
gene	I-DNA
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	B-protein
in	O
this	O
regulation	O
.	O


Calcineurin	B-protein
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
is	O
the	O
FK-506	O
-and	O
CsA-sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O


By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL-2R	B-protein
alpha	I-protein
and	O
in	O
IL-2R	B-protein
beta	I-protein
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen-stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


In	O
the	O
present	O
in-vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady-state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
)	O
.	O


This	O
mutant	O
inhibited	O
TCR	B-protein
-induced	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
by	O
interfering	O
with	O
both	O
intracellular	O
calcium	O
increase	O
and	O
Ras	B-protein
-regulated	O
activation	O
of	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
.	O


ZAP-70	B-protein
will	O
then	O
be	O
able	O
to	O
effectively	O
control	O
phosphorylation	O
of	O
its	O
substrates	O
and	O
lead	O
to	O
gene	O
activation	O
.	O


In	O
addition	O
,	O
a	O
significant	O
correlation	O
was	O
noted	O
between	O
the	O
degree	O
of	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50	O
)	O
and	O
the	O
binding	O
affinity	O
of	O
dexamethasone	O
to	O
the	O
GCR	B-protein
.	O


Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
.	O


B	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	B-protein
factors	I-protein
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O


The	O
following	O
transcription	B-protein
factors	I-protein
were	O
studied	O
:	O
the	O
Octamer	B-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
members	O
of	O
the	O
AP-1	B-protein
factor	I-protein
family	I-protein
,	O
NF-AT	B-protein
factors	I-protein
,	O
in	O
particular	O
NF-ATp	B-protein
,	O
and	O
members	O
of	O
the	O
Rel/NF-kB	B-protein
family	I-protein
.	O


Constitutive	O
binding	O
of	O
further	O
factor	B-protein
proteins	I-protein
to	O
DNA	O
,	O
such	O
as	O
JunD	B-protein
,	O
c-Fos	B-protein
and	O
FosB	B-protein
,	O
was	O
detected	O
in	O
several	O
patients	O
whereas	O
the	O
localisation	O
and	O
DNA	O
binding	O
of	O
other	O
factors	O
such	O
as	O
c-Jun	B-protein
,	O
RelA/p65	B-protein
and	O
c-Rel	B-protein
was	O
unaltered	O
.	O


The	O
magnitude	O
and	O
kinetics	O
of	O
intracellular	O
ROI	O
were	O
similar	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
differences	O
in	O
ROI-forming	O
mechanisms	O
or	O
antioxidative	O
capacities	O
.	O


Cells	O
need	O
to	O
distinguish	O
between	O
transient	O
Ca2+	O
signals	O
that	O
induce	O
events	O
such	O
as	O
muscle	O
contraction	O
,	O
secretion	O
,	O
adhesion	O
and	O
synaptic	O
transmission	O
,	O
and	O
sustained	O
Ca2+	O
signals	O
that	O
are	O
involved	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
.	O


Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	B-protein
RelA	I-protein
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
but	O
also	O
with	O
other	O
ankyrin	B-protein
motif-rich	I-protein
proteins	I-protein
including	O
the	O
products	O
of	O
the	O
NF-kappa	B-DNA
B2	I-DNA
(	I-DNA
p100	I-DNA
)	I-DNA
and	I-DNA
NF-kappa	I-DNA
B1	I-DNA
(	I-DNA
p105	I-DNA
)	I-DNA
genes	I-DNA
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	B-protein
-I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
RelA-p100	B-protein
cytoplasmic	I-protein
complexes	I-protein
are	O
not	O
dissociated	O
following	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
activation	O
;	O
(	O
iii	O
)	O
p100	B-protein
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	B-protein
-mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	B-protein
and	O
p100	B-protein
involves	O
the	O
conserved	B-protein
Rel	I-protein
homology	I-protein
domain	I-protein
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	B-protein
localization	I-protein
signal	I-protein
of	O
RelA	B-protein
,	O
which	O
is	O
required	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
binding	O
;	O
(	O
v	O
)	O
p100	B-protein
inhibition	O
of	O
RelA	B-protein
function	O
requires	O
the	O
C-terminal	B-protein
ankyrin	I-protein
motif	I-protein
domain	I-protein
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	B-protein
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
nuclear	O
RelA	B-protein
stimulates	O
p100	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
.	O


The	O
expression	O
of	O
GM-CSF	B-protein
and	O
IL-2	B-protein
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O


The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	B-protein
A	I-protein
subunit	I-protein
,	O
which	O
lacks	O
the	O
auto-inhibitory	B-protein
and	O
calmodulin-binding	B-protein
domains	I-protein
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O


NF-	O
CLE0	B-DNA
gamma	O
binding	O
is	O
induced	O
by	O
PMA/A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O


This	O
atrophy	O
induction	O
does	O
not	O
involve	O
apoptotic	O
mechanisms	O
in	O
thymocytes	B-cell_type
affected	O
by	O
the	O
bcl-2	B-DNA
proto-oncogene	I-DNA
.	O


The	O
Bcd	B-DNA
proto-oncogene	B-DNA
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	B-DNA
'	I-DNA
UTR	I-DNA
.	O


ORF1	B-DNA
consists	O
of	O
240	O
bp	O
that	O
would	O
encode	O
80	O
amino	O
acids	O
,	O
while	O
the	O
major	B-DNA
ORF2	I-DNA
consists	O
of	O
648	O
bp	O
capable	O
of	O
coding	O
for	O
216	O
amino	O
acids	O
.	O


Transfection	O
of	O
an	O
expression	B-DNA
vector	I-DNA
containing	O
ORF2	B-DNA
but	O
not	O
full	B-DNA
length	I-DNA
cDNA	I-DNA
was	O
able	O
to	O
transform	O
NIH3T3	B-cell_line
cells	I-cell_line
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O


Within	O
the	O
PBL	B-cell_type
,	O
Bcd	B-DNA
gene	O
expression	O
was	O
restricted	O
to	O
CD19+	B-cell_type
B-cells	I-cell_type
and	O
absent	O
from	O
CD14+	B-cell_type
monocytes	I-cell_type
and	O
T-cells	B-cell_type
.	O


These	O
observations	O
suggest	O
that	O
a	O
so-far-unrecognized	O
SP-1	B-DNA
site	I-DNA
in	O
the	O
human	B-DNA
IL-1beta	I-DNA
promoter	I-DNA
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	B-cell_type
.	O


Stat3	B-protein
recruitment	O
by	O
two	O
distinct	O
ligand-induced	B-protein
,	I-protein
tyrosine-phosphorylated	I-protein
docking	I-protein
sites	I-protein
in	O
the	O
interleukin-10	B-protein
receptor	I-protein
intracellular	I-protein
domain	I-protein
.	O


To	O
define	O
the	O
mechanism	O
underlying	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
protein	I-protein
recruitment	O
to	O
the	O
interleukin	B-protein
10	I-protein
(	I-protein
IL-10	I-protein
)	I-protein
receptor	I-protein
,	O
the	O
STAT	B-protein
proteins	I-protein
activated	O
by	O
IL-10	B-protein
in	O
different	O
cell	O
populations	O
were	O
first	O
defined	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O


We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	B-protein
,	O
while	O
human	B-protein
beta-globin	I-protein
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma-globin	B-RNA
transcripts	I-RNA
are	O
elevated	O
approximately	O
5-fold	O
.	O


Impaired	O
silencing	O
of	O
gamma-globin	B-protein
expression	O
identifies	O
EKLF	B-protein
as	O
the	O
first	O
transcription	B-protein
factor	I-protein
participating	O
quantitatively	O
in	O
the	O
gamma-globin	B-protein
to	O
beta-globin	B-protein
switch	O
.	O


Here	O
,	O
we	O
show	O
that	O
zinc	O
addition	O
in	O
a	O
serum-	O
and	O
lipopolysaccharide-free	O
cell	O
culture	O
system	O
leads	O
to	O
significantly	O
enhanced	O
levels	O
of	O
interleukin	B-protein
1	I-protein
beta	I-protein
(	O
IL-1	B-protein
beta	I-protein
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
to	O
expression	O
of	O
the	O
corresponding	O
mRNA	B-RNA
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O


Therefore	O
,	O
monokine	O
induction	O
is	O
a	O
zinc-specific	O
effect	O
influenced	O
by	O
the	O
physicochemical	O
properties	O
of	O
the	O
ion	O
.	O


E3	B-protein
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate-early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O


Multifactor	O
cis-dominant	O
negative	O
regulation	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
anergized	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Because	O
the	O
-180	B-DNA
site	I-DNA
is	O
not	O
required	O
for	O
trans-activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	B-DNA
IL-2	I-DNA
enhancer	I-DNA
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O


This	O
multiple	O
cytokine	B-protein
production	O
deficiency	O
could	O
not	O
be	O
restored	O
by	O
IL-2	B-protein
or	O
co-stimulatory	O
signals	O
provided	O
by	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
APC	B-cell_type
)	O
.	O


Whereas	O
AP-1	B-protein
,	O
NF-kappa	O
B	O
,	O
Oct	B-protein
,	O
CREB	B-protein
and	O
SP1	B-protein
displayed	O
normal	O
binding	O
activities	O
in	O
nuclear	O
extracts	O
,	O
the	O
binding	O
of	O
NF-AT	B-protein
to	O
its	O
IL-2	B-protein
promoter	O
response	O
element	O
was	O
barely	O
detectable	O
both	O
before	O
and	O
after	O
T	O
cell	O
stimulation	O
.	O


Deletion	O
of	O
the	O
EBNA2-dependent	B-DNA
enhancer	I-DNA
located	O
upstream	O
of	O
Cp	B-DNA
resulted	O
in	O
a	O
ca.	O
two-	O
to	O
fivefold	O
reduction	O
in	O
Cp	B-DNA
activity	O
in	O
the	O
LCLs	B-cell_line
assayed	O
.	O


Since	O
recent	O
studies	O
have	O
shown	O
that	O
lipopolysaccharide-induced	O
tyrosine	B-protein
kinase	I-protein
activation	O
is	O
not	O
required	O
for	O
NFkappaB	B-protein
nuclear	O
translocation	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
NFkappaB	B-protein
translocated	O
in	O
the	O
absence	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
was	O
active	O
in	O
stimulating	O
transcription	O
.	O


Nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
subunits	I-protein
may	O
ultimately	O
increase	O
the	O
intracellular	O
pool	O
of	O
NF-kappaB/IkappaBalpha	B-protein
by	O
an	O
autoregulatory	O
mechanism	O
.	O


The	O
transcription	O
and	O
transformation	O
activity	O
of	O
c-Jun	B-protein
is	O
governed	O
by	O
a	O
27-amino	B-protein
acid	I-protein
regulatory	I-protein
motif	I-protein
,	O
labeled	O
the	O
delta-domain	B-protein
,	O
which	O
is	O
deleted	O
in	O
v-Jun	B-protein
.	O


Moreover	O
,	O
alteration	O
of	O
any	O
one	O
of	O
these	O
features	O
(	O
e.g.	O
,	O
cis-element	B-DNA
,	O
trans-factor	B-DNA
,	O
or	O
cell-specific	O
background	O
)	O
switched	O
c-Jun	B-protein
to	O
a	O
transcriptional	B-protein
activator	I-protein
of	O
the	O
rPRL	B-DNA
promoter	I-DNA
.	O


Because	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
regulatory	I-protein
factors	I-protein
(	O
IRF-1	B-protein
and	O
IRF-2	B-protein
)	O
and	O
other	O
IFN-inducible	B-protein
gene	I-protein
products	I-protein
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O


Transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O


Transactivation	O
by	O
recombinant	O
NFAT1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
requires	O
dual	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
;	O
this	O
activity	O
is	O
potentiated	O
by	O
coexpression	O
of	O
constitutively	O
active	O
calcineurin	B-protein
and	O
is	O
inhibited	O
by	O
CsA	O
.	O


When	O
expressed	O
in	O
COS	B-cell_line
cells	I-cell_line
,	O
however	O
,	O
NFAT1	B-protein
is	O
capable	O
of	O
transactivation	O
,	O
but	O
it	O
is	O
not	O
regulated	O
correctly	O
:	O
its	O
subcellular	O
localization	O
and	O
transcriptional	O
function	O
are	O
not	O
affected	O
by	O
stimulation	O
of	O
the	O
COS	B-cell_line
cells	I-cell_line
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O


Human	B-protein
TAFII	I-protein
105	I-protein
is	O
a	O
cell	B-protein
type-specific	I-protein
TFIID	I-protein
subunit	I-protein
related	O
to	O
hTAFII130	B-protein
.	O


The	O
cDNA	B-DNA
encoding	O
hTAFII105	B-protein
reveals	O
a	O
highly	O
conserved	O
C-terminal	B-protein
domain	I-protein
shared	O
by	O
hTAFII130	B-protein
and	O
oTAFII110	B-protein
,	O
while	O
the	O
N-terminal	B-protein
coactivator	I-protein
domain	I-protein
has	O
diverged	O
significantly	O
.	O


These	O
properties	O
suggest	O
that	O
TAFII105	B-protein
is	O
a	O
cell	O
type-specific	O
subunit	O
of	O
TFIID	B-protein
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	B-cell_type
cells	I-cell_type
.	O


Interstitial	O
deletion	O
constitutes	O
the	O
major	O
mechanism	O
for	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	B-DNA
20q	I-DNA
in	O
polycythemia	O
vera	O
.	O


Abnormalities	O
of	O
retinoblastoma	B-protein
protein	I-protein
(	O
pRB	B-protein
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Activation	O
of	O
TGF-beta	B-protein
2	I-protein
transcription	O
correlates	O
with	O
the	O
loss	O
of	O
binding	O
activity	O
for	O
an	O
80	B-protein
kDA	I-protein
glial	I-protein
labile	I-protein
repressor	I-protein
protein	I-protein
,	O
GLRP	B-protein
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG-beta	B-DNA
2	I-DNA
promoter	I-DNA
.	O


These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF-beta	B-protein
2	I-protein
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T-lymphocytes	B-cell_type
and	O
astrocytes	B-cell_type
via	O
TGF-beta	B-protein
2	I-protein
to	O
regulate	O
the	O
immune	O
response	O
.	O


The	O
Id1	O
protein	O
was	O
found	O
to	O
repress	O
ALF1	B-protein
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


Moreover	O
,	O
ectopic	B-protein
Id1	I-protein
repressed	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
-directed	O
but	O
not	O
EA/S	B-DNA
-directed	O
MLV	O
transcription	O
in	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	B-protein
,	O
induced	O
Ad5E1A	B-protein
-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A	B-protein
-expressing	O
tumors	O
.	O


NGFI-B/nur77	B-protein
is	O
a	O
member	O
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
.	O


NGFI-B/nur77	B-protein
binds	O
to	O
the	O
response	B-DNA
element	I-DNA
by	O
monomer	O
or	O
heterodimer	O
with	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
.	O


Assuming	O
that	O
9-cis-retinoic	O
acid	O
(	O
9-cis-RA	O
)	O
inhibits	O
TCR-mediated	O
apoptosis	O
,	O
nur77	B-protein
may	O
cause	O
apoptosis	O
by	O
monomer	O
in	O
the	O
absence	O
of	O
9-cis-RA	O
and	O
may	O
inhibit	O
apoptosis	O
by	O
heterodimer	O
with	O
RXR	B-protein
in	O
the	O
presence	O
of	O
9-cis-RA	O
.	O


In	O
this	O
study	O
we	O
show	O
that	O
the	O
structurally	O
unrelated	O
antioxidant	O
agents	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
butylated	O
hydroxyanisole	O
,	O
and	O
Nacetylcysteine	O
activated	O
JNK	B-protein
(	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Transfection	O
of	O
trans-dominant	B-DNA
negative	I-DNA
expression	I-DNA
vectors	I-DNA
of	O
ras	B-DNA
and	O
raf	B-DNA
,	O
together	O
with	O
AP-1-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti-ERK	B-protein
(	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
)	I-protein
antibodies	I-protein
,	O
indicated	O
that	O
the	O
Ras/Raf/ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant	O
.	O


It	O
is	O
directly	O
implicated	O
in	O
the	O
emergence	O
of	O
the	O
age-related	O
immune	O
deficiency	O
.	O


Induction	O
of	O
bcl-2	B-protein
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B-cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O


Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O


We	O
have	O
located	O
the	O
major	O
positive	O
regulatory	O
region	O
for	O
control	O
of	O
bcl-2	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
.	O


bcl-2	B-protein
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	B-DNA
site	I-DNA
.	O


It	O
is	O
possible	O
that	O
the	O
CRE	B-DNA
site	I-DNA
is	O
responsible	O
for	O
induction	O
of	O
bcl-2	B-protein
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
.	O


MNDA	B-protein
(	O
myeloid	B-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
)	O
is	O
an	O
interferon	B-protein
alpha	I-protein
regulated	I-protein
nuclear	I-protein
protein	I-protein
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	B-cell_type
myelomonocytic	I-cell_type
lineage	I-cell_type
.	O


Importantly	O
,	O
nucleoprotein	O
extracts	O
showing	O
decreased	O
DNA-binding	O
activity	O
had	O
normal	O
amounts	O
of	O
Oct-1	B-protein
proteins	O
as	O
determined	O
by	O
immunoprecipitation	O
,	O
implying	O
a	O
functional	O
defect	O
in	O
the	O
Oct-1	B-protein
protein	I-protein
.	O


Although	O
NFAT	B-protein
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non-T	B-cell_type
immune	I-cell_type
cells	I-cell_type
,	O
the	O
NFAT	B-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	B-cell_type
cells	I-cell_type
.	O


To	O
further	O
characterize	O
NFAT	B-protein
function	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	B-protein
proteins	I-protein
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	B-DNA
clone	I-DNA
from	O
the	O
Raji	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


alpha	O
in	O
the	O
first	O
NH2-terminal	B-protein
29	I-protein
residues	I-protein
and	O
contains	O
an	O
additional	O
region	O
of	O
142	B-protein
residues	I-protein
at	O
the	O
COOH	B-protein
terminus	I-protein
.	O


However	O
,	O
NFATc.beta	B-protein
neither	O
bound	O
to	O
the	O
kappa3	B-DNA
element	I-DNA
(	O
an	O
NFAT-binding	B-DNA
site	I-DNA
)	O
in	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
nor	O
activated	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
in	O
cotransfection	O
assays	O
.	O


Interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
,	O
also	O
known	O
as	O
type	B-protein
II	I-protein
interferon	I-protein
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O


In	O
this	O
review	O
,	O
I	O
describe	O
how	O
DNA	O
methylation	O
and	O
specific	O
DNA	B-protein
binding	I-protein
proteins	I-protein
may	O
regulate	O
transcription	O
of	O
the	O
IFN-gamma	B-DNA
gene	I-DNA
in	O
response	O
to	O
extracellular	O
signals	O
.	O


In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV-positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
will	O
benefit	O
.	O


BZLF1	B-RNA
mRNA	I-RNA
and	O
the	O
product	O
,	O
an	O
immediate-early	B-DNA
gene	I-DNA
for	O
EBV	O
replication	O
,	O
was	O
not	O
expressed	O
in	O
any	O
of	O
them	O
,	O
thereby	O
suggesting	O
that	O
the	O
tumour	B-cell_type
cells	I-cell_type
carried	O
EBV	B-DNA
genomes	I-DNA
in	O
a	O
tightly	O
latent	O
form	O
.	O


These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	B-cell_type
carcinoma	I-cell_type
cells	I-cell_type
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
's	O
lymphoma	O
than	O
'latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O


The	O
75-kD	B-protein
protein	I-protein
is	O
recognized	O
by	O
antibodies	O
to	O
SLP-76	B-protein
,	O
which	O
has	O
recently	O
been	O
isolated	O
from	O
T	B-cell_type
cells	I-cell_type
and	O
sequenced	O
.	O


An	O
unidentified	O
Ets	B-protein
family	I-protein
protein	I-protein
binds	O
to	O
the	O
EBS	B-DNA
overlapping	O
the	O
consensus	B-DNA
GAS	I-DNA
motif	I-DNA
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	B-DNA
IL-2R	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O


Immunodepletion	O
studies	O
show	O
that	O
PTF	B-protein
beta	I-protein
is	O
required	O
for	O
transcription	O
of	O
both	O
classes	O
of	O
snRNA	B-DNA
genes	I-DNA
in	O
vitro	O
.	O


The	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
.	O


In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
,	O
tissue	B-protein
factor	I-protein
,	O
endothelial	B-protein
leukocyte	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
genes	I-DNA
.	O


Induction	O
of	O
NF-kappaB	B-protein
-dependent	O
gene	O
expression	O
in	O
transiently	O
transfected	O
human	B-cell_line
monocytic	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
elevated	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
.	O


Analysis	O
of	O
10	O
matched	O
pairs	O
of	O
high	O
grade	O
malignant	O
astrocytomas	O
and	O
their	O
subsequent	O
recurrences	O
identified	O
three	O
distinct	O
groups	O
.	O


The	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
A	O
did	O
not	O
show	O
structural	O
alterations	O
in	O
the	O
p16	B-DNA
,	I-DNA
p15	I-DNA
or	I-DNA
CDK4	I-DNA
genes	I-DNA
,	O
whereas	O
homozygous	O
codeletion	O
of	O
p16	B-DNA
and	O
p15	B-DNA
was	O
observed	O
in	O
both	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
B	O
.	O


BCL-6	B-protein
,	O
a	O
POZ/zinc-finger	B-protein
protein	I-protein
,	O
is	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
repressor	I-protein
.	O


These	O
results	O
indicate	O
that	O
the	O
BCL-6	B-protein
protein	I-protein
can	O
function	O
as	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
repressor	I-protein
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	B-protein
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O


Signals	O
leading	O
to	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
are	O
stronger	O
in	O
neonatal	B-cell_type
than	I-cell_type
adult	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
antibodies	B-protein
directed	O
against	O
the	O
major	O
components	O
of	O
NF-kappa	B-protein
B	I-protein
the	O
p50	B-protein
and	I-protein
RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
proteins	I-protein
,	O
indicated	O
that	O
the	O
composition	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
similar	O
in	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
cells	I-cell_type
.	O


In	O
preliminary	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
hematopoietic	B-protein
growth	I-protein
factor	I-protein
(	O
HGF	B-protein
)	O
requirement	O
of	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPCs	B-cell_type
)	O
purified	O
from	O
embryonic-fetal	O
liver	O
(	O
FL	O
)	O
and	O
grown	O
in	O
fetal	O
calf	O
serum-supplemented	O
(	O
FCS+	O
)	O
clonogenic	O
culture	O
.	O


Altogether	O
,	O
these	O
results	O
suggest	O
that	O
ATRA/9-cis	O
RA	O
may	O
play	O
a	O
key	O
role	O
in	O
FL	O
hematopoiesis	O
via	O
a	O
dual	O
effect	O
hypothetically	O
mediated	O
by	O
interaction	O
with	O
the	O
RAR/RXR	B-protein
heterodimer	I-protein
,	O
ie	O
,	O
inhibition	O
of	O
HSC/	B-cell_line
primitive	I-cell_line
HPC	I-cell_line
proliferation	O
and	O
induction	O
of	O
CFU-GEMM/	O
BFU-E/CFU-M	O
shift	O
from	O
the	O
multipotent/erythroid/monocytic	O
to	O
the	O
granulocytic-neutrophilic	O
differentiation	O
program	O
.	O


We	O
previously	O
suggested	O
that	O
the	O
measurement	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
is	O
an	O
index	O
of	O
an	O
analogous	O
pattern	O
in	O
brain	O
.	O


In	O
the	O
present	O
study	O
,	O
corticosteroid	B-protein
Type	I-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
measured	O
in	O
10	O
elderly	O
subjects	O
and	O
in	O
9	O
young	O
adults	O
,	O
before	O
and	O
after	O
overnight	O
DST	O
(	O
1	O
mg	O
)	O
.	O


The	O
number	O
of	O
Type	B-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
before	O
the	O
test	O
was	O
lower	O
in	O
elderly	O
subjects	O
than	O
in	O
adults	O
.	O


Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	B-protein
alpha-LBD	I-protein
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
.	O


With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R-276	O
and	O
R-394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O


Calcineurin	B-protein
mutants	I-protein
render	O
T	B-cell_type
lymphocytes	I-cell_type
resistant	O
to	O
cyclosporin	O
A	O
.	O


It	O
is	O
known	O
that	O
expression	O
of	O
a	O
single	O
viral	B-protein
immediate-early	I-protein
protein	I-protein
,	O
BZLF1	B-protein
,	O
is	O
sufficient	O
to	O
initiate	O
the	O
switch	O
from	O
latent	O
to	O
lytic	O
infection	O
in	O
B	B-cell_type
cells	I-cell_type
.	O


Similarly	O
,	O
CTL	B-cell_type
raised	O
against	O
the	O
parent	O
peptide	O
did	O
not	O
recognize	O
the	O
succinimide	O
derivative	O
of	O
this	O
peptide	O
.	O


Moreover	O
,	O
since	O
succinimide	O
intermediates	O
of	O
deamidated	O
peptides	O
can	O
occasionally	O
be	O
very	O
stable	O
,	O
these	O
peptides	O
have	O
the	O
potential	O
to	O
act	O
as	O
altered	O
self-Ags	O
with	O
significant	O
implications	O
for	O
autoimmunity	O
.	O


In	O
addition	O
,	O
unwanted	O
and	O
potentially	O
hazardous	O
specificities	O
may	O
be	O
elicited	O
when	O
using	O
synthetic	O
peptides	O
in	O
subunit	O
vaccines	O
in	O
which	O
succinimide	O
residues	O
may	O
form	O
spontaneously	O
during	O
storage	O
or	O
chemical	O
synthesis	O
.	O


The	O
Ets	O
protein	O
Spi-B	B-protein
is	O
expressed	O
exclusively	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
during	O
development	O
.	O


In	O
situ	O
hybridizations	O
of	O
adult	O
murine	O
tissues	O
demonstrate	O
Spi-B	B-RNA
mRNA	I-RNA
in	O
the	O
medulla	O
of	O
the	O
thymus	O
,	O
the	O
white	O
pulp	O
of	O
the	O
spleen	O
,	O
and	O
the	O
germinal	O
centers	O
of	O
lymph	O
nodes	O
.	O


The	O
point	O
mutations	O
resulted	O
in	O
a	O
2.5-	O
to	O
3-fold	O
reduction	O
of	O
CAT	B-protein
activity	O
.	O


The	O
results	O
suggest	O
that	O
a	O
combination	O
of	O
the	O
three	O
proximal	O
cis-acting	B-DNA
elements	I-DNA
may	O
constitute	O
a	O
minimal	O
region	O
responsible	O
for	O
CTL-specific	O
expression	O
of	O
perforin	B-protein
.	O


The	O
primary	B-RNA
RNA	I-RNA
transcript	I-RNA
of	O
the	O
gene	O
is	O
subject	O
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O


The	O
forms	O
produced	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
have	O
a	O
predominantly	O
activating	O
effect	O
on	O
gene	O
expression	O
whereas	O
those	O
produced	O
in	O
neuronal	B-cell_type
cells	I-cell_type
have	O
a	O
predominantly	O
inhibitory	O
effect	O
and	O
can	O
repress	O
the	O
expression	O
of	O
both	O
the	O
herpes	B-DNA
simplex	I-DNA
virus	I-DNA
immediate-early	I-DNA
genes	I-DNA
and	O
the	O
cellular	B-DNA
tyrosine	I-DNA
hydroxylase	I-DNA
gene	I-DNA
.	O


Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	B-protein
footprinting	O
of	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	B-protein
demonstrated	O
that	O
the	O
-76	B-DNA
site	I-DNA
binds	O
to	O
NFATp	B-protein
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	B-DNA
3	I-DNA
site	I-DNA
.	O


Anergic	B-cell_line
CD4+	I-cell_line
Th	I-cell_line
cells	I-cell_line
do	O
not	O
produce	O
IL-2	B-protein
when	O
challenged	O
with	O
Ag-pulsed	B-cell_line
accessory	I-cell_line
cells	I-cell_line
because	O
of	O
a	O
transcriptional	O
defect	O
.	O


We	O
find	O
that	O
OCA-B	B-protein
binds	O
DNA	O
directly	O
in	O
the	O
major	O
groove	O
between	O
the	O
two	O
subdomains	O
of	O
the	O
POU	B-DNA
domain	I-DNA
,	O
requiring	O
both	O
an	O
A	O
at	O
the	O
fifth	B-DNA
position	I-DNA
of	O
the	O
octamer	B-DNA
element	I-DNA
and	O
contact	O
with	O
the	O
POU	B-DNA
domain	I-DNA
.	O


[	O
Cortisone-resistant	O
bronchial	O
asthma	O
]	O


New	O
knowledge	O
on	O
the	O
mechanism	O
of	O
steroid	O
resistance	O
may	O
have	O
important	O
implications	O
for	O
the	O
treatment	O
of	O
chronic	O
asthma	O
and	O
other	O
diseases	O
.	O


The	O
activity	O
of	O
the	O
NH2-terminal	B-protein
transactivation	I-protein
domain	I-protein
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	B-protein
region	I-protein
that	O
contains	O
several	O
conserved	B-DNA
sequence	I-DNA
motifs	I-DNA
represented	O
only	O
in	O
the	O
NFAT	B-protein
family	I-protein
.	O


Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT-dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	B-protein
complexes	I-protein
containing	O
different	O
NFAT-family	B-protein
proteins	I-protein
.	O


A	O
major	O
obstacle	O
in	O
understanding	O
the	O
signaling	O
events	O
that	O
follow	O
CD28	B-protein
receptor	O
ligation	O
arises	O
from	O
the	O
fact	O
that	O
CD28	B-protein
acts	O
as	O
a	O
costimulus	O
to	O
TCR	B-protein
engagement	O
,	O
making	O
it	O
difficult	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
CD28	B-protein
signals	O
as	O
distinct	O
from	O
those	O
of	O
the	O
TCR	B-protein
.	O


This	O
finding	O
may	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
reasons	O
for	O
the	O
prevalence	O
of	O
lupus	O
in	O
females	O
and	O
of	O
the	O
estrogenic	O
effects	O
on	O
SLE	O
disease	O
activity	O
.	O


The	O
cytokines	B-protein
IFN-beta	B-protein
,	O
IFN-gamma	B-protein
,	O
IL-4	B-protein
,	O
and	O
LPS	O
,	O
although	O
unable	O
to	O
induce	O
sialoadhesin	B-protein
expression	O
by	O
themselves	O
,	O
were	O
able	O
to	O
enhance	O
GC-mediated	O
induction	O
of	O
sialoadhesin	B-protein
.	O


The	O
regulation	O
of	O
sialoadhesin	B-protein
expression	O
was	O
mediated	O
by	O
the	O
GC	B-protein
receptor	I-protein
,	O
and	O
not	O
by	O
mineralocorticoid	B-protein
receptor	I-protein
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O


In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl-2	B-protein
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	B-protein
protease	I-protein
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
while	O
reducing	O
the	O
yields	O
of	O
viral	B-protein
structural	I-protein
proteins	I-protein
,	O
infectivity	O
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O


Furthermore	O
,	O
the	O
dose	O
of	O
OKT3	B-protein
required	O
to	O
achieve	O
half-maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
ligands	O
.	O


Indeed	O
,	O
erythroid	B-DNA
gene	I-DNA
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O


These	O
findings	O
establish	O
that	O
STAT1	B-protein
and	O
STAT5	B-protein
,	O
and	O
possibly	O
STAT3	B-protein
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
IL-7	B-protein
.	O


The	O
data	O
further	O
indicate	O
that	O
the	O
IL-7R	B-protein
alpha	I-protein
chains	I-protein
are	O
directly	O
involved	O
in	O
the	O
activation	O
of	O
JAKs	B-protein
and	O
STATs	B-protein
and	O
have	O
a	O
major	O
role	O
in	O
proliferative	O
signaling	O
in	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Stimulation	O
of	O
human	O
lymphocyte	O
proliferation	O
and	O
CD40	B-protein
antigen	O
expression	O
by	O
phosphorothioate	O
oligonucleotides	O
complementary	O
to	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
genome	I-DNA
.	O


Activation	B-protein
protein	I-protein
1	I-protein
-dependent	O
transcriptional	O
activation	O
of	O
interleukin	B-DNA
2	I-DNA
gene	I-DNA
by	O
Ca2+/calmodulin	B-protein
kinase	I-protein
type	I-protein
IV/Gr	I-protein
.	O


The	O
responses	O
of	O
lymphocytes	B-cell_type
to	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
involving	O
proliferation	O
,	O
differentiation	O
,	O
and	O
cytokine	B-protein
production	O
,	O
are	O
only	O
partially	O
overlapping	O
,	O
and	O
may	O
depend	O
on	O
induced	O
differential	O
expression	O
of	O
specific	O
sets	O
of	O
genes	B-protein
.	O


Analysis	O
of	O
the	O
expression	O
of	O
genes	B-protein
reported	O
to	O
regulate	O
cytokine	B-protein
-induced	O
proliferation	O
demonstrated	O
that	O
both	O
IL-2	B-protein
and	O
IL-12	B-protein
induce	O
c-myc	B-RNA
mRNA	I-RNA
accumulation	O
in	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
only	O
IL-2	B-protein
induces	O
bcl-2	B-DNA
expression	O
.	O


This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2-	B-cell_line
and	I-cell_line
IL-12-stimulated	I-cell_line
cells	I-cell_line
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O


Transfection	O
of	O
a	O
cDNA	O
containing	O
the	O
human	B-DNA
CIITA	I-DNA
coding	I-DNA
sequence	I-DNA
under	O
the	O
control	O
of	O
an	O
heterologous	B-DNA
promoter	I-DNA
restores	O
expression	O
of	O
human	B-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	B-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
both	O
the	O
mouse	B-cell_line
plasmacytoma	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
the	O
hybrids	B-cell_line
.	O


Increasing	O
the	O
levels	O
of	O
BCL-2	B-protein
retarded	O
the	O
G0	O
--	O
>	O
S	O
transition	O
,	O
sustained	O
the	O
levels	O
of	O
cyclin-dependent	B-protein
kinase	I-protein
inhibitor	O
p27Kip1	O
,	O
and	O
repressed	O
postactivation	O
death	O
.	O


InterleUkin	B-protein
2	I-protein
expression	O
requires	O
several	O
transcription	B-protein
factors	I-protein
of	O
which	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
and	O
NFAT	B-protein
-mediated	O
transactivation	O
were	O
impaired	O
by	O
BCL-2	B-protein
.	O


On	O
the	O
basis	O
of	O
several	O
independent	O
assays	O
,	O
we	O
now	O
report	O
a	O
physical	O
and	O
functional	O
interaction	O
between	O
Tax	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
,	O
TFIIA	B-protein
.	O


Second	O
,	O
a	O
glutathione-S-transferase	O
(	O
GST	B-protein
)	O
affinity-binding	O
assay	O
showed	O
that	O
the	O
interaction	O
of	O
holo-	O
TFIIA	B-protein
with	O
GST-Tax	B-protein
was	O
20-fold	O
higher	O
than	O
that	O
observed	O
with	O
either	O
the	O
GST-Tax	B-protein
M32	I-protein
activation	I-protein
mutant	I-protein
or	O
the	O
GST	O
control	O
.	O


Finally	O
,	O
TFIIA	B-protein
facilitates	O
Tax	B-protein
transactivation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


In	O
addition	O
,	O
transfection	O
of	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
with	O
TFIIA	B-DNA
expression	I-DNA
vectors	I-DNA
enhanced	O
Tax	B-protein
-activated	O
transcription	O
of	O
an	O
HTLV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat-chloramphenicol	I-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
.	O


cAMP	O
signaling	O
inhibited	O
Stat1	B-protein
at	O
several	O
different	O
levels	O
,	O
including	O
suppression	O
of	O
DNA	O
binding	O
and	O
down-regulation	O
of	O
Stat1	O
protein	O
and	O
mRNA	O
levels	O
.	O


In	O
selecting	O
the	O
most	O
specific	O
and	O
potent	O
oligonucleotide	O
sequence	O
,	O
we	O
performed	O
extensive	O
analyses	O
for	O
the	O
binding	O
specificity	O
between	O
all	O
candidates	O
of	O
c-jun	B-DNA
AS	O
oligonucleotides	O
and	O
the	O
whole	O
sequences	O
in	O
GenBank	O
database	O
,	O
using	O
a	O
computer	O
program	O
.	O


These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c-jun	B-DNA
in	O
both	O
cell	O
proliferation	O
and	O
PMA-induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA-induced	O
respiratory	O
burst	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O


Effects	O
of	O
IL-10	B-protein
and	O
IL-4	B-protein
on	O
LPS-induced	O
transcription	B-protein
factors	I-protein
(	O
AP-1	B-protein
,	O
NF-IL6	B-protein
and	O
NF-kappa	B-protein
B	I-protein
)	O
which	O
are	O
involved	O
in	O
IL-6	B-protein
regulation	O
.	O


Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	B-DNA
linked	I-DNA
binding	I-DNA
sites	I-DNA
for	O
CBF	B-protein
,	O
AP-1	B-protein
,	O
and	O
NFATp	B-protein
.	O


Stepwise	O
deletions	O
into	O
the	O
proximal	B-DNA
promoter	I-DNA
also	O
revealed	O
that	O
the	O
CBF	B-protein
site	O
,	O
but	O
not	O
the	O
YY-1	B-DNA
site	I-DNA
,	O
was	O
required	O
for	O
efficient	O
induction	O
of	O
transcriptional	O
activation	O
.	O


The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
transcriptional	O
activities	O
mediated	O
by	O
c-Fos/c-Jun	B-protein
AP-1	B-protein
and	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
.	O


Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF-AT	B-protein
and	O
IL-2	B-DNA
reporters	I-DNA
as	O
well	O
as	O
the	O
expression	O
of	O
IL-2	B-RNA
mRNA	I-RNA
in	O
cells	O
stimulated	O
with	O
PHA/PMA	O
.	O


The	O
underlying	O
molecular	O
mechanism	O
for	O
Pb	O
's	O
complex	O
effects	O
on	O
the	O
immune	O
system	O
remain	O
obscure	O
.	O


Many	O
of	O
Pb	O
's	O
effects	O
on	O
the	O
immune	O
system	O
could	O
be	O
explained	O
through	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O


Functional	O
activation	O
of	O
gene	O
expression	O
by	O
Pb	O
was	O
confirmed	O
using	O
primary	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
transfected	O
with	O
an	O
NF-kappa	B-DNA
B	I-DNA
dependent	I-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
.	O


However	O
,	O
IFN	B-protein
(	I-protein
alpha	I-protein
)	I-protein
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid-dependent	O
regulation	O
of	O
the	O
myeloid	B-protein
surface	I-protein
markers	I-protein
CD11b	B-protein
and	O
CD33	B-protein
.	O


Thus	O
,	O
stress	O
may	O
cause	O
a	O
selective	O
suppression	O
of	O
TH1	O
functions	O
and	O
a	O
shift	O
toward	O
a	O
TH2	B-protein
cytokine	I-protein
pattern	O
rather	O
than	O
generalized	O
TH	O
suppression	O
.	O


Activation	O
of	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
Treponema	B-protein
pallidum	I-protein
and	I-protein
Borrelia	I-protein
burgdorferi	I-protein
lipoproteins	I-protein
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF-kappa	B-protein
B	I-protein
.	O


By	O
using	O
70Z/3-derived	B-cell_line
pre-B-cell	I-cell_line
lines	I-cell_line
either	O
lacking	O
or	O
expressing	O
human	B-protein
CD14	I-protein
(	O
the	O
LPS	B-protein
receptor	I-protein
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	B-protein
CD14	I-protein
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B-protein
or	O
spirochetal	B-protein
lipopeptides	I-protein
(	O
assessed	O
by	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
expression	O
of	O
surface	B-protein
immunoglobulin	I-protein
M	I-protein
)	O
.	O


The	O
PML	B-DNA
gene	I-DNA
is	O
fused	O
to	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
RAR	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
in	O
t	O
(	O
15	O
;	O
17	O
)	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
,	O
creating	O
a	O
PML-RAR	B-protein
alpha	I-protein
fusion	I-protein
oncoprotein	I-protein
.	O


The	O
PML	B-protein
gene	I-protein
product	I-protein
has	O
been	O
localized	O
to	O
subnuclear	B-cell_line
dot-like	I-cell_line
structures	I-cell_line
variously	O
termed	O
PODs	O
,	O
ND10s	O
,	O
Kr	O
bodies	O
,	O
or	O
PML	O
nuclear	O
bodies	O
(	O
PML	O
NBs	O
)	O
.	O


By	O
immunofluorescence	O
,	O
LYSP100	B-DNA
was	O
localized	O
to	O
nuclear	O
dots	O
that	O
were	O
surprisingly	O
largely	O
nonoverlapping	O
with	O
PML	O
NBs	O
.	O


LANDs	O
were	O
most	O
often	O
found	O
in	O
the	O
nucleoplasm	O
,	O
but	O
were	O
also	O
found	O
at	O
the	O
nuclear	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
,	O
suggesting	O
that	O
these	O
structures	O
may	O
traffic	O
between	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
.	O


GR	B-protein
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate-limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	B-protein
-mediated	O
induction	O
of	O
an	O
integrated	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
(	I-DNA
MMTV	I-DNA
)	I-DNA
LTR	I-DNA
reporter	I-DNA
gene	I-DNA
was	O
observed	O
.	O


The	O
induction	O
of	O
AP-1	B-protein
by	O
p21ras	B-protein
also	O
requires	O
Rac-1	B-protein
function	O
.	O


Moreover	O
,	O
the	O
combination	O
of	O
activated	O
MAPKK-1	B-protein
and	O
Rac-1	B-protein
could	O
not	O
substitute	O
for	O
activated	O
p21ras	B-protein
and	O
synergize	O
with	O
calcium	O
signals	O
to	O
induce	O
NFAT	B-protein
.	O


Thus	O
,	O
p21ras	B-protein
regulation	O
of	O
NFAT	B-protein
in	O
T	B-cell_type
cells	I-cell_type
requires	O
the	O
activity	O
of	O
multiple	O
effector	O
pathways	O
including	O
those	O
regulated	O
by	O
MAPKK-1	B-protein
/ERK-2	B-protein
and	O
Rac-1	B-protein
.	O


Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
specific	O
type	O
of	O
acute	O
myeloid	O
leukemia	O
characterized	O
by	O
the	O
morphology	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
,	O
a	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
,	O
and	O
risks	O
of	O
definite	O
coagulopathy	O
.	O


Although	O
IL-2	B-protein
and	O
IFN-alpha	B-protein
activated	O
STAT1	B-protein
alpha	I-protein
and	O
STAT5	B-protein
,	O
IL-2	B-protein
predominantly	O
activated	O
STAT5	B-protein
,	O
while	O
IFN-alpha	B-protein
predominantly	O
activated	O
STAT1	B-protein
alpha	I-protein
.	O


However	O
,	O
supershift	O
analyses	O
using	O
the	O
c-fos	B-DNA
promoter	I-DNA
sis-inducible	I-DNA
element	I-DNA
probe	I-DNA
showed	O
that	O
IL-12	B-protein
activated	O
STAT4	B-protein
,	O
STAT1	B-protein
alpha	I-protein
,	O
and	O
STAT3	B-protein
,	O
and	O
induced	O
complexes	O
containing	O
STAT4	B-protein
only	O
,	O
STAT4	B-protein
with	O
STAT1	B-protein
alpha	I-protein
,	O
STAT3	B-protein
with	O
STAT1	B-protein
alpha	I-protein
,	O
or	O
STAT1	B-protein
alpha	I-protein
only	O
in	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O


Differential	O
phosphorylation	O
and	O
consequent	O
differential	O
activation	O
of	O
both	O
separate	O
and	O
overlapping	O
STAT	B-protein
proteins	I-protein
by	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IFN-alpha	B-protein
may	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
similarities	O
and	O
differences	O
in	O
the	O
actions	O
of	O
these	O
cytokines	B-protein
on	O
NK	B-cell_type
cells	I-cell_type
.	O


In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	B-protein
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N-tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O


The	O
discovery	O
of	O
these	O
signaling	O
pathways	O
has	O
led	O
to	O
important	O
new	O
insights	O
into	O
their	O
role	O
in	O
lymphocyte	O
maturation	O
,	O
as	O
it	O
has	O
emerged	O
that	O
mutations	O
in	O
the	O
genes	O
encoding	O
both	O
gamma	B-protein
c	I-protein
and	O
JAK3	B-protein
result	O
in	O
similar	O
forms	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
.	O


In	O
this	O
review	O
we	O
examine	O
the	O
structure	O
and	O
function	O
of	O
cytokine	B-protein
receptors	I-protein
and	O
the	O
signaling	O
pathways	O
involved	O
in	O
their	O
regulation	O
of	O
gene	O
expression	O
.	O


We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL-6	B-protein
protein	I-protein
and	O
mRNA	B-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


We	O
also	O
demonstrated	O
that	O
the	O
CMV	B-protein
immediate	I-protein
early	I-protein
1	I-protein
gene	I-protein
product	I-protein
increased	O
expression	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O


This	O
effect	O
of	O
the	O
CMV	B-protein
immediate	I-protein
early	I-protein
1	I-protein
gene	I-protein
product	I-protein
was	O
dependent	O
upon	O
the	O
presence	O
of	O
specific	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O


Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	B-protein
RA	I-protein
and	I-protein
VitD3	I-protein
receptors	I-protein
[	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
,	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
,	O
and	O
VitD3	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
]	O
in	O
the	O
U-937	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O


VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR/RXR	B-protein
DNA-binding	I-protein
complexes	I-protein
on	O
both	O
VitD3	B-DNA
response	I-DNA
elements	I-DNA
and	O
RA	B-DNA
response	I-DNA
elements	I-DNA
(	O
RAREs	B-DNA
)	O
.	O


Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA-stimulated	O
formation	O
of	O
RAR	B-protein
beta/RXR	I-protein
heterodimers	I-protein
,	O
favoring	O
VDR	B-protein
/RXR	B-protein
binding	O
to	O
the	O
RARE	B-DNA
.	O


Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	B-protein
and	O
CD49f	B-protein
,	O
characteristic	O
markers	O
of	O
retinoid-induced	O
U-937	B-cell_line
cell	I-cell_line
differentiation	O
.	O


These	O
findings	O
are	O
consistent	O
with	O
a	O
model	O
for	O
Rex	B-protein
-mediated	O
trans-activation	O
in	O
which	O
Rex-viral	B-protein
mRNA	I-protein
complexes	I-protein
are	O
targeted	O
for	O
nuclear	O
export	O
by	O
the	O
direct	O
action	O
of	O
the	O
activation	B-protein
domain	I-protein
.	O


Whereas	O
94-kD	B-protein
STAT5A	I-protein
was	O
clearly	O
tyrosine	O
phosphorylated	O
and	O
bound	O
to	O
the	O
enhancer	B-DNA
element	I-DNA
,	O
the	O
gamma	B-DNA
response	I-DNA
region	I-DNA
(	O
GRR	B-DNA
)	O
,	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RI	I-DNA
gene	I-DNA
,	O
substantially	O
less	O
tyrosine	O
phosphorylated	O
STAT5B	B-protein
bound	O
to	O
the	O
immobilized	O
GRR	B-DNA
element	I-DNA
.	O


Transgenic	O
expression	O
of	O
PML/RARalpha	B-protein
impairs	O
myelopoiesis	O
.	O


Cell	O
sorter	O
analysis	O
of	O
CD11b+	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
revealed	O
similar	O
CD11b+	B-cell_type
populations	I-cell_type
in	O
transgenic	O
and	O
control	O
mice	O
.	O


Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O


Retinoic	O
acid	O
treatment	O
of	O
irradiated	O
PML/RARalpha	B-protein
mice	O
enhanced	O
granulocyte	B-cell_type
recovery	O
.	O


This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP-1	B-DNA
and	I-DNA
Elf-1	I-DNA
sites	I-DNA
in	O
the	O
IL-3	B-DNA
promoter	I-DNA
.	O


The	O
AC	B-DNA
unit	I-DNA
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O


T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN-gamma	B-protein
.	O


Age-related	O
decreases	O
in	O
IL-2	B-protein
production	O
by	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
associated	O
with	O
impaired	O
activation	O
of	O
nuclear	B-protein
transcriptional	I-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O


IL-13	B-protein
induces	O
phosphorylation	O
and	O
activation	O
of	O
JAK2	B-protein
Janus	I-protein
kinase	I-protein
in	O
human	B-cell_line
colon	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
similarities	O
between	O
IL-4	B-protein
and	O
IL-13	B-protein
signaling	O
.	O


Both	O
IL-4	B-protein
and	O
IL-10	B-protein
were	O
seen	O
to	O
inhibit	O
IL-6	B-protein
production	O
and	O
the	O
expression	O
of	O
IL-6	B-RNA
mRNA	I-RNA
in	O
both	O
monocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
.	O


On	O
the	O
other	O
hand	O
,	O
IL-10	B-protein
enhanced	O
the	O
degradation	O
of	O
IL-6	B-RNA
mRNA	I-RNA
in	O
a	O
mRNA	O
stability	O
assay	O
.	O


Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
/alphaCD28	B-protein
produced	O
IL-2	B-protein
in	O
the	O
presence	O
of	O
CsA	O
.	O


We	O
compared	O
the	O
effects	O
of	O
the	O
deactivating	B-protein
cytokine	I-protein
interleukin	B-protein
10	I-protein
(	O
IL-10	B-protein
)	O
on	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
(	O
PBMC	B-cell_type
)	O
responses	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Cryptococcus	O
neoformans	O
,	O
and	O
Candida	O
albicans	O
.	O


Identification	O
as	O
lymphocyte-specific	B-protein
protein	I-protein
1	I-protein
(	O
LSP1	B-protein
)	O
.	O


Furthermore	O
,	O
we	O
demonstrate	O
that	O
several	O
of	O
these	O
agents	O
can	O
significantly	O
increase	O
HIV	O
replication	O
and	O
accelerate	O
CD4	B-protein
-positive	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O


The	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
receptor	O
for	O
interleukin	B-protein
10	I-protein
(	O
IL-10R	B-protein
)	O
contains	O
two	O
box	B-protein
3	I-protein
sequence	I-protein
motifs	I-protein
that	O
have	O
been	O
identified	O
in	O
the	O
signal-transducing	B-protein
receptor	I-protein
subunits	I-protein
for	O
IL-6-type	B-protein
cytokines	I-protein
and	O
noted	O
to	O
be	O
required	O
for	O
activating	O
STAT3	B-protein
and	O
inducing	O
transcription	O
through	O
IL-6-responsive	B-DNA
elements	I-DNA
.	O


The	O
cell	O
response	O
to	O
IL-10	B-protein
characteristically	O
differed	O
from	O
that	O
to	O
IL-2/IL-15	B-protein
,	O
IL-4	B-protein
,	O
and	O
interferon	B-protein
gamma	I-protein
.	O


This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
induction	O
is	O
studied	O
in	O
a	O
``	B-cell_type
physiologic	I-cell_type
''	I-cell_type
cell	I-cell_type
lineage	I-cell_type
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	B-cell_type
cells	I-cell_type
.	O


Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
generation	O
,	O
on	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O


We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
(	I-DNA
TNF	I-DNA
)	I-DNA
-alpha	I-DNA
gene	I-DNA
and	O
on	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activation	O
.	O


Western	O
blotting	O
analysis	O
with	O
anti-I	B-protein
kappa	I-protein
B-alpha	I-protein
antibody	I-protein
indicated	O
that	O
E3330	O
inhibited	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
which	O
is	O
an	O
inhibitory	B-protein
protein	I-protein
of	O
NF-kappa	B-protein
B	I-protein
,	O
in	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
.	O


E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O


Second	O
messenger	O
up-regulation	O
of	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
is	O
absent	O
in	O
androgen	B-cell_line
insensitive	I-cell_line
human	I-cell_line
prostatic	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
PC-3	B-cell_line
and	O
DU-145	B-cell_line
.	O


Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte/macrophages	B-cell_type
.	O


Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	B-DNA
-158	I-DNA
to	I-DNA
-90	I-DNA
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


We	O
directly	O
tested	O
the	O
amino	O
acid	O
polymorphism	O
at	O
this	O
site	O
as	O
a	O
determinant	O
for	O
peptide	O
binding	O
and	O
for	O
antigen-specific	O
T	O
cell	O
stimulation	O
.	O


These	O
binding	O
studies	O
were	O
paralleled	O
by	O
specific	O
T	O
cell	O
recognition	O
of	O
the	O
class	B-protein
II-peptide	I-protein
complex	I-protein
,	O
in	O
which	O
the	O
substituted	O
peptide	O
abolished	O
T	O
cell	O
reactivity	O
,	O
which	O
was	O
directed	O
to	O
the	O
DQ3.2-peptide	B-protein
complex	I-protein
,	O
whereas	O
the	O
same	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
recognized	O
the	O
substituted	O
peptide	O
presented	O
by	O
DQ3.3	O
,	O
a	O
class	O
II	O
restriction	O
element	O
differing	O
from	O
DQ3.2	O
only	O
at	O
residue	O
57	O
.	O


The	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
and	O
co-stimulatory	B-protein
molecules	I-protein
,	O
and	O
results	O
in	O
the	O
triggering	O
of	O
several	O
signaling	O
pathways	O
which	O
lead	O
rapidly	O
to	O
the	O
nuclear	O
translocation	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
and	O
NF-AT	B-protein
.	O


Appearance	O
of	O
the	O
STAT1	B-protein
factor	O
is	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
cyclosporin	O
A	O
,	O
and	O
blocked	O
by	O
cycloheximide	O
,	O
indicating	O
that	O
its	O
activation	O
is	O
dependent	O
upon	O
a	O
protein	O
(	O
s	O
)	O
synthesized	O
in	O
response	O
to	O
initial	O
signaling	O
events	O
.	O


Neutralizing	O
antiserum	O
against	O
IFN-gamma	B-protein
,	O
but	O
not	O
other	O
cytokines	B-protein
tested	O
,	O
blocked	O
activation	O
of	O
the	O
factor	O
almost	O
completely	O
,	O
and	O
IFN-gamma	B-protein
was	O
found	O
in	O
the	O
culture	O
supernatants	O
of	O
stimulated	B-cell_line
cells	I-cell_line
at	O
levels	O
at	O
which	O
recombinant	O
IFN-gamma	B-protein
could	O
activate	O
the	O
factor	O
in	O
naive	B-cell_type
cells	I-cell_type
.	O


Therefore	O
,	O
a	O
STAT1	B-protein
transcription	B-protein
factor	I-protein
is	O
activated	O
by	O
IFN-gamma	B-protein
synthesized	O
and	O
released	O
upon	O
stimulation	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
populations	I-cell_type
.	O


The	O
information	O
obtained	O
from	O
these	O
cell	B-cell_line
lines	I-cell_line
has	O
also	O
been	O
used	O
in	O
arguments	O
for	O
a	O
lymphoid	O
origin	O
of	O
H-RS	B-cell_line
cells	I-cell_line
in	O
tissue	O
despite	O
the	O
frequent	O
absence	O
of	O
lymphoid	B-protein
markers	I-protein
and	O
Ig/TcR	B-DNA
gene	I-DNA
rearrangements	I-DNA
in	O
these	O
cells	O
.	O


An	O
AP-1	O
site	O
at	O
-146	O
to	O
-140	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	I-DNA
.	O


Within	O
this	O
region	O
,	O
an	O
NF-kappaB	B-DNA
site	I-DNA
at	O
-59	B-DNA
to	I-DNA
-50	I-DNA
and	O
its	O
adjacent	O
20-base	B-DNA
pair	I-DNA
upstream	I-DNA
sequence	I-DNA
were	O
demonstrated	O
to	O
play	O
a	O
critical	O
role	O
for	O
the	O
IL-9	B-DNA
promoter	I-DNA
activity	O
.	O


Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	O
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O


We	O
have	O
shown	O
that	O
1-	O
(	O
5-chloronaphthalene-1-sulfonyl	O
)	O
-1H-hexahydro-1	O
,	O
4-diazepine	O
hydrochloride	O
(	O
ML-9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
,	O
induces	O
differentiation	O
of	O
monocytoid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
U937	B-cell_line
and	O
THP-1	B-cell_line
but	O
not	O
of	O
myeloblastic	B-cell_line
leukemic	I-cell_line
ML-1	I-cell_line
cell	I-cell_line
or	O
erythroleukemia	B-cell_line
K562	I-cell_line
cells	I-cell_line
.	O


ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-reducing	O
activity	O
of	O
U937	B-cell_line
cell	I-cell_line
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O


Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	B-cell_line
monoblastic	I-cell_line
cells	I-cell_line
,	O
THP-1	B-cell_line
.	O


Costimulation	O
of	O
U1	B-cell_line
cells	I-cell_line
with	O
LPS	O
plus	O
GM-CSF	B-protein
resulted	O
in	O
the	O
accumulation	O
of	O
steady-state	O
levels	O
of	O
HIV	B-RNA
RNA	I-RNA
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
,	O
was	O
noted	O
.	O


To	O
date	O
,	O
a	O
large	O
number	O
of	O
receptors	O
for	O
IL-12	B-protein
have	O
been	O
found	O
only	O
on	O
PBMC	B-cell_type
following	O
activation	O
with	O
PHA	B-protein
or	O
IL-2	B-protein
.	O


In	O
humans	O
infected	O
with	O
the	O
HIV-1	O
virus	O
there	O
may	O
be	O
a	O
disproportionate	O
severity	O
of	O
signs	O
and	O
symptoms	O
of	O
illness	O
compared	O
to	O
the	O
fraction	O
of	O
CD4+	B-cell_line
infected	I-cell_line
T-lymphoid	I-cell_line
cells	I-cell_line
.	O


At	O
the	O
cellular	O
level	O
,	O
it	O
is	O
known	O
that	O
both	O
acute	O
HIV	O
infection	O
and	O
glucocorticoids	O
can	O
cause	O
apoptotic	O
cell	O
death	O
in	O
thymic	B-cell_type
lymphocytes	I-cell_type
.	O


In	O
vitro	O
,	O
chronically	B-cell_line
HIV-infected	I-cell_line
cells	I-cell_line
of	O
the	O
lymphoid	B-cell_line
CEM	I-cell_line
line	I-cell_line
displayed	O
resistance	O
to	O
glucocorticoid-induced	O
apoptosis	O
.	O


HL-60	B-cell_line
cells	I-cell_line
were	O
found	O
to	O
express	O
mafK	B-RNA
mRNA	I-RNA
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF-E2	B-protein
complex	I-protein
in	O
the	O
cells	O
.	O


PU.1	B-protein
(	O
spi-1	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
Ets	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
is	O
predominantly	O
expressed	O
in	O
myeloid	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
activates	O
many	O
B	B-DNA
cell	I-DNA
and	I-DNA
myeloid	I-DNA
genes	I-DNA
,	O
and	O
is	O
critical	O
for	O
development	O
of	O
both	O
of	O
these	O
lineages	O
.	O


Here	O
we	O
show	O
that	O
the	O
murine	B-DNA
PU.1	I-DNA
promoter	I-DNA
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
well	O
.	O


This	O
B	B-protein
cell	I-protein
restricted	I-protein
coactivator	I-protein
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU.1	B-protein
mediated	O
by	O
the	O
octamer	B-DNA
site	I-DNA
.	O


Inhibition	O
of	O
p105	B-protein
processing	O
by	O
NF-kappaB	B-protein
proteins	I-protein
in	O
transiently	B-cell_line
transfected	I-cell_line
cells	I-cell_line
.	O


In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal-mediated	O
induction	O
of	O
p105	B-protein
processing	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	B-protein
protein	I-protein
.	O


We	O
further	O
demonstrate	O
that	O
p105	B-protein
undergoes	O
degradation	O
in	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O


The	O
appearance	O
of	O
the	O
CMAT	B-protein
binding	I-protein
complex	I-protein
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O


Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI-	O
1493	O
inhibits	O
TNF	B-protein
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O


r-hTBP-1	B-protein
and	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
also	O
decreased	O
p24	B-protein
antigen	I-protein
synthesized	O
by	O
U1	B-cell_line
cells	I-cell_line
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	B-protein
(	I-protein
PHA	I-protein
)	I-protein
-induced	I-protein
supernatant	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
interleukin-6	B-protein
,	O
and	O
TNF	B-protein
.	O


r-hTBP-1	B-protein
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O


Both	O
r-hTBP-1	B-protein
and	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
blocked	O
PMA	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NK	I-protein
)	I-protein
-	I-protein
kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
in	O
U1	B-cell_line
cells	I-cell_line
in	O
association	O
with	O
decreases	O
in	O
HIV-1	O
replication	O
.	O


These	O
data	O
suggest	O
that	O
Tax	B-protein
stimulates	O
RNA	B-DNA
polymerase	I-DNA
III-dependent	I-DNA
gene	I-DNA
expression	O
by	O
accelerating	O
the	O
rate	O
and/or	O
extent	O
of	O
transcription	B-protein
initiation	I-protein
complex	I-protein
assembly	O
.	O


The	O
MTCP1	B-DNA
gene	I-DNA
is	O
involved	O
in	O
the	O
t	B-DNA
(	I-DNA
X	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q28	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
translocation	I-DNA
associated	O
with	O
these	O
T-cell	O
proliferations	O
.	O


The	O
p13MTCP1	B-protein
protein	I-protein
was	O
detected	O
in	O
the	O
three	O
T-cell	O
proliferations	O
with	O
MTCP1	B-DNA
rearrangements	I-DNA
because	O
of	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
,	O
but	O
neither	O
in	O
normal	O
resting	O
and	O
activated	B-cell_type
lymphocytes	I-cell_type
nor	O
in	O
the	O
other	O
T-cell	B-cell_type
leukemias	O
.	O


Preassociation	O
of	O
STAT1	B-protein
with	O
STAT2	B-protein
and	O
STAT3	B-protein
in	O
separate	O
signalling	B-protein
complexes	I-protein
prior	O
to	O
cytokine	B-protein
stimulation	O
.	O


Similarly	O
,	O
STAT1	B-protein
-STAT3	B-protein
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O


In	O
view	O
of	O
these	O
findings	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
IFN-gamma	B-protein
on	O
the	O
expression	O
of	O
different	O
transcription	B-protein
factors	I-protein
in	O
activated	O
human	B-cell_type
monocytes	I-cell_type
.	O


It	O
is	O
also	O
expressed	O
in	O
transformed	B-cell_line
B-cells	I-cell_line
.	O


Recently	O
,	O
we	O
reported	O
that	O
HIV-1	B-protein
tat	I-protein
downregulates	O
MIP-1	B-protein
alpha	I-protein
expression	O
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
.	O


Expression	O
of	O
neither	O
HTLV-1	B-protein
tax	I-protein
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
nor	O
EBV	O
in	O
B-cells	B-cell_type
had	O
any	O
effect	O
on	O
MNP-1	B-protein
or	O
MNP-2	B-protein
expression	O
,	O
showing	O
that	O
the	O
effect	O
is	O
specific	O
for	O
HIV-1	B-protein
tat	I-protein
.	O


Cytokine	B-protein
stimulation	O
leads	O
to	O
the	O
phosphorylation	O
of	O
specific	O
tyrosine	O
residues	O
within	O
the	O
intracellular	B-protein
domain	I-protein
of	O
the	O
corresponding	O
cytokine	B-protein
receptor	I-protein
.	O


In	O
Jurkat	B-cell_line
cells	I-cell_line
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	B-cell_line
cells	I-cell_line
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O


These	O
data	O
suggest	O
a	O
general	O
role	O
for	O
Tax	B-protein
induction	O
of	O
IL-1alpha	B-DNA
gene	I-DNA
transcription	O
by	O
the	O
NF-kappaB	B-protein
pathway	O
.	O


Transient-transfection	O
experiments	O
demonstrated	O
that	O
plasmids	B-DNA
containing	O
446	O
bp	O
of	O
c-fes	B-DNA
5'-flanking	I-DNA
sequences	I-DNA
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
active	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O


However	O
,	O
the	O
first	O
two	O
footprints	O
resided	O
in	O
sequences	O
that	O
were	O
largely	O
dispensable	O
for	O
transient	O
activity	O
.	O


Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	B-DNA
region	I-DNA
contains	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
sites	I-DNA
for	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and/or	O
Elf-1	B-protein
,	O
and	O
a	O
novel	B-protein
factor	I-protein
.	O


IL-10	B-protein
markedly	O
reduces	O
nuclear	O
factor	O
(	B-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B/Rel	I-protein
nuclear	O
activity	O
induced	O
in	O
PBMC	B-cell_type
by	O
stimulation	O
with	O
the	O
anti-CD3	B-protein
mAb	I-protein
OKT3	B-protein
.	O


Since	O
inappropriate	O
activation	O
of	O
kappa	B-DNA
B-driven	I-DNA
genes	I-DNA
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	B-protein
factors	I-protein
.	O


The	O
functional	O
Ets	B-DNA
binding	I-DNA
site	I-DNA
was	O
found	O
to	O
bind	O
Ets	B-protein
family	I-protein
proteins	I-protein
,	O
principally	O
GA-binding	B-protein
protein	I-protein
and	O
Elf-1	B-protein
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	B-protein
and	O
-beta	B-protein
synergistically	O
.	O


Because	O
relatively	O
little	O
is	O
known	O
about	O
these	O
events	O
in	O
nonhuman	O
primates	O
,	O
our	O
laboratory	O
defined	O
optimal	O
conditions	O
,	O
reagents	O
,	O
and	O
assays	O
for	O
the	O
study	O
of	O
signal	O
transduction	O
events	O
in	O
cells	O
from	O
nonhuman	O
primates	O
.	O


The	O
protein	O
phosphorylation	O
patterns	O
in	O
the	O
two	O
monkeys	O
exhibited	O
quantitative	O
,	O
qualitative	O
,	O
and	O
kinetic	O
differences	O
.	O


Detection	O
of	O
various	O
other	O
intracellular	B-protein
signaling	I-protein
proteins	I-protein
is	O
also	O
described	O
.	O


We	O
constructed	O
a	O
yeast	O
reporter	O
strain	O
containing	O
the	O
lacZ	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
CYC1	B-DNA
promoter	I-DNA
associated	O
with	O
three	O
copies	O
of	O
TRE-1	B-DNA
.	O


Expression	O
of	O
either	O
the	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
or	O
CREB	B-protein
fused	O
to	O
the	O
GAL4	B-protein
activation	I-protein
domain	I-protein
(	O
GAD	B-protein
)	O
in	O
this	O
strain	O
did	O
not	O
modify	O
the	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O


Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	B-protein
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O


The	O
human	B-DNA
IL-13	I-DNA
gene	I-DNA
was	O
located	O
12.5-kb	B-DNA
upstream	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
and	O
2-kb	B-DNA
downstream	I-DNA
of	O
a	O
CpG	B-DNA
island	I-DNA
.	O


The	O
IL-13	B-DNA
gene	I-DNA
5	I-DNA
'	I-DNA
flank	I-DNA
region	I-DNA
included	O
a	O
segment	O
with	O
sequence	O
homology	O
to	O
P	B-DNA
elements	I-DNA
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
involved	O
in	O
transcriptional	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


Similar	O
to	O
IL-4	B-protein
,	O
IL-13	B-RNA
mRNA	I-RNA
expression	O
was	O
highest	O
in	O
T-cell	B-cell_line
populations	I-cell_line
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL-13	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
in	O
a	O
coordinate	O
manner	O
.	O


In	O
this	O
report	O
,	O
we	O
demonstrated	O
that	O
phorbol	O
ester	O
treatment	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
dramatically	O
inhibits	O
activation	O
of	O
IFN-alpha/B-stimulated	O
early	O
response	O
genes	O
but	O
by	O
a	O
mechanism	O
which	O
does	O
not	O
involve	O
abrogation	O
of	O
the	O
ISRE	O
binding	O
of	O
ISGF3gamma	O
.	O


Moreover	O
,	O
PMA	O
caused	O
the	O
dephosphorylation	O
of	O
Tyk2	B-protein
but	O
not	O
of	O
Jak1	B-protein
,	O
which	O
was	O
activated	O
by	O
IFN	B-protein
.	O


These	O
observations	O
suggest	O
that	O
PMA	O
exerts	O
its	O
inhibitory	O
effects	O
by	O
activation	O
of	O
a	O
tyrosine	B-protein
phosphatase	I-protein
which	O
selectively	O
regulates	O
Tyk2	B-protein
but	O
not	O
Jak1	B-protein
activity	O
.	O


Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	B-protein
or	O
antibodies	B-protein
to	I-protein
CD3	I-protein
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	B-protein
antibodies	I-protein
or	O
B7-positive	B-cell_type
(	I-cell_type
B	I-cell_type
cells	I-cell_type
)	I-cell_type
or	O
B7-negative	B-cell_type
(	I-cell_type
endothelial	I-cell_type
)	I-cell_type
accessory	I-cell_type
cells	I-cell_type
,	I-cell_type
are	O
mediated	O
through	O
the	O
same	O
cis-elements	B-DNA
.	O


Previous	O
studies	O
have	O
shown	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
similar	O
to	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
can	O
act	O
as	O
a	O
bifunctional	O
regulator	O
of	O
the	O
growth	O
of	O
bone	B-cell_type
marrow	I-cell_type
progenitors	I-cell_type
,	O
in	O
that	O
it	O
can	O
stimulate	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
-	O
or	O
interleukin-3	O
(	O
IL-3	O
)	O
-induced	O
GM	O
colony	O
formation	O
,	O
but	O
potently	O
inhibit	O
G-CSF	B-protein
-induced	O
growth	O
.	O


A	O
specific	O
,	O
retarded	O
band	O
containing	O
VDR-RXR	B-protein
was	O
identified	O
when	O
wild	O
type	O
cell	O
but	O
not	O
when	O
vitamin	O
D-resistant	O
cell	O
nuclear	O
extract	O
was	O
used	O
in	O
the	O
binding	O
reaction	O
with	O
either	O
probe	O
.	O


Stimulation	O
of	O
mouse	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
anti-IgM	B-protein
or	I-protein
IgD	I-protein
antibodies	I-protein
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	B-protein
ligand	I-protein
led	O
to	O
a	O
five-fold	O
to	O
35-fold	O
decrease	O
in	O
BCL-6	B-RNA
mRNA	I-RNA
levels	O
.	O


Inactivation	O
of	O
IkappaBbeta	B-protein
by	O
the	O
tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
:	O
a	O
potential	O
mechanism	O
for	O
constitutive	O
induction	O
of	O
NF-kappaB	B-protein
.	O


During	O
normal	O
T-cell	O
activation	O
,	O
IkappaBalpha	B-protein
is	O
rapidly	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
by	O
the	O
26S	B-protein
proteasome	I-protein
,	O
thus	O
permitting	O
the	O
release	O
of	O
functional	O
NF-kappaB	B-protein
.	O


The	O
mouse	O
mammary	O
tumor	O
virus	O
env	B-DNA
gene	I-DNA
contains	O
a	O
transcriptional	B-DNA
activator	I-DNA
(	O
META	B-DNA
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
region	I-DNA
.	O


It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	B-protein
antigens	I-protein
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O


Binding	O
parameters	O
of	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
were	O
Kd	O
=	O
5.53	O
nM	O
and	O
Bmax	O
=	O
2	O
,	O
647	O
sites/cell	O
.	O


Pretreatment	O
with	O
B.pertussis	O
,	O
V.cholera.	O
or	O
C.botulinum	O
toxin	O
did	O
not	O
influence	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
.	O


Histamine	O
induced	O
mRNA	B-RNA
expression	O
of	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
c-fos	B-DNA
.	O


A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	B-protein
has	O
recently	O
been	O
elaborated	O
.	O


The	O
JAK	B-protein
kinases	I-protein
and	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O


By	O
using	O
a	O
SOX9	B-DNA
coding	I-DNA
sequence	I-DNA
polymorphism	I-DNA
,	O
expression	O
of	O
both	O
SOX9	B-DNA
alleles	O
has	O
been	O
demonstrated	O
by	O
the	O
reverse	B-protein
transcriptase	I-protein
polymerase	O
chain	O
reaction	O
in	O
lymphoblastoid	B-cell_type
cells	I-cell_type
from	O
one	O
of	O
the	O
translocation	O
cases	O
.	O


Spi-B	B-protein
is	O
an	O
Ets	B-protein
transcription	I-protein
factor	I-protein
related	O
to	O
the	O
oncoprotein	B-protein
Spi-1/PU.1	B-protein
and	O
highly	O
expressed	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


Binding	O
and	O
cooperative	O
interactions	O
between	O
two	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivators	I-protein
.	O


Stimulation	O
of	O
the	O
cAMP-dependent	O
signaling	O
pathway	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
and	O
effector	O
functions	O
of	O
T	B-cell_type
cells	I-cell_type
.	O


Thus	O
,	O
the	O
induction	O
of	O
ICER	B-protein
in	O
T	B-cell_type
cells	I-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
cAMP-induced	O
quiescence	O
and	O
the	O
persistent	O
latency	O
of	O
HTLV-I	O
.	O


We	O
propose	O
that	O
the	O
hydrophobic	B-protein
C-terminal	I-protein
tail	I-protein
of	O
CAML	B-protein
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N-terminal	B-protein
hydrophilic	I-protein
domain	I-protein
in	O
a	O
regulatory	O
role	O
.	O


We	O
describe	O
a	O
patient	O
with	O
APL	O
in	O
whom	O
the	O
leukaemic	O
clone	O
was	O
characterized	O
by	O
a	O
true	O
variant	O
of	O
the	O
classical	B-DNA
t	I-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
.	O


Forty	O
animals	O
were	O
inoculated	O
intranasally	O
with	O
10	O
(	O
7.0	O
)	O
pfu	O
of	O
Ad5/animal	O
,	O
and	O
15	O
animals	O
inoculated	O
with	O
sterile	O
culture	O
media	O
served	O
as	O
controls	O
.	O


In	O
situ	O
hybridization	O
to	O
viral	B-DNA
DNA	I-DNA
and	O
immunocytochemistry	O
for	O
Ad5	O
E1A	B-protein
protein	I-protein
localized	O
the	O
virus	O
to	O
airway	O
and	O
alveolar	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O


Ad5	B-DNA
E1A	I-DNA
DNA	I-DNA
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
five	O
of	O
six	O
animals	O
20	O
days	O
after	O
infection	O
and	O
in	O
five	O
of	O
five	O
animals	O
47	O
days	O
after	O
infection	O
.	O


We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
genome-positive	I-cell_line
B	I-cell_line
cells	I-cell_line
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate-early	B-DNA
EBV	I-DNA
Zebra	I-DNA
gene	I-DNA
,	O
followed	O
by	O
virus	O
replication	O
(	O
L.Flamand	O
,	O
I.Stefanescu	O
,	O
D.V.Ablashi	O
,	O
and	O
J.Menezes	O
,	O
J.Virol.67	O
:	O
6768-6777	O
,	O
1993	O
)	O
.	O


Using	O
human	B-cell_line
B-	I-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
transfected	O
with	O
ZpCat	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	B-DNA
domain	I-DNA
of	O
Zp	B-DNA
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O


Regulation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
stably	O
transfected	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
.	O


Upon	O
stimulation	O
,	O
they	O
express	O
high	O
levels	O
of	O
secreted	O
heat	O
stable	O
placental	B-protein
alkaline	I-protein
phosphatase	I-protein
.	O


Selective	O
phosphatase	O
inhibitors	O
for	O
protein	B-protein
phosphatase	I-protein
1	I-protein
(	O
PP1	B-protein
)	O
and	O
2A	B-protein
(	O
PP2A	B-protein
)	O
that	O
do	O
not	O
inhibit	O
calcineurin	B-protein
,	O
such	O
as	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
also	O
inhibited	O
NFAT	B-protein
activation	O
with	O
IC50s	O
of	O
87	O
nM	O
and	O
4	O
nM	O
,	O
respectively	O
,	O
suggesting	O
that	O
okadaic	O
acid	O
and	O
related	O
inhibitors	O
may	O
block	O
NFAT	B-protein
activation	O
through	O
the	O
inhibition	O
of	O
PP1	B-protein
,	O
instead	O
of	O
PP2A	B-protein
.	O


We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	B-DNA
present	O
in	O
the	O
reporter	B-DNA
plasmid	I-DNA
as	O
well	O
as	O
on	O
the	O
cell	B-cell_line
line	I-cell_line
tested	O
.	O


The	O
onset	O
of	O
apoptosis	O
in	O
both	O
cell	O
types	O
can	O
be	O
delayed	O
by	O
hemopoietins	B-protein
and	O
inflammatory	B-protein
mediators	I-protein
.	O


This	O
work	O
aimed	O
to	O
ascertain	O
the	O
role	O
of	O
kappaB-responsive	B-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
enhancer	I-DNA
not	O
only	O
in	O
early	O
initiation	O
but	O
also	O
in	O
long-term	O
maintenance	O
of	O
proviral	O
transcription	O
in	O
cells	O
of	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
.	O


The	O
third	O
approach	O
was	O
to	O
monitor	O
the	O
replication	O
competence	O
in	O
U937	B-cell_line
cells	I-cell_line
of	O
an	O
infectious	O
HIV-1	O
provirus	O
carrying	O
point	O
mutations	O
in	O
the	O
kappaB-responsive	B-DNA
elements	I-DNA
of	O
both	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
.	O


The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
(	I-protein
IL-2R	I-protein
alpha	I-protein
)	I-protein
chain	I-protein
(	O
CD25	B-protein
)	O
,	O
CD69	B-protein
and	O
L-selectin	B-protein
(	O
CD62	B-protein
)	O
is	O
normal	O
in	O
mitogen-activated	B-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
but	O
cytokine	B-protein
production	O
is	O
impaired	O
.	O


In	O
contrast	O
,	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
stimulated	O
Rel-/-	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	B-protein
.	O


The	O
IL-2	B-protein
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O


Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF-MATp35	B-protein
.	O


Similar	O
to	O
its	O
effect	O
on	O
IL-2	B-protein
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF-MATp35	B-protein
.	O


Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B-DNA
iNOS	I-DNA
promoter	I-DNA
to	O
LPS	O
+/-	O
IFN-gamma	B-protein
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	B-DNA
element	I-DNA
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS/	O
IFN-gamma	B-protein
induced	O
expression	O
of	O
the	O
mouse	B-DNA
iNOS	I-DNA
gene	I-DNA
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	B-protein
factors	I-protein
in	O
human	B-cell_type
macrophages	I-cell_type
(	O
e.g.	O
,	O
an	O
LPS-inducible	B-protein
nuclear	I-protein
factor-kappa	I-protein
B/Rel	I-protein
complex	I-protein
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O


The	O
function	O
of	O
oriP	B-DNA
depends	O
on	O
a	O
trans-acting	B-protein
factor	I-protein
(	O
s	O
)	O
encoded	O
by	O
the	O
viral	B-DNA
genome	I-DNA
.	O


In	O
vivo	O
anergized	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
express	O
perturbed	O
AP-1	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O


In	O
this	O
study	O
,	O
we	O
used	O
the	O
T-cell-activating	B-protein
superantigen	I-protein
staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
(	O
SEA	B-protein
)	O
to	O
investigate	O
molecular	O
mechanisms	O
of	O
T-lymphocyte	O
anergy	O
in	O
vivo	O
.	O


Stimulation	O
through	O
the	O
Fas/APO-1	B-protein
receptor	I-protein
results	O
in	O
apoptosis	O
through	O
an	O
incompletely	O
characterized	O
signaling	O
pathway	O
.	O


The	O
active	O
vitamin	O
D3	O
metabolite	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
acts	O
as	O
an	O
antiproliferative	O
and	O
differentiating	O
agent	O
for	O
the	O
monoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
and	O
as	O
an	O
important	O
immunologic	O
mediator	O
implicated	O
particularly	O
in	O
the	O
function	O
of	O
cells	O
belonging	O
to	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O


The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
U937	B-cell_line
transfectants	O
expressing	O
antisense	O
VDR	B-RNA
mRNA	I-RNA
,	O
and	O
to	O
use	O
these	O
to	O
examine	O
the	O
role	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	B-protein
interaction	O
in	O
this	O
lineage	O
.	O


A	O
subpopulation	O
of	O
smaller	O
cells	O
did	O
not	O
express	O
the	O
differentiation	O
markers	O
after	O
cadmium	O
stimulation	O
.	O


Galectin-3	O
is	O
a	O
beta-galactoside-binding	B-protein
lectin	I-protein
previously	O
designated	O
as	O
epsilon	B-protein
BP	I-protein
(	O
IgE-binding	B-protein
protein	I-protein
)	O
,	O
CBP35	B-protein
,	O
Mac-2	B-protein
,	O
L-29	B-protein
,	O
and	O
L-34	B-protein
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O


LPS	O
treatment	O
of	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
murine	B-cell_type
bone	I-cell_type
marrow-derived	I-cell_type
macrophages	I-cell_type
,	O
and	O
the	O
human	B-cell_line
monocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
resulted	O
in	O
rapid	O
activation	O
of	O
the	O
p46	B-protein
and	I-protein
p54	I-protein
isoforms	I-protein
of	O
JNK	B-protein
.	O


These	O
results	O
suggest	O
that	O
LPS	O
activation	O
of	O
JNK	B-protein
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
is	O
a	O
CD14-	O
and	O
protein	O
tyrosine	O
phosphorylation-dependent	O
event	O
that	O
may	O
mediate	O
the	O
early	O
activation	O
of	O
AP-1	B-protein
in	O
regulating	O
LPS-triggered	O
gene	O
induction	O
.	O


In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	O
TNF	B-RNA
mRNA	I-RNA
and	O
secretion	O
(	O
85	O
+/-	O
4	O
%	O
mean	O
percent	O
inhibition	O
+/-	O
SEM	O
by	O
Exosurf	O
;	O
71	O
+/-	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin-stimulated	B-cell_line
THP-1	I-cell_line
,	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


To	O
identify	O
the	O
molecular	O
basis	O
for	O
specificity	O
and	O
inducibility	O
,	O
the	O
chromatin	B-DNA
configuration	O
of	O
the	O
human	B-DNA
B7.1	I-DNA
gene	I-DNA
was	O
examined	O
in	O
intact	O
nuclei	O
from	O
various	O
cell	O
types	O
.	O


This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	B-DNA
elements	I-DNA
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	B-protein
costimulatory	I-protein
molecule	I-protein
.	O


Ubiquitinylation	O
of	O
transcription	B-protein
factors	I-protein
c-Jun	B-protein
and	O
c-Fos	B-protein
using	O
reconstituted	B-protein
ubiquitinylating	I-protein
enzymes	I-protein
.	O


Recombinant	O
c-Jun	B-protein
and	O
c-Fos	B-protein
were	O
ubiquitinylated	O
by	O
the	O
ubiquitin	B-protein
carrier	I-protein
enzymes	I-protein
E214K	B-protein
,	O
E220K	B-protein
,	O
or	O
E232K	B-protein
in	O
the	O
presence	O
of	O
the	O
ubiquitin-activating	B-protein
enzyme	I-protein
,	O
E1	B-protein
.	O


The	O
E3-dependent	O
ubiquitinylation	O
of	O
c-Jun	B-protein
was	O
inhibited	O
upon	O
the	O
heterodimerization	O
of	O
c-Jun	B-protein
with	O
c-Fos	B-protein
.	O


Further	O
addition	O
of	O
E220K	B-protein
significantly	O
enhanced	O
ubiquitinylation	O
of	O
c-Jun	B-protein
in	O
the	O
heterodimer	O
suggesting	O
a	O
regulatory	O
role	O
of	O
E220K	B-protein
.	O


Cloning	O
and	O
characterization	O
of	O
the	O
murine	B-protein
B-cell	I-protein
specific	I-protein
transcriptional	I-protein
coactivator	I-protein
Bob1	B-protein
.	O


mBob1	B-protein
interacts	O
with	O
the	O
octamer	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O


In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
the	O
major	B-protein
envelope	I-protein
glycoprotein	I-protein
of	O
HIV	O
,	O
glycoprotein	B-protein
120	I-protein
(	O
gp120	B-protein
)	O
,	O
to	O
regulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
,	O
because	O
ICAM-1	B-protein
is	O
important	O
in	O
mediating	O
immune	O
responsiveness	O
in	O
the	O
CNS	O
,	O
facilitating	O
entry	O
of	O
HIV-infected	B-cell_type
cells	I-cell_type
into	O
the	O
CNS	O
,	O
and	O
promoting	O
syncytia	O
formation	O
.	O


Our	O
results	O
indicate	O
that	O
gp120	B-protein
enhances	O
ICAM-1	B-protein
gene	O
expression	O
in	O
primary	B-cell_type
rat	I-cell_type
astrocytes	I-cell_type
,	O
primary	B-cell_type
human	I-cell_type
astrocytes	I-cell_type
,	O
a	O
human	B-cell_line
astroglioma	I-cell_line
cell	I-cell_line
line	I-cell_line
CRT	I-cell_line
,	O
and	O
primary	B-cell_type
rat	I-cell_type
microglia	I-cell_type
.	O


IL-10	B-protein
is	O
elevated	O
in	O
HIV-1-infected	O
individuals	O
and	O
has	O
been	O
implicated	O
in	O
disease	O
progression	O
.	O


Neutralizing	O
mAbs	B-protein
to	O
IL-10	B-protein
and	O
TNF-alpha	B-protein
indicated	O
that	O
both	O
cytokines	B-protein
were	O
essential	O
for	O
the	O
induction	O
and	O
were	O
required	O
to	O
generate	O
a	O
synergistic	O
increase	O
in	O
virus	O
expression	O
.	O


In	O
combination	O
with	O
TNF-alpha	B-protein
,	O
IL-10	B-protein
stimulated	O
activating	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
binding	O
activities	O
and	O
cooperated	O
to	O
increase	O
HIV-1	O
steady-state	O
mRNA	O
levels	O
and	O
enhance	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-directed	O
transcription	O
through	O
activation	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
,	O
suggesting	O
the	O
IL-10	B-protein
effect	O
occurs	O
at	O
least	O
in	O
part	O
at	O
the	O
transcriptional	O
level	O
.	O


Similarly	O
,	O
the	O
p105	B-protein
precursor	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	B-protein
subunit	I-protein
is	O
also	O
post-translationally	O
processed	O
in	O
the	O
proteasome	B-protein
.	O


The	O
mechanisms	O
by	O
which	O
Tax	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
remain	O
unclear	O
,	O
and	O
findings	O
presented	O
in	O
the	O
literature	O
are	O
often	O
controversial	O
.	O


All	O
seven	O
IDCs	O
associated	O
with	O
Paget	O
's	O
disease	O
showed	O
positive	O
reactions	O
for	O
HER-2/neu	B-protein
.	O


The	O
immunophenotype	O
of	O
IDC	O
is	O
helpful	O
in	O
subclassifying	O
an	O
IDC	O
and	O
could	O
prove	O
useful	O
as	O
a	O
prognostic	O
indicator	O
for	O
local	O
control	O
in	O
patients	O
treated	O
by	O
breast-conserving	O
therapy	O
.	O


Here	O
,	O
we	O
studied	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
STAT3	B-protein
signaling	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
cutaneous	B-cell_line
T	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
,	O
expressing	O
a	O
constitutively	O
activated	O
STAT3	B-protein
.	O


We	O
show	O
that	O
an	O
inhibitor	O
of	O
protein	B-protein
phosphatases	I-protein
(	O
PPs	B-protein
)	O
PP1/PP2A	B-protein
,	O
calyculin	B-protein
A	I-protein
,	O
induces	O
(	O
i	O
)	O
phosphorylation	O
of	O
STAT3	B-protein
on	O
serine	O
and	O
threonine	O
residues	O
,	O
(	O
ii	O
)	O
inhibition	O
of	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
,	O
and	O
(	O
iii	O
)	O
relocation	O
of	O
STAT3	B-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O


Polyamines	O
have	O
been	O
determined	O
in	O
tissue	O
and	O
erythrocyte	O
samples	O
from	O
100	O
patients	O
with	O
primary	O
invasive	O
breast	O
cancer	O
and	O
30	O
patients	O
with	O
fibroadenomas	O
.	O


In	O
malignant	O
tissues	O
,	O
polyamine	O
levels	O
were	O
significantly	O
higher	O
than	O
in	O
benign	O
tissues	O
.	O


Erythrocyte	O
polyamines	O
levels	O
were	O
identical	O
between	O
cancer	O
patients	O
and	O
controls	O
.	O


The	O
knowledge	O
of	O
the	O
polyamine	O
pattern	O
in	O
breast	O
cancer	O
could	O
become	O
useful	O
in	O
clinical	O
practice	O
particularly	O
if	O
polyamine	O
metabolism	O
is	O
targeted	O
as	O
a	O
therapeutic	O
approach	O
.	O


Tyrosine	B-protein
kinase	I-protein
-dependent	O
,	O
and	O
not	O
protein	B-protein
kinase	I-protein
C	I-protein
-dependent	O
,	O
pathways	O
mediate	O
CD23	B-protein
-triggered	O
NF-kappaB	B-protein
activation	O
but	O
do	O
not	O
participate	O
in	O
the	O
direct	O
phosphorylation	O
of	O
IkappaBalpha	B-protein
.	O


Flavonoids	O
are	O
a	O
group	O
of	O
naturally-occurring	O
phenolic	O
compounds	O
in	O
the	O
plant	O
kingdom	O
,	O
and	O
many	O
flavonoids	O
are	O
found	O
with	O
vascular	O
protective	O
properties	O
.	O


In	O
view	O
of	O
the	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
atherosclerosis	O
,	O
prevention	O
of	O
the	O
activation	O
of	O
NFkappaB	B-protein
represents	O
an	O
important	O
role	O
in	O
protecting	O
vascular	O
injury	O
.	O


Furthermore	O
,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	B-protein
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	B-cell_line
cells	I-cell_line
.	O


The	O
decrease	O
using	O
weaker	O
binding	O
peptides	O
was	O
gradual	O
as	O
stimulation	O
with	O
a	O
peptide	O
with	O
intermediate	O
affinity	O
yielded	O
intermediate	O
T	B-cell_type
cell	I-cell_type
proliferation	O
and	O
the	O
poorest	O
binding	O
peptide	O
induced	O
an	O
even	O
weaker	O
T	B-cell_type
cell	I-cell_type
response	O
.	O


MHC	B-protein
class	I-protein
II	I-protein
density	O
on	O
the	O
APC	B-cell_type
was	O
modified	O
using	O
DQ2	B-cell_line
homo	I-cell_line
-and	I-cell_line
heterozygous	I-cell_line
B-LCLs	I-cell_line
as	O
APCs	B-cell_type
,	O
however	O
this	O
variation	O
of	O
MHC	O
concentration	O
had	O
no	O
effect	O
on	O
T	B-cell_type
cell	I-cell_type
proliferation	O
.	O


We	O
interpret	O
this	O
as	O
a	O
reflection	O
of	O
a	O
low	O
threshold	O
for	O
activation	O
of	O
the	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
,	O
in	O
which	O
peptide-	O
MHC	B-protein
avidity	O
is	O
the	O
over-riding	O
determinant	O
of	O
the	O
strength	O
of	O
ligand	O
signal	O
.	O


Exogenously	O
administered	O
IL-11	B-protein
substantially	O
reduced	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	B-cell_type
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	B-protein
.	O


These	O
in	O
vivo	O
anti-inflammatory	O
effects	O
of	O
IL-11	B-protein
were	O
associated	O
with	O
reduced	O
NF-kappaB	B-protein
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up-regulation	O
of	O
lung	B-protein
vascular	I-protein
ICAM-1	I-protein
.	O


However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL-11	B-protein
.	O


Thrombopoietin	B-protein
also	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
FDCP-2	B-cell_line
cells	I-cell_line
genetically	O
engineered	O
to	O
constitutively	O
express	O
human	B-protein
c-Mpl	I-protein
.	O


The	O
latter	O
mechanism	O
is	O
especially	O
important	O
because	O
evasion	O
of	O
the	O
impending	O
immune	O
response	O
is	O
a	O
prerequisite	O
for	O
the	O
progression	O
of	O
lymphoproliferative	O
diseases	O
.	O


Dehydroepiandrosterone	O
modulation	O
of	O
lipopolysaccharide-stimulated	O
monocyte	O
cytotoxicity	O
.	O


Dehydroepiandrosterone	O
(	O
DHEA	O
)	O
,	O
the	O
predominant	O
androgen	O
secreted	O
by	O
the	O
adrenal	O
cortex	O
,	O
can	O
be	O
converted	O
to	O
both	O
potent	O
androgens	O
and	O
estrogens	O
.	O


Cytotoxicity	B-protein
markers	I-protein
assessed	O
include	O
tumor	O
cell	O
killing	O
,	O
IL-1	B-protein
secretion	O
,	O
reactive	O
oxygen	O
intermediate	O
release	O
,	O
nitric	B-protein
oxide	I-protein
synthetase	I-protein
activity	O
as	O
measured	O
by	O
the	O
release	O
of	O
reactive	O
nitrogen	O
intermediates	O
,	O
complement	B-protein
receptor-1	I-protein
cell	I-protein
surface	I-protein
protein	I-protein
,	O
and	O
TNF-alpha	B-protein
protein	I-protein
presence	O
.	O


Interferons	B-protein
(	O
IFNs	B-protein
)	O
inhibit	O
induction	O
by	O
IL-4	B-protein
of	O
multiple	O
genes	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	B-protein
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O


IL-4	B-protein
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	B-protein
transcription	I-protein
factor	I-protein
,	O
STAT6	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-6	I-protein
)	O
.	O


In	O
humans	O
,	O
there	O
are	O
two	O
highly	O
homologous	B-DNA
genes	I-DNA
encoding	O
SCM-1alpha	B-protein
and	O
SCM-1beta	B-protein
.	O


Collectively	O
,	O
a	O
unique	O
mechanism	O
involving	O
NF-ATp	B-protein
appears	O
to	O
regulate	O
the	O
cell	O
type-specific	O
and	O
activation-dependent	O
expression	O
of	O
the	O
SCM-1	B-DNA
genes	I-DNA
.	O


The	O
combination	O
of	O
dopamine	O
and	O
TNF-alpha	B-protein
led	O
to	O
a	O
stimulation	O
of	O
HIV-1	O
transcription	O
and	O
replication	O
.	O


[	O
Hormonal	O
metabolic	O
status	O
in	O
breast	O
cancer	O
patients	O
after	O
conservative	O
surgery	O
:	O
comparison	O
with	O
known	O
prognostic	O
criteria	O
]	O


Said	O
anthropometric	O
,	O
metabolic	O
and	O
hormonal	O
parameters	O
were	O
compared	O
with	O
the	O
index	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
selected	O
as	O
a	O
prognostic	O
factor	O
.	O


Also	O
,	O
smoking	O
contributed	O
to	O
loss	O
of	O
body	O
mass	O
and	O
fat	O
;	O
however	O
,	O
it	O
caused	O
lymphocytic	O
infiltration	O
to	O
rise	O
.	O


It	O
has	O
been	O
demonstrated	O
that	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
have	O
various	O
reverse	O
effects	O
on	O
macrophages	B-cell_type
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
of	O
this	O
difference	O
has	O
not	O
been	O
fully	O
understood	O
.	O


IL-10-activated	B-protein
STAT1	I-protein
could	O
bind	O
to	O
the	O
GAS-motif	B-DNA
sequence	I-DNA
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	B-protein
receptor	I-protein
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
COX-2	B-DNA
gene	I-DNA
,	O
whereas	O
IFN-gamma-activated	B-protein
STAT1	I-protein
and	O
STAT5	B-protein
could	O
bind	O
to	O
both	O
sequences	O
.	O


IL-10	B-protein
inhibited	O
IFN-gamma	B-protein
-induced	O
STAT	B-protein
activation	O
without	O
newly	B-protein
synthesized	I-protein
protein	I-protein
.	O


This	O
may	O
explain	O
the	O
difference	O
between	O
IL-10	B-protein
and	O
IFN-gamma	B-protein
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL-10	B-protein
on	O
IFN-gamma	B-protein
activities	O
.	O


A	O
truncated	O
version	O
of	O
430-444	O
,	O
i.e.	O
,	O
VP16	O
433-442	O
,	O
binds	O
with	O
an	O
affinity	O
10-fold	O
lower	O
compared	O
to	O
430-444	O
at	O
acidic	O
pH	O
,	O
and	O
binding	O
at	O
neutral	O
pH	O
was	O
barely	O
detectable	O
.	O


Both	O
the	O
wild	O
type	O
430-444	O
and	O
433-442	O
peptides	O
stimulated	O
a	O
HSV-specific	O
T	O
cell	O
clone	O
after	O
a	O
brief	O
incubation	O
with	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
(	O
APC	B-cell_type
)	O
expressing	O
DQ0302	O
at	O
acidic	O
pH	O
.	O


E2F-1	B-protein
blocks	O
terminal	O
differentiation	O
and	O
causes	O
proliferation	O
in	O
transgenic	B-cell_type
megakaryocytes	I-cell_type
.	O


E2F-1	B-protein
activity	O
is	O
regulated	O
by	O
a	O
number	O
of	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
susceptibility	B-DNA
gene	I-DNA
product	O
,	O
cyclin-dependent	B-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
,	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
the	O
control	O
of	O
certain	O
developmental	O
processes	O
.	O


These	O
data	O
indicate	O
that	O
E2F-1	B-protein
can	O
prevent	O
terminal	O
differentiation	O
,	O
probably	O
through	O
its	O
cell	O
cycle-stimulatory	O
activity	O
.	O


Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	B-protein
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	B-DNA
gene	I-DNA
and	O
multiple	O
minor	O
susceptibility	B-DNA
genes	I-DNA
.	O


A	O
recent	O
sib-pair	O
analysis	O
revealed	O
a	O
tight	O
linkage	O
between	O
markers	O
on	O
5q31.1	B-DNA
and	O
a	O
major	B-DNA
susceptibility	I-DNA
gene	I-DNA
controlling	O
total	O
serum	O
IgE	B-protein
levels	O
.	O


In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL-4-positive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


These	O
results	O
suggest	O
that	O
an	O
age-associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
activated	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O


Here	O
,	O
we	O
have	O
readdressed	O
the	O
issue	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
specific	O
for	O
the	O
72-kDa	B-protein
major	I-protein
immediate-early	I-protein
protein	I-protein
(	O
IE-1	B-protein
)	O
,	O
which	O
is	O
nonstructural	O
but	O
is	O
found	O
very	O
early	O
and	O
throughout	O
the	O
replicative	O
cycle	O
.	O


For	O
this	O
purpose	O
,	O
81	O
pentadecamer	O
peptides	O
covering	O
the	O
complete	O
491-amino-acid	B-protein
sequence	I-protein
of	O
IE-1	B-protein
were	O
tested	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
anti-HCMV	O
immunoglobulin	O
G-seropositive	O
donors	O
.	O


AIDS-related	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
AIDS	O
NHL	O
)	O
comprises	O
a	O
diverse	O
and	O
heterogeneous	O
group	O
of	O
high-grade	O
B	O
cell	O
tumors	O
.	O


Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	B-DNA
or	O
tumor-suppressor	B-DNA
genes	I-DNA
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O


However	O
,	O
the	O
clinically	O
significant	O
class	O
of	O
AIDS	O
NHL	O
designated	O
immunoblastic	O
lymphoma	O
plasmacytoid	O
(	O
AIDS	O
IBLP	O
)	O
lacks	O
any	O
consistent	O
genetic	O
alterations	O
.	O


Hyperplastic	O
lymph	O
node	O
and	O
tonsil	O
also	O
exhibit	O
strong	O
TCL1	B-protein
protein	O
expression	O
in	O
mantle	B-cell_type
zone	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
in	O
rare	O
interfollicular	B-cell_type
zone	I-cell_type
cells	I-cell_type
,	O
whereas	O
follicle-center	B-cell_type
B	I-cell_type
cells	I-cell_type
(	O
centroblasts	B-cell_type
and	O
centrocytes	B-cell_type
)	O
show	O
weaker	O
expression	O
.	O


IL-2	B-protein
-independent	O
activation	O
and	O
proliferation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
induced	O
by	O
CD28	B-protein
.	O


The	O
data	O
imply	O
that	O
JAK	B-protein
/STAT	B-protein
signaling	O
has	O
a	O
role	O
in	O
EBV-associated	O
malignancies	O
.	O


Alveolar	B-cell_type
macrophages	I-cell_type
are	O
located	O
directly	O
in	O
the	O
surrounding	O
of	O
these	O
cells	O
,	O
so	O
that	O
we	O
suppose	O
an	O
interaction	O
between	O
epithelial	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
regarding	O
to	O
the	O
release	O
of	O
inflammatory	B-protein
mediators	I-protein
.	O


After	O
up	O
to	O
90	O
min	O
exposure	O
time	O
ELISA	O
,	O
EMSA	O
(	O
electromobility	O
shift	O
assay	O
)	O
and	O
RT-PCR	O
were	O
used	O
to	O
measure	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
protein	O
activity	O
of	O
NF-kappaB	B-protein
and	O
cytokine	B-protein
(	O
IL-1beta	B-protein
,	O
IL-6	B-protein
,	O
TNF-alpha	B-protein
)	O
specific	O
mRNA	B-RNA
levels	O
in	O
BEAS-2B	B-cell_type
cells	I-cell_type
.	O


These	O
data	O
suggest	O
a	O
ROI-dependent	O
NF-kappaB	B-protein
mediated	O
transcription	O
of	O
inflammatory	B-protein
cytokines	I-protein
in	O
bronchial	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O


PMA	O
and	O
TNF	B-protein
alpha	I-protein
induced	O
activation	O
of	O
(	B-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
human	O
Jurkat	B-cell_line
T-cells	I-cell_line
was	O
partially	O
inhibited	O
by	O
ADT	O
(	O
0.1	O
mM	O
)	O
pretreatment	O
.	O


ADT	O
,	O
a	O
pro-glutathione	O
antioxidant	O
,	O
was	O
observed	O
to	O
be	O
capable	O
of	O
modulating	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


Induction	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
by	O
the	O
cytokine	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
can	O
occur	O
independently	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
activation	O
of	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
)	O
by	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
endothelial	B-cell_type
cells	I-cell_type
.	O


PKC-zeta	B-protein
belongs	O
to	O
this	O
family	O
and	O
is	O
known	O
to	O
be	O
an	O
important	O
step	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
other	O
cell	O
systems	O
.	O


Induction	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
expression	O
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
through	O
NF-kappaB	B-protein
in	O
apoptosis-resistant	B-cell_line
T-cell	I-cell_line
transfectants	I-cell_line
with	O
Tax	B-protein
.	O


Transient-transfection	O
assays	O
showed	O
that	O
bcl-x	B-DNA
promoter	I-DNA
was	O
transactivated	O
by	O
wild-type	B-protein
Tax	I-protein
.	O


Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
induced	O
by	O
Tax	B-protein
through	O
the	O
NF-kappaB	B-protein
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	B-cell_line
cells	I-cell_line
after	O
IL-2	B-protein
deprivation	O
.	O


In	O
this	O
report	O
,	O
we	O
use	O
the	O
PIN*POINT	O
assay	O
to	O
study	O
the	O
role	O
of	O
the	O
promoter	O
on	O
the	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS2	B-DNA
and	O
5'HS3	B-DNA
of	O
the	O
LCR	B-DNA
.	O


Furthermore	O
,	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS3	B-DNA
only	O
occurred	O
in	O
beta-globin-expressing	B-cell_type
murine	I-cell_type
erythroid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
whereas	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS2	B-DNA
occurred	O
in	O
both	O
gamma-globin-expressing	B-cell_line
K562	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_type
erythroid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O


Transient	O
transfection	O
studies	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
an	O
E	O
(	O
2	O
)	O
receptor-negative	O
line	O
,	O
suggest	O
that	O
E	O
(	O
2	O
)	O
inhibits	O
TNF	B-protein
gene	O
expression	O
through	O
an	O
effect	O
mediated	O
by	O
estrogen	B-protein
receptor	I-protein
beta	I-protein
(	O
ERbeta	B-protein
)	O
.	O


Compared	O
with	O
IL-2	B-protein
,	O
CD3	B-protein
ligation	O
induces	O
a	O
delayed	O
Stat3	B-protein
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM-1	B-protein
and	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O


We	O
report	O
that	O
both	O
natural	O
and	O
synthetic	O
PPARgamma	O
agonists	O
induce	O
time-	O
and	O
dose-dependent	O
increases	O
in	O
aP2	B-RNA
mRNA	I-RNA
in	O
both	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
.	O


Identification	O
of	O
a	O
physical	O
interaction	O
between	O
calcineurin	B-protein
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFATp	B-protein
)	O
.	O


Consistent	O
with	O
these	O
data	O
,	O
CD40	B-protein
signals	O
up-regulate	O
c-jun	B-RNA
but	I-RNA
not	I-RNA
c-fos	I-RNA
mRNA	I-RNA
and	O
alter	O
the	O
transcription	B-protein
factor	I-protein
ATF2	B-protein
but	O
not	O
the	O
Raf-1	B-protein
protein	I-protein
.	O


Side-chain	O
modified	O
vitamin	O
D	O
analogs	O
including	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a-trihomo-1alpha	O
,	O
2	O
5-dihydroxyvitamin	O
D3	O
(	O
KH1060	O
)	O
,	O
and	O
1	O
,	O
24-dihydroxy-22-ene-24-cyclopropyl-vitamin	O
D3	O
(	O
MC903	O
)	O
were	O
originally	O
designed	O
to	O
aid	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
including	O
psoriasis	O
and	O
cancer	O
.	O


Human	B-DNA
T-cell	I-DNA
lymphotrophic	I-DNA
virus	I-DNA
type-I	I-DNA
tax	I-DNA
gene	I-DNA
induces	O
secretion	O
of	O
human	B-protein
macrophage	I-protein
inflammatory	I-protein
protein-1alpha	I-protein
.	O


Induced	O
MIP-1alpha	B-protein
expression	O
and	O
secretion	O
in	O
PMA/PHA	B-cell_line
stimulated	I-cell_line
tax	I-cell_line
transfected	I-cell_line
cells	I-cell_line
correlate	O
with	O
the	O
noninduction	O
of	O
MNP-1	B-protein
transcription	B-protein
factor	I-protein
,	O
which	O
is	O
intimately	O
involved	O
in	O
downmodulating	O
the	O
MIP-1alpha	B-DNA
gene	I-DNA
.	O


DC	O
at	O
many	O
effector	O
sites	O
have	O
a	O
characteristic	O
pattern	O
of	O
infiltration	O
and	O
differentiation	O
.	O


Furthermore	O
,	O
expression	O
of	O
physiological	O
levels	O
of	O
Bcl-x	B-cell_type
protected	I-cell_type
B	I-cell_type
cells	I-cell_type
from	O
Fas-mediated	O
apoptosis	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-protein
signaling	O
.	O


Stimulation	O
of	O
neutrophil	B-cell_type
interleukin-8	B-protein
production	O
by	O
eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
.	O


We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
to	O
stimulate	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	I-protein
production	O
by	O
neutrophils	B-cell_type
.	O


MBP	B-protein
over	O
the	O
concentration	O
range	O
of	O
0.1	O
to	O
10	O
microM	O
stimulated	O
the	O
release	O
of	O
up	O
to	O
approximately	O
8	O
ng/ml	O
IL-8	B-protein
.	O


No	O
NF-IL-6	B-protein
binding	O
activity	O
was	O
detected	O
in	O
the	O
same	O
nuclear	O
extracts	O
.	O


T-PLL	O
is	O
also	O
seen	O
in	O
non-A-T	O
individuals	O
where	O
expression	O
of	O
either	O
TCL1	B-protein
(	O
at	O
14q32	B-DNA
)	O
or	O
the	O
c6.1B/MTCP1	B-protein
A1	I-protein
transcript	I-protein
(	O
at-Xq28	B-DNA
)	O
has	O
been	O
demonstrated	O
in	O
just	O
a	O
few	O
instances	O
.	O


We	O
also	O
show	O
that	O
expression	O
of	O
the	O
B1	B-RNA
transcript	I-RNA
from	O
a	O
second	O
gene	O
,	O
MTCP1	B-DNA
,	O
occurred	O
at	O
a	O
relatively	O
high	O
level	O
only	O
in	O
two	O
T-PLL	O
tumours	O
from	O
A-T	O
patients	O
with	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
whereas	O
the	O
MTCP1/A1	B-RNA
transcript	I-RNA
is	O
much	O
more	O
widely	O
expressed	O
in	O
both	O
tumour	B-cell_type
and	I-cell_type
non	I-cell_type
tumour	I-cell_type
cells	I-cell_type
of	O
A-T	O
and	O
non-A-T	O
individuals	O
.	O


Transcription	B-protein
factors	I-protein
,	O
such	O
as	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
AP-1	B-protein
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O


This	O
peptide	O
potently	O
inhibited	O
NFAT	B-protein
activation	O
and	O
NFAT	B-protein
-dependent	O
expression	O
of	O
endogenous	B-DNA
cytokine	I-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
without	O
affecting	O
the	O
expression	O
of	O
other	O
cytokines	B-protein
that	O
require	O
calcineurin	B-protein
but	O
not	O
NFAT	B-protein
.	O


However	O
,	O
BRL49653	O
,	O
a	O
PPARgamma	B-protein
ligand	O
,	O
failed	O
to	O
induce	O
MCP-1	B-protein
secretion	O
either	O
alone	O
or	O
to	O
modify	O
the	O
expression	O
level	O
induced	O
by	O
RA	O
.	O


Other	O
peroxisome	B-protein
proliferator	I-protein
activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	O
ligands	O
,	O
15d-PGJ	O
(	O
2	O
)	O
and	O
troglitazone	O
(	O
PPARgamma	B-protein
)	O
,	O
Wy14	O
,	O
643	O
(	O
PPARalpha	B-protein
)	O
,	O
and	O
PD195599	O
(	O
PPARbeta	B-protein
)	O
inhibited	O
the	O
induction	O
of	O
MCP-1	B-protein
by	O
RA	O
.	O


Thus	O
,	O
both	O
copies	O
of	O
BRCA1	B-DNA
were	O
retained	O
in	O
tumor	O
.	O


The	O
DNA	O
variation	O
,	O
233G	O
--	O
>	O
A	O
,	O
does	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
,	O
and	O
is	O
considered	O
a	O
benign	O
polymorphism	O
.	O


Myb-transformed	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
as	O
a	O
model	O
for	O
monocyte	O
differentiation	O
into	O
dendritic	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O


Immune	O
induction	O
is	O
effected	O
through	O
the	O
interaction	O
of	O
antigen-presenting	B-cell_type
cells	I-cell_type
with	O
specific	O
receptors	B-protein
on	O
the	O
surface	O
of	O
thymus-derived	B-cell_type
lymphocytes	I-cell_type
.	O


MTHC	B-cell_line
in	O
the	O
presence	O
of	O
TNF-alpha	B-protein
and	O
IL-4	B-protein
will	O
differentiate	O
into	O
cells	O
that	O
have	O
many	O
of	O
the	O
properties	O
of	O
macrophages	B-cell_type
.	O


These	O
data	O
suggest	O
that	O
L.	O
pneumophila	O
possesses	O
a	O
growth	O
phase-dependent	O
resistance	O
to	O
stress	O
that	O
is	O
independent	O
of	O
RpoS	B-protein
control	O
and	O
that	O
RpoS	B-protein
likely	O
regulates	O
genes	O
that	O
enable	O
it	O
to	O
survive	O
in	O
the	O
environment	O
within	O
protozoa	O
.	O


Recently	O
we	O
have	O
reported	O
that	O
the	O
Pax5	B-DNA
gene	I-DNA
is	O
subject	O
to	O
allele	B-DNA
-specific	O
regulation	O
during	O
B	O
cell	O
development	O
.	O


However	O
,	O
disruption	O
of	O
a	O
membrane-proximal	B-protein
proline-rich	I-protein
sequence	I-protein
motif	I-protein
(	O
'	O
box1	B-protein
'	O
)	O
in	O
either	O
subunit	O
of	O
the	O
bipartite	B-protein
IL-4R	I-protein
abolished	O
not	O
only	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Janus	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK3	B-protein
,	O
but	O
also	O
IL-4	B-protein
-triggered	O
activation	O
of	O
STAT5	B-protein
and	O
concomitant	O
cell	O
proliferation	O
.	O


When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	B-protein
-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
``	B-DNA
B-subunit	I-DNA
knock-out	I-DNA
''	I-DNA
(	I-DNA
BKO	I-DNA
)	I-DNA
construct	I-DNA
suppressed	O
reporter	B-DNA
gene	I-DNA
activity	O
driven	O
by	O
NF-AT	B-protein
,	O
the	O
pivotal	O
promoter	B-DNA
element	I-DNA
for	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
induction	O
.	O


These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	B-protein
-mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	B-protein
active	I-protein
dimer	I-protein
of	O
calcineurin	B-protein
A	I-protein
and	I-protein
B	I-protein
subunits	I-protein
.	O


Monoclonal	B-protein
anti-D	I-protein
antibodies	I-protein
submitted	O
to	O
the	O
Third	O
Monoclonal	O
International	O
Workshop	O
were	O
evaluated	O
against	O
a	O
number	O
of	O
D	B-cell_line
variant	I-cell_line
cells	I-cell_line
using	O
standard	O
serological	O
techniques	O
.	O


The	O
monoclonal	B-protein
antibodies	I-protein
were	O
able	O
to	O
discriminate	O
between	O
the	O
cells	O
of	O
Categories	B-cell_line
Va	I-cell_line
,	I-cell_line
VI	I-cell_line
and	I-cell_line
DFR	I-cell_line
but	I-cell_line
not	I-cell_line
Category	I-cell_line
III	I-cell_line
cells	I-cell_line
.	O


In	O
addition	O
,	O
H-7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine/threonine	B-protein
kinases	I-protein
,	O
significantly	O
blocked	O
IL-10	B-protein
mediated	O
c-fos	B-DNA
expression	O
(	O
p	O
<	O
0.05	O
)	O
.	O


A	O
subset	O
of	O
B	B-cell_type
cell	I-cell_type
neoplasms	I-cell_type
expressing	O
MNDA	B-protein
included	O
hairy	O
cell	O
leukemia	O
,	O
parafollicular	O
(	O
monocytoid	O
)	O
B	O
cell	O
lymphoma	O
,	O
mantle	O
cell	O
lymphoma	O
,	O
and	O
small	O
lymphocytic	O
lymphoma	O
.	O


Intracellular	O
adhesion	O
molecule-1	O
induction	O
by	O
PMA	O
was	O
unaffected	O
by	O
any	O
of	O
the	O
molecules	O
tested	O
.	O


Inactive	B-protein
SHP1-D421A	I-protein
and	O
wild-type	B-protein
SHP2	I-protein
were	O
without	O
effects	O
.	O


However	O
,	O
the	O
two	O
SH2	B-protein
domains	I-protein
of	O
SHP1	B-protein
did	O
not	O
facilitate	O
its	O
recognition	O
of	O
ZAP-70	B-protein
and	O
Syk	B-protein
as	O
substrates	O
in	O
intact	O
cells	O
.	O


Therefore	O
,	O
we	O
suggest	O
that	O
SHP1	B-protein
is	O
not	O
actively	O
recruited	O
to	O
inhibit	O
TCR	B-protein
signaling	O
induced	O
by	O
ligation	O
of	O
this	O
receptor	O
alone	O
.	O


Further	O
analysis	O
of	O
the	O
MBP	B-DNA
promoter	I-DNA
region	I-DNA
identified	O
a	O
C/EBP	B-DNA
(	I-DNA
CCAAT/enhancer-binding	I-DNA
protein	I-DNA
)	I-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA-binding	B-DNA
site	I-DNA
in	O
the	O
MBP	B-DNA
gene	I-DNA
.	O


Tissue-specific	O
regulation	O
of	O
the	O
ecto-5'-nucleotidase	B-DNA
promoter	I-DNA
.	O


STAT3	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	B-protein
or	O
growth	B-protein
factors	I-protein
.	O


(	O
2-Amino-3'-methoxyphenyl	O
)	O
oxanaphthalen-4-one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal-regulated	B-protein
protein	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B-protein
induced	O
by	O
chemotactic	B-protein
factors	I-protein
or	O
PMA	O
.	O


The	O
GATA-1	B-protein
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co-localization	O
with	O
nuclear	B-protein
antigens	I-protein
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	B-protein
(	I-protein
Spl	I-protein
,	I-protein
c-Jun	I-protein
and	I-protein
TBP	I-protein
)	I-protein
or	I-protein
haemopoietic	I-protein
(	I-protein
NF-E2	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
.	O


This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	B-protein
transcription	I-protein
factors	I-protein
and	O
suggests	O
a	O
protein-protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	B-protein
zinc	I-protein
finger	I-protein
domain	I-protein
.	O


Following	O
PCr	O
administration	O
we	O
observed	O
lower	O
blood	O
lactate	O
concentrations	O
and	O
different	O
patterns	O
of	O
some	O
enzyme	O
activities	O
,	O
less	O
pronounced	O
changes	O
in	O
plasma	B-protein
ACTH	I-protein
and	O
cortisol	O
concentrations	O
and	O
in	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
,	O
but	O
no	O
changes	O
in	O
plasma	O
growth	O
hormone	O
concentrations	O
compared	O
to	O
the	O
placebo	O
.	O


These	O
bacterially-produced	B-DNA
MR	I-DNA
constructs	I-DNA
had	O
no	O
steroid	O
binding	O
activity	O
per	O
se	O
.	O


The	O
Kd	O
value	O
for	O
aldosterone	O
was	O
0.3	O
nM	O
and	O
the	O
Bmax	O
=	O
32	O
pmol/mg	O
.	O


Hormone	O
binding	O
specificity	O
was	O
assessed	O
by	O
competition	O
studies	O
with	O
various	O
steroid	O
ligands	O
.	O


Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	B-protein
E	I-protein
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands	O
,	O
agonists	O
or	O
antagonists	O
,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	B-protein
.	O


Renal	O
cell	O
carcinoma-derived	O
gangliosides	O
suppress	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
is	O
impaired	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O


In	O
circulating	O
T	B-cell_type
cells	I-cell_type
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	B-protein
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus-induced	O
degradation	O
of	O
the	O
cytoplasmic	B-protein
factor	I-protein
IkappaBalpha	B-protein
.	O


These	O
data	O
indicate	O
that	O
TNFalpha	B-protein
induces	O
a	O
delayed	O
ROS-dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF-kappaB	B-protein
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O


Although	O
estrogens	O
initiate	O
vascular	O
responses	O
,	O
genomic	O
sex	O
may	O
influence	O
and/or	O
limit	O
expression	O
of	O
estrogen	O
receptors	O
and	O
therefore	O
actions	O
of	O
sex	O
steroid	O
hormones	O
throughout	O
the	O
vasculature	O
.	O


M0/M1	B-cell_line
leukemic	I-cell_line
cells	I-cell_line
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	B-cell_line
leukemic	I-cell_line
cells	I-cell_line
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O


M2	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	I-cell_line
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O


To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2-type	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	B-cell_line
blast	I-cell_line
cells	I-cell_line
as	O
well	O
as	O
in	O
Kasumi-1	B-cell_line
cells	I-cell_line
(	O
an	O
acute	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M2-type	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
.	O


Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O


The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	B-protein
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O


mRNA	B-RNA
levels	O
for	O
IL-13R	B-protein
alpha1	I-protein
,	O
but	O
not	O
IL-4R	B-protein
alpha	I-protein
,	O
were	O
markedly	O
decreased	O
in	O
in	B-cell_line
vitro	I-cell_line
monocyte-derived	I-cell_line
macrophages	I-cell_line
(	O
MDMac	B-cell_line
)	O
,	O
and	O
with	O
increasing	O
time	O
of	O
monocytes	B-cell_type
in	O
culture	O
correlated	O
with	O
the	O
loss	O
of	O
IL-13	B-protein
regulation	O
of	O
lipopolysaccharide-induced	O
TNF-alpha	B-protein
production	O
.	O


Experiments	O
with	O
a	O
blocking	O
antibody	O
to	O
IL-4R	B-protein
alpha	I-protein
showed	O
that	O
this	O
chain	O
remains	O
an	O
essential	O
component	O
of	O
the	O
IL-13	B-protein
receptor	I-protein
complex	I-protein
on	O
MDMac	B-cell_line
.	O


Both	O
TNF-alpha	B-protein
and	O
NF-kappa	B-protein
B	I-protein
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
I	I-protein
molecules	I-protein
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	B-cell_type
cells	I-cell_type
.	O


The	O
human	O
B29	B-DNA
gene	I-DNA
lacks	O
either	O
a	O
TATA	B-DNA
or	I-DNA
a	I-DNA
CAAT	I-DNA
box	I-DNA
and	O
transcription	O
is	O
initiated	O
at	O
multiple	B-DNA
sites	I-DNA
.	O


The	O
minimal	O
promoter	O
of	O
the	O
human	B-DNA
B29	I-DNA
gene	I-DNA
is	O
contained	O
within	O
a	O
193-bp	B-DNA
region	I-DNA
5	O
'	O
of	O
these	O
multiple	B-DNA
start	I-DNA
sites	I-DNA
.	O


A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	B-protein
inhibitory	I-protein
factor	I-protein
,	O
CIF	B-protein
)	O
inhibits	O
interleukin	B-protein
2	I-protein
(	O
IL2	B-protein
)	O
production	O
in	O
activated	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
by	O
blocking	O
the	O
accumulation	O
of	O
IL2	B-RNA
mRNA	I-RNA
.	O


Heat	O
shock	O
induces	O
HIV-1	O
replication	O
in	O
chronically	O
infected	O
promyelocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
OM10.1	I-cell_line
.	O


Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF-kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5-3335	O
(	O
HIV-1	O
Tat	B-protein
inhibitor	O
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O


Thus	O
,	O
the	O
present	O
observations	O
will	O
provide	O
a	O
further	O
insight	O
into	O
the	O
pathogenesis	O
of	O
HIV-1	O
infections	O
.	O


Activation	O
of	O
N-WASP	B-protein
by	O
IcsA	B-protein
unmasks	O
two	O
domains	O
acting	O
together	O
in	O
insertional	O
actin	B-protein
polymerization	O
.	O


On	O
the	O
other	O
hand	O
,	O
the	O
NH	B-protein
(	I-protein
2	I-protein
)	I-protein
-terminal	I-protein
domain	I-protein
of	O
N-WASP	B-protein
interacts	O
with	O
F-actin	B-protein
,	O
mediating	O
the	O
attachment	O
of	O
the	O
actin	B-protein
tail	I-protein
to	O
the	O
bacterium	O
surface	O
.	O


c-Maf	B-protein
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	B-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
.	O


AML1	B-protein
(	I-protein
CBFalpha2	I-protein
)	I-protein
cooperates	O
with	O
B	B-protein
cell-specific	I-protein
activating	I-protein
protein	I-protein
(	I-protein
BSAP/PAX5	I-protein
)	I-protein
in	O
activation	O
of	O
the	O
B	B-DNA
cell-specific	I-DNA
BLK	I-DNA
gene	I-DNA
promoter	I-DNA
.	O


Physical	O
interaction	O
of	O
AML1	B-protein
with	O
BSAP	B-protein
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	B-protein
and	O
BSAP	B-protein
synergistically	O
activate	O
blk	B-DNA
promoter	O
transcription	O
by	O
more	O
than	O
50-fold	O
.	O


These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	B-protein
and	O
BSAP	B-protein
and	O
suggest	O
that	O
AML1	B-protein
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	B-DNA
cell-specific	I-DNA
gene	I-DNA
,	O
blk	B-DNA
.	O


Analysis	O
of	O
MSR	B-DNA
promoter	I-DNA
activity	O
in	O
THP-1	B-cell_line
cells	I-cell_line
transfected	O
with	O
an	O
MSR	B-DNA
promoter-reporter	I-DNA
gene	I-DNA
construct	I-DNA
demonstrated	O
decreased	O
activity	O
of	O
the	O
MSR	B-DNA
promoter	I-DNA
in	O
IL-6	B-protein
-treated	O
THP-1	B-cell_line
macrophages	B-cell_type
.	O


Electrophoretic	O
mobility	O
gel	O
shift	O
assay	O
also	O
showed	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
a	O
transcription	B-protein
factor	I-protein
to	O
the	O
MSR	B-DNA
promoter	I-DNA
AP-1/ets	I-DNA
elements	I-DNA
in	O
IL-6	B-protein
-treated	O
cells	O
.	O


Retinoblastoma	O
protein	O
expression	O
leads	O
to	O
reduced	O
Oct-1	B-protein
DNA	O
binding	O
activity	O
and	O
enhances	O
interleukin-8	B-protein
expression	O
.	O


The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	B-protein
production	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF-kB	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	B-protein
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF-kB	B-protein
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O


This	O
staining	O
pattern	O
clearly	O
differed	O
from	O
that	O
of	O
classical	O
HD	O
,	O
whose	O
cellular	O
background	O
was	O
made	O
up	O
of	O
CD3+/CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
showing	O
the	O
BCL-6	B-protein
-/	O
CD40L	B-protein
+	O
phenotype	O
.	O


The	O
eukaryotic	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
is	O
involved	O
in	O
the	O
inducible	O
expression	O
of	O
various	O
inflammatory	B-DNA
genes	I-DNA
as	O
well	O
as	O
in	O
HIV-1	O
replication	O
.	O


Activation	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	B-protein
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators	O
.	O


The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
since	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP-1	B-protein
was	O
not	O
suppressed	O
.	O


To	O
better	O
understand	O
the	O
assembly	O
mechanism	O
for	O
the	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
,	O
we	O
have	O
developed	O
cell-free	O
systems	O
for	O
studying	O
interactions	O
of	O
PR	B-protein
,	O
hsp90	B-protein
,	O
and	O
other	O
associated	B-protein
proteins	I-protein
.	O


We	O
have	O
studied	O
two	O
pre-formed	B-protein
hsp90	I-protein
complexes	I-protein
that	O
may	O
participate	O
in	O
the	O
assembly	O
of	O
PR	B-protein
complexes	I-protein
.	O


A	O
second	O
complex	O
contains	O
hsp90	B-protein
bound	O
to	O
p23	B-protein
plus	O
the	O
three	O
immunophilins	B-protein
and	O
some	O
hsp70	B-protein
.	O


In	O
further	O
studies	O
we	O
have	O
shown	O
that	O
purified	O
hsp90	B-protein
can	O
bind	O
to	O
purified	O
p23	B-protein
and	O
this	O
interaction	O
requires	O
both	O
ATP	O
and	O
molybdate	O
.	O


Nuclear	O
extracts	O
and	O
total	O
cell	O
lysates	O
were	O
prepared	O
from	O
MNC	B-cell_type
by	O
standard	O
techniques	O
.	O


It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O


Peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
were	O
isolated	O
by	O
density	O
centrifugation	O
methods	O
with	O
a	O
purity	O
of	O
>	O
90	O
%	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
.	O


Continuous	O
treatment	O
of	O
monocytes	B-cell_type
with	O
IL-1beta	B-protein
,	O
but	O
not	O
with	O
TNF-alpha	B-protein
,	O
could	O
almost	O
completely	O
prevent	O
GC-induced	O
cell	O
death	O
.	O


Second	O
,	O
we	O
studied	O
the	O
modulation	O
of	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
dexamethasone	O
by	O
preincubation	O
with	O
TNFalpha	B-protein
or	O
IL-10	B-protein
and	O
measurement	O
of	O
LPS-stimulated	O
IL-6	B-protein
secretion	O
.	O


TNFalpha	B-protein
decreased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
IL-10	B-protein
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O


Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	B-cell_line
cells	I-cell_line
by	O
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	I-DNA
but	O
not	O
by	O
highly	O
expressed	O
Bcl-2	B-protein
.	O


On	O
the	O
contrary	O
,	O
32Dcl3	B-cell_line
cells	I-cell_line
stably	O
expressing	O
AML1/ETO	B-DNA
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G-CSF	B-protein
.	O


When	O
compared	O
with	O
normal	B-cell_type
cells	I-cell_type
,	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O


Human	B-protein
Toll-like	I-protein
receptor	I-protein
2	I-protein
(	I-protein
TLR2	I-protein
)	I-protein
is	O
a	O
signaling	B-protein
receptor	I-protein
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF-kappaB	B-protein
.	O


PU.1	B-protein
is	O
a	O
hematopoietic-specific	B-protein
Ets	I-protein
family	I-protein
transcription	I-protein
factor	I-protein
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
lineages	I-cell_type
.	O


Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU.1	B-protein
interferes	O
with	O
erythroid	O
differentiation	O
.	O


We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
PU.1	B-protein
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O


IL-12	B-protein
induces	O
IFN	B-protein
regulating	I-protein
factor-1	I-protein
(	I-protein
IRF-1	I-protein
)	I-protein
gene	O
expression	O
in	O
human	O
NK	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O


First	O
,	O
STAT4	B-protein
was	O
required	O
for	O
the	O
IL-12	B-protein
-dependent	O
transactivation	O
of	O
an	O
IRF-1	B-DNA
reporter	I-DNA
construct	I-DNA
,	O
and	O
second	O
,	O
STAT4	B-protein
binding	O
to	O
the	O
IRF-1	B-DNA
promoter	I-DNA
was	O
shown	O
using	O
EMSA	O
.	O


To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	B-DNA
beta-globin	I-DNA
promoter	I-DNA
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid-specific	B-DNA
DNase	I-DNA
1	I-DNA
hypersensitive	I-DNA
site-forming	I-DNA
element	I-DNA
(	O
HSFE	B-DNA
)	O
immediately	O
upstream	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
and	I-DNA
gene	I-DNA
.	O


The	O
HSFE	B-DNA
induced	O
an	O
area	O
of	O
enhanced	O
DNase	B-protein
1	I-protein
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-300bp	O
of	O
the	O
artificial	B-DNA
promoter	I-DNA
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta-globin	B-DNA
promoters	I-DNA
in	O
an	O
open	O
chromatin	O
configuration	O
.	O


These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis-acting	B-DNA
element	I-DNA
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta-globin	B-DNA
gene	I-DNA
expression	O
.	O


NF-kappaB	B-protein
activation	O
is	O
required	O
for	O
C5a-induced	B-DNA
interleukin-8	I-DNA
gene	I-DNA
expression	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
.	O


Pertussis	O
toxin	O
,	O
which	O
ADP-ribosylates	O
the	O
Gi	B-protein
proteins	I-protein
known	O
to	O
couple	O
to	O
the	O
C5a	B-protein
receptor	I-protein
,	O
produced	O
minimal	O
inhibition	O
of	O
C5a-induced	O
IL-8	B-protein
expression	O
and	O
had	O
little	O
effect	O
on	O
C5a-induced	O
calcium	O
mobilization	O
in	O
RAW264.7	B-cell_line
cells	I-cell_line
.	O


Increased	O
glucocorticoid	B-protein
receptor	I-protein
beta	I-protein
in	O
airway	B-cell_type
cells	I-cell_type
of	O
glucocorticoid-insensitive	O
asthma	O
.	O


We	O
also	O
examined	O
the	O
expression	O
of	O
GCRbeta	B-protein
in	O
specimens	O
from	O
the	O
airways	O
of	O
patients	O
with	O
chronic	O
bronchitis	O
.	O


Therefore	O
,	O
we	O
studied	O
the	O
CD40	B-protein
pathway	O
in	O
highly	O
purified	O
human	B-cell_type
monocytes	I-cell_type
and	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


After	O
CD40	B-protein
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF-kappaB	B-protein
(	O
but	O
not	O
of	O
the	O
AP-1	B-protein
)	O
transcription	B-protein
factor	I-protein
complex	I-protein
occurred	O
in	O
both	O
cell	O
preparations	O
.	O


These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
differ	O
following	O
CD40	B-protein
stimulation	O
.	O


This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	B-protein
-induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	B-protein
ligand+	O
hyper	O
IgM	B-protein
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	B-protein
-induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O


For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O


Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss-of-function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O


Here	O
,	O
we	O
propose	O
gain-of-function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss-of-function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV-1	O
.	O


Thus	O
,	O
IkappaB-alphaS32/36A	B-protein
offers	O
proof-of-principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O


TCR	B-protein
affinities	O
were	O
then	O
indirectly	O
estimated	O
by	O
blocking	O
CD8	B-protein
interaction	O
with	O
an	O
anti-CD8	B-protein
mAb	I-protein
.	O


In	O
response	O
to	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta-catenin	B-protein
accumulates	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF/TCF	B-protein
(	O
for	O
lymphoid	B-protein
enhancer	I-protein
factor	I-protein
and	I-protein
T-cell	I-protein
factor	I-protein
)	O
transcription	B-protein
factors	I-protein
to	O
activate	O
gene	O
expression	O
.	O


We	O
have	O
introduced	O
a	O
small	O
deletion	O
within	O
beta-catenin	B-protein
(	O
Delta19	B-DNA
)	O
that	O
disrupts	O
binding	O
to	O
LEF-1	B-protein
,	O
E-cadherin	B-protein
,	O
and	O
APC	B-protein
but	O
not	O
axin	B-protein
.	O


Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	B-cell_type
modified	I-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O


Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O


These	O
results	O
indicate	O
that	O
ALG-4	B-protein
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	B-protein
expression	O
.	O


Fas/	O
FasL	B-protein
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O


LMP1	B-protein
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF-kappaB	B-protein
or	O
synergize	O
with	O
TRADD	B-protein
in	O
NF-kappaB	B-protein
activation	O
,	O
while	O
TNFR1	B-protein
requires	O
approximately	O
70	O
residues	O
.	O


Unlike	O
TNFR1	B-protein
,	O
LMP1	B-protein
can	O
interact	O
directly	O
with	O
receptor-interacting	B-protein
protein	I-protein
(	O
RIP	B-protein
)	O
and	O
stably	O
associates	O
with	O
RIP	B-protein
in	O
EBV-transformed	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


In	O
marked	O
contrast	O
to	O
neutrophils	B-cell_type
and	O
MO7e	B-cell_type
cells	I-cell_type
,	O
GM-CSF	B-protein
did	O
not	O
induce	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
ERK	B-protein
in	O
monocytes	B-cell_type
.	O


PD98059	O
inhibited	O
GM-CSF	B-protein
-dependent	O
proliferation	O
of	O
MO7e	B-cell_type
cells	I-cell_type
.	O


Possible	O
roles	O
of	O
ERK	B-protein
in	O
proliferation	O
of	O
transformed	B-cell_line
cells	I-cell_line
were	O
also	O
suggested	O
.	O


Indirect	O
immunofluorescence	O
shows	O
that	O
IL-2	B-protein
controls	O
the	O
cellular	O
distribution	O
of	O
Aiolos	B-protein
and	O
induces	O
its	O
tyrosine	O
phosphorylation	O
,	O
required	O
for	O
dissociation	O
from	O
Ras	B-protein
.	O


In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL-5	B-protein
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O


We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL-2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O


PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
PMA	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
blocks	O
that	O
induced	O
by	O
CD40	B-protein
cross-linking	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O


Control	O
of	O
IL-5	B-protein
production	O
may	O
be	O
effective	O
for	O
the	O
management	O
of	O
allergic	O
diseases	O
.	O


pIL-5	B-DNA
(	I-DNA
-511	I-DNA
)	I-DNA
Luc	I-DNA
was	O
transcribed	O
by	O
T-cell	B-cell_line
hybridomas	I-cell_line
derived	O
from	O
fusion	O
between	O
IL-5-producing	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
and	O
an	O
IL-5	B-cell_line
gene-nonexpressing	I-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
but	O
not	O
by	O
hybridomas	B-cell_line
derived	O
from	O
IL-5-nonproducing	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
.	O


IL-5	B-protein
synthesis	O
was	O
not	O
only	O
induced	O
by	O
T-cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL-2	B-protein
receptor	O
stimulation	O
.	O


CONCLUSION	O
:	O
IL-5	B-protein
synthesis	O
by	O
human	B-cell_type
helper	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O


However	O
,	O
little	O
is	O
known	O
regarding	O
whether	O
follicles	O
in	O
the	O
liver	O
belong	O
to	O
functional	O
lymphoid	O
tissues	O
,	O
where	O
B	O
cells	O
are	O
activated	O
,	O
differentiated	O
,	O
and	O
proliferated	O
,	O
or	O
if	O
the	O
lymphocytes	O
are	O
merely	O
infiltrated	O
after	O
recruitment	O
from	O
the	O
secondary	O
lymphoid	O
organs	O
.	O


The	O
Wilms	B-DNA
'	I-DNA
tumor	I-DNA
gene	I-DNA
(	O
WT1	B-DNA
)	O
encodes	O
a	O
transcription	B-protein
factor	I-protein
of	O
the	O
zinc	B-protein
finger	I-protein
type	I-protein
.	O


A	O
high	O
expression	O
of	O
WT1	B-DNA
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	B-DNA
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


In	O
this	O
study	O
,	O
each	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	B-DNA
was	O
constitutively	O
overexpressed	O
in	O
the	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O


IL-4	B-protein
conducts	O
its	O
biological	O
activities	O
through	O
binding	O
to	O
the	O
IL-4	B-protein
receptor	I-protein
(	O
IL-4R	B-protein
)	O
on	O
the	O
surface	O
of	O
target	B-cell_type
cells	I-cell_type
.	O


In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr-113	O
and	O
Tyr-128	O
,	O
of	O
SLP-76	B-protein
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	B-protein
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O


However	O
,	O
little	O
is	O
known	O
about	O
the	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
its	O
expression	O
.	O


Consistent	O
with	O
its	O
Rel/NF-kappaB	B-protein
-dependent	O
induction	O
,	O
Jagged1	B-protein
was	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
splenic	B-cell_type
B	I-cell_type
cells	I-cell_type
where	O
c-Rel	B-protein
is	O
expressed	O
constitutively	O
.	O


These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF-kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O


Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram-positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	B-protein
in	O
macrophages	B-cell_type
through	O
CD14	B-protein
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O


Interleukin	O
(	O
IL	O
)	O
6	O
levels	O
were	O
determined	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O


ICSAT	B-protein
overexpression	O
is	O
not	O
sufficient	O
to	O
cause	O
adult	O
T-cell	O
leukemia	O
or	O
multiple	O
myeloma	O
.	O


Th2	B-cell_line
cells	I-cell_line
could	O
be	O
induced	O
in	O
all	O
healthy	O
controls	O
by	O
priming	O
with	O
anti-CD28	B-protein
in	O
the	O
absence	O
of	O
TCR	B-protein
ligation	O
.	O


The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	B-cell_type
cells	I-cell_type
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O


Consequently	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	B-protein
negative	I-protein
mutant	I-protein
forms	O
of	O
components	O
of	O
the	O
NF-kappaB	B-protein
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	B-protein
or	O
p65	B-protein
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	B-cell_type
parva-transformed	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite-induced	O
constitutive	O
NF-kappaB	B-protein
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	B-cell_type
cells	I-cell_type
.	O


Genetic	O
variation	O
in	O
cytokine	B-DNA
promoter	I-DNA
regions	I-DNA
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O


A	O
semiquantitative	O
reverse	B-protein
transcriptase	I-protein
-linked	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	B-cell_type
cells	I-cell_type
.	O


Together	O
,	O
these	O
results	O
indicate	O
that	O
UV-induced	O
CYP1A1	B-protein
gene	O
expression	O
in	O
mammalian	B-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
an	O
Ah	B-protein
receptor	I-protein
ligand	O
formed	O
from	O
tryptophan	O
.	O


Here	O
we	O
show	O
that	O
the	O
lymphoid	B-protein
lineage-determining	I-protein
factors	I-protein
Ikaros	B-protein
and	O
Aiolos	B-protein
can	O
function	O
as	O
strong	B-protein
transcriptional	I-protein
repressors	I-protein
.	O


PI3-kinase	B-protein
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB/Akt	B-protein
because	O
the	O
PI3-kinase	B-protein
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB/Akt	B-protein
and	O
factor-dependent	O
PKB/Akt	B-protein
activity	O
.	O


The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57-SREI	B-cell_line
and	O
HCD57	B-cell_line
cells	I-cell_line
correlated	O
with	O
the	O
activity	O
of	O
PKB/Akt	B-protein
;	O
however	O
,	O
PKB/Akt	B-protein
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O


Disruption	O
of	O
alpha	O
beta	O
but	O
not	O
of	O
gamma	O
delta	O
T	O
cell	O
development	O
by	O
overexpression	O
of	O
the	O
helix-loop-helix	B-protein
protein	I-protein
Id3	B-protein
in	O
committed	B-cell_type
T	I-cell_type
cell	I-cell_type
progenitors	I-cell_type
.	O


These	O
cells	O
had	O
properties	O
of	O
both	O
natural	B-cell_type
killer	I-cell_type
(	O
NK	B-cell_type
)	O
and	O
pre-T	B-cell_type
cells	I-cell_type
.	O


These	O
findings	O
suggest	O
that	O
bHLH	B-protein
factors	I-protein
are	O
required	O
to	O
control	O
T	O
cell	O
development	O
after	O
the	O
T/NK	O
developmental	O
checkpoint	O
.	O


HIV-1	O
reactivation	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	B-protein
cross-linking	O
by	O
ligands	O
of	O
the	O
CDR2-loop	B-protein
in	O
extracellular	B-protein
domain	I-protein
1	I-protein
.	O


HIV-1	O
infects	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O


This	O
viral	O
reactivation	O
was	O
associated	O
with	O
increased	O
NF-kappaB	B-protein
nuclear	O
translocation	O
in	O
patients	O
'	O
PBMCs	B-cell_type
.	O


The	O
level	O
of	O
ongoing	O
HIV-1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV-1	O
pathogenesis	O
.	O


Given	O
the	O
critical	O
role	O
that	O
LT-alpha1beta2	B-protein
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT-alpha1beta2	B-protein
may	O
be	O
involved	O
in	O
HIV-associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O


The	O
secretion	O
levels	O
of	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O


The	O
activated	B-cell_line
EC	I-cell_line
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U937	B-cell_line
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
,	O
intercellular	O
adhesion	O
molecule	O
1	O
,	O
and	O
E-selectin	B-protein
.	O


RESULTS	O
:	O
Six	O
mAECA	B-protein
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	B-protein
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	B-cell_line
.	O


In	O
addition	O
,	O
these	O
mAECA	B-protein
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
.	O


We	O
report	O
that	O
NF-AT1	B-protein
and	O
NF-AT4	B-protein
are	O
expressed	O
cytoplasmically	O
in	O
resting	B-cell_type
eosinophils	I-cell_type
,	O
whereas	O
NF-AT2	B-protein
and	O
NF-AT3	B-protein
have	O
not	O
been	O
seen	O
.	O


Likewise	O
,	O
NF-AT1	B-RNA
mRNA	I-RNA
and	O
NF-AT4	B-RNA
mRNA	I-RNA
have	O
been	O
detected	O
in	O
resting	B-cell_type
eosinophils	I-cell_type
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up-regulated	O
by	O
the	O
Th2-associated	B-protein
cytokines	I-protein
IL-4	B-protein
and	O
IL-5	B-protein
.	O


However	O
NF-ATs	B-protein
appear	O
in	O
the	O
nuclei	O
of	O
IL-4-	B-cell_line
,	I-cell_line
IL-5-	I-cell_line
,	I-cell_line
or	I-cell_line
ionomycin-stimulated	I-cell_line
eosinophils	I-cell_line
.	O


METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	B-cell_type
carotid	I-cell_type
artery	I-cell_type
ECs	I-cell_type
express	O
PPARalpha	B-protein
.	O


Transient	O
transfection	O
of	O
deletional	O
VCAM-1	B-DNA
promoter	I-DNA
constructs	I-DNA
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM-1	B-protein
transcription	O
in	O
part	O
by	O
inhibiting	O
NF-kappaB	B-protein
.	O


NF-ATc	B-protein
,	O
an	O
inducibly	O
expressed	O
transcription	B-protein
factor	I-protein
,	O
controls	O
gene	O
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
cardiomyocytes	B-cell_type
.	O


The	O
interaction	O
of	O
LMP1	B-protein
and	O
JAK3	B-protein
leads	O
to	O
the	O
enhanced	O
tyrosine	O
auto/transphosphorylation	O
of	O
JAK3	B-protein
within	O
minutes	O
after	O
crosslinking	O
of	O
a	O
conditional	O
NGF-R	B-protein
:	I-protein
LMP1	I-protein
chimera	I-protein
and	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O


In	O
contrast	O
,	O
rolling	O
of	O
monocytes	B-cell_type
was	O
increased	O
by	O
IkappaB-alpha	B-protein
transfer	O
and	O
was	O
partly	O
mediated	O
by	O
P-selectin	B-protein
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	O
of	O
E-selectin	B-protein
induction	O
.	O


Recognition	O
of	O
NFATp/AP-1	B-DNA
composite	I-DNA
elements	I-DNA
within	O
genes	O
induced	O
upon	O
the	O
activation	O
of	O
immune	B-cell_type
cells	I-cell_type
.	O


A	O
well-studied	O
example	O
is	O
nuclear	B-DNA
factors	I-DNA
of	I-DNA
activated	I-DNA
T-cell	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
sites	I-DNA
which	O
are	O
composite	O
elements	O
of	O
a	O
NFATp/c	B-DNA
and	I-DNA
an	I-DNA
activating	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
AP-1	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
.	O


We	O
have	O
identified	O
an	O
E	B-DNA
box	I-DNA
around	O
-260	B-DNA
and	O
a	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
around	O
-300	B-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O


Suppression	O
of	O
NF-kappaB	B-protein
activation	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O


RCC-S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	B-protein
and	O
NF-kappaB1	B-protein
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA/NF-kappaB1	B-protein
binding	I-protein
complexes	I-protein
.	O


The	O
mediator	O
(	O
s	O
)	O
of	O
this	O
maturation	O
process	O
has	O
not	O
been	O
yet	O
defined	O
.	O


STAT1	B-protein
activity	O
was	O
evident	O
on	O
the	O
STAT	B-DNA
binding	I-DNA
sequences	I-DNA
(	O
SBE	B-DNA
)	O
present	O
in	O
the	O
promoters	B-DNA
of	O
genes	O
which	O
are	O
up-regulated	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
such	O
as	O
FcgammaRI	B-DNA
and	O
ICAM-1	B-DNA
,	O
and	O
in	O
the	O
promoter	O
of	O
the	O
transcription	B-DNA
factor	I-DNA
IFN	I-DNA
regulatory	I-DNA
factor-1	I-DNA
.	O


These	O
findings	O
suggest	O
that	O
PML	B-protein
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O


Furthermore	O
,	O
PML	B-protein
and	O
pRb	B-protein
105	I-protein
were	O
co-immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	B-cell_type
precursors	I-cell_type
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O


The	O
activity	O
of	O
JNK1	B-protein
was	O
also	O
significantly	O
induced	O
,	O
with	O
JNK1	B-protein
protein	O
levels	O
increasing	O
moderately	O
during	O
exposure	O
to	O
TPA	O
.	O


63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	B-DNA
base	I-DNA
pairs	I-DNA
(	O
86	O
%	O
identity	O
)	O
.	O


These	O
findings	O
demonstrate	O
differential	O
lineage	O
requirements	O
for	O
expression	O
within	O
the	O
HS	B-DNA
I	I-DNA
element	I-DNA
.	O


Recent	O
studies	O
have	O
shown	O
that	O
the	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	B-protein
shock	I-protein
transcription	I-protein
factor	I-protein
(	O
HSF1	B-protein
)	O
from	O
a	O
latent	B-protein
cytoplasmic	I-protein
form	I-protein
to	O
a	O
nuclear	B-protein
,	I-protein
DNA	I-protein
binding	I-protein
state	I-protein
.	O


In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	B-RNA
mRNA	I-RNA
species	I-RNA
.	O


Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	B-DNA
genes	I-DNA
and	O
HSF1	B-protein
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O


Copyright	O
1999	O
Academic	O
Press	O
.	O


FGF-1	B-protein
is	O
abundantly	O
expressed	O
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune-mediated	O
inflammation	O
.	O


Analogous	O
to	O
costimulation	O
via	O
CD28	B-protein
,	O
this	O
activity	O
is	O
mediated	O
through	O
activation	O
of	O
Rel/kappaB	B-protein
,	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
known	O
to	O
regulate	O
IL-2	B-protein
and	O
other	O
activation-inducible	B-protein
proteins	I-protein
.	O


The	O
signaling	O
events	O
that	O
link	O
FGF	B-protein
receptor-1	I-protein
engagement	O
and	O
NF-kappaB	B-protein
activation	O
in	O
Jurkat	B-cell_line
are	O
probably	O
distinct	O
from	O
the	O
CD28	B-protein
costimulation	O
pathway	O
,	O
since	O
FGF-1	B-protein
-induced	O
Rel/kappaB	B-protein
binding	I-protein
proteins	I-protein
do	O
not	O
contain	O
significant	O
levels	O
of	O
c-Rel	B-protein
and	O
are	O
not	O
identical	O
with	O
the	O
CD28	B-protein
response	I-protein
complex	I-protein
.	O


3-deazaadenosine	O
,	O
a	O
S-adenosylhomocysteine	B-protein
hydrolase	I-protein
inhibitor	O
,	O
has	O
dual	O
effects	O
on	O
NF-kappaB	B-protein
regulation	O
.	O


Inhibition	O
of	O
NF-kappaB	B-protein
transcriptional	O
activity	O
and	O
promotion	O
of	O
IkappaBalpha	B-protein
degradation	O
.	O


DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
through	O
the	O
hindrance	O
of	O
p65	B-protein
(	O
Rel-A	B-protein
)	O
phosphorylation	O
without	O
reduction	O
of	O
its	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
activity	O
.	O


The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF-kappaB	B-protein
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O


PROBLEM	O
:	O
Due	O
to	O
the	O
lack	O
of	O
classical	B-protein
HLA	I-protein
antigens	I-protein
on	O
the	O
trophoblast	O
,	O
fetal	B-protein
antigens	I-protein
are	O
possibly	O
presented	O
in	O
a	O
non	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	B-protein
)	O
restricted	O
way	O
.	O


Ninety-seven	O
percent	O
of	O
gamma/delta	B-cell_type
TCR+	I-cell_type
pregnancy	I-cell_type
lymphocytes	I-cell_type
expressed	O
progesterone	B-protein
receptor	I-protein
.	O


Monocyte	O
adhesion	O
and	O
spreading	O
on	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
Rho	B-protein
-regulated	O
receptor	O
clustering	O
.	O


Although	O
recognized	O
as	O
fundamental	O
aspects	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
development	O
,	O
only	O
recently	O
have	O
the	O
mechanisms	O
governing	O
positive	O
and	O
negative	O
selection	O
been	O
examined	O
at	O
a	O
molecular	O
level	O
.	O


This	O
review	O
focuses	O
on	O
interactions	O
during	O
thymocyte	B-cell_type
maturation	O
that	O
define	O
the	O
T	O
cell	O
repertoire	O
,	O
with	O
an	O
emphasis	O
placed	O
on	O
current	O
literature	O
within	O
this	O
field	O
.	O


LP	B-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
enhanced	O
IL-2	B-protein
secretion	O
when	O
activated	O
through	O
the	O
CD2	B-protein
pathway	O
.	O


The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	B-protein
cosignaling	O
and	O
regulation	O
of	O
IL-2	B-protein
secretion	O
in	O
LP	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Upon	O
HBsAg	B-protein
stimulation	O
,	O
expression	O
of	O
IFN-gamma	B-protein
,	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-10	B-protein
was	O
detected	O
in	O
41	O
%	O
,	O
8	O
%	O
,	O
41	O
%	O
,	O
and	O
50	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O


Control	O
of	O
cell	O
cycle	O
entry	O
and	O
apoptosis	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
infected	O
by	O
Epstein-Barr	O
virus	O
.	O


Our	O
data	O
suggests	O
that	O
NF-kappaB	B-protein
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	B-cell_type
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


To	O
date	O
no	O
SOCS	B-protein
proteins	I-protein
have	O
been	O
specifically	O
implicated	O
in	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
signaling	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


Studies	O
over	O
the	O
past	O
few	O
years	O
have	O
identified	O
lymphotoxin	O
as	O
a	O
critical	O
signaling	O
molecule	O
not	O
only	O
for	O
the	O
organogenesis	O
of	O
secondary	O
lymphoid	O
tissues	O
but	O
for	O
the	O
maintenance	O
of	O
aspects	O
of	O
their	O
microarchitecture	O
as	O
well	O
.	O


In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha-	O
and	O
beta-binding	O
activities	O
.	O


CD4+	O
and	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
differ	O
in	O
their	O
beta-binding	O
profiles	O
,	O
which	O
may	O
explain	O
the	O
more	O
pronounced	O
down-regulation	O
of	O
CD28	B-protein
in	O
senescent	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


We	O
have	O
now	O
used	O
this	O
assay	O
to	O
identify	O
another	O
export	O
factor	O
.	O


The	O
RanQ69L	B-protein
preincubation	O
leads	O
to	O
accumulation	O
of	O
CRM1	B-protein
at	O
the	O
cytoplasmic	O
periphery	O
of	O
the	O
nuclear	B-protein
pore	I-protein
complex	I-protein
(	O
NPC	B-protein
)	O
in	O
association	O
with	O
the	O
p62	B-protein
complex	I-protein
and	O
Can/Nup214	O
.	O


In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	B-protein
was	O
upregulated	O
,	O
whereas	O
CD34	B-protein
,	O
c-kit	B-protein
,	O
PU.1	B-protein
,	O
and	O
GATA-2	B-protein
were	O
barely	O
or	O
not	O
detected	O
.	O


Furthermore	O
,	O
expression	O
of	O
SHP-1	B-protein
phosphatase	I-protein
which	O
is	O
a	O
negative	O
regulator	O
of	O
cytokine	B-protein
receptor	I-protein
signaling	O
,	O
was	O
lost	O
in	O
most	O
IL-2	B-cell_line
independent	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
3/4	O
)	O
but	O
not	O
in	O
the	O
leukemic	O
ATLL	B-cell_type
cells	I-cell_type
(	O
0/3	O
)	O
.	O


We	O
conclude	O
that	O
(	O
1	O
)	O
HTLV-I	O
infection	O
per	O
se	O
does	O
not	O
result	O
in	O
a	O
constitutive	O
phosphorylation	O
of	O
the	O
Jak3	B-protein
,	O
STAT3	B-protein
,	O
and	O
STAT5	B-protein
proteins	O
;	O
(	O
2	O
)	O
malignant	O
transformation	O
in	O
at	O
least	O
some	O
cases	O
of	O
ATLL	O
does	O
not	O
require	O
the	O
constitutive	O
,	O
but	O
may	O
require	O
IL-2	B-protein
-induced	O
,	O
activation	O
of	O
the	O
IL-2R	B-protein
Jak/STAT	B-protein
pathway	O
;	O
and	O
(	O
3	O
)	O
there	O
are	O
major	O
differences	O
in	O
T-cell	O
immortalization	O
mechanism	O
(	O
s	O
)	O
which	O
appear	O
to	O
involve	O
SHP-1	B-protein
and	O
target	O
molecules	O
for	O
rapamycin	O
and	O
RAD	O
.	O


Clonality	O
analysis	O
using	O
X-chromosome	B-DNA
inactivation	O
at	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
Humara	B-DNA
)	O
.	O


Here	O
we	O
report	O
that	O
in	O
erythroid	B-cell_type
cells	I-cell_type
,	O
GATA-1	B-protein
strongly	O
induces	O
the	O
expression	O
of	O
the	O
anti-apoptotic	B-protein
protein	I-protein
bcl-xL	B-protein
,	O
but	O
not	O
the	O
related	O
proteins	O
bcl-2	B-protein
and	O
mcl-1	B-protein
.	O


Consistent	O
with	O
a	O
role	O
for	O
bcl-xL	B-protein
in	O
mediating	O
GATA-1	B-protein
-induced	O
erythroid	O
cell	O
survival	O
,	O
in	O
vitro-differentiated	B-cell_line
bcl-xL-/-	I-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
fail	O
to	O
generate	O
viable	O
mature	O
definitive	O
erythroid	B-cell_type
cells	I-cell_type
,	O
a	O
phenotype	O
resembling	O
that	O
of	O
GATA-1	B-DNA
gene	I-DNA
disruption	O
.	O


PI	B-protein
3-kinase	I-protein
also	O
regulates	O
the	O
activity	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
,	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
kinase	I-protein
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O


Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
,	O
IL-2	B-protein
and	O
PI	B-protein
3-kinase	I-protein
activation	O
of	O
E2Fs	B-protein
have	O
not	O
been	O
characterized	O
.	O


Evidence	O
is	O
also	O
presented	O
,	O
using	O
Fe2+/Cu2+	O
ions	O
,	O
that.OH	O
generated	O
from	O
H2O2	O
through	O
Fenton	O
reactions	O
could	O
be	O
a	O
candidate	O
oxygen	O
reactive	O
species	O
to	O
directly	O
activate	O
STAT3	B-protein
.	O


These	O
results	O
demonstrate	O
that	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-protein
can	O
be	O
modulated	O
by	O
oxidizing	O
agents	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
JAK	B-protein
-STAT	B-protein
signaling	O
pathway	O
.	O


These	O
include	O
the	O
Ikaros	B-protein
,	O
LKLF	B-protein
,	O
and	O
GATA3	B-protein
zinc-finger	I-protein
proteins	I-protein
;	O
the	O
Ets	B-protein
,	O
CREB/ATF	B-protein
,	O
and	O
NF-kappa	B-protein
B/Rel/NFAT	I-protein
transcription	I-protein
factors	I-protein
;	O
the	O
Stat	B-protein
proteins	I-protein
;	O
and	O
HMG	B-protein
box	I-protein
transcription	I-protein
factors	I-protein
such	O
as	O
LEF1	B-protein
,	O
TCF1	B-protein
,	O
and	O
Sox4	B-protein
.	O


TNF	B-RNA
mRNA	I-RNA
expression	O
induced	O
by	O
LPS	O
was	O
decreased	O
when	O
the	O
pre-treatment	O
of	O
PBMC	B-cell_type
with	O
IL-10	B-protein
was	O
performed	O
on	O
plastic	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
when	O
cells	O
were	O
pre-cultured	O
with	O
IL-10	B-protein
on	O
Teflon	O
.	O


Cell	O
growth-regulated	O
expression	O
of	O
mammalian	B-DNA
MCM5	I-DNA
and	I-DNA
MCM6	I-DNA
genes	I-DNA
mediated	O
by	O
the	O
transcription	B-protein
factor	I-protein
E2F	B-protein
.	O


Human	B-DNA
MCM5	I-DNA
and	I-DNA
MCM6	I-DNA
promoters	I-DNA
with	O
mutation	O
in	O
the	O
E2F	B-DNA
sites	I-DNA
failed	O
in	O
promoter	O
regulation	O
following	O
serum	O
stimulation	O
and	O
exogenous	O
E2F	B-protein
expression	O
.	O


It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	B-protein
T-cell	I-protein
mitogens	I-protein
.	O


To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
were	O
transfected	O
with	O
recombinant	B-DNA
plasmid	I-DNA
containing	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
promoter	I-DNA
,	O
which	O
is	O
regulated	O
by	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O


Previous	O
studies	O
have	O
implicated	O
activation	O
of	O
both	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTK	B-protein
)	O
in	O
LPS-induced	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
production	O
.	O


We	O
hypothesized	O
that	O
inhibition	O
of	O
either	O
PKC	B-protein
or	O
PTK	B-protein
would	O
decrease	O
LPS-induced	O
NF-kappaB	B-protein
DNA	O
binding	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


MATERIALS	O
AND	O
METHODS	O
:	O
Human	B-cell_type
monocytes	I-cell_type
were	O
stimulated	O
with	O
PMA	O
(	O
50	O
ng/ml	O
)	O
alone	O
or	O
LPS	O
(	O
100	O
ng/ml	O
)	O
with	O
and	O
without	O
a	O
nonspecific	O
serine/threonine	B-protein
protein	I-protein
kinase	I-protein
inhibitor	O
staurosporine	O
(	O
Stauro	O
)	O
,	O
a	O
specific	O
pan-	O
PKC	B-protein
inhibitor	O
bisindolylmaleimide	O
(	O
Bis	O
)	O
,	O
or	O
an	O
inhibitor	O
of	O
PTK	B-protein
genistein	O
(	O
Gen	O
)	O
.	O


The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	B-protein
amylase	I-protein
and	I-protein
lipase	I-protein
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	B-protein
factor	I-protein
KB	I-protein
(	O
NF-KB	B-protein
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g/kg/h	O
)	O
for	O
6	O
h	O
.	O


GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	B-cell_type
neutrophils	I-cell_type
stimulated	O
by	O
N-formyl-methionine-leucine-phenyl-alanine	O
(	O
fMLP	O
)	O
or	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O


These	O
results	O
demonstrate	O
a	O
beneficial	O
effect	O
of	O
GDSP	O
,	O
a	O
novel	O
specific	O
elastase	O
inhibitor	O
,	O
on	O
the	O
development	O
of	O
rat	O
cerulein	O
pancreatitis	O
.	O


Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF-alpha	B-protein
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF-alpha	B-protein
gene	O
expression	O
must	O
be	O
tightly	O
regulated	O
.	O


Our	O
previous	O
studies	O
pertaining	O
to	O
macrophage	O
response	O
to	O
LPS	O
identified	O
a	O
novel	O
DNA-binding	B-protein
domain	I-protein
located	O
from	O
-550	O
to	O
-487	O
in	O
the	O
human	B-DNA
TNF-alpha	I-DNA
promoter	I-DNA
that	O
contains	O
transcriptional	O
activity	O
,	O
but	O
lacks	O
any	O
known	O
NF-kappaB	B-protein
-binding	B-DNA
sites	I-DNA
.	O


A	O
novel	O
cDNA	B-DNA
clone	I-DNA
(	O
1.8	O
kb	O
)	O
was	O
isolated	O
and	O
fully	O
sequenced	O
.	O


In	O
addition	O
,	O
high	O
level	O
of	O
expression	O
of	O
LITAF	B-RNA
mRNA	I-RNA
was	O
observed	O
predominantly	O
in	O
the	O
placenta	O
,	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
lymph	O
nodes	O
,	O
and	O
the	O
spleen	O
.	O


Together	O
,	O
these	O
findings	O
suggest	O
that	O
LITAF	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
activation	O
of	O
the	O
human	B-DNA
TNF-alpha	I-DNA
gene	I-DNA
and	O
proposes	O
a	O
new	O
mechanism	O
to	O
control	O
TNF-alpha	B-protein
gene	O
expression	O
.	O


The	O
immunogenetic	O
basis	O
of	O
severe	O
infections	O
caused	O
by	O
bacille	O
Calmette-Guerin	O
vaccine	O
and	O
environmental	O
mycobacteria	O
in	O
humans	O
remains	O
largely	O
unknown	O
.	O


The	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	B-protein
We	O
show	O
here	O
that	O
NF-kappaB	B-protein
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	B-protein
/	O
APO-1	B-protein
/	O
CD95	B-protein
-mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	B-cell_type
T	I-cell_type
cell	I-cell_type
death	O
.	O


Correspondingly	O
,	O
transfection	O
of	O
p50	B-protein
and	O
p65	B-protein
provided	O
considerable	O
protection	O
from	O
TCR-mediated	O
apoptosis	O
.	O


In	O
addition	O
,	O
blocking	O
TNF	B-protein
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF-kappaB	B-protein
,	O
with	O
neutralizing	B-protein
antibodies	I-protein
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti-Fas-mediated	O
apoptosis	O
.	O


Whereas	O
IL-4	B-protein
appears	O
to	O
repress	O
functional	O
IL-12	B-protein
signaling	O
through	O
inhibition	O
of	O
IL-12R	B-protein
beta	I-protein
2	I-protein
expression	O
,	O
IFN-gamma	B-protein
in	O
the	O
mouse	O
,	O
and	O
IFN-alpha	B-protein
in	O
the	O
human	O
appear	O
to	O
induce	O
IL-12R	B-protein
beta	I-protein
2	I-protein
expression	O
and	O
promote	O
IL-12	B-protein
responsiveness	O
.	O


Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	B-cell_type
cells	I-cell_type
undergoing	O
TNF-alpha	B-protein
-induced	O
apoptosis	O
.	O


The	O
female	O
steroid	O
hormones	O
estrogen	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
Prog	O
)	O
are	O
known	O
to	O
modulate	O
the	O
reactivity	O
of	O
the	O
immune	O
system	O
;	O
recently	O
it	O
has	O
been	O
demonstrated	O
that	O
they	O
can	O
regulate	O
induction	O
of	O
apoptosis	O
of	O
endothelial	B-cell_type
cells	I-cell_type
and	O
osteoblasts	B-cell_type
.	O


Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	B-cell_type
cells	I-cell_type
undergoing	O
TNF-alpha	B-protein
-inuced	O
apoptosis	O
.	O


Dicarba-closo-dodecaboranes	O
as	O
a	O
pharmacophore	O
.	O


Efforts	O
to	O
pinpoint	O
the	O
exact	O
site	O
of	O
action	O
and	O
specificity	O
of	O
HePTP	B-protein
in	O
the	O
signaling	O
cascade	O
revealed	O
that	O
HePTP	B-protein
acts	O
directly	O
on	O
the	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
Erk1	B-protein
and	I-protein
2	I-protein
and	O
consequently	O
reduces	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
catalytic	O
activation	O
in	O
intact	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


In	O
contrast	O
,	O
HePTP	B-protein
had	O
no	O
effects	O
on	O
N-terminal	B-protein
c-Jun	I-protein
kinase	I-protein
or	O
on	O
events	O
upstream	O
of	O
the	O
MAP	O
kinases	O
.	O


Optimal	O
T	O
cell	O
activation	O
requires	O
two	O
signals	O
,	O
one	O
generated	O
by	O
TCR	B-protein
and	O
another	O
by	O
the	O
CD28	B-protein
costimulatory	I-protein
receptor	I-protein
.	O


In	O
contrast	O
,	O
PMA-induced	O
JNK	B-protein
activation	O
is	O
inhibited	O
by	O
Ca2+	O
ionophore	O
.	O


The	O
UT-7	B-cell_line
cell	I-cell_line
line	I-cell_line
exhibits	O
both	O
erythroid	O
and	O
megakaryocytic	O
characteristics	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
pathway	O
by	O
Epo	B-protein
or	O
the	O
megakaryocytic	O
pathway	O
by	O
phorbol	O
myristic	O
acetate	O
.	O


Epo	B-protein
caused	O
an	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
expressing	O
cell	O
surface	O
glycophorin	B-protein
A	I-protein
(	O
GPA	B-protein
)	O
and	O
up-regulated	O
beta-	B-protein
and	I-protein
gamma-globin	I-protein
by	O
several	O
fold	O
.	O


Both	O
haemin	O
and	O
delta-ALA	O
caused	O
a	O
de	O
novo	O
increase	O
in	O
alpha-globin	B-protein
expression	O
as	O
well	O
as	O
enhancing	O
Epo	B-protein
-induced	O
beta-globin	B-protein
expression	O
,	O
leading	O
to	O
a	O
marked	O
increase	O
in	O
haemoglobin	O
production	O
.	O


These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF-kappaB	B-protein
occurs	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
and	O
the	O
ensuing	O
production	O
of	O
TNF-alpha	B-protein
may	O
propagate	O
NF-kappaB	B-protein
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O


Interferon-beta	B-protein
mediates	O
stromal	O
cell	O
rescue	O
of	O
T	B-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O


Cytokines	B-protein
that	O
bind	O
to	O
the	O
common	O
gamma	B-protein
chain	I-protein
of	O
the	O
IL-2	B-protein
receptor	O
promote	O
the	O
survival	O
of	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
,	O
but	O
also	O
induce	O
proliferation	O
.	O


We	O
also	O
show	O
that	O
this	O
mechanism	O
may	O
play	O
a	O
fundamental	O
role	O
in	O
the	O
persistence	O
of	O
T	B-cell_type
cells	I-cell_type
at	O
sites	O
of	O
chronic	O
inflammation	O
;	O
suggesting	O
that	O
chronic	O
inflammation	O
is	O
an	O
aberrant	O
consequence	O
of	O
immunological	O
memory	O
.	O


The	O
authors	O
have	O
previously	O
demonstrated	O
that	O
in	O
vitro	O
exposure	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
to	O
DFX	O
decreases	O
the	O
bioavailability	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
which	O
has	O
a	O
stimulatory	O
effect	O
on	O
HIV-1	O
replication	O
.	O


Smad6	B-protein
and	O
Smad7	B-protein
prevent	O
ligand-induced	O
activation	O
of	O
signal-transducing	B-protein
Smad	I-protein
proteins	I-protein
in	O
the	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
family	I-protein
.	O


These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	B-cell_type
,	O
respectively	O
.	O


All	O
agents	O
tested	O
induced	O
expression	O
of	O
Hsp60	B-protein
6	O
hr	O
after	O
application	O
.	O


METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O


However	O
,	O
we	O
detected	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B-RNA
mRNA	I-RNA
levels	O
in	O
the	O
endobronchial	O
biopsy	O
specimens	O
after	O
FP	O
treatment	O
(	O
36.6	O
+/-	O
23.1	O
and	O
25.0	O
+/-	O
10.9	O
amol	O
GR	B-RNA
mRNA	I-RNA
/microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.01	O
)	O
.	O


CONCLUSION	O
:	O
The	O
results	O
in	O
this	O
study	O
confirm	O
the	O
potency	O
of	O
the	O
inhaled	O
corticosteroid	O
FP	O
and	O
provide	O
evidence	O
for	O
a	O
considerable	O
tissue-specific	O
interindividual	O
variation	O
in	O
the	O
expression	O
of	O
the	O
GR	B-protein
.	O


When	O
activated	O
,	O
glucocorticoid	B-protein
receptors	I-protein
form	O
a	O
dimer	B-protein
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O


The	O
influence	O
on	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IL-4	B-protein
and	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
production	O
;	O
IL-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
alpha	I-protein
-	O
,	O
beta	B-protein
-	O
,	O
and	O
gamma-chain	B-protein
;	O
and	O
the	O
signaling	B-protein
pathway	I-protein
molecules	I-protein
Janus	B-protein
kinase	I-protein
(	B-protein
Jak	I-protein
)	I-protein
1	I-protein
,	O
Jak3	B-protein
,	O
signal	O
transducers	O
and	O
activators	B-protein
of	I-protein
transcription	I-protein
(	B-protein
Stat	I-protein
)	I-protein
1	I-protein
,	O
Stat3	B-protein
,	O
and	O
Stat5	B-protein
should	O
be	O
investigated	O
.	O


METHOD	O
OF	O
STUDY	O
:	O
For	O
assessment	O
of	O
IL	O
production	O
,	O
whole	O
peripheral	O
venous	O
blood	O
from	O
healthy	O
donors	O
was	O
stimulated	O
with	O
phorbol-myristate-acetate	O
and	O
ionomycine	O
.	O


RESULTS	O
:	O
Phorbol-myristate-acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent-age	O
of	O
IL-2+	B-cell_line
cells	I-cell_line
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	B-cell_type
cells	I-cell_type
.	O


In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	B-DNA
reporter	I-DNA
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF-kappaB	B-protein
activation	O
.	O


The	O
Th2-type	B-protein
cytokines	I-protein
,	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
,	O
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
including	O
FcepsilonRIIb	B-protein
(	O
CD23	B-protein
)	O
,	O
15-lipoxygenase	B-protein
,	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
(	O
IL-1ra	B-protein
)	O
,	O
and	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IL-1	I-protein
receptors	I-protein
(	O
IL-1R	B-protein
)	O
.	O


We	O
also	O
discuss	O
our	O
recent	O
findings	O
that	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IFNs	I-protein
suppress	O
IL-4	B-protein
/	O
IL-13	B-protein
-inducible	O
gene	O
expression	O
by	O
inhibiting	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B-protein
.	O


HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	B-DNA
E	I-DNA
-mediated	O
inactivation	O
of	O
Rb	O
function	O
and	O
induction	O
of	O
E2F	B-protein
activity	O
.	O


Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O


Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O


This	O
loss	O
of	O
STAT1	B-protein
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O


Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	O
to	O
degrade	O
IkappaB-alpha	B-protein
in	O
cytosols	O
of	O
TNF-treated	B-cell_type
T	I-cell_type
cells	I-cell_type
pretreated	O
with	O
PAO	O
is	O
due	O
to	O
its	O
interference	O
with	O
the	O
phosphorylation	O
of	O
IkappaB-alpha	B-protein
and	O
not	O
due	O
to	O
its	O
inhibitory	O
effect	O
on	O
proteasomal	O
degradation	O
.	O


Spi-C	B-protein
,	O
a	O
novel	O
Ets	B-protein
protein	I-protein
that	O
is	O
temporally	O
regulated	O
during	O
B	O
lymphocyte	O
development	O
.	O


In	O
contrast	O
to	O
the	O
negative	O
autoregulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
expression	O
seen	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
GR	B-protein
expression	O
is	O
positively	O
autoregulated	O
in	O
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
in	O
other	O
cells	O
sensitive	O
to	O
glucocorticoid-induced	O
cell	O
death	O
.	O


However	O
,	O
the	O
HTLV-I	B-DNA
genes	I-DNA
including	O
Tax	B-protein
are	O
not	O
expressed	O
significantly	O
in	O
primary	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
ATL	O
patients	O
.	O


Interestingly	O
,	O
the	O
NF-kappaB	B-protein
in	O
TL-Om1	O
consists	O
of	O
p50/p50	B-protein
and	O
p50/p65	B-protein
like	O
that	O
in	O
fresh	O
primary	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O


Data	O
regarding	O
the	O
processes	O
by	O
which	O
these	O
cytokines	B-protein
transduce	O
signals	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
are	O
becoming	O
increasingly	O
complex	O
.	O


Finally	O
,	O
the	O
results	O
demonstrate	O
that	O
IFN-alpha	B-protein
exerts	O
an	O
antiproliferative	O
effect	O
in	O
all	O
three	O
cell	O
lines	O
.	O


Activation	O
of	O
leukocytes	B-cell_type
by	O
proinflammatory	O
stimuli	O
selectively	O
initiates	O
intracellular	O
signal	O
transduction	O
via	O
sequential	O
phosphorylation	O
of	O
kinases	B-protein
.	O


Specific	O
inhibitors	O
of	O
p38alpha	B-protein
MAPk	I-protein
blocked	O
LPS-induced	O
adhesion	O
,	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappaB	B-protein
)	O
activation	O
,	O
and	O
synthesis	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O


The	O
I	B-protein
gamma	I-protein
3	I-protein
ECS	B-DNA
lies	O
upstream	O
of	O
the	O
major	B-DNA
I	I-DNA
gamma	I-DNA
3	I-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	B-DNA
I	I-DNA
gamma	I-DNA
1	I-DNA
,	O
I	B-DNA
gamma	I-DNA
2	I-DNA
,	O
and	O
I	B-DNA
gamma	I-DNA
4	I-DNA
regions	O
.	O


Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
motif	I-DNA
is	O
critical	O
for	O
the	O
gamma	B-DNA
3	I-DNA
ECS	I-DNA
responsiveness	O
to	O
both	O
CD40L	B-protein
and	O
IL-4	B-protein
,	O
while	O
a	O
STAT-6-binding	B-DNA
site	I-DNA
is	O
additionally	O
required	O
for	O
IL-4	B-protein
inducibility	O
.	O


Precise	O
regulation	O
of	O
MHC	B-cell_type
class	I-cell_type
II	I-cell_type
expression	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
control	O
of	O
the	O
immune	O
response	O
.	O


We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	B-protein
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
higher-order	O
protein	O
complex	O
formed	O
on	O
DNA	O
by	O
RFX	B-protein
,	O
X2BP	B-protein
and	O
NF-Y	B-protein
.	O


Increased	O
expression	O
of	O
IFNgamma	B-protein
-induced	O
IP-10	B-RNA
mRNA	I-RNA
following	O
the	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
was	O
mediated	O
largely	O
by	O
augmented	O
transcriptional	O
activity	O
of	O
the	O
gene	O
and	O
was	O
related	O
to	O
differentiation-dependent	O
changes	O
of	O
the	O
proteins	O
bound	O
to	O
IFN	B-DNA
stimulus	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
ISRE	I-DNA
)	I-DNA
and	O
kB	B-DNA
sites	I-DNA
,	O
suggesting	O
that	O
these	O
nuclear	B-protein
proteins	I-protein
may	O
determine	O
the	O
IP-10	B-RNA
mRNA	I-RNA
inducibility	O
by	O
IFNgamma	B-protein
.	O


Cleavage	O
of	O
transcription	B-protein
factor	I-protein
SP1	B-protein
by	O
caspases	B-protein
during	O
anti-IgM-induced	O
B-cell	B-cell_type
apoptosis	O
.	O


DNA	O
band-shift	O
assays	O
revealed	O
a	O
decrease	O
in	O
the	O
intensity	O
of	O
the	O
full	O
length	O
SP1	B-protein
/DNA	O
complex	O
and	O
an	O
increase	O
in	O
the	O
intensity	O
of	O
a	O
smaller	O
complex	O
due	O
to	O
the	O
binding	O
of	O
one	O
SP1	B-protein
cleavage	O
product	O
.	O


Our	O
results	O
show	O
the	O
cleavage	O
of	O
the	O
human	O
transcription	B-protein
factor	I-protein
SP1	B-protein
in	O
vivo	O
and	O
in	O
vitro	O
,	O
underlining	O
the	O
central	O
role	O
of	O
caspase	B-protein
3-like	I-protein
proteases	I-protein
during	O
the	O
process	O
of	O
anti-IgM-induced	O
apoptosis	O
.	O


In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HIV-HD	O
histogenesis	O
and	O
correlated	O
their	O
expression	O
status	O
to	O
the	O
virologic	O
features	O
of	O
this	O
disease	O
.	O


Although	O
BCL-6	B-protein
(	O
-	O
)	O
/syn-1	O
(	O
+	O
)	O
RS	B-cell_line
cells	I-cell_line
of	O
HIV-HD	O
express	O
CD40	B-protein
,	O
they	O
are	O
not	O
surrounded	O
by	O
CD40	B-cell_type
ligand-positive	I-cell_type
(	I-cell_type
CD40L+	I-cell_type
)	I-cell_type
reactive	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
which	O
,	O
in	O
HD	O
of	O
the	O
general	O
population	O
,	O
are	O
thought	O
to	O
regulate	O
the	O
disease	O
phenotype	O
through	O
CD40	B-protein
/CD40L	B-protein
interactions	O
.	O


MDS1/EVI1	B-DNA
,	O
located	O
on	O
chromosome	B-DNA
3	I-DNA
band	I-DNA
q26	I-DNA
,	O
encodes	O
a	O
zinc-finger	B-protein
DNA-binding	I-protein
transcription	I-protein
activator	I-protein
not	O
detected	O
in	O
normal	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
but	O
expressed	O
in	O
several	O
normal	O
tissues	O
.	O


They	O
are	O
growth-inhibited	O
by	O
TGF-beta1	B-protein
.	O


Abnormalities	O
of	O
cyclic	O
adenosine	O
monophosphate	O
signaling	O
in	O
platelets	B-cell_type
from	O
untreated	O
patients	O
with	O
bipolar	O
disorder	O
.	O


BACKGROUND	O
:	O
Abnormalities	O
in	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
-dependent	O
phosphorylation	O
system	O
have	O
been	O
recently	O
reported	O
in	O
patients	O
with	O
bipolar	O
disorder	O
.	O


The	O
levels	O
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
and	O
Rap1	B-protein
were	O
assessed	O
by	O
Western	O
blot	O
analysis	O
,	O
immunostaining	O
,	O
and	O
computer-assisted	O
imaging	O
.	O


CONCLUSIONS	O
:	O
Levels	O
of	O
Rap1	B-protein
and	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
are	O
altered	O
in	O
the	O
platelets	B-cell_type
of	O
bipolar	O
patients	O
.	O


Cytokine	B-protein
expression	O
by	O
immune	O
system	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
.	O


Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	B-protein
profiles	O
have	O
been	O
described	O
.	O


Tcf-1	B-protein
-mediated	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
:	O
differential	O
role	O
for	O
glycogen	B-protein
synthase	I-protein
kinase-3	I-protein
in	O
fibroblasts	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O


Here	O
we	O
report	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
Tcf-1	B-protein
also	O
becomes	O
transcriptionally	O
active	O
through	O
interaction	O
with	O
beta-catenin	B-protein
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
as	O
well	O
.	O


That	O
is	O
,	O
a	O
dominant	B-protein
negative	I-protein
GSK-3beta	I-protein
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	B-protein
)	O
that	O
inhibit	O
GSK-3beta	B-protein
activity	O
also	O
do	O
not	O
activate	O
Tcf	B-DNA
reporter	I-DNA
genes	I-DNA
.	O


Thus	O
,	O
inhibition	O
of	O
GSK-3beta	B-protein
is	O
insufficient	O
to	O
activate	O
Tcf-dependent	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
family	I-protein
members	O
extracellular-regulated	B-protein
kinase	I-protein
1/2	I-protein
(	O
ERK1/2	B-protein
)	O
and	O
c-	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
in	O
mediating	O
IL-6	B-protein
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
in	O
particular	O
their	O
role	O
in	O
enhancing	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O


The	O
ERK	O
pathway-specific	O
inhibitor	O
PD98059	O
inhibited	O
IL-6	B-protein
secretion	O
from	O
monocytes	B-cell_type
.	O


Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA2	B-protein
)	O
,	O
a	O
protein	O
involved	O
in	O
cell	O
transformation	O
,	O
interferes	O
with	O
the	O
cellular	O
response	O
to	O
type	B-protein
I	I-protein
interferons	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
.	O


We	O
investigated	O
the	O
function	O
of	O
conditionally	O
expressed	O
EBNA2	B-protein
in	O
the	O
context	O
of	O
the	O
IFN	B-protein
response	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Similar	O
glucocorticoid-mediated	O
potentiation	O
was	O
observed	O
with	O
5-day	O
M	O
phi	O
uptake	O
of	O
alternative	O
apoptotic	O
``	O
targets	O
''	O
(	O
eosinophils	B-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
)	O
and	O
in	O
uptake	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
by	O
alternative	O
phagocytes	B-cell_type
(	O
human	B-cell_type
glomerular	I-cell_type
mesangial	I-cell_type
cells	I-cell_type
and	O
murine	B-cell_line
M	I-cell_line
phi	I-cell_line
elicited	O
into	O
the	O
peritoneum	O
or	O
derived	O
from	O
bone	O
marrow	O
)	O
.	O


However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	B-cell_type
cells	I-cell_type
are	O
still	O
unclear	O
.	O


RXRs	B-protein
heterodimerize	O
with	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
[	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
]	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O


Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O


Taken	O
together	O
,	O
we	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
induces	O
increased	O
expression	O
of	O
cdk	B-protein
inhibitors	I-protein
,	O
which	O
mediates	O
a	O
G1	O
arrest	O
,	O
and	O
this	O
may	O
be	O
associated	O
with	O
differentiation	O
of	O
RA-resistant	O
UF-1	B-cell_line
cells	I-cell_line
toward	O
mature	O
granulocytes	B-cell_type
.	O


Molecular	O
mechanisms	O
of	O
neutrophil-endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O


This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG/GSH-induced	O
adhesion	O
response	O
.	O


These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia/reoxygenation	O
.	O


The	O
percentage	O
of	O
CD3+	B-cell_type
cells	I-cell_type
among	O
all	O
immunocompetent	B-cell_type
cells	I-cell_type
in	O
the	O
tubal	O
epithelium	O
was	O
46.6	O
%	O
(	O
39.9	O
%	O
of	O
CD3+	B-cell_type
were	O
also	O
CD8+	B-cell_type
)	O
;	O
the	O
other	O
53.4	O
%	O
were	O
CD68+	B-cell_type
cells	I-cell_type
.	O


Angiotensin	B-protein
II	I-protein
activates	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O


ANG	B-protein
II	I-protein
,	O
like	O
TNFalpha	B-protein
,	O
caused	O
rapid	O
activation	O
of	O
NF-kappaB	B-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O


Specificity	O
of	O
ANG	B-protein
II	I-protein
-induced	O
NF-kappaB	B-protein
activation	O
was	O
ascertained	O
by	O
supershift	O
and	O
competition	O
experiments	O
.	O


We	O
report	O
the	O
case	O
of	O
a	O
54-year-old	O
woman	O
with	O
multifocal	O
cancer	O
of	O
the	O
colon	O
,	O
who	O
developed	O
PHA	O
after	O
subtotal	O
colectomy	O
,	O
ileal	O
resection	O
and	O
jejunostomy	O
.	O


However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg/100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8-15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg/ml	O
,	O
N	O
:	O
10-60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	O
activity	O
(	O
>	O
37	O
ng/ml/h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	O
(	O
869	O
pg/ml	O
;	O
N	O
supine	O
:	O
1.120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg/ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol/l	O
;	O
N	O
:	O
0.5-2.5	O
)	O
.	O


The	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
was	O
reduced	O
.	O


Induction	O
of	O
HL-60	B-cell_line
and	O
U-937	B-cell_line
cell	O
differentiation	O
into	O
monocytes/macrophages	B-cell_type
by	O
IFN-gamma	B-protein
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E-BP1	B-protein
.	O


Most	O
mutations	O
were	O
outside	O
the	O
motifs	O
potentially	O
important	O
for	O
transcription	O
,	O
suggesting	O
they	O
were	O
not	O
important	O
in	O
lymphomagenesis	O
but	O
may	O
,	O
like	O
Ig	O
mutation	O
,	O
represent	O
an	O
inherent	O
feature	O
of	O
the	O
lymphoma	B-cell_type
precursor	I-cell_type
cells	I-cell_type
.	O


The	O
frequency	O
,	O
distribution	O
,	O
and	O
nature	O
of	O
these	O
mutations	O
were	O
similar	O
to	O
those	O
resulting	O
from	O
the	O
Ig	O
hypermutation	O
process	O
.	O


We	O
analyzed	O
the	O
ability	O
of	O
the	O
trans-dimer	O
encoded	O
by	O
HLA-DQA1*0501/DQB1*0302	B-protein
to	O
bind	O
a	O
peptide	O
antigen	O
which	O
interacts	O
with	O
DQ	B-protein
molecules	I-protein
encoded	O
by	O
both	O
parental	O
haplotypes	O
.	O


Detection	O
of	O
intracellular	B-protein
phosphorylated	I-protein
STAT-1	I-protein
by	O
flow	O
cytometry	O
.	O


Consequently	O
,	O
cytosolic	O
activation	O
,	O
nuclear	O
translocation	O
and	O
DNA-binding	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
were	O
decreased	O
.	O


Thus	O
,	O
this	O
therapeutic	O
potency	O
may	O
reside	O
in	O
retention	O
of	O
inactive	O
nuclear	B-protein
factor-kappaB	I-protein
in	O
the	O
cytosol	B-cell_type
thereby	O
abrogating	O
interleukin-1beta	B-protein
gene	O
transcription	O
.	O


1.	O
Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically-reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O


Bcl-6	B-protein
expression	O
in	O
reactive	O
follicular	O
hyperplasia	O
,	O
follicular	O
lymphoma	O
,	O
and	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
with	O
hyperplastic	O
germinal	O
centers	O
:	O
heterogeneity	O
of	O
intrafollicular	B-cell_type
T-cells	I-cell_type
and	O
their	O
altered	O
distribution	O
in	O
the	O
pathogenesis	O
of	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
.	O


An	O
occasional	O
GC	O
with	O
an	O
ill-defined	O
border	O
was	O
invariably	O
surrounded	O
by	O
a	O
broad	O
mantle	O
zone	O
;	O
those	O
with	O
indistinct	O
mantle	O
zones	O
had	O
well-defined	O
,	O
regular	O
borders	O
.	O


Intrafollicular	O
CD57+	B-cell_type
cells	I-cell_type
did	O
not	O
stain	O
for	O
Bcl-6	B-protein
,	O
and	O
were	O
also	O
depleted	O
in	O
AITL/GC	O
.	O


First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	O
a	O
number	O
of	O
immunoregulatory	B-cell_type
genes	I-cell_type
(	O
IL-1beta	B-protein
,	O
A20	B-protein
,	O
NF-kappaB-p105/p50	B-protein
,	O
and	O
IkappaBalpha	B-protein
)	O
in	O
unactivated	O
monocytes	B-cell_type
and	O
that	O
neutralizing	B-protein
Abs	I-protein
to	O
the	O
major	O
HCMV	B-protein
glycoproteins	I-protein
,	O
gB	B-protein
(	O
UL55	B-protein
)	O
and	O
gH	B-protein
(	O
UL75	B-protein
)	O
,	O
inhibited	O
the	O
induction	O
of	O
these	O
genes	O
.	O


Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	B-protein
kinase	O
activity	O
played	O
a	O
central	O
role	O
in	O
IL-1beta	B-protein
production	O
and	O
that	O
it	O
was	O
rapidly	O
up-regulated	O
following	O
infection	O
.	O


Previous	O
characterization	O
of	O
the	O
GPIX	B-DNA
promoter	I-DNA
identified	O
a	O
functional	O
Ets	O
site	O
that	O
,	O
when	O
disrupted	O
,	O
reduced	O
promoter	O
activity	O
.	O


However	O
,	O
the	O
Ets	B-protein
protein	I-protein
(	O
s	O
)	O
that	O
regulated	O
GPIX	B-DNA
promoter	I-DNA
expression	O
was	O
unknown	O
.	O


In	O
addition	O
,	O
Fli-1	B-protein
binding	O
of	O
the	O
GPIX	B-DNA
Ets	I-DNA
site	I-DNA
was	O
identified	O
in	O
antibody	O
supershift	O
experiments	O
in	O
nuclear	O
extracts	O
derived	O
from	O
hematopoietic	B-cell_type
human	I-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O


We	O
demonstrate	O
the	O
nuclear	O
localization	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
in	O
PBL	B-cell_type
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O


Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA-activated	B-cell_type
human	I-cell_type
PBL	I-cell_type
,	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
is	O
present	O
in	O
the	O
nucleus	O
in	O
an	O
apparently	O
inactive	O
form	O
unable	O
to	O
disrupt	O
NF-kappaB	B-protein
binding	O
from	O
DNA	O
.	O


We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus-mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O


Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B-protein
beta-chain	I-protein
.	O


The	O
FECa2+	O
was	O
measured	O
as	O
the	O
ionomycin-evoked	O
Ca2+	O
release	O
(	O
in	O
the	O
presence	O
of	O
thapsigargin	O
)	O
in	O
Ca2+-free	O
medium	O
.	O


SERCA	B-protein
activity	O
was	O
measured	O
as	O
the	O
thapsigargin	O
sensitive	O
,	O
Ca2+	O
dependent	O
and	O
ouabain	O
resistant	O
,	O
ATP	O
hydrolyses	O
in	O
platelet	O
membranes	O
.	O


Highly	O
significant	O
correlations	O
were	O
observed	O
for	O
FECa2+	O
in	O
the	O
dense	O
tubules	O
with	O
:	O
1	O
)	O
the	O
maximal	O
reaction	O
velocity	O
(	O
Vmax	O
)	O
of	O
the	O
SERCA	B-protein
(	O
r	O
=	O
0.592	O
,	O
P	O
=	O
.0014	O
)	O
,	O
and	O
2	O
)	O
Rapl	B-protein
(	O
r	O
=	O
0.551	O
,	O
P	O
=	O
.0035	O
)	O
.	O


No	O
correlations	O
were	O
observed	O
for	O
these	O
variables	O
with	O
blood	O
pressure	O
or	O
serum	B-protein
lipoproteins	I-protein
.	O


We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O


Inhibitors	O
of	O
MAP	B-protein
kinase	I-protein
(	O
PD98059	O
)	O
or	O
platelet-activating	O
factor	O
(	O
PAF	O
)	O
-	O
receptor	O
antagonist	O
(	O
CV3988	O
)	O
inhibited	O
the	O
CoCl2-induced	O
NF-kappaB	B-protein
activation	O
and	O
VCAM-1	B-protein
expression	O
.	O


LPS-induced	O
activation	O
of	O
NF-kappaB-responsive	B-DNA
reporter	I-DNA
gene	I-DNA
was	O
not	O
inhibited	O
by	O
IL-1	B-protein
receptor	O
antagonist	O
.	O


Signal	O
transduction	O
through	O
interferon-gamma	B-protein
receptor	I-protein
on	O
human	B-cell_type
eosinophils	I-cell_type
.	O


To	O
investigate	O
its	O
biological	O
role	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
E2A-HLF	B-protein
using	O
Ig	B-DNA
enhancer	I-DNA
and	I-DNA
promoter	I-DNA
,	O
which	O
direct	O
transgene	O
expression	O
in	O
cells	O
committed	O
to	O
the	O
lymphoid	O
lineage	O
.	O


Unexpectedly	O
,	O
we	O
observed	O
that	O
an	O
RXR	B-protein
-specific	O
,	O
rather	O
than	O
an	O
RAR	B-protein
-specific	O
,	O
agonist	O
induces	O
terminal	O
granulocytic	O
differentiation	O
of	O
MPRO	B-cell_type
promyelocytes	I-cell_type
,	O
and	O
this	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
DNA	B-DNA
response	I-DNA
elements	I-DNA
corresponding	O
to	O
RAR-RXR	B-protein
heterodimers	I-protein
rather	O
than	O
RXR-RXR	B-protein
homodimers	I-protein
.	O


In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
we	O
observed	O
that	O
this	O
RXR	B-protein
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	B-protein
-mediated	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte	B-cell_type
lineage	I-cell_type
or	O
in	O
transactivating	O
RAR-RXR	B-DNA
response	I-DNA
elements	I-DNA
.	O


A	O
specific	O
inhibitor	O
of	O
p38	O
MAP	O
kinase	O
completely	O
inhibits	O
the	O
serine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
induced	O
by	O
IL-12	B-protein
and	O
IL-2	B-protein
and	O
abrogates	O
the	O
functional	O
synergy	O
between	O
IL-12	B-protein
and	O
IL-2	B-protein
without	O
affecting	O
STAT	O
tyrosine	O
phosphorylation	O
.	O


Furthermore	O
,	O
the	O
two	O
VDR	B-DNA
3'-UTR	I-DNA
haplotypes	O
conferred	O
an	O
identical	O
half-life	O
on	O
a	O
heterologous	B-DNA
beta-globin	I-DNA
reporter	I-DNA
gene	I-DNA
,	O
in	O
an	O
in	O
vitro	O
assay	O
.	O


The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL-2	B-protein
does	O
not	O
induce	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
degradation	O
or	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
respond	O
to	O
IL-2	B-protein
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O


We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	B-protein
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	B-protein
-TRAF2	B-protein
interaction	O
.	O


One	O
of	O
the	O
prominent	O
substrates	O
for	O
these	O
kinases	B-protein
is	O
the	O
adaptor	B-protein
protein	I-protein
Cbl	O
[	O
3	O
]	O
and	O
recent	O
studies	O
suggest	O
that	O
Cbl	B-protein
negatively	O
regulates	O
upstream	B-protein
kinases	I-protein
such	O
as	O
Syk	B-protein
and	O
Zap-70	B-protein
[	O
4	O
]	O
[	O
5	O
]	O
.	O


Incidentally	O
,	O
Grf40	B-protein
binds	O
to	O
linker	B-protein
for	I-protein
activation	I-protein
of	I-protein
T	I-protein
cells	I-protein
(	O
LAT	B-protein
)	O
possibly	O
via	O
its	O
SH2	B-protein
domain	I-protein
.	O


Overexpression	O
of	O
wild-type	B-protein
Grf40	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
induced	O
a	O
significant	O
increase	O
of	O
SLP-76-dependent	B-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
promoter	I-DNA
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	O
NF-AT	B-protein
)	O
activation	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
stimulation	O
,	O
whereas	O
the	O
COOH-terminal	B-protein
SH3-deleted	I-protein
Grf40	I-protein
mutant	I-protein
lacked	O
any	O
recognizable	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O


Several	O
new	O
functions	O
of	O
Ras	B-protein
,	O
such	O
as	O
downregulation	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
molecules	I-protein
,	O
upregulation	O
of	O
certain	O
cytokines	B-protein
,	O
growth	B-protein
factors	I-protein
and	O
degradative	B-protein
enzymes	I-protein
have	O
been	O
uncovered	O
in	O
the	O
last	O
decade	O
.	O


Modulation	O
of	O
E2F	B-protein
complexes	I-protein
during	O
G0	O
to	O
S	O
phase	O
transition	O
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	I-cell_type
.	O


We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	B-protein
components	I-protein
,	O
DP1	B-protein
and	O
E2F4	B-protein
,	O
as	O
B-lymphocytes	B-cell_type
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O


NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O


In	O
addition	O
,	O
DNA-binding	O
activities	O
of	O
Jun-Fos	B-protein
heterodimers	I-protein
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O


Evidence	O
for	O
a	O
polyclonal	O
etiology	O
of	O
palmar	O
fibromatosis	O
.	O


The	O
tissue	O
from	O
both	O
patients	O
generated	O
a	O
polyclonal	O
pattern	O
of	O
X	B-DNA
chromosome	I-DNA
inactivation	O
of	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
.	O


This	O
finding	O
supports	O
a	O
polyclonal	O
reactive	O
process	O
as	O
the	O
underlying	O
etiology	O
for	O
palmar	O
fibromatosis	O
.	O


This	O
observation	O
was	O
further	O
confirmed	O
in	O
a	O
rat	O
air	O
pouch	O
model	O
in	O
vivo	O
,	O
in	O
which	O
both	O
aspirin	O
and	O
triflusal	O
inhibited	O
PGE2	O
production	O
(	O
ID50	O
=	O
18.9	O
and	O
11.4	O
mg/kg	O
p.o.	O
,	O
respectively	O
)	O
but	O
only	O
triflusal-treated	O
animals	O
showed	O
a	O
decrease	O
in	O
COX-2	B-protein
expression	O
.	O


Thus	O
,	O
in	O
addition	O
to	O
inhibiting	O
the	O
COX-2	O
activity	O
at	O
therapeutic	O
concentrations	O
,	O
triflusal	O
is	O
able	O
to	O
block	O
through	O
its	O
metabolite	O
HTB	O
the	O
expression	O
of	O
new	O
enzyme	O
,	O
and	O
hence	O
the	O
resumption	O
of	O
PGE2	O
synthesis	O
.	O


The	O
CD34+	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
KG1	B-cell_line
differentiates	O
into	O
dendritic-like	O
cells	O
in	O
response	O
to	O
granulocyte-macrophage	B-protein
CSF	I-protein
plus	O
TNF-alpha	B-protein
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF-alpha	B-protein
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O


Functional	O
DC	B-cell_type
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC-dextran	O
)	O
and	O
activation	O
of	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Comparison	O
of	O
KG1	B-cell_line
to	O
the	O
PMA-unresponsive	B-cell_line
subline	I-cell_line
KG1a	I-cell_line
reveals	O
differences	O
in	O
expression	O
of	O
TNF	B-protein
receptors	I-protein
1	I-protein
and	I-protein
2	I-protein
;	O
PKC	B-protein
isoforms	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
I	I-protein
,	I-protein
beta	I-protein
II	I-protein
,	I-protein
and	I-protein
mu	I-protein
;	O
and	O
RelB	B-protein
,	O
suggesting	O
that	O
these	O
components/pathways	O
are	O
important	O
for	O
DC	B-cell_type
differentiation	O
.	O


The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O


The	O
transcription	B-protein
factors	I-protein
PU.1	B-protein
and	O
C/EBPalpha	B-protein
are	O
responsible	O
for	O
normal	O
myeloid	O
differentiation	O
from	O
stem	B-cell_type
cells	I-cell_type
to	O
monocytes	B-cell_type
or	O
granulocytes	O
.	O


On	O
the	O
other	O
hand	O
,	O
the	O
PML/RARalpha	B-protein
fusion	I-protein
protein	I-protein
causes	O
transcriptional	O
repression	O
by	O
recruiting	O
the	O
nuclear	B-protein
corepressor	I-protein
(	I-protein
N-CoR	I-protein
)	I-protein
histone	I-protein
deacetylase	I-protein
complex	I-protein
to	O
the	O
DNA	O
,	O
which	O
results	O
in	O
decreased	O
histone	B-protein
acetylation	O
and	O
a	O
repressive	O
chromatin	B-DNA
organization	O
.	O


However	O
,	O
the	O
phenotypic	O
analysis	O
of	O
NF-AT	B-protein
-deficient	O
mice	O
supports	O
the	O
idea	O
that	O
there	O
are	O
tissue-	O
and	O
gene-	O
specific	O
functions	O
as	O
well	O
.	O


Despite	O
minimal	O
discrepancies	O
in	O
the	O
coding	B-DNA
region	I-DNA
,	O
there	O
are	O
striking	O
tissue-	O
and	O
cell	O
type-specific	O
differences	O
in	O
isoform	O
expression	O
patterns	O
.	O


These	O
results	O
demonstrate	O
another	O
level	O
of	O
regulation	O
within	O
the	O
NF-AT	B-protein
family	I-protein
that	O
can	O
contribute	O
to	O
cell	O
type-specific	O
gene	O
expression	O
.	O


The	O
CTL	B-cell_line
clones	I-cell_line
that	O
recognized	O
viral	O
and	O
self	O
peptides	O
were	O
more	O
oligoclonal	O
,	O
whereas	O
clones	O
that	O
strictly	O
recognized	O
the	O
viral	O
peptide	O
displayed	O
a	O
diverse	O
TCR	B-protein
profile	O
.	O


RFLAT-1	B-protein
is	O
a	O
novel	O
,	O
phosphorylated	O
,	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
that	O
is	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
3	O
days	O
after	O
activation	O
,	O
coincident	O
with	O
RANTES	B-protein
expression	O
.	O


Here	O
,	O
we	O
report	O
that	O
expression	O
of	O
FasL	B-protein
protein	I-protein
and	O
mRNA	B-RNA
in	O
activated	B-cell_type
NK	I-cell_type
cells	I-cell_type
is	O
also	O
regulated	O
by	O
redox	O
.	O


These	O
data	O
suggest	O
that	O
CD16	B-protein
stimulation	O
requires	O
cellular	O
reducing	O
status	O
for	O
FasL	B-protein
induction	O
in	O
NK	B-cell_type
cells	I-cell_type
.	O


Purified	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stimulated	O
with	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
either	O
human	B-protein
CD80	I-protein
(	O
CHO-CD80	B-protein
)	O
or	O
human	B-protein
CD86	I-protein
(	O
CHO-CD86	B-protein
)	O
or	O
with	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
.	O


In	O
the	O
presence	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
both	O
CHO-CD80	B-protein
and	O
CHO-CD86	B-protein
,	O
like	O
anti-CD28	B-protein
mAb	I-protein
,	O
were	O
capable	O
of	O
stimulating	O
cytokine	B-protein
production	O
from	O
both	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


In	O
addition	O
,	O
the	O
association	O
of	O
phosphoinositide	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
and	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	O
Cgamma	O
were	O
seen	O
after	O
anti-CD28	O
mAb	O
and	O
CHO-CD80	O
stimulation	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
after	O
CHO-CD86	B-protein
stimulation	O
.	O


Thus	O
,	O
ligation	O
of	O
CD28	B-protein
with	O
either	O
CD80	B-protein
or	O
CD86	B-protein
leads	O
to	O
shared	O
early	O
signal	O
transduction	O
events	O
such	O
as	O
the	O
tyrosine	O
phosphorylation	O
of	O
CBL	B-protein
and	O
VAV	B-protein
,	O
to	O
NFAT	B-protein
-mediated	O
transcriptional	O
activation	O
,	O
and	O
to	O
the	O
costimulation	O
of	O
interleukin-2	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
production	O
.	O


We	O
previously	O
showed	O
that	O
repression	O
of	O
the	O
beta-globin	O
gene	O
appears	O
to	O
be	O
mediated	O
through	O
two	O
DNA	B-DNA
sequences	I-DNA
,	O
silencers	B-DNA
I	I-DNA
and	I-DNA
II	I-DNA
,	O
and	O
identified	O
a	O
protein	O
termed	O
BP1	B-protein
which	O
binds	O
to	O
both	O
silencer	O
sequences	O
.	O


These	O
cDNAs	B-DNA
correspond	O
to	O
HMG-I	B-protein
and	O
HMG-Y	B-protein
,	O
isoforms	O
regarded	O
as	O
architectural	B-protein
proteins	I-protein
.	O


HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
also	O
binds	O
to	O
a	O
second	O
oligonucleotide	O
containing	O
a	O
BP1	B-DNA
binding	I-DNA
site	I-DNA
located	O
in	O
a	O
negative	B-DNA
control	I-DNA
region	I-DNA
upstream	O
of	O
the	O
delta-globin	B-DNA
gene	I-DNA
,	O
suggesting	O
a	O
role	O
for	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
in	O
repression	O
of	O
adult	O
globin	O
genes	O
.	O


We	O
present	O
a	O
model	O
in	O
which	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
alters	O
DNA	O
conformation	O
to	O
allow	O
binding	O
of	O
repressor	B-protein
proteins	I-protein
,	O
and	O
in	O
which	O
the	O
relative	O
amount	O
of	O
HMG-I	O
(	O
Y	O
)	O
helps	O
to	O
determine	O
the	O
repressive	O
state	O
of	O
the	O
beta-globin	B-DNA
gene	I-DNA
.	O


We	O
hypothesized	O
that	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
signaling	O
pathway	O
may	O
inhibit	O
NF-kappaB	B-protein
-mediated	O
transcription	O
by	O
phosphorylating	O
proteins	O
,	O
such	O
as	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
which	O
compete	O
for	O
limiting	O
amounts	O
of	O
the	O
coactivator	O
CBP	B-protein
.	O


Glucocorticoid	B-protein
receptors	I-protein
in	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
healthy	O
neonates	O
and	O
of	O
preterms	O
suffering	O
from	O
respiratory	O
distress	O
syndrome	O
.	O


Seven	O
preterms	O
developed	O
neonatal	O
respiratory	O
distress	O
syndrome	O
(	O
NRDS	O
)	O
.	O


Sensitivity	O
(	O
ID50	O
)	O
of	O
the	O
lymphocytes	B-cell_type
for	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
the	O
same	O
in	O
all	O
groups	O
.	O


In	O
this	O
study	O
on	O
the	O
number	O
and	O
function	O
of	O
GR	B-protein
in	O
lymphocytes	B-cell_type
,	O
we	O
were	O
unable	O
to	O
find	O
a	O
relation	O
between	O
the	O
functionality	O
of	O
the	O
GR	B-protein
and	O
the	O
development	O
of	O
NRDS	O
.	O


Such	O
NF-ATp	B-protein
-/-	O
mice	O
are	O
born	O
and	O
appear	O
to	O
develop	O
a	O
normal	O
immune	O
system	O
.	O


Apart	O
from	O
clear-cut	O
defects	O
in	O
the	O
synthesis	O
of	O
mRNAs	B-RNA
for	O
Th2-type	B-protein
lymphokines	I-protein
,	O
such	O
as	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-10	B-protein
and	O
IL-13	B-protein
,	O
in	O
primary	O
and	O
secondary	O
stimulations	O
of	O
spleen	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
of	O
a	O
distinct	O
impaired	O
deletion	O
of	O
V	B-cell_line
beta	I-cell_line
11+/CD4+	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
from	O
these	O
mice	O
was	O
detected	O
after	O
superantigen	O
injection	O
.	O


Daidzein	O
and	O
genistein	O
glucuronides	O
in	O
vitro	O
are	O
weakly	O
estrogenic	O
and	O
activate	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
at	O
nutritionally	O
relevant	O
concentrations	O
.	O


DG	O
and	O
GG	O
were	O
further	O
purified	O
by	O
a	O
Sephadex	O
LH-20	O
column	O
.	O


Cross-linking	O
of	O
CD44	B-protein
on	O
rheumatoid	B-cell_type
synovial	I-cell_type
cells	I-cell_type
up-regulates	O
VCAM-1	B-protein
.	O


CD44	O
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O


However	O
,	O
the	O
cellular	O
functions	O
and	O
its	O
role	O
in	O
inflammation	O
,	O
for	O
example	O
,	O
rheumatoid	O
synovitis	O
,	O
are	O
currently	O
unknown	O
.	O


In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O


We	O
therefore	O
propose	O
that	O
such	O
cross-talking	O
among	O
distinct	O
adhesion	O
molecules	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
,	O
including	O
RA	O
synovitis	O
.	O


NF-kappaB	B-protein
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O


Although	O
overexpressed	O
Egr-1	B-protein
was	O
ineffective	O
,	O
overexpressed	O
Egr-2	B-protein
was	O
as	O
potent	O
as	O
Egr-3	B-protein
in	O
inducing	O
fasL	B-DNA
promoter-dependent	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up-regulated	O
endogenous	O
fasL	B-RNA
mRNA	I-RNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O


In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
regulation	O
of	O
NF-Y	B-protein
expression	O
during	O
human	O
monocyte	O
to	O
macrophage	O
maturation	O
.	O


The	O
protein	O
tyrosine	O
kinase	O
ZAP-70	B-protein
plays	O
an	O
important	O
role	O
in	O
T-cell	O
activation	O
and	O
development	O
.	O


Previously	O
,	O
we	O
demonstrated	O
that	O
Y292	O
negatively	O
regulates	O
ZAP-70	B-protein
function	O
and	O
that	O
Y315	O
positively	O
regulates	O
ZAP-70	B-protein
function	O
by	O
interacting	O
with	O
Vav	B-protein
.	O


Recent	O
studies	O
have	O
suggested	O
that	O
Y319	O
also	O
positively	O
regulate	O
ZAP-70	B-protein
function	O
.	O


Here	O
we	O
show	O
that	O
Delta	B-protein
still	O
utilizes	O
the	O
same	O
pathways	O
as	O
wild-type	O
ZAP-70	B-protein
to	O
mediate	O
NF-AT	B-protein
induction	O
.	O


Lysates	O
from	O
CD19	B-protein
cross-linked	O
1E8	B-cell_line
cells	I-cell_line
induced	O
robust	O
phosphorylation	O
of	O
an	O
Elk-1	B-protein
fusion	I-protein
protein	I-protein
in	O
vitro	O
,	O
whereas	O
no	O
phosphorylation	O
of	O
Elk-1	B-protein
fusion	I-protein
protein	I-protein
occurred	O
using	O
lysates	O
from	O
CD19	B-cell_line
cross-linked	I-cell_line
BLIN-1	I-cell_line
cells	I-cell_line
.	O


Identification	O
of	O
target	B-DNA
genes	I-DNA
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct2	I-protein
.	O


Whereas	O
CD36	B-protein
and	O
mEI	B-protein
were	O
expressed	O
in	O
all	O
hematopoetic	B-cell_line
cell	I-cell_line
lines	I-cell_line
containing	O
Oct2	B-protein
,	O
.	O


We	O
have	O
purified	O
the	O
RFX	B-protein
complex	I-protein
and	O
sequenced	O
its	O
three	O
subunits	O
.	O


The	O
sequence	O
of	O
the	O
smallest	O
subunit	O
describes	O
a	O
novel	O
gene	O
,	O
termed	O
RFX-B	B-DNA
.	O


A	O
characteristic	O
of	O
HTLV-I-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	O
factors	O
,	O
which	O
appears	O
to	O
be	O
essential	O
for	O
the	O
growth	O
of	O
these	O
transformed	B-cell_type
cells	I-cell_type
.	O


Using	O
sequential	B-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
human	B-DNA
fas	I-DNA
promoter	I-DNA
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47-bp	B-DNA
sequence	I-DNA
(	O
positions	B-DNA
-306	I-DNA
to	I-DNA
-260	I-DNA
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation-driven	O
fas	O
upregulation	O
.	O


Sp1	B-protein
and	O
NF-kappaB	B-protein
transcription	O
factor	O
binding	O
was	O
shown	O
to	O
be	O
mutually	O
exclusive	O
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	B-protein
and	O
recombinant	O
p50	B-protein
.	O


The	O
functional	O
contribution	O
of	O
the	O
kappaB-Sp1	B-DNA
composite	I-DNA
site	I-DNA
in	O
P/I-inducible	B-DNA
fas	I-DNA
promoter	I-DNA
activation	O
was	O
verified	O
by	O
using	O
kappaB-	O
Sp1	B-protein
concatamers	O
(	O
-295	B-DNA
to	I-DNA
-286	I-DNA
)	O
in	O
a	O
thymidine	B-DNA
kinase	I-DNA
promoter-driven	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
native	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
overexpressing	O
IkappaB-alpha	B-protein
.	O


Fusion	O
of	O
anergic	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
human	B-cell_type
Jurkat	I-cell_type
T	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
formation	O
of	O
heterokaryons	B-cell_line
failed	O
to	O
result	O
in	O
a	O
complementation	O
of	O
this	O
signaling	O
defect	O
and	O
restoration	O
of	O
murine	B-RNA
IL-2	I-RNA
mRNA	I-RNA
inducibility	O
.	O


We	O
demonstrate	O
that	O
amounts	O
of	O
transcriptionally	O
active	O
phosphorylated	B-protein
CREB	I-protein
protein	I-protein
(	O
P-CREB	B-protein
)	O
differ	O
between	O
activated	O
PBMC	B-cell_type
and	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
determined	O
that	O
the	O
pattern	O
of	O
band	O
migration	O
differed	O
between	O
the	O
two	O
cell	O
types	O
.	O


Inhibition	O
of	O
NO	B-protein
synthase	I-protein
(	O
NOS	B-protein
)	O
during	O
the	O
second	O
A/R	O
challenge	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O


Oxidized	O
low-density	B-protein
lipoproteins	I-protein
(	O
oxLDLs	B-protein
)	O
are	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
lesions	O
,	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
oxLDLs	B-protein
inhibit	O
not	O
only	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2-receptor	I-protein
expression	O
on	O
the	O
surface	O
of	O
in	O
vitro-activated	O
T-lymphocytes	O
but	O
also	O
their	O
proliferation	O
.	O


We	O
have	O
now	O
investigated	O
the	O
effect	O
of	O
oxLDLs	B-protein
on	O
blast	O
differentiation	O
,	O
on	O
IL-2	B-protein
synthesis	O
and	O
on	O
the	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
system	O
in	O
activated	O
lymphocytes	O
.	O


The	O
B29	B-DNA
(	I-DNA
immunoglobulin	I-DNA
beta-chain	I-DNA
)	I-DNA
gene	I-DNA
is	O
a	O
genetic	O
target	O
for	O
early	B-protein
B-cell	I-protein
factor	I-protein
.	O


The	O
lack	O
of	O
B29	B-RNA
transcripts	I-RNA
,	O
coding	O
for	O
the	O
beta	B-protein
subunit	I-protein
of	O
the	O
B-cell	O
receptor	O
complex	O
,	O
in	O
pro-B	B-cell_type
cells	I-cell_type
from	O
EBF	B-protein
-deficient	O
mice	O
suggested	O
that	O
B29	O
might	O
be	O
a	O
genetic	O
target	O
for	O
EBF	B-protein
.	O


DOR1	B-protein
ligation	O
by	O
a	O
specific	O
DOR1	B-protein
agonist	O
,	O
deltorphin	O
,	O
augmented	O
IL-2	B-protein
secretion	O
by	O
synergizing	O
with	O
signals	O
from	O
TCR-CD3	B-protein
and	O
CD28	B-protein
.	O


Although	O
DOR1	B-protein
signaling	O
increased	O
[	O
Ca2+	O
]	O
i	O
,	O
deltorphin	O
enhanced	O
transcriptional	O
activity	O
of	O
the	O
NF-AT/AP-1-binding	B-DNA
site	I-DNA
via	O
a	O
mechanism	O
independent	O
of	O
calcineurin	B-protein
and	O
distinct	O
from	O
the	O
effects	O
of	O
elevated	O
[	O
Ca2+	O
]	O
i	O
.	O


In	O
the	O
present	O
study	O
,	O
we	O
have	O
characterized	O
the	O
transcriptional	O
induction	O
of	O
p40	B-protein
by	O
CD40	B-protein
ligation	O
in	O
a	O
human	B-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Daudi	B-cell_line
,	O
and	O
a	O
human	B-cell_line
acute	I-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
.	O


These	O
results	O
suggest	O
that	O
the	O
NF-kappaB	B-DNA
binding	I-DNA
site	I-DNA
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
in	O
murine	B-DNA
and	I-DNA
human	I-DNA
p40	I-DNA
promoter	I-DNA
regions	I-DNA
could	O
be	O
important	O
for	O
the	O
p40	B-protein
induction	O
by	O
CD40	B-protein
ligation	O
via	O
activation	O
of	O
NF-kappaB	B-protein
.	O


No	O
mutation	O
was	O
identified	O
in	O
either	O
of	O
the	O
genes	O
in	O
the	O
gynecomastias	O
.	O


Reactive	O
oxygen	O
intermediate-dependent	O
NF-kappaB	B-protein
activation	O
by	O
interleukin-1beta	B-protein
requires	O
5-lipoxygenase	B-protein
or	O
NADPH	O
oxidase	O
activity	O
.	O


Stimulation	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
with	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
led	O
to	O
ROI	O
production	O
and	O
NF-kappaB	B-protein
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	B-protein
inhibitors	O
,	O
confirming	O
that	O
5-LOX	B-protein
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF-kappaB	B-protein
activation	O
in	O
these	O
cells	O
.	O


However	O
,	O
reintroduction	O
of	O
a	O
functional	O
5-LOX	B-protein
system	O
in	O
these	O
cells	O
allowed	O
ROI	O
production	O
and	O
5-LOX	B-protein
-dependent	O
NF-kappaB	B-protein
activation	O
.	O


In	O
conclusion	O
,	O
three	O
different	O
cell-specific	O
pathways	O
lead	O
to	O
NF-kappaB	B-protein
activation	O
by	O
IL-1beta	B-protein
:	O
a	O
pathway	O
dependent	O
on	O
ROI	O
production	O
by	O
5-LOX	B-protein
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
an	O
ROI-	O
and	O
5-LOX	B-protein
-independent	O
pathway	O
in	O
epithelial	B-cell_type
cells	I-cell_type
,	O
and	O
a	O
pathway	O
requiring	O
ROI	O
production	O
by	O
NADPH	B-protein
oxidase	I-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


Two	O
variants	O
of	O
the	O
IL-4R	B-DNA
alpha-chain	I-DNA
(	I-DNA
IL-4Ralpha	I-DNA
)	I-DNA
gene	I-DNA
have	O
been	O
recently	O
identified	O
in	O
association	O
with	O
different	O
atopic	O
disorders	O
.	O


In	O
agar	O
cultures	O
,	O
47.10	B-cell_line
cells	I-cell_line
form	O
7-	O
and	O
14-day	O
colonies	O
in	O
response	O
to	O
a	O
cocktail	O
of	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
2.5	O
ng/mL	O
)	O
,	O
interleukin-3	B-protein
(	O
1	O
ng/mL	O
)	O
,	O
and	O
mouse	O
CSF-1	B-protein
(	O
10	O
ng/mL	O
)	O
.	O


In	O
conclusion	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
continuous	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
line	I-cell_line
presenting	O
a	O
hierarchical	O
structure	O
similar	O
to	O
that	O
of	O
the	O
bone	B-cell_line
marrow	I-cell_line
progenitor	I-cell_line
cell	I-cell_line
compartment	I-cell_line
.	O


Previous	O
studies	O
found	O
that	O
P1	B-DNA
,	O
an	O
element	O
of	O
the	O
interleukin	B-DNA
4	I-DNA
(	I-DNA
IL-4	I-DNA
)	I-DNA
promoter	I-DNA
that	O
binds	O
AP-1	O
,	O
is	O
important	O
for	O
Th2-restricted	O
IL-4	B-protein
expression	O
.	O


However	O
,	O
we	O
show	O
that	O
JunB	B-protein
binds	O
directly	O
to	O
the	O
P1	B-DNA
site	I-DNA
and	O
synergizes	O
with	O
c-Maf	B-protein
to	O
activate	O
an	O
IL-4	B-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O


Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
.	O


Tax	B-protein
stimulated	O
transcription	O
through	O
NF-kappaB	B-protein
and	O
the	O
cyclic	B-DNA
AMP-responsive	I-DNA
element-like	I-DNA
sequence	I-DNA
in	O
the	O
HTLV-1	O
promoter	O
.	O


The	O
finding	O
of	O
Tax	B-protein
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF-kappaB	B-protein
pathway	O
was	O
essential	O
for	O
IL-2	B-protein
-independent	O
growth	O
of	O
CTLL-2	B-cell_type
cells	I-cell_type
while	O
the	O
CRE	B-DNA
pathway	O
was	O
unnecessary	O
.	O


Regulation	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
gene	I-DNA
by	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
isoforms	I-protein
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O


In	O
humans	O
,	O
alternative	O
splicing	O
of	O
the	O
GR	B-RNA
precursor	I-RNA
mRNA	I-RNA
gives	O
rise	O
to	O
two	O
receptor	O
isoforms	O
,	O
termed	O
GRalpha	B-protein
and	O
GRbeta	B-protein
.	O


We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	B-DNA
gene	I-DNA
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
essential	O
for	O
Ig	B-DNA
gene	I-DNA
transcription	O
.	O


By	O
isolating	O
Daudi	B-cell_line
x	I-cell_line
HeLa	I-cell_line
heterokaryons	I-cell_line
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
involved	O
in	O
Ig	B-DNA
gene	I-DNA
transcription	O
,	O
Oct-2	B-DNA
and	O
NF-kappa	B-protein
B	I-protein
.	O


Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFAT1	B-protein
at	O
its	O
proximal	B-DNA
binding	I-DNA
element	I-DNA
P0	B-DNA
in	O
the	O
IL-4	B-DNA
promoter	I-DNA
associated	O
with	O
enhanced	O
IL-4	B-DNA
gene	I-DNA
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
atopic	O
patients	O
.	O


IL-4	B-DNA
gene	I-DNA
regulation	O
in	O
general	O
involves	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
of	O
which	O
NFAT1	B-protein
and	O
NFAT2	B-protein
are	O
most	O
prominent	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


At	O
the	O
most	O
proximal	O
P0	B-DNA
site	O
,	O
NFAT-containing	O
complexes	O
devoid	O
of	O
NFAT2	B-protein
were	O
readily	O
inducible	O
in	O
the	O
Th1	B-cell_line
clones	I-cell_line
,	O
but	O
hardly	O
or	O
not	O
in	O
the	O
Th2	B-cell_line
clones	I-cell_line
.	O


In	O
contrast	O
,	O
both	O
in	O
Th1	B-cell_line
and	I-cell_line
Th2	I-cell_line
clones	I-cell_line
NFAT-containing	O
complexes	O
were	O
strongly	O
inducible	O
at	O
the	O
P1	B-DNA
site	I-DNA
,	O
consisting	O
of	O
NFAT2	B-protein
and	O
a	O
P0	B-DNA
-compatible	O
NFAT	B-protein
activity	O
,	O
without	O
apparent	O
differences	O
between	O
Th1	B-cell_line
and	I-cell_line
Th2	I-cell_line
clones	I-cell_line
.	O


Glucocorticoid	O
resistance	O
in	O
the	O
squirrel	O
monkey	O
is	O
associated	O
with	O
overexpression	O
of	O
the	O
immunophilin	B-protein
FKBP51	I-protein
.	O


The	O
immunophilin	B-protein
FKBP51	I-protein
was	O
13-fold	O
higher	O
in	O
SML	B-cell_type
than	O
in	O
HL	O
cytosol	O
;	O
FKBP52	B-protein
in	O
SML	B-cell_type
was	O
42	O
%	O
of	O
that	O
in	O
HL	O
cytosol	O
.	O


We	O
have	O
previously	O
demonstrated	O
that	O
interaction	O
of	O
infected	O
thymocytes	B-cell_type
with	O
autologous	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
(	O
TEC	B-cell_type
)	O
is	O
a	O
prerequisite	O
for	O
a	O
high	O
level	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
thymocytes	B-cell_type
(	O
M.Rothe	O
,	O
L.Chene	O
,	O
M.Nugeyre	O
,	O
F.Barre-Sinoussi	O
,	O
and	O
N.Israel	O
,	O
J.Virol.72	O
:	O
5852-5861	O
,	O
1998	O
)	O
.	O


The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	B-protein
p50-p65	I-protein
.	O


In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk-1	B-protein
expression	O
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	O
of	O
elk-1	B-DNA
expression	O
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O


Immunohistochemical	O
study	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
infiltrated	O
into	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
during	O
radiation	O
therapy	O
and	O
its	O
clinical	O
significance	O
.	O


In	O
this	O
study	O
,	O
we	O
have	O
attempted	O
to	O
determine	O
whether	O
c-fos	B-DNA
expression	O
is	O
induced	O
by	O
radiotherapy	O
in	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
and	O
to	O
establish	O
a	O
possible	O
correlation	O
between	O
c-fos	B-DNA
expression	O
and	O
the	O
therapeutic	O
effects	O
of	O
radiation	O
therapy	O
.	O


In	O
patients	O
whose	O
infiltration	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
into	O
tumor	O
tissues	O
were	O
moderate	O
or	O
remarkable	O
at	O
4	O
Gy	O
of	O
radiotherapy	O
,	O
the	O
tumors	O
responded	O
significantly	O
well	O
to	O
radiation	O
therapy	O
(	O
P	O
<	O
0.025	O
,	O
chi2	O
test	O
)	O
,	O
and	O
the	O
patients	O
took	O
a	O
significantly	O
favorable	O
clinical	O
course	O
(	O
P	O
<	O
0.05	O
,	O
chi2	O
test	O
)	O
.	O


We	O
examined	O
the	O
allele-specific	O
expression	O
of	O
WT1	B-protein
in	O
cultured	O
human	B-cell_type
fibroblasts	I-cell_type
from	O
15	O
individuals	O
.	O


The	O
allele-specific	O
expression	O
profiles	O
of	O
other	O
imprinted	B-DNA
genes	I-DNA
,	O
IGF2	B-DNA
and	O
H19	B-DNA
,	O
on	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O


Many	O
patients	O
with	O
primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
make	O
high	O
titer	O
IgG	B-protein
autoantibodies	I-protein
to	O
the	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
antigen	O
,	O
suggesting	O
antigen	O
specific	O
T	O
cell-B	O
cell	O
interactions	O
.	O


RESULTS	O
.	O


Anti-	O
HLA-DR	B-protein
abrogated	O
proliferation	O
to	O
SSB	B-protein
and	O
tetanus	O
toxoid	O
.	O


Down-regulation	O
of	O
NF-kappaB	B-protein
activation	O
is	O
known	O
to	O
inhibit	O
HIV	O
replication	O
from	O
the	O
latently	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O


Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF-kappaB	B-protein
-DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O


After	O
corticosteroid	O
suppression	O
of	O
her	O
blood	O
eosinophilia	O
,	O
a	O
clonal	O
population	O
of	O
eosinophils	B-cell_type
could	O
no	O
longer	O
be	O
detected	O
in	O
purified	B-cell_type
eosinophils	I-cell_type
.	O


The	O
finding	O
of	O
clonal	O
eosinophilia	O
in	O
a	O
patient	O
presenting	O
with	O
IHES	O
indicates	O
that	O
such	O
patients	O
may	O
have	O
,	O
in	O
reality	O
,	O
a	O
low-grade	O
clonal	O
disorder	O
that	O
can	O
be	O
distinguished	O
from	O
reactive	O
eosinophilias	O
by	O
HUMARA	B-DNA
analysis	O
.	O


Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	B-cell_type
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O


Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O


Inhibition	O
of	O
adenylyl	B-protein
cyclase	I-protein
by	O
pretreatment	O
with	O
2'-deoxy-3'-adenosine	B-protein
monophosphate	I-protein
partially	O
reversed	O
the	O
inhibition	O
of	O
TF	O
activity	O
promoted	O
by	O
lysoPC	O
.	O


LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O


T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	B-protein
factors	I-protein
important	O
for	O
cytokine	B-DNA
gene	I-DNA
regulation	O
.	O


Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation-induced	O
apoptosis	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
dependent	O
on	O
FasL	O
transcription	O
and	O
expression	O
.	O


In	O
contrast	O
,	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
is	O
not	O
required	O
for	O
activation-induced	O
FasL	B-protein
promoter	O
activity	O
.	O


Promoter	B-DNA
sequence	I-DNA
,	O
exon	O
:	O
intron	O
structure	O
,	O
and	O
synteny	O
of	O
genetic	O
location	O
show	O
that	O
a	O
chicken	B-protein
cytokine	I-protein
with	O
T-cell	O
proliferative	O
activity	O
is	O
IL2	B-protein
and	O
not	O
IL15	B-protein
.	O


The	O
results	O
show	O
that	O
this	O
cytokine	B-protein
is	O
chicken	O
IL2	B-protein
and	O
not	O
IL15	B-protein
.	O


A	O
number	O
of	O
potential	B-DNA
regulatory	I-DNA
sequences	I-DNA
similar	O
to	O
those	O
found	O
in	O
mammals	O
have	O
been	O
identified	O
in	O
the	O
promoter	B-DNA
.	O


Interestingly	O
,	O
Nmi	B-protein
lacks	O
an	O
intrinsic	O
transcriptional	B-protein
activation	I-protein
domain	I-protein
;	O
instead	O
,	O
Nmi	B-protein
enhances	O
the	O
association	O
of	O
CBP/p300	B-protein
coactivator	I-protein
proteins	I-protein
with	O
Stat1	B-protein
and	O
Stat5	B-protein
,	O
and	O
together	O
with	O
CBP/p300	B-protein
can	O
augment	O
IL-2-	O
and	O
IFNgamma-dependent	O
transcription	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	O
difference	O
in	O
the	O
pattern	O
of	O
TNF	B-protein
-stimulated	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
between	O
HUVECs	B-cell_type
and	O
HUAECs	B-cell_type
.	O


To	O
assess	O
the	O
phosphorylation	O
of	O
serine	O
residues	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
in	O
CLL	B-cell_line
cells	I-cell_line
,	O
we	O
raised	O
antibodies	O
that	O
specifically	O
recognize	O
the	O
form	O
of	O
STAT1	B-protein
phosphorylated	O
on	O
ser-727	O
and	O
the	O
form	O
of	O
STAT3	B-protein
phosphorylated	O
on	O
ser-727	O
.	O


The	O
STAT	O
serine	O
kinase	O
in	O
CLL	O
cells	O
has	O
not	O
been	O
identified	O
,	O
and	O
appears	O
to	O
be	O
neither	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
nor	O
pp70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
.	O


Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O


Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O


In	O
the	O
present	O
study	O
,	O
the	O
clonal	O
relationship	O
was	O
investigated	O
between	O
peripheral	B-cell_type
blood	I-cell_type
polymorphonuclear	I-cell_type
cells	I-cell_type
(	O
PMNCs	B-cell_type
)	O
and	O
marrow	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
the	O
origin	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
in	O
patients	O
with	O
refractory	O
anemia	O
with	O
ring	B-cell_type
sideroblasts	I-cell_type
(	O
RARS	B-cell_type
)	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
of	O
HUMARA	B-DNA
gene	I-DNA
.	O


All	O
erythroid	B-cell_line
colonies	I-cell_line
consisted	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
exclusively	O
showed	O
one	O
pattern	O
dominant	O
in	O
those	O
of	O
PMNCs	B-cell_type
.	O


Our	O
findings	O
suggest	O
that	O
non-clonal	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
persist	O
in	O
some	O
RARS	B-cell_type
cases	O
,	O
that	O
erythroid	B-cell_type
progenitors	I-cell_type
show	O
mosaicism	O
,	O
and	O
that	O
ringed	B-cell_type
sideroblasts	I-cell_type
may	O
be	O
derived	O
from	O
an	O
abnormal	O
clone	O
involved	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O


BACKGROUND	O
AND	O
METHODS	O
:	O
Because	O
the	O
use	O
of	O
immunohistochemistry	O
in	O
the	O
diagnosis	O
of	O
granulosa	O
cell	O
tumor	O
(	O
GCT	O
)	O
has	O
not	O
been	O
fully	O
explored	O
,	O
routinely	O
processed	O
(	O
formalin-fixed	O
,	O
paraffin-embedded	O
)	O
tissue	O
from	O
11	O
GCT	O
,	O
adult	O
type	O
,	O
was	O
investigated	O
immunohistochemically	O
(	O
ABC	O
method	O
)	O
with	O
a	O
broad	O
spectrum	O
of	O
antibodies	O
against	O
various	O
markers	O
,	O
including	O
p53	B-protein
and	O
Ki-67	B-protein
.	O


RESULTS	O
:	O
All	O
the	O
tumors	O
exhibited	O
strong	O
expression	O
of	O
vimentin	B-protein
,	O
but	O
most	O
other	O
antigens	O
(	O
including	O
smooth	B-protein
muscle	I-protein
actin	I-protein
)	O
were	O
expressed	O
infrequently	O
by	O
a	O
minority	O
of	O
tumor	B-cell_type
cells	I-cell_type
or	O
not	O
at	O
all	O
.	O


Tumor	O
cells	O
in	O
9	O
GCT	O
expressed	O
inhibin	O
A	O
.	O


The	O
data	O
presented	O
below	O
indicate	O
that	O
Notch-1	B-protein
expression	O
provides	O
significant	O
protection	O
to	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
TCR	B-protein
-mediated	O
apoptosis	O
.	O


Monocytes	B-cell_type
were	O
effective	O
APC	B-cell_type
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O


Although	O
this	O
reversal	O
by	O
IL-2	B-protein
was	O
pronounced	O
,	O
it	O
was	O
not	O
complete	O
,	O
suggesting	O
that	O
IL-10	B-protein
may	O
have	O
some	O
effects	O
not	O
directly	O
related	O
to	O
the	O
suppression	O
of	O
IL-2	B-protein
production	O
.	O


These	O
include	O
Fc	B-protein
epsilonRII	I-protein
(	O
CD23	B-protein
)	O
,	O
15-lipoxygenase	B-protein
,	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
(	O
IL-1ra	B-protein
)	O
,	O
and	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IL-1	I-protein
receptors	I-protein
(	O
IL-1R	B-protein
)	O
.	O


Inhibition	O
of	O
IL-1RI	B-protein
and	O
IL-1RII	O
mRNA	O
levels	O
by	O
IFN-gamma	B-protein
was	O
transcriptionally	O
mediated	O
,	O
and	O
correlated	O
directly	O
with	O
decreased	O
production	O
of	O
soluble	O
IL-1RII	B-protein
.	O


Inhibition	O
of	O
IL-1R	B-DNA
gene	I-DNA
expression	O
by	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
was	O
not	O
due	O
to	O
down-regulation	O
of	O
surface	B-protein
IL-4R	I-protein
because	O
pretreatment	O
with	O
these	O
cytokines	O
did	O
not	O
decrease	O
the	O
number	O
of	O
IL-4	B-protein
binding	O
sites	O
per	O
cell	O
.	O


Cytokine	B-protein
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	B-protein
.	O


In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	B-protein
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	B-protein
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX-induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	B-cell_type
and	I-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O


We	O
identified	O
a	O
cell-type-specific	O
differential	O
response	O
:	O
CREB	B-DNA
,	I-DNA
CTF	I-DNA
,	I-DNA
OTF-1	I-DNA
,	I-DNA
OFT-2	I-DNA
,	I-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
genes	I-DNA
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	B-cell_type
no	O
significant	O
changes	O
were	O
detected	O
.	O


In	O
a	O
3	O
day	O
intervention	O
study	O
in	O
which	O
600	O
mg	O
of	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
alpha-lipoic	O
acid	O
)	O
per	O
day	O
were	O
given	O
to	O
nine	O
patients	O
with	O
diabetic	O
nephropathy	O
oxidative	O
stress	O
in	O
plasma	O
samples	O
was	O
decreased	O
by	O
48	O
%	O
and	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
38	O
%	O
.	O


When	O
cultured	O
on	O
bone	O
,	O
VR+	B-cell_line
,	I-cell_line
TRAP+	I-cell_line
cells	I-cell_line
of	O
low	O
multinuclearity	O
appear	O
and	O
cover	O
up	O
to	O
50	O
%	O
of	O
the	O
surface	O
.	O


Because	O
oleic	O
acid	O
is	O
implicated	O
in	O
the	O
antiatherogenic	O
effects	O
attributed	O
to	O
the	O
Mediterranean	O
diet	O
,	O
we	O
investigated	O
whether	O
this	O
fatty	O
acid	O
can	O
modulate	O
endothelial	O
activation	O
,	O
ie	O
,	O
the	O
concerted	O
expression	O
of	O
gene	B-protein
products	I-protein
involved	O
in	O
leukocyte	O
recruitment	O
and	O
early	O
atherogenesis	O
.	O


At	O
10	O
to	O
100	O
micromol/L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	O
the	O
expression	O
of	O
all	O
adhesion	B-protein
molecules	I-protein
tested	O
.	O


Although	O
less	O
potent	O
than	O
polyunsaturated	O
fatty	O
acids	O
in	O
inhibiting	O
endothelial	O
activation	O
,	O
oleic	O
acid	O
may	O
contribute	O
to	O
the	O
prevention	O
of	O
atherogenesis	O
through	O
selective	O
displacement	O
of	O
saturated	O
fatty	O
acids	O
in	O
cell	O
membrane	O
phospholipids	O
and	O
a	O
consequent	O
modulation	O
of	O
gene	O
expression	O
for	O
molecules	O
involved	O
in	O
monocyte	O
recruitment	O
.	O


Involvement	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
in	O
interleukin-8	B-protein
production	O
by	O
human	B-cell_type
monocytes	I-cell_type
and	O
polymorphonuclear	B-cell_type
cells	I-cell_type
stimulated	O
with	O
lipopolysaccharide	O
or	O
Mycoplasma	B-protein
fermentans	I-protein
membrane	I-protein
lipoproteins	I-protein
.	O


IL-8	B-protein
is	O
secreted	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
notably	O
bacterial	O
products	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
by	O
which	O
these	O
agents	O
mediate	O
IL-8	B-protein
induction	O
.	O


These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	B-protein
and	O
its	O
circulating	O
des-Arg	B-protein
form	I-protein
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O


These	O
observations	O
can	O
be	O
linked	O
with	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
when	O
uninfected	O
monocytes	O
are	O
induced	O
by	O
either	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O


In	O
the	O
absence	O
of	O
tetracyclines	O
,	O
the	O
transfected	O
T	B-cell_type
cells	I-cell_type
were	O
shown	O
to	O
express	O
the	O
chimeric	B-protein
receptor	I-protein
on	O
the	O
cell	O
surface	O
and	O
could	O
be	O
activated	O
by	O
its	O
cognate	B-protein
Ag	I-protein
,	O
leading	O
to	O
the	O
secretion	O
of	O
IL-2	B-protein
.	O


Prolonged	O
suppression	O
of	O
trans-gene	O
expression	O
for	O
up	O
to	O
7	O
days	O
was	O
observed	O
after	O
doxycycline	O
was	O
removed	O
from	O
the	O
cultures	O
,	O
but	O
eventual	O
recovery	O
of	O
surface	O
expression	O
was	O
complete	O
,	O
and	O
the	O
absolute	O
time	O
to	O
recovery	O
was	O
directly	O
proportional	O
to	O
the	O
initial	O
concentration	O
of	O
the	O
drug	O
.	O


We	O
suggested	O
that	O
negative	O
feedback	O
of	O
cortisol	O
could	O
be	O
deranged	O
.	O


The	O
role	O
of	O
the	O
GR	B-protein
and	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
in	O
the	O
CRH	O
regulation	O
in	O
the	O
FMS	O
patients	O
remains	O
to	O
be	O
solved	O
.	O


Temporal	O
control	O
of	O
IgH	B-DNA
gene	I-DNA
expression	O
in	O
developing	B-cell_type
B	I-cell_type
cells	I-cell_type
by	O
the	O
3	B-DNA
'	I-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O


HLA	O
binding	O
characteristics	O
and	O
generation	O
of	O
cytotoxic	B-cell_type
lymphocytes	I-cell_type
against	O
peptides	O
derived	O
from	O
oncogenic	B-protein
proteins	I-protein
.	O


RESULTS	O
:	O
We	O
identified	O
peptides	O
derived	O
from	O
EWS/FLI-1	B-protein
fusion	I-protein
protein	I-protein
and	O
from	O
mutated	B-protein
K-RAS	I-protein
protein	I-protein
(	O
encompassing	O
respectively	O
the	O
fusion	B-protein
point	I-protein
and	O
the	O
mutation	O
at	O
position	B-protein
12	I-protein
)	O
that	O
showed	O
binding	B-protein
motif	I-protein
for	O
HLA-Cw*0702	B-protein
and	O
HLA-A3	B-protein
respectively	O
.	O


OCA-B	B-protein
is	O
a	O
B-cell-specific	B-protein
coregulator	I-protein
of	O
the	O
broadly	O
expressed	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
Oct-1	B-protein
.	O


However	O
,	O
nuclear	O
targets	O
for	O
PI3K	B-protein
are	O
not	O
known	O
.	O


A	O
yeast	O
two-hybrid	O
screen	O
identified	O
TES2	B-protein
interacting	I-protein
proteins	I-protein
,	O
including	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
death	I-protein
domain	I-protein
protein	I-protein
(	O
TRADD	B-protein
)	O
.	O


In	O
transfection	O
assays	O
,	O
TRADD	B-protein
and	O
TES2	B-protein
synergistically	O
mediated	O
high-level	O
NF-kappaB	B-protein
activation	O
.	O


Furthermore	O
,	O
this	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
accumulation	O
did	O
not	O
require	O
synthesis	O
of	O
new	O
protein	B-protein
factors	I-protein
because	O
9-cis	O
RA	O
induced	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
accumulation	O
in	O
the	O
absence	O
of	O
new	O
protein	O
synthesis	O
.	O


This	O
study	O
tested	O
the	O
hypothesis	O
that	O
anti-LPS	B-protein
Abs	I-protein
neutralize	O
endotoxin	O
by	O
blocking	O
cellular	O
uptake	O
through	O
mCD14	B-protein
.	O


LPS-specific	B-protein
Abs	I-protein
thus	O
mediate	O
anti-inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	B-protein
and	O
augmenting	O
uptake	O
through	O
CR1	B-protein
or	O
other	O
cell	B-protein
receptors	I-protein
.	O


Four	O
P-like	B-DNA
elements	I-DNA
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	B-DNA
IL-4	I-DNA
gene	I-DNA
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
and	O
activator	B-protein
protein-1	I-protein
family	I-protein
proteins	I-protein
.	O


Cross-competition	O
assays	O
among	O
the	O
P-like	B-DNA
elements	I-DNA
revealed	O
element-specific	B-protein
and	I-protein
common	I-protein
complexes	I-protein
.	O


We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal/neonatal	O
T-cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
elements	I-protein
required	O
for	O
T-cell	O
activation	O
.	O


N-Acetylcysteine	O
,	O
alpha	O
,	O
alpha'-dipyridyl	O
,	O
aminotriazole	O
or	O
nitrofurantoin	O
did	O
not	O
show	O
any	O
effect	O
.	O


The	O
inhibition	O
by	O
PDTC	O
was	O
reversible	O
unless	O
glutathione	O
synthesis	O
was	O
blocked	O
by	O
buthionine	O
sulfoximine	O
.	O


A	O
better	O
understanding	O
of	O
transcriptional	O
regulation	O
at	O
this	O
important	O
stage	O
of	O
T-cell	O
maturation	O
may	O
yield	O
new	O
insights	O
into	O
T-cell	O
development	O
and	O
new	O
immunotherapeutic	O
targets	O
.	O


All	O
fusions	O
splice	O
the	O
5	B-DNA
'	I-DNA
ends	I-DNA
of	O
the	O
3q21	B-DNA
genes	I-DNA
into	O
exon	B-DNA
2	I-DNA
of	O
the	O
EVI1	B-DNA
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1-EVI1	B-DNA
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
and	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
12	I-DNA
)	I-DNA
,	O
in	O
which	O
acute	O
myelogenous	B-DNA
leukemia	I-DNA
1-EVI1	I-DNA
fusions	I-DNA
and	O
ETV6-EVI1	B-DNA
fusions	I-DNA
,	O
respectively	O
,	O
occur	O
.	O


Both	O
have	O
been	O
shown	O
to	O
be	O
transcription	B-protein
factors	I-protein
.	O


It	O
was	O
recently	O
shown	O
by	O
us	O
that	O
the	O
protein	O
is	O
located	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
their	O
neoplastic	B-cell_type
counterparts	I-cell_type
.	O


Squamous	O
cell	O
carcinomas	O
showed	O
a	O
variety	O
of	O
expression	O
levels	O
,	O
while	O
two	O
undifferentiated	O
spindle-shaped	O
carcinomas	O
and	O
one	O
undifferentiated	O
SCC	B-cell_line
cell	I-cell_line
line	I-cell_line
remained	O
unstained	O
.	O


These	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
bcl-6	B-protein
protein	I-protein
may	O
be	O
associated	O
with	O
morphological	O
differentiation	O
in	O
normal	O
and	O
neoplastic	B-cell_type
epidermal	I-cell_type
cells	I-cell_type
.	O


The	O
leukocyte	B-DNA
integrin	I-DNA
genes	I-DNA
CD11c	B-DNA
and	O
CD11b	B-DNA
are	O
expressed	O
predominately	O
in	O
myelomonocytic	O
cells	O
.	O


Cotransfection	O
of	O
Sp3	B-protein
along	O
with	O
CD11c	B-DNA
promoter-luciferase	I-DNA
constructs	I-DNA
into	O
Sp-deficient	B-cell_line
Drosophila	I-cell_line
Schneider	I-cell_line
2	I-cell_line
cells	I-cell_line
showed	O
that	O
Sp3	B-protein
could	O
activate	O
the	O
CD11c	B-DNA
promoter	I-DNA
.	O


We	O
have	O
now	O
studied	O
Trident	B-protein
expression	O
in	O
cell	B-cell_line
lines	I-cell_line
,	O
differentiating	B-cell_type
thymocytes	I-cell_type
and	O
in	O
lymphocytes	O
derived	O
from	O
peripheral	O
blood	O
.	O


In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
ER	B-protein
alpha	I-protein
(	O
referred	O
to	O
throughout	O
as	O
ER	B-protein
)	O
on	O
DNA-binding	O
activities	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
regulating	O
the	O
expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
,	O
and	O
,	O
in	O
particular	O
,	O
the	O
histone	B-DNA
H5	I-DNA
gene	I-DNA
.	O


Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	B-protein
ER	I-protein
reduced	O
the	O
binding	O
activities	O
of	O
chicken	B-protein
immature	I-protein
erythrocyte	I-protein
nuclear	I-protein
extracted	I-protein
proteins	I-protein
to	O
GATA	B-DNA
and	I-DNA
CACCC	I-DNA
sites	I-DNA
in	O
the	O
H5	B-DNA
promoter	I-DNA
and	I-DNA
enhancer	I-DNA
.	O


Both	O
GATA-1	B-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
.	O


Cdk2-dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1-to-S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	B-protein
and	O
modulates	O
its	O
target	O
bHLH	B-protein
specificity	O
.	O


Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	B-protein
cDNA	I-protein
encoding	I-protein
transcription	I-protein
factor	I-protein
NFATc	B-protein
.	O


Transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
(	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	I-protein
family	I-protein
play	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
encoding	O
cytokines	B-protein
and	O
immunoregulatory	B-protein
proteins	I-protein
.	O


These	O
downstream	B-DNA
sequence	I-DNA
elements	I-DNA
,	O
termed	O
DSE	B-DNA
,	O
can	O
bind	O
both	O
AP-1	B-protein
and	O
CREB/ATF	B-protein
transcription	B-protein
factors	I-protein
.	O


Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	B-DNA
are	O
also	O
cAMP-responsive	B-DNA
elements	I-DNA
(	O
CRE	B-DNA
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	B-protein
toxin	I-protein
(	O
Ctx	B-protein
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP-dependent	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
signal	O
transduction	O
pathway	O
.	O


Because	O
the	O
DSE	B-DNA
are	O
also	O
TRE	B-DNA
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP-1	B-protein
-dependent	O
transcription	O
.	O


Copyright	O
1997	O
Academic	O
Press	O
.	O


Association	O
of	O
glucocorticoid	O
insensitivity	O
with	O
increased	O
expression	O
of	O
glucocorticoid	B-protein
receptor	I-protein
beta	I-protein
.	O


In	O
many	O
chronic	O
inflammatory	O
disorders	O
,	O
glucocorticoid	O
(	O
GC	O
)	O
insensitivity	O
is	O
a	O
challenging	O
clinical	O
problem	O
associated	O
with	O
life-threatening	O
disease	O
progression	O
.	O


A	O
survey	O
of	O
promoters	O
has	O
revealed	O
that	O
the	O
wild-type	B-protein
,	I-protein
unfused	I-protein
EBNA3C	I-protein
can	O
specifically	O
repress	O
expression	O
from	O
reporter	B-DNA
plasmids	I-DNA
containing	O
the	O
Epstein-Barr	O
virus	O
Cp	B-DNA
latency-associated	I-DNA
promoter	I-DNA
.	O


Since	O
repression	O
by	O
these	O
fusions	O
was	O
not	O
observed	O
in	O
all	O
cell	O
types	O
,	O
it	O
seems	O
likely	O
that	O
EBNA3C	B-protein
either	O
depends	O
on	O
a	O
corepressor	B-protein
which	O
may	O
interact	O
with	O
amino	B-protein
acids	I-protein
346	I-protein
to	I-protein
543	I-protein
or	O
is	O
modified	O
in	O
a	O
cell-specific	O
manner	O
in	O
order	O
to	O
repress	O
.	O


Finally	O
,	O
although	O
it	O
has	O
been	O
reported	O
that	O
EBNA3C	B-protein
can	O
upregulate	O
CD21	B-protein
in	O
some	O
B	B-cell_type
cells	I-cell_type
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
effect	O
of	O
EBNA3C	B-protein
on	O
reporter	B-DNA
plasmids	I-DNA
which	O
contain	O
the	O
CD21	B-DNA
promoter	I-DNA
.	O


The	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	I-protein
were	O
measured	O
using	O
a	O
whole-cell	O
binding	O
assay	O
.	O


CONCLUSIONS	O
:	O
The	O
increased	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	I-protein
are	O
closely	O
associated	O
with	O
the	O
effectiveness	O
of	O
glucocorticoid	O
therapy	O
.	O


Ig	B-protein
heavy	I-protein
chain	I-protein
class	O
switching	O
is	O
directed	O
by	O
cytokines	B-protein
inducing	O
transcription	O
from	O
unrearranged	O
CH	B-DNA
genes	I-DNA
.	O


In	O
the	O
case	O
of	O
IgE	B-protein
class	O
switching	O
,	O
IL-4	B-protein
activates	O
the	O
IgE	B-DNA
germline	I-DNA
promoter	I-DNA
by	O
inducing	O
the	O
interaction	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
(	O
IL-4STAT	B-protein
)	O
with	O
a	O
responsive	B-DNA
DNA	I-DNA
element	I-DNA
in	O
the	O
proximal	B-DNA
region	I-DNA
of	O
the	O
promoter	B-DNA
.	O


When	O
monocytes	B-cell_type
are	O
stimulated	O
with	O
LPS	O
(	O
lipopolysaccharide	O
)	O
repeatedly	O
then	O
the	O
initially	O
high	O
expression	O
of	O
the	O
TNF	B-DNA
(	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
)	I-DNA
gene	I-DNA
is	O
only	O
very	O
low	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
to	O
LPS	O
.	O


Tolerant	O
cells	O
still	O
express	O
the	O
CD14	B-protein
receptor	I-protein
and	O
they	O
can	O
still	O
be	O
activated	O
to	O
mobilize	O
NF-kappa	B-protein
B	I-protein
into	O
nucleus	O
.	O


Conversely	O
,	O
the	O
murine	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancer	I-DNA
motif	I-DNA
(	O
GGGGACTTTCCG	O
)	O
does	O
not	O
efficiently	O
bind	O
the	O
nuclear	O
p50p50	B-protein
from	O
tolerant	B-cell_line
murine	I-cell_line
P388	I-cell_line
macrophages	I-cell_line
.	O


Using	O
a	O
sensitive	O
,	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assay	O
,	O
G0S2	B-DNA
mRNA	O
levels	O
were	O
assayed	O
in	O
cultured	B-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
.	O


Repression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
through	O
the	O
novel	O
cooperation	O
of	O
human	B-protein
factors	I-protein
YY1	B-protein
and	O
LSF	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Virol	O
1998	O
Feb	O
;	O
72	O
(	O
2	O
)	O
:	O
1709	O
]	O


We	O
report	O
that	O
both	O
YY1	B-protein
and	O
LSF	B-protein
participate	O
in	O
the	O
formation	O
of	O
a	O
complex	O
that	O
recognizes	O
the	O
initiation	O
region	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O


Here	O
we	O
report	O
a	O
real-time	O
study	O
of	O
factor/DNA	O
interactions	O
using	O
a	O
surface	O
plasmon	O
resonance	O
approach	O
and	O
further	O
characterization	O
of	O
recovered	B-protein
proteins	I-protein
involved	O
in	O
this	O
interaction	O
.	O


In	O
particular	O
,	O
the	O
part	O
played	O
by	O
the	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
,	O
which	O
are	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
nuclear	I-protein
receptor	I-protein
family	I-protein
,	O
has	O
not	O
been	O
explored	O
.	O


The	O
combination	O
of	O
RA	O
and	O
DHCC	O
together	O
inhibited	O
growth	O
of	O
both	O
sense	O
and	O
antisense	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


In	O
addition	O
,	O
alpha	B-protein
G2S	I-protein
exhibited	O
increased	O
expression	O
of	O
CD11b	B-protein
and	O
CD54	B-protein
,	O
while	O
alpha	B-cell_line
B5A	I-cell_line
cells	I-cell_line
showed	O
increased	O
expression	O
of	O
CD102	B-protein
,	O
suggesting	O
that	O
RXR-alpha	B-protein
has	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
in	O
U937	B-cell_line
cells	I-cell_line
.	O


The	O
HIV-1	B-protein
accessory	I-protein
gene	I-protein
product	I-protein
Vpr	B-protein
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O


In	O
the	O
absence	O
of	O
TCR	B-protein
-mediated	O
activation	O
,	O
Vpr	B-protein
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	B-protein
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O


The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
(	O
pRB	B-protein
)	O
plays	O
an	O
important	O
role	O
in	O
controlling	O
both	O
cell	O
release	O
from	O
the	O
G1	O
phase	O
and	O
apoptosis	O
.	O


The	O
shift	O
in	O
pRB	B-protein
molecular	O
weight	O
was	O
reproduced	O
by	O
adding	O
exogenous	O
purified	O
tTG	O
to	O
extracts	O
obtained	O
from	O
viable	O
U937	B-cell_line
cells	I-cell_line
and	O
was	O
prevented	O
by	O
dansylcadaverine	O
,	O
a	O
potent	O
enzyme	O
inhibitor	O
.	O


The	O
effect	O
of	O
the	O
pRB	B-protein
posttranslational	O
modification	O
during	O
apoptosis	O
was	O
investigated	O
by	O
determining	O
the	O
E2F-1	B-protein
levels	O
and	O
by	O
isolating	O
and	O
characterizing	O
pRB-null	B-cell_line
clones	I-cell_line
from	O
U937	B-cell_line
cells	I-cell_line
.	O


Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
tTG	B-protein
,	O
acting	O
on	O
the	O
pRB	B-protein
protein	I-protein
,	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
cell	O
progression	O
through	O
the	O
death	O
program	O
.	O


Interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
induces	O
tyrosine	O
phosphorylation	O
of	O
STATs	B-protein
3	I-protein
and	I-protein
5	I-protein
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
.	O


NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
members	I-protein
regulating	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
in	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O


The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	B-DNA
through	O
XPG	B-DNA
.	O


Of	O
these	O
,	O
the	O
XPB	B-DNA
and	I-DNA
XPD	I-DNA
genes	I-DNA
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	B-protein
transcription	I-protein
factor	I-protein
,	O
TFIIH	B-protein
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O


Binding	O
capacity	O
(	O
4978+/-391	O
versus	O
4131+/-321	O
sites/cell	O
)	O
,	O
Kd	O
values	O
for	O
dexamethasone	O
(	O
6.7+/-0.5	O
versus	O
5.7+/-0.3	O
nmol/L	O
)	O
,	O
and	O
IC50	O
values	O
for	O
dexamethasone	O
(	O
3.4+/-0.3	O
versus	O
3.1+/-0.2	O
nmol/L	O
)	O
and	O
cortisol	O
(	O
12.2+/-1.6	O
versus	O
9.5+/-0.3	O
nmol/L	O
)	O
were	O
not	O
significantly	O
different	O
.	O


Patients	O
with	O
renin	B-protein
values	O
less	O
than	O
0.13	O
ng	O
angiotensin	O
I/L	O
per	O
second	O
were	O
markedly	O
less	O
sensitive	O
to	O
cortisol	O
than	O
those	O
with	O
higher	O
values	O
.	O


Both	O
Kd	O
(	O
30.3+/-2.5	O
versus	O
19.2+/-2.4	O
nmol/L	O
)	O
and	O
IC50	O
values	O
(	O
15.5+/-1.8	O
versus	O
8.9+/-1.2	O
nmol/L	O
)	O
for	O
cortisol	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
lower	O
renin	B-protein
values	O
(	O
P	O
<	O
.03	O
)	O
.	O


PU.1/Pip	B-protein
and	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
zipper	I-protein
transcription	I-protein
factors	I-protein
interact	O
with	O
binding	B-DNA
sites	I-DNA
in	O
the	O
CD20	B-DNA
promoter	I-DNA
to	O
help	O
confer	O
lineage-	O
and	O
stage-specific	O
expression	O
of	O
CD20	B-protein
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O


These	O
findings	O
indicate	O
that	O
cortisol	O
and	O
its	O
receptors	O
are	O
critically	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
function	O
in	O
HIV	O
infection	O
.	O


In	O
conclusion	O
,	O
we	O
propose	O
that	O
Bcl-xL	B-protein
expression	O
is	O
associated	O
with	O
differentiation	O
and	O
survival	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
along	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O


Evidence	O
that	O
calcineurin	O
is	O
rate-limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O


Cyclosporine	O
(	O
CsA	O
)	O
is	O
both	O
a	O
clinical	O
immunosuppressive	O
drug	O
and	O
a	O
probe	O
to	O
dissect	O
intracellular	O
signaling	O
pathways	O
.	O


We	O
have	O
selected	O
16	B-DNA
sequences	I-DNA
and	O
confirmed	O
their	O
down-regulation	O
along	O
the	O
TPA-induced	O
monocytic	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O


A	O
single-chain	B-protein
Fv	I-protein
(	O
sFv	B-protein
)	O
was	O
expressed	O
from	O
the	O
variable	B-protein
regions	I-protein
of	O
the	O
CD40-specific	O
mAb	B-protein
G28-5	I-protein
.	O


Surprisingly	O
,	O
G28-5	B-protein
sFv	I-protein
was	O
a	O
potent	O
CD40	B-protein
agonist	I-protein
that	O
rapidly	O
crosslinked	O
CD40	B-protein
on	O
the	O
cell	O
surface	O
but	O
did	O
not	O
crosslink	O
CD40-Ig	B-protein
in	O
solution	O
.	O


G28-5	B-protein
IgG	I-protein
partially	O
blocked	O
,	O
whereas	O
G28-5	B-protein
sFv	I-protein
augmented	O
CD40	B-protein
responses	O
during	O
stimulation	O
with	O
natural	B-protein
ligand	I-protein
(	O
gp39-CD8	B-protein
fusion	I-protein
protein	I-protein
)	O
.	O


The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
identify	O
whether	O
transcription	O
factors	O
,	O
associated	O
with	O
cytokine	O
signalling	O
,	O
affected	O
promoter	O
activity	O
of	O
the	O
corticotropin	B-DNA
releasing	I-DNA
hormone	I-DNA
(	I-DNA
CRH	I-DNA
)	I-DNA
gene	I-DNA
.	O


Increased	O
CRH	B-protein
promoter	O
activity	O
following	O
phorbol	O
ester	O
treatment	O
was	O
inhibited	O
by	O
a	O
dominant	O
negative	O
NF-IL6	B-protein
mutant	I-protein
,	O
showing	O
that	O
the	O
effects	O
of	O
phorbol	O
ester	O
were	O
principally	O
mediated	O
by	O
C/EBP	B-protein
.	O


While	O
we	O
can	O
not	O
exclude	O
that	O
alterations	O
in	O
TSG101	B-DNA
and	O
FHIT	B-DNA
occur	O
during	O
cancer	O
development	O
,	O
our	O
data	O
indicate	O
that	O
in	O
this	O
context	O
the	O
commonly	O
observed	O
transcript	O
abnormalities	O
are	O
misleading	O
.	O


Inhibition	O
of	O
proliferation	O
and	O
apoptosis	O
of	O
human	B-cell_type
and	I-cell_type
rat	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
curcumin	O
,	O
a	O
curry	O
pigment	O
.	O


Complete	O
suppression	O
of	O
AP-1	B-protein
activity	O
was	O
observed	O
in	O
Con	B-cell_line
A-treated	I-cell_line
,	I-cell_line
proliferating	I-cell_line
thymocytes	I-cell_line
.	O


Production	O
of	O
IL-2	B-protein
requires	O
the	O
formation	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
IL-2-gene	B-DNA
regulation	O
.	O


The	O
spatial	O
distribution	O
of	O
human	B-DNA
immunoglobulin	I-DNA
genes	I-DNA
within	O
the	O
nucleus	O
:	O
evidence	O
for	O
gene	O
topography	O
independent	O
of	O
cell	O
type	O
and	O
transcriptional	O
activity	O
.	O


The	O
three-dimensional	O
positioning	O
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	I-DNA
within	O
the	O
nucleus	O
of	O
human	B-cell_type
cells	I-cell_type
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O


Although	O
subtle	O
gene	O
movements	O
within	O
those	O
defined	O
topographical	O
regions	O
can	O
not	O
be	O
excluded	O
by	O
this	O
study	O
,	O
the	O
results	O
indicate	O
that	O
tissue	O
specificity	O
of	O
gene	O
expression	O
is	O
not	O
accompanied	O
by	O
drastic	O
changes	O
in	O
gene	O
nuclear	O
topography	O
,	O
rather	O
suggesting	O
that	O
gene	O
organization	O
within	O
the	O
nucleus	O
may	O
be	O
primarily	O
dependent	O
on	O
structural	O
constraints	O
imposed	O
on	O
the	O
respective	O
chromosomes	B-DNA
.	O


Dominant	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
response	O
to	O
the	O
immediate-early	B-protein
trans-activator	I-protein
protein	I-protein
,	O
BZLF1	B-protein
,	O
in	O
persistent	O
type	O
A	O
or	O
B	O
Epstein-Barr	O
virus	O
infection	O
.	O


Using	O
limiting-dilution	O
analysis	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
a	O
high	O
RAKFKQLLQ-specific	O
CTL	O
precursor	O
frequency	O
was	O
demonstrated	O
after	O
specific	O
peptide	O
or	O
autologous	O
lymphoblastoid	O
cell	O
line	O
stimulation	O
in	O
both	O
type	O
A	O
and	O
type	O
B	O
EBV	O
carriers	O
.	O


These	O
findings	O
show	O
that	O
healthy	O
virus	O
carriers	O
maintain	O
a	O
high	O
frequency	O
of	O
BZLF1-specific	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
potentially	O
to	O
control	O
virus	O
spread	O
from	O
lytically	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O


We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A-MYB	B-protein
and	O
its	O
regulation	O
in	O
several	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
using	O
co-transfection	O
assays	O
and	O
show	O
that	O
A-MYB	B-protein
is	O
transcriptionally	O
active	O
in	O
all	O
the	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
,	O
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


In	O
particular	O
the	O
best	O
responder	B-cell_line
cell	I-cell_line
line	I-cell_line
was	O
the	O
Burkitt	B-cell_line
's	I-cell_line
cell	I-cell_line
line	I-cell_line
Namalwa	I-cell_line
.	O


To	O
identify	O
such	O
target	B-DNA
genes	I-DNA
,	O
we	O
established	O
Egr-1-overexpressing	B-cell_line
transfectants	I-cell_line
from	O
the	O
murine	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
K46	I-cell_line
and	O
from	O
human	B-cell_line
Ramos	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O


Thus	O
,	O
Egr-1	B-protein
seems	O
to	O
control	O
the	O
expression	O
of	O
downstream	B-DNA
target	I-DNA
genes	I-DNA
not	O
only	O
as	O
a	O
transcriptional	O
activator	O
,	O
but	O
also	O
as	O
a	O
repressor	B-protein
molecule	I-protein
.	O


Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
turnover	O
of	O
pre-	O
and	O
post-inductive	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


Repertoire	O
selection	O
was	O
monitored	O
by	O
determining	O
the	O
TCR	B-protein
beta	I-protein
chain	I-protein
sequences	I-protein
of	O
RAKFKQLLQ-specific	B-cell_line
CTL	I-cell_line
established	O
from	O
primary	O
infected	O
and	O
healthy	O
virus	O
carriers	O
.	O


Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
containing	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
or	O
activator	B-protein
protein-1	I-protein
cognate	B-DNA
DNA	I-DNA
sequences	I-DNA
significantly	O
attenuated	O
phase-2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O


Surface	O
expression	O
of	O
ICAM-1	B-protein
,	O
P-selectin	B-protein
,	O
and	O
E-selectin	B-protein
on	O
HUVECs	B-cell_line
correlated	O
with	O
the	O
phase-1	O
and	O
-2	O
neutrophil	O
adhesion	O
responses	O
.	O


Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R	O
elicits	O
a	O
two-phase	O
neutrophil-endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
.	O


To	O
define	O
the	O
CD40	B-protein
signaling	O
components	O
upstream	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
the	O
functional	O
consequences	O
downstream	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
examined	O
mouse	B-cell_line
B	I-cell_line
cell	I-cell_line
transfectants	I-cell_line
expressing	O
wild-type	B-protein
or	I-protein
mutant	I-protein
human	I-protein
CD40	I-protein
.	O


NF-kappa	B-protein
B	I-protein
activation	O
correlated	O
with	O
the	O
ability	O
of	O
CD40	B-protein
to	O
induce	O
Ab	O
secretion	O
and	O
the	O
up-regulation	O
of	O
ICAM-1	B-protein
and	O
LFA-1	B-protein
.	O


CD30	B-protein
is	O
a	O
cell-surface	B-protein
receptor	I-protein
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O


CD30	B-protein
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	B-cell_type
.	O


During	O
CD30	B-protein
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	B-protein
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
CD30	B-protein
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	B-protein
and	O
the	O
associated	O
protein	O
TRAF1	B-protein
by	O
proteolysis	O
.	O


Different	O
cocktails	O
of	O
the	O
identified	O
ligands	O
were	O
added	O
to	O
sorted	B-cell_line
CD34+Thy-1+	I-cell_line
single	I-cell_line
cells	I-cell_line
.	O


Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	B-cell_type
to	O
production	O
of	O
cytokines	B-protein
.	O


Further	O
,	O
M.	O
tuberculosis	O
and	O
its	O
tuberculin	B-protein
,	O
purified	B-protein
protein	I-protein
derivative	I-protein
,	O
induced	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
the	O
expression	O
of	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
monocytes	B-cell_type
.	O


Although	O
devoid	O
of	O
any	O
effect	O
by	O
itself	O
,	O
a	O
mutant	B-protein
p53	I-protein
cooperated	O
with	O
Spi-1	B-protein
and	O
EpoR	B-protein
(	I-protein
R129C	I-protein
)	I-protein
to	O
reinforce	O
both	O
phenotypes	O
.	O


As	O
shown	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	B-RNA
mRNA	I-RNA
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	B-DNA
promotor	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


IL-2	B-protein
and	O
IL-7	B-protein
induce	O
heterodimerization	O
of	O
STAT5	B-protein
isoforms	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O


Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	B-protein
with	O
each	O
STAT5	B-protein
isomer	I-protein
.	O


Suppression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
by	O
human	B-DNA
class	I-DNA
II	I-DNA
trans-activator	I-DNA
constructs	I-DNA
lacking	O
the	O
N-terminal	B-protein
domain	I-protein
.	O


While	O
these	O
compounds	O
affect	O
various	O
cellular	O
processes	O
,	O
current	O
data	O
do	O
not	O
fully	O
explain	O
how	O
sesquiterpene	O
lactones	O
exert	O
their	O
anti-inflammatory	O
effect	O
.	O


This	O
difference	O
in	O
efficacy	O
,	O
which	O
correlates	O
with	O
the	O
compounds	O
'	O
anti-inflammatory	O
potency	O
in	O
vivo	O
,	O
may	O
be	O
explained	O
by	O
differences	O
in	O
structure	O
and	O
conformation	O
.	O


The	O
tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c-sis/platelet-derived	B-DNA
growth	I-DNA
factor-B	I-DNA
promoter	I-DNA
through	O
interactions	O
with	O
the	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
Sp1	B-protein
and	O
NGFI-A/Egr-1	B-protein
.	O


In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c-sis/PDGF-B	B-DNA
promoter	I-DNA
,	O
Tax-responsive	B-DNA
element	I-DNA
1	I-DNA
(	O
TRE1	B-DNA
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	B-protein
.	O


RelB	B-protein
protein	O
and	O
mRNA	B-RNA
were	O
detected	O
constitutively	O
in	O
lymphocytes	B-cell_type
and	O
in	O
activated	B-cell_type
monocytes	I-cell_type
,	O
differentiated	B-cell_type
DC	I-cell_type
,	O
and	O
monocyte-derived	B-cell_line
DC	I-cell_line
.	O


A	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	O
for	O
CAML	B-protein
.	O


Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O


In	O
most	O
cells	O
,	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O


Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF/CREB	B-protein
factors	I-protein
functionally	O
modulate	O
histone	B-DNA
H4	I-DNA
gene	I-DNA
transcription	O
at	O
distal	B-DNA
and	I-DNA
proximal	I-DNA
promoter	I-DNA
elements	I-DNA
.	O


Dimers	O
encoded	O
by	O
HLA-DR	B-protein
haplotypes	O
may	O
be	O
the	O
primary	B-DNA
restriction	I-DNA
elements	I-DNA
for	O
lectin-like	O
,	O
gliadin	O
peptides	O
while	O
the	O
degree	O
of	O
immune	O
suppression	O
(	O
or	O
lack	O
thereof	O
)	O
to	O
ingested	O
gliadins	O
is	O
governed	O
by	O
inherited	O
HLA-DQ	B-DNA
haplotypes	O
.	O


The	O
Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein-1	I-protein
(	O
LMP-1	B-protein
)	O
is	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
which	O
transforms	O
fibroblasts	B-cell_type
and	O
is	O
essential	O
for	O
EBV-mediated	O
B-cell	O
immortalization	O
.	O


Here	O
we	O
show	O
that	O
LMP-1	B-protein
induces	O
the	O
activity	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
,	O
a	O
dimer	O
of	O
Jun/Jun	B-protein
or	I-protein
Jun/Fos	I-protein
proteins	I-protein
.	O


Consequently	O
,	O
LMP-1	B-protein
triggers	O
the	O
activity	O
of	O
the	O
c-Jun	B-protein
N-terminal	I-protein
transactivation	I-protein
domain	I-protein
which	O
is	O
known	O
to	O
be	O
activated	O
upon	O
JNK	B-protein
-mediated	O
phosphorylation	O
.	O


Deletion	O
analysis	O
indicates	O
that	O
the	O
55	O
C-terminal	B-protein
amino	I-protein
acids	I-protein
of	O
the	O
LMP-1	B-protein
molecule	I-protein
,	O
but	O
not	O
its	O
TRAF	B-protein
interaction	I-protein
domain	I-protein
,	O
are	O
essential	O
for	O
AP-1	B-protein
activation	O
.	O


1.	O
In	O
this	O
study	O
we	O
hypothesized	O
that	O
in	O
individuals	O
with	O
certain	O
genetic	O
makeup	O
,	O
MTBE	O
,	O
benzene	O
or	O
their	O
metabolites	O
act	O
as	O
adducts	O
and	O
may	O
induce	O
programmed	O
cell	O
death	O
.	O


3	O
.	O
Peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
of	O
both	O
groups	O
were	O
tested	O
for	O
the	O
percentage	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
and	O
cell	O
cycle	O
progression	O
using	O
flow	O
cytometry	O
.	O


5.	O
One	O
of	O
the	O
signaling	B-protein
molecules	I-protein
which	O
mediates	O
programmed	O
cell	O
death	O
is	O
nuclear	B-protein
factor	I-protein
Kappa-B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O


This	O
reversal	O
of	O
apoptosis	O
almost	O
to	O
the	O
control	O
level	O
by	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
may	O
indicate	O
involvement	O
of	O
this	O
signaling	B-protein
molecule	I-protein
in	O
MTBE	O
and	O
benzene	O
induction	O
of	O
programmed	O
cell	O
death	O
.	O


When	O
studying	O
the	O
binding	O
of	O
SR	O
31747A	O
on	O
membranes	O
from	O
yeast	O
expressing	O
SR-BP	B-protein
,	O
we	O
found	O
a	O
pharmacological	O
profile	O
of	O
sigma	B-protein
1	I-protein
receptors	I-protein
;	O
binding	O
was	O
displaced	O
by	O
(	O
+	O
)	O
-pentazocine	O
,	O
haloperidol	O
,	O
and	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
,	O
with	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
being	O
a	O
more	O
potent	O
competitor	O
than	O
(	O
-	O
)	O
-SKF	O
10	O
,	O
047	O
.	O


Scatchard	O
plot	O
analysis	O
revealed	O
Kd	O
values	O
of	O
7.1	O
nM	O
and	O
0.15	O
nM	O
for	O
(	O
+	O
)	O
-pentazocine	O
and	O
SR	O
31747A	O
,	O
respectively	O
,	O
indicating	O
an	O
affinity	O
of	O
SR-BP	B-protein
50-fold	O
higher	O
for	O
SR	O
31747A	O
than	O
for	O
pentazocine	O
.	O


Taken	O
together	O
,	O
these	O
findings	O
strongly	O
suggest	O
that	O
SR-BP	B-protein
represents	O
the	O
molecular	O
target	O
for	O
SR	O
31747A	O
in	O
mammalian	O
tissues	O
,	O
which	O
could	O
be	O
critical	O
for	O
T	O
cell	O
proliferation	O
.	O


Phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
overexpression	O
and	O
activation	O
induced	O
by	O
interferon	B-protein
beta	I-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
:	O
an	O
ISGF3	B-protein
-independent	O
response	O
.	O


None	O
of	O
these	O
polymorphisms	B-DNA
change	O
the	O
translated	B-protein
protein	I-protein
.	O


Anti-TNF-alpha	B-protein
also	O
prevented	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
,	O
and	O
a	O
good	O
correlation	O
between	O
this	O
inhibition	O
and	O
inhibition	O
of	O
HIV	O
replication	O
was	O
observed	O
.	O


The	O
synergistic	O
effect	O
on	O
growth	O
inhibition	O
and	O
induction	O
of	O
differentiation	O
required	O
simultaneous	O
treatment	O
with	O
differanisole	O
A	O
and	O
9cisRA	O
.	O


Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
transcription	I-protein
factors	I-protein
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF-kappa	B-protein
B	I-protein
in	O
human	O
atherosclerotic	O
lesions	O
.	O


The	O
intracellular	O
localization	O
of	O
NFkappaB	B-protein
after	O
TNFalpha	B-protein
simulation	O
was	O
determined	O
by	O
confocal	O
immunocytochemistry	O
using	O
an	O
anti-p65	B-protein
antibody	I-protein
.	O


This	O
increased	O
adhesion	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
anti-CD18	B-protein
antibody	I-protein
(	O
157.6+/-25.1	O
cells/mm2	O
,	O
n	O
=	O
8	O
,	O
P	O
<	O
0.01	O
)	O
and	O
by	O
pretreatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	O
(	O
207.9+/-31.5	O
cells/mm2	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0.01	O
)	O
.	O


Immunocytochemistry	O
60	O
minutes	O
after	O
stimulation	O
revealed	O
that	O
NFkappaB	B-protein
was	O
located	O
in	O
the	O
cytoplasm	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
;	O
however	O
,	O
the	O
addition	O
of	O
TNFalpha	B-protein
caused	O
NFkappaB	B-protein
to	O
translocate	O
into	O
the	O
nucleus	O
.	O


CONCLUSIONS	O
:	O
Leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
was	O
shown	O
to	O
be	O
mediated	O
by	O
CD18	B-protein
expressed	O
on	O
activated	B-cell_type
leukocytes	I-cell_type
.	O


Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	B-protein
entry	O
into	O
the	O
nucleus	O
.	O


The	O
protein	O
is	O
believed	O
to	O
bind	O
small	O
lipophilic	O
substances	O
such	O
as	O
bacterial	O
derived	O
formylpeptides	O
and	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
might	O
function	O
as	O
a	O
modulator	O
of	O
inflammation	O
.	O


The	O
NGAL	B-protein
gene	O
is	O
highly	O
homologous	O
to	O
the	O
mouse	B-DNA
gene	I-DNA
24p3	I-DNA
.	O


Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B-protein
resembled	O
that	O
of	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
as	O
it	O
inhibited	O
TNF-	O
and	O
anti-Fas-induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
and	O
caspase-3/CPP32	B-protein
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF-kappaB-like	B-protein
transcription	I-protein
factors	I-protein
.	O


Among	O
the	O
regulatory	B-DNA
promoter	I-DNA
elements	I-DNA
potentially	O
regulating	O
eotaxin	B-DNA
gene	I-DNA
expression	O
and/or	O
mediating	O
the	O
effects	O
of	O
anti-inflammatory	O
drugs	O
we	O
identified	O
consensus	B-DNA
sequences	I-DNA
known	O
to	O
interact	O
with	O
nuclear	B-protein
factors	I-protein
like	O
NF-IL6	B-protein
,	O
AP-1	B-protein
,	O
a	O
NF-kappa-B	B-DNA
like	I-DNA
consensus	I-DNA
sequence	I-DNA
and	O
gamma-interferon-	B-DNA
as	I-DNA
well	I-DNA
as	I-DNA
glucocorticoid	I-DNA
response	I-DNA
elements	I-DNA
.	O


We	O
previously	O
detected	O
a	O
tissue-specific	B-DNA
promoter	I-DNA
preceding	O
the	O
exon	O
encoding	O
the	O
N	B-protein
terminus	I-protein
of	O
the	O
pp52	B-protein
leukocyte	I-protein
protein	I-protein
.	O


Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV-1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV-1	O
transcription	O
and	O
replication	O
.	O


METHODS	O
AND	O
RESULTS	O
:	O
Incubation	O
of	O
human	O
whole	O
blood	O
with	O
platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
,	O
1	O
mumol/L	O
)	O
evoked	O
downregulation	O
of	O
L-selectin	B-protein
and	O
upregulation	O
of	O
CD11/CD18	B-protein
adhesion	B-protein
receptors	I-protein
on	O
neutrophils	O
as	O
measured	O
by	O
flow	O
cytometry	O
.	O


While	O
dexamethasone	O
(	O
0.1	O
nmol/L	O
to	O
100	O
mumol/L	O
)	O
did	O
not	O
affect	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
on	O
resting	B-cell_type
neutrophils	I-cell_type
,	O
it	O
attenuated	O
the	O
PAF	B-protein
-induced	O
changes	O
in	O
L-selectin	B-protein
and	O
CD18	B-protein
expression	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
fashion	O
with	O
IC50	O
values	O
of	O
31	O
and	O
13	O
nmol/L	O
,	O
respectively	O
.	O


Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	B-DNA
shock	I-DNA
genes	I-DNA
in	O
hemin-treated	O
K562	B-cell_line
cells	I-cell_line
undergoing	O
erythroid	O
differentiation	O
.	O


Previous	O
studies	O
revealed	O
that	O
HSF2	B-protein
consists	O
of	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
HSF2-alpha	B-protein
and	O
HSF2-beta	B-protein
,	O
whose	O
relative	O
abundance	O
is	O
developmentally	O
regulated	O
and	O
varies	O
between	O
different	O
tissues	O
.	O


These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	B-protein
zeta	I-protein
chain	I-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O


Deletion	O
analysis	O
showed	O
that	O
expression	O
from	O
the	O
DM	B-DNA
promoters	I-DNA
is	O
dependent	O
on	O
the	O
conserved	O
S-X-Y	B-DNA
region	I-DNA
.	O


None	O
of	O
the	O
other	O
putative	O
regulatory	O
sites	O
was	O
occupied	O
in	O
vivo	O
,	O
indicating	O
that	O
they	O
may	O
not	O
be	O
functional	O
.	O


Finally	O
,	O
gel	O
shift	O
analysis	O
showed	O
synergistic	O
complex	O
formation	O
between	O
proteins	O
that	O
bind	O
to	O
the	O
putative	O
X	B-DNA
boxes	I-DNA
of	O
the	O
DM	O
genes	O
,	O
as	O
is	O
found	O
for	O
the	O
DRA	B-DNA
gene	I-DNA
.	O


No	O
virus	O
replication	O
and	O
no	O
transcription	O
of	O
the	O
Ad2	B-DNA
early	I-DNA
genes	I-DNA
was	O
observed	O
in	O
either	O
of	O
the	O
cells	O
.	O


In	O
macrophages	B-cell_type
,	O
a	O
slight	O
enhancement	O
of	O
TNF-alpha	B-protein
production	O
was	O
seen	O
,	O
whereas	O
IL-1	B-protein
beta	I-protein
was	O
not	O
detected	O
.	O


This	O
sequence	O
contains	O
consensus	B-DNA
elements	I-DNA
consistent	O
with	O
myeloid-specific	O
gene	O
expression	O
,	O
including	O
a	O
PU.1	B-DNA
consensus	I-DNA
site	I-DNA
near	O
the	O
major	O
transcription	B-DNA
start	I-DNA
site	I-DNA
and	O
a	O
cluster	O
of	O
c-Myb	B-DNA
sites	I-DNA
located	O
several	O
hundred	O
bases	O
upstream	O
of	O
this	O
region	O
.	O


A	O
4-bp	O
mutation	O
of	O
the	O
core	B-DNA
Sp1	I-DNA
consensus	I-DNA
element	I-DNA
(	O
GC	B-DNA
box	I-DNA
)	O
(	O
-20	O
)	O
reduced	O
overall	O
promoter	O
activity	O
of	O
the	O
1-kb	B-DNA
fragment	I-DNA
.	O


These	O
results	O
suggest	O
that	O
cooperation	O
or	O
cross-talk	O
of	O
signaling	O
molecules	O
associated	O
with	O
different	O
domains	O
of	O
IL-9Ralpha	B-protein
other	O
than	O
STAT3	B-protein
is	O
essential	O
for	O
IL-9	B-protein
-mediated	O
cell	O
growth	O
.	O


In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan'su	O
,	O
caused	O
apoptosis	O
in	O
human	B-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
by	O
anomalous	O
activation	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	B-protein
,	O
Raf-1	B-protein
,	O
and	O
MAPK	B-protein
kinase-1	I-protein
.	O


Bufalin	O
treatment	O
activated	B-protein
activator	I-protein
protein-1	I-protein
transcriptional	O
activity	O
;	O
however	O
,	O
this	O
activation	O
was	O
decreased	O
to	O
40	O
%	O
in	O
bcl-2	B-protein
-overexpressed	O
U937	B-cell_line
cells	I-cell_line
.	O


The	O
transcriptional	O
hierarchy	O
of	O
HNFs	O
suggests	O
that	O
other	O
proteins	O
of	O
the	O
regulatory	O
cascade	O
might	O
be	O
responsible	O
for	O
other	O
forms	O
of	O
MODY	O
and/or	O
late-onset	O
type	O
2	O
diabetes	O
.	O


Human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
was	O
treated	O
with	O
E.	O
chaffeensis	O
which	O
had	O
been	O
preincubated	O
with	O
human	O
anti-E.	O
chaffeensis	O
serum	O
for	O
2	O
h	O
,	O
and	O
the	O
levels	O
of	O
cytokine	B-RNA
mRNAs	I-RNA
were	O
evaluated	O
by	O
competitive	O
reverse	O
transcription-PCR	O
.	O


Fab	O
fragment	O
of	O
anti-E.	B-protein
chaffeensis	I-protein
immunoglobulin	I-protein
G	I-protein
complexed	O
with	O
E.	O
chaffeensis	O
did	O
not	O
induce	O
any	O
of	O
these	O
three	O
cytokines	O
,	O
indicating	O
that	O
ehrlichial	O
binding	O
is	O
required	O
for	O
IL-1beta	B-RNA
mRNA	I-RNA
expression	O
and	O
that	O
binding	O
of	O
the	O
immune	B-protein
complex	I-protein
to	O
the	O
Fc	B-protein
gamma	I-protein
receptor	I-protein
is	O
required	O
for	O
TNF-alpha	B-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
and	O
enhanced	O
IL-1beta	B-RNA
mRNA	I-RNA
expression	O
.	O


Furthermore	O
,	O
prolonged	O
degradation	O
of	O
IkappaB-alpha	B-protein
and	O
activation	O
of	O
NF-kappaB	B-protein
were	O
demonstrated	O
in	O
THP-1	B-cell_line
cells	I-cell_line
exposed	O
to	O
anti-E.	O
chaffeensis	O
serum	O
and	O
E.	O
chaffeensis	O
.	O


However	O
,	O
the	O
cellular	O
or	O
molecular	B-protein
factors	I-protein
responsible	O
for	O
a	O
delay	O
in	O
B-CLL	O
cell	O
death	O
are	O
unknown	O
.	O


The	O
interleukin-10	B-protein
(	I-protein
IL-10	I-protein
)	I-protein
receptor	I-protein
is	O
another	O
member	O
of	O
the	O
IFN	B-protein
receptor	I-protein
family	I-protein
,	O
but	O
its	O
ligand	O
,	O
IL-10	B-protein
,	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
B-CLL	B-cell_line
cells	I-cell_line
.	O


Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B-CLL	B-cell_line
cells	I-cell_line
,	O
the	O
addition	O
of	O
IL-10	B-protein
inhibited	O
B-CLL	B-cell_line
proliferation	O
,	O
enhanced	O
B-CLL	B-cell_line
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O


To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
(	O
hMR	B-protein
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	B-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
raised	O
against	O
the	O
hormone-binding	B-protein
domain	I-protein
(	O
HBD	B-protein
)	O
.	O


The	O
prolactin	B-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
hematopoietin/cytokine	B-protein
receptor	I-protein
superfamily	I-protein
,	O
is	O
ubiquitously	O
expressed	O
by	O
cells	O
in	O
the	O
immune	O
system	O
.	O


From	O
analyses	O
of	O
mice	O
deficient	O
in	O
transcription	B-DNA
factor	I-DNA
genes	I-DNA
and	O
from	O
the	O
characterizations	O
of	O
chromosome	B-DNA
breakpoints	I-DNA
in	O
human	O
leukemias	O
,	O
it	O
has	O
become	O
evident	O
that	O
transcription	B-protein
factors	I-protein
are	O
important	O
regulators	O
of	O
hematopoiesis	O
.	O


Induction	O
of	O
HIV	O
by	O
C.	O
neoformans	O
was	O
enhanced	O
by	O
anti-capsular	B-protein
antibody	I-protein
,	O
while	O
induction	O
by	O
both	O
organisms	O
was	O
inhibited	O
by	O
anti-TNF-alpha	B-protein
antibody	I-protein
.	O


In	O
THP-1	O
cells	O
transfected	O
with	O
HIV	B-DNA
plasmid	I-DNA
constructs	I-DNA
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
that	O
was	O
dependent	O
on	O
intact	O
NF-kappaB	B-DNA
binding	I-DNA
sequences	I-DNA
.	O


Nuclear	O
levels	O
of	O
NF-kappaB	B-protein
correlate	O
with	O
syncytium-forming	O
capacity	O
of	O
8e51	B-cell_line
cells	I-cell_line
,	O
expressing	O
a	O
defective	O
HIV	O
virus	O
.	O


The	O
double	B-DNA
NF-kappaB	I-DNA
site	I-DNA
identified	O
in	O
the	O
LTR	B-DNA
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
necessary	O
for	O
efficient	O
viral	O
transcription	O
.	O


These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	B-DNA
genes	I-DNA
.	O


Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c-Myb	B-protein
and	O
Ets	B-protein
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O


We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive/negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-protein
integrin	I-protein
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	B-cell_type
leukocytes	I-cell_type
.	O


They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	B-protein
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O


Both	O
cytokines	B-protein
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O


The	O
glucocorticoid	B-protein
receptor	I-protein
was	O
able	O
to	O
further	O
enhance	O
IL-4	B-protein
-induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	B-protein
.	O


Deletion	O
analysis	O
of	O
the	O
carboxyl-terminal	B-protein
region	I-protein
of	O
Stat6	B-protein
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-protein
.	O


ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
synergistically	O
transactivate	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O


Data	O
reported	O
herein	O
support	O
the	O
hypothesis	O
that	O
cognate	O
interactions	O
between	O
tissue	B-cell_type
fibroblasts	I-cell_type
and	O
infiltrating	O
T	O
lymphocytes	O
,	O
via	O
the	O
CD40	B-protein
/CD40L	B-protein
pathway	O
,	O
augment	O
inflammation	O
and	O
may	O
promote	O
fibrogenesis	O
by	O
activating	O
both	O
cell	O
types	O
.	O


In	O
fact	O
,	O
mAb	B-protein
L243	I-protein
but	O
not	O
the	O
staphylococcal	B-protein
superantigens	I-protein
,	O
staphylococcal	B-protein
exotoxin	I-protein
toxic	I-protein
shock	I-protein
syndrome	I-protein
toxin-I	I-protein
or	O
staphylococcal	B-protein
enterotoxin	I-protein
B	I-protein
,	O
regulate	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
.	O


Additional	O
major	O
protein-DNA	O
interactions	O
do	O
not	O
occur	O
within	O
the	O
promoter	O
region	O
after	O
T	O
lymphocyte	O
activation	O
,	O
indicating	O
a	O
requirement	O
for	O
additional	O
protein-protein	O
interactions	O
and/or	O
post-translational	O
modifications	O
of	O
pre-bound	B-protein
transcription	I-protein
factors	I-protein
to	O
account	O
for	O
the	O
observed	O
increase	O
in	O
IMPDH	O
type	O
II	O
gene	O
expression	O
.	O


Monocytic	O
cell	O
adhesion	O
to	O
EC	B-cell_type
in	O
response	O
to	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
alpha-thrombin	B-protein
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
was	O
similarly	O
inhibited	O
by	O
NAC	O
.	O


NAC	O
had	O
no	O
effect	O
on	O
the	O
half-life	O
of	O
E-selectin	B-RNA
or	I-RNA
VCAM-1	I-RNA
mRNA	I-RNA
.	O


Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	B-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
and	O
the	O
PML	B-protein
or	O
PLZF	B-protein
nuclear	I-protein
protein	I-protein
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O


Deletion	O
of	O
the	O
PLZF	B-protein
POZ	I-protein
domain	I-protein
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
on	O
RA-induced	O
differentiation	O
and	O
on	O
RA-mediated	O
type	B-protein
II	I-protein
TGase	I-protein
up-regulation	O
,	O
suggesting	O
that	O
POZ-mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
.	O


The	O
mechanisms	O
that	O
control	O
the	O
initial	O
induction	O
of	O
these	O
signals	O
upon	O
infection	O
are	O
poorly	O
understood	O
.	O


Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF-kappaB	B-protein
to	O
DNA	O
in	O
TNF-alpha-stimulated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O


Human	O
cytomegalovirus	O
induces	O
interleukin-8	B-protein
production	O
by	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
through	O
acting	O
concurrently	O
on	O
AP-1-	B-DNA
and	I-DNA
NF-kappaB-binding	I-DNA
sites	I-DNA
of	O
the	O
interleukin-8	B-DNA
gene	I-DNA
.	O


The	O
combination	O
of	O
the	O
immune	B-protein
costimulatory	I-protein
molecule	I-protein
B7.1	B-protein
and	O
IL-12	B-protein
has	O
been	O
shown	O
to	O
be	O
synergistic	O
for	O
T	O
cell	O
activation	O
.	O


By	O
transfecting	O
tumor	O
cells	O
with	O
both	O
IL-12	B-DNA
and	I-DNA
B7.1	I-DNA
cDNAs	I-DNA
,	O
it	O
may	O
be	O
possible	O
to	O
use	O
these	O
modified	O
targets	O
as	O
vaccines	O
.	O


A	O
major	O
obstacle	O
in	O
designing	O
a	O
vector	O
to	O
deliver	O
these	O
genes	O
results	O
from	O
the	O
structure	O
of	O
IL-12	B-protein
.	O


We	O
have	O
also	O
shown	O
that	O
tyrosine	O
phosphorylation	O
of	O
the	O
STAT	B-protein
4	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
unique	O
to	O
the	O
IL-12	B-protein
signaling	O
pathway	O
,	O
occurs	O
with	O
Flexi-12	B-protein
at	O
levels	O
similar	O
to	O
those	O
seen	O
with	O
rIL-12	B-protein
.	O


While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	B-protein
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O


Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	O
of	O
CD95	B-protein
ligand	I-protein
,	O
a	O
required	O
step	O
for	O
TCR	B-protein
-induced	O
apoptosis	O
.	O


There	O
is	O
a	O
clearly	O
defined	O
and	O
substantial	O
role	O
for	O
free	O
radicals	O
or	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
periodontitis	O
,	O
but	O
little	O
research	O
has	O
been	O
performed	O
in	O
this	O
area	O
.	O


The	O
recent	O
discovery	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
reviewed	O
and	O
several	O
potential	O
pathways	O
for	O
cytokine	B-protein
-induced	O
periodontal	O
tissue	O
damage	O
,	O
mediated	O
by	O
NF-kappa	B-protein
B1	I-protein
are	O
discussed	O
.	O


The	O
link	O
between	O
cellular	O
production	O
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF-kappa	B-protein
B	I-protein
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O


Three	O
cases	O
were	O
predicted	O
to	O
be	O
TSC2	B-DNA
mutations	I-DNA
on	O
the	O
basis	O
of	O
linkage	O
analysis	O
or	O
because	O
a	O
hamartoma	O
from	O
the	O
patient	O
showed	O
loss	O
of	O
heterozygosity	O
for	O
16p13.3	B-DNA
markers	I-DNA
.	O


Five	O
of	O
these	O
were	O
caused	O
by	O
mutations	O
predicted	O
to	O
produce	O
a	O
truncated	B-protein
protein	I-protein
:	O
(	O
i	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
32	B-DNA
bp	I-DNA
deletion	I-DNA
in	O
exon	B-RNA
11	I-RNA
,	O
and	O
a	O
mutant	B-RNA
mRNA	I-RNA
without	O
exon	B-RNA
11	I-RNA
was	O
produced	O
;	O
the	O
normal	O
exon	O
10	O
was	O
also	O
spliced	O
out	O
;	O
(	O
ii	O
)	O
a	O
sporadic	O
case	O
had	O
a	O
1	B-DNA
bp	I-DNA
deletion	I-DNA
in	O
exon	B-RNA
12	I-RNA
(	O
1634delT	B-RNA
)	O
;	O
(	O
iii	O
)	O
a	O
TSC2-linked	B-RNA
mother	I-RNA
and	I-RNA
daughter	I-RNA
pair	I-RNA
had	O
a	O
G	O
--	O
>	O
T	O
transversion	O
in	O
exon	B-RNA
23	I-RNA
(	O
G2715T	B-RNA
)	O
introducing	O
a	O
cryptic	O
splice	O
site	O
causing	O
a	O
29	O
bp	O
truncation	O
of	O
mRNA	O
from	O
exon	B-RNA
23	I-RNA
;	O
(	O
iv	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
2	B-DNA
bp	I-DNA
deletion	I-DNA
in	O
exon	B-RNA
36	I-RNA
;	O
(	O
v	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
1	B-DNA
bp	I-DNA
insertion	I-DNA
disrupting	O
the	O
donor	O
splice	O
site	O
of	O
exon	B-RNA
37	I-RNA
(	O
5007+2insA	B-RNA
)	O
,	O
resulting	O
in	O
the	O
use	O
of	O
an	O
upstream	B-RNA
exonic	I-RNA
cryptic	I-RNA
splice	I-RNA
site	I-RNA
to	O
cause	O
a	O
29	B-RNA
bp	I-RNA
truncation	I-RNA
of	O
mRNA	B-RNA
from	O
exon	B-RNA
37	I-RNA
.	O


Electrophoretic	O
mobility-shift	O
assays	O
of	O
HUVEC	B-cell_line
nuclear	B-protein
proteins	I-protein
revealed	O
a	O
decrease	O
in	O
TNF-alpha-stimulated	B-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	B-cell_line
with	O
TCP	O
succinate	O
but	O
not	O
with	O
TCP	O
,	O
TCP	O
acetate	O
,	O
or	O
succinate	O
alone	O
.	O


The	O
Eed	B-protein
-mediated	O
transcriptional	O
effects	O
are	O
likely	O
to	O
reflect	O
the	O
interaction	O
of	O
Eed	B-protein
with	O
multiple	O
molecular	O
partners	O
,	O
including	O
K	B-protein
protein	I-protein
.	O


We	O
have	O
characterized	O
the	O
expression	O
of	O
STAT	B-protein
and	I-protein
IFN	I-protein
regulatory	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
family	I-protein
transcription	I-protein
factors	I-protein
in	O
primary	B-cell_type
human	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
in	O
response	O
to	O
IFN-alpha	O
and	O
IFN-gamma	O
stimulation	O
.	O


When	O
macrophages	B-cell_type
were	O
pretreated	O
with	O
low	O
doses	O
of	O
IFN-gamma	B-protein
and	O
then	O
stimulated	O
with	O
IFN-alpha	B-protein
,	O
clearly	O
enhanced	O
formation	O
of	O
specific	O
transcription	B-protein
factor	I-protein
complexes	O
was	O
detected	O
.	O


Liberated	O
NF-kappa	B-protein
B	I-protein
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	B-DNA
promoter	I-DNA
sites	I-DNA
and	O
activates	O
gene	O
transcription	O
.	O


Recently	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
linked	O
to	O
ARDS	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
critical	O
proximal	O
step	O
in	O
the	O
initiation	O
of	O
neutrophilic	O
inflammation	O
in	O
animal	O
models	O
.	O


Chimeric	B-protein
oncoprotein	I-protein
E2a-Pbx1	B-protein
induces	O
apoptosis	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
by	O
a	O
p53	B-protein
-independent	O
mechanism	O
that	O
is	O
suppressed	O
by	O
Bcl-2	B-protein
.	O


C/EBPepsilon	B-RNA
mRNA	I-RNA
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	B-cell_type
primary	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O


We	O
now	O
report	O
that	O
PO-B	B-protein
DNA-binding	O
in	O
HL-60	B-cell_line
cells	I-cell_line
is	O
similarly	O
induced	O
during	O
differentiation	O
to	O
the	O
granulocytic	B-cell_type
lineage	I-cell_type
(	O
with	O
either	O
retinoic	O
acid	O
or	O
dimethylsulfoxide	O
)	O
.	O


These	O
studies	O
have	O
prompted	O
our	O
interest	O
in	O
the	O
dynamics	O
of	O
other	O
transcription	B-protein
factor	I-protein
changes	O
during	O
HL-60	O
differentiation	O
.	O


Of	O
these	O
,	O
we	O
observed	O
that	O
another	O
transcription	B-protein
factor	I-protein
(	O
AP-1	B-protein
)	O
is	O
also	O
robustly	O
induced	O
at	O
the	O
DNA-binding	O
level	O
during	O
macrophage-like	O
HL-60	O
differentiation	O
,	O
but	O
not	O
during	O
granulocytic	O
differentiation	O
.	O


One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
was	O
found	O
to	O
derepress	O
beta-galactosidase	B-protein
activity	O
in	O
the	O
Oct-2	B-protein
-harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O


The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein-protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O


By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	O
in	O
mRNA	B-RNA
was	O
associated	O
with	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
STAT1-containing	B-protein
DNA-binding	I-protein
complex	I-protein
that	O
binds	O
to	O
Fc	B-DNA
gammaRI	I-DNA
promoter	I-DNA
elements	I-DNA
.	O


These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
integrin	B-protein
-mediated	O
cell	O
adhesion	O
can	O
modulate	O
the	O
magnitude	O
of	O
cytokine	B-protein
-induced	O
signal	O
transduction	O
pathways	O
,	O
thereby	O
amplifying	O
cellular	O
events	O
leading	O
to	O
monocyte	O
activation	O
and	O
inflammation	O
.	O


The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	B-protein
regulator	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O


We	O
used	O
gel	O
shift	O
assays	O
to	O
determine	O
whether	O
SP-A	B-protein
activated	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
THP-1	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


Triggering	O
of	O
the	O
T-cell	B-protein
receptor-CD3	I-protein
complex	I-protein
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
(	O
i	O
)	O
Ca2+-dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	B-protein
kinase	I-protein
cascades	O
.	O


We	O
show	O
here	O
that	O
c-Raf	B-protein
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP-	O
Erk	B-protein
cascade	O
,	O
contributes	O
to	O
IL-2	B-protein
induction	O
through	O
a	O
distal	B-DNA
enhancer	I-DNA
element	I-DNA
spanning	O
the	O
nucleotides	O
from	O
positions	O
-502	O
to	O
-413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O


These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	O
of	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
is	O
mediated	O
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis-acting	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O


The	O
control	O
of	O
cell	O
survival	O
and	O
cell	O
death	O
is	O
of	O
central	O
importance	O
in	O
tissues	O
with	O
high	O
cell	O
turnover	O
such	O
as	O
the	O
lymphoid	O
system	O
.	O


IFN-alpha/beta	B-protein
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
2	I-protein
protein	I-protein
in	O
the	O
T	B-cell_line
cell	I-cell_line
clones	I-cell_line
.	O


Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
is	O
a	O
potent	O
monocyte	B-protein
regulatory	I-protein
cytokine	I-protein
that	O
inhibits	O
gene	O
expression	O
of	O
proinflammatory	B-protein
mediators	I-protein
.	O


Nuclear	O
run-on	O
transcription	O
assays	O
showed	O
that	O
IL-10	B-protein
inhibited	O
the	O
rate	O
of	O
IFN-gamma	B-protein
-induced	O
transcription	O
of	O
the	O
ICAM-1	B-DNA
gene	I-DNA
,	O
and	O
mRNA	O
stability	O
studies	O
showed	O
that	O
IL-10	B-protein
did	O
not	O
alter	O
the	O
half-life	O
of	O
IFN-gamma-induced	B-RNA
ICAM-1	I-RNA
message	I-RNA
.	O


Instead	O
,	O
IL-10	B-protein
prevented	O
IFN-gamma	B-protein
-induced	O
binding	O
activity	O
at	O
the	O
NF-kappaB	B-protein
site	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
-responsive	I-DNA
NF-kappaB/C-EBP	I-DNA
composite	I-DNA
element	I-DNA
in	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
.	O


Finally	O
,	O
a	O
direct	O
interaction	O
between	O
RFX5	B-protein
and	O
CIITA	B-protein
was	O
detected	O
with	O
the	O
yeast	O
two-hybrid	O
and	O
far-Western	O
blot	O
assays	O
.	O


To	O
further	O
explore	O
the	O
involvement	O
of	O
PI3-K	B-protein
in	O
T	O
cell	O
activation	O
,	O
we	O
created	O
a	O
set	O
of	O
potentially	O
dominant	B-DNA
negative	I-DNA
PI3-K	I-DNA
constructs	I-DNA
comprising	O
individual	O
or	O
tandem	B-DNA
domains	I-DNA
of	O
the	O
regulatory	B-protein
p85	I-protein
subunit	I-protein
and	O
tested	O
their	O
effect	O
on	O
downstream	O
signaling	O
events	O
like	O
Erk2	B-protein
activation	O
and	O
transcription	O
from	O
an	O
NFAT	B-DNA
(	I-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
)	I-DNA
element	I-DNA
taken	O
from	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O


Wortmannin	O
did	O
not	O
interfere	O
with	O
NFAT	B-protein
activation	O
,	O
although	O
it	O
inhibited	O
PI3-K	B-protein
and	O
Erk2	B-protein
activation	O
in	O
the	O
same	O
experiment	O
.	O


Constitutive	O
and	O
inducible	O
protein/DNA	O
interactions	O
of	O
the	O
interferon-gamma	B-DNA
promoter	I-DNA
in	O
vivo	O
in	O
[	O
corrected	O
]	O
CD45RA	B-cell_type
and	I-cell_type
CD45R0	I-cell_type
T	I-cell_type
helper	I-cell_type
subsets	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
Eur	O
J	O
Immunol	O
1997	O
Jul	O
;	O
27	O
(	O
7	O
)	O
:	O
1830	O
]	O


ZEBRA	B-protein
is	O
also	O
indispensable	O
for	O
viral	O
replication	O
and	O
binds	O
directly	O
to	O
the	O
EBV	O
lytic	O
origin	O
of	O
replication	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
cholecystokinin	B-protein
(	I-protein
CCK	I-protein
(	I-protein
B	I-protein
)	I-protein
)	I-protein
receptor	I-protein
in	O
human	B-cell_line
lymphoblastic	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


The	O
involvement	O
of	O
the	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
antagonist	O
PD-135	O
,	O
158	O
.	O


Our	O
investigation	O
of	O
the	O
human	B-DNA
TCR	I-DNA
beta	I-DNA
gene	I-DNA
uncovers	O
a	O
surprisingly	O
complex	O
and	O
tissue-specific	O
structure	O
at	O
the	O
TCR	B-DNA
Vbeta	I-DNA
8.1	I-DNA
promoter	I-DNA
.	O


While	O
the	O
activation	O
of	O
JAK2	B-protein
,	O
Shc	B-protein
,	O
Erk	B-protein
,	O
and	O
STAT5	B-protein
proteins	I-protein
correlated	O
with	O
hGM-CSF	B-protein
-mediated	O
cell	O
growth	O
,	O
cellular	O
differentiation	O
occurred	O
in	O
the	O
absence	O
of	O
activation	O
of	O
these	O
signal	O
transduction	O
pathways	O
.	O


Northern	O
blot	O
analysis	O
in	O
mouse	O
cell	O
lines	O
suggests	O
that	O
its	O
expression	O
is	O
found	O
in	O
a	O
variety	O
of	O
cells	O
,	O
including	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
macrophages	B-cell_type
.	O


A	O
TBP	O
mutant	O
defective	O
in	O
interaction	O
with	O
TBP-associated	B-protein
factor	I-protein
TAFII250	B-protein
also	O
failed	O
to	O
mediate	O
transactivation	O
through	O
the	O
CIITA	B-protein
activation	I-protein
domain	I-protein
.	O


Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	B-protein
antibodies	I-protein
directed	O
at	O
CD2	B-protein
and	O
CD28	B-protein
adhesion	B-protein
molecules	I-protein
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	O
of	O
accessory	B-cell_type
cells	I-cell_type
.	O


We	O
have	O
recently	O
reported	O
a	O
series	O
(	O
A	O
)	O
of	O
1	O
,	O
25D3-resistant	O
variants	O
of	O
HL60	B-cell_line
cells	I-cell_line
which	O
proliferate	O
in	O
the	O
presence	O
of	O
1	O
,	O
25D3	O
and	O
do	O
not	O
express	O
differentiation	O
markers	O
(	O
Exp.	O
Cell	O
Res.	O
224	O
,	O
312	O
,	O
1996	O
)	O
.	O


Thus	O
,	O
the	O
availability	O
of	O
these	O
variant	O
cells	O
should	O
provide	O
a	O
system	O
for	O
studying	O
the	O
link	O
between	O
differentiation	O
and	O
cell	O
cycle	O
arrest	O
.	O


In	O
addition	O
,	O
the	O
combined	O
use	O
of	O
anti-Tat	B-protein
sFv	I-protein
intrabodies	I-protein
and	O
the	O
two	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
retained	O
the	O
virus	O
in	O
the	O
latent	O
state	O
for	O
as	O
long	O
as	O
45	O
days	O
.	O


In	O
contrast	O
,	O
the	O
characterization	O
of	O
transcription	B-protein
factors	I-protein
selectively	O
regulating	O
cytokine	O
production	O
by	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
is	O
at	O
a	O
very	O
early	O
stage	O
.	O


These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	B-DNA
and	O
the	O
AP-1-binding	B-DNA
sites	I-DNA
influence	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
CD28	B-protein
-costimulated	O
T	B-cell_type
cells	I-cell_type
.	O


BOB.1/OBF.1	B-protein
is	O
a	O
transcriptional	B-protein
coactivator	I-protein
that	O
is	O
constitutively	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
interacts	O
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	B-protein
factors	I-protein
.	O


Thrombin	B-protein
generation	O
by	O
apoptotic	B-cell_type
vascular	I-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O


We	O
have	O
previously	O
shown	O
that	O
anionic	O
phosphatidylserine	O
is	O
exposed	O
by	O
rat	B-cell_type
vascular	I-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
(	O
VSMCs	B-cell_type
)	O
undergoing	O
apoptosis	O
after	O
serum	O
withdrawal	O
.	O


In	O
this	O
study	O
,	O
using	O
a	O
chromogenic	O
assay	O
,	O
we	O
have	O
shown	O
thrombin	B-protein
generation	O
by	O
apoptotic	B-cell_type
VSMCs	I-cell_type
expressing	O
c-myc	B-protein
(	O
VSMC-myc	B-cell_line
)	O
with	O
an	O
area	O
under	O
the	O
thrombin	B-protein
-generation	O
curve	O
(	O
AUC	O
)	O
of	O
305	O
+/-	O
17	O
nmol	O
x	O
min/L	O
and	O
a	O
peak	O
thrombin	B-protein
(	O
PT	O
)	O
of	O
154	O
+/-	O
9	O
nmol/L	O
.	O


VSMCs	B-cell_type
derived	O
from	O
human	O
coronary	O
atherosclerotic	O
plaques	O
that	O
apoptose	O
even	O
in	O
serum	O
also	O
generated	O
thrombin	B-protein
(	O
AUC	O
of	O
260	O
+/-	O
2	O
nmol	O
x	O
min/L	O
;	O
PT	O
of	O
128	O
+/-	O
4	O
nmol/L	O
)	O
.	O


Patients	O
with	O
one	O
type	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
HLA-DR	B-DNA
,	I-DNA
-DQ	I-DNA
,	I-DNA
and	I-DNA
-DP	I-DNA
.	O


In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	B-cell_line
13	I-cell_line
and	O
RJ2.2.5	B-cell_line
restored	O
expression	O
of	O
the	O
HLA-DQ	B-DNA
haplotype	O
encoded	O
by	O
the	O
RJ2.2.5	B-DNA
DQB	I-DNA
gene	I-DNA
.	O


The	O
IL-4	B-protein
receptor	I-protein
(	O
IL-4R	B-protein
)	O
in	O
B	B-cell_type
cells	I-cell_type
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL-4-binding	B-protein
IL-4Ralpha	I-protein
chain	I-protein
,	O
which	O
is	O
shared	O
with	O
the	O
IL-13R	B-protein
,	O
and	O
the	O
IL-2Rgamma	B-protein
(	I-protein
gammac	I-protein
)	I-protein
chain	I-protein
,	O
which	O
is	O
shared	O
with	O
IL-7R	B-protein
,	O
IL-9R	B-protein
,	O
and	O
IL-15R	B-protein
.	O


Alternatively	O
,	O
the	O
IL-4Ralpha	B-protein
chain	I-protein
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	B-DNA
gene	I-DNA
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O


Furthermore	O
,	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
a	O
chimeric	B-protein
CD8alpha/IL-4Ralpha	I-protein
receptor	I-protein
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	B-protein
,	O
constitutively	O
expressed	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
.	O


Thus	O
,	O
Elf-1	B-protein
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	B-cell_type
.	O


However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4+	B-cell_type
T-cells	I-cell_type
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV-I	O
infection	O
,	O
activation	O
of	O
the	O
CREB/ATF	O
and	O
SRF	O
pathways	O
is	O
also	O
required	O
.	O


Importantly	O
,	O
despite	O
high	O
ligand	O
binding	O
affinity	O
,	O
the	O
prototypic	O
dissociated	O
compound	O
,	O
RU24858	O
,	O
acted	O
as	O
a	O
weak	O
agonist	O
and	O
did	O
not	O
efficiently	O
antagonize	O
dexamethasone-induced	O
transcription	O
in	O
transfected	B-cell_type
cells	I-cell_type
.	O


In	O
vivo	O
footprinting	O
and	O
mutational	O
analysis	O
of	O
the	O
proximal	B-DNA
CD19	I-DNA
promoter	I-DNA
reveal	O
important	O
roles	O
for	O
an	O
SP1/Egr-1	B-DNA
binding	I-DNA
site	I-DNA
and	O
a	O
novel	O
site	O
termed	O
the	O
PyG	B-DNA
box	I-DNA
.	O


Reporter	O
constructs	O
spanning	O
portions	O
of	O
the	O
promoter	O
identified	O
a	O
region	B-DNA
between	I-DNA
-85	I-DNA
and	I-DNA
-200	I-DNA
that	O
produced	O
high	O
levels	O
of	O
reporter	O
gene	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O


Gel	O
shift	O
assays	O
demonstrated	O
SP1	O
and	O
Egr-1	B-protein
binding	O
to	O
the	O
CD19	B-DNA
GC	I-DNA
box	I-DNA
,	O
while	O
unknown	O
nuclear	O
proteins	O
bound	O
the	O
PyG	B-DNA
and	I-DNA
AT	I-DNA
boxes	I-DNA
.	O


Early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
and	O
E47	B-protein
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O


Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-protein
and	O
E47	B-protein
synergize	O
to	O
activate	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
that	O
define	O
an	O
early	O
stage	O
of	O
the	O
B	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O


This	O
has	O
led	O
to	O
the	O
suggestion	O
that	O
a	O
surrogate	B-protein
gamma'-chain	I-protein
,	O
which	O
can	O
interact	O
with	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
to	O
mediate	O
signaling	O
,	O
is	O
expressed	O
on	O
cells	O
lacking	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
.	O


An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
,	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O


Dose-dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	O
values	O
for	O
cAMP	O
production	O
and	O
c-fos	B-DNA
increase	O
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c-fos	B-DNA
induction	O
via	O
H2	B-protein
receptors	I-protein
.	O


Furthermore	O
,	O
studies	O
carried	O
out	O
using	O
H7	B-protein
,	O
a	O
protein	B-protein
kinase	I-protein
A/protein	I-protein
kinase	I-protein
C	I-protein
inhibitor	I-protein
,	O
blocked	O
c-fos	B-DNA
induction	O
,	O
whereas	O
no	O
effect	O
was	O
observed	O
with	O
bisindolylmaleimide	O
,	O
a	O
specific	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	O
.	O


Nevertheless	O
,	O
dibutyryl	O
cAMP	O
induced	O
a	O
down-regulation	O
of	O
the	O
levels	O
of	O
this	O
proto-oncogene	B-DNA
.	O


METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O


The	O
present	O
work	O
shows	O
that	O
the	O
primary	O
CD8+	O
CTL	O
response	O
to	O
EBV	O
in	O
infectious	O
mononucleosis	O
patients	O
contains	O
multiple	O
lytic	O
antigen-specific	O
reactivities	O
at	O
levels	O
at	O
least	O
as	O
high	O
as	O
those	O
seen	O
against	O
latent	B-protein
antigens	I-protein
;	O
similar	O
reactivities	O
are	O
also	O
detectable	O
in	O
CTL	O
memory	O
.	O


This	O
contrasts	O
with	O
findings	O
in	O
alpha-	O
and	O
beta-	O
herpesvirus	O
systems	O
(	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
)	O
where	O
viral	O
interference	O
with	O
the	O
antigen-processing	O
pathway	O
during	O
lytic	O
infection	O
renders	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	I-protein
much	O
less	O
immunogenic	O
.	O


Triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
differentially	O
modulates	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
release	O
by	O
B	B-cell_type
cells	I-cell_type
at	O
distinct	O
stage	O
of	O
maturation	O
.	O


We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	B-protein
in	O
IL-5	B-DNA
promoter	I-DNA
activation	O
in	O
EL-4	B-cell_line
cells	I-cell_line
,	O
which	O
express	O
both	O
Th1-	B-protein
and	I-protein
Th2-type	I-protein
cytokines	I-protein
.	O


Whereas	O
mutations	O
in	O
the	O
GATA-3	B-protein
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	B-protein
in	O
Th1	B-cell_type
cells	I-cell_type
or	O
in	O
a	O
non-lymphoid	B-cell_line
,	I-cell_line
non-IL-5-producing	I-cell_line
cell	I-cell_line
line	I-cell_line
activated	O
the	O
IL-5	B-DNA
promoter	I-DNA
.	O


Inhibition	O
of	O
GATA-3	B-protein
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O


The	O
ratio	O
of	O
adult	B-RNA
beta-globin/alpha-globin	I-RNA
mRNA	I-RNA
in	O
the	O
mutant	B-cell_line
ES	I-cell_line
cells	I-cell_line
was	O
1/15	O
of	O
that	O
in	O
wild-type	B-cell_type
ES	I-cell_type
cells	I-cell_type
.	O


RP1	B-DNA
,	O
a	O
new	O
member	O
of	O
the	O
adenomatous	B-DNA
polyposis	I-DNA
coli-binding	I-DNA
EB1-like	I-DNA
gene	I-DNA
family	I-DNA
,	O
is	O
differentially	O
expressed	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


The	O
predictive	B-DNA
protein-coding	I-DNA
region	I-DNA
of	O
RP1	B-DNA
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	B-DNA
polyposis	I-DNA
coli	I-DNA
(	I-DNA
APC	I-DNA
)	I-DNA
protein-binding	I-DNA
EB1	I-DNA
gene	I-DNA
family	I-DNA
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O


Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
,	O
but	O
not	O
with	O
the	O
processing	O
of	O
p105/	O
NF-kappa	B-protein
B1	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O


Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O


In	O
contrast	O
,	O
synthesis	O
of	O
IFN-gamma	B-RNA
mRNA	I-RNA
was	O
only	O
slightly	O
decreased	O
,	O
and	O
expression	O
of	O
TGF-beta1	B-protein
was	O
unaffected	O
.	O


Following	O
an	O
initial	O
genotype	O
screening	O
of	O
85	O
normal	O
volunteers	O
by	O
polymerase	O
chain	O
reaction	O
or	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
analysis	O
,	O
14	O
individuals	O
with	O
the	O
Bb	O
genotype	O
,	O
12	O
with	O
the	O
bb	O
genotype	O
,	O
and	O
12	O
with	O
the	O
BB	O
genotype	O
were	O
selected	O
.	O


We	O
conclude	O
that	O
VDR	B-protein
polymorphism	O
does	O
not	O
affect	O
the	O
abundance	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
.	O


EMS	O
analyses	O
utilizing	O
a	O
series	O
of	O
mutated	B-DNA
pp	I-DNA
repeat	I-DNA
elements	I-DNA
demonstrate	O
that	O
the	O
nucleotide	O
sequence	O
requirements	O
for	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
formation	O
are	O
separable	O
from	O
those	O
required	O
for	O
C1-C3	B-DNA
formation	O
.	O


Thus	O
,	O
STAT3	B-protein
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
antigen-specific	O
signaling	O
responses	O
,	O
and	O
its	O
constitutive	O
activation	O
is	O
associated	O
with	O
a	O
normal	O
cell	O
population	O
exhibiting	O
intrinsic	O
proliferative	O
behavior	O
.	O


Recently	O
,	O
we	O
have	O
developed	O
a	O
quantitative	O
assay	O
using	O
competitive	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	O
reaction	O
that	O
estimates	O
the	O
number	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
in	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
in	O
order	O
to	O
determine	O
the	O
degree	O
of	O
leukemic	O
cell	O
contamination	O
in	O
PBSC	B-cell_type
harvests	O
,	O
and	O
to	O
monitor	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
quantitatively	O
in	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
AML	O
.	O


Synergistic	O
transactivation	O
of	O
the	O
LPS	B-DNA
response	I-DNA
element	I-DNA
in	O
Drosophila	B-cell_line
Schneider	I-cell_line
cells	I-cell_line
by	O
coexpression	O
of	O
c-Fos	B-protein
,	O
c-Jun	B-protein
,	O
c-Rel	B-protein
,	O
and	O
p65	B-protein
or	O
c-Jun	B-protein
and	O
p65	B-protein
required	O
the	O
transactivation	B-protein
domains	I-protein
of	O
c-Jun	B-protein
and	O
p65	B-protein
.	O


The	O
effect	O
of	O
GH	O
appears	O
to	O
occur	O
in	O
an	O
autocrine	O
fashion	O
,	O
since	O
the	O
inhibitory	O
effect	O
on	O
TNF-alpha	B-protein
secretion	O
by	O
constitutive	O
GH	O
production	O
could	O
be	O
abolished	O
in	O
the	O
presence	O
of	O
anti-hGH	B-protein
mAb	I-protein
.	O


On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	O
inhibit	O
NF-kappaB	B-protein
activation	O
by	O
LPS	O
.	O


By	O
contrast	O
,	O
phosphatidic	O
acid	O
accumulation	O
,	O
pleckstrin	O
phosphorylation	O
,	O
and	O
calcium	O
mobilization	O
produced	O
by	O
the	O
combination	O
of	O
NE	B-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
were	O
not	O
significantly	O
different	O
from	O
those	O
measured	O
with	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
alone	O
(	O
p	O
>	O
0.05	O
)	O
,	O
indicating	O
that	O
the	O
phospholipase	B-protein
C	I-protein
/protein	B-protein
kinase	I-protein
C	I-protein
pathway	O
is	O
not	O
involved	O
in	O
the	O
potentiation	O
of	O
aggregation	O
.	O


The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	B-protein
coreceptors	I-protein
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	B-protein
factors	I-protein
,	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
activator	B-protein
protein-1	I-protein
.	O


To	O
test	O
the	O
hypothesis	O
that	O
the	O
chimera	B-protein
PMLRAR	I-protein
alpha	I-protein
plays	O
a	O
role	O
in	O
leukemogenesis	O
,	O
we	O
expressed	O
a	O
PMLRAR	B-DNA
alpha	I-DNA
cDNA	I-DNA
in	O
myeloid	B-cell_type
cells	I-cell_type
of	O
transgenic	O
mice	O
.	O


PMLRAR	O
alpha	O
transgenic	O
mice	O
exhibited	O
impaired	O
neutrophil	O
maturation	O
early	O
in	O
life	O
,	O
which	O
progressed	O
at	O
a	O
low	O
frequency	O
over	O
the	O
course	O
of	O
several	O
months	O
to	O
overt	O
APL	O
.	O


The	O
model	O
should	O
be	O
useful	O
for	O
exploring	O
the	O
molecular	O
pathogenesis	O
of	O
APL	O
and	O
the	O
mechanisms	O
of	O
the	O
therapeutic	O
response	O
to	O
retinoic	O
acid	O
,	O
as	O
well	O
as	O
for	O
preclinical	O
studies	O
of	O
therapeutic	O
regimens	O
.	O


Such	O
hypermethylation-associated	O
silencing	O
of	O
gene	O
expression	O
has	O
been	O
shown	O
for	O
several	O
genes	O
regulating	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
including	O
the	O
estrogen	B-DNA
receptor	I-DNA
(	I-DNA
ER	I-DNA
)	I-DNA
gene	I-DNA
,	O
P15	O
,	O
P16	O
and	O
others	O
.	O


To	O
extend	O
these	O
initial	O
observations	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
the	O
activity	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
erk1	B-protein
and	O
erk2	B-protein
,	O
as	O
members	O
of	O
a	O
signal	O
transduction	O
pathway	O
known	O
to	O
directly	O
regulate	O
transcription	O
factor	O
function	O
.	O


These	O
observations	O
provide	O
further	O
evidence	O
to	O
suggest	O
a	O
role	O
for	O
intracellular	O
oxidant	O
generation	O
as	O
a	O
regulatory	O
mechanism	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
establish	O
a	O
link	O
between	O
oxidative	O
signalling	O
and	O
other	O
aspects	O
of	O
the	O
intracellular	O
signalling	O
network	O
that	O
is	O
activated	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
.	O


Using	O
the	O
yeast	O
two-hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B-protein
,	O
we	O
isolated	O
the	O
B	B-protein
subunit	I-protein
of	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF-Y	B-protein
from	O
a	O
HeLa	B-DNA
cDNA	I-DNA
library	I-DNA
.	O


In	O
addition	O
,	O
mutation	O
of	O
the	O
Y-box	B-DNA
element	I-DNA
alone	O
abrogated	O
Tax1	B-protein
-mediated	O
activation	O
.	O


High	O
levels	O
of	O
the	O
DNA-binding	O
activity	O
of	O
E2F	B-protein
in	O
adult	O
T-cell	O
leukemia	O
and	O
human	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
virus	I-cell_type
type	I-cell_type
I-infected	I-cell_type
cells	I-cell_type
:	O
possible	O
enhancement	O
of	O
DNA-binding	O
of	O
E2F	B-protein
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
I	I-protein
transactivating	I-protein
protein	I-protein
,	O
Tax	B-protein
.	O


In	O
this	O
study	O
,	O
we	O
examined	O
early	O
signaling	O
events	O
in	O
proliferating	B-cell_type
and	O
terminally	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
following	O
G-CSF	B-protein
stimulation	O
to	O
determine	O
whether	O
identical	O
signaling	O
cascades	O
are	O
activated	O
.	O


BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune-modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O


Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	B-protein
(	O
Ig	O
)	O
response	O
.	O


These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR-alpha	B-protein
.	O


Characterization	O
of	O
the	O
DNA-binding	B-protein
protein	I-protein
by	O
UV	O
cross-linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation/supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	B-protein
factor	I-protein
designated	O
SAF	B-protein
.	O


Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O


Interleukin-6	B-protein
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O


These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL-6	B-protein
production	O
.	O


In	O
addition	O
,	O
ALY	B-protein
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	B-protein
and	O
AML	B-protein
proteins	I-protein
.	O


On	O
the	O
other	O
hand	O
,	O
AML1b	B-protein
conferred	O
a	O
similar	O
differentiation-inducing	O
capacity	O
upon	O
K562	B-cell_line
cells	I-cell_line
transfected	O
with	O
vector	O
alone	O
.	O


AML1a	B-protein
expression	O
was	O
associated	O
with	O
enhanced	O
sensitivity	O
to	O
megakaryocytic	O
differentiation	O
induced	O
by	O
phorbol	O
ester	O
.	O


Two	O
sets	O
of	O
independent	O
evidences	O
are	O
presented	O
here	O
that	O
demonstrate	O
a	O
biological	O
relevance	O
for	O
this	O
model	O
.	O


Secondly	O
,	O
we	O
investigated	O
whether	O
polyomavirus	O
reactivation	O
occurs	O
in	O
SLE	O
patients	O
,	O
and	O
whether	O
antibodies	B-protein
to	O
T-antigen	B-protein
,	O
DNA	O
,	O
and	O
to	O
TBP	B-protein
and	O
CREB	B-protein
are	O
linked	O
to	O
such	O
events	O
.	O


Both	O
within	O
and	O
among	O
these	O
SLE	O
patients	O
,	O
frequent	O
polyomavirus	O
reactivations	O
were	O
observed	O
that	O
could	O
not	O
be	O
explained	O
by	O
certain	O
rearrangements	O
of	O
the	O
noncoding	O
control	O
regions	O
,	O
nor	O
by	O
corticosteroid	O
treatment	O
.	O


The	O
results	O
described	O
here	O
indicate	O
that	O
cognate	O
interaction	O
of	O
B	O
cells	O
recognizing	O
DNA	O
or	O
DNA-associated	B-protein
proteins	I-protein
and	O
T	B-cell_type
cells	I-cell_type
recognizing	O
T	B-protein
antigen	I-protein
had	O
taken	O
place	O
as	O
a	O
consequence	O
of	O
complex	O
formation	O
between	O
T	B-protein
ag	I-protein
and	O
DNA	O
in	O
vivo	O
in	O
the	O
context	O
of	O
polyomavirus	O
reactivations	O
.	O


We	O
show	O
that	O
engagement	O
of	O
CD40	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak3	B-protein
as	O
well	O
as	O
of	O
STAT3	B-protein
.	O


Jak3	B-protein
is	O
constitutively	O
associated	O
with	O
CD40	B-protein
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline-rich	B-protein
sequence	I-protein
in	O
the	O
membrane-proximal	B-protein
region	I-protein
of	O
CD40	B-protein
.	O


Transcription	B-protein
factors	I-protein
required	O
for	O
lymphoid	O
lineage	O
commitment	O
.	O


These	O
results	O
suggest	O
that	O
two	O
distinct	O
IL-4	B-protein
signaling	O
pathways	O
exist	O
.	O


HIV-1	B-DNA
LTR	I-DNA
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus-encoded	B-protein
and	I-protein
cellular	I-protein
proteins	I-protein
.	O


Cell-to-cell	O
contact	O
activates	O
in	O
vitro	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
p50/p65	I-protein
heterodimer	I-protein
to	O
an	O
HIV-1	O
kappaB	O
oligonucleotide	O
.	O


Both	O
IL-4	B-protein
and	O
anti-	O
CD40	B-protein
mAb	I-protein
induced	O
activation	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-kinase	B-protein
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


Activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O


Activated	B-cell_type
neutrophils	I-cell_type
have	O
the	O
ability	O
to	O
upregulate	O
the	O
expression	O
of	O
many	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B-protein
and	O
chemokines	B-protein
,	O
and	O
to	O
subsequently	O
release	O
the	O
corresponding	O
proteins	O
.	O


To	O
delineate	O
the	O
regulatory	O
mechanisms	O
of	O
human	O
IL-5	B-protein
synthesis	O
,	O
we	O
established	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
from	O
asthmatic	O
patients	O
.	O


Human	O
IL-5	B-protein
promoter/enhancer-luciferase	O
gene	O
construct	O
transfected	O
to	O
T-cell	B-cell_line
clones	I-cell_line
was	O
transcribed	O
on	O
either	O
TCR	B-protein
or	O
IL-2R	B-protein
stimulation	O
and	O
was	O
clearly	O
downregulated	O
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500-bp	B-DNA
human	I-DNA
IL-5	I-DNA
gene	I-DNA
segment	I-DNA
located	O
5	B-DNA
'	I-DNA
upstream	I-DNA
of	O
the	O
coding	O
region	O
contains	O
activation-inducible	B-DNA
enhancer	I-DNA
elements	I-DNA
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O


Our	O
results	O
showing	O
that	O
GC	O
suppressed	O
IL-5	B-protein
production	O
by	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
by	O
two	O
distinct	O
stimuli	O
,	O
TCR	B-protein
and	O
IL-2R	B-protein
stimulation	O
,	O
underscore	O
the	O
efficacy	O
of	O
GC	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
via	O
suppression	O
of	O
T-cell	O
IL-5	B-protein
synthesis	O
.	O


Itk	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
is	O
required	O
for	O
CD2-mediated	B-DNA
interleukin-2	I-DNA
promoter	I-DNA
activation	O
in	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
.	O


Stimulation	O
of	O
CD2	B-protein
or	O
TCR/CD3	B-protein
induced	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
the	O
binding	B-DNA
site	I-DNA
of	O
which	O
is	O
included	O
in	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
.	O


Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3/BCL6	B-protein
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non-B	O
NHL	O
.	O


Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
kappa	I-protein
beta	I-protein
.	O


Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro-inflammatory	B-protein
mediators	I-protein
and	O
adhesion	B-protein
molecules	I-protein
.	O


or	O
intranasally	O
with	O
wild-type	O
Ad	O
or	O
an	O
Ad	O
vector	O
lacking	O
most	O
of	O
the	O
E1	B-DNA
region	I-DNA
,	O
subdominant	O
epitopes	O
outside	O
this	O
region	O
were	O
recognized	O
.	O


In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild-type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	B-DNA
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	B-DNA
and	O
E1B	B-DNA
,	O
no	O
immunorecessive	B-protein
epitopes	I-protein
were	O
recognized	O
.	O


CTLs	B-cell_type
from	O
BALB/c	O
mice	O
inoculated	O
i.p.	O
with	O
wild-type	O
Ad	O
recognized	O
E1B	B-DNA
in	O
the	O
context	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
I	I-DNA
Dd	I-DNA
allele	I-DNA
and	O
a	O
region	O
outside	O
E1	B-DNA
associated	O
with	O
the	O
Kd	B-DNA
allele	I-DNA
.	O


When	O
BALB/c	O
mice	O
were	O
inoculated	O
with	O
E1	B-DNA
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	B-protein
Kd-restricted	I-protein
epitope	I-protein
was	O
recognized	O
,	O
and	O
Dd-restricted	O
CTLs	B-cell_type
did	O
not	O
develop	O
.	O


Putative	O
cis-acting	B-DNA
control	I-DNA
elements	I-DNA
present	O
within	O
a	O
300-bp	B-DNA
core	I-DNA
promoter	I-DNA
included	O
two	O
ets	B-DNA
sites	I-DNA
,	O
an	O
Sp1	B-DNA
site	I-DNA
,	O
tandem	O
E-box	B-DNA
domains	I-DNA
,	O
two	O
GATA-associated	B-DNA
sites	I-DNA
(	O
CACCC	O
)	O
,	O
an	O
AP-2	B-DNA
binding	I-DNA
site	I-DNA
,	O
and	O
a	O
GATA	B-DNA
element	I-DNA
at	O
-24	B-DNA
.	O


We	O
have	O
identified	O
a	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
in	O
the	O
region	O
between	O
-685	B-DNA
and	I-DNA
-395	I-DNA
.	O


This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	B-DNA
regulatory	I-DNA
region	I-DNA
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	B-DNA
gene	I-DNA
.	O


One	O
of	O
these	O
subregions	O
,	O
NRE	B-DNA
gamma	I-DNA
,	O
is	O
active	O
in	O
both	O
HeLa	B-cell_line
cervical	I-cell_line
carcinoma	I-cell_line
cells	I-cell_line
and	O
Huh7	B-cell_line
hepatoma	I-cell_line
cells	I-cell_line
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O


Clinical	O
CR	O
was	O
achieved	O
in	O
nine	O
of	O
10	O
(	O
90	O
%	O
)	O
patients	O
treated	O
with	O
As2O3	O
alone	O
and	O
in	O
the	O
remaining	O
five	O
patients	O
treated	O
by	O
the	O
combination	O
of	O
As2O3	O
and	O
low-dose	O
chemotherapeutic	O
drugs	O
or	O
ATRA	O
.	O


In	O
addition	O
,	O
increased	O
amounts	O
of	O
arsenic	O
appeared	O
in	O
the	O
urine	O
,	O
with	O
a	O
daily	O
excretion	O
accounting	O
for	O
approximately	O
1	O
%	O
to	O
8	O
%	O
of	O
the	O
total	O
daily	O
dose	O
administered	O
.	O


This	O
identification	O
,	O
initially	O
made	O
by	O
microsequence	O
analysis	O
,	O
was	O
verified	O
by	O
showing	O
that	O
(	O
i	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
increased	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
a	O
nucleolin	B-DNA
cDNA	I-DNA
expression	I-DNA
construct	I-DNA
;	O
(	O
ii	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
was	O
recognized	O
by	O
antibodies	O
raised	O
against	O
recombinant	B-protein
human	I-protein
nucleolin	I-protein
;	O
and	O
(	O
iii	O
)	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
epitope-tagged	B-DNA
nucleolin	I-DNA
expression	I-DNA
constructs	I-DNA
,	O
the	O
LR1-DNA	B-protein
complex	I-protein
was	O
recognized	O
by	O
the	O
anti-tag	B-protein
antibody	I-protein
.	O


Glucocorticoid-resistance	O
in	O
peripheral-blood	B-cell_type
lymphocytes	I-cell_type
does	O
not	O
correlate	O
with	O
number	O
of	O
affinity	O
of	O
glucocorticoid-receptors	B-protein
in	O
chronic	O
renal	O
failure	O
patients	O
.	O


In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
2.89	O
+/-	O
1.23	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+/-	O
2.24	O
nM	O
,	O
respectively	O
.	O


We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF-kappaB	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
(	O
MDMs	B-cell_type
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	B-cell_type
macrophages	I-cell_type
(	O
AMs	B-cell_type
)	O
.	O


As	O
in	O
MDMs	B-cell_type
,	O
AMs	B-cell_type
constitutively	O
expressed	O
p50/p65	B-protein
and	O
p50/RelB	B-protein
although	O
at	O
lower	O
levels	O
.	O


Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
lymphocytic	I-cell_type
cells	I-cell_type
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	B-protein
cytokine	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O


Pretreatment	O
of	O
ACH-2	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF-alpha	B-protein
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O


One	O
of	O
these	O
NFAT-like	B-DNA
elements	I-DNA
encompassed	O
overlapping	O
Oct-	B-DNA
and	I-DNA
NFATp/c-binding	I-DNA
sites	I-DNA
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O


Early	O
viral	O
RNA	O
splicing	O
patterns	O
also	O
differ	O
between	O
wild-type	B-cell_line
and	I-cell_line
dl337-infected	I-cell_line
cells	I-cell_line
.	O


TCC	B-protein
also	O
stimulate	O
a	O
variety	O
of	O
cellular	O
activities	O
,	O
which	O
include	O
cytokine	B-protein
synthesis	O
,	O
proto-oncogene	B-DNA
activation	O
,	O
and	O
mitotic	O
signaling	O
.	O


These	O
observations	O
imply	O
that	O
during	O
persistent	O
infection	O
Ad5	O
underwent	O
spontaneous	O
mutations	O
by	O
sequence-specific	O
breakage	O
and	O
nonhomologous	O
end-end	O
joining	O
recombination	O
events	O
.	O


These	O
E1a	O
reiteration	O
mutants	O
could	O
be	O
propagated	O
in	O
HeLa	B-cell_line
,	O
A549	B-cell_line
,	O
and	O
KB	B-cell_line
cells	I-cell_line
;	O
they	O
were	O
genetically	O
stable	O
;	O
and	O
they	O
killed	O
CREF	B-cell_line
cells	I-cell_line
at	O
a	O
strikingly	O
high	O
frequency	O
.	O


The	O
observed	O
E1a	B-DNA
reiterations	I-DNA
provide	O
a	O
model	O
to	O
gain	O
insight	O
into	O
understanding	O
the	O
evolutionary	O
events	O
of	O
some	O
,	O
if	O
not	O
all	O
,	O
adenovirus	O
types	O
during	O
many	O
years	O
of	O
symbiotic	O
,	O
persistent	O
relationship	O
in	O
human	O
tonsils	O
and	O
adenoids	O
and	O
possibly	O
other	O
lymphoid	O
organs	O
.	O


Binding	O
of	O
viral	O
peptide	O
to	O
cell	O
lines	O
bearing	O
DQA1*0201	B-protein
,	O
in	O
comparison	O
to	O
DQA1*0501	B-protein
,	O
was	O
only	O
moderately	O
reduced	O
and	O
may	O
not	O
explain	O
this	O
effect	O
.	O


Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	B-protein
in	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
since	O
over-expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	B-RNA
class	I-RNA
II	I-RNA
mRNA	I-RNA
expression	O
.	O


The	O
hypothesis	O
that	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
may	O
influence	O
HIV-1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV-1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O


These	O
results	O
link	O
regulatory	B-protein
factors	I-protein
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV-1	O
replication	O
.	O


Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	B-protein
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	B-cell_type
cells	I-cell_type
into	O
either	O
eTh1	B-cell_type
or	O
eTh2	B-cell_type
cells	I-cell_type
to	O
mediate	O
the	O
expression	O
of	O
IL-2	B-protein
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O


During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte/macrophage	B-protein
receptors	I-protein
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	B-protein
cytokines	I-protein
.	O


No	O
degradation	O
of	O
p105	B-protein
and	I-protein
p100	I-protein
inhibitors	I-protein
was	O
observed	O
under	O
these	O
conditions	O
.	O


The	O
transduction	O
pathway	O
leading	O
to	O
NF-kappaB	B-protein
activation	O
in	O
U937	B-cell_line
cells	I-cell_line
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF-kappaB	B-protein
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O


c-Rel	B-protein
is	O
a	O
target	O
of	O
pentoxifylline-mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O


We	O
found	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
anti-CD3-induced	O
c-Rel	B-protein
expression	O
was	O
blocked	O
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF-kappaB	B-protein
family	I-protein
members	I-protein
was	O
not	O
significantly	O
affected	O
.	O


A	O
negative	O
role	O
for	O
phosphoinositide	B-protein
3-kinase	I-protein
in	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
function	O
.	O


Phosphoinositide	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
is	O
activated	O
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T-cell	O
function	O
,	O
including	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
,	O
the	O
costimulatory	B-protein
receptor	I-protein
CD28	I-protein
,	O
and	O
negative	B-protein
regulators	I-protein
of	O
T-cell	O
activation	O
such	O
as	O
CTLA-4	B-protein
.	O


CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	B-protein
3-kinase	I-protein
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T-cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	B-protein
3-kinase	I-protein
in	O
T	B-cell_type
cells	I-cell_type
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR	B-protein
-signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T-cell	O
homeostasis	O
.	O


Isoforms	O
Pax-5d	O
and	O
Pax-5e	B-protein
have	O
deleted	O
the	O
3'-region	B-protein
,	O
which	O
encodes	O
the	O
transactivating	O
domain	O
,	O
and	O
replaced	O
it	O
with	O
a	O
novel	O
sequence	O
.	O


Using	O
this	O
assay	O
,	O
we	O
also	O
showed	O
that	O
Pax-5d	B-protein
was	O
present	O
in	O
nuclear	O
extracts	O
of	O
some	O
(	O
but	O
not	O
all	O
)	O
B-lymphoid	B-cell_line
lines	I-cell_line
and	O
interacts	O
with	O
the	O
B-cell-specific	B-DNA
activator	I-DNA
protein-binding	I-DNA
site	I-DNA
.	O


Reconstitution	O
of	O
T	O
cell	O
antigen	O
receptor-induced	O
Erk2	B-protein
kinase	I-protein
activation	O
in	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	I-cell_line
by	O
Syk	B-protein
.	O


The	O
two	O
related	O
protein-tyrosine	B-protein
kinases	I-protein
Syk	B-protein
and	O
Zap	B-protein
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
and	O
enzymatically	O
activated	O
upon	O
crosslinking	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O


Here	O
we	O
report	O
that	O
overexpression	O
of	O
Syk	B-protein
in	O
the	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	I-cell_line
enabled	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor/CD3	I-protein
complex	I-protein
to	O
induce	O
a	O
normal	O
activation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
and	O
expression	O
of	O
a	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
reporter	O
construct	O
.	O


In	O
parallel	O
,	O
Syk	B-protein
was	O
phosphorylated	O
on	O
tyrosine	O
,	O
while	O
Zap	B-protein
was	O
not	O
.	O


The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
or	O
long-term	B-cell_line
cultured	I-cell_line
NK	I-cell_line
clones	I-cell_line
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
measured	O
by	O
gel	O
retardation	O
.	O


The	O
predominant	O
E2F	B-protein
complex	I-protein
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
and	O
in	O
AML	B-cell_type
blasts	I-cell_type
contains	O
E2F-4	B-protein
,	O
DP-1	B-protein
and	O
p130	B-protein
.	O


Therefore	O
we	O
analysed	O
the	O
expression	O
of	O
E2F	B-protein
-DNA	O
binding	O
activity	O
and	O
the	O
constituent	O
proteins	O
found	O
in	O
the	O
complexes	O
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
of	O
various	O
lineages	O
.	O


Characterization	O
of	O
a	O
mutant	B-cell_line
cell	I-cell_line
line	I-cell_line
that	O
does	O
not	O
activate	O
NF-kappaB	B-protein
in	O
response	O
to	O
multiple	O
stimuli	O
.	O


The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	B-protein
kappaB	I-protein
inactivation	O
remain	O
poorly	O
understood	O
.	O


Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF-kappa	B-protein
B	I-protein
regulates	O
the	O
NF-kappa	B-DNA
B1	I-DNA
gene	I-DNA
.	O


Characterization	O
of	O
the	O
NF-kappa	B-DNA
B1	I-DNA
promoter	I-DNA
identified	O
an	O
Egr-1	B-DNA
site	I-DNA
which	O
was	O
found	O
to	O
be	O
essential	O
for	O
both	O
the	O
PMA/	O
PHA	B-protein
-mediated	O
induction	O
as	O
well	O
as	O
the	O
synergistic	O
activation	O
observed	O
after	O
the	O
expression	O
of	O
the	O
RelA	O
subunit	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Egr-1	B-protein
.	O


Furthermore	O
,	O
Egr-1	B-protein
induction	O
was	O
required	O
for	O
endogenous	O
NF-kappa	B-DNA
B1	I-DNA
gene	O
expression	O
,	O
since	O
PMA/	O
PHA-stimulated	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
antisense	O
Egr-1	B-RNA
RNA	I-RNA
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF-kappa	O
B1	O
transcription	O
.	O


The	O
synthesis	O
and	O
immunogenicity	O
of	O
varicella-zoster	B-protein
virus	I-protein
glycoprotein	I-protein
E	I-protein
and	O
immediate-early	B-protein
protein	I-protein
(	O
IE62	B-protein
)	O
expressed	O
in	O
recombinant	O
herpes	O
simplex	O
virus-1	O
.	O


When	O
tested	O
in	O
cytotoxicity	O
assays	O
using	O
T-lymphocytes	B-cell_type
from	O
VZV	O
immune	O
human	O
donors	O
,	O
the	O
range	O
of	O
precursor	O
frequencies	O
for	O
T-lymphocytes	B-cell_type
that	O
recognized	O
VZV	B-protein
gE	I-protein
or	O
VZV	B-protein
IE62	I-protein
was	O
similar	O
whether	O
these	O
proteins	O
were	O
expressed	O
by	O
HSV-1	O
or	O
a	O
vaccinia	O
vector	O
.	O


Using	O
a	O
panel	O
of	O
specific	O
antisera	O
in	O
immunoprecipitation	O
assays	O
,	O
we	O
found	O
that	O
NFATp	B-protein
(	O
135	B-protein
kDa	I-protein
)	O
is	O
constitutively	O
expressed	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
synthesis	O
of	O
NFATc	B-protein
(	O
predominant	O
form	O
of	O
86	B-protein
kDa	I-protein
)	O
is	O
induced	O
by	O
ionomycin	O
treatment	O
.	O


Higher-molecular-weight	B-protein
species	I-protein
of	O
NFATc	B-protein
(	O
of	O
110	O
and	O
140	O
kDa	O
)	O
were	O
also	O
detected	O
.	O


Of	O
the	O
GATA-binding	B-protein
proteins	I-protein
,	O
only	O
GATA-4	B-protein
selectively	O
regulates	O
the	O
human	B-DNA
IL-5	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
IL-5	B-cell_type
producing	I-cell_type
cells	I-cell_type
which	O
express	O
multiple	B-protein
GATA-binding	I-protein
proteins	I-protein
.	O


By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O


Neuronal	B-protein
(	I-protein
type	I-protein
I	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
regulates	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activity	O
and	O
immunologic	B-protein
(	I-protein
type	I-protein
II	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
expression	O
.	O


NO	O
is	O
produced	O
from	O
at	O
least	O
three	O
different	O
NO	B-protein
synthase	I-protein
(	I-protein
NOS	I-protein
)	I-protein
isoforms	I-protein
:	O
neuronal	B-protein
NOS	I-protein
(	O
nNOS	B-protein
)	O
,	O
endothelial	B-protein
NOS	I-protein
,	O
and	O
immunologic	B-protein
NOS	I-protein
(	O
iNOS	B-protein
)	O
.	O


NF	B-protein
kappaB	I-protein
activation	O
in	O
glia	B-cell_type
from	O
mice	O
lacking	O
nNOS	B-protein
responds	O
more	O
rapidly	O
to	O
PDTC	O
compared	O
with	O
astrocytes	B-cell_type
from	O
wild-type	O
mice	O
.	O


Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
is	O
an	O
important	O
B-cell	B-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	I-protein
.	O


However	O
,	O
in	O
differentiating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
,	O
which	O
must	O
incorporate	O
high	O
levels	O
of	O
iron	O
to	O
sustain	O
hemoglobin	B-protein
synthesis	O
,	O
and	O
in	O
macrophages	B-cell_type
,	O
which	O
are	O
involved	O
in	O
iron	O
storage	O
,	O
transcriptional	O
regulation	O
seemed	O
to	O
be	O
a	O
relevant	O
mechanism	O
.	O


Rap1	B-protein
is	O
a	O
small	O
,	O
Ras-like	B-protein
GTPase	I-protein
whose	O
function	O
and	O
regulation	O
are	O
still	O
largely	O
unknown	O
.	O


Despite	O
these	O
findings	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
cooperatively	O
regulate	O
inducible	O
T-cell	O
gene	O
expression	O
remained	O
unknown	O
.	O


An	O
acute	B-DNA
myeloid	I-DNA
leukemia	I-DNA
gene	I-DNA
,	O
AML1	B-DNA
,	O
regulates	O
transcriptional	O
activation	O
and	O
hemopoietic	O
myeloid	O
cell	O
differentiation	O
antagonistically	O
by	O
two	O
alternative	O
spliced	O
forms	O
.	O


Both	O
forms	O
have	O
DNA-binding	B-protein
domain	I-protein
,	O
but	O
AML1a	B-protein
lacks	O
a	O
putative	O
transcriptional	O
activation	O
domain	O
which	O
AML1b	B-protein
has	O
.	O


Furthermore	O
a	O
dominant	B-protein
negative	I-protein
form	I-protein
of	O
AML1	B-protein
,	O
AML1a	B-protein
,	O
totally	O
suppressed	O
granulocytic	O
differentiation	O
otherwise	O
induced	O
by	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
when	O
AML1a	B-protein
was	O
overexpressed	O
in	O
32Dc13	B-cell_type
murine	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
.	O


These	O
data	O
strongly	O
suggest	O
that	O
a	O
transcriptionally	O
active	O
form	O
of	O
AML1	B-protein
is	O
essential	O
for	O
the	O
myeloid	O
cell	O
differentiation	O
.	O


RANTES	B-protein
(	O
regulated	B-protein
upon	I-protein
activation	I-protein
,	I-protein
normal	I-protein
T	I-protein
cell	I-protein
expressed	I-protein
and	I-protein
secreted	I-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
belongs	O
to	O
the	O
beta-chemokine	B-protein
family	I-protein
;	O
it	O
is	O
chemoattractant	O
for	O
CD4+/CD45RO	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
it	O
is	O
produced	O
by	O
various	O
cell	O
types	O
including	O
CD8+	B-cell_type
and	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
monocytes/macrophages	B-cell_type
,	O
and	O
has	O
recently	O
been	O
shown	O
to	O
suppress	O
replication	O
of	O
macrophage-tropic	O
strains	O
of	O
HIV	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


We	O
demonstrate	O
that	O
:	O
1	O
)	O
RANTES	B-protein
promoter	O
activity	O
is	O
up-regulated	O
by	O
PMA	O
plus	O
ionomycin	O
,	O
coexpression	O
of	O
the	O
p65	B-protein
subunit	I-protein
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
,	O
the	O
proinflammatory	B-protein
cytokines	I-protein
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
,	O
and	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
;	O
2	O
)	O
the	O
RANTES	B-DNA
promoter	I-DNA
region	I-DNA
contains	O
four	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
at	O
positions	B-DNA
-30	I-DNA
,	I-DNA
-44	I-DNA
,	I-DNA
-213	I-DNA
,	I-DNA
and	I-DNA
-579	I-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
;	O
3	O
)	O
one	O
site	O
(	O
-213	O
)	O
is	O
an	O
NF-AT	B-DNA
(	I-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
that	O
also	O
has	O
weak	O
affinity	O
to	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
most	O
distal	O
site	O
(	O
-579	O
)	O
also	O
serves	O
as	O
a	O
CD28-responsive	B-DNA
element	I-DNA
;	O
and	O
4	O
)	O
mutation	O
on	O
any	O
of	O
those	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
or	O
coexpression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
cytoplasmic	B-protein
inhibitor	I-protein
of	I-protein
NF-kappa	I-protein
B	I-protein
)	O
markedly	O
reduced	O
the	O
promoter	O
activity	O
.	O


A	O
specific	O
p38	B-protein
MAPk	I-protein
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	B-protein
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	B-protein
or	O
FMLP	B-protein
.	O


Chicken	B-protein
NF-M	I-protein
transcription	I-protein
factor	I-protein
,	O
in	O
cooperation	O
with	O
either	O
c-Myb	B-protein
or	O
v-Myb	B-protein
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid-cell-specific	B-DNA
genes	I-DNA
in	O
heterologous	B-cell_type
cell	I-cell_type
types	I-cell_type
,	O
such	O
as	O
embryonic	B-cell_type
fibroblasts	I-cell_type
.	O


In	O
humans	O
,	O
similar	O
effects	O
were	O
observed	O
with	O
homologous	O
members	O
of	O
the	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
family	I-protein
of	O
transcriptional	B-protein
regulators	I-protein
,	O
especially	O
the	O
human	O
homolog	O
of	O
chicken	B-protein
NF-M	I-protein
,	O
C/EBP-beta	B-protein
(	O
NF-IL6	B-protein
)	O
.	O


However	O
,	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
variety	O
of	O
nonmyeloid	O
cell	O
types	O
and	O
is	O
strongly	O
inducible	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
making	O
it	O
an	O
unlikely	O
candidate	O
to	O
have	O
an	O
exclusive	O
role	O
as	O
a	O
combinatorial	O
differentiation	O
switch	O
during	O
myelopoiesis	O
in	O
human	B-cell_type
cells	I-cell_type
.	O


Primer	O
extension	O
analysis	O
of	O
C/EBP-epsilon	B-RNA
mRNA	I-RNA
detected	O
a	O
single	O
major	O
transcription	B-DNA
start	I-DNA
site	I-DNA
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	B-DNA
codon	I-DNA
.	O


The	O
putative	O
promoter	O
area	O
is	O
similar	O
to	O
those	O
of	O
several	O
other	O
myeloid-cell-specific	O
genes	O
in	O
that	O
it	O
contains	O
no	O
TATAAA	B-DNA
box	I-DNA
but	O
has	O
a	O
number	O
of	O
purine-rich	B-DNA
stretches	I-DNA
with	O
multiple	O
sites	O
for	O
the	O
factors	O
of	O
the	O
Ets	B-protein
family	I-protein
of	O
transcriptional	B-protein
regulators	I-protein
.	O


The	O
human	O
C/EBP-epsilon	B-protein
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	O
to	O
double-stranded	B-DNA
DNA	I-DNA
containing	I-DNA
consensus	I-DNA
C/EBP	I-DNA
sites	I-DNA
.	O


Cotransfection	O
of	O
the	O
C/EBP-epsilon	B-protein
sense	O
and	O
antisense	O
expression	O
constructs	O
together	O
with	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
vectors	I-DNA
containing	O
myeloid-cell-specific	B-DNA
c-mim	I-DNA
and	I-DNA
human	I-DNA
myeloperoxidase	I-DNA
promoters	I-DNA
suggested	O
a	O
role	O
for	O
C/EBP-epsilon	B-protein
transcription	B-protein
factor	I-protein
in	O
the	O
regulation	O
of	O
a	O
subset	O
of	O
myeloid-cell-specific	B-DNA
genes	I-DNA
.	O


The	O
A6H	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
recognizes	O
a	O
120	B-protein
,	I-protein
000-140	I-protein
,	I-protein
000	I-protein
MW	I-protein
antigen	I-protein
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85-90	O
%	O
of	O
human	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O


Furthermore	O
,	O
no	O
induction	O
of	O
AP-1	B-protein
was	O
seen	O
in	O
A6H	B-protein
costimulated	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Twenty-two	O
differences	O
from	O
the	O
human	O
sequence	O
were	O
found	O
in	O
the	O
N-terminal	B-protein
region	I-protein
(	O
amino	B-protein
acids	I-protein
1-421	I-protein
)	O
of	O
the	O
squirrel	O
monkey	O
receptor	O
.	O


Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
is	O
necessary	O
for	O
IL-7R	B-protein
signal	O
transduction	O
.	O


We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S-allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	B-cell_type
pulmonary	I-cell_type
artery	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O


In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
Jurkat	B-cell_line
cells	I-cell_line
)	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-	B-protein
alpha	I-protein
)	O
and	O
H2O2	O
.	O


Supershift	O
with	O
specific	O
antibodies	O
to	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65-p50	B-protein
heterodimer	I-protein
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
protein	I-protein
.	O


This	O
protein	O
was	O
named	O
elf-2	B-protein
because	O
its	O
DNA-binding	B-protein
domain	I-protein
is	O
virtually	O
identical	O
to	O
that	O
of	O
ets	B-protein
family	I-protein
member	I-protein
elf-1	B-protein
.	O


The	O
expression	O
patterns	O
suggest	O
that	O
RBTN-2	B-protein
normally	O
interacts	O
equally	O
with	O
elf-2a	B-protein
and	O
elf-2b	B-protein
.	O


In	O
contrast	O
,	O
when	O
RBTN-2	B-protein
is	O
inappropriately	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
RBTN-2	B-protein
would	O
interact	O
predominantly	O
with	O
elf-2b	B-protein
;	O
this	O
interaction	O
may	O
lead	O
to	O
T	O
cell	O
proliferation	O
.	O


Although	O
no	O
single	O
chromosome	O
was	O
found	O
to	O
correlate	O
with	O
Ig	B-DNA
gene	I-DNA
silencing	O
,	O
we	O
discovered	O
that	O
the	O
two	O
types	O
of	O
hybrids	O
had	O
undergone	O
distinct	O
patterns	O
of	O
chromosome	O
loss	O
.	O


Moreover	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
a	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
Oct-2	B-protein
)	O
dramatically	O
altered	O
both	O
the	O
phenotype	O
and	O
chromosome	O
constitution	O
of	O
hybrids	O
arising	O
in	O
these	O
cell	O
fusions	O
.	O


Reactivation	O
of	O
Kaposi	O
's	O
sarcoma-associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	O
of	O
the	O
ORF	B-protein
50	I-protein
transactivator	I-protein
,	O
a	O
homolog	O
of	O
the	O
EBV	B-protein
R	I-protein
protein	I-protein
.	O


Here	O
we	O
show	O
that	O
deregulated	O
expression	O
of	O
a	O
single	O
viral	B-DNA
gene	I-DNA
,	O
ORF	B-DNA
50	I-DNA
,	O
which	O
encodes	O
a	O
transactivator	O
able	O
to	O
selectively	O
upregulate	O
delayed-early	B-DNA
viral	I-DNA
genes	I-DNA
,	O
suffices	O
to	O
disrupt	O
latency	O
and	O
induce	O
the	O
lytic	O
gene	O
cascade	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Copyright	O
1998	O
Academic	O
Press	O
.	O


Thus	O
,	O
the	O
requirement	O
for	O
CD28	B-protein
in	O
IL-2	B-DNA
promoter	I-DNA
activation	O
appears	O
to	O
be	O
due	O
to	O
RE/AP	B-protein
and	O
not	O
the	O
NFAT	B-DNA
or	I-DNA
AP-1	I-DNA
sites	I-DNA
.	O


In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
RE/AP	B-protein
is	O
not	O
mediated	O
by	O
NFAT	B-protein
,	O
because	O
activation	O
of	O
a	O
NFAT	B-protein
reporter	O
is	O
not	O
affected	O
by	O
the	O
addition	O
of	O
CTLA4Ig	O
.	O


Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O


Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O


This	O
strategy	O
depends	O
on	O
a	O
separation	O
of	O
latency	O
and	O
the	O
lytic	O
replication	O
,	O
either	O
by	O
time	O
due	O
to	O
differentiation-dependent	O
mechanisms	O
or	O
by	O
spatial	O
separation	O
as	O
the	O
result	O
of	O
different	O
host	O
cell	O
types	O
.	O


B	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
have	O
a	O
pivotal	O
role	O
in	O
the	O
life	O
cycle	O
of	O
the	O
virus	O
.	O


These	O
factors	O
control	O
the	O
activity	O
of	O
the	O
regulatory	B-DNA
immediate-early	I-DNA
genes	I-DNA
and	O
,	O
in	O
addition	O
,	O
lytic	O
and	O
latent	O
cycle	O
regulatory	O
genes	O
negatively	O
interfere	O
with	O
each	O
other	O
and	O
thus	O
link	O
cellular	O
and	O
viral	B-DNA
gene	I-DNA
regulatory	O
mechanisms	O
.	O


Using	O
a	O
yeast	O
two-hybrid	O
screen	O
to	O
identify	O
Syk	B-protein
kinases-interacting	I-protein
proteins	I-protein
(	O
SKIPs	B-protein
)	O
,	O
we	O
isolated	O
3BP2	B-protein
,	O
an	O
Abl	B-protein
SH3-interacting	I-protein
protein	I-protein
of	O
unknown	O
function	O
.	O


In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	B-cell_type
cells	I-cell_type
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases-1	B-protein
.	O


In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
(	I-cell_line
BL	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
assayed	O
for	O
their	O
expression	O
of	O
tissue	B-protein
inhibitor	I-protein
of	I-protein
metalloproteinases	I-protein
(	I-protein
TIMP	I-protein
)	I-protein
-1	I-protein
.	O


To	O
investigate	O
in	O
vivo	O
regulatory	O
mechanisms	O
that	O
control	O
the	O
population	O
of	O
type	B-cell_type
2	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
disease	O
susceptibility	O
,	O
we	O
have	O
created	O
lines	O
of	O
transgenic	O
mice	O
in	O
which	O
expression	O
of	O
a	O
chimeric	B-protein
cytokine	I-protein
receptor	I-protein
(	O
the	O
mouse	B-protein
interleukin	I-protein
2	I-protein
receptor	I-protein
beta	I-protein
chain	I-protein
[	I-protein
IL-2Rbeta	I-protein
]	I-protein
extracellular	I-protein
domain	I-protein
fused	O
to	O
the	O
cytoplasmic	B-protein
tail	I-protein
of	O
IL-4Ralpha	B-protein
)	O
is	O
targeted	O
to	O
the	O
T	B-cell_type
lymphoid	I-cell_type
lineage	I-cell_type
using	O
the	O
proximal	B-DNA
lck	I-DNA
promoter	I-DNA
.	O


This	O
chimera	O
transduced	O
IL-4	B-protein
-specific	O
signals	O
in	O
response	O
to	O
IL-2	B-protein
binding	O
and	O
dramatically	O
enhanced	O
type	O
2	O
responses	O
(	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
and	O
immunoglobulin	B-protein
E	I-protein
production	O
)	O
upon	O
in	O
vitro	O
TCR	B-protein
stimulation	O
or	O
in	O
vivo	O
antigen	O
challenge	O
.	O


In	O
PMA-treated	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
we	O
could	O
detect	O
three	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	B-RNA
antisense	I-RNA
RNA	I-RNA
probes	I-RNA
.	O


Furthermore	O
,	O
Ikaros-null	B-cell_type
thymocytes	I-cell_type
hyperproliferate	O
in	O
response	O
to	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
signaling	O
;	O
within	O
days	O
after	O
their	O
appearance	O
in	O
the	O
thymus	O
,	O
clonally	O
expanding	O
populations	O
are	O
detected	O
.	O


Here	O
we	O
demonstrate	O
that	O
the	O
putative	O
GAS	B-DNA
element	I-DNA
in	O
the	O
CAEV	B-DNA
LTR	I-DNA
binds	O
specifically	O
to	O
a	O
cellular	B-protein
factor	I-protein
induced	O
by	O
IFN-gamma	B-protein
in	O
promonocytic	B-cell_type
cells	I-cell_type
.	O


The	O
mechanism	O
underlying	O
this	O
association	O
is	O
so	O
far	O
not	O
explored	O
.	O


In	O
the	O
present	O
study	O
we	O
have	O
performed	O
electrophoretic	O
mobility-shift	O
assays	O
to	O
investigate	O
the	O
pattern	O
of	O
protein	O
binding	O
to	O
a	O
150	B-DNA
bp	I-DNA
fragment	I-DNA
of	O
the	O
proximal	B-DNA
5'-flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
monoamine	I-DNA
oxidase	I-DNA
B	I-DNA
gene	I-DNA
.	O


Receptor	B-protein
activator	I-protein
of	I-protein
NF-kappaB	I-protein
(	O
RANK	B-protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
and	O
is	O
expressed	O
on	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
dendritic	B-cell_type
cells	I-cell_type
.	O


When	O
this	O
membrane-proximal	B-protein
TRAF6	I-protein
interaction	I-protein
domain	I-protein
was	O
deleted	O
,	O
RANK	B-protein
-mediated	O
NF-kappaB	B-protein
signaling	O
was	O
completely	O
inhibited	O
while	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
activation	O
was	O
partially	O
inhibited	O
.	O


Stat6	B-protein
inhibits	O
human	O
interleukin-4	B-DNA
promoter	I-DNA
activity	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


The	O
molecular	O
mechanisms	O
by	O
which	O
IL-4	B-protein
induces	O
expression	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
are	O
not	O
known	O
,	O
although	O
the	O
IL-4-activated	B-protein
transcription	I-protein
factor	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
6	I-protein
(	O
Stat6	B-protein
)	O
is	O
required	O
for	O
this	O
effect	O
.	O


We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	B-protein
is	O
highly	O
dependent	O
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	O
IL-4	B-protein
gene	O
expression	O
in	O
an	O
indirect	O
manner	O
.	O


BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O


Human	O
intestinal	B-cell_type
epithelial	I-cell_type
cell	I-cell_type
inflammatory	O
responses	O
to	O
amebic	O
infection	O
were	O
inhibited	O
by	O
the	O
intraluminal	O
administration	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
the	O
human	B-protein
p65	I-protein
subunit	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
,	O
and	O
the	O
role	O
of	O
neutrophils	O
in	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
was	O
studied	O
by	O
depleting	O
neutrophils	B-cell_type
from	O
SCID-HU-INT	O
mice	O
.	O


In	O
attempting	O
to	O
investigate	O
its	O
effect	O
on	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
we	O
found	O
triptolide	O
induces	O
apoptotic	O
death	O
of	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
and	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
that	O
of	O
thymocytes	B-cell_type
.	O


Our	O
results	O
seem	O
to	O
confirm	O
a	O
possible	O
role	O
of	O
the	O
transcriptional	B-protein
complex	I-protein
AP-1	B-protein
in	O
activating	O
GST-pi	B-DNA
promoter	I-DNA
in	O
human	B-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O


Recently	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signal	O
transduction	O
pathways	O
activated	O
by	O
these	O
cytokines	B-protein
in	O
eosinophils	B-cell_type
.	O


Moreover	O
,	O
antisense	O
oligodeoxynucleotides	O
targeting	O
either	O
GATA-1	B-protein
or	O
p45	B-protein
NF-E2	I-protein
proteins	O
inhibited	O
both	O
protein	O
expression	O
and	O
BA-induced	O
differentiation	O
.	O


In	O
contrast	O
,	O
BA-induced	O
cell	O
growth	O
inhibition	O
was	O
not	O
affected	O
.	O


These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
for	O
the	O
requirement	O
of	O
GATA-1	B-protein
and	O
NF-E2	B-protein
in	O
BA-induced	O
differentiation	O
process	O
.	O


Characterisation	O
of	O
regulatory	O
sequences	O
at	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
BamHI	I-DNA
W	I-DNA
promoter	I-DNA
.	O


The	O
initiation	O
of	O
this	O
growth	O
transforming	O
infection	O
depends	O
on	O
a	O
viral	B-DNA
promoter	I-DNA
in	O
BamHI	O
W	O
(	O
Wp	O
)	O
whose	O
regulation	O
is	O
poorly	O
understood	O
.	O


By	O
contrast	O
,	O
UAS1	B-DNA
(	O
-140	B-DNA
to	I-DNA
-87	I-DNA
)	O
was	O
B	O
cell	O
specific	O
and	O
was	O
the	O
key	O
determinant	O
of	O
the	O
promoter	O
's	O
increased	O
activity	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Following	O
EBV	O
infection	O
,	O
Epstein-Barr	O
nuclear	O
antigen	O
(	O
EBNA	B-protein
)	O
expression	O
could	O
be	O
detected	O
in	O
T	B-cell_type
rosetting	I-cell_type
CD4+	I-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


In	O
contrast	O
to	O
myeloid-related	B-cell_type
DC	I-cell_type
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
is	O
not	O
required	O
for	O
the	O
development	O
of	O
these	O
lymphoid-related	B-cell_type
DC	I-cell_type
in	O
vivo	O
or	O
in	O
vitro	O
.	O


Post	O
HIV-1	O
entry	O
,	O
productive	O
HIV-1	O
infection	O
of	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
requires	O
overcoming	O
several	O
cellular	O
blocks	O
to	O
provirus	O
establishment	O
and	O
replication	O
.	O


Regulation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
STAT1	B-protein
nuclear	O
import	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
by	O
noninvasive	O
delivery	O
of	O
peptide	O
carrying	O
the	O
nuclear	B-protein
localization	I-protein
sequence	I-protein
of	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
.	O


NLS	B-protein
peptide-mediated	O
disruption	O
of	O
the	O
nuclear	O
import	O
of	O
these	O
transcription	B-protein
factors	I-protein
results	O
in	O
inhibition	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
IL-2	O
gene	O
expression	O
,	O
processes	O
dependent	O
on	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
combination	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
and	O
NFAT	B-protein
.	O


Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
STAT1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
can	O
be	O
regulated	O
by	O
NLS	B-protein
peptide	O
delivered	O
noninvasively	O
to	O
the	O
cytoplasm	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
to	O
target	O
members	O
of	O
the	O
importin	B-protein
(	I-protein
karyopherin	I-protein
)	I-protein
-alpha	I-protein
beta	I-protein
NLS	B-protein
receptor	I-protein
complex	I-protein
.	O


Forty-eight	O
hours	O
after	O
transfection	O
,	O
EC	B-cell_type
were	O
stimulated	O
with	O
NK	B-cell_type
cells	I-cell_type
or	O
NK	B-cell_type
cell	I-cell_type
membrane	I-cell_type
extracts	I-cell_type
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	B-protein
assay	O
.	O


Furthermore	O
,	O
LTalpha	B-protein
was	O
secreted	O
in	O
NK	B-cell_line
:	I-cell_line
EC	I-cell_line
co-cultures	I-cell_line
.	O


Coexpression	O
of	O
dominant	B-protein
negative	I-protein
Ras	I-protein
abrogated	O
the	O
basal	O
or	O
ionomycin-stimulated	O
,	O
70Z/3	B-protein
-mediated	O
NFAT	B-protein
activation	O
,	O
suggesting	O
a	O
functional	B-protein
Ras	I-protein
is	O
required	O
for	O
this	O
activation	O
.	O


We	O
previously	O
reported	O
that	O
monocyte	O
adhesion	O
to	O
tumor	B-cell_line
necrosis	I-cell_line
factor-alpha	I-cell_line
(	I-cell_line
TNF-alpha	I-cell_line
)	I-cell_line
-treated	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
increased	O
expression	O
of	O
tissue	O
factor	O
and	O
CD36	B-protein
on	O
monocytes	O
.	O


To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	B-DNA
genes	I-DNA
by	O
CD15	O
engagement	O
,	O
a	O
CAT	O
plasmid	O
reporter	O
construct	O
containing	O
IL-1	B-DNA
beta	I-DNA
promoter/enhancer	I-DNA
sequences	I-DNA
was	O
introduced	O
into	O
MM6	B-cell_line
.	O


In	O
addition	O
to	O
its	O
well-recognized	O
adhesive	O
role	O
,	O
CD15	O
may	O
function	O
as	O
an	O
important	O
signaling	O
molecule	O
capable	O
of	O
initiating	O
proinflammatory	O
events	O
in	O
monocytes	B-cell_type
that	O
come	O
into	O
contact	O
with	O
activated	O
endothelium	O
.	O


CD2	B-protein
cross-linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	B-protein
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O


The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS-related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O


Activation	O
of	O
the	O
human	B-DNA
delta-globin	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
primary	B-cell_type
adult	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O


Restoration	O
of	O
the	O
CCAAT	B-DNA
box	I-DNA
or	O
insertion	O
of	O
an	O
erythroid	B-DNA
Kruppel-like	I-DNA
factor	I-DNA
(	I-DNA
EKLF	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
delta	B-DNA
promoter	I-DNA
activates	O
its	O
expression	O
in	O
several	O
erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
lung	B-cell_type
macrophage	I-cell_type
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	B-protein
mediators	I-protein
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
the	O
chemokines	B-protein
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	I-protein
and	I-protein
-6	I-protein
,	O
and	O
matrix	B-protein
metalloproteinase-9	I-protein
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O


Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	B-cell_type
cells	I-cell_type
,	O
bronchial	B-cell_type
cells	I-cell_type
,	O
and	O
fibroblasts	B-cell_type
failed	O
to	O
produce	O
IL-8	B-protein
in	O
response	O
to	O
a	O
prolonged	O
cyclic	O
pressure-stretching	O
load	O
.	O


In	O
this	O
system	O
,	O
simultaneous	O
exposure	O
to	O
CD40L	B-protein
together	O
with	O
either	O
IL-4	B-protein
or	O
IFN-gamma	B-protein
does	O
not	O
lead	O
to	O
the	O
activation	O
of	O
novel	O
Rel/STAT	B-protein
complexes	I-protein
.	O


Human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
express	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
when	O
stimulated	O
with	O
the	O
extracellular	B-protein
matrix	I-protein
glycoprotein	I-protein
,	O
fibronectin	B-protein
(	O
FN	B-protein
)	O
.	O


Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activation	O
is	O
considered	O
important	O
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	B-protein
acts	O
upon	O
to	O
mediate	O
the	O
FN	B-protein
-induced	O
IL-1beta	B-protein
response	O
remain	O
unclear	O
.	O


U937	O
cells	O
transfected	O
with	O
the	O
human	O
full-length	B-DNA
IL-1beta	I-DNA
promoter	I-DNA
connected	O
to	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O


To	O
approach	O
this	O
issue	O
,	O
we	O
used	O
CD36	B-protein
transfected	O
Chinese	B-cell_type
hampster	I-cell_type
ovary	I-cell_type
(	I-cell_type
CHO	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
exposed	O
them	O
to	O
Ox	O
LDL	O
,	O
and	O
determined	O
changes	O
in	O
the	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O


The	O
structural	O
organization	O
of	O
the	O
393	B-protein
amino	I-protein
acid	I-protein
long	I-protein
human	I-protein
TRAMP	I-protein
is	O
most	O
homologous	O
to	O
TNF	B-protein
receptor	I-protein
1	I-protein
.	O


The	O
effect	O
of	O
both	O
cytokines	B-protein
on	O
the	O
monocyte	O
maturation/differentiation	O
(	O
CD11b	B-protein
,	O
CD13	B-protein
,	O
and	O
CD26	B-protein
)	O
and	O
other	O
macrophage	B-protein
markers	I-protein
(	O
CD14	B-protein
and	O
CD68	B-protein
)	O
was	O
examined	O
.	O


Mice	O
lacking	O
the	O
transcription	B-protein
factor	I-protein
CIITA	B-protein
--	O
a	O
second	O
look	O
.	O


Our	O
and	O
the	O
previously	O
published	O
lines	O
differ	O
in	O
the	O
deletion	O
that	O
was	O
engineered	O
and	O
by	O
the	O
fact	O
that	O
we	O
removed	O
the	O
neomycin-resistance	B-DNA
promoter	I-DNA
and	O
structural	B-DNA
gene	I-DNA
via	O
the	O
cre-loxP	O
recombination	O
system	O
.	O


Second	O
,	O
in	O
contrast	O
to	O
recent	O
results	O
on	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CIITA	B-protein
is	O
not	O
critically	O
involved	O
in	O
the	O
IFN-gamma	B-protein
-induced	O
up-regulation	O
of	O
MHC	B-DNA
class	I-DNA
I	I-DNA
genes	I-DNA
.	O


NF-kappaB	B-protein
activation	O
in	O
response	O
to	O
inflammatory	O
signals	O
is	O
dependent	O
upon	O
degradation	O
of	O
its	O
associated	O
inhibitory	O
peptide	O
,	O
inhibitory	B-protein
kappaB-alpha	I-protein
(	O
IkappaB-alpha	B-protein
)	O
.	O


Following	O
stimulation	O
,	O
TNF-alpha	B-protein
was	O
measured	O
in	O
cell	O
supernatants	O
by	O
ELISA	O
,	O
NF-kappaB	B-protein
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
IkappaB-alpha	B-protein
levels	O
by	O
Western	O
blot	O
.	O


After	O
LPS	O
stimulation	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
IkappaB-alpha	B-protein
protein	O
levels	O
decreased	O
,	O
and	O
NF-kappaB	B-protein
DNA	O
binding	O
increased	O
.	O


Dexamethasone	O
inhibits	O
binding	O
to	O
the	O
Ikaros	B-protein
and	O
AP-1	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
.	O


Dexamethasone	O
,	O
a	O
glucocorticoid	O
that	O
is	O
widely	O
used	O
as	O
an	O
immunomodulatory	O
and	O
anti-inflammatory	O
agent	O
,	O
inhibits	O
granzyme	B-RNA
B	I-RNA
mRNA	I-RNA
transcript	I-RNA
in	O
phytohemagglutinin-activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


Glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
polycystic	O
ovary	O
syndrome	O
.	O


METHOD	O
:	O
For	O
this	O
purpose	O
,	O
the	O
number	O
and	O
affinity	O
of	O
GR	B-protein
in	O
peripheral	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	O
)	O
of	O
10	O
patients	O
with	O
PCOS	O
and	O
10	O
healthy	O
women	O
(	O
controls	O
)	O
were	O
determined	O
.	O


NGAL	B-protein
levels	O
varied	O
in	O
these	O
tumors	O
from	O
undetectable	O
to	O
exceeding	O
those	O
in	O
normal	O
breast	O
parenchyma	O
.	O


BASH	B-protein
shows	O
a	O
substantial	O
sequence	O
similarity	O
to	O
SLP-76	B-protein
,	O
an	O
adaptor	O
protein	O
functioning	O
in	O
TCR	B-protein
-signal	O
transduction	O
.	O


This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
composition	O
of	O
StatG	B-protein
in	O
mature	B-cell_type
normal	I-cell_type
human	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
i.e	O
.	O
polymorphonuclear	B-cell_type
neutrophilic	I-cell_type
granulocytes	I-cell_type
(	O
PMN	B-cell_type
)	O
.	O


Stat3gamma	B-protein
is	O
derived	O
from	O
Stat3alpha	B-protein
by	O
limited	O
proteolysis	O
and	O
lacks	O
the	O
carboxyl-terminal	B-protein
portion	I-protein
of	O
Stat3alpha	B-protein
.	O


In	O
order	O
to	O
investigate	O
the	O
factors	O
that	O
influence	O
the	O
induction	O
of	O
ICAM-1	B-protein
molecules	O
,	O
Northern	O
blot	O
analysis	O
to	O
measure	O
the	O
expression	O
level	O
of	O
ICAM-1	B-RNA
mRNAs	I-RNA
and	O
Southern	O
blot	O
hybridization	O
to	O
analyze	O
the	O
integration	O
of	O
human	O
T-cell-leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
provirus	O
were	O
done	O
.	O


These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV-1	O
provirus	O
to	O
the	O
genome	O
of	O
T	B-cell_type
cell	I-cell_type
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	O
of	O
ICAM-1	B-protein
molecules	I-protein
.	O


In	O
addition	O
,	O
both	O
heat	O
and	O
cadmium	O
produced	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
intermediate	B-protein
filament	I-protein
protein	I-protein
vimentin	B-protein
,	O
as	O
determined	O
by	O
immunoblot	O
and	O
immunofluorescence	O
assays	O
.	O


By	O
contrast	O
,	O
the	O
amounts	O
of	O
actin	B-protein
and	O
beta-tubulin	B-protein
were	O
not	O
significantly	O
altered	O
.	O


Ovarian	O
and	O
breast	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
can	O
recognize	O
peptides	O
from	O
the	O
amino	O
enhancer	O
of	O
split	O
protein	O
of	O
the	O
Notch	B-protein
complex	I-protein
.	O


Three	O
of	O
these	O
peptides	O
designated	O
as	O
G75	O
:	O
AES1/2	O
(	O
128-135	B-protein
)	O
,	O
G60	O
:	O
AES1/2	O
(	O
127-137	B-protein
)	O
and	O
G61	O
:	O
AES1/2	O
(	O
125-133	B-protein
)	O
correspond	O
to	O
the	O
wildtype	B-DNA
AES	I-DNA
sequence	I-DNA
,	O
while	O
the	O
fourth	O
G76	O
:	O
GPLTPLPV	O
,	O
AES1/2	B-protein
(	I-protein
128-135	I-protein
)	I-protein
corresponds	O
to	O
a	O
variant	O
sequence	O
of	O
the	O
peptide	O
G75	O
with	O
the	O
N-terminal	O
Leu	O
substituted	O
to	O
glycine	O
.	O


Our	O
data	O
suggest	O
that	O
stimulation	O
of	O
PML	B-DNA
expression	O
by	O
interferons	B-protein
and	O
IL-1	B-protein
may	O
account	O
for	O
upregulation	O
of	O
PML	B-protein
proteins	I-protein
observed	O
in	O
inflammatory	O
tissues	O
and	O
in	O
proliferative	O
states	O
.	O


EBV	O
encodes	O
a	O
unique	O
transcriptional	O
activator	O
,	O
known	O
as	O
ZEBRA	B-protein
,	O
which	O
can	O
disrupt	O
viral	O
latency	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
induce	O
lytic	O
viral	O
replication	O
.	O


These	O
mutants	O
were	O
used	O
to	O
demonstrate	O
that	O
the	O
ability	O
of	O
ZEBRA	B-protein
's	I-protein
wild	I-protein
type	I-protein
domain	I-protein
to	O
function	O
in	O
the	O
complex	O
biological	O
process	O
of	O
virus	O
activation	O
is	O
not	O
compromised	O
by	O
altering	O
its	O
position	O
within	O
the	O
protein	O
.	O


Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor	I-protein
beta	I-protein
(	O
TGF-beta	B-protein
)	O
are	O
inhibitory	O
for	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
IgE	B-protein
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	B-cell_type
.	O


The	O
IL-10	B-protein
gene	O
polymorphism	O
was	O
a	O
C-to-A	O
exchange	O
571	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
from	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
and	O
was	O
present	O
between	O
consensus	B-DNA
binding	I-DNA
sequences	I-DNA
for	O
Sp1	B-protein
and	O
elevated	O
total	O
serum	O
.	O


Since	O
the	O
activation	O
of	O
NFAT	B-protein
is	O
MAPK	B-protein
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
Tpl-2	B-protein
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B-protein
and	O
MEK2	B-protein
.	O


Experiments	O
in	O
COS-1	B-cell_line
and	O
EL-4	B-cell_line
cells	I-cell_line
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	B-protein
is	O
NF-kappaB	B-protein
.	O


While	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
NFAT	B-protein
delta418	I-protein
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	B-protein
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	B-protein
-mediated	O
NFAT	B-protein
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin-dependent	O
and	O
independent	O
pathways	O
.	O


The	O
finding	O
that	O
functionally	O
distinct	O
isoforms	O
of	O
STAT5	B-protein
are	O
activated	O
during	O
the	O
early	O
and	O
late	O
differentiation	O
stages	O
of	O
granulocytes	O
suggests	O
that	O
they	O
might	O
be	O
involved	O
in	O
regulating	O
different	O
biological	O
functions	O
in	O
these	O
cells	O
.	O


In	O
sharp	O
contrast	O
,	O
in	O
B	B-cell_type
cells	I-cell_type
treated	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
strong	O
interactions	O
between	O
the	O
X2	B-DNA
box	I-DNA
and	O
NF-X2	B-DNA
containing	O
c-Fos	B-protein
were	O
observed	O
.	O


We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	B-DNA
,	O
the	O
promoter	B-DNA
and	O
the	O
silencer	B-DNA
of	O
the	O
human	B-DNA
CD4	I-DNA
gene	I-DNA
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O


Immunofluorescence	O
studies	O
on	O
thymic	B-cell_type
populations	I-cell_type
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	B-DNA
DNA	I-DNA
elements	I-DNA
revealed	O
that	O
thymocytes	B-cell_type
control	O
the	O
CD4	B-DNA
gene	I-DNA
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


Glucocorticoids	O
can	O
induce	O
apoptosis	O
on	O
normal	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
play	O
a	O
key	O
role	O
in	O
the	O
physiology	O
of	O
thymic	O
selection	O
.	O


In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha-zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O


Unlike	O
the	O
mycoestrogens	O
,	O
none	O
of	O
the	O
compounds	O
,	O
with	O
the	O
exception	O
of	O
genistein	O
,	O
synergized	O
with	O
LPS	O
to	O
enhance	O
IL-1beta	B-DNA
promoter	I-DNA
activity	O
.	O


Dendritic	B-cell_type
cells	I-cell_type
and	O
autologous	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
a	O
series	O
of	O
density-gradient	O
centrifugations	O
or	O
magnetic	O
bead	O
separations	O
(	O
or	O
both	O
)	O
.	O


Peptides	O
corresponding	O
to	O
residues	O
of	O
the	O
immediate	B-protein
early	I-protein
protein	I-protein
,	O
IE62	B-protein
,	O
of	O
varicella-zoster	O
virus	O
(	O
VZV	O
)	O
were	O
used	O
as	O
stimulating	B-protein
antigens	I-protein
,	O
and	O
persons	O
with	O
no	O
history	O
of	O
varicella	O
and	O
no	O
humoral	O
or	O
cellular	O
immunity	O
to	O
VZV	O
served	O
as	O
naive	O
donors	O
for	O
the	O
assays	O
.	O


This	O
assay	O
has	O
potential	O
as	O
a	O
screen	O
to	O
establish	O
the	O
immunogenicity	O
of	O
viral	O
antigens	O
in	O
vitro	O
using	O
T	B-cell_type
cells	I-cell_type
from	O
naive	O
donors	O
.	O


Anaphylatoxins	B-protein
C5a	B-protein
and	O
C3a	B-protein
induce	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activation	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O


These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	B-protein
C5a	B-protein
and	O
C3a	B-protein
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein-coupled	O
transcription	O
factor	O
activation	O
.	O


Thrombopoietin	B-protein
and	O
its	O
receptor	O
.	O


TPO	B-protein
is	O
a	O
hormone	O
constitutively	O
produced	O
mainly	O
by	O
the	O
liver	O
and	O
kidney	O
.	O


TAL1	B-protein
and	O
LIM-only	B-protein
proteins	I-protein
synergistically	O
induce	O
retinaldehyde	B-protein
dehydrogenase	I-protein
2	I-protein
expression	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	B-protein
.	O


As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so-called	O
glucose	O
toxicity	O
to	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
,	O
we	O
induced	O
glycation	O
in	O
HIT-T15	B-cell_type
cells	I-cell_type
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D-ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O


The	O
results	O
of	O
reporter	B-DNA
gene	I-DNA
analyses	O
revealed	O
that	O
the	O
insulin	B-DNA
gene	I-DNA
promoter	I-DNA
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta-actin	B-DNA
gene	I-DNA
promoter	I-DNA
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	B-DNA
gene	I-DNA
promoter	I-DNA
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D-ribose	O
,	O
respectively	O
.	O


Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
rheumatic	O
diseases	O
:	O
a	O
preliminary	O
report	O
.	O


The	O
activation	O
of	O
this	O
nuclear	O
factor	O
is	O
qualitatively	O
different	O
in	O
rheumatoid	B-cell_type
synovial	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
that	O
in	O
other	O
forms	O
of	O
non-rheumatoid	O
arthritis	O
(	O
for	O
example	O
,	O
osteoarthritis	O
,	O
spondyloarthropathies	O
)	O
.	O


In-vitro	O
transcription/translation	O
of	O
this	O
cDNA	B-DNA
expressed	O
a	O
protein	O
of	O
approximately	O
20	O
kDa	O
.	O


Conserved	B-DNA
elements	I-DNA
containing	O
NF-E2	B-DNA
and	I-DNA
tandem	I-DNA
GATA	I-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
erythroid-specific	O
chromatin	O
structure	O
reorganization	O
within	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O


These	O
domains	O
,	O
which	O
have	O
been	O
characterized	O
as	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
HSs	B-DNA
)	O
,	O
comprise	O
the	O
active	O
elements	O
of	O
the	O
LCR	B-DNA
.	O


Our	O
previous	O
investigations	O
on	O
the	O
formation	O
of	O
LCR	B-DNA
HS4	I-DNA
demonstrated	O
that	O
NF-E2	B-DNA
and	I-DNA
tandem	I-DNA
,	I-DNA
inverted	I-DNA
GATA	I-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
the	O
formation	O
of	O
the	O
native	B-DNA
HS	I-DNA
.	O


Similarly	O
arranged	O
NF-E2	B-DNA
and	I-DNA
tandem	I-DNA
GATA	I-DNA
sites	I-DNA
are	O
present	O
within	O
the	O
core	B-DNA
regions	I-DNA
of	O
the	O
other	O
human	B-DNA
LCR	I-DNA
HSs	I-DNA
and	O
are	O
evolutionarily	O
conserved	O
.	O


AU-DD	B-DNA
is	O
an	O
AU-motif-directed	B-DNA
differential	I-DNA
display	I-DNA
that	O
permits	O
the	O
identification	O
of	O
ARE-containing	B-DNA
genes	I-DNA
differentially	O
expressed	O
after	O
cell	O
activation	O
.	O


When	O
introduced	O
in	O
front	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
this	O
promoter	O
is	O
able	O
to	O
direct	O
a	O
high	O
luciferase	B-protein
activity	O
in	O
a	O
human	B-cell_line
B-LCL	I-cell_line
.	O


In	O
contrast	O
with	O
endometriosis	O
,	O
adenomyotic	O
lesions	O
showed	O
identical	O
steroid	B-protein
hormone	I-protein
receptor	I-protein
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	B-protein
expression	O
and	O
leukocyte	O
subpopulations	O
to	O
eutopic	O
endometrium	O
,	O
indicating	O
different	O
aetiologies	O
for	O
these	O
disorders	O
.	O


CD27	B-protein
/CD70	O
interaction	O
augments	O
IgE	B-protein
secretion	O
by	O
promoting	O
the	O
differentiation	O
of	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
into	O
plasma	B-cell_type
cells	I-cell_type
.	O


The	O
induction	O
of	O
IgE	B-protein
switching	O
in	O
B	B-cell_type
cells	I-cell_type
requires	O
several	O
signals	O
given	O
by	O
cytokines	B-protein
and	O
cell	O
contact-delivered	O
signals	O
.	O


Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5'-untranslated	B-DNA
leader	I-DNA
region	I-DNA
(	O
5'-UTR	B-DNA
)	O
also	O
contains	O
important	O
transcriptional	B-DNA
elements	I-DNA
.	O


These	O
regulatory	B-DNA
elements	I-DNA
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	B-protein
factors	I-protein
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV-1	O
transcription	O
and	O
replication	O
.	O


The	O
5'-UTR	B-DNA
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	B-protein
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O


Furthermore	O
,	O
transfection	O
with	O
LMP1	B-DNA
expression	I-DNA
vector	I-DNA
into	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Daudi	B-cell_line
,	O
led	O
to	O
p40	B-protein
production	O
with	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
activation	O
.	O


These	O
results	O
suggest	O
that	O
transformation	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
EBV	O
induces	O
IL-12	B-protein
expression	O
potentially	O
through	O
LMP1	B-protein
expression	O
.	O


The	O
human	B-DNA
gene	I-DNA
encoding	O
the	O
lectin-type	B-protein
oxidized	I-protein
LDL	I-protein
receptor	I-protein
(	O
OLR1	B-protein
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
with	O
a	O
unique	O
expression	O
profile	O
.	O


LOX-1	B-protein
has	O
the	O
highest	O
homology	O
with	O
C-type	B-protein
lectin	I-protein
receptors	I-protein
expressed	O
on	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O


These	O
results	O
demonstrate	O
that	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
is	O
a	O
new	O
member	O
of	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
with	O
a	O
unique	O
expression	O
profile	O
.	O


In	O
apparent	O
contradiction	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Ras	B-protein
,	O
RasN17	B-protein
,	O
also	O
inhibited	O
IL-2	B-protein
-induced	O
activation	O
of	O
the	O
promoter	O
containing	O
the	O
minimal	O
beta-casein	B-DNA
STAT5	I-DNA
element	I-DNA
as	O
well	O
as	O
the	O
promoters	O
of	O
CIS	B-protein
and	O
OSM	B-protein
.	O


In	O
addition	O
,	O
Ras	B-protein
(	I-protein
G12V	I-protein
)	I-protein
complemented	O
signaling	O
by	O
an	O
erythropoietin	B-protein
receptor	I-protein
mutant	I-protein
defective	O
in	O
Ras	B-protein
activation	O
and	O
augmented	O
the	O
activation	O
of	O
the	O
beta-casein	B-DNA
promoter	I-DNA
by	O
the	O
mutant	B-protein
erythropoietin	I-protein
receptor	I-protein
signaling	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
Ras	B-protein
in	O
Stat5	B-protein
-mediated	O
gene	O
expression	O
.	O


These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	B-protein
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O


We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	B-protein
receptors	I-protein
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	B-protein
in	O
monocytes	B-cell_type
.	O


We	O
further	O
demonstrated	O
that	O
IL-2	B-protein
,	I-protein
-7	I-protein
,	I-protein
and	I-protein
-15	I-protein
induce	O
multiple	B-protein
STAT	I-protein
proteins	I-protein
,	O
including	O
STAT5a	B-protein
,	O
STAT5b	B-protein
,	O
STAT1	B-protein
alpha	I-protein
,	O
STAT3	B-protein
,	O
and	O
another	O
unidentified	O
Fc	B-protein
gamma	I-protein
RI	I-protein
GAS	I-protein
DNA-binding	I-protein
protein	I-protein
.	O


Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	B-protein
and	O
STAT5b	B-protein
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O


Our	O
data	O
provide	O
evidence	O
that	O
the	O
differential	O
responses	O
in	O
gene	O
expression	O
and	O
cell	O
activation	O
seen	O
in	O
primary	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
on	O
direct	O
stimulation	O
with	O
different	O
cytokines	B-protein
may	O
be	O
a	O
direct	O
result	O
of	O
distinct	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O


To	O
study	O
the	O
molecular	O
mechanisms	O
of	O
transcriptional	O
control	O
of	O
CD95L	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
investigated	O
the	O
human	B-DNA
CD95L	I-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


A	O
mouse	O
carrying	O
genetic	O
defect	O
in	O
the	O
choice	O
between	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


Downstream	O
activation	O
of	O
a	O
TATA-less	B-DNA
promoter	I-DNA
by	O
Oct-2	B-protein
,	O
Bob1	O
,	O
and	O
NF-kappaB	B-protein
directs	O
expression	O
of	O
the	O
homing	B-protein
receptor	I-protein
BLR1	I-protein
to	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


The	O
long-term	O
exposure	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
to	O
hormone	O
eventually	O
results	O
in	O
a	O
selection	O
of	O
cell	B-cell_line
clones	I-cell_line
that	O
have	O
lost	O
Tax	B-protein
activity	O
.	O


This	O
study	O
suggests	O
a	O
therapeutic	O
approach	O
against	O
AIDS	O
by	O
application	O
of	O
two	O
drugs	O
,	O
one	O
against	O
a	O
cellular	O
and	O
the	O
other	O
a	O
viral	O
target	O
,	O
which	O
may	O
provide	O
an	O
approach	O
to	O
the	O
problem	O
of	O
frequent	O
emergence	O
of	O
resistant	O
variants	O
to	O
combinations	O
of	O
drugs	O
that	O
target	O
only	O
HIV	B-DNA
genes	I-DNA
.	O


Intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
can	O
express	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
may	O
function	O
as	O
antigen-presenting	B-cell_type
cells	I-cell_type
to	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
within	O
the	O
intestinal	O
mucosa	O
.	O


Tobacco	O
smoke	O
(	O
TS	O
)	O
exposure	O
is	O
a	O
major	O
risk	O
factor	O
for	O
human	O
disease	O
,	O
and	O
macrophages	B-cell_type
of	O
healthy	O
smokers	O
have	O
a	O
depressed	O
capacity	O
to	O
release	O
cytokines	B-protein
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
alpha	I-protein
.	O


HSF	B-protein
activation	O
has	O
been	O
shown	O
to	O
inhibit	O
NFkappaB	B-protein
.	O


The	O
altered	O
cytokine	B-protein
profile	I-protein
observed	O
in	O
smokers	O
may	O
relate	O
to	O
an	O
HSF	B-protein
/	O
Hsp70	B-protein
-mediated	O
inhibition	O
of	O
NFkappaB	B-protein
activity	O
.	O


Activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
mediated	O
by	O
the	O
T	O
cell	O
receptor	O
induces	O
a	O
series	O
of	O
biochemical	O
events	O
.	O


We	O
propose	O
that	O
one	O
of	O
the	O
targets	O
of	O
PGE2	O
,	O
whose	O
effect	O
distinguishes	O
Th1	B-cell_line
from	O
Th2	O
,	O
resides	O
in	O
the	O
downstream	O
PKC/Ras	B-protein
-mediated	O
pathway	O
.	O


This	O
translocation	O
process	O
coupled	O
to	O
the	O
subsequent	O
active	O
maintenance	O
of	O
NFAT	B-protein
in	O
the	O
nucleus	O
compartment	O
is	O
critical	O
for	O
the	O
induction	O
of	O
expression	O
of	O
several	O
genes	O
encoding	O
cytokines	B-protein
and	O
membrane	B-protein
proteins	I-protein
that	O
modulate	O
immune	O
responses	O
.	O


Differential	O
RNA	O
display	O
identifies	O
novel	B-DNA
genes	I-DNA
associated	O
with	O
decreased	O
vitamin	B-protein
D	I-protein
receptor	I-protein
expression	O
.	O


Experiments	O
conducted	O
with	O
different	O
HIV-1	B-DNA
LTR-based	I-DNA
vectors	I-DNA
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O


In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	B-protein
factors	I-protein
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
.	O


Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
.	O


Low	O
CD3+CD28-induced	O
interleukin-2	B-protein
production	O
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


We	O
analysed	O
IL-2	B-protein
production	O
in	O
purified	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
T	I-cell_type
cells	I-cell_type
using	O
polyclonal	O
activator	O
phorbol	O
ester	O
+	O
calcium	O
ionophore	O
(	O
PDBu	O
+	O
iono	O
)	O
or	O
receptor-mediated	O
anti-CD3	B-protein
/anti-CD3+	O
anti-CD28	B-protein
stimulation	O
.	O


Expression	O
of	O
CD30	B-protein
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	B-protein
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL-6	B-protein
and	O
IL-12	B-protein
.	O


Finally	O
,	O
it	O
would	O
be	O
useful	O
to	O
know	O
what	O
the	O
inhibitory	O
effects	O
of	O
CyA	O
are	O
on	O
tolerance	O
and	O
negative	O
regulatory	O
events	O
.	O


During	O
B	O
and	O
T	O
cell	O
differentiation	O
and	O
proliferation	O
many	O
genes	O
are	O
induced	O
or	O
repressed	O
while	O
certain	O
genes	O
are	O
constitutively	O
expressed	O
.	O


Also	O
genes	O
encoding	O
proteins	O
involved	O
in	O
DNA	O
replication	O
,	O
binding	O
,	O
transcription	O
and	O
translation	O
were	O
induced	O
.	O


Large	O
part	O
of	O
the	O
activated	B-DNA
genes	I-DNA
were	O
under	O
very	O
stringent	O
regulation	O
being	O
expressed	O
only	O
after	O
stimulation	O
.	O


The	O
mechanism	O
and	O
function	O
of	O
the	O
expressed	B-DNA
genes	I-DNA
during	O
lymphocyte	O
differentiation	O
and	O
in	O
disorders	O
is	O
discussed	O
.	O


Interleukin	B-protein
2	I-protein
and	I-protein
15	I-protein
activate	O
Stat3alpha	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


It	O
is	O
unknown	O
which	O
Stat3	B-protein
isoform	I-protein
(	O
s	O
)	O
is	O
activated	O
in	O
response	O
to	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
and	O
IL-15	B-protein
.	O


Here	O
,	O
cytokine	B-protein
-induced	O
activation	O
of	O
Stat3	B-protein
in	O
previously	O
activated	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
examined	O
using	O
Stat3	B-protein
antibodies	O
directed	O
against	O
different	O
regions	O
of	O
Stat3	B-protein
.	O


In	O
contrast	O
,	O
minimal	O
or	O
no	O
activation	O
of	O
Stat3beta	B-protein
was	O
observed	O
,	O
suggesting	O
that	O
IL-2	B-protein
and	O
IL-15	B-protein
predominantly	O
activate	O
Stat3alpha	B-protein
in	O
human	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


The	O
cell	O
type-specific	O
increase	O
in	O
LAL	B-protein
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP-1	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O


In	O
order	O
to	O
determine	O
the	O
cis-acting	B-DNA
elements	I-DNA
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12-myristate-13	O
acetate	O
(	O
PMA	O
)	O
-enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	B-DNA
gene	I-DNA
assays	O
.	O


Relationship	O
between	O
IkappaBalpha	B-protein
constitutive	O
expression	O
,	O
TNFalpha	B-protein
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV-infected	B-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
.	O


Potent	O
inhibition	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
an	O
antiinflammatory	O
alkaloid	O
,	O
cepharanthine	O
,	O
in	O
chronically	B-cell_type
infected	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O


Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O


Two	O
chronically	B-cell_line
HIV-1-infected	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
U1	B-cell_line
(	O
monocytic	O
)	O
and	O
ACH-2	B-cell_line
(	O
T	O
lymphocytic	O
)	O
,	O
were	O
stimulated	O
with	O
TNF-alpha	B-protein
or	O
PMA	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
the	O
compound	O
.	O


NF-kappaB	B-protein
only	O
partially	O
mediates	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
activation	O
of	O
B	O
cells	O
.	O


The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF-kappaB	B-protein
induction	O
in	O
the	O
up-regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM-1	B-protein
and	O
CD71	B-protein
by	O
LMP1	B-protein
.	O


Furthermore	O
,	O
LMP1	B-protein
-induced	O
cell	O
size	O
increase	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
was	O
unaffected	O
by	O
IkappaB	B-protein
expression	O
.	O


It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	B-protein
is	O
unable	O
to	O
activate	O
NF-kappaB	B-protein
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
strongly	O
suggesting	O
that	O
LMP1	B-protein
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF-kappaB	B-protein
.	O


A	O
new	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
with	O
an	O
eosinophilic	O
phenotype	O
,	O
designated	O
YJ	B-cell_line
,	O
was	O
established	O
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
a	O
patient	O
with	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMMoL	O
)	O
with	O
eosinophilia	O
.	O


The	O
eosinophilic	O
characteristics	O
of	O
YJ	B-cell_line
cells	I-cell_line
were	O
confirmed	O
by	O
histochemical	O
staining	O
with	O
Fast-Green/Neutral-Red	O
and	O
by	O
the	O
expression	O
of	O
mRNAs	B-RNA
for	O
eosinophil-associated	B-protein
granule	I-protein
proteins	I-protein
,	O
eosinophil	B-protein
cationic	I-protein
protein	I-protein
(	O
ECP	B-protein
)	O
,	O
eosinophil-derived	B-protein
neurotoxin	I-protein
(	O
EDN	B-protein
)	O
,	O
eosinophil	B-protein
peroxidase	I-protein
(	O
EPO	B-protein
)	O
,	O
and	O
major	B-protein
basic	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
,	O
and	O
for	O
the	O
Charcot-Leyden	B-protein
crystal	I-protein
(	I-protein
CLC	I-protein
)	I-protein
protein	I-protein
.	O


Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	B-protein
and	O
recruitment	O
of	O
neutrophils	B-cell_type
(	O
PMN	B-cell_type
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O


Increased	O
IL-6	B-protein
protein	O
expression	O
was	O
localized	O
to	O
bronchial	B-cell_type
and	I-cell_type
alveolar	I-cell_type
cells	I-cell_type
.	O


We	O
showed	O
that	O
the	O
interaction	O
of	O
SS	B-cell_type
RBC	I-cell_type
at	O
2	O
%	O
concentration	O
in	O
the	O
presence	O
of	O
multimers	O
of	O
von	B-protein
Willebrand	I-protein
factor	I-protein
(	O
vWf	B-protein
)	O
,	O
derived	O
from	O
endothelial	O
cell-derived	O
conditioned	O
medium	O
(	O
E-CM	O
)	O
with	O
cultured	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVEC	B-cell_line
)	O
,	O
resulted	O
in	O
a	O
fivefold	O
increased	O
formation	O
of	O
thiobarbituric	O
acid-reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
,	O
both	O
indicators	O
of	O
cellular	O
oxidant	O
stress	O
.	O


Additionally	O
,	O
preincubation	O
of	O
HUVEC	B-cell_line
with	O
a	O
synthetic	O
peptide	O
Arg-Gly-Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf	B-protein
-mediated	O
adhesion	O
of	O
SS	B-cell_type
RBC	I-cell_type
reduced	O
the	O
surface	O
expression	O
of	O
VCAM-1	B-protein
and	O
NF-kB	B-protein
activation	O
.	O


Correlations	O
of	O
TCRzeta	B-protein
or	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	B-protein
levels	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O


The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O


In	O
order	O
to	O
understand	O
this	O
block	O
the	O
cascade	O
of	O
molecular	O
events	O
needs	O
to	O
be	O
characterized	O
.	O


CD38+	B-cell_type
cells	I-cell_type
committed	O
towards	O
this	O
lineage	O
were	O
enriched	O
and	O
a	O
population	O
of	O
these	O
cells	O
treated	O
with	O
dihydroxyvitamin	O
D3	O
to	O
induce	O
neutrophil	O
maturation	O
.	O


The	O
pattern	O
of	O
gene	O
expression	O
was	O
suggested	O
from	O
the	O
number	O
of	O
clones	O
in	O
each	O
group	O
at	O
neutrophil	O
commitment	O
and	O
maturation	O
.	O


Interleukin-4	B-protein
and	I-protein
-13	I-protein
induce	O
upregulation	O
of	O
the	O
murine	O
macrophage	O
12/15-lipoxygenase	B-protein
activity	I-protein
:	O
evidence	O
for	O
the	O
involvement	O
of	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
.	O


To	O
investigate	O
whether	O
both	O
lipoxygenase	B-protein
isoforms	I-protein
exhibit	O
a	O
similar	O
regulatory	O
response	O
toward	O
cytokine	B-protein
stimulation	O
,	O
we	O
studied	O
the	O
regulation	O
of	O
the	O
leukocyte-type	B-protein
12-lipoxygenase	I-protein
of	O
murine	B-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
by	O
interleukins	B-protein
and	O
found	O
that	O
the	O
activity	O
of	O
this	O
enzyme	B-protein
is	O
upregulated	O
in	O
a	O
dose-dependent	O
manner	O
when	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
IL-4	B-protein
or	O
IL-13	B-protein
but	O
not	O
by	O
IL-10	B-protein
.	O


The	O
intermediate	O
complex	O
appeared	O
to	O
react	O
with	O
both	O
anti-STAT	B-protein
6	I-protein
and	O
anti-STAT	B-protein
1	I-protein
.	O


Although	O
IFN-gamma	B-protein
alone	O
did	O
not	O
induce	O
CD23	B-RNA
mRNA	I-RNA
transcription	O
,	O
Northern	O
blot	O
analysis	O
revealed	O
a	O
transient	O
up-regulation	O
of	O
the	O
IL-4-induced	B-RNA
CD23	I-RNA
mRNA	I-RNA
by	O
IFN-gamma	B-protein
within	O
2	O
h	O
of	O
IFN-gamma	B-protein
treatment	O
in	O
these	O
tonsillar	B-cell_type
cells	I-cell_type
.	O


CD2	B-protein
-mediated	O
interleukin-2	B-protein
production	O
occurs	O
via	O
activation	O
of	O
Jun	B-protein
kinase	I-protein
in	O
cell	O
lines	O
lacking	O
p56	B-protein
.	O


These	O
data	O
elucidate	O
differences	O
between	O
TCR	B-protein
and	O
CD2	B-protein
signaling	O
pathways	O
in	O
the	O
same	O
T	B-cell_type
cells	I-cell_type
.	O


Inhibition	O
of	O
iNO	B-protein
synthase	I-protein
(	O
iNOS	B-protein
)	O
activity	O
with	O
N	O
omega-monomethyl-L-arginine	O
in	O
endothelial-RAW264.7	B-cell_line
cocultures	I-cell_line
,	O
stimulated	O
with	O
murine-specific	B-protein
IFN-gamma	I-protein
and	O
LPS	O
,	O
decreased	O
iNO	O
production	O
by	O
86	O
%	O
,	O
augmented	O
VCAM-1	B-protein
and	O
iNOS	B-protein
expression	O
in	O
endothelial	O
and	O
RAW264.7	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
and	O
increased	O
monocyte	O
adhesion	O
to	O
the	O
endothelial	O
cell	O
surface	O
.	O


Transient	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
constructs	O
demonstrated	O
that	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
VCAM-1	B-protein
gene	O
transcription	O
were	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
kappa	B-DNA
B	I-DNA
cis-acting	I-DNA
elements	I-DNA
.	O


The	O
presence	O
of	O
aberrant	O
ER	B-protein
forms	O
in	O
Oestrogen-dependent	O
tumours	O
has	O
been	O
discussed	O
in	O
correlation	O
with	O
tumour	O
progression	O
.	O


p21ras	B-protein
initiates	O
Rac-1	B-protein
but	O
not	O
phosphatidyl	B-protein
inositol	I-protein
3	I-protein
kinase/PKB	I-protein
,	O
mediated	O
signaling	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


In	O
fibroblasts	B-cell_type
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	B-DNA
oncogene	I-DNA
is	O
Phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PtdIns	B-protein
3-kinase	I-protein
)	O
.	O


Activation	O
of	O
this	O
lipid	B-protein
kinase	I-protein
is	O
able	O
to	O
induce	O
critical	O
Rac-1	B-protein
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	B-protein
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine/threonine	B-protein
kinase	I-protein
Akt/PKB	I-protein
.	O


Ras	B-protein
can	O
initiate	O
Rac-1	B-protein
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
function	O
independently	O
of	O
PtdIns	B-protein
3-kinase	I-protein
activity	O
.	O


In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
whether	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
that	O
exhibit	O
anti-tumour	O
activity	O
in	O
haematopoietic	O
and	O
solid	O
tumours	O
influence	O
growth	O
and	O
secretion	O
in	O
the	O
LNCaP	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O


In	O
a	O
different	O
study	O
,	O
GATA-3	B-protein
was	O
shown	O
to	O
be	O
sufficient	O
for	O
the	O
expression	O
of	O
IL-4	B-protein
and	O
other	O
Th2	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O


The	O
two	O
Duffy	B-protein
polymorphic	I-protein
antigens	I-protein
,	O
Fya	B-protein
and	O
Fyb	B-protein
(	O
coded	O
by	O
the	O
FY*A	B-DNA
and	I-DNA
FY*B	I-DNA
alleles	I-DNA
)	O
,	O
are	O
present	O
on	O
erythrocyte	B-protein
membranes	I-protein
.	O


The	O
271C	O
--	O
>	O
T	O
and	O
304G	O
--	O
>	O
A	O
can	O
be	O
identified	O
by	O
restriction	B-DNA
enzyme-generated	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	I-DNA
.	O


The	O
mutation	O
may	O
have	O
implications	O
for	O
some	O
physiological	O
roles	O
of	O
DARC	B-protein
and	O
be	O
of	O
interest	O
in	O
malaria	O
research	O
and	O
in	O
studies	O
of	O
population	O
genetics	O
.	O


Although	O
treatment	O
with	O
TNF-alpha	B-protein
induced	O
nuclear	O
localization	O
of	O
NFkappaB	B-protein
in	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
,	O
irrespective	O
of	O
the	O
age	O
of	O
the	O
donor	O
,	O
the	O
levels	O
of	O
induced	O
NFkappaB	B-protein
were	O
significantly	O
lower	O
in	O
both	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
obtained	O
from	O
the	O
elderly	O
,	O
when	O
compared	O
to	O
those	O
in	O
young	O
.	O


Examination	O
of	O
IkappaB	B-protein
alpha	I-protein
regulation	O
revealed	O
that	O
TNF-alpha	B-protein
-mediated	O
degradation	O
of	O
IkappaB	B-protein
alpha	I-protein
in	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
was	O
severely	O
impaired	O
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	B-protein
.	O


Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
age-related	O
hyporesponsiveness	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
T	O
cell	O
population	O
towards	O
a	O
memory	O
phenotype	O
in	O
the	O
elderly	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
bis	O
[	O
4-	O
[	O
2	O
,	O
4-dioxo-5-thiazolidinyl	O
)	O
methyl	O
]	O
phenyl	O
]	O
methane	O
(	O
YM-268	O
)	O
,	O
a	O
thiazolidinedione	O
derivative	O
,	O
on	O
glucose	O
uptake	O
,	O
adipocyte	B-cell_type
differentiation	O
through	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
and	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
activity	O
in	O
cultured	B-cell_line
cells	I-cell_line
.	O


To	O
examine	O
the	O
possible	O
involvement	O
of	O
the	O
increased	O
activity	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
YM268-stimulated	O
glucose	O
uptake	O
,	O
the	O
enzyme	O
activity	O
was	O
estimated	O
by	O
measuring	O
the	O
phosphatidylinositol-3	O
,	O
4	O
,	O
5-trisphosphate	O
(	O
PI-3	O
,	O
4	O
,	O
5-P3	O
)	O
concentration	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O


Work	O
reported	O
over	O
the	O
past	O
year	O
has	O
provided	O
insights	O
into	O
the	O
mechanisms	O
whereby	O
ligand	O
activation	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
peroxisome	I-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
regulates	O
systemic	O
glucose	O
and	O
lipid	O
homeostasis	O
.	O


The	O
role	O
of	O
caspases	O
in	O
T	O
cell	O
development	O
and	O
the	O
control	O
of	O
immune	O
responses	O
.	O


Cross-priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
does	O
not	O
require	O
antigenic	O
peptides	O
in	O
the	O
endoplasmic	O
reticulum	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O


Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
B-cell	B-cell_type
lymphomas	I-cell_type
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL-6	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
and	O
CD138/syndecan-1	B-protein
(	O
syn-1	B-protein
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post-GC	O
,	O
terminal	O
B-cell	O
differentiation	O
.	O


p130	B-protein
,	O
p107	B-protein
,	O
and	O
pRb	B-protein
are	O
differentially	O
regulated	O
in	O
proliferating	B-cell_type
cells	I-cell_type
and	O
during	O
cell	O
cycle	O
arrest	O
by	O
alpha-interferon	B-protein
.	O


In	O
contrast	O
,	O
p107	B-protein
is	O
dephosphorylated	O
and	O
is	O
then	O
depleted	O
from	O
cells	O
as	O
they	O
exit	O
the	O
cell	O
cycle	O
.	O


The	O
phosphorylated	O
forms	O
of	O
E2F-4	B-protein
that	O
bind	O
to	O
the	O
E2F	B-DNA
DNA	I-DNA
site	I-DNA
are	O
different	O
from	O
hyperphosphorylated	O
E2F-4	B-protein
,	O
which	O
predominates	O
in	O
primary	B-cell_type
hemopoietic	I-cell_type
cells	I-cell_type
in	O
G0	O
.	O


The	O
entry	O
of	O
microorganisms	O
into	O
the	O
body	O
induces	O
inflammatory	O
processes	O
.	O


MRP14	B-DNA
(	O
Macrophage	B-protein
migration	I-protein
inhibitory	I-protein
related	I-protein
protein	I-protein
)	O
and	O
MRP8	B-protein
,	O
two	O
S-100	B-protein
proteins	I-protein
contained	O
in	O
high	O
concentrations	O
in	O
these	O
cells	O
are	O
obviously	O
essential	O
for	O
adhesion	O
and	O
migration	O
of	O
monocytes	B-cell_type
and	O
granulocytes	B-cell_type
.	O


Decreased	O
IL-12	B-protein
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid-mediated	O
inhibition	O
of	O
NF-kappaB	B-protein
.	O


ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL-12	B-protein
heterodimer	I-protein
as	O
well	O
as	O
p40	B-protein
monomer	I-protein
by	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O


In	O
CAT	B-DNA
reporter	I-DNA
constructions	I-DNA
no	O
appreciable	O
level	O
of	O
CAT	B-protein
activity	O
was	O
supported	O
by	O
the	O
beta	B-DNA
globin	I-DNA
promoter	I-DNA
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	B-DNA
promoter	I-DNA
.	O


Analysis	O
of	O
cytokine	B-protein
signaling	O
in	O
patients	O
with	O
extrinsic	O
asthma	O
and	O
hyperimmunoglobulin	O
E	O
.	O


BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
class	O
switching	O
to	O
IgE	B-protein
by	O
cytokines	B-protein
is	O
mediated	O
by	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O


The	O
induction	O
of	O
IgE	B-protein
by	O
IL-4	B-protein
and	O
IL-13	B-protein
occurs	O
through	O
the	O
activation	O
of	O
the	O
intracellular	B-protein
signal-transducing	I-protein
protein	I-protein
Stat6	I-protein
,	O
whereas	O
the	O
inhibition	O
of	O
IgE	B-protein
class	O
switching	O
by	O
interferon-y	B-protein
(	O
IFN-gamma	B-protein
)	O
occurs	O
through	O
the	O
activation	O
of	O
Statl	B-protein
.	O


METHODS	O
:	O
PBMCs	B-cell_type
and	O
sera	O
from	O
8	O
patients	O
with	O
extrinsic	O
asthma	O
(	O
mean	O
IgE	B-protein
,	O
285+/-100	O
IU/mL	O
)	O
,	O
3	O
patients	O
with	O
HIE	O
(	O
mean	O
IgE	B-protein
,	O
7050+/-1122	O
IU/mL	O
)	O
,	O
and	O
14	O
nonatopic	O
control	O
subjects	O
(	O
mean	O
IgE	B-protein
,	O
112+/-28	O
IU/mL	O
)	O
were	O
analyzed	O
.	O


RESULTS	O
:	O
The	O
mean	O
IL-4	B-protein
level	O
detected	O
by	O
ELISA	O
was	O
much	O
greater	O
in	O
patients	O
with	O
HIE	O
than	O
control	O
subjects	O
(	O
88.6+/-11.5	O
pg/mL	O
vs	O
11.5+/-7.1	O
pg/mL	O
,	O
P	O
=	O
.005	O
)	O
,	O
and	O
increased	O
IL-4	B-protein
levels	O
among	O
patients	O
with	O
both	O
asthma	O
and	O
HIE	O
correlated	O
with	O
the	O
increased	O
IgE	B-protein
levels	O
.	O


Interestingly	O
,	O
this	O
15-amino	B-protein
acid	I-protein
transactivation	I-protein
sequence	I-protein
is	O
well	O
conserved	O
in	O
NFAT	B-protein
family	I-protein
proteins	I-protein
,	O
although	O
the	O
sequences	O
contiguous	O
to	O
the	O
carboxyl-terminal	B-protein
regions	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
are	O
much	O
less	O
conserved	O
.	O


We	O
also	O
report	O
three	O
additional	O
isoforms	O
of	O
NFATx	B-protein
,	O
designated	O
NFATx2	B-protein
,	O
NFATx3	B-protein
,	O
and	O
NFATx4	B-protein
.	O


Here	O
we	O
demonstrate	O
that	O
expression	O
of	O
Rta	B-protein
is	O
also	O
sufficient	O
for	O
disruption	O
of	O
latency	O
in	O
a	O
permissive	B-cell_line
B-cell	I-cell_line
line	I-cell_line
.	O


We	O
show	O
that	O
increased	O
transcription	O
of	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
responsible	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
induction	O
of	O
NF-IL6	B-RNA
mRNA	I-RNA
following	O
activation	O
of	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O


Using	O
interspecies	O
hybrids	O
,	O
the	O
segregation	O
of	O
human	B-DNA
chromosomes	I-DNA
allowed	O
us	O
to	O
establish	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
extinction	O
is	O
linked	O
to	O
the	O
presence	O
in	O
the	O
hybrids	O
of	O
the	O
chromosomes	B-DNA
from	O
the	O
epithelial	B-cell_type
fusion	I-cell_type
partner	I-cell_type
.	O


Class	O
II	O
transactivator-independent	O
endothelial	O
cell	O
MHC	B-protein
class	I-protein
II	I-protein
gene	O
activation	O
induced	O
by	O
lymphocyte	O
adhesion	O
.	O


The	O
Janus	B-cell_line
kinase-1-deficient	I-cell_line
cell	I-cell_line
line	I-cell_line
U4A	I-cell_line
expresses	O
HLA-DR	B-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
response	O
to	O
NK	O
cell	O
activation	O
,	O
and	O
HLA-DR	B-DNA
alpha	I-DNA
promoter	I-DNA
constructs	I-DNA
transfected	O
into	O
these	O
cells	O
are	O
induced	O
by	O
NK	B-cell_line
cells	I-cell_line
but	O
not	O
IFN-gamma	B-protein
.	O


The	O
association	O
and	O
activation	O
of	O
the	O
IL-1	B-protein
receptor-associated	I-protein
protein	I-protein
kinase	I-protein
(	O
IRAK	B-protein
)	O
to	O
the	O
IL-1	B-protein
receptor	I-protein
complex	I-protein
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL-1	B-protein
signal	O
transduction	O
.	O


Inhibition	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
in	O
human	B-cell_type
cells	I-cell_type
by	O
synthetic	O
DNA-binding	O
ligands	O
[	O
see	O
comments	O
]	O


The	O
MBP	B-protein
-selected	O
line	O
could	O
likewise	O
be	O
rendered	O
unresponsive	O
by	O
incubation	O
with	O
supraoptimal	O
concentrations	O
of	O
immunodominant	O
peptide	O
and	O
anergy	O
induction	O
was	O
accompanied	O
by	O
IL-10	B-protein
release	O
.	O


Copyright	O
1998	O
Academic	O
Press	O
.	O


Previously	O
,	O
we	O
demonstrated	O
that	O
granulocyte	B-RNA
colony-stimulating	I-RNA
factor	I-RNA
(	I-RNA
G-CSF	I-RNA
)	I-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
undetectable	O
and	O
granulocyte	O
maturation	O
blocked	O
in	O
CCAAT	B-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
alpha	I-protein
(	O
C/EBPalpha	B-protein
)	O
-deficient	O
mice	O
.	O


Protein	B-protein
kinase	I-protein
C	I-protein
regulates	O
Fas	B-protein
(	O
CD95/APO-1	B-protein
)	O
expression	O
.	O


Fas	B-protein
(	O
CD95/APO-1	B-protein
)	O
is	O
a	O
transmembrane	B-protein
protein	I-protein
of	O
the	O
TNF/neuron	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
family	I-protein
.	O


Since	O
the	O
inhibition	O
of	O
Ca2+	O
redistribution	O
by	O
an	O
inhibitor	O
of	O
intracellular	O
Ca2+	O
mobilization	O
,	O
8-	O
(	O
diethylamino	O
)	O
-octyl-3	O
,	O
4	O
,	O
5-trimethoxybenzoate	O
hydrochloride	O
,	O
inhibited	O
TCR-induced	B-protein
FasL	I-protein
but	O
not	O
Fas	B-protein
,	O
the	O
expression	O
of	O
Fas	B-protein
appears	O
to	O
be	O
independent	O
of	O
Ca2+	O
mobilization	O
.	O


To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti-CD40	B-protein
+	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
-mediated	O
B-cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
RA	O
was	O
studied	O
in	O
anti-CD40	B-protein
(	O
1	O
microgram/mL	O
)	O
+	O
IL-4	B-protein
(	O
5	O
ng/mL	O
)	O
-mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
B	B-cell_type
cells	I-cell_type
in	O
healthy	O
donors	O
.	O


Anti-CD40	B-protein
+	O
IL-4	B-protein
-mediated	O
proliferation	O
of	O
PBMC	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
+/-	O
5	O
%	O
in	O
PBMC	B-cell_type
and	O
55	O
%	O
+/-	O
4.4	O
%	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
all-trans	O
RA	O
,	O
and	O
58	O
%	O
+/-	O
6.7	O
%	O
and	O
51	O
%	O
+/-	O
4.7	O
%	O
,	O
respectively	O
by	O
13-cis	O
RA	O
.	O


Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	B-protein
production	O
shows	O
that	O
epsilon	O
germline	B-DNA
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	O
of	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
was	O
not	O
enhanced	O
in	O
the	O
presence	O
of	O
RA	O
.	O


Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-protein
induction	O
of	O
NF-kappaB	B-protein
involves	O
activation	O
of	O
the	O
IkappaB	B-protein
kinase	I-protein
alpha	I-protein
(	O
IKKalpha	B-protein
)	O
and	O
IKKbeta	B-protein
cellular	B-protein
kinases	I-protein
.	O


Tax	B-protein
expression	O
promotes	O
N-terminal	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaB	B-protein
alpha	I-protein
,	O
a	O
principal	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappaB	B-protein
.	O


At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O


Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	B-protein
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O


These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB-dependent	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
requires	O
activation	O
of	O
IKK2	B-protein
.	O


Whereas	O
IL-4	B-protein
had	O
little	O
or	O
no	O
effect	O
,	O
IL-7	B-protein
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v-Abl	B-protein
kinase	O
inactivation	O
.	O


These	O
results	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
promoter	O
function	O
of	O
CPO	B-protein
gene	O
between	O
erythroid	B-cell_type
and	I-cell_type
nonerythroid	I-cell_type
cells	I-cell_type
.	O


Tumor	B-protein
suppressor	I-protein
proteins	I-protein
as	O
regulators	O
of	O
cell	O
differentiation	O
.	O


The	O
products	O
of	O
the	O
tumor	B-DNA
suppressor	I-DNA
genes	I-DNA
are	O
considered	O
to	O
function	O
as	O
specific	O
inhibitors	O
of	O
tumor	O
cell	O
growth	O
.	O


It	O
was	O
found	O
that	O
expression	O
of	O
wild-type	B-protein
RXR	I-protein
and	O
of	O
the	O
RXR	B-protein
mutants	I-protein
devoid	O
of	O
AF-1	B-protein
and/or	O
AF-2	B-protein
supported	O
a	O
transient	O
outgrowth	O
of	O
erythroid	B-cell_type
cells	I-cell_type
.	O


T	B-cell_type
lymphocytes	I-cell_type
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	B-protein
phosphatase	I-protein
,	O
map	B-protein
kinase	I-protein
phosphatase-1	I-protein
(	O
MKP-1	B-protein
)	O
.	O


We	O
studied	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
dissociation	O
constant	O
in	O
isolated	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
as	O
well	O
as	O
blood	O
concentrations	O
of	O
hormones	O
produced	O
by	O
the	O
hypothalamic-hypophyseal-adrenocortical	O
system	O
in	O
three	O
experimental	O
series	O
:	O
at	O
normal	O
(	O
17	O
subjects	O
)	O
,	O
decreased	O
(	O
10	O
subjects	O
,	O
a	O
360-d	O
head-down	O
bed	O
rest	O
)	O
and	O
increased	O
(	O
8	O
subjects	O
,	O
physical	O
exercise	O
on	O
bicycle	O
ergometer	O
)	O
levels	O
of	O
motor	O
activity	O
.	O


The	O
small	B-protein
GTP-binding	I-protein
protein	I-protein
Rho	I-protein
potentiates	O
AP-1	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


The	O
Rho	B-protein
family	O
of	O
small	B-protein
GTP-binding	I-protein
proteins	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O


To	O
evaluate	O
a	O
potential	O
mechanism	O
for	O
these	O
differences	O
in	O
function	O
,	O
we	O
evaluated	O
expression	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
isoforms	I-protein
.	O


One	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	B-protein
can	O
be	O
increased	O
expression	O
of	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
pathways	O
.	O


Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF-kappaB	B-protein
requires	O
dual	O
signals	O
.	O


To	O
investigate	O
further	O
,	O
we	O
then	O
purified	O
a	O
number	O
of	O
different	O
kinases	O
,	O
including	O
PKC	B-protein
,	O
PhK	B-protein
,	O
ZAP-70	B-protein
,	O
ERK	B-protein
,	O
and	O
MEK	B-protein
1	I-protein
(	O
a	O
MKK	B-protein
)	O
,	O
and	O
showed	O
that	O
Ro	O
09-2210	O
was	O
a	O
selective	O
inhibitor	O
of	O
MEK1	B-protein
in	O
vitro	O
(	O
IC50	O
=	O
59	O
nM	O
)	O
.	O


Molecular	O
dissection	O
of	O
the	O
B-cell-specific	O
transcription	O
coactivator	O
OCA-B	B-protein
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	B-DNA
promoters	I-DNA
through	O
interaction	O
with	O
octamer-bound	B-protein
Oct-1	I-protein
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O


In	O
addition	O
,	O
the	O
transcription	B-protein
factor	I-protein
Stat-3	B-protein
was	O
tyrosine	O
phosphorylated	O
in	O
the	O
cytoplasm	O
and	O
subsequently	O
translocated	O
to	O
the	O
cell	O
nucleus	O
.	O


To	O
investigate	O
the	O
function	O
of	O
the	O
activated	O
Stat-3	B-protein
,	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
Stat-3	B-protein
isoform	I-protein
lacking	O
the	O
transactivating	B-protein
domain	I-protein
.	O


This	O
dominant-negative	B-protein
acting	I-protein
Stat-3	I-protein
isoform	I-protein
significantly	O
inhibited	O
apoptosis	O
induced	O
by	O
ligation	O
of	O
MHC-I	B-protein
.	O


Flow	O
cytometry	O
revealed	O
that	O
primary	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
from	O
a	O
patient	O
with	O
CD8+	O
T-PLL	O
expressed	O
IL-2Ralpha	B-protein
and	I-protein
beta	I-protein
chains	I-protein
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	O
in	O
IL-2Ralpha	B-protein
expression	O
on	O
culture	O
with	O
exogeneous	O
IL-2	B-protein
.	O


Electrophoretic	O
mobility-shift	O
assays	O
revealed	O
that	O
recombinant	O
IL-2	B-protein
increased	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	B-cell_type
cells	I-cell_type
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL-2	B-protein
increased	O
the	O
abundance	O
of	O
mRNAs	O
encoding	O
the	O
NF-kappaB	B-protein
components	O
c-Rel	B-protein
and	O
KBF1	B-protein
in	O
these	O
cells	O
.	O


These	O
apparent	O
inconsistencies	O
reflect	O
the	O
complexity	O
of	O
the	O
DTCs	O
biological	O
activities	O
and	O
are	O
probably	O
due	O
in	O
part	O
to	O
differences	O
in	O
dose	O
,	O
route	O
of	O
exposure	O
,	O
animal	O
species	O
used	O
and/or	O
specific	O
compound	O
tested	O
.	O


The	O
studies	O
described	O
herein	O
were	O
undertaken	O
to	O
investigate	O
the	O
immunotoxicity	O
of	O
one	O
member	O
of	O
this	O
family	O
,	O
dimethyldithiocarbamate	O
(	O
DMDTC	O
)	O
.	O


These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O


After	O
5-day	O
anti-CD3	B-protein
/IL-2	B-protein
activation	O
,	O
levels	O
of	O
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O


These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
in	O
LN	B-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O


We	O
have	O
previously	O
demonstrated	O
that	O
a	O
mutated	O
form	O
of	O
the	O
human	B-DNA
CIITA	I-DNA
gene	I-DNA
,	O
coding	O
for	O
a	O
protein	O
lacking	O
the	O
amino	B-protein
terminal	I-protein
151	I-protein
amino	I-protein
acids	I-protein
,	O
acts	O
as	O
a	O
potent	O
dominant-negative	O
suppressor	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
expression	O
.	O


PIEC	B-cell_line
clones	I-cell_line
stably	O
transfected	O
with	O
one	O
of	O
these	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
SLA-DR	B-protein
and	O
SLA-DQ	B-protein
antigen	O
induction	O
and	O
marked	O
suppression	O
of	O
SLA-DRA	B-RNA
mRNA	I-RNA
induction	O
.	O


Peroxisomal	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
in	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
various	O
activators	O
,	O
including	O
15-deoxy-delta12	O
,	O
14-prostaglandin	O
J2	O
and	O
the	O
antidiabetic	O
agent	O
troglitazone	O
.	O


Human	B-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
cultured	O
for	O
6	O
days	O
in	O
5	O
%	O
human	O
serum	O
expressed	O
PPARgamma	B-RNA
mRNA	I-RNA
and	O
protein	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
,	O
respectively	O
.	O


Thus	O
,	O
PPARgamma	B-protein
is	O
present	O
in	O
macrophages	B-cell_type
in	O
human	O
atherosclerotic	O
lesions	O
and	O
may	O
regulate	O
expression	O
and	O
activity	O
of	O
MMP-9	B-protein
,	O
an	O
enzyme	O
implicated	O
in	O
plaque	O
rupture	O
.	O


PPARgamma	B-protein
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
monocyte/macrophage	O
function	O
with	O
relevance	O
for	O
human	O
atherosclerotic	O
disease	O
.	O


Erythropoietin	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B-protein
,	O
STAT5A	B-protein
,	O
and	O
STAT5B	B-protein
in	O
primary	B-cell_type
cultured	I-cell_type
human	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
.	O


Crkl	B-protein
,	O
an	O
SH2/SH3	B-protein
adapter	I-protein
protein	I-protein
,	O
becomes	O
coimmunoprecipitated	O
specifically	O
with	O
STAT5	B-protein
from	O
erythropoietin-stimulated	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
;	O
although	O
it	O
was	O
shown	O
to	O
become	O
associated	O
with	O
c-Cbl	B-protein
in	O
the	O
studies	O
using	O
cell	B-cell_line
lines	I-cell_line
.	O


DNA-binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	B-protein
factors	I-protein
:	O
NFkappaB	B-protein
,	O
AP-1	B-protein
and	O
NFAT	B-protein
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	B-cell_type
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O


The	O
lymphocytes	B-cell_type
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O


Cells	O
were	O
analyzed	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
.	O


Consistent	O
with	O
the	O
ability	O
of	O
IL-4	B-protein
to	O
regulate	O
eosinophil	O
responses	O
,	O
IL-4	B-protein
signaling	I-protein
molecules	I-protein
are	O
present	O
in	O
human	B-cell_type
eosinophils	I-cell_type
.	O


A	O
recent	O
study	O
showed	O
a	O
MLL/AF10	B-DNA
fusion	I-DNA
in	O
all	O
cases	O
of	O
AML	O
with	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
and	O
various	O
breakpoints	O
on	O
chromosome	B-DNA
11	I-DNA
ranging	O
from	O
q13	B-DNA
to	O
q23	B-DNA
.	O


We	O
recently	O
cloned	O
CALM	B-DNA
(	O
Clathrin	B-DNA
Assembly	I-DNA
Lymphoid	I-DNA
Myeloid	I-DNA
leukemia	I-DNA
gene	I-DNA
)	O
,	O
the	O
fusion	O
partner	O
of	O
AF10	B-DNA
at	O
11q14	B-DNA
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O


For	O
the	O
7	O
AML	O
cases	O
that	O
were	O
uniformly	O
treated	O
according	O
to	O
the	O
AMLCG86/92	O
protocols	O
,	O
disease-free	O
and	O
overall	O
survival	O
was	O
significantly	O
worse	O
than	O
for	O
the	O
overall	O
study	O
group	O
(	O
P	O
=	O
.03	O
and	O
P	O
=	O
.01	O
,	O
respectively	O
)	O
.	O


IkappaB	B-protein
alpha	I-protein
phosphorylation	O
on	O
Ser-32	O
and	O
Ser-36	O
is	O
followed	O
by	O
its	O
degradation	O
and	O
NF-kappaB	B-protein
activation	O
.	O


Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	B-protein
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	B-protein
receptor	I-protein
as	O
well	O
as	O
IL-18	B-protein
receptor	I-protein
.	O


Using	O
this	O
RAR-selective	O
antagonist	O
,	O
and	O
RXR	B-protein
and	O
RAR	B-protein
agonist	O
,	O
we	O
demonstrate	O
the	O
RAR	B-protein
-mediated	O
signaling	O
pathway	O
is	O
important	O
for	O
differentiation	O
and	O
apoptosis	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O


Additional	O
experiments	O
showed	O
that	O
levels	O
of	O
BCL-2	B-protein
protein	I-protein
decreased	O
during	O
differentiation	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O


We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT-7/GMT	B-cell_line
,	O
from	O
the	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
UT-7/GM	I-cell_line
(	O
N.	O
Komatsu	O
,	O
et	O
al.	O
,	O
Blood	O
,	O
89	O
:	O
4021-4033	O
,	O
1997	O
)	O
.	O


Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	B-protein
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O


To	O
elucidate	O
the	O
contributions	O
of	O
GATA-1	B-protein
to	O
definitive	O
hematopoiesis	O
in	O
vivo	O
,	O
we	O
have	O
examined	O
adult	O
mice	O
that	O
were	O
rendered	O
genetically	O
defective	O
in	O
GATA-1	B-protein
synthesis	O
(	O
Takahashi	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
12611	O
,	O
1997	O
)	O
.	O


Proerythroblasts	B-cell_type
and	O
megakaryocytes	B-cell_type
massively	O
accumulated	O
in	O
the	O
spleens	O
of	O
the	O
heterozygotes	O
,	O
and	O
we	O
showed	O
that	O
the	O
neomycin	B-DNA
resistance	I-DNA
gene	I-DNA
(	O
which	O
is	O
the	O
positive	O
selection	O
marker	O
in	O
ES	B-cell_type
cells	I-cell_type
)	O
was	O
expressed	O
profusely	O
in	O
the	O
abnormally	O
abundant	O
cells	O
generated	O
in	O
the	O
GATA-1.05	B-protein
mutant	O
females	O
.	O


Furthermore	O
,	O
we	O
demonstrate	O
that	O
IL-13	B-protein
,	O
like	O
IL-4	B-protein
,	O
induces	O
distinct	O
STAT6-DNA	B-protein
binding	I-protein
complexes	I-protein
and	O
tyrosine	O
phosphorylation	O
of	O
STAT6	B-protein
and	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
in	O
NK	O
and	O
T	B-cell_type
cells	I-cell_type
.	O


These	O
findings	O
show	O
that	O
IL-13	B-protein
and	O
IL-4	B-protein
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL-13	B-protein
is	O
a	O
potent	O
regulator	O
of	O
STAT6	B-protein
and	O
JAK3	B-protein
in	O
these	O
cell	O
types	O
.	O


The	O
human	O
homologue	O
of	O
Drosophila	B-protein
Toll	I-protein
(	O
hToll	B-protein
)	O
is	O
a	O
recently	O
cloned	O
receptor	O
of	O
the	O
interleukin	B-protein
1	I-protein
receptor	I-protein
(	I-protein
IL-1R	I-protein
)	I-protein
superfamily	I-protein
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
adaptive	O
immunity	O
.	O


Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	B-protein
failed	O
to	O
block	O
hToll	B-protein
-induced	O
activation	O
of	O
stress-activated	B-protein
protein	I-protein
kinase/c-Jun	I-protein
NH2-terminal	I-protein
kinases	I-protein
,	O
thus	O
suggesting	O
an	O
early	O
divergence	O
of	O
the	O
two	O
pathways	O
.	O


The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O


Reactivity	O
with	O
the	O
tegument	B-protein
protein	I-protein
encoded	O
by	O
UL21	B-DNA
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O


Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	O
receptor	O
transcripts	O
similar	O
to	O
those	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O


The	O
presence	O
of	O
variants	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
or	O
medication	O
.	O


Mutations	O
in	O
the	O
relevant	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
eliminated	O
these	O
responses	O
.	O


The	O
percentages	O
of	O
the	O
T/NK-cell	B-cell_type
subsets	I-cell_type
in	O
the	O
PB	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O


Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O


The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	B-cell_type
cell	I-cell_type
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O


These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4-expressing	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O


Human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
quasispecies	I-DNA
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	B-protein
factor	I-protein
recruitment	O
in	O
human	B-cell_type
glial	I-cell_type
cells	I-cell_type
and	I-cell_type
lymphocytes	I-cell_type
.	O


TCF/LEF	B-protein
proteins	I-protein
have	O
recently	O
been	O
found	O
to	O
constitute	O
a	O
downstream	O
component	O
of	O
the	O
Wingless/Wnt	O
signal	O
transduction	O
pathway	O
.	O


Deregulation	O
of	O
the	O
pathway	O
occurs	O
in	O
several	O
human	O
tumors	O
.	O


Molecular	O
genetic	O
characterization	O
of	O
the	O
variant	B-DNA
allele	I-DNA
can	O
serve	O
as	O
a	O
primary	O
tool	O
for	O
diagnosis	O
and	O
subsequent	O
therapy	O
,	O
and	O
can	O
provide	O
a	O
basis	O
for	O
distinguishing	O
heterozygous	O
carriers	O
in	O
familial	O
androgen	O
resistance	O
.	O


METHODS	O
.	O


RESULTS	O
.	O


Tumors	O
with	O
high	O
Ki-67	B-protein
proliferation	O
indices	O
(	O
>	O
20	O
%	O
)	O
were	O
associated	O
with	O
a	O
higher	O
4-year	O
probability	O
of	O
relapse	O
of	O
disease	O
(	O
55.3	O
%	O
versus	O
79.1	O
%	O
;	O
P	O
=	O
0.003	O
)	O
and	O
death	O
(	O
71	O
%	O
versus	O
95.6	O
%	O
;	O
P	O
=	O
0.00005	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
low	O
Ki-67	B-protein
values	O
.	O


Tumor	O
proliferative	O
activity	O
as	O
evaluated	O
by	O
the	O
monoclonal	B-protein
antibody	I-protein
Ki-67	I-protein
seems	O
to	O
be	O
an	O
effective	O
indicator	O
of	O
prognosis	O
in	O
breast	O
cancer	O
for	O
DFS	O
and	O
OS	O
.	O


Sequence	O
analysis	O
of	O
nine	O
different	O
2.3-kb	O
cDNA	O
clones	O
obtained	O
from	O
NK-derived	O
polyA+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
.	O


All	O
NK	B-cell_line
clones	I-cell_line
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA-3-specific	B-RNA
mRNA	I-RNA
,	O
suggesting	O
that	O
hGATA-3	B-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
expression	O
in	O
NK	B-cell_type
cells	I-cell_type
.	O


Finally	O
,	O
no	O
transcription	O
of	O
the	O
RAG-1	B-DNA
gene	I-DNA
could	O
be	O
detected	O
in	O
all	O
NK	B-cell_line
cell	I-cell_line
lines	I-cell_line
or	O
clones	O
analyzed	O
.	O


Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
,	O
a	O
mediator	O
of	O
lipopolysaccharide	O
effects	O
.	O


This	O
event	O
is	O
also	O
triggered	O
under	O
various	O
other	O
conditions	O
of	O
biomedical	O
importance	O
.	O


This	O
common	O
pathway	O
may	O
involve	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
as	O
messenger	O
molecules	O
.	O


The	O
lymphoid-specific	B-protein
transcription	I-protein
complex	I-protein
,	O
NF-AT	B-protein
,	O
is	O
involved	O
in	O
early	O
gene	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
is	O
assembled	O
from	O
a	O
pre-existing	O
,	O
T	B-protein
cell	I-protein
restricted	I-protein
cytoplasmic	I-protein
factor	I-protein
and	O
an	O
inducible	O
ubiquitous	B-protein
nuclear	B-protein
component	I-protein
within	O
30	O
min	O
after	O
activation	O
through	O
the	O
antigen	B-protein
receptor	I-protein
.	O


Finally	O
,	O
we	O
have	O
partially	O
purified	O
the	O
cytoplasmic	O
component	O
of	O
NF-AT	O
and	O
show	O
by	O
elution	O
and	O
renaturation	O
from	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
gels	O
that	O
it	O
has	O
a	O
molecular	O
mass	O
between	O
94	O
and	O
116	O
kDa	O
and	O
may	O
have	O
multiple	O
differentially	O
modified	O
forms	O
.	O


4	O
patients	O
were	O
receiving	O
dopamine	O
,	O
which	O
did	O
not	O
affect	O
the	O
GR	B-protein
count	O
.	O


The	O
study	O
of	O
human	O
disorders	O
known	O
as	O
premature	O
aging	O
syndromes	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
cellular	O
senescence	O
.	O


In	O
the	O
transient-transfection	O
assay	O
,	O
ICP0	B-protein
,	O
but	O
not	O
ICP4	B-protein
,	O
activated	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
promoter	I-DNA
region	I-DNA
and	O
the	O
effect	O
of	O
ICP0	B-protein
was	O
greatly	O
enhanced	O
in	O
the	O
presence	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
,	O
suggesting	O
that	O
induction	O
of	O
the	O
HIV-1	O
provirus	O
involves	O
cooperation	O
between	O
the	O
HSV-1-activated	B-protein
cellular	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
virus-encoded	B-protein
transactivator	I-protein
,	O
ICP0	B-protein
.	O


Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
Mo	B-cell_type
)	O
constitutively	O
display	O
the	O
beta-chain	O
of	O
the	O
receptor	O
for	O
IL-2	B-protein
,	O
whereas	O
expression	O
of	O
the	O
IL-2R	B-protein
alpha-chain	I-protein
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL-2	B-protein
.	O


The	O
cytokines	O
interleukin-1	O
beta	O
(	O
IL-1	B-protein
beta	I-protein
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B-protein
)	O
are	O
released	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
in	O
vitro	O
after	O
stimulation	O
with	O
mycobacteria	O
and	O
are	O
considered	O
to	O
mediate	O
pathophysiologic	O
events	O
,	O
including	O
granuloma	O
formation	O
and	O
systemic	O
symptoms	O
.	O


Site-directed	O
mutagenesis	O
demonstrated	O
that	O
the	O
two	O
NF-IL-6	B-DNA
motifs	I-DNA
could	O
be	O
independently	O
activated	O
by	O
LAM	O
,	O
LPS	O
,	O
or	O
TNF-alpha	B-protein
and	O
that	O
they	O
acted	O
in	O
an	O
orientation-independent	O
manner	O
.	O


An	O
enhancement	O
of	O
NK	O
activity	O
by	O
E2	O
was	O
also	O
seen	O
in	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
obtained	O
from	O
normal	O
subjects	O
,	O
and	O
it	O
was	O
again	O
suppressed	O
by	O
Tx	O
.	O


These	O
data	O
suggest	O
that	O
E2	O
is	O
one	O
of	O
the	O
activating	O
factors	O
for	O
NK/LGL	B-cell_line
cells	I-cell_line
.	O


The	O
proximal	B-DNA
element	I-DNA
contains	O
the	O
sequence	O
5'-GGCCAATGGG-3	O
'	O
,	O
which	O
closely	O
resembles	O
the	O
consensus	O
binding	O
motif	O
for	O
the	O
CCAAT-binding	B-DNA
factor	I-DNA
NF-Y	B-protein
(	O
CBF	B-protein
,	O
CP1	B-protein
,	O
alpha	B-protein
CP1	I-protein
)	O
.	O


We	O
conclude	O
that	O
the	O
serum	O
response	O
of	O
the	O
human	O
TSP	B-DNA
1	I-DNA
gene	I-DNA
requires	O
the	O
coordinated	O
function	O
of	O
an	O
SRE-	B-DNA
and	I-DNA
NF-Y-binding	I-DNA
site	I-DNA
.	O


There	O
were	O
two	O
main	O
goals	O
:	O
(	O
1	O
)	O
to	O
evaluate	O
whether	O
workers	O
with	O
a	O
moderately	O
increased	O
PCDD/PCDF-body	O
burden	O
[	O
25-140	O
ppt	O
TCDD	O
or	O
104-522	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
exhibit	O
changes	O
in	O
the	O
surface	B-protein
receptors	I-protein
of	O
white	B-cell_type
blood	I-cell_type
cells	I-cell_type
,	O
as	O
observed	O
in	O
previous	O
studies	O
in	O
non-human	O
primates	O
,	O
and	O
(	O
2	O
)	O
to	O
clarify	O
whether	O
persons	O
at	O
the	O
upper	O
range	O
[	O
10-23	O
ppt	O
TCDD	O
or	O
30-90	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
of	O
the	O
body	O
burden	O
reference	O
values	O
of	O
a	O
not	O
particularly	O
exposed	O
population	O
show	O
detectable	O
deviations	O
in	O
these	O
immunological	O
variables	O
,	O
when	O
compared	O
with	O
persons	O
at	O
the	O
lower	O
and	O
medium	O
range	O
[	O
1-3	O
ppt	O
TCDD	O
or	O
9-29	O
ppt	O
I-TE	O
]	O
of	O
these	O
body	O
burden	O
reference	O
values	O
.	O


None	O
of	O
the	O
alterations	O
observed	O
are	O
of	O
medical	O
relevance	O
.	O


The	O
slight	O
increase	O
in	O
the	O
percentage	O
of	O
CD4+CD45R0+	B-cell_type
cells	I-cell_type
remained	O
significant	O
even	O
after	O
covariant	O
analysis	O
taking	O
age-related	O
changes	O
into	O
account	O
.	O


Inhibition	O
of	O
HIV-1	O
latency	O
reactivation	O
by	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
and	O
an	O
analog	O
of	O
DHEA	O
.	O


So	O
far	O
,	O
there	O
are	O
no	O
drugs	O
or	O
therapy	O
available	O
that	O
can	O
provide	O
protection	O
against	O
HIV-1	O
latency	O
reactivation	O
.	O


In	O
the	O
immune	O
system	O
the	O
first	O
activation	O
of	O
a	O
naive	B-cell_type
T	I-cell_type
cell	I-cell_type
by	O
antigen	O
is	O
a	O
key	O
step	O
in	O
the	O
shaping	O
of	O
the	O
peripheral	O
T	O
cell	O
specificity	O
repertoire	O
and	O
maintenance	O
of	O
self-tolerance	O
.	O


In	O
the	O
present	O
study	O
,	O
analysis	O
of	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
activation	O
shows	O
that	O
naive	B-cell_type
human	I-cell_type
helper	I-cell_type
T	I-cell_type
cells	I-cell_type
(	O
cord	B-cell_type
blood	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
adult	B-cell_type
CD4+CD45RO-	I-cell_type
T	I-cell_type
cells	I-cell_type
)	O
regulate	O
IL-2	B-protein
transcription	O
by	O
a	O
mechanism	O
involving	O
both	O
a	O
silencer	B-DNA
and	O
an	O
activator	B-DNA
acting	O
on	O
the	O
purine-rich	B-DNA
IL-2	I-DNA
promoter	I-DNA
elements	I-DNA
(	O
NF-AT	B-DNA
binding	I-DNA
sites	I-DNA
)	O
.	O


Their	O
IL-2	B-protein
transcription	O
seems	O
to	O
be	O
controlled	O
solely	O
by	O
the	O
transition	O
from	O
inactive	O
to	O
active	O
functional	O
state	O
of	O
a	O
positive	B-protein
transcription	I-protein
factor	I-protein
binding	O
to	O
these	O
promoter	O
elements	O
as	O
well	O
as	O
its	O
cytoplasmic	O
or	O
nuclear	O
location	O
:	O
in	O
resting	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
the	O
activator	B-DNA
is	O
located	O
in	O
the	O
cytoplasm	O
and	O
is	O
inactive	O
,	O
whereas	O
in	O
stimulated	B-cell_line
cells	I-cell_line
it	O
is	O
functional	O
in	O
promoting	O
transcription	O
and	O
now	O
resides	O
in	O
the	O
nucleus	O
.	O


Thus	O
,	O
the	O
regulation	O
of	O
the	O
gene	O
coding	O
for	O
the	O
main	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
changes	O
irreversibly	O
after	O
the	O
first	O
encounter	O
of	O
T	O
cells	O
with	O
antigen	O
.	O


To	O
examine	O
the	O
effect	O
of	O
Trx	B-protein
in	O
intact	O
cells	O
,	O
we	O
performed	O
transient	O
assay	O
with	O
a	O
chloramphenicol	B-DNA
acetyltransferase-expressing	I-DNA
plasmid	I-DNA
under	O
the	O
control	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
and	O
an	O
effector	B-DNA
plasmid	I-DNA
expressing	O
human	B-protein
Trx	I-protein
.	O


Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA-binding	B-protein
proteins	I-protein
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O


We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3/TCR	B-protein
complex	I-protein
with	O
the	O
CD2	B-protein
antigen	I-protein
results	O
in	O
the	O
proliferation	O
of	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O


The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O


Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O


Activated	O
ras	B-protein
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	B-protein
stimulation	O
in	O
activation	O
of	O
the	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
NF-AT	B-protein
.	O


A	O
dominant	B-protein
inhibitory	I-protein
ras	I-protein
mutant	I-protein
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	B-protein
activity	O
is	O
required	O
for	O
antigen	B-protein
receptor	I-protein
signaling	O
.	O


The	O
effect	O
of	O
the	O
Tat	B-protein
protein	I-protein
constitutively	O
expressed	O
by	O
these	O
cells	O
upon	O
their	O
differentiation	O
was	O
then	O
evaluated	O
by	O
looking	O
for	O
the	O
expression	O
of	O
the	O
c-fos	B-DNA
and	O
of	O
the	O
c-fms	B-DNA
proto-oncogenes	I-DNA
which	O
are	O
linked	O
to	O
the	O
differentiation	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O


We	O
show	O
that	O
the	O
ability	O
to	O
detect	O
NF-ATp	B-protein
in	O
a	O
gel	O
shift	O
assay	O
,	O
which	O
is	O
essential	O
for	O
purification	O
and	O
biochemical	O
studies	O
of	O
this	O
protein	O
,	O
is	O
strikingly	O
dependent	O
on	O
the	O
precise	O
sequence	O
of	O
the	O
NF-AT	B-protein
oligonucleotide	O
used	O
as	O
the	O
labeled	O
probe	O
.	O


The	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
a	O
model	O
relating	O
the	O
two	O
nuclear	O
NF-AT	B-protein
complexes	I-protein
to	O
NF-ATp	B-protein
.	O


Cell	O
cycle	O
analysis	O
of	O
E2F	B-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
reveals	O
novel	B-protein
E2F	I-protein
complexes	I-protein
and	O
biochemically	O
distinct	O
forms	O
of	O
free	O
E2F	B-protein
.	O


The	O
results	O
demonstrate	O
that	O
multidrug-resistant	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
,	O
designated	O
HL-60/vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c-jun	B-RNA
transcripts	I-RNA
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O


The	O
finding	O
that	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c-jun	B-DNA
expression	O
,	O
suggests	O
that	O
c-jun	B-DNA
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O


Since	O
TPA	O
activates	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	B-protein
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O


Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA-induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	B-protein
-mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun/fos	B-DNA
early	I-DNA
response	I-DNA
gene	I-DNA
expression	O
.	O


Both	O
p105	B-protein
and	O
p98	B-protein
were	O
found	O
to	O
form	O
stable	O
complexes	O
with	O
other	O
Rel/NF-kappa	B-protein
B	I-protein
family	I-protein
members	I-protein
,	O
including	O
p65	B-protein
and	O
c-Rel	B-protein
.	O


In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
DNA	B-DNA
sequences	I-DNA
and	O
specific	O
protein	O
interactions	O
necessary	O
for	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
prointerleukin	I-DNA
1	I-DNA
beta	I-DNA
(	I-DNA
proIL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	I-DNA
.	O


A	O
cell-type-independent	B-DNA
lipopolysaccharide	I-DNA
(	I-DNA
LPS	I-DNA
)	I-DNA
-responsive	I-DNA
enhancer	I-DNA
element	I-DNA
located	O
between	O
-3757	B-DNA
and	I-DNA
-2729	I-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
cap	B-DNA
site	I-DNA
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	B-cell_line
monocytes	I-cell_line
.	O


Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	B-protein
factor	I-protein
in	O
resting	B-cell_line
and	I-cell_line
stimulated	I-cell_line
granulocytes	I-cell_line
.	O


These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	B-protein
integrin	B-protein
expression	O
on	O
the	O
surface	O
of	O
treated	B-cell_line
cells	I-cell_line
.	O


Furthermore	O
,	O
the	O
p65	B-protein
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	B-protein
that	O
was	O
produced	O
by	O
formyl-met-leu-phe	O
and	O
TPA	O
.	O


Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	B-protein
ester-sensitive	I-protein
protein	I-protein
kinase	I-protein
C	I-protein
.	O


Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c-Rel	B-protein
,	O
p105	B-protein
,	O
and	O
p50	B-protein
in	O
the	O
cytosol	O
.	O


However	O
,	O
a	O
hybrid	O
receptor	O
composed	O
of	O
the	O
extracellular	B-protein
and	I-protein
transmembrane	I-protein
regions	I-protein
of	O
the	O
human	B-protein
type	I-protein
II	I-protein
interleukin-1	I-protein
fused	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
human	B-protein
type	I-protein
I	I-protein
IL-1R	I-protein
was	O
capable	O
of	O
transducing	O
a	O
signal	O
across	O
the	O
membrane	O
resulting	O
in	O
a	O
pattern	O
of	O
gene	O
activation	O
identical	O
to	O
that	O
mediated	O
by	O
the	O
type	B-protein
I	I-protein
IL-1R	I-protein
.	O


Our	O
results	O
indicated	O
that	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
type	B-protein
II	I-protein
IL-1R	I-protein
was	O
capable	O
of	O
functionally	O
interacting	O
with	O
interleukin-1	B-protein
and	O
transmitting	O
the	O
resulting	O
signal	O
to	O
a	O
heterologous	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O


Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
's	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	B-DNA
cDNAs	I-DNA
,	O
and	O
the	O
entire	O
hGR	B-DNA
cDNA	I-DNA
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O


When	O
the	O
wild-type	B-protein
hGR	I-protein
and	O
hGR-Ile	B-protein
729	I-protein
were	O
expressed	O
in	O
COS-1	B-cell_line
cells	I-cell_line
and	O
assayed	O
for	O
[	O
3H	O
]	O
-Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0.799	O
+/-	O
0.068	O
and	O
1.54	O
+/-	O
0.06	O
nM	O
(	O
mean	O
+/-	O
SEM	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O


Overexpression	O
of	O
the	O
p50	B-protein
,	O
p65	B-protein
and	O
Rel	B-protein
proteins	I-protein
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL-2R	B-protein
alpha	I-protein
kappa	B-DNA
B	I-DNA
site	I-DNA
was	O
observed	O
only	O
with	O
Rel	B-protein
and	O
Rel	B-protein
plus	O
p65	B-protein
.	O


Transcriptional	O
regulation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O


We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
gene	O
expression	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
following	O
CD3	O
and	O
CD2	O
receptor	O
stimulation	O
or	O
activation	O
by	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
.	O


Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	B-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O


We	O
have	O
previously	O
found	O
that	O
NFKB2	B-protein
(	I-protein
p49/p52	I-protein
)	I-protein
acts	O
in	O
concert	O
with	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
to	O
stimulate	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
Jurkat	O
T-leukemia	B-cell_line
cells	I-cell_line
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


These	O
inhibitory	O
effects	O
of	O
c-Rel	B-protein
correlate	O
with	O
its	O
DNA-binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B-protein
,	O
suggesting	O
that	O
c-Rel	B-protein
inhibition	O
involves	O
competition	O
with	O
p50/p65	B-protein
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O


Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c-Rel	B-protein
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
and	O
IL-2R	B-protein
alpha	I-protein
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B-protein
.	O


In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


The	O
B	B-protein
cell	I-protein
NFAT	I-protein
complex	I-protein
,	O
however	O
,	O
was	O
not	O
functional	O
,	O
since	O
it	O
failed	O
to	O
activate	O
transcription	O
from	O
an	O
NFAT-driven	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
construct	I-DNA
.	O


Induction	O
of	O
CD8	B-protein
antigen	I-protein
and	O
suppressor	O
activity	O
by	O
glucocorticoids	O
in	O
a	O
CEM	B-cell_line
human	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
clone	I-cell_line
.	O


The	O
relationship	O
between	O
glucocorticoid	O
effect	O
and	O
regulation	O
of	O
cell	B-protein
surface	I-protein
antigens	I-protein
was	O
investigated	O
in	O
two	O
models	O
of	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CEM	B-cell_line
C7	I-cell_line
denoted	O
(	O
r+	O
,	O
ly+	O
)	O
and	O
CEM	B-cell_line
C1	I-cell_line
(	O
r+	O
,	O
ly-	O
)	O
.	O


Dexamethasone	O
treatment	O
of	O
a	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
clone	I-cell_line
CEM	I-cell_line
C7	I-cell_line
caused	O
an	O
increase	O
in	O
a	O
subset	O
of	O
cells	O
expressing	O
the	O
surface	B-protein
antigen	I-protein
CD8	I-protein
,	O
which	O
is	O
present	O
on	O
suppressor	O
and	O
cytotoxic	B-cell_type
T-lymphocytes	I-cell_type
.	O


In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	B-protein
antigen	I-protein
expression	O
in	O
a	O
CD4+	B-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	B-cell_line
receptor	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
.	O


DNA	O
sequence	O
homology	O
of	O
E1A	B-DNA
genes	O
between	O
different	O
Ad	O
groups	O
(	O
group	O
A	O
,	O
Ad12	O
;	O
group	O
C	O
,	O
Ad5	O
)	O
is	O
limited	O
almost	O
entirely	O
to	O
three	O
conserved	O
regions	O
located	O
within	O
the	O
first	O
exon	O
of	O
E1A	B-DNA
.	O


In	O
summary	O
,	O
the	O
expression	O
of	O
E1A	B-protein
gene	I-protein
products	I-protein
inhibited	O
IFN	B-protein
-MCP	O
independently	O
of	O
virus	O
infection	O
.	O


We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	B-cell_type
cells	I-cell_type
,	O
an	O
AP-1	B-protein
protein	I-protein
is	O
a	O
component	O
of	O
the	O
NF-AT	B-protein
protein	I-protein
complex	I-protein
.	O


We	O
find	O
that	O
a	O
short	O
enhancer	O
element	O
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
gene	I-DNA
(	O
IL-2R	B-protein
alpha	I-protein
)	O
is	O
preferentially	O
activated	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


We	O
propose	O
a	O
model	O
in	O
which	O
NF-kappa	B-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
mutually	O
regulate	O
each	O
other	O
in	O
a	O
cycle	O
:	O
saturating	O
amounts	O
of	O
the	O
inhibitory	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
are	O
destroyed	O
upon	O
stimulation	O
,	O
allowing	O
rapid	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O


Three	O
mutants	O
(	O
-201/-184	O
NXS	O
,	O
-165/-148	O
NXS	O
,	O
and	O
-147/-130	O
NXS	O
)	O
had	O
effects	O
on	O
viral	O
replication	O
that	O
were	O
much	O
more	O
severe	O
than	O
the	O
effects	O
predicted	O
from	O
their	O
performance	O
in	O
transfection	O
analyses	O
,	O
and	O
the	O
effects	O
of	O
two	O
LS	O
mutations	O
(	O
-201/-184	O
NXS	O
and	O
-183/-166	O
NXS	O
)	O
were	O
not	O
predicted	O
by	O
their	O
effects	O
in	O
transfection	O
.	O


Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	O
be	O
possible	O
to	O
define	O
important	O
regulatory	O
domains	O
that	O
can	O
then	O
be	O
assayed	O
using	O
less	O
stringent	O
systems	O
,	O
such	O
as	O
cell-free	O
extracts	O
for	O
in	O
vitro	O
transcription	O
.	O


The	O
ideal	O
situation	O
would	O
be	O
analyses	O
conducted	O
in	O
GATA-1	B-cell_line
-erythroid	I-cell_line
cells	I-cell_line
.	O


A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
homologous	O
to	O
a	O
rodent	B-DNA
gene	I-DNA
encoding	O
a	O
zinc-binding	B-protein
potential	I-protein
transcription	I-protein
factor	I-protein
.	O


Group	O
1	O
contains	O
G0S24	B-DNA
and	O
the	O
rat	B-DNA
and	I-DNA
mouse	I-DNA
TIS11	I-DNA
genes	I-DNA
(	O
also	O
known	O
as	O
TTP	B-DNA
,	O
Nup475	B-DNA
,	O
and	O
Zfp36	B-DNA
)	O
.	O


Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	B-protein
region	I-protein
and	O
an	O
``	O
arginine	B-protein
element	I-protein
``	O
(	O
RRLPIF	B-protein
)	O
at	O
the	O
carboxyl	B-protein
terminus	I-protein
.	O


A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O


Protein	O
and	O
genomic	O
sequences	O
show	O
similarities	O
with	O
those	O
of	O
a	O
variety	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
suggesting	O
that	O
the	O
G0S24	B-protein
product	I-protein
has	O
a	O
similar	O
role	O
.	O


Co-expression	O
of	O
both	O
PU.1	B-protein
and	O
Ets-1	B-protein
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
trans-activated	B-DNA
reporter	I-DNA
plasmids	I-DNA
that	O
contained	O
the	O
minimal	O
mu	B-DNA
enhancer	I-DNA
.	O


1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
interact	O
synergistically	O
to	O
induce	O
monocytic	O
differentiation	O
of	O
U937	B-cell_line
histiocytic	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O


The	O
kinetics	O
of	O
induced	O
differentiation	O
are	O
consistent	O
with	O
a	O
G1	O
specific	O
cellular	O
response	O
to	O
initiate	O
the	O
metabolic	O
cascade	O
culminating	O
in	O
cell	O
differentiation	O
.	O


When	O
stably	O
introduced	O
into	O
primary	B-cell_type
erythroblasts	I-cell_type
or	O
conditionally	B-cell_line
transformed	I-cell_line
erythroid	I-cell_line
progenitors	I-cell_line
cells	I-cell_line
,	O
exogenous	O
GATA-2/ER	B-protein
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen-dependent	O
manner	O
.	O


Thus	O
,	O
the	O
GATA-2	B-protein
transcription	I-protein
factor	I-protein
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self-renewal	O
capacity	O
of	O
early	B-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O


However	O
,	O
TNF	B-protein
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	B-protein
to	O
induce	O
NF-kappa	B-protein
B	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
TNFRp55	B-protein
-deficient	O
mice	O
.	O


We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	B-DNA
embryonic	I-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
and	O
the	O
alpha	B-DNA
globin	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
HS-40	B-DNA
)	O
located	O
40	B-DNA
kb	I-DNA
upstream	I-DNA
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
.	O


Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA-1	O
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF-E2/AP1	O
motifs	O
together	O
formed	O
the	O
functional	O
core	O
of	O
HS-40	B-DNA
in	O
the	O
erythroid-specific	O
activation	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
.	O


On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	B-DNA
sequence	I-DNA
motifs	I-DNA
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O


In	O
addition	O
to	O
the	O
wild-type	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
Raji	I-cell_line
,	O
two	B-cell_line
class	I-cell_line
II	I-cell_line
transcriptional	I-cell_line
mutant	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
SJO	B-cell_line
and	O
RJ2.2.5	B-cell_line
,	O
and	O
Jurkat	B-cell_line
,	O
a	O
class	B-cell_line
II	I-cell_line
negative	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
examined	O
.	O


The	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O


In	O
comparison	O
,	O
PBMC	B-cell_type
from	O
two	O
children	O
with	O
fatal	O
adenoviral	O
infection	O
were	O
both	O
strongly	O
positive	O
for	O
adenovirus	B-DNA
DNA	I-DNA
.	O


DESIGN	O
:	O
Infected	O
promyelocytic	B-cell_type
and	O
promonocytic	B-cell_type
cells	I-cell_type
were	O
examined	O
because	O
they	O
normally	O
express	O
both	O
types	O
of	O
TNF	B-protein
receptors	I-protein
.	O


A	O
series	O
of	O
uninfected	B-cell_line
parental	I-cell_line
HL-60	I-cell_line
subclones	I-cell_line
all	O
reduced	O
TR75	B-protein
surface	O
expression	O
in	O
response	O
to	O
TNF-alpha	B-protein
treatment	O
.	O


We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O


These	O
results	O
,	O
combined	O
with	O
previous	O
studies	O
,	O
suggest	O
that	O
the	O
Y	O
chromosome	O
in	O
great	O
apes	O
has	O
a	O
conserved	O
region	O
including	O
the	O
pseudoautosomal	B-DNA
region	I-DNA
and	O
the	O
testis-determining	O
region	O
.	O


A	O
reporter	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
a	O
T-cell	B-DNA
antigen	I-DNA
receptor	I-DNA
element	I-DNA
was	O
activated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
a	O
calcium	O
ionophore	O
.	O


Thus	O
p59fyn	B-protein
could	O
replace	O
the	O
calcium	O
ionophore	O
but	O
not	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O


The	O
levels	O
of	O
GATA-1	B-protein
,	O
Epo-R	B-protein
and	O
globin	B-RNA
mRNA	I-RNA
expressed	O
were	O
not	O
affected	O
by	O
a	O
24-hour	O
incubation	O
of	O
either	O
cell	O
line	O
with	O
Epo	B-protein
,	O
GM-CSF	B-protein
or	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
.	O


Protein	B-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O


Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin-1	B-protein
beta	I-protein
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O


This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL-1	B-RNA
beta	I-RNA
convertase	I-RNA
mRNA	I-RNA
accumulation	O
.	O


The	O
stimulation	O
of	O
interleukin-1	B-protein
alpha	I-protein
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin-1	B-protein
beta	I-protein
.	O


It	O
is	O
also	O
shown	O
in	O
this	O
report	O
that	O
,	O
in	O
response	O
to	O
PMA/anti-CD28	B-protein
mAb	I-protein
or	O
anti-CD3/anti-CD28	B-protein
mAb	I-protein
,	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
are	O
associated	O
with	O
CD28-responsive	B-DNA
element	I-DNA
present	O
in	O
the	O
promoter	B-DNA
of	O
the	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
gene	I-DNA
.	O


Tal-1	B-DNA
gene	I-DNA
encodes	O
a	O
putative	O
transcription	B-protein
factor	I-protein
with	O
a	O
basic	B-protein
helix-loop-helix	I-protein
domain	I-protein
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O


Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA-1	B-protein
modulates	O
the	O
transcription	O
of	O
tal-1	B-protein
during	O
the	O
differentiation	O
of	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
basosophilic	I-cell_type
lineages	I-cell_type
.	O


We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O


We	O
detected	O
an	O
association	O
between	O
the	O
reduced	O
mitogenic	O
response	O
and	O
low	O
expression	O
of	O
both	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
the	O
alpha	B-protein
chain	I-protein
(	O
CD25	B-protein
)	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
.	O


Altogether	O
,	O
the	O
data	O
provide	O
the	O
evidence	O
that	O
both	O
pathways	O
complement	O
each	O
other	O
in	O
regulating	O
gene	O
expression	O
and	O
,	O
conversely	O
,	O
downregulate	O
the	O
TcR	B-protein
transduction	O
mechanisms	O
.	O


The	O
lymphotoxin	B-DNA
promoter	I-DNA
is	O
stimulated	O
by	O
HTLV-I	B-protein
tax	I-protein
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O


Tax	B-protein
co-transfected	O
with	O
reporter	B-DNA
constructs	I-DNA
into	O
Jurkat	B-cell_line
cells	I-cell_line
maximally	O
activated	O
HTLV-I-LTR-CAT	B-protein
and	O
kappa	B-protein
B-fos-CAT	I-protein
and	O
also	O
activated	O
LT-293	B-DNA
to	O
a	O
lesser	O
extent	O
.	O


Restriction	O
enzyme	O
analysis	O
followed	O
by	O
Southern	O
blot	O
hybridization	O
identified	O
a	O
significant	O
increase	O
in	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	B-DNA
DNA	I-DNA
.	O


Southern	O
blot	O
analysis	O
of	O
in	O
situ	O
lysing	O
gels	O
revealed	O
that	O
the	O
cellular	O
content	O
of	O
linear	B-DNA
EBV	I-DNA
DNA	I-DNA
was	O
also	O
increased	O
significantly	O
after	O
the	O
initiation	O
of	O
the	O
viral	O
lytic	O
cycle	O
,	O
while	O
the	O
amount	O
of	O
circular	O
DNA	O
remained	O
approximately	O
constant	O
.	O


gamma-Interferon	B-protein
expression	O
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
's	O
goiter	O
.	O


1	O
,	O
25	O
alpha-Dihydroxicholecalciferol	O
(	O
VitD3	O
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
important	O
regulators	O
of	O
the	O
proliferation	O
and	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O


While	O
inducing	O
CD14	B-protein
expression	O
,	O
VitD3	O
concomitantly	O
suppressed	O
the	O
basal	O
,	O
PMA-	O
,	O
and	O
RA-inducible	O
CD23	B-protein
expression	O
in	O
a	O
dose-dependent	O
manner	O
.	O


Furthermore	O
,	O
the	O
VitD3	O
-and	O
the	O
PMA-induced	O
CD14	B-protein
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA-induced	O
differentiation	O
.	O


The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	B-protein
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	B-protein
.	O


Increased	O
c-jun	B-protein
,	O
jun-B	B-protein
,	O
and	O
jun-D	B-protein
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP-1/TPA	B-DNA
responsive	I-DNA
elements	I-DNA
fused	O
to	O
chloramphenicol	B-DNA
acetyl-transferase	I-DNA
vectors	I-DNA
were	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O


Conversely	O
,	O
c-jun	B-protein
and	O
jun-B	B-protein
transfection	O
blunted	O
GR	B-protein
-dependent	O
transcription	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O


Furthermore	O
overexpression	O
of	O
exogenous	B-protein
c-fos	I-protein
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B-protein
-dependent	O
transcription	O
from	O
GRE	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O


This	O
sequence	B-DNA
element	I-DNA
was	O
referred	O
to	O
as	O
the	O
BAT	B-DNA
box	I-DNA
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	O
promoter-CAT	O
construct	O
in	O
B	O
cells	O
.	O


Southwestern	O
blotting	O
and	O
UV	O
cross-linking	O
studies	O
confirmed	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O


The	O
autologous	B-cell_line
DE	I-cell_line
LCL	I-cell_line
containing	O
a	O
transduced	O
pml/RAR	B-DNA
alpha	I-DNA
fusion	I-DNA
gene	I-DNA
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml/RAR	B-protein
alpha	I-protein
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	B-cell_line
anti-BCR1/25	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O


It	O
is	O
concluded	O
that	O
the	O
bcr1	B-protein
type-pml/RAR	I-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
of	O
APL	B-cell_line
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	B-cell_line
CD4+	I-cell_line
lymphocytes	I-cell_line
.	O


In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O


Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	B-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O


Further	O
studies	O
will	O
have	O
to	O
prove	O
if	O
Urapidil	O
is	O
suited	O
for	O
prepartal	O
treatment	O
of	O
PIH	O
as	O
well	O
.	O


Interleukin-4	B-protein
inhibits	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
c-jun	B-RNA
and	I-RNA
c-fos	I-RNA
messenger	I-RNA
RNA	I-RNA
and	O
activator	B-protein
protein-1	I-protein
binding	O
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	B-protein
receptors	I-protein
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O


Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
related	O
rapid	O
responses	O
.	O


The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O


This	O
activation	O
is	O
mediated	O
by	O
the	O
host	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
[	O
G.Nabel	O
and	O
D.Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711-717	O
,	O
1987	O
]	O
.	O


Our	O
analyses	O
show	O
that	O
several	O
Oct2	B-protein
isoforms	I-protein
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
.	O


This	O
high-affinity	B-DNA
site	I-DNA
has	O
been	O
conserved	O
in	O
the	O
promoters	B-DNA
of	O
both	O
human	B-DNA
and	I-DNA
mouse	I-DNA
CD19	I-DNA
genes	I-DNA
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B-cell	O
specificity	O
to	O
a	O
beta-globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O


In	O
addition	O
,	O
BSAP	B-protein
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA-binding	O
activity	O
of	O
B-cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	B-DNA
promoter	I-DNA
.	O


Eicosanoids	O
in	O
breast	O
cancer	O
patients	O
before	O
and	O
after	O
mastectomy	O
.	O


In	O
19	O
patients	O
with	O
a	O
malignant	O
breast	O
tumor	O
,	O
tumor	O
tissue	O
and	O
blood	O
were	O
taken	O
to	O
determine	O
the	O
eicosanoid	O
profile	O
and	O
platelet	B-cell_type
aggregation	O
.	O


Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre-	O
and	O
postoperative	O
values	O
.	O


MR	B-protein
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	O
group	O
(	O
148	O
+/-	O
9	O
binding	O
sites/cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
+/-	O
17	O
binding	O
sites/cell	O
;	O
mean	O
+/-	O
SEM	O
)	O
.	O


Plasma	O
aldosterone	O
in	O
women	O
with	O
PIH	O
was	O
281	O
+/-	O
61	O
pmol/L	O
;	O
in	O
normal	O
pregnant	O
women	O
it	O
was	O
697	O
+/-	O
172	O
pmol/L	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O


The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	B-cell_line
promyeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
(	O
HL-60	B-cell_line
)	O
agreed	O
well	O
with	O
their	O
bone-resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O


Initial	O
and	O
post-dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	O
different	O
between	O
major	O
depressive	O
disorder	O
and	O
non-depressed	O
control	O
subjects	O
.	O


High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	B-cell_type
leukocytes	I-cell_type
:	O
is	O
there	O
a	O
membrane	B-protein
receptor	I-protein
for	O
mineralocorticoids	O
?	O


High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	O
Kd	O
of	O
approximately	O
0.1	O
nM	O
was	O
found	O
.	O


These	O
data	O
are	O
perfectly	O
compatible	O
with	O
major	O
properties	O
of	O
steroidal	O
effects	O
on	O
the	O
sodium-proton-antiport	B-protein
in	O
HML	B-cell_type
and	O
thus	O
very	O
likely	O
represent	O
membrane	B-protein
receptors	I-protein
for	O
aldosterone	O
.	O


Natural	O
variants	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
:	O
analysis	O
of	O
promoters	B-DNA
with	O
duplicated	O
DNA	B-DNA
regulatory	I-DNA
motifs	I-DNA
.	O


Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	B-DNA
sites	I-DNA
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	B-DNA
control	I-DNA
LTR	I-DNA
with	O
three	O
Sp1	B-DNA
sites	I-DNA
.	O


The	O
helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
proteins	I-protein
are	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O


To	O
address	O
the	O
role	O
of	O
Oct-2	B-protein
in	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
nontransformed	B-cell_line
human	I-cell_line
and	I-cell_line
mouse	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


The	O
GR	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
aged	O
runner	O
was	O
65	O
%	O
of	O
the	O
control	O
.	O


MR	B-protein
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+/-	O
27	O
receptors/cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
+/-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	B-protein
,	O
242	O
+/-	O
79	O
;	O
SPD	O
,	O
14.0	O
+/-	O
4	O
mV	O
)	O
.	O


Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
in	O
human	B-cell_line
HL60	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
--	O
coincident	O
rise	O
of	O
DNA-relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O


Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites/nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	B-cell_line
cells	I-cell_line
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites/nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	B-cell_type
.	O


The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	B-cell_type
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	B-cell_line
.	O


Enhanced	O
activity	O
of	O
topoisomerases	B-protein
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B-protein
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA-unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O


The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	O
cancer	O
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O


Estrogen	B-cell_line
receptor	I-cell_line
positive	I-cell_line
(	I-cell_line
ER+	I-cell_line
:	I-cell_line
MCF-7	I-cell_line
)	I-cell_line
and	I-cell_line
negative	I-cell_line
(	I-cell_line
ER-	I-cell_line
:	I-cell_line
MDA-MB-231	I-cell_line
)	I-cell_line
human	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
(	I-cell_type
LAK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O


Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
which	O
is	O
itself	O
a	O
DNA-binding	B-protein
protein	I-protein
and	O
transcriptional	B-protein
transactivator	I-protein
,	O
can	O
interact	O
synergistically	O
with	O
Z	B-protein
in	O
activating	O
the	O
BMRF1	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
T-cell	B-cell_line
line	I-cell_line
)	O
or	O
Raji	B-cell_line
cells	I-cell_line
(	O
an	O
EBV-positive	B-cell_line
B-cell	I-cell_line
)	O
,	O
whereas	O
the	O
c-myb	B-protein
gene	I-protein
product	I-protein
by	O
itself	O
has	O
little	O
effect	O
.	O


Reticuloendotheliosis	B-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
elements	I-DNA
are	O
efficient	O
promoters	B-DNA
in	O
cells	O
of	O
various	O
species	O
and	O
tissue	O
origin	O
,	O
including	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O


The	O
latent	O
phases	O
of	O
both	O
HIV-1	O
and	O
HIV-2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T-cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O


Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf-1	B-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
induction	O
of	O
HIV-2	O
transcription	O
following	O
T-cell-receptor-mediated	O
T-cell	O
activation	O
.	O


Moreover	O
,	O
Elf-1	B-protein
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O


Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


c-myc	B-RNA
mRNA	I-RNA
expression	O
in	O
minor	O
salivary	O
glands	O
of	O
patients	O
with	O
Sjogren	O
's	O
syndrome	O
.	O


In	O
this	O
study	O
,	O
c-myc	B-RNA
protooncogene	I-RNA
mRNA	I-RNA
expression	O
in	O
29	O
labial	O
minor	O
salivary	O
gland	O
biopsies	O
from	O
patients	O
with	O
primary	O
SS	O
and	O
15	O
controls	O
was	O
examined	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
.	O


All	O
of	O
the	O
parameters	O
were	O
also	O
tested	O
for	O
correlation	O
,	O
and	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
age	O
and	O
type	B-protein
I	I-protein
and	O
type	B-protein
II	I-protein
receptors	I-protein
when	O
all	O
subjects	O
were	O
plotted	O
and	O
between	O
aged	O
and	O
CD4	B-cell_type
and	O
age	O
and	O
CD4/CD8	B-cell_type
in	O
the	O
aged	O
group	O
.	O


Transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
development	O
:	O
the	O
alpha	B-DNA
TCR	I-DNA
gene	I-DNA
as	O
a	O
molecular	O
model	O
.	O


Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O


In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	B-protein
or	O
p65	B-protein
.	O


However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	O
question	O
of	O
the	O
optimal	O
DNA	O
sequences	O
preferred	O
by	O
each	O
homodimer	O
has	O
not	O
been	O
addressed	O
.	O


NF-kappa	B-protein
B	I-protein
-dependent	O
induction	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	B-DNA
subunit	I-DNA
gene	I-DNA
promoter	I-DNA
underlies	O
self-perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF-kappa	B-protein
B	I-protein
levels	O
were	O
increased	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
.	O


In	O
contrast	O
to	O
the	O
transient	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF-kappa	B-protein
B	I-protein
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	B-protein
isoenzymes	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O


In	O
addition	O
,	O
IL-2	B-protein
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	B-protein
gene	O
coding	O
for	O
the	O
p50	B-protein
subunit	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	B-protein
NF-kappa	B-DNA
B	I-DNA
gene	I-DNA
remained	O
unchanged	O
.	O


Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	B-cell_line
human	I-cell_line
dermal	I-cell_line
fibroblasts	I-cell_line
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O


We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	B-protein
activity	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/	O
CD69	B-protein
activation	O
pathway	O
.	O


Gangliosides	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O


On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester-induced	O
production	O
of	O
O2-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	O
gangliosides	O
.	O


In	O
vitro-translated	B-protein
proteins	I-protein
,	O
truncated	O
downstream	O
of	O
the	O
Rel	B-DNA
domain	I-DNA
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O


Transient-transfection	O
experiments	O
in	O
embryonal	B-cell_line
carcinoma	I-cell_line
cells	I-cell_line
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	B-protein
and	O
RelB	B-protein
or	O
p65	B-protein
in	O
transactivation	O
of	O
a	O
reporter	B-DNA
plasmid	I-DNA
dependent	O
on	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
.	O


We	O
have	O
investigated	O
whether	O
a	O
palmitate	B-protein
conjugate	I-protein
of	O
a	O
human	B-protein
monoclonal	I-protein
antibody	I-protein
specific	O
for	O
thyroglobulin	B-protein
(	O
TG	B-protein
)	O
could	O
function	O
as	O
a	O
surrogate	B-protein
TG	I-protein
receptor	I-protein
on	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
separated	O
into	O
fractions	O
enriched	O
for	O
T	B-cell_type
cells	I-cell_type
or	O
depleted	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
non-T	B-cell_type
cells	I-cell_type
)	O
.	O


v-Fos	B-protein
protein	I-protein
,	O
the	O
retroviral	O
counterpart	O
of	O
c-Fos	B-protein
,	O
was	O
not	O
susceptible	O
to	O
degradation	O
targeted	O
by	O
c-Jun	B-protein
.	O


These	O
AP-2	B-DNA
and	O
AP-1	B-DNA
sites	I-DNA
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O


While	O
all	O
the	O
M10-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV-1	O
.	O


In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	B-cell_line
CEM	I-cell_line
clones	I-cell_line
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O


Expression	O
of	O
M10	B-protein
did	O
not	O
affect	O
induction	O
of	O
HIV	O
transcription	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
regulatory	I-DNA
element	I-DNA
or	O
Tat	B-protein
.	O


The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B-protein
1	I-protein
and	I-protein
2A	I-protein
protein	I-protein
phosphatases	I-protein
,	O
on	O
the	O
regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O


Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c-jun	B-DNA
gene	I-DNA
is	O
autoinduced	O
by	O
Jun/AP-1	B-protein
,	O
we	O
also	O
studied	O
transcription	O
of	O
c-jun	B-DNA
promoter	I-DNA
(	I-DNA
positions	I-DNA
-132/+170	I-DNA
)	I-DNA
-reporter	I-DNA
gene	I-DNA
constructs	I-DNA
with	O
and	O
without	O
a	O
mutated	O
AP-1	B-DNA
element	I-DNA
.	O


The	O
mitogen-induced	O
increase	O
of	O
c-Fos	B-protein
and	O
c-Jun	B-protein
immunoreactivity	O
was	O
inhibited	O
by	O
H-7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H-8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide-dependent	O
kinases	O
.	O


An	O
11-base-pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	B-DNA
interleukin	I-DNA
4	I-DNA
gene	I-DNA
confers	O
responsiveness	O
to	O
T-cell	O
activation	O
signals	O
.	O


We	O
have	O
identified	O
a	O
DNA	B-DNA
segment	I-DNA
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	B-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
4	I-DNA
gene	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	B-protein
factors	I-protein
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
after	O
LTB4	O
stimulation	O
.	O


Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
7-fold	O
and	O
the	O
c-jun	B-DNA
gene	I-DNA
1.4-fold	O
.	O


Resting	B-cell_type
monocytes	I-cell_type
contained	O
nuclear	B-protein
factors	I-protein
binding	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
,	O
but	O
stimulation	O
of	O
monocytes	B-cell_type
with	O
LTB4	O
induced	O
greater	O
AP-1	B-protein
-binding	O
activity	O
of	O
nuclear	B-protein
proteins	I-protein
.	O


Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	B-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	B-DNA
kinase	I-DNA
oncogene	I-DNA
.	O


Expression	O
of	O
the	O
human	B-protein
RAR-alpha	I-protein
in	O
receptor-negative	B-cell_line
erythroblasts	I-cell_line
conferred	O
RA-induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	B-cell_type
cells	I-cell_type
,	O
thus	O
showing	O
that	O
the	O
RAR-alpha	B-protein
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O


GM2	B-DNA
defines	O
a	O
binding	B-DNA
site	I-DNA
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O


The	O
viral	B-protein
trans-activators	I-protein
appear	O
to	O
target	O
specific	O
DNA	B-protein
binding	I-protein
protein	I-protein
such	O
as	O
NF-kB	B-protein
and	O
Sp1	B-protein
to	O
cis-acting	B-DNA
DNA	I-DNA
site	I-DNA
and	O
promote	O
lymphokine	B-DNA
gene	I-DNA
expression	O
without	O
TCR	B-protein
-mediated	O
stimulation	O
.	O


We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	B-protein
.	O


The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
investigate	O
the	O
modulation	O
of	O
the	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
obtained	O
from	O
peripheral	O
blood	O
by	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
isoproterenol	O
(	O
ISO	O
)	O
,	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
.	O


Although	O
DEX	O
and	O
PGE2	O
were	O
equipotent	O
in	O
suppressing	O
T-cell	O
proliferation	O
,	O
ISO	O
was	O
much	O
less	O
effective	O
.	O


Class	B-cell_line
II	I-cell_line
antigen	I-cell_line
expressing	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
maintained	O
contacts	O
identical	O
to	O
B-cell	B-cell_line
lines	I-cell_line
,	O
while	O
class	B-cell_line
II-negative	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
exhibited	O
no	O
interactions	O
.	O


Interferon	B-protein
gamma	I-protein
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O


3	O
.	O


This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O


The	O
potential	O
clinical	O
usefulness	O
of	O
these	O
CL	O
assays	O
was	O
suggested	O
by	O
the	O
ability	O
of	O
both	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
to	O
respond	O
to	O
red	B-cell_type
cells	I-cell_type
,	O
platelets	B-cell_type
or	O
granulocytes	B-cell_type
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	O
haemolytic	O
disease	O
of	O
the	O
newborn	O
(	O
HDN	O
)	O
,	O
alloimmune	O
thrombocytopenia	O
or	O
alloimmune	O
neutropenia	O
respectively	O
.	O


In	O
addition	O
,	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
both	O
responded	O
to	O
red	B-cell_type
cells	I-cell_type
sensitized	O
with	O
antibodies	B-protein
against	O
a	O
variety	O
of	O
specificities	O
of	O
assumed	O
(	O
although	O
not	O
documented	O
)	O
clinical	O
significance	O
for	O
blood	O
transfusion	O
recipients	O
.	O


In	O
vitro	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture-adapted	B-cell_line
Tax-transformed	I-cell_line
fibroblasts	I-cell_line
as	O
well	O
as	O
an	O
HTLV-I-transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
.	O


This	O
includes	O
a	O
very	O
low	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
0.1	O
nM	O
for	O
both	O
aldosterone	O
and	O
the	O
effect	O
on	O
the	O
Na	B-protein
(	I-protein
+	I-protein
)	I-protein
-H	I-protein
(	I-protein
+	I-protein
)	I-protein
-antiport	I-protein
,	O
a	O
high	O
turnover	O
rate	O
,	O
and	O
the	O
almost	O
exclusive	O
binding	O
selectivity	O
for	O
aldosterone	O
.	O


Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O


PLB-985	B-cell_line
cells	I-cell_line
represent	O
a	O
bipotential	B-cell_line
myelomonoblastic	I-cell_line
cell	I-cell_line
population	I-cell_line
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O


The	O
diurnal	O
rhythm	O
of	O
ACTH	O
and	O
cortisol	O
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O


A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O


In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O


The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O


However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O


Whereas	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen-driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	O
is	O
exactly	O
the	O
same	O
phenomenon	O
that	O
occurs	O
in	O
the	O
thymic	O
cortex	O
.	O


The	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
subunit	I-protein
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	O
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
termed	O
I	O
kappa	O
B	O
.	O


[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones.	O
I.	O
Estrogens	O
]	O


Their	O
action	O
mechanism	O
is	O
not	O
completely	O
cleared	O
.	O


Currently	O
it	O
is	O
accepted	O
the	O
existence	O
of	O
a	O
cytoplasmic	B-protein
and/or	I-protein
nuclear	I-protein
receptor	I-protein
,	O
without	O
explaining	O
satisfactorily	O
how	O
the	O
hormones	O
come	O
to	O
the	O
nucleus	O
.	O


The	O
endocrine	O
events	O
that	O
are	O
rapidly	O
expressed	O
(	O
seconds	O
)	O
are	O
due	O
to	O
a	O
possible	O
interaction	O
with	O
cellular	O
membrane	O
.	O


Since	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
contains	O
two	O
functional	O
nuclear	B-DNA
factor	I-DNA
kB	I-DNA
(	I-DNA
NF-kB	I-DNA
)	I-DNA
regulatory	I-DNA
elements	I-DNA
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF-kB	B-protein
binding	O
activity	O
by	O
different	O
assays	O
.	O


Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF-kB	B-protein
binding	I-protein
proteins	I-protein
from	O
their	O
cytoplasmic	O
pools	O
.	O


The	O
nuclear	B-protein
factor	I-protein
NF-AT	I-protein
(	O
ref.	O
1	O
)	O
is	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
through	O
the	O
T-cell	B-protein
receptor/CD3	I-protein
complex	I-protein
,	O
and	O
is	O
required	O
for	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
induction	O
.	O


NF-AT	B-protein
induction	O
may	O
require	O
two	O
activation-dependent	O
events	O
:	O
the	O
CsA-sensitive	O
translocation	O
of	O
a	O
pre-existing	O
component	O
and	O
the	O
CsA-resistant	O
synthesis	O
of	O
a	O
nuclear	B-protein
component	I-protein
.	O


In	O
particular	O
,	O
the	O
c-Rel	B-protein
homodimer	I-protein
has	O
a	O
high	O
affinity	O
for	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
and	O
beta	B-DNA
interferon	I-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
.	O


We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B-protein
receptor	I-protein
activation	O
.	O


Glucocorticoid	B-protein
receptor	I-protein
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+/-	O
9.4	O
fmol/million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+/-	O
2.6	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age-matched	O
controls	O
(	O
3.15	O
+/-	O
2.3	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O


In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	B-protein
glucocorticoid	I-protein
receptors	I-protein
on	O
lymphocytes	B-cell_type
.	O


The	O
constitutive	B-protein
transcription	I-protein
factor	I-protein
SP1	B-protein
was	O
unaffected	O
by	O
addition	O
of	O
TPA	O
.	O


In	O
THP-1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster-migrating	B-protein
NF	I-protein
kappa	I-protein
B	I-protein
species	I-protein
not	O
induced	O
in	O
monocytes	B-cell_type
.	O


The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	B-cell_type
leukocytes	I-cell_type
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	B-protein
molecules	I-protein
for	O
leukocytes	B-cell_type
[	O
e.g.	O
,	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ELAM-1	B-protein
)	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ICAM-1	B-protein
)	O
]	O
.	O


Treatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	B-protein
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane-associated	B-protein
ELAM-1	I-protein
and	O
ICAM-1	B-protein
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O


As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	O
tetrahydrocortisol	O
inhibited	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
.	O


BSAP	B-protein
expression	O
persists	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
is	O
also	O
seen	O
in	O
the	O
testis	O
of	O
the	O
adult	O
mouse	O
.	O


The	O
programmed	O
activation/repression	O
of	O
transcription	B-protein
factors	I-protein
in	O
early	O
hematopoietic	O
differentiation	O
has	O
not	O
yet	O
been	O
explored	O
.	O


Little	O
effect	O
was	O
observed	O
with	O
50-kDa	B-protein
forms	I-protein
of	O
p105	B-protein
NF-kappa	B-protein
B	I-protein
or	O
rel	B-protein
,	O
in	O
combination	O
with	O
p65	B-protein
or	O
full-length	B-protein
c-rel	I-protein
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
these	O
cells	O
.	O


Stable	O
transfectants	O
of	O
HB24	B-DNA
were	O
established	O
that	O
expressed	O
high	O
levels	O
of	O
HB24	B-RNA
mRNA	I-RNA
and	O
possessed	O
an	O
altered	O
phenotype	O
suggestive	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O


Thus	O
,	O
stable	O
expression	O
of	O
HB24	B-DNA
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	B-protein
factor	I-protein
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O


The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	B-DNA
binding	I-DNA
sequence	I-DNA
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
promoters	B-DNA
and	O
enhancers	B-DNA
of	O
many	O
inducible	B-DNA
T-cell	I-DNA
genes	I-DNA
.	O


Transcription	O
of	O
the	O
hypersensitive	B-DNA
site	I-DNA
HS2	I-DNA
enhancer	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O


The	O
mechanism	O
of	O
HS2	B-DNA
enhancer	I-DNA
function	O
is	O
not	O
known	O
.	O


In	O
directing	O
the	O
synthesis	O
of	O
RNA	B-RNA
through	O
the	O
intervening	O
DNA	B-DNA
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	B-DNA
enhancer	I-DNA
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	B-DNA
structure	I-DNA
of	O
a	O
gene	B-DNA
domain	I-DNA
and	O
(	O
ii	O
)	O
deliver	O
enhancer	B-protein
binding	I-protein
proteins	I-protein
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	B-DNA
site	I-DNA
.	O


The	O
palindromic	B-DNA
site	I-DNA
(	O
site	B-DNA
B	I-DNA
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	B-DNA
binding	I-DNA
sites	I-DNA
of	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
.	O


Further	O
,	O
we	O
observe	O
that	O
TAR-deleted	B-DNA
mutants	I-DNA
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	B-protein
p24	I-protein
antigen	I-protein
.	O


Mutagenesis	O
indicates	O
that	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	B-protein
activation	O
.	O


We	O
demonstrated	O
that	O
AP-2	B-RNA
mRNA	I-RNA
was	O
present	O
in	O
T-lymphocytes	B-cell_type
and	O
that	O
cellular	O
factors	O
from	O
both	O
non-transformed	O
and	O
transformed	O
T-lymphocytes	B-cell_type
specifically	O
bound	O
to	O
the	O
consensus	B-DNA
motif	I-DNA
for	O
AP-2	B-protein
in	O
each	O
21	O
bp	O
.	O


Transfection	O
of	O
an	O
AP-2	B-DNA
expression	I-DNA
construct	I-DNA
into	O
T-lymphocytes	B-cell_type
activated	O
gene	O
expression	O
from	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
.	O


Several	O
DNA-binding	B-protein
proteins	I-protein
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O


Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid-specific	B-protein
octamer-binding	I-protein
factor	I-protein
in	O
DRA	O
gene	O
transcription	O
.	O


Interferon	B-protein
gamma	I-protein
activated	O
strongly	O
c-fos	B-DNA
and	O
weakly	O
c-jun	B-DNA
and	O
AP1	B-protein
.	O


Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	B-protein
beta	I-protein
production	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
.	O


When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA-induced	B-RNA
mRNA	I-RNA
)	O
.	O


Only	O
the	O
activities	O
for	O
NF-AT	B-DNA
and	I-DNA
AP-1	I-DNA
sites	I-DNA
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	O
plus	O
either	O
lectin	B-protein
or	O
antibody	B-protein
to	O
the	O
CD3	B-protein
or	O
CD28	B-protein
surface	I-protein
molecules	I-protein
.	O


This	O
region	O
contains	O
two	O
DNA-binding	B-DNA
motifs	I-DNA
,	O
GM2	B-DNA
and	O
GC-box	B-DNA
.	O


The	O
MAD-3	B-DNA
cDNA	I-DNA
encodes	O
an	O
I	B-protein
kappa	I-protein
B-like	I-protein
protein	I-protein
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF-kappa	B-protein
B	I-protein
,	O
including	O
adhesion-dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O


In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	B-cell_type
express	O
detectable	O
HIV	B-protein
proteins	I-protein
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O


We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	B-protein
factor	I-protein
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
permanently	O
increased	O
HIV	B-DNA
enhancer	I-DNA
activity	O
.	O


In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	B-protein
kilodaltons	I-protein
(	O
kD	O
)	O
.	O


In	O
addition	O
,	O
the	O
65-kD	B-protein
protein	I-protein
associated	O
with	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
and	O
the	O
kappa	B-DNA
B	I-DNA
probe	I-DNA
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF-kappa	B-protein
B-DNA	I-protein
complex	I-protein
.	O


All	O
three	O
cell	O
lines	O
expressed	O
vitamin	O
D	O
receptor	O
and	O
had	O
increased	O
levels	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
in	O
response	O
to	O
LPS	O
.	O


Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
appearance	O
in	O
response	O
to	O
LPS	O
.	O


Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc-finger-encoding	B-DNA
genes	I-DNA
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
of	O
resting	B-cell_type
fibroblasts	I-cell_type
.	O


v-erbA	B-protein
overexpression	O
is	O
required	O
to	O
extinguish	O
c-erbA	B-protein
function	O
in	O
erythroid	B-cell_type
cell	I-cell_type
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	B-DNA
target	I-DNA
gene	I-DNA
CAII	B-DNA
.	O


The	O
c-erbA	B-protein
-dependent	O
activation	O
of	O
this	O
CAII	B-DNA
reporter	I-DNA
construct	I-DNA
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v-erbA	B-protein
.	O


The	O
CD2	B-protein
T	I-protein
lymphocyte	I-protein
glycoprotein	I-protein
surface	I-protein
molecule	I-protein
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O


In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti-CD2	B-protein
antibodies	I-protein
stimulate	O
viral	O
production	O
.	O


The	O
KBF1/p50	B-protein
factor	I-protein
binds	O
as	O
a	O
homodimer	B-protein
but	O
can	O
also	O
form	O
heterodimers	B-protein
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	B-DNA
and	I-DNA
v-rel	I-DNA
(	I-DNA
proto	I-DNA
)	I-DNA
oncogenes	I-DNA
.	O


A	O
mutant	O
of	O
KBF1/p50	B-protein
(	O
delta	B-protein
SP	I-protein
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	B-protein
,	O
has	O
been	O
constructed	O
.	O


Tissue-specific	O
expression	O
of	O
the	O
platelet	B-DNA
GPIIb	I-DNA
gene	I-DNA
.	O


One	O
region	O
,	O
centered	O
at	O
-54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	B-DNA
factor	I-DNA
E1-binding	I-DNA
site	I-DNA
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-233	O
contains	O
a	O
CCAAT	B-DNA
motif	I-DNA
.	O


These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand-induced	O
plasticity	O
of	O
glucocorticoid	B-protein
receptor	I-protein
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
during	O
depression	O
.	O


Every	O
enhancer	O
works	O
with	O
every	O
promoter	B-DNA
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O


Towards	O
a	O
molecular	O
understanding	O
of	O
T-cell	O
differentiation	O
.	O


Deletion	O
of	O
all	O
the	O
Sp	B-DNA
1-binding	I-DNA
sites	I-DNA
from	O
the	O
enhancer	B-DNA
reduces	O
transcription	O
by	O
80-90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA-B	B-cell_line
cells	I-cell_line
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer-binding	B-DNA
site	I-DNA
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O


The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	B-DNA
and	O
the	O
adjacent	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
in	O
BJA-B	B-cell_line
cells	I-cell_line
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	B-DNA
expresses	O
wild-type	O
levels	O
of	O
U2	B-RNA
snRNA	I-RNA
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer-binding	B-DNA
site	I-DNA
is	O
combined	O
with	O
a	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
.	O


TCF-1	B-protein
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	B-protein
kD	I-protein
polypeptide	I-protein
of	O
NF-kB	B-protein
.	O


Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	B-DNA
motif	I-DNA
abolishes	O
its	O
T	O
cell-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	B-cell_line
cells	I-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O


The	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
mediates	O
the	O
cell-type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O


Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	B-protein
antibody	I-protein
recognizing	O
a	O
17-amino	B-protein
acid	I-protein
epitope	I-protein
of	O
the	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
[	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
]	I-protein
receptor	I-protein
,	O
we	O
have	O
detected	O
two	O
crossreacting	B-protein
proteins	I-protein
in	O
activated	B-cell_type
normal	I-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O


Regulation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
's	O
disease	O
and	O
ketoconazole	O
.	O


Glucocorticoid	B-protein
receptors	I-protein
(	O
GcR	B-protein
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	B-cell_type
mononulear	I-cell_type
leukocytes	I-cell_type
(	O
hMNL	B-cell_type
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
's	O
disease	O
patients	O
with	O
or	O
without	O
ketoconazole	O
therapy	O
.	O


In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down-regulatory	O
effect	O
.	O


Furthermore	O
,	O
GcR	B-protein
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O


Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O


The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	B-protein
protein	I-protein
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
were	O
examined	O
.	O


The	O
receptor	O
from	O
OKT3	B-protein
and	O
OKT3	B-protein
+	O
phorbol	O
myristate	O
acetate	O
-activated	B-cell_type
lymphocytes	I-cell_type
exhibited	O
decreased	O
binding	O
to	O
DNA-cellulose	O
compared	O
to	O
PHA-activated	B-cell_type
lymphocytes	I-cell_type
.	O


However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O


We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	B-DNA
B-related	I-DNA
sequence	I-DNA
elements	I-DNA
in	O
two	O
different	O
cell	O
types	O
.	O


Interferons	B-protein
(	O
IFNs	B-protein
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	B-protein
proteins	I-protein
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O


Previously	O
,	O
a	O
nuclear	B-protein
factor	I-protein
,	O
IRF-1	B-protein
(	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
)	O
,	O
which	O
binds	O
to	O
type	B-DNA
I	I-DNA
IFN	I-DNA
and	O
some	O
IFN-inducible	B-DNA
gene	I-DNA
promoters	I-DNA
,	O
was	O
identified	O
and	O
cloned	O
.	O


Preparation	O
and	O
analysis	O
of	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	B-cell_type
population	I-cell_type
.	O


However	O
,	O
DCoH	B-protein
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O


The	O
finding	O
that	O
dexamethasone	O
has	O
no	O
effect	O
on	O
TPA-induced	O
activation	O
of	O
PKC	B-protein
suggests	O
that	O
this	O
glucocorticoid	O
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	B-protein
.	O


Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O


1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O


These	O
studies	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
therapy	O
of	O
HIV-1	O
infection	O
.	O


In	O
contrast	O
,	O
TGF-beta	B-protein
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	B-protein
cell	I-protein
membrane	I-protein
proteins	I-protein
,	O
HLA-DR	B-protein
and	O
CD20	B-protein
.	O


Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti-IgM	B-protein
,	O
anti-kappa	B-protein
,	O
and	O
anti-lambda	B-protein
antibodies	I-protein
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	B-protein
L	I-protein
chain	I-protein
in	O
the	O
presence	O
of	O
TGF-beta	B-protein
.	O


Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
forms	I-RNA
of	O
mu	B-RNA
and	O
gamma	B-RNA
to	O
their	O
respective	O
secreted	B-RNA
forms	I-RNA
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF-beta	B-protein
.	O


These	O
findings	O
demonstrate	O
that	O
TGF-beta	B-protein
decreases	O
B	O
lymphocyte	O
Ig	B-protein
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	B-RNA
mRNA	I-RNA
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	I-RNA
to	O
the	O
secreted	B-RNA
forms	I-RNA
of	O
mu	B-RNA
and	I-RNA
gamma	I-RNA
mRNA	I-RNA
.	O


One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	B-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O


Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
the	O
HIV-1	B-protein
protease	I-protein
during	O
acute	O
infection	O
.	O


T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O


1	O
,	O
25-Dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O


Levels	O
of	O
occupied	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
protein	I-protein
increased	O
in	O
these	O
HL-60	B-cell_line
cells	I-cell_line
;	O
but	O
the	O
total	O
number	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O


These	O
data	O
suggest	O
a	O
role	O
for	O
HSP27	B-protein
in	O
the	O
signal	O
transduction	O
events	O
of	O
platelet	B-cell_type
activation	O
.	O


We	O
have	O
isolated	O
a	O
human	B-DNA
cDNA	I-DNA
clone	I-DNA
encoding	O
a	O
zinc	B-protein
finger	I-protein
protein	I-protein
(	O
NF-E1	B-protein
)	O
that	O
binds	O
to	O
the	O
negative-acting	B-DNA
segment	I-DNA
of	O
the	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
enhancer	I-DNA
.	O


A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
containing	O
a	O
CpG-rich	B-DNA
island	I-DNA
encodes	O
a	O
small	B-protein
basic	I-protein
protein	I-protein
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O


This	O
paper	O
presents	O
studies	O
of	O
G0S2	B-DNA
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	B-RNA
genes	I-RNA
,	O
for	O
which	O
cDNAs	B-DNA
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O


The	O
derived	O
103-amino-acid	B-protein
basic	I-protein
protein	I-protein
has	O
two	O
potential	O
alpha-helical	B-protein
domains	I-protein
separated	O
by	O
a	O
hydrophobic	B-protein
region	I-protein
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O


The	O
gene	O
contains	O
a	O
CpG-rich	B-protein
island	I-protein
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O


An	O
upstream	B-DNA
segment	I-DNA
contains	O
tandem	B-DNA
dinucleotide	I-DNA
repeats	I-DNA
(	B-DNA
CT	I-DNA
)	I-DNA
19/	I-DNA
(	I-DNA
CA	I-DNA
)	I-DNA
16	I-DNA
.	O


These	O
results	O
suggest	O
that	O
HIV-TF1	B-protein
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O


The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O


Three	O
DNA	O
clones	O
containing	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
genomic	I-DNA
fragments	I-DNA
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
cotransfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Using	O
amino	O
acid	O
sequence	O
information	O
derived	O
from	O
the	O
DNA	B-protein
affinity-purified	I-protein
protein	I-protein
,	O
we	O
have	O
now	O
isolated	O
cDNA	B-DNA
clones	I-DNA
encoding	O
TCF-1	B-protein
alpha	I-protein
.	O


The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	B-DNA
LTR	I-DNA
.	O


In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	B-protein
are	O
able	O
to	O
activate	O
an	O
octamer	B-DNA
containing	O
promoter	B-DNA
element	I-DNA
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O


[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O


This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF-kappa	B-DNA
B	I-DNA
region	I-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
;	O
the	O
65-kDa	B-protein
plus	I-protein
50-kDa	I-protein
NF-kappa	I-protein
B	I-protein
heterodimer	I-protein
was	O
preferentially	O
lost	O
.	O


Glucocorticoid	B-protein
receptors	I-protein
in	O
normal	B-cell_type
leukocytes	I-cell_type
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O


Eight	O
patients	O
with	O
dermatomyositis/polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B-protein
in	O
MNL	B-cell_type
could	O
be	O
down-regulated	O
by	O
their	O
cognate	O
ligands	O
.	O


The	O
C26	B-DNA
element	I-DNA
conferred	O
partial	O
responsiveness	O
to	O
p40tax	B-protein
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	B-DNA
element	I-DNA
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	B-protein
.	O


In	O
contrast	O
,	O
the	O
C26	B-DNA
element	I-DNA
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O


Human	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


We	O
have	O
generated	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
BZ1	B-protein
,	O
to	O
BZLF1	B-protein
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B-protein
,	I-protein
dimeric	I-protein
form	I-protein
and	O
the	O
inactive	B-protein
,	I-protein
monomeric	I-protein
form	I-protein
of	O
the	O
protein	O
.	O


A	O
differentiation-associated	O
pattern	O
of	O
BZLF1	B-protein
expression	O
was	O
observed	O
,	O
BZ1	B-protein
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O


[	O
Changes	O
in	O
levels	O
of	O
leucocytic	B-protein
estrogen	I-protein
receptor	I-protein
in	O
patients	O
with	O
menopausal	O
type	O
II	O
diabetes	O
and	O
its	O
significance	O
]	O


OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	B-protein
receptor	I-protein
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O


Also	O
,	O
in	O
a	O
promonocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
chronically	O
infected	O
with	O
HIV	O
,	O
NF-kappa	B-protein
B	I-protein
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	B-protein
alpha	I-protein
.	O


Thus	O
,	O
stimulation	O
of	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
phorbol	O
esters	O
or	O
TNF	B-protein
alpha	I-protein
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O


We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	B-protein
localized	O
in	O
the	O
nucleus	O
from	O
isolated	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
from	O
single	B-cell_type
tumor	I-cell_type
cells	I-cell_type
derived	O
from	O
malignant	O
effusions	O
.	O


Pleural	O
effusions	O
from	O
20	O
patients	O
with	O
breast	O
cancer	O
were	O
tested	O
.	O


Here	O
we	O
examined	O
the	O
activation	O
of	O
NF-kB	B-protein
in	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
thymic	I-cell_type
progenitors	I-cell_type
.	O


These	O
observations	O
imply	O
that	O
TCF-1	B-protein
is	O
involved	O
in	O
the	O
control	O
of	O
several	O
T	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
might	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O


The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B-protein
ALAS	I-protein
isozymes	I-protein
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O


The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M-CSF	B-protein
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O


Moreover	O
,	O
M-CSF	B-protein
-induced	O
expression	O
of	O
the	O
fos-related	B-DNA
gene	I-DNA
,	O
fra-1	B-DNA
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c-fos	B-DNA
and	O
fos-B	B-DNA
.	O


Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B-protein
receptors	I-protein
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O


Kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	B-cell_line
autocrine	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


In	O
agreement	O
with	O
this	O
finding	O
,	O
both	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
promoters	I-DNA
are	O
active	O
in	O
transient	O
transfection	O
assays	O
in	O
IARC	B-cell_line
301	I-cell_line
cells	I-cell_line
.	O


Protein	B-protein
kinase	I-protein
C	I-protein
activation	O
and	O
protooncogene	B-DNA
expression	O
in	O
differentiation/retrodifferentiation	O
of	O
human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O


Treatment	O
of	O
U-937	B-cell_line
cells	I-cell_line
with	O
TPA	O
resulted	O
in	O
a	O
rapid	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
from	O
the	O
cytosol	O
to	O
cell	O
membrane	O
fractions	O
within	O
2-8	O
min	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O


Kappa	B-protein
B	I-protein
(	I-protein
kappa	I-protein
B	I-protein
)	I-protein
enhancer	I-protein
binding	I-protein
proteins	I-protein
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
produce	O
two	O
distinct	O
nucleoprotein	B-protein
complexes	I-protein
when	O
incubated	O
with	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor-alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
.	O


[	O
Changes	O
in	O
leucocytic	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O


Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	B-protein
vitro	I-protein
synthesized	I-protein
human	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O


We	O
have	O
used	O
a	O
DNA-binding/immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
hGR	B-protein
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O


In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
(	O
tuberculosis	O
and	O
sarcoidosis	O
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O


Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	O
those	O
from	O
normal	O
control	O
subjects	O
,	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	O
by	O
the	O
presence	O
of	O
unlabeled	O
25	O
(	O
OH	O
)	O
D3	O
(	O
receptor-positive	B-cell_type
lymphocytes	I-cell_type
:	O
sarcoidosis	O
,	O
20	O
+/-	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
+/-	O
17	O
%	O
)	O
.	O


1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
than	O
on	O
CD4+	B-cell_type
T-lymphocytes	I-cell_type
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4+	B-cell_type
than	O
of	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor-positive	O
.	O


During	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
six	B-protein
viral	I-protein
nuclear	I-protein
antigen	I-protein
(	O
EBNAs	B-protein
)	O
are	O
expressed	O
from	O
long	B-RNA
primary	I-RNA
transcripts	I-RNA
by	O
means	O
of	O
alternative	B-RNA
splicing	I-RNA
and	O
alternative	B-RNA
polyadenylylation	I-RNA
sites	I-RNA
.	O


These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	O
the	O
gene	O
encoding	O
EBNA	B-protein
2	I-protein
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	B-DNA
usage	O
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	B-DNA
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-429	B-DNA
to	I-DNA
-245	I-DNA
base	I-DNA
pairs	I-DNA
upstream	O
of	O
Cp	B-DNA
is	O
essential	O
for	O
Cp	B-DNA
activity	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
sequences	I-DNA
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
;	O
and	O
(	O
iv	O
)	O
DNase	B-protein
I	I-protein
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
revealed	O
a	O
B-cell-specific	B-DNA
footprint	I-DNA
in	O
the	O
region	O
of	O
the	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
.	O


Using	O
recombinant	B-protein
HBxAg	I-protein
protein	I-protein
,	O
we	O
found	O
HBxAg	B-protein
-specific	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
patients	O
with	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	O
in	O
healthy	O
individuals	O
.	O


Five	O
T-cell	B-cell_line
clones	I-cell_line
specific	O
for	O
a	O
T-cell	B-protein
epitope	I-protein
located	O
at	O
the	O
carboxyterminal	B-protein
region	I-protein
of	O
HBxAg	B-protein
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2/CD4-positive	B-cell_line
,	I-cell_line
CD8-negative	I-cell_line
subtype	I-cell_line
.	O


It	O
suggested	O
that	O
increase	O
of	O
ER	O
levels	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gynecomastia	O
.	O


Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	B-protein
or	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O


The	O
rate	O
of	O
LTR	B-DNA
-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
if	O
either	O
the	O
NFAT-1	B-protein
or	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O


Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B-protein
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP-	B-DNA
,	I-DNA
phorbol	I-DNA
ester-	I-DNA
,	I-DNA
and	I-DNA
Ca	I-DNA
(	I-DNA
2+	I-DNA
)	I-DNA
-inducible	I-DNA
enhancer	I-DNA
,	O
and	O
JunD	B-protein
is	O
shown	O
to	O
bind	O
the	O
enhancer	B-DNA
as	O
a	O
homodimer	B-protein
.	O


Another	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
complex	I-protein
,	O
JunB	B-protein
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-protein
.	O


[	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
deficiency-cold	O
vs	O
deficiency-heat	O
syndromes	O
]	O


Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	B-protein
appears	O
.	O


This	O
tight	O
correlation	O
between	O
c-jun	B-DNA
expression	O
,	O
the	O
generation	O
of	O
AP-1	B-protein
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	B-protein
complex	I-protein
during	O
this	O
process	O
.	O


The	O
putative	B-protein
intracellular	I-protein
receptors	I-protein
for	O
FK506	O
and	O
cyclosporin	O
are	O
cis-trans	O
prolyl	O
isomerases	O
.	O


FK506	O
and	O
cyclosporin	O
A	O
block	O
translocation	O
of	O
the	O
cytoplasmic	B-protein
component	I-protein
without	O
affecting	O
synthesis	O
of	O
the	O
nuclear	B-protein
subunit	I-protein
.	O


Glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
in	O
anorexia	O
nervosa	O
.	O


Cloning	O
of	O
murine	B-protein
TCF-1	I-protein
,	O
a	O
T	O
cell-specific	O
transcription	B-protein
factor	I-protein
interacting	O
with	O
functional	B-DNA
motifs	I-DNA
in	O
the	O
CD3-epsilon	B-DNA
and	I-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
enhancers	I-DNA
.	O


The	O
T	O
lineage-specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR-alpha	B-DNA
and	I-DNA
CD3-epsilon	I-DNA
enhancers	I-DNA
imply	O
an	O
important	O
role	O
for	O
TCF-1	B-protein
in	O
the	O
establishment	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O


Cloning	O
of	O
a	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
that	O
resembles	O
a	O
diverged	B-DNA
Drosophila	I-DNA
homeobox	I-DNA
gene	I-DNA
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	B-cell_type
.	O


In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	B-protein
factor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O


We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet-activating	B-protein
factor	I-protein
binding	O
to	O
B	B-cell_type
cells	I-cell_type
by	O
measuring	O
platelet-activating	B-protein
factor	I-protein
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production	O
.	O


Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
by	O
a	O
novel	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
.	O


A	O
new	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
has	O
been	O
identified	O
3	O
'	O
of	O
E4	B-DNA
and	I-DNA
the	I-DNA
octamerlike	I-DNA
motifs	I-DNA
in	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O


Tandem	O
copies	O
of	O
this	O
67-bp	B-DNA
MnlI-AluI	I-DNA
fragment	I-DNA
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
driven	O
by	O
the	O
conalbumin	B-DNA
promoter	I-DNA
,	O
stimulated	O
transcription	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O


Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-stimulated	O
K+	O
channels	O
.	O


These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand-dependent	O
opening	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channels	I-protein
are	O
not	O
involved	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
activation	O
and	O
mitogenesis	O
.	O


The	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	B-cell_line
expressing	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O


These	O
are	O
prominent	O
enzymes	B-protein
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	B-protein
protein	I-protein
Ag	I-protein
enter	O
APC	B-protein
,	O
and	O
resistant	B-protein
segments	I-protein
in	O
Ag	B-protein
may	O
,	O
therefore	O
,	O
be	O
expected	O
to	O
contain	O
more	O
T-cell	B-protein
determinants	I-protein
than	O
susceptible	B-protein
segments	I-protein
.	O


By	O
searching	O
protein	O
Ag	B-protein
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	O
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T-cell	B-protein
determinants	I-protein
in	O
the	O
Ag	B-protein
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(	O
positive	O
)	O
predictions	O
.	O


Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T-cell	B-protein
determinants	I-protein
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described	O
.	O


Starting	O
with	O
a	O
replication-incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
present	O
in	O
the	O
native	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
proviruses	O
containing	O
reconstructed	B-DNA
LTRs	I-DNA
with	O
individual	O
or	O
combinations	O
of	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
Sp1	I-DNA
elements	I-DNA
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection-cocultivation	O
.	O


For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	B-DNA
containing	O
one	O
or	O
two	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
(	O
and	O
no	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
=	O
MT4	B-cell_line
greater	O
than	O
H9	B-cell_line
greater	O
than	O
CEM	B-cell_line
greater	O
than	O
Jurkat	B-cell_line
)	O
was	O
observed	O
.	O


Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	B-DNA
LTR	I-DNA
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	B-DNA
box	I-DNA
.	O


These	O
results	O
suggest	O
that	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
LTR	I-DNA
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	B-cell_type
types	I-cell_type
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	B-protein
factors	I-protein
present	O
.	O


From	O
HeLa	B-cell_line
cells	I-cell_line
,	O
two	O
major	O
proteins	O
of	O
52	B-protein
and	I-protein
45	I-protein
kilodaltons	I-protein
(	I-protein
kD	I-protein
)	I-protein
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T-cells	B-cell_type
,	O
four	O
proteins	O
--	O
a	O
major	B-protein
protein	I-protein
of	O
52	B-protein
kD	I-protein
and	O
three	O
minor	B-protein
proteins	I-protein
of	O
82	B-protein
,	O
67	B-protein
,	O
and	O
43-47	B-protein
kD	I-protein
--	O
were	O
purified	O
.	O


Also	O
,	O
an	O
induction	O
specific	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
was	O
purified	O
from	O
HeLa	B-cell_line
cells	I-cell_line
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	B-DNA
sequence	I-DNA
and	O
the	O
PRDI	B-DNA
domain	I-DNA
.	O


Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	B-DNA
beta	I-DNA
promoter	I-DNA
deletions	I-DNA
.	O


Deletions	O
upstream	O
of	O
the	O
PRDII	B-DNA
element	I-DNA
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	B-DNA
.	O


The	O
rhombotin	B-DNA
family	I-DNA
of	O
cysteine-rich	B-DNA
LIM-domain	I-DNA
oncogenes	I-DNA
:	O
distinct	O
members	O
are	O
involved	O
in	O
T-cell	B-DNA
translocations	I-DNA
to	O
human	B-DNA
chromosomes	I-DNA
11p15	I-DNA
and	I-DNA
11p13	I-DNA
.	O


NF-kappa	B-protein
B	I-protein
activation	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
is	O
independent	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-regulated	I-protein
kinases	I-protein
.	O


Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
both	O
TNF	B-protein
alpha	I-protein
and	O
PKC	B-protein
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	B-protein
B	I-protein
/I	B-protein
kappa	I-protein
B	I-protein
dissociation	O
without	O
affecting	O
the	O
NF-kappa	B-protein
B	I-protein
translocation	O
step	O
.	O


It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	B-DNA
site	I-DNA
.	O


DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	B-protein
factors	I-protein
to	O
these	O
elements	B-DNA
,	O
including	O
Sp1	B-protein
and	O
CP1	B-protein
.	O


Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	B-DNA
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
CP1	B-protein
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	B-DNA
sequences	I-DNA
.	O


Upon	O
activation	O
,	O
T	B-cell_type
lymphocytes	I-cell_type
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-RNA
mRNA	I-RNA
in	O
the	O
cells	O
.	O


Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
an	O
NF-kappa	B-protein
B	I-protein
-like	O
binding	O
activity	O
to	O
the	O
B2	B-DNA
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
.	O


The	O
purified	O
homodimer	B-protein
(	O
two	O
p50s	B-protein
)	O
of	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
binds	O
the	O
B2	B-DNA
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B-protein
(	O
two	O
p65s	B-protein
plus	O
two	O
p50s	B-protein
)	O
form	O
of	O
the	O
factor	O
.	O


Induction	O
of	O
NF-KB	B-protein
during	O
monocyte	B-cell_type
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O


Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	B-protein
transactivation	I-protein
factor	I-protein
NF-KB	B-protein
to	O
the	O
double	B-DNA
repeat-KB	I-DNA
enhancer	I-DNA
sequence	I-DNA
located	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O


In	O
nuclear	O
extracts	O
from	O
monocytes	B-cell_type
or	O
macrophages	B-cell_type
,	O
induction	O
of	O
NF-KB	B-protein
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O


A	O
fusion	B-DNA
complementary	I-DNA
DNA	I-DNA
in	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
HSB-2	I-cell_line
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
SCL	B-protein
.	O


Thus	O
,	O
in	O
lymphocytes	B-cell_type
,	O
growth-affecting	B-DNA
genes	I-DNA
other	O
than	O
immune	B-protein
receptors	I-protein
risk	O
rearrangements	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B-RNA
RNA	I-RNA
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
compared	O
with	O
U937	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
HIV-infected	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
produced	O
higher	O
levels	O
of	O
TNF-alpha	B-protein
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O


In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis-acting	B-DNA
elements	I-DNA
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	B-DNA
promoter	I-DNA
construct	I-DNA
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	B-cell_type
cells	I-cell_type
than	O
in	O
extracts	O
from	O
class	B-cell_line
II-negative	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
.	O


1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
produced	O
both	O
by	O
lavage	B-cell_type
cells	I-cell_type
(	O
12/12	O
tuberculosis	O
patients	O
,	O
2/6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
3/5	O
tuberculosis	O
patients	O
,	O
0/3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls	O
,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O


Megakaryocytic	B-cell_line
and	I-cell_line
erythrocytic	I-cell_line
lineages	I-cell_line
share	O
specific	O
transcription	B-protein
factors	I-protein
.	O


Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	B-cell_line
and	I-cell_line
the	I-cell_line
megakaryocytic	I-cell_line
lineages	I-cell_line
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
in	O
most	O
erythroblastic	B-cell_line
and	I-cell_line
megakaryoblastic	I-cell_line
permanent	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


Cultured	B-cell_line
MCF-7	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
a	O
pleural	O
effusion	O
of	O
a	O
breast	O
cancer	O
patient	O
,	O
known	O
to	O
contain	O
high	O
levels	O
of	O
ER	B-protein
were	O
used	O
as	O
a	O
positive	O
control	O
(	O
40-48	O
%	O
ER	B-cell_type
positive	I-cell_type
cells	I-cell_type
by	O
immunocytochemistry	O
;	O
200	O
fmol/mg	O
protein	O
by	O
EIA	O
)	O
.	O


The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type-II	B-protein
EBS	I-protein
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O


In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	B-DNA
promoter	I-DNA
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O


Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	O
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O


The	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O


Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O


Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O


The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O


There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O


In	O
addition	O
,	O
the	O
erythroid-specific	B-protein
transcription	I-protein
factor	I-protein
NF-E1	B-protein
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	B-protein
in	O
embryoid	B-cell_type
bodies	I-cell_type
.	O


A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA-binding	B-protein
protein	I-protein
which	O
interacts	O
specifically	O
with	O
the	O
kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
found	O
in	O
many	O
inducible	B-DNA
genes	I-DNA
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O


The	O
sodium/proton	B-protein
exchanger	I-protein
of	O
the	O
cell	O
membrane	O
could	O
be	O
identified	O
as	O
the	O
primary	O
target	O
of	O
the	O
aldosterone	O
action	O
,	O
possibly	O
non-genomically	O
mediated	O
through	O
membrane	B-protein
receptors	I-protein
.	O


Additionally	O
,	O
an	O
abnormal	O
effector	O
mechanism	O
could	O
be	O
demonstrated	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
from	O
essential	O
hypertensives	O
.	O


Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O


Immunostained	B-cell_type
tumor	I-cell_type
cells	I-cell_type
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O


We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O


Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
in	O
interleukin-1	B-cell_line
(	I-cell_line
IL-1	I-cell_line
)	I-cell_line
-responsive	I-cell_line
cells	I-cell_line
blocked	O
IL-1-induced	B-DNA
gene	I-DNA
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
enhancer	I-DNA
or	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O


However	O
,	O
there	O
is	O
an	O
EB1-binding	B-DNA
site	I-DNA
(	O
ZRE-B	B-DNA
)	O
located	O
within	O
the	O
R-responsive	B-DNA
enhancer	I-DNA
region	I-DNA
.	O


Binding	O
of	O
[	O
3H	O
]	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T-lymphocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
S-LB1	B-cell_line
)	O
from	O
a	O
normal	O
individual	O
.	O


In	O
a	O
fourth	O
cell	B-cell_line
line	I-cell_line
,	O
A1-VDR	B-cell_line
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-protein
(	I-protein
OH	I-protein
)	I-protein
D3-24-hydroxylase	I-protein
activity	O
was	O
not	O
detectable	O
.	O


Induction	O
of	O
24	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	B-cell_line
line	I-cell_line
,	O
designated	O
Ro-VDR	B-cell_line
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	B-cell_line
cell	I-cell_line
line	I-cell_line
from	O
a	O
normal	O
donor	O
.	O


Binding	O
and	O
elution	O
properties	O
to	O
DNA-cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro-VDR	B-cell_line
and	O
A1-VDR	B-cell_line
cells	I-cell_line
where	O
elution	O
from	O
DNA-cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O


Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O


Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	B-DNA
expression	O
.	O


It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	B-protein
receptors	I-protein
,	O
thyroid	O
hormones	O
that	O
the	O
low	O
level	O
of	O
steroid	B-protein
receptors	I-protein
,	O
thyroid	O
hormones	O
(	O
T3	O
and	O
T4	O
)	O
and	O
cortisol	O
is	O
typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	O
dysplasia	O
.	O


To	O
determine	O
whether	O
different	O
cellular	B-protein
factors	I-protein
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	B-cell_type
as	O
compared	O
with	O
HeLa	B-cell_line
cells	I-cell_line
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-DNA
promoter	I-DNA
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O


The	O
predicted	O
periplasmic	B-protein
domain	I-protein
of	O
the	O
PhoQ	B-protein
protein	I-protein
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	B-protein
proteins	I-protein
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	B-protein
.	O


Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O


In	O
two	O
patients	O
,	O
VDR	B-protein
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O


These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B-protein
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O


Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O


TAR	B-DNA
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O
ester	O
stimulated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


Multiple	B-DNA
regulatory	I-DNA
elements	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
HIV	B-DNA
LTR	I-DNA
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O


These	O
constructs	O
were	O
transfected	O
into	O
either	O
HeLa	B-cell_line
cells	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
phorbol	O
esters	O
which	O
have	O
previously	O
been	O
demonstrated	O
to	O
activate	O
HIV	O
gene	O
expression	O
.	O


At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
M-CSF	B-protein
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O


We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	B-DNA
specific	I-DNA
tyrosine	I-DNA
kinase	I-DNA
hck	I-DNA
gene	I-DNA
simultaneously	O
with	O
the	O
other	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O


Inducible	O
nuclear	B-protein
factor	I-protein
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal-dependent	O
manner	O
.	O


In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O


This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B-protein
B	I-protein
complexes	I-protein
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O


Curiously	O
,	O
the	O
TCF-1	B-protein
alpha	I-protein
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O


Purified	O
OTF1	B-protein
from	O
HeLa	B-cell_line
cells	I-cell_line
and	O
OTF1	B-protein
and	O
OTF2	B-protein
from	O
B	B-cell_type
cells	I-cell_type
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy-chain	B-DNA
promoter	I-DNA
.	O


The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B-DNA
element	I-DNA
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B-protein
factors	I-protein
involves	O
cooperation	O
between	O
octamer	B-DNA
and	I-DNA
heptamer	I-DNA
sites	I-DNA
in	O
this	O
promoter	B-DNA
.	O


The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
,	O
depending	O
on	O
promoter	B-DNA
elements	I-DNA
that	O
bind	O
the	O
inducible	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
(	O
or	O
an	O
NF-kappa	B-protein
B-like	I-protein
factor	I-protein
)	O
.	O


Two	O
kappa	B-DNA
B-like	I-DNA
motifs	I-DNA
at	O
positions	B-DNA
-98	I-DNA
to	I-DNA
-108	I-DNA
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O


PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	B-protein
.	O


To	O
be	O
or	O
not	O
to	O
be	O
a	O
responder	O
in	O
T-cell	O
responses	O
:	O
ubiquitous	O
oligopeptides	O
in	O
all	O
proteins	O
.	O


Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B-protein
receptor	I-protein
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O


We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	B-RNA
encoding	O
profibrotic	O
growth	B-protein
factors	I-protein
such	O
as	O
platelet-derived	B-protein
growth	I-protein
factor	I-protein
B	I-protein
subunit	I-protein
(	O
PDGF	B-protein
[	I-protein
B	I-protein
]	I-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
.	O


After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O


No	O
increase	O
in	O
TGF-beta	B-RNA
mRNA	I-RNA
was	O
observed	O
.	O


Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
accumulation	O
.	O


The	O
increased	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
observed	O
in	O
adherent	B-cell_type
monocytes	I-cell_type
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	B-RNA
of	O
the	O
early	B-DNA
growth	I-DNA
response	I-DNA
genes	I-DNA
c-fos	B-DNA
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O


These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
EGR2	I-RNA
,	I-RNA
and	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
.	O


Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O


Unexpectedly	O
,	O
stimulation	O
of	O
cloned	B-cell_line
stably	I-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta-gal	B-protein
and	O
others	O
express	O
high	O
levels	O
.	O


We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	B-DNA
(	O
BMRF1	B-DNA
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	B-protein
viral	I-protein
transactivators	I-protein
,	O
BZLF1	B-protein
(	O
Z	B-protein
)	O
and	O
BRLF1	B-protein
(	O
R	B-protein
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O


These	O
data	O
suggest	O
that	O
EA-D	B-DNA
(	I-DNA
BMRF1	I-DNA
)	I-DNA
promoter	I-DNA
regulation	O
by	O
Z	B-protein
and	O
R	B-protein
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O


The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O


DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	B-protein
protein	I-protein
binds	O
to	O
the	O
microB	B-DNA
DNA	I-DNA
motif	I-DNA
.	O


Depletion	O
of	O
CD8+	B-cell_line
cells	I-cell_line
was	O
accompanied	O
by	O
62	O
+/-	O
18	O
%	O
loss	O
of	O
progesterone	B-cell_line
receptor-bearing	I-cell_line
cells	I-cell_line
,	O
while	O
depletion	O
of	O
CD4+	B-cell_line
cells	I-cell_line
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	B-cell_line
.	O


In	O
nonpregnancy	B-cell_line
lymphocytes	I-cell_line
a	O
3-day	O
PHA	B-protein
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor-containing	B-cell_type
cells	I-cell_type
.	O


Activation	O
of	O
human	B-cell_line
CD4	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O


In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B-protein
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-protein
-VLA-5	O
fibronectin	B-protein
receptor	I-protein
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B-protein
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B-protein
transcriptional	I-protein
factor	I-protein
.	O


Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O


Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	B-protein
Tax	I-protein
protein	I-protein
.	O


Transient	O
short-term	O
expression	O
of	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O


Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
the	O
nucleus	O
of	O
Namalwa	B-cell_line
B	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
which	O
constitutively	O
express	O
Tax	B-protein
.	O


Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	B-protein
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O


Cloning	O
of	O
a	O
transcriptionally	B-protein
active	I-protein
human	I-protein
TATA	I-protein
binding	I-protein
factor	I-protein
.	O


Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	B-protein
T-cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
TCF-1	B-protein
(	O
for	O
T-Cell	B-protein
Factor-1	I-protein
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	B-DNA
response	I-DNA
element	I-DNA
(	O
TCE	B-DNA
)	O
located	O
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O


Second	O
,	O
TRE-DNA	B-protein
binding	I-protein
proteins	I-protein
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O


The	O
cAMP-response	B-DNA
element	I-DNA
CRE	B-DNA
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	B-DNA
base-pair	I-DNA
sequence	I-DNA
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	B-DNA
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O


The	O
complementary	B-DNA
DNAs	I-DNA
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	B-protein
and	O
ITF-2	B-protein
are	O
structurally	O
and	O
functionally	O
similar	O
.	O


The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O


Using	O
constructs	O
in	O
which	O
mRNA	B-RNA
production	O
controlled	O
by	O
a	O
specific	O
transcription	B-protein
factor	I-protein
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF-AT	B-protein
,	O
NFIL2	B-protein
A	I-protein
,	O
NFIL2	B-protein
B	I-protein
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O


Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O


These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	B-cell_line
glioblastoma	I-cell_line
and	I-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
relationship	O
of	O
the	O
N-Oct	B-protein
proteins	I-protein
to	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
proteins	O
.	O


with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O
both	O
serum-supplemented	B-cell_line
and	I-cell_line
serum-free	I-cell_line
cultures	I-cell_line
(	O
viability	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
)	O
.	O


The	O
increased	O
sensitivity	O
of	O
CEM-C7	B-cell_line
cells	I-cell_line
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum-free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum-containing	O
medium	O
.	O


[	O
Glucocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O


The	O
ubiquitous	B-protein
octamer-binding	I-protein
protein	I-protein
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O


In	O
the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	O
.	O


The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O
mechanism	O
in	O
the	O
HML	B-cell_type
of	O
patients	O
with	O
essential	O
hypertension	O
.	O


Inhibition	O
of	O
sequence-specific	B-protein
DNA-binding	I-protein
proteins	I-protein
was	O
achieved	O
with	O
double-stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	B-DNA
or	I-DNA
kappa	I-DNA
B	I-DNA
consensus	I-DNA
sequences	I-DNA
.	O


Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	B-DNA
consensus	I-DNA
to	O
Jurkat	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
inhibited	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	B-DNA
octamer	I-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O


The	O
plasma	O
cortisol	O
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GCR	B-protein
)	O
in	O
the	O
peripheral	B-cell_type
lymphocytes	I-cell_type
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O


Exposure	O
of	O
CML	B-cell_type
cells	I-cell_type
to	O
IFN-alpha	B-protein
diminished	O
the	O
effect	O
of	O
the	O
CML	B-protein
cytoplasmic	I-protein
proteins	I-protein
on	O
these	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O


Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
transactivates	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O


LMP1	B-protein
is	O
a	O
potent	O
effector	O
of	O
B-lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
induce	O
cellular	O
CD23	O
gene	O
expression	O
.	O


Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O


[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	B-cell_type
leukocytes	I-cell_type
]	O


Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	B-cell_type
leukocytes	I-cell_type
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O


The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O
significant	O
statistically	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O


Using	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
Lt-4	B-protein
,	O
directed	O
against	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
trans-activator	I-protein
(	I-protein
tax1	I-protein
)	I-protein
antigen	I-protein
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B-protein
and	O
related	O
antigens	B-protein
in	O
a	O
variety	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
bearing	O
HTLV-I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV-I	O
)	O
and	O
HTLV-II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O


Characterization	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
enhancer-binding	I-protein
proteins	I-protein
from	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Jurkat	B-cell_line
.	O


The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O


Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	B-DNA
domain	I-DNA
.	O


Both	O
C1	B-protein
and	O
C2	B-protein
proteins	I-protein
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	I-DNA
.	O


Differences	O
in	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
HIV-1	O
and	O
HIV-2	O
.	O


In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
comprise	O
the	O
transcriptional	B-DNA
enhancer	I-DNA
,	O
which	O
contains	O
two	O
conserved	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
.	O


In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	B-protein
kappa	I-protein
B	I-protein
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	B-DNA
transcriptional	I-DNA
enhancer	I-DNA
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	B-DNA
transcriptional	I-DNA
enhancer	I-DNA
.	O


When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B-protein
1	I-protein
receptor	I-protein
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O


For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O


Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B-protein
factor	I-protein
.	O


By	O
targeting	O
NFAT-1	B-protein
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	B-protein
activity	O
.	O


Progesterone	O
suppression	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O


RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	B-protein
factor	I-protein
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O


These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	B-protein
receptors	I-protein
and	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
are	O
not	O
involved	O
.	O


The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	B-protein
antibody	I-protein
is	O
a	O
56-kDa	B-protein
protein	I-protein
(	O
p56	B-protein
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O


The	O
ORF	B-DNA
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
30-kD	B-protein
protein	I-protein
product	I-protein
was	O
shown	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
by	O
mobility-shift	O
assays	O
,	O
Southwestern	O
blot	O
analysis	O
,	O
and	O
methylation	O
interference	O
.	O


In	O
postmenopausal	O
women	O
the	O
mean	O
type	B-protein
II	I-protein
EBS	I-protein
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle	O
.	O


Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O


Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down-regulated	O
Bmax	O
after	O
DEX	O
.	O


Ras-related	B-protein
GTP-binding	I-protein
proteins	I-protein
and	O
leukocyte	B-cell_type
signal	O
transduction	O
.	O


Recent	O
progress	O
in	O
understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	I-protein
by	O
the	O
Rac	B-protein
GTP-binding	I-protein
proteins	I-protein
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O


Besides	O
p50	B-protein
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
,	O
namely	O
c-rel	B-protein
.	O


The	O
myeloid	B-DNA
zinc	I-DNA
finger	I-DNA
gene	I-DNA
,	O
MZF-1	B-DNA
,	O
regulates	O
the	O
CD34	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O


MZF-1	B-DNA
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	B-DNA
reporter	I-DNA
plasmids	I-DNA
regulated	O
by	O
the	O
CD34	B-DNA
promoter	I-DNA
into	O
both	O
nonhematopoietic	B-cell_line
and	I-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


The	O
cell	O
type-specific	O
regulation	O
of	O
the	O
CD34	B-DNA
promoter	I-DNA
by	O
MZF-1	B-DNA
suggests	O
the	O
presence	O
of	O
tissue-specific	O
regulators/adapters	O
or	O
differential	O
MZF-1	B-DNA
modifications	O
that	O
determine	O
MZF-1	B-DNA
transcriptional	O
regulatory	O
function	O
.	O


These	O
results	O
suggest	O
that	O
BCL6	B-protein
plays	O
a	O
role	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
as	O
an	O
immediate	O
early	O
gene	O
.	O


Avian	O
cells	O
express	O
three	O
heat	B-DNA
shock	I-DNA
transcription	I-DNA
factor	I-DNA
(	I-DNA
HSF	I-DNA
)	I-DNA
genes	I-DNA
corresponding	O
to	O
a	O
novel	B-protein
factor	I-protein
,	O
HSF3	B-protein
,	O
and	O
homologs	O
of	O
mouse	O
and	O
human	O
HSF1	B-protein
and	O
HSF2	B-protein
.	O


Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	B-protein
reveals	O
that	O
HSF3	B-protein
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B-protein
and	O
HSF2	B-protein
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O


HSF3	B-protein
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	B-cell_line
cell	I-cell_line
line	I-cell_line
HD6	I-cell_line
,	O
the	O
lymphoblast	B-cell_line
cell	I-cell_line
line	I-cell_line
MSB	I-cell_line
,	O
and	O
embryo	B-cell_line
fibroblasts	I-cell_line
,	O
and	O
yet	O
its	O
DNA-binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O


Acquisition	O
of	O
HSF3	B-protein
DNA-binding	O
activity	O
in	O
HD6	B-cell_line
cells	I-cell_line
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non-DNA-binding	B-protein
dimer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B-protein
is	O
oligomerization	O
of	O
an	O
inert	B-protein
monomer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
.	O


Induction	O
of	O
HSF3	B-protein
DNA-binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	B-protein
.	O


As	O
occurs	O
for	O
HSF1	B-protein
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B-protein
to	O
the	O
nucleus	O
.	O


The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B-protein
synthesis	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O


The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	B-protein
and	I-protein
NFATc-	I-protein
specific	I-protein
antibodies	I-protein
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	B-protein
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	B-protein
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O


The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B-protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O


p94	B-protein
and	O
p95	B-protein
share	O
homology	O
with	O
Stat1	B-protein
at	O
the	O
phosphorylation	B-protein
site	I-protein
and	O
in	O
the	O
Src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
domain	I-protein
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B-protein
.	O


Expression	O
of	O
c-fos	B-DNA
correlates	O
with	O
IFN-alpha	B-protein
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O


Menopause	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
blood	O
monocyte	O
number	O
and	O
a	O
relative	O
decrease	O
in	O
the	O
expression	O
of	O
estrogen	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O


In	O
addition	O
,	O
the	O
monocyte	O
and	O
lymphocyte	O
counts	O
and	O
the	O
blood	O
estrogen	O
levels	O
of	O
each	O
patient	O
were	O
determine	O
.	O


Transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
are	O
controlled	O
by	O
inhibitory	B-protein
I	I-protein
kappa	I-protein
B	I-protein
proteins	I-protein
,	O
mainly	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
.	O


The	O
activation	O
of	O
Janus	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
(	O
Jak	B-protein
)	O
and	O
STAT	B-protein
(	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	B-protein
.	O


Analysis	O
of	O
the	O
expression	O
of	O
human	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
in	O
stable	O
transfectants	O
of	O
mouse	B-cell_line
70Z/3	I-cell_line
cells	I-cell_line
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O


By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	B-cell_line
line	I-cell_line
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand-induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


Although	O
the	O
interrelationship	O
between	O
the	O
two	O
messengers	O
Ca2+	O
and	O
cyclic	O
AMP	O
in	O
platelet	O
function	O
is	O
well	O
documented	O
,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established	O
.	O


3	O
)	O
In	O
Cushing	O
's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B-protein
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O


Whether	O
the	O
putative	O
new	O
retrovirus	O
(	O
es	O
)	O
and	O
EBV	O
have	O
any	O
causal	O
relationship	O
to	O
MS	O
is	O
still	O
not	O
known	O
,	O
but	O
the	O
findings	O
support	O
this	O
possibility	O
.	O


Activation	O
through	O
the	O
Ca2+/	O
calcineurin	B-protein
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	B-DNA
genes	I-DNA
.	O


The	O
conserved	B-DNA
cis-acting	I-DNA
sequence	I-DNA
,	O
GGAAAA	O
,	O
and	O
transcription	B-protein
factors	I-protein
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2+	O
concentrations	O
.	O


This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
,	O
which	O
synergizes	O
with	O
the	O
constitutive	B-protein
transcription	I-protein
factor	I-protein
Sp1	B-protein
to	O
drive	O
the	O
HIV-1	B-DNA
promoter	I-DNA
.	O


The	O
B4-2	B-DNA
clone	O
coded	O
for	O
an	O
mRNA	B-RNA
of	O
2061	O
bp	O
in	O
length	O
.	O


A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B-protein
B4-2	I-protein
recognizes	O
a	O
32-34	B-protein
kDa	I-protein
protein	I-protein
in	O
lymphocytes	B-cell_type
.	O


Bound	O
[	O
3H	O
]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O


They	O
have	O
also	O
shown	O
that	O
proteasome	B-protein
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long-term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-protein
receptor	I-protein
status	O
,	O
in	O
hirsute	O
women	O
.	O


A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH-stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha-hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O


Androgen	O
receptor	O
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O


Here	O
we	O
show	O
,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B-protein
protein	I-protein
,	O
and	O
a	O
specific	O
antiserum	O
against	O
AML-1	B-protein
proteins	I-protein
in	O
DNA-binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family	O
,	O
AML-1B	B-protein
,	O
binds	O
specifically	O
to	O
OSE2	O
and	O
is	O
immunologically	O
related	O
to	O
OSF2	B-protein
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O
that	O
binds	O
to	O
OSE2	O
.	O


Thus	O
,	O
this	O
study	O
demonstrates	O
that	O
AML-1B	B-protein
can	O
increase	O
gene	O
expression	O
of	O
an	O
osteoblast-specific	B-DNA
gene	I-DNA
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	I-DNA
and	O
presents	O
evidence	O
that	O
OSF2	B-protein
is	O
a	O
member	O
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O


Initiation	B-protein
binding	I-protein
repressor	I-protein
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
histone	B-DNA
h5	I-DNA
gene	I-DNA
,	O
is	O
a	O
glycosylated	B-protein
member	I-protein
of	O
a	O
family	O
of	O
cell	B-protein
growth	I-protein
regulators	I-protein
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O


We	O
present	O
evidence	O
that	O
IBR	B-protein
and	O
IBF	B-protein
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O


This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	B-protein
Sp1	I-protein
factor	I-protein
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN-gamma	B-protein
.	O


Males	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	B-DNA
receptor	I-DNA
gamma	I-DNA
chain	I-DNA
(	I-DNA
gamma	I-DNA
c	I-DNA
)	I-DNA
gene	I-DNA
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-9	B-protein
,	O
and	O
IL-15	B-protein
.	O


An	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
cell	I-cell_line
line	I-cell_line
derived	O
from	O
her	O
lymphocytes	B-cell_type
had	O
normal	O
gamma	B-protein
c	I-protein
expression	O
but	O
lacked	O
Jak3	B-protein
protein	I-protein
and	O
had	O
greatly	O
diminished	O
Jak3	B-RNA
messenger	I-RNA
RNA	I-RNA
.	O


Intravenous	O
injection	O
of	O
a	O
rat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
that	O
overexpresses	O
L-selectin	B-protein
showed	O
increased	O
organ	O
infiltration	O
.	O


Here	O
we	O
have	O
confirmed	O
and	O
extended	O
such	O
observations	O
,	O
showing	O
that	O
(	O
1	O
)	O
this	O
phenomenon	O
is	O
restricted	O
to	O
the	O
variant	O
A	O
of	O
HHV-6	O
:	O
in	O
fact	O
two	O
isolates	O
belonging	O
to	O
the	O
HHV-6	O
variant	O
B	O
(	O
BA92	O
and	O
Z29	O
)	O
were	O
neither	O
able	O
to	O
infect	O
any	O
B	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
independently	O
of	O
the	O
EBV	O
status	O
,	O
nor	O
to	O
induce	O
the	O
EBV	O
genome	O
expression	O
.	O


Absorptive	O
hypercalciuria	O
(	O
a	O
stone-forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O


Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O


The	O
coding	O
region	O
of	O
VDR	B-RNA
messenger	I-RNA
RNA	I-RNA
was	O
also	O
normal	O
,	O
as	O
determined	O
by	O
both	O
DNA	B-DNA
sequence	I-DNA
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	O
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O
.	O


Platelet	B-protein
thromboxane	I-protein
receptors	I-protein
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O


Promoter	O
function	O
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter/chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
chimera	I-DNA
plasmids	I-DNA
into	O
platelet-like	O
K562	B-cell_line
cells	I-cell_line
.	O


Functional	O
analysis	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
constructs	I-DNA
in	O
transfected	O
K562	B-cell_line
cells	I-cell_line
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter	O
to	O
a	O
cluster	O
of	O
activator	B-DNA
protein-2	I-DNA
(	I-DNA
AP-2	I-DNA
)	I-DNA
binding	I-DNA
consensus	I-DNA
sites	I-DNA
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O


These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	B-protein
thromboxane	I-protein
receptors	I-protein
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
in	O
platelet-progenitor	B-cell_type
cells	I-cell_type
.	O


Confirmation	O
of	O
a	O
model	O
.	O


In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O


Helices	B-protein
I	I-protein
and	I-protein
II	I-protein
are	O
positioned	O
in	O
an	O
antiparallel	B-protein
mode	I-protein
and	O
form	O
one	O
arm	O
of	O
the	O
HMG	B-protein
box	I-protein
.	O


PRE-I	B-DNA
forms	O
multiple	B-protein
DNA-protein	I-protein
complexes	I-protein
with	O
nuclear	O
extracts	O
from	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	B-protein
by	O
using	O
anti-C/EBP	B-protein
beta	I-protein
Abs	I-protein
.	O


Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	B-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
positions	O
-44	O
to	O
-36	O
(	O
C/EBP	B-protein
proximal	I-protein
)	O
and	O
-87	O
to	O
-79	O
(	O
C/EBP	B-protein
medial	I-protein
)	O
,	O
respectively	O
.	O


Our	O
results	O
demonstrate	O
that	O
NF-IL6	B-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O


Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
.	O


Mutational	O
analyses	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	B-protein
sites	I-protein
by	O
the	O
bound	O
kinase	B-protein
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C-terminal	B-protein
acidic	I-protein
domain	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O


The	O
survival-promoting	O
activity	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	B-protein
proteins	I-protein
.	O


In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O


In	O
addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF-1	B-protein
expression	O
can	O
serve	O
as	O
a	O
pan-T-lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O


TCL1	O
oncogene	O
activation	O
in	O
preleukemic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
a	O
case	O
of	O
ataxia-telangiectasia	O
.	O


We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C/EBP	B-protein
proteins	I-protein
and	O
C/EBP	B-DNA
sites	I-DNA
in	O
regulating	O
transcription	O
from	O
the	O
HIV-	B-DNA
1	I-DNA
LTR	I-DNA
in	O
monocytes/macrophages	B-cell_type
.	O


Mutational	O
analyses	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
showed	O
that	O
one	O
C/EBP	B-DNA
site	I-DNA
is	O
required	O
for	O
normal	O
LTR	B-DNA
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C/EBP	B-DNA
sites	I-DNA
are	O
functionally	O
equivalent	O
.	O


Several	O
models	O
are	O
suggested	O
for	O
how	O
elevated	O
NF-IL6	B-protein
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	B-protein
expression	O
,	O
and	O
HIV	O
replication	O
.	O


Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	B-DNA
elements	I-DNA
in	O
their	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
(	O
LTRs	B-DNA
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B-DNA
elements	I-DNA
in	O
the	O
HIV-2	B-DNA
LTR	I-DNA
.	O


The	O
HIV-2	B-DNA
LTR	I-DNA
was	O
found	O
to	O
contain	O
two	O
enhancers	B-DNA
.	O


One	O
of	O
these	O
enhancers	B-DNA
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
.	O


The	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B-protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B-protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O


Together	O
these	O
data	O
suggest	O
that	O
ETS1	B-protein
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM-CSF	B-protein
production	O
associated	O
with	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O


Thyroid	O
hormones	O
act	O
by	O
binding	O
to	O
nuclear	B-protein
receptor	I-protein
proteins	I-protein
,	O
the	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
(	I-protein
TR	I-protein
)	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
.	O


Similar	O
levels	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
detected	O
in	O
thyroid	O
gland	O
from	O
euthyroid	O
patients	O
.	O


The	O
effects	O
of	O
CsA	O
on	O
endothelial	B-cell_type
cells	I-cell_type
were	O
also	O
detected	O
at	O
the	O
chromatin	B-DNA
structure	O
level	O
,	O
as	O
DNasel	B-DNA
hypersensitive	I-DNA
sites	I-DNA
within	O
both	O
the	O
GM-CSF	B-protein
enhancer	O
and	O
the	O
E-selectin	B-DNA
promoter	I-DNA
were	O
suppressed	O
by	O
CsA	O
.	O


Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	I-cell_type
by	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	B-protein
factors	I-protein
.	O


CD4+	B-cell_line
macrophages	I-cell_line
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	B-cell_type
cells	I-cell_type
in	O
bone	O
marrow	O
,	O
and	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O


B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B-DNA
motif	I-DNA
requires	O
the	O
Oct1	B-protein
or	O
Oct2	B-protein
protein	I-protein
and	O
additional	O
B	B-protein
cell-restricted	I-protein
cofactors	I-protein
.	O


One	O
such	O
cofactor	B-protein
,	O
BOB.1/OBF.1	B-protein
,	O
was	O
recently	O
isolated	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Consistent	O
with	O
the	O
failure	O
of	O
full-length	B-protein
BOB.1/OBF.1	I-protein
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
elements	I-DNA
in	O
non	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
the	O
GAL4	B-protein
fusions	I-protein
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	O
position	O
.	O


Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	B-protein
specific	O
for	O
CaM	B-protein
kinase	I-protein
II	I-protein
.	O


In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
higher	O
activation	O
levels	O
were	O
observed	O
,	O
suggesting	O
that	O
distinct	O
B-cell-specific	B-protein
cofactors	I-protein
in	O
concert	O
with	O
the	O
effector	B-protein
domains	I-protein
of	O
Oct-2a	B-protein
might	O
be	O
involved	O
in	O
mediating	O
transcription	O
from	O
proximal	O
and	O
remote	O
positions	O
.	O


Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O


The	O
presence	O
of	O
a	O
flagellum	O
was	O
not	O
required	O
for	O
binding	O
of	O
P.	O
aeruginosa	O
to	O
macrophages	B-cell_type
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O


Gel	O
shift	O
assays	O
and	O
site-directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	B-DNA
and	O
Ets	B-DNA
binding	I-DNA
motifs	I-DNA
93	B-DNA
and	I-DNA
150	I-DNA
nucleotides	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O


In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
induced	O
following	O
CD30	B-protein
engagement	O
were	O
shown	O
to	O
contain	O
p50	B-protein
NF-kappa	I-protein
B1	I-protein
,	O
p65	B-protein
RelA	I-protein
,	O
and	O
possibly	O
other	O
transcription	B-protein
factors	I-protein
.	O


It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
are	O
expressed	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
activation	O
but	O
not	O
in	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O


SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
and	O
inhibition	O
of	O
IL-12	B-protein
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O


Triggering	O
of	O
complement	B-protein
receptors	I-protein
CR1	B-protein
(	O
CD35	B-protein
)	O
and	O
CR3	B-protein
(	O
CD11b/CD18	B-protein
)	O
induces	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O


The	O
effect	O
of	O
LPS	O
and	O
TNF-alpha	B-protein
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA-binding	B-protein
heterodimer	I-protein
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV-long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O


Stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell-associated	O
and	O
released	O
p24	B-protein
Ag	I-protein
in	O
cell	B-cell_line
cultures	I-cell_line
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	B-cell_line
cultures	I-cell_line
triggered	O
with	O
LPS	O
.	O


Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	B-cell_type
monocytes	I-cell_type
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement-opsonized	B-protein
particles	I-protein
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	B-protein
receptor	I-protein
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O


Tyrosine	O
phosphorylation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
increased	O
markedly	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
in	O
U-937	B-cell_line
cells	I-cell_line
incubated	O
with	O
gamma	B-protein
interferon	I-protein
.	O


Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	B-cell_line
cells	I-cell_line
were	O
also	O
obtained	O
with	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O


Growth	B-protein
factor	I-protein
receptors	I-protein
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O


Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
directs	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O


Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA
site	I-DNA
or	O
the	O
C/EBP	B-DNA
site	I-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
only	O
.	O


This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B-protein
on	O
a	O
myeloid	B-DNA
PU.1	I-DNA
binding	I-DNA
site	I-DNA
.	O


Expression	O
of	O
PU.1	B-protein
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
can	O
activate	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O


We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	B-protein
protein	I-protein
HMG-I	B-protein
to	O
the	O
human	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
.	O


Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well-documented	O
biological	O
phenomenon	O
.	O


Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O


In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
an	O
increase	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
.	O


T-lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
mRNA	O
levels	O
.	O


We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B-protein
expression	O
by	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O


VDR	B-protein
DNA-binding	I-protein
mutants	I-protein
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B-protein
DNA-binding	I-protein
domain	I-protein
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	B-protein
expression	O
.	O


This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-protein
activators	I-protein
of	O
the	O
IL-2	B-DNA
gene	I-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O


Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	I-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
.	O


Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B-protein
or	O
alkaline	B-protein
phosphatase	I-protein
restores	O
NFATp	B-protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O


We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O


In	O
addition	O
,	O
resting	B-cell_type
PBL	I-cell_type
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B-RNA
mRNA	I-RNA
,	O
but	O
not	O
Id3	B-RNA
mRNA	I-RNA
.	O


Upon	O
PHA	B-protein
-stimulation	O
,	O
Id2	B-protein
expression	O
decreased	O
and	O
Id3	B-protein
levels	O
increased	O
with	O
biphasic	O
kinetics	O
.	O


TF	O
expression	O
by	O
circulating	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O


In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O


The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B-protein
with	O
TCR	B-protein
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O


In	O
purified	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
nuclear	B-protein
STAT	I-protein
proteins	I-protein
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	B-protein
Abs	I-protein
.	O


Expression	O
of	O
the	O
chemokine	B-protein
receptor	I-protein
BLR2/EBI1	B-protein
is	O
specifically	O
transactivated	O
by	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
.	O


BLR2-specific	B-RNA
mRNA	I-RNA
could	O
be	O
detected	O
in	O
all	O
Epstein-Barr	B-cell_line
virus	I-cell_line
positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O


We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c-Myb	B-DNA
binding	I-DNA
site	I-DNA
.	O


c-Myb	B-protein
protein	I-protein
was	O
strongly	O
evident	O
in	O
T	B-cell_type
lymphoblasts	I-cell_type
in	O
which	O
the	O
enhancer	B-DNA
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O


In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
enhancer	I-DNA
,	O
which	O
contains	O
DNA-binding	B-DNA
sites	I-DNA
for	O
LEF-1	B-protein
and	O
Ets-1	O
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF-1	B-protein
.	O


Addition	O
of	O
TFE-3	B-protein
,	O
which	O
binds	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
upstream	O
of	O
the	O
LEF-1	B-DNA
and	I-DNA
Ets-1	I-DNA
sites	I-DNA
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O


A	O
truncation	B-protein
mutant	I-protein
of	O
LEF-1	B-protein
(	O
HMG-88	B-protein
)	O
,	O
which	O
contains	O
the	O
HMG	B-protein
box	I-protein
but	O
lacks	O
the	O
trans-activation	B-protein
domain	I-protein
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B-DNA
DNA	I-DNA
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B-protein
domain	I-protein
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O


Immunoprecipitation	O
of	O
the	O
gp	B-protein
160	I-protein
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-protein
antibodies	I-protein
to	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
indicates	O
that	O
AP-1	B-protein
complex	I-protein
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O


